
<html lang="en"     class="pb-page"  data-request-id="530046b2-f8ea-46d1-bd3d-8d7bdf434d3d"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2018.61.issue-20;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.8b00667;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Kinase Inhibitors for the Treatment of Immunological Disorders: Recent Advances" /></meta><meta name="dc.Creator" content="Marian C.  Bryan" /></meta><meta name="dc.Creator" content="Naomi S.  Rajapaksa" /></meta><meta name="dc.Description" content="Small molecule inhibitors targeting autoimmune and inflammatory processes have been an area of intense focus within academia and industry. Much of this work has been aimed at key kinases operating ..." /></meta><meta name="Description" content="Small molecule inhibitors targeting autoimmune and inflammatory processes have been an area of intense focus within academia and industry. Much of this work has been aimed at key kinases operating ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="June 5, 2018" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.8b00667" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2018 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b00667" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.8b00667" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b00667" /></link>
        
    
    

<title>Kinase Inhibitors for the Treatment of Immunological Disorders: Recent Advances | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.8b00667" /></meta><meta property="og:title" content="Kinase Inhibitors for the Treatment of Immunological Disorders: Recent Advances" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0029.jpeg" /></meta><meta property="og:description" content="Small molecule inhibitors targeting autoimmune and inflammatory processes have been an area of intense focus within academia and industry. Much of this work has been aimed at key kinases operating as central nodes in inflammatory signaling pathways. While this focus has led to over 30 FDA-approved small molecule kinase inhibitors, only one is currently approved for autoimmune and inflammatory diseases. Despite this lack of success, there remains tremendous reason for excitement. Our growing understanding of the biology involved in the inflammatory response, the factors that lead to safer small molecule kinase inhibitors, and the availability of selective tool molecules for interrogating specific nodes and pathways are all pushing the field forward. This article focuses on recent developments requiring novel approaches to create safe and effective small molecule kinase inhibitors and where further work is needed to realize the promise of small molecule kinase inhibitors for patient benefit." /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta><meta name="twitter:description" content="Small molecule inhibitors targeting autoimmune and inflammatory processes have been an area of intense focus within academia and industry. Much of this work has been aimed at key kinases operating as central nodes in inflammatory signaling pathways. While this focus has led to over 30 FDA-approved small molecule kinase inhibitors, only one is currently approved for autoimmune and inflammatory diseases. Despite this lack of success, there remains tremendous reason for excitement. Our growing understanding of the biology involved in the inflammatory response, the factors that lead to safer small molecule kinase inhibitors, and the availability of selective tool molecules for interrogating specific nodes and pathways are all pushing the field forward. This article focuses on recent developments requiring novel approaches to create safe and effective small molecule kinase inhibitors and where further work is needed to realize the promise of small molecule kinase inhibitors for patient benefit." /></meta><meta name="twitter:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0029.jpeg" /></meta><meta name="twitter:title" content="Kinase Inhibitors for the Treatment of Immunological Disorders: Recent Advances" /></meta>
        
            <meta property="og:type" content="Article" /></meta>
        

        
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.8b00667"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/ke1q~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-6ee29527b3d8ff00a106.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b00667">
            
        





































    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-12/achre4.2021.54.issue-12/20210615/achre4.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-25/aamick.2021.13.issue-25/20210630/aamick.2021.13.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-6/aapmcd.2021.3.issue-6/20210611/aapmcd.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-6/abseba.2021.7.issue-6/20210614/abseba.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-12/accacs.2021.11.issue-12/20210618/accacs.2021.11.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-12/acncdm.2021.12.issue-12/20210616/acncdm.2021.12.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-6/aelccp.2021.6.issue-6/20210611/aelccp.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-6/aeecco.2021.1.issue-6/20210611/aeecco.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-6/aewcaa.2021.1.issue-6/20210611/aewcaa.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-6/aidcbc.2021.7.issue-6/20210611/aidcbc.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-6/amlcef.2021.3.issue-6/20210607/amlcef.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-6/amclct.2021.12.issue-6/20210610/amclct.2021.12.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-25/acsodf.2021.6.issue-25/20210629/acsodf.2021.6.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-25/ascecg.2021.9.issue-25/20210628/ascecg.2021.9.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-25/ancham.2021.93.issue-25/20210629/ancham.2021.93.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-25/bichaw.2021.60.issue-25/20210629/bichaw.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-6/bomaf6.2021.22.issue-6/20210614/bomaf6.2021.22.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-12/cmatex.2021.33.issue-12/20210622/cmatex.2021.33.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-6/cgdefu.2021.21.issue-6/20210602/cgdefu.2021.21.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-12/enfuem.2021.35.issue-12/20210617/enfuem.2021.35.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-12/esthag.2021.55.issue-12/20210615/esthag.2021.55.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-6/estlcu.2021.8.issue-6/20210608/estlcu.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-25/iecred.2021.60.issue-25/20210630/iecred.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-12/inocaj.2021.60.issue-12/20210621/inocaj.2021.60.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-25/jafcau.2021.69.issue-25/20210630/jafcau.2021.69.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-6/jceaax.2021.66.issue-6/20210610/jceaax.2021.66.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-6/jceda8.2021.98.issue-6/20210608/jceda8.2021.98.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-6/jctcce.2021.17.issue-6/20210608/jctcce.2021.17.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/jmcmar.2021.64.issue-12/20210624/jmcmar.2021.64.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-12/joceah.2021.86.issue-12/20210618/joceah.2021.86.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-24/jpcafh.2021.125.issue-24/20210624/jpcafh.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-24/jpcbfk.2021.125.issue-24/20210624/jpcbfk.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-24/jpccck.2021.125.issue-24/20210624/jpccck.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-24/jpclcd.2021.12.issue-24/20210624/jpclcd.2021.12.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-6/jprobs.2021.20.issue-6/20210604/jprobs.2021.20.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-25/jacsat.2021.143.issue-25/20210630/jacsat.2021.143.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-6/jamsef.2021.32.issue-6/20210602/jamsef.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-25/langd5.2021.37.issue-25/20210629/langd5.2021.37.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-12/mamobx.2021.54.issue-12/20210622/mamobx.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-6/mpohbp.2021.18.issue-6/20210607/mpohbp.2021.18.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-12/orlef7.2021.23.issue-12/20210618/orlef7.2021.23.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-12/orgnd7.2021.40.issue-12/20210628/orgnd7.2021.40.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.8b00667&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.8b00667&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.8b00667&amp;href=/doi/10.1021/acs.jmedchem.8b00667" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2018</span><span class="cit-fg-volume">, 61</span><span class="cit-fg-issue">, 20</span><span class="cit-fg-pageRange">, 9030-9058</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/61/20" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.8b00378" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.8b01405" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Kinase Inhibitors for the Treatment of Immunological Disorders: Recent Advances</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Marian C. Bryan</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Marian C. Bryan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: +1 (650) 225-6532. E-mail: <a href="/cdn-cgi/l/email-protection#83e1f1fae2edadeee2f1eae2edc3e4e6ede6ade0ecee"><span class="__cf_email__" data-cfemail="e98b9b908887c784889b808887a98e8c878cc78a8684">[email protected]</span></a></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Marian+C.++Bryan">Marian C. Bryan</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-3138-6888" title="Orcid link">http://orcid.org/0000-0002-3138-6888</a></div></div></span></li><span class="comma-separator"> and </span><li><span><span class="hlFld-ContribAuthor">Naomi S. Rajapaksa</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Naomi S. Rajapaksa</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Naomi+S.++Rajapaksa">Naomi S. Rajapaksa</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b00667&amp;href=/doi/10.1021%2Facs.jmedchem.8b00667" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2018</span></span><span class="cit-volume">, 61</span><span class="cit-issue">, 20</span><span class="cit-pageRange">, 9030–9058</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">June 5, 2018</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>26 April 2018</li><li><span class="item_label"><b>Published</b> online</span>5 June 2018</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 25 October 2018</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.8b00667" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00667</a></div><div class="article_header-article-copyright"><strong>Copyright © 2018 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D9030%26pageCount%3D29%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DMarian%2BC.%2BBryan%252C%2BNaomi%2BS.%2BRajapaksa%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D61%26issueNum%3D20%26contentID%3Dacs.jmedchem.8b00667%26title%3DKinase%2BInhibitors%2Bfor%2Bthe%2BTreatment%2Bof%2BImmunological%2BDisorders%253A%2BRecent%2BAdvances%26numPages%3D29%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D9058%26publicationDate%3DOctober%2B2018">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.8b00667"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">5598</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">27</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.8b00667" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Kinase Inhibitors for the Treatment of Immunological Disorders: Recent Advances&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Marian&quot;,&quot;last_name&quot;:&quot;C. Bryan&quot;},{&quot;first_name&quot;:&quot;Naomi&quot;,&quot;last_name&quot;:&quot;S. Rajapaksa&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2018&quot;,&quot;month&quot;:&quot;06&quot;,&quot;day&quot;:&quot;05&quot;,&quot;issue&quot;:&quot;20&quot;,&quot;volume&quot;:&quot;61&quot;,&quot;pages&quot;:&quot;9030-9058&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.8b00667&quot;},&quot;abstract&quot;:&quot;Small molecule inhibitors targeting autoimmune and inflammatory processes have been an area of intense focus within academia and industry. Much of this work has been aimed at key kinases operating as central nodes in inflammatory signaling pathways. While this focus has led to over 30 FDA-approved small molecule kinase inhibitors, only one is currently approved for autoimmune and inflammatory diseases. Despite this lack of success, there remains tremendous reason for excitement. Our growing understanding of the biology involved in the inflammatory response, the factors that lead to safer small molecule kinase inhibitors, and the availability of selective tool molecules for interrogating specific nodes and pathways are all pushing the field forward. This article focuses on recent developments requiring novel approaches to create safe and effective small molecule kinase inhibitors and where further work is needed to realize the promise of small molecule kinase inhibitors for patient benefit.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00667&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00667" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00667&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00667" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00667&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00667" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b00667&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00667&amp;href=/doi/10.1021/acs.jmedchem.8b00667" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.8b00667" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.8b00667" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (8 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00667&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.8b00667%26sid%3Dliteratum%253Aachs%26pmid%3D29870256%26genre%3Darticle%26aulast%3DBryan%26date%3D2018%26atitle%3DKinase%2BInhibitors%2Bfor%2Bthe%2BTreatment%2Bof%2BImmunological%2BDisorders%253A%2BRecent%2BAdvances%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D61%26issue%3D20%26spage%3D9030%26epage%3D9058%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291297" title="Cell signaling">Cell signaling</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291161" title="Inflammation">Inflammation</a>,</li><li><a href="/action/doSearch?ConceptID=291754" title="Molecules">Molecules</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/61/20" title="Go to Volume 61, Issue 20"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/jmcmar.2018.61.issue-20/20181025/jmcmar.2018.61.issue-20.largecover.jpg" alt="Go to Volume 61, Issue 20"/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/medium/jm-2018-00667b_0029.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00667&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Small molecule inhibitors targeting autoimmune and inflammatory processes have been an area of intense focus within academia and industry. Much of this work has been aimed at key kinases operating as central nodes in inflammatory signaling pathways. While this focus has led to over 30 FDA-approved small molecule kinase inhibitors, only one is currently approved for autoimmune and inflammatory diseases. Despite this lack of success, there remains tremendous reason for excitement. Our growing understanding of the biology involved in the inflammatory response, the factors that lead to safer small molecule kinase inhibitors, and the availability of selective tool molecules for interrogating specific nodes and pathways are all pushing the field forward. This article focuses on recent developments requiring novel approaches to create safe and effective small molecule kinase inhibitors and where further work is needed to realize the promise of small molecule kinase inhibitors for patient benefit.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60506" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60506" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">“Immunological disorders” include allergies, autoimmune diseases, autoinflammatory syndromes, and immunological deficiencies that result from dysfunctions of the immune system. With normal immune system function, self-antigens are presented to naive T cells leading to T-cell activation, differentiation, and expansion.<a onclick="showRef(event, 'ref1 ref2 ref3 ref4 ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3 ref4 ref5 ref6">(1−6)</a> Activation is controlled by co-stimulatory molecules and soluble factors, such as cytokines. Upon activation, T cells can secrete additional cytokines to attract and activate other cells of the immune system, including macrophages, natural killer (NK) cells, and neutrophils. When this immune tolerance or unresponsiveness to self-antigens is broken, a chronic inflammatory state can persist that can also contribute to further tissue damage.<a onclick="showRef(event, 'ref1 ref2 ref3 ref4 ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3 ref4 ref5 ref6">(1−6)</a> In some cases (particularly in the inherited genetic disorders) the causative pathways are known. In most cases however causations are multifactorial and remain elusive.</div><div class="NLM_p">While these diseases and disorders are detrimental and potentially life-threatening, the past decade has seen tremendous progress in the advancement of therapies for their treatment. Approval of both large and small molecules targeting diseases such as rheumatoid arthritis (RA) and psoriatic arthritis (PA), as well as the first new approved treatment for systemic lupus erythematosus (SLE) in over 50 years, the monoclonal antibody belimumab (Benlysta)<a onclick="showRef(event, 'ref7 ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref7 ref8 ref9">(7−9)</a> have all made significant inroads in patient care. Of these, it is the large molecules in particular that have made tremendous strides in targeting autoimmune and inflammatory processes. Antibodies capable of neutralizing TNF-α, a major cytokine involved in various aspects of innate and adaptive immunity, in particular have made significant impact on RA, PA, Crohn’s disease, and ulcerative colitis.<a onclick="showRef(event, 'ref7 ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref7 ref8 ref9">(7−9)</a> Like belimumab, which binds B cell activating factor (BAFF), the anti-TNF-α antibodies and decoy receptors work by sequestering inflammation signals away from their immune receptors, thereby preventing or dampening the inflammatory signaling cascades.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Novel inhibitors remain highly desirable with small molecules enabling inhibition of intracellular targets for improved efficacy. In addition, small molecule inhibitors provide an alternative for patients who have failed on large molecule therapies or who would benefit from combination therapies where multiple pathways are involved or where synergy leads to improved efficacy.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a></div><div class="NLM_p">Over 30 FDA-approved small molecule kinase inhibitors are available for use outside of inflammatory diseases. In particular, inhibition of kinase enzymatic activity has become a powerful tool for disease treatment in the oncology setting.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> These include both reversible and irreversible inhibitors targeting receptor and nonreceptor tyrosine kinases as well as serine/threonine kinases.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Numerous clinical trials have been executed hailing only one approved drug demonstrating clear patient benefit for autoimmune diseases: tofacitinib (Xeljanz).<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> The reasons behind these failures include both efficacy and safety concerns. A majority failed to show adequate safety in preclinical or phase I clinical trials. For those that advanced to phase II, insufficient efficacy was observed such as those targeting kinases IκB kinase (IKK) and p38α. In these cases, the kinase inhibitors failed in the clinic despite encouraging animal preclinical models or proof-of-concept studies.<a onclick="showRef(event, 'ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref14 ref15">(14,15)</a> Extended exposure to inhibitors of the Janus kinase (JAK) family led to loss in response in animal models which was recapitulated in patients.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Factors leading to this escape mechanism are not fully understood, but functional adaptation and reactivation of signaling from chronic JAK1 inhibition have been reported.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a></div><div class="NLM_p">Higher doses that would fully inhibit multiple pathways for highly heterogeneous inflammatory diseases may drive greater efficacy but may also lead to broad immunosuppression.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Uncovering the right balance here has been largely empirical and varies widely depending on the drug, target pathway, half-life, and disease indication. A number of cases described below will highlight the safety challenges of targeting such critical nodes of the innate and/or adaptive immune response. There is still much hope for the field, though. Growing understanding over the past 10 years within medicinal chemistry in targeting immunologically relevant kinases, achieving ever-higher kinase selectivity, and applying emerging biological tool and techniques continues to drive excitement. Even concern around the risk of malignancy and lymphoma from TNF inhibitors and other disease-modifying antirheumatic drug treatments (DMARDs, e.g., methotrexate) in RA have not come to pass with the rate of lymphomas and other lymphoproliferative disorders being consistent between small molecule kinase inhibitor tofacitinib and other DMARDs.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Despite this, the safety bar is still very high as patients with these conditions may require lifelong treatment.</div><div class="NLM_p last">The focus of this review will center on recent advances in small molecule kinase inhibitors for autoinflammatory and immunological diseases, seeking to highlight the “<i>good</i>” (where medicinal chemistry has led to safe and effective small molecule kinase inhibitors), the “<i>bad</i>” (where chemistry has not been successful for a variety of reasons), and the “<i>ugly</i>” (where chemistry may need to go beyond the standard rule of five and competitive inhibitor paradigm to significantly benefit patients). In an effort to limit redundancy, the goal of this Perspective is not to comprehensively review all targeted kinases for autoimmune and inflammatory disease but to summarize recent advances in the field including clinical candidates and recently disclosed preclinical molecules by highlighting the progress of drug development in several (but not all) key immune signaling kinases. Given our ever-advancing knowledge of crosstalk in signaling cascades within immunology, the authors have divided sections among kinase families with the multiple and varied immunological disorders potentially impacted covered within each section.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">2.  JAK Family and the JAK/STAT Pathway</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77054" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77054" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Interfering in the JAK-STAT pathway has yielded the only approved small molecule kinase inhibitor for immunological indications. This pathway forms a critical node affecting multiple signaling pathways in both the innate and adaptive immune responses.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> The JAK family is an example of nonreceptor tyrosine kinases (or receptor-associated signaling kinases) that were first discovered in the early 1990s.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> In contrast to transmembrane receptors whose intracellular component contains kinase activity, the cytoplasmic domain of type I and type II cytokine receptors activate JAK family members upon cytokine binding to the receptor leading to JAK phosphorylation and subsequent downstream signaling (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17,18)</a> Interleukins, interferons, colony-stimulating factors, and hormone-like cytokines all exert their effects through the activation of JAK family members. Dysregulation can lead to hematologic malignancies, autoimmune disorders, and immunodeficiencies.<a onclick="showRef(event, 'ref16 ref18'); return false;" href="javascript:void(0);" class="ref ref16 ref18">(16,18)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/medium/jm-2018-00667b_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. JAK/STAT pathway. Step 1: Cytokine binding, complex formation, activation, and phosphorylation of JAK. Step 2: Recruitment and phosphorylation of STAT. Step 3: Phosphorylated STAT (p-STAT) dimerization. Step 4: Nuclear translocation and DNA binding of p-STAT dimer. Step 5: Gene transcription.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00667&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">JAK family members include Janus kinases 1, 2, and 3 (JAK1, JAK2, and JAK3, respectively) and tyrosine kinase 2 (TYK2).<a onclick="showRef(event, 'ref5 ref19'); return false;" href="javascript:void(0);" class="ref ref5 ref19">(5,19)</a> JAK1 and JAK2 and TYK2 are broadly activated by different cytokines across cell types, while JAK3 is limited to primarily hematopoietic cells.<a onclick="showRef(event, 'ref8 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref8 ref18 ref19">(8,18,19)</a> Named for the two-faced Roman God, Janus, the JAK family members all have two protein kinase domains within a single polypeptide chain, a true kinase domain and a pseudokinase domain. As the diverse roles of family members have been well reviewed, only a brief introduction to their mechanism of action will be discussed here in order to give context to recent efforts to identify selective family member inhibitors.</div><div class="NLM_p">A simplified version of the signaling cascade is shown in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>. Type I and type II cytokine receptors bind cytokines and form activated and phosphorylated homo- or heteropolymers with their JAK partners (step 1). Cytosolic DNA-binding STAT (signal transducers and activators of transcription) proteins then bind the receptor:JAK complex and are themselves phosphorylated by JAK family members (step 2). Upon phosphorylation, phosphorylated STAT (p-STAT) proteins form homo- and heteropolymers (step 3) which translocate to the nucleus (step 4). p-STAT dimer transcription factors bind specific DNA binding sites regulating gene transcription and cellular function (step 5).<a onclick="showRef(event, 'ref5 ref8 ref17 ref18 ref20'); return false;" href="javascript:void(0);" class="ref ref5 ref8 ref17 ref18 ref20">(5,8,17,18,20)</a> While <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a> represents the basic molecular mechanism underlying cytokine signaling through the JAK/STAT pathway, the reality is that JAK/STAT signaling is much more complex. Combinatorial association of JAK family members with different cytokine receptors followed by activation of specific STAT family members can involve JAK1, JAK2, JAK3, and/or TYK2 assembled into homo- or heterodimeric or multimeric complexes, with this association determined by specific receptor chains.<a onclick="showRef(event, 'ref16 ref20'); return false;" href="javascript:void(0);" class="ref ref16 ref20">(16,20)</a></div><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4">2.A.  Challenges of Targeting the JAK Family</h3><div class="NLM_p">Underlying the importance of the JAK family to biological processes are the dramatic effects seen when they are mutated, dysregulated or lost.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Significant effort has been expended into understanding the impact of inhibiting specific JAK family members. Significant safety concerns for targeting JAK family members for inhibition arose early with reported lethality in two JAK1 and JAK2 rodent knockout studies. Perinatal lethality upon JAK1 knockout was due to the kinase’s critical roles in IFN-α/β and IFN-γ signaling, mostly through heterodimer formation with either JAK2 or TYK2 and in IL-2 receptor signaling through heterodimer formation with JAK3.<a onclick="showRef(event, 'ref16 ref20'); return false;" href="javascript:void(0);" class="ref ref16 ref20">(16,20)</a> Loss of JAK2 leads to embryonic lethality via loss of definitive erythropoiesis<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> due to dysregulated hormone-like cytokine receptor signaling.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> While lethality is a dramatic response to loss of a family member, mutations and deficiencies can also have broad impact. JAK1 or JAK2-deficient humans have not been described, most likely due to immune deficiency, neurological defects (JAK1 deficient), or defective erythropoiesis (JAK2 deficient).<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></div><div class="NLM_p last">Mutations in JAK3 were the first mutations reported in the JAK family. Loss-of-function mutations of JAK3 and TYK2 profoundly inhibit immune response in both mice and humans. Inactivating JAK3 mutations give rise to severe combined immunodeficiency caused by poor lymphocyte development and proliferation through JAK3 deficiency.<a onclick="showRef(event, 'ref5 ref8 ref16 ref18'); return false;" href="javascript:void(0);" class="ref ref5 ref8 ref16 ref18">(5,8,16,18)</a> TYK2 deficiency affects type I and type II interferons through its association with JAK1 and JAK2. This leads to increased susceptibility to viral and intracellular infection in mouse knockouts.<a onclick="showRef(event, 'ref16 ref18'); return false;" href="javascript:void(0);" class="ref ref16 ref18">(16,18)</a> This is recapitulated in humans with the single patient reported with TYK2 deficiency experiencing multiple opportunistic infections of various organs from viruses, bacteria, and fungi.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> In addition, mutations also led to atopic dermatitis and elevated serum immunoglobulin E (IgE). JAK2 gain-of-function mutations are also a predominant trait in polycythemia vera patients and those suffering from myeloproliferative diseases.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Finally, mutations in the signaling proteins downstream of TYK2 and JAK1 are responsible for the immune defects seen in autosomal dominant hyper-IgE syndrome (also known as Job syndrome) characterized by abnormally high levels of IgE in the blood. All of this cross-talk highlights how JAK/STAT signaling forms a complex web critical for cellular function and cannot be segregated between innate and adaptive immunity due to the multiple different components and immune cell types involved. It was therefore of critical importance to understand the implications of small molecule inhibition of this pathway in a clinical setting.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5">2.B.  First-Generation JAK Inhibitors</h3><div class="NLM_p">While other family members are ubiquitously expressed and play key roles throughout the innate and adaptive immune system, JAK3 was an attractive preliminary target due to its restriction to hematopoeitic cells, its selective association with type I cytokine receptors with the common γ chain (γc),<a onclick="showRef(event, 'ref8 ref18'); return false;" href="javascript:void(0);" class="ref ref8 ref18">(8,18)</a> and its nonredundant function in lymphocytes.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Research targeting JAK3 culminated in the first JAK family inhibitors evaluated in the clinic and later approved as tofacitinb (<b>1</b>, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>), the first and currently only approved JAK inhibitor for immunological indications.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/medium/jm-2018-00667b_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Example inhibitors of the JAK/STAT pathway in the clinic for the treatment of immunological diseases or approved by the FDA. Atoms participating in binding to the hinge region of the active site are shown in red with dashed lines for putative hydrogen bonds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00667&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In order to frame discussions around how JAK family inhibitors build on and depart from this first-generation inhibitor, the cocrystal structure of tofacitinib is highlighted briefly in this paragraph and shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>. Structural features of the JAK family as well as the discovery of tofacitinib and first-generation JAK inhibitiors have been reviewed previously.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Briefly, hinge binding is through a two-pronged interaction between the pyrole NH and the pyrimidine N1 with the backbone of hinge residues Tyr904 and Glu903 in JAK3.<a onclick="showRef(event, 'ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref21 ref22">(21,22)</a> This is a common motif among JAK inhibitors. The C6 hydrogen points back toward gatekeeper residue Met902 and a Met for all members of the JAK family. The aminopiperidine presents the acyl nitrile under the P-loop cleft while the piperidine methyl groups helps maximize interaction with a hydrophobic pocket.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/medium/jm-2018-00667b_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Tofacitinib (<b>1</b>) cocrystallized with JAK3 (3LXK).<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Hydrogen bonds to hinge residues Tyr904 and Glu903 and a conserved water are presented as black dashes. In addition, gatekeeper residue Met902 is highlighted.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00667&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Much of the interest in this first generation inhibitor was due to its impressive efficacy in preclinical models. Tofacitinib was advanced into clinical development based on the prevention of cartilage damage in both collagen-induced and adjuvant-induced arthritis models in rodents.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Once in RA patients, tofacitinib was effective as a monotherapy or in combination with the standard of care, methotrexate. It was tofacitinib’s efficacy in distinct patient populations such as methotrexate nonresponders that generated the most excitement.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> In 2012, tofacitinib was approved by the FDA for the treatment of RA<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> and remains in the clinic for additional indications including psoriatic arthritis (NCT01976364), SLE (NCT02535689), and alopecia (NCT02812342). Further exploration in RA is ongoing (NCT02092467, NCT02831855, NCT02321930).</div><div class="NLM_p">As the JAK family functions at critical nodes in the immune response, there was significant interest in the safety and tolerability of tofacitinib in patients. Safety signals including overall risk of infection were similar for patients receiving either monotherapy or in combination with nonbiologics for RA.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Some of the safety concerns, including increased incidence of infection as well as dose-dependent neutropenia and significant lymphopenia, could be related to both JAK1 and inhibition of other kinases.<a onclick="showRef(event, 'ref18 ref20 ref25'); return false;" href="javascript:void(0);" class="ref ref18 ref20 ref25">(18,20,25)</a> While touted as a JAK3 inhibitor, tofacitinib, like many first generation kinase inhibitors, is not a single-kinase inhibitor. The molecule exhibits a high degree of broad kinome selectivity but is in fact a pan-JAK-inhibitor with kinase enzymatic inhibition values ranging from equipotent among JAK family members to a small degree of TYK2 selectivity (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).<a onclick="showRef(event, 'ref8 ref23'); return false;" href="javascript:void(0);" class="ref ref8 ref23">(8,23)</a> Potency reported for cellular assays appear more consistent among reports, and tofacitinib is active in multiple cellular readouts for p-STAT signaling through various JAK1- and JAK3-mediated heterodimers.<a onclick="showRef(event, 'ref5 ref23'); return false;" href="javascript:void(0);" class="ref ref5 ref23">(5,23)</a></div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Reported Enzymatic Potency for JAK Family Members for Disclosed Molecules</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="4" align="center">enzyme assay IC<sub>50</sub> (nM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">JAK1</th><th class="colsep0 rowsep0" align="center">JAK2</th><th class="colsep0 rowsep0" align="center">JAK3</th><th class="colsep0 rowsep0" align="center">TYK2</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b><a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a></td><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left">77</td><td class="colsep0 rowsep0" align="left">55</td><td class="colsep0 rowsep0" align="left">489</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b><a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left"><1</td><td class="colsep0 rowsep0" align="left">5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b><a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a></td><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="left">9</td><td class="colsep0 rowsep0" align="left">487</td><td class="colsep0 rowsep0" align="left">30</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b><a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a></td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">7</td><td class="colsep0 rowsep0" align="left">787</td><td class="colsep0 rowsep0" align="left">61</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b><a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></td><td class="colsep0 rowsep0" align="left">105<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">1002<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">405<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b><a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></td><td class="colsep0 rowsep0" align="left">360</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">75</td><td class="colsep0 rowsep0" align="left">66</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b><a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a></td><td class="colsep0 rowsep0" align="left">112</td><td class="colsep0 rowsep0" align="left">619</td><td class="colsep0 rowsep0" align="left">74.4</td><td class="colsep0 rowsep0" align="left">>10K</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b><a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a></td><td class="colsep0 rowsep0" align="left">363</td><td class="colsep0 rowsep0" align="left">2400</td><td class="colsep0 rowsep0" align="left">>10k</td><td class="colsep0 rowsep0" align="left">2600</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b><a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></td><td class="colsep0 rowsep0" align="left">29</td><td class="colsep0 rowsep0" align="left">803</td><td class="colsep0 rowsep0" align="left">>10k</td><td class="colsep0 rowsep0" align="left">1253</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b><a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a></td><td class="colsep0 rowsep0" align="left">43</td><td class="colsep0 rowsep0" align="left">120</td><td class="colsep0 rowsep0" align="left">2300</td><td class="colsep0 rowsep0" align="left">4700</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b><a class="ref internalNav" href="#t1fn1" aria-label="a">a</a><sup>,</sup><a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a></td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">68<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">280</td><td class="colsep0 rowsep0" align="left">12</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last"><i>k</i><sub>i</sub> values reported.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Estimated <i>k</i><sub>i</sub> using reported JAK1 selectivity index.</p></div></div></div><div class="NLM_p">The lack of JAK3 specificity is not surprising given the high sequence homology among JAK family members in the ATP binding domain (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>).<a onclick="showRef(event, 'ref5 ref21'); return false;" href="javascript:void(0);" class="ref ref5 ref21">(5,21)</a> The crystal structures have only recently become available, highlighting only a small handful of subtle amino acid differences across the JAK family in the region where tofactinib binds.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Most larger changes do not face into the binding pocket and are therefore not involved in tofacitinib binding (e.g., Asn832 and Arg830 in JAK3 versus His and Glu in JAK1 and TYK) or are understated (Ala966 in JAK3 versus Gly in other members, Ile960 in TYK2 versus Val in others, etc.).</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/medium/jm-2018-00667b_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. X-ray cocrystal structures with sequence alignment for JAK1 (green, 3EYG), JAK2 (magenta, 3FUP), JAK3 (blue, 3LXK), and TYK2 (orange, 5WAL).<a onclick="showRef(event, 'ref5 ref21 ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref5 ref21 ref32 ref33">(5,21,32,33)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00667&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Tofacitinib shows greater inhibitory effect against JAK1/3-dependent processes like IL-2-dependent T cell proliferation in a cellular setting.<a onclick="showRef(event, 'ref20 ref25'); return false;" href="javascript:void(0);" class="ref ref20 ref25">(20,25)</a> Inhibition of other JAK family members, particularly JAK2, is most likely the cause of the neutropenia. Inhibition of JAK2 may lead to anemia and other hematologic toxicities due to its role in hematopoiesis.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> The severity of these findings can limit dose escalation.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> These safety concerns, including increased incidence of infection and dose-dependent neutropenia and significant lymphopenia, may lessen tofacitinib’s applicability to certain indications requiring additional target coverage which may be related to kinase selectivity.<a onclick="showRef(event, 'ref18 ref20 ref25'); return false;" href="javascript:void(0);" class="ref ref18 ref20 ref25">(18,20,25)</a> Treatment in some indications is not being pursued further, such as in Crohn’s disease and psoriasis where either lack of efficacy or potential safety concerns hamper future developmennt.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> The other JAK3 inhibitor currently in the clinic for immunological disorders, peficitinib (<b>2</b>) from Astellas, has a similar selectivity profile to tofacitinib<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> and is currently in phase 3 for RA (NCT01638013).</div><div class="NLM_p">In addition to tofacitinib, there is one other JAK inhibitor approved for patient treatment by the FDA, though not for immunological disorders: ruxolitinib (<b>3</b>, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). This inhibitor of JAK1 and JAK2 is currently approved for myelofibrosis and polycythemia vera, where JAK2 gain-of-function mutations are common.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Others, though, are in development.<a onclick="showRef(event, 'ref4 ref35'); return false;" href="javascript:void(0);" class="ref ref4 ref35">(4,35)</a> Pyrolopyrimidine baricitinib (<b>4</b>) is similar in structure to <b>3</b>, both replacing the aminopiperidine of <b>1</b> with a pyrazole functionalized with a cyanoethyl moiety. In a phase III study, patients with RA and inadequate response to biologic DMARDs showed clinical improvement upon receiving baricitinib.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></div><div class="NLM_p">In the cases of ruxolitinib and baricitinib, the number of safety concerns reported including thrombocytopenia are potentially related to their JAK2 inhibition.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Fedratinib (<b>5</b>), a selective JAK2 inhibitor,<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> was placed under a clinical hold for safety concerns related to Wernicke’s encephalopathy.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Development in the oncology space is still being pursued for JAK2 inhibitors including ruxolitinib and BMS-911543 (<b>6</b>), a recently disclosed and highly selective JAK2 inhibitor for myeloproliferative neoplasms.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Ruxolitinib remains under clinical investigation for a number of oncologic and bone marrow disorders as well as for atopic dermatitis and alopecia areata but only as a topical cream for these immunological disorders (NCT03011892, NCT03257644, NCT02553330). Topical treatment may be ideal for ruxolitinib in the immunology setting as this is less likely to cause systemic adverse effects.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></div><div class="NLM_p last">TYK2 is another JAK family kinase involved in regulating the immune response. TYK2 function has been associated with Th1 and Th17 cell differentiation and activation through its essential role in IL-12 and IL-23 signaling. The Th1 and Th17 pathways have been implicated in the pathogenesis of psoriasis and IBD and an IL-12/IL-23 antibody (ustekinumab) is already approved for psoriasis and is in clinical development for other indications. As such TYK2 is a promising target for therapeutic intervention.<a onclick="showRef(event, 'ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref40 ref41">(40,41)</a> While several research programs have reported efforts toward selectively targeting TYK2 including multiple patent filings by Takeda, Roche/Genentech, and Array Biopharma, no highly selective TYK2 molecules have advanced into the clinic.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Pfizer’s PF-06700841 (structure undisclosed), which targets TYK2 and JAK1, is currently under investigation for a number of indications in the clinic including chronic plaque psoriasis (NCT02969018), alopecia areata (NCT02974868), and ulcerative colitis (UC) (NCT02958865), all in phase II.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7">2.C.  Advances in Selective JAK Inhibitors</h3><div class="NLM_p">As a result of our increasing knowledge of the importance of kinase selectivity for safety along with the desire to understand the roles and impact of the individual JAK family members on disease, a new wave of more selective JAK inhibitors have been recently reported.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> These include inhibitors of both JAK1 and JAK3. Decernotinib (<b>7</b>, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) was recently disclosed as a more JAK3 selective molecule.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> The pyrolopyridine is a potent inhibitor of JAK3 with mild selectivity over other JAK family members in enzymatic assays but improved selectivity over other JAK family members in cellular assays relative to <b>1</b> (<b>7</b>, JAK1/2/TYK2-mediated IL-6 p-STAT3 cell IC<sub>50</sub> > 11 200 nM vs JAK3/1 mediated IL-2 p-STAT3 cell IC<sub>50</sub> = 99 nM (113×); <b>1</b>, JAK1/2/TYK2-mediated IL-6 p-STAT3 cell IC<sub>50</sub> = 666 nM vs JAK3/1-mediated IL-2 p-STAT3 cell IC<sub>50</sub> = 30 nM (22×)).<a onclick="showRef(event, 'ref5 ref44'); return false;" href="javascript:void(0);" class="ref ref5 ref44">(5,44)</a> The differences in magnitude of cellular potency shift compared to biochemical potency are well-known across JAK family members and have only recently been exploited to drive our understanding of selectivity.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Members display different affinities for ATP with <i>K</i><sub>M</sub> values ranging from 4 to 40 μM. This has a significant impact on the enzyme to cell inhibition translation. Elegant work from Pfizer compared assay results for several JAK inhibitors across biochemical assays in the presence of ATP at 1 mM or the family member’s <i>K</i><sub>M</sub> for ATP and in their primary cellular assays. The resulting analysis illustrated the importance of determining biochemical IC<sub>50</sub> values under a physiologically relevant ATP concentration in order to properly assess compound selectivity and to better predict cellular function.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Decernotinib progressed through phase II where it reduced the signs and symptoms of RA in patients in combination with a DMARD at 12 weeks (NCT01784938).<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Further RA studies have been completed (NCT01590459), but results have not been disclosed and Vertex has not listed further development in their more recent pipeline disclosures.</div><div class="NLM_p">More selective JAK1 molecules recently reported include triazolopyridine filgotinib (<b>8</b>, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> This molecule is described as JAK2-sparing by design with modest selectivity over other family members that increases in a cellular setting.<a onclick="showRef(event, 'ref5 ref34 ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref5 ref34 ref47 ref48">(5,34,47,48)</a> While filgotinib may be less potent than other JAK1 inhibitors with reported IC<sub>50</sub> values ranging from 10 nM to >300 nM depending on ATP concentration in the assay,<a onclick="showRef(event, 'ref5 ref47'); return false;" href="javascript:void(0);" class="ref ref5 ref47">(5,47)</a> the compound nonetheless showed efficacy in a rat collagen-induced arthritis (CIA) model with significant reduction in clinical score seen at levels well below the measured whole blood IC<sub>50</sub>. Additional coverage is provided by a JAK1-selective metabolite <b>13</b> wherein the amide bond is cleaved by a carboxylesterase to unmask the free amine (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). While less potent than the parent, amine <b>13</b> exhibits higher exposure leading to relatively long duration of JAK1 inhibition following filgotinib dosing.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> Compound <b>8</b> is currently recruiting for multiple phase II and phase III studies across indications including Crohn’s disease (NCT02914600, NCT02914561), UC (NCT03201445, NCT02914535, NCT02914522), RA (NCT02889796, NCT03025308, NCT02886728, NCT02873936), cutaneous lupus erythematosus (CLE, NCT03134222), and psoriatic arthritis (NCT03101670). Speaking to the benefit of selective JAK inhibition, early side effects observed with other less selective JAK inhibitors such as anemia (presumedly JAK2-related) or neutropenia were not observed.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Whether this is due to its improved JAK1 selectivity or a result of weakened JAK activity in general is unclear.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/medium/jm-2018-00667b_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Metabolism of JAK1-selective molecule filgotinib by carboxylesterase leads to active metabolite <b>13</b>. IC<sub>50</sub> values correspond to inhibition of cytokine-induced STAT phosphorylation in CD4<sup>+</sup> cells or CD33<sup>+</sup> cells in human whole blood.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00667&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Other JAK1-selective molecules reported in the literature include PF-04965842 (<b>9</b>), itacitinib from Incyte (<b>10</b>), imidazopyrrolopyridines <b>11</b> from Abbvie, and <b>12</b> from Genentech (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).<a onclick="showRef(event, 'ref30 ref31 ref43 ref51'); return false;" href="javascript:void(0);" class="ref ref30 ref31 ref43 ref51">(30,31,43,51)</a> PF-04965842, under development by Pfizer, is undergoing clinical investigation in two phase III studies in atopic dermatitis (NCT03422822, NCT03349060) as well as phase I (NCT03386279). Cyclobutane sulfonamide <b>9</b> had previously terminated a phase II study in moderate to severe psoriasis (NCT02201524) for portfolio reasons despite results suggesting the molecule was well tolerated and improved patient symptoms.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> While noting selectivity of >20× relative to JAK2 and >100× relative to other family members, the discovery story of itacitinib has yet to be publicly disclosed and currently there are no trials described for immunological disorders.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> Lastly, two imidazopyrrolopyridines have been reported: upadacitinib (<b>11</b>, ABT-494) and compound <b>12</b> from Genentech.<a onclick="showRef(event, 'ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref30 ref31">(30,31)</a></div><div class="NLM_p last">Compound <b>11</b> was covered extensively in a patent from Abbvie in 2015 where they profiled the molecule in various cellular and in vivo settings including PK, efficacy, and preliminary phase I study results.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> While <b>11</b> is reported as 43 nM in the biochemical assay when performed with 0.1 mM ATP, the potency shifts greater than an order of magnitude to <3 nM when the concentration of ATP is lowered. Good selectivity over >60 kinases was also noted though the data were not included.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> It is interesting to note that compound <b>11</b> potency and JAK family member selectivity were improved when analyzed in various JAK-mediated cellular assays. These include 74-fold selectivity over JAK2 (8 nM vs 608 nM for phospho-STAT6 in TF1 cells) compared to tofacitinib (<b>1</b>) which showed 24-fold selectivity over JAK2 (44 nM vs 1110 nM for phospho-STAT6 in TF1 cells).<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Upadacitinib has been reported as well as tolerated by patients under clinical evaluation and continues to be evaluated in phase II and phase III for a range of autoinflammatory and immune diseases including Crohn’s disease (NCT02782663, NCT03345849, NCT03345823, NCT03345836), atopic dermatitis (NCT02925117), ankylosing spondylitis (NCT03178487), ulcerative colitis (NCT02819635, NCT03006068), psoriatic arthritis (NCT03104374, NCT03104400), and RA (NCT02720523, NCT02955212, NCT02706873, NCT02706951, NCT02049138, NCT02629159, NCT02706847, NCT02675426). Genentech reported imidazopyrrolopyridine <b>12</b> with >30× selectivity over JAK2 (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> This enhanced selectivity is attributed to a hydrogen bond between the hydroxyl moiety on <b>12</b> and glutamic acid E966 which is an aspartic acid in JAK2 and hypothesized to make a weaker water-mediated interaction. Tricycle <b>12</b> was highly efficacious in a rat CIA efficacy model though no further development has been reported.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8">2.D.  Alternative JAK Modalities</h3><div class="NLM_p">Given the difficulties in generating exquisitely selective inhibitors for individual JAK family members, a number of strategies are being explored. One potential is to exploit modalities to avoid systemic safety concerns, such as tissue-targeted formulations as mentioned above which would be useful for alopecia, psoriasis, IBD, and asthma. Due to the importance of JAK family members in the signaling of multiple cytokines involved in asthma, another route being explored is inhaled administration.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> In murine chronic house dust mite models of asthma, the pan-JAK inhibitor VR588<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> has demonstrated potent anti-inflammatory activity. A proof-of-concept phase I trial evaluating the molecule (structure not disclosed) on airway epithelial cells of patients with severe asthma has been completed (NCT02740049), but results have not been disclosed. Pfizer has also reported on their pan-JAK inhibitor PF-06263276 for inhaled and topical delivery (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>).<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> In this report, the in vitro and in vivo potency, pharmacokinetic, and safety profile demonstrated that compound <b>14</b> is potentially well suited for use as an inhaled or topical therapy, through direct administration to the lungs or skin, while avoiding any systemic-based JAK inhibition.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a></div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/medium/jm-2018-00667b_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Chemical and cocrystal structures of pan-JAK inhibitor PF-06263276 (<b>14</b>) and JAK3 covalent inhibitor PF-06651600 (<b>15</b>).<a onclick="showRef(event, 'ref54 ref56'); return false;" href="javascript:void(0);" class="ref ref54 ref56">(54,56)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00667&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">There is also a particularly interesting case for targeting covalent inhibition of JAK3 due to the presence of Cys909, which is a Ser in other family members (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>).<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> Reported irreversible inhibitors have been able to sufficiently block the development of inflammation in rodent RA models without effects on hematopoiesis.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> These contain PF-06651600 (<b>15</b>), whose discovery was previously disclosed.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> The pyrrolopyrimidine acrylamide showed superior PK properties to previously described JAK3 covalent inhibitors and exhibited strong anti-inflammatory properties in two rodent models of RA and multiple sclerosis (MS), suggesting that inhibition of JAK3 alone is sufficient for intervention in inflammatory and autoimmunes diseases. As such, this compound is currently being investigated in phase II for UC (NCT02958865), alopecia areata (NCT02974868), and RA (NCT02969044).</div><div class="NLM_p">Finally, targeting either the pseudokinase domain (JH2) or other allosteric sites is an approach that could yield inhibitors with improved selectivity and overcome resistance to JAK inhibitors due to target-specific mutations in the ATP-binding site.<a onclick="showRef(event, 'ref16 ref18 ref40 ref57'); return false;" href="javascript:void(0);" class="ref ref16 ref18 ref40 ref57">(16,18,40,57)</a> As previously noted, all JAK family members contain both a kinase and pseudokinase domain. Targeting the pseudokinase domain provides an alternative enticing area for small molecule inhibition through the pseudokinase domain’s role in inhibiting the functional protein kinase domain. The structures of the pseudokinase and kinase domains of several JAK family members have been reported<a onclick="showRef(event, 'ref57 ref58'); return false;" href="javascript:void(0);" class="ref ref57 ref58">(57,58)</a> along with small molecule binders. These include JNJ-7706621 (<b>16</b>), which targets the pseudokinase domain for JAK2,<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> and imidazolopyridazine <b>17</b> was recently described by BMS, which targets the pseudokinase domain of TYK2 (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>).<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Potential development of covalent allosteric inhibitors to the pseudokinase domain has also been hypothesized around indole <b>18</b> where a covalent warhead is attached to the piperidine for the selective targeting of TYK2 cysteine C736.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> Whether these alternative modalities will suffer from the loss in response that has been seen with chronic exposure to JAK inhibitors in animal models and recapitulated in patients remains to be seen.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a></div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/medium/jm-2018-00667b_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Reported pseudokinase inhibitors of JAK family members.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00667&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">3.  SYK, BTK, and ITK: T-Cells, B-Cells, and Beyond</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02201" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02201" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">T cell receptors (TCRs), B cell receptors (BCRs), and Fc receptors (FcRs), which are collectively termed classical immunoreceptors, signal by a conceptually similar mechanism. Like the JAK-STAT pathway for TCRs, B cells rely on signaling cascades through nonreceptor tyrosine kinases to mediate inflammatory responses in their role as key players in adaptive immunity. Three main protein families, the Src family of kinases like Lyn, spleen tyrosine kinase (SYK), and the TEC-family kinase Bruton’s tyrosine kinase (BTK; <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>), have been identified and targeted for both their immune and nonimmune functions.<a onclick="showRef(event, 'ref13 ref61 ref62'); return false;" href="javascript:void(0);" class="ref ref13 ref61 ref62">(13,61,62)</a> Despite the significant interest in all of these three protein families, we will only focus on those currently being pursued clinically for immunologic intervention: SYK and BTK.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/medium/jm-2018-00667b_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Role of SYK in BCR and FcγR1 signaling.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00667&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10">3.A.  Spleen Tyrosine Kinase (SYK)</h3><div class="NLM_p">SYK is a member of the Src family that has attracted significant attention in the context of immunological disorders.<a onclick="showRef(event, 'ref63 ref64'); return false;" href="javascript:void(0);" class="ref ref63 ref64">(63,64)</a> Primarily expressed in hematopoietic cells, such as B cells, monocytes, mast cells, and neutrophils, SYK is involved in several immunoreceptor signaling pathways.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> It is also expressed in nonimmune cells such as osteoclasts, where it plays a role in bone resorption. Two examples of signaling pathways involving SYK, one with BCRs and the other with FcRs, are summarized in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>. Ligand engagement of cell surface immunoreceptors induces phosphorylation of two tyrosine residues on the short peptide sequences known as immunoreceptor tyrosine-based activation motifs (ITAMs) in the cytosolic portion of the receptor or associated transmembrane adaptor protein. This phosphorylation step is generally carried out by a Src family kinase (e.g., Lyn in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). SYK binding to the phosphorylated ITAMs leads to SYK being phosphorylated by Lyn.</div><div class="NLM_p">SYK has several phosphorylation sites and, through selective phosphorylation, has the flexibility to interact with a large diversity of effector molecules and trigger inflammatory events in multiple cell types.<a onclick="showRef(event, 'ref62 ref63'); return false;" href="javascript:void(0);" class="ref ref62 ref63">(62,63)</a> ZAP70, a homolog of SYK expressed in T cells, plays a similar role in TCR signaling (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>). Because SYK is a key component in various signaling cascades, it is considered a “master regulator” of inflammatory responses.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> As such, there is potentially a greater advantage to inhibiting SYK, which is upstream in cell signaling pathways.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a></div><div class="NLM_p">As described earlier in the JAK family, there is a concern with inhibiting such crucial and ubiquitous messengers. A tremendous amount of research has studied the impact of SYK inhibition with murine genetic SYK knockouts initially leading to safety concerns. Homozygous <i>syk</i><sup><i>-</i></sup>/<i>syk</i><sup><i>-</i></sup> knockout mice were perinatal lethal due to vascular lymphatic shunting.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> Generation of SYK-deficient bone marrow chimeric mice by transplanting <i>syk</i><sup><i>-</i></sup>/<i>syk</i><sup><i>-</i></sup> fetal liver cells to lethally irradiated wild type mice resulted in viable animal models.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> The chimeric mice did not have the developmental defects in the lymphatic system and were found to effectively ablate SYK expression in the hematopoietic compartment.<a onclick="showRef(event, 'ref65 ref67'); return false;" href="javascript:void(0);" class="ref ref65 ref67">(65,67)</a> Importantly, these mice showed no signs of arthritis upon treatment with arthritogenic serum in a passive transfer model.<a onclick="showRef(event, 'ref65 ref67'); return false;" href="javascript:void(0);" class="ref ref65 ref67">(65,67)</a> Additional mouse studies demonstrated that SYK is involved in a variety of disease processes, including RA, allergic asthma and rhinitis, SLE and immune thrombocytopenic purpura.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> Together, these studies have provided ample evidence that SYK inhibition may be a safe and effective means of treating several immunological diseases.</div><div class="NLM_p">With such critical importance, it is unsurprising that the discovery and development of SYK inhibitors have been a very active area of research. While a SYK-selective inhibitor has yet to be approved, a number of them have entered clinical evaluation. Rigel Pharmaceuticals has brought forward multiple compounds centered on a diaminopyrimidine scaffold (<b>19</b>–<b>21</b>, <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>).<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> R-343 (<b>19</b>) was one of the earliest clinical candidates and, while promising phase I clinical trials, did not achieve expected end points upon further evaluation and was discontinued.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> R-406 (<b>21</b>) is the metabolite of prodrug fostamatinib (<b>20</b>), which was approved by the FDA for adult patients with chronic immune thrombocytopenia in April 2018. In this example, the phosphate is rapidly and extensively cleaved to give <b>21</b>, an ATP-competitive inhibitor that binds to the receptor in a U-shape conformation and interacts with the hinge through the pyrimidine N1 and N2 on the linker.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a></div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/medium/jm-2018-00667b_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Select clinical SYK inhibitors. Areas of the molecule that participate in binding the hinge region are shown in red with dashed lines for putative hydrogen bonds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00667&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">While the prodrug discovery efforts leading to <b>20</b> have not been disclosed, its PK profile has been reported.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> Phosphate <b>20</b> overcomes the challenge of low aqueous solubility of <b>21</b>, while the PK profile of the active metabolite potentially allows for once daily or twice daily oral administration of fostamatinib.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> Both <b>20</b> and <b>21</b> have been evaluated in several animal models where they suppressed joint swelling and bone erosion in preclinical arthritic rat models.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> On the basis of these findings, both were advanced into clinical trials for multiple indications. Two phase 2 trials showed <b>20</b> afforded clinically significant improvements in RA patients over a DMARD background (NCT00326339 and NCT00665925).<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> Despite these promising results, several subsequent studies demonstrated inferior response or limited/no efficacy with fostamatinib.<a onclick="showRef(event, 'ref71 ref72 ref73'); return false;" href="javascript:void(0);" class="ref ref71 ref72 ref73">(71−73)</a></div><div class="NLM_p">While fostamatinib displayed insufficient efficacy in patients, it was well tolerated in phase I and II trials. The most common treatment-related adverse events were gastrointestinal intolerance, neutropenia, and elevated liver transaminases, resolving upon discontinuation of treatment. This may be due to off-target kinase inhibition by <b>20</b>, <b>21</b>, or both. Although initially presented as SYK-selective inhibitors, many subsequent reports have demonstrated that they are actually promiscuous and inhibit some kinases to an even greater extent than SYK.<a onclick="showRef(event, 'ref74 ref75'); return false;" href="javascript:void(0);" class="ref ref74 ref75">(74,75)</a> For example, it is known that <b>21</b> has inhibitory potency against the JAK pathway.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> This poor kinase selectivity may be both beneficial and problematic toward therapeutic benefit as well as impacted dose-limiting adverse events in clinical trials.<a onclick="showRef(event, 'ref74 ref75'); return false;" href="javascript:void(0);" class="ref ref74 ref75">(74,75)</a> On the basis of the hypothesis that more selective molecule will be advantageous, many other discovery programs have prioritized identification of SYK inhibitors with improved kinase selectivity. One such program culminated in entospletinib (<b>22</b>, <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>) from Gilead Sciences, which showed significantly improved kinase selectivity.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a></div><div class="NLM_p">Crystallographic studies reveal similar binding poses for both <b>21</b> and <b>22</b>. The authors hypothesized that pyrimidine <b>21</b> has a greater degree of rotational freedom allowing it to adopt alternative conformations that can interact with several kinases, and these are not accessible to the more conformationally restricted <b>22</b> (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>).<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> Compound <b>22</b> is currently in clinical trials for several hematological malignancies and in the recruiting stage for a phase 2 trial in chronic graft versus host disease (NCT02701634). Another SYK inhibitor, MK-8457 (<b>23</b>, <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>), was also evaluated in two phase II RA trials (NCT01651936, NCT01569152).<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> Both were terminated in 2013 and 2014 due to serious infections. Other SYK inhibitors are being evaluated in the oncology setting including PRT062607 and cerdulatinib (<b>24</b> and <b>25</b>, <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>) which is reported to be a dual SYK/JAK inhibitor (NCT01994382).<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a></div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/medium/jm-2018-00667b_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Overlay of first generation SYK inhibitor R406 (<b>21</b>, magenta, 3FQS) and entospletinib (<b>22</b>, blue, 4PUZ).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00667&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In addition to those described above, multiple SYK inhibitors with largely undisclosed structures have recently undergone clinical evaluation in patients for immunological disorders. These include GlaxoSmithKline’s GSK2646264, Hutchison MediPharma Limited’s HMPL-523, Gilead’s GS-9876, and Ascena Biopharmaceuticals’ ASN002 (<b>26</b>, <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>). GSK2646264 is currently under recruitment for a phase I trial in CLE (NCT02927457) using topical application after completion of a phase I for urticaria (NCT02424799), also as a topical cream. Neither the discovery stories or the results from this or SYK inhibitor HMPL-523’s phase I trial in RA (NCT02105129) have been disclosed.</div><div class="NLM_p">A recent presentation of preclinical data on GS-9876 suggests that the compound is a highly selective SYK inhibitor and demonstrates efficacy in rat collagen-induced arthritis models.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> Clinical trials are currently planned or recruiting in adults with impaired renal function (NCT02959138), lupus membranous neuropathy (NCT03285711), Sjorgren’s syndrome (NCT03100942), and CLE (NCT03134222). In a number of these cases, GS-9876 is being investigated in combination with JAK and/or BTK inhibitors. Lastly, pyrimidopyridazinone <b>26</b>, a dual JAK/SYK inhibitor, was being evaluated in a phase I trial in subjects with atopic dermatitis (NCT03139981).<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> The study has been recently completed, and we look forward to the results.</div><div class="NLM_p last">Early clinical and preclinical successes of <b>20</b>/<b>21</b> have validated SYK as a target for inhibition in the context of immunological diseases. However, the revelation that they are poorly selective has made the interpretation of those results challenging. Additionally, while the treatment-associated adverse events associated with fostamatanib have been suggested to arise from off-target kinase inhibition, the serious infections resulting from treatment with <b>23</b> call into question the selectivity profile of that compound along with the safety of inhibiting SYK. These observations have compelled some to develop more highly selective SYK inhibitors and others to intentionally tune broader inhibitory activity against multiple kinases. Both the combination approach being investigated with GS-9876 and the dual JAK/SYK approach of compound <b>26</b> are very interesting and speak to the antithesis of single kinase inhibition for disease modulation. Indeed, the assumption that improved selectivity will lead to higher likelihood of safety and efficacy is being challenged with JAK family inhibitors.<a onclick="showRef(event, 'ref17 ref19'); return false;" href="javascript:void(0);" class="ref ref17 ref19">(17,19)</a> With a rich diversity of SYK inhibitors entering the clinic representing varying degrees of kinase selectivity, the results of these trials will have very interesting implications far beyond SYK, likely bringing some clarity and further questions.</div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11">3.B.  Bruton’s Tyrosine Kinase (BTK)</h3><div class="NLM_p">The key kinase in the BCR signaling cascade is Bruton’s tyrosine kinase (BTK), a nonreceptor cytoplasmic tyrosine kinase in the Tec family.<a onclick="showRef(event, 'ref61 ref80 ref81'); return false;" href="javascript:void(0);" class="ref ref61 ref80 ref81">(61,80,81)</a> In addition to BTK the Tec family includes bone marrow kinase (Bmx), interleukin-2 inducible T cell kinase (ITK), resting lymphocyte kinase (RLK), tyrosine kinase expressed in hepatocellular carcinoma (TEC), and Txk. Tec kinases are mainly expressed in hematopoietic cells, and BTK expression has been found in B cells, marrow-derived stem cells, mast cells, monocytes/macrophages, neutrophils, dendritic cells, erythroid cells, platelets, plasmablasts, hematopoietic stem cells, multipotent progenitors, and developing myeloid cells. However, it is not expressed or downregulated in plasma cells, natural killer cells, or T cells.<a onclick="showRef(event, 'ref81 ref82'); return false;" href="javascript:void(0);" class="ref ref81 ref82">(81,82)</a></div><div class="NLM_p">As shown in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>, BTK acts downstream of SYK where it amplifies signals from ITAMs to phospholipase C γ 2 (PLCγ2), which in turn mobilizes Ca<sup>2+</sup> and activates NF-κB. BTK also plays a role in TLR and FcR signaling in myeloid cells.<a onclick="showRef(event, 'ref19 ref81 ref82 ref83'); return false;" href="javascript:void(0);" class="ref ref19 ref81 ref82 ref83">(19,81−83)</a> In so doing, BTK regulates several phases of the cell life cycle including development, differentiation, proliferation, and apoptosis of B-lineage cells. As a consequence of its distribution and key signaling roles, alterations in BTK synthesis, expression, or activation are related to different human diseases.</div><div class="NLM_p">BTK is overexpressed or hyperactivated in a number of autoimmune diseases and cancers.<a onclick="showRef(event, 'ref84 ref85'); return false;" href="javascript:void(0);" class="ref ref84 ref85">(84,85)</a> Studies using BTK deficient and transgenic mice as well as BTK inhibitors demonstrate the central role BTK plays in these disease associated pathways and cellular responses. BTK-deficient dendritic cells show impaired secretion of inflammatory cytokines, and BTK-deficient mast cells are impaired in degranulation in response to FcR activation.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Transgenic animal models have shown overexpression of BTK is related to spontaneous germinal center formation in lymph nodes, autoantibody production, and SLE-like autoimmune pathology. Inhibitors of BTK have shown activity in both BCR and FcγR-driven models of autoimmune disease, and BTK-deficient mice are also protected from SLE and autoimmune arthritis, even if associated inflammatory responses are not blocked.<a onclick="showRef(event, 'ref80 ref81 ref83 ref85'); return false;" href="javascript:void(0);" class="ref ref80 ref81 ref83 ref85">(80,81,83,85)</a> The role of BCRs and B cell signaling in autoimmune disease and the knowledge that BTK-deficient patients can live relatively normal lives with regular immunoglobin transfusions suggest that BTK inhibitors may be useful in treating a variety of immunological disorders including RA, SLE, MS as well as B cell lymphomas.<a onclick="showRef(event, 'ref19 ref61 ref83 ref85'); return false;" href="javascript:void(0);" class="ref ref19 ref61 ref83 ref85">(19,61,83,85)</a> BTK inhibitors are currently in the clinic for a number of these disorders.</div><div class="NLM_p">With the strong interest in BTK as a therapeutic target, there has been much interest in both its structure and activation. Structural elucidation reveals five domains: the amino-terminal pleckstrin homology domain, a Tec homology domain, two Src homology domains (SH2 and SH3), and a C-terminal catalytic domain containing tyrosine kinase activity.<a onclick="showRef(event, 'ref83 ref84 ref85'); return false;" href="javascript:void(0);" class="ref ref83 ref84 ref85">(83−85)</a> The first domain contains sites for interaction with transcription factors and with phosphatidylinositol 3,4,5-trisphosphate (PIP3), allowing for BTK to associate with the plasma membrane, while the Tec homology domain contains conserved BTK motifs.<a onclick="showRef(event, 'ref83 ref84 ref85'); return false;" href="javascript:void(0);" class="ref ref83 ref84 ref85">(83−85)</a> Activation happens first at the catalytic domain, also referred to as SH1 with further activation in the SH2 and SH3 domains. Both covalent and noncovalent inhibitors of SH1 have been targeted and show a broad range of shapes and properties for the ATP binding region, as highlighted in <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>, despite similar interactions with hinge residues Met477 and Glu475.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> Some inhibitors have been shown to bind to the active state conformation where the DFG sequence is in the “in” position, while others bind and stabilize the DFG “out” conformation. Furthermore, induced pockets have also been noted where helix C is stabilized by salt bridges.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a></div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/medium/jm-2018-00667b_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Overlay of ATP-binding site inhibitors of BTK: (A) <b>27</b> (purple, 5P9J) and <b>36</b> (orange, 5VFI); (B) <b>27</b> (purple, 5P9J) and <b>37</b> (blue, 5T18).<a onclick="showRef(event, 'ref61 ref80'); return false;" href="javascript:void(0);" class="ref ref61 ref80">(61,80)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00667&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Two general approaches have been used to take advantage of these structural topographies to design selective BTK inhibitors: target amino acid residues found in BTK but rare in the kinome with covalent inhibitors or target more uncommon binding pockets of inactive BTK conformations with noncovalent inhibitors.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> There is currently only one approved BTK inhibitor to date, the covalent modifier ibrutinib (<b>27</b>, <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a> and <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a>). To date, ibrutinib is approved in only nonimmunological disease settings for certain lymphoproliferative malignancies.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> Molecule <b>27</b> features an α,β-unsaturated amide electrophile, in this case an acrylamide, as a Michael acceptor to irreversibly covalently modify an active-site cysteine, Cys481 (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>), in the ATP-binding pocket in SH1.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> With the approval of ibrutinib, there has been increased excitement for the target with close to 70 active clinical trials for inhibitors of BTK as of February 2018 (<a href="http://www.clinicaltrials.gov" class="extLink">www.clinicaltrials.gov</a>), many of which are in oncology settings.</div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/medium/jm-2018-00667b_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Representative examples of BTK inhibitors including those disclosed and under clinical evaluation. Areas of the molecule that participate in binding the hinge region of the active site are shown in red with dashed lines for putative hydrogen bonds where crystallographic data are available.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00667&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Several of the inhibitors that have been and/or continue to be assessed in both oncological and autoimmune diseases are covalent inhibitors of BTK, all of which rely on covalent interaction with Cys481.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> Those being pursued for autoinflammatory and immunological disorders are shown in the top box in <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>. These include olmutinib (HM71224, <b>28</b>), acalabrutinib (<b>29</b>), spebrutinib (<b>30</b>), evobrutinib (<b>31</b>), PRN1008 (<b>32</b>), and BMS-986195 (<b>33</b>).<a onclick="showRef(event, 'ref61 ref81 ref87 ref88 ref89'); return false;" href="javascript:void(0);" class="ref ref61 ref81 ref87 ref88 ref89">(61,81,87−89)</a> With the exception of alkynes <b>29</b> and <b>33</b>, all contain an acrylamide for covalent modification. Olmutinib shows comparable potency to ibrutinib (<b>27</b> IC<sub>50</sub> = 0.7 nM vs <b>27</b> IC<sub>50</sub> = 2 nM) and a slight improvement in kinase selectivity versus other Tec kinase family members which carry a conserved cysteine in the binding pocket.<a onclick="showRef(event, 'ref61 ref81 ref88'); return false;" href="javascript:void(0);" class="ref ref61 ref81 ref88">(61,81,88)</a> Compound <b>28</b> has completed a phase I study in RA that completed in 2015 (NCT01765478), but the results have not been made public though they have disclosed activity in experimental mouse models of arthritis.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> Reported potency values for acalabrutinib (ACP-196, <b>29</b>) appear more modest, with biochemical IC<sub>50</sub> values ranging from 3 nM to 18 nM. Molecule <b>29</b> exhibits superior kinase selectivity when compared to ibrutinib across a 456-member kinase panel, and an in vivo study showed that oral administration of ACP-196 led to superior inhibition of BCR-induced CD69 expression in murine splenic lymphocytes when compared to ibrutinib.<a onclick="showRef(event, 'ref81 ref85 ref90'); return false;" href="javascript:void(0);" class="ref ref81 ref85 ref90">(81,85,90)</a> Compound <b>30</b> is currently undergoing several clinical trial evaluations, though largely in the oncology setting. One phase II clinical trial in RA (NCT02387762) was completed in 2016, though results have not been disclosed.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a></div><div class="NLM_p">Spebrutinib (CC-292, <b>30</b>) and evobrutinib (M2951, <b>31</b>) both feature a monocyclic pyrimidine core for putative hinge binding. Pyrimidine <b>30</b> bears a similar architecture to thienopyrimidine <b>28</b> with a few changes including the replacement of an ether linkage with an aniline and the thiophene with a fluorine atom. Spebrutinib completed a phase II clinical trial in RA in July 2017 (NCT01975610) though results have not been disclosed. Evobrutinib <b>31</b> contains a similar substitution pattern to ibrutinib off the central pyrimidine core with the exception of the methylamino chain to the acrylamide. The amine is tied into a pyrazole in the case of <b>27</b>.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> Evobrutinib is currently recruiting for a phase II clinical trial in RA (NCT03233230). Other covalent inhibitors either have recently been evaluated in the clinic or are currently being evaluated for immunological disorders including BIIB068 (NCT02829541) and PRN1008 (<b>32</b>, NCT03395210, NCT02704429) and BMS-986195 (<b>33</b>) whose clinical candidate structures were just disclosed.<a onclick="showRef(event, 'ref87 ref89'); return false;" href="javascript:void(0);" class="ref ref87 ref89">(87,89)</a></div><div class="NLM_p">All of the inhibitors for BTK discussed thus far and shown in the top box in <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a> are either reversible or irreversible covalent inhibitors relying on covalent bond formation with Cys481. PRN1008, for example, is a reversible covalent inhibitor while ibrutinib is an irreversible covalent inhibitor.<a onclick="showRef(event, 'ref91 ref92'); return false;" href="javascript:void(0);" class="ref ref91 ref92">(91,92)</a> Application of an irreversible versus reversible covalent strategy may impact both the target engagement and off-target kinase selectivity.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> Irreversible inhibition can impact PD through target engagement where the level and frequency of dosing relate to the restoration of pharmacological activity via protein target resynthesis in the case of a true irreversible inhibitor. This uncoupling of response from PK has the ability to enable less frequent dosing and potentially lower dosing.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a></div><div class="NLM_p">In terms of off-target activity, as mentioned earlier, covalent modification can be very useful in promoting kinase selectivity where an uncommon amino acid in the active site can be targeted. In the case of BTK, there are 10 known additional human kinases in the vast kinome that possess Cys residues equivalent to Cys481 in their active site.<a onclick="showRef(event, 'ref61 ref91'); return false;" href="javascript:void(0);" class="ref ref61 ref91">(61,91)</a> Ibrutinib is reported to inhibit all of these and the other covalent members mentioned inhibit some if not all of the Tec family where kinase information is available.<a onclick="showRef(event, 'ref81 ref84 ref85 ref90'); return false;" href="javascript:void(0);" class="ref ref81 ref84 ref85 ref90">(81,84,85,90)</a></div><div class="NLM_p">In addition, a collaboration between Scripps Research Institute and Pfizer has called into question the claims of exceptional kinase selectivity that covalent inhibitors have enjoyed, suggesting that a window of proteome-wide selectivity is a more accurate description.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> Furthermore, these covalent inhibitors can also inhibit other kinases through noncovalent binding given their ATP-like binding mode, further increasing safety concerns due to selectivity.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> Whether those other kinases are inhibited in a reversible or irreversible manner will factor into their off-target potency.</div><div class="NLM_p">Of potentially greater impact to the long-term use of covalent inhibitors in chronic indications such as those in autoimmune and inflammatory conditions is treatment resistance through mutation. This is indeed the case for <b>27</b> with C481S being the most common mechanism for ibrutinib-acquired resistance.<a onclick="showRef(event, 'ref61 ref81 ref83 ref85'); return false;" href="javascript:void(0);" class="ref ref61 ref81 ref83 ref85">(61,81,83,85)</a> Ibrutinib-resistant patients have also presented with C481R, C481F, and C481Y, and mutations of the gatekeeper Thr (T474I, T474S) have also been disclosed.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> These mutations lead to loss in activity for many covalent inhibitors that were tested against the mutants in biochemical assays performed by Johnson and colleagues at Genentech.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> Second-generation, potentially more selective BTK inhibitors including reversible covalent and noncovalent inhibitors are now being evaluated clinically after showing efficacy in various RA models with three such being recently reported.</div><div class="NLM_p">Examples of noncovalent inhibitors of BTK kinase activity are shown in the lower box of <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a> and include RN486 (<b>34</b>), GDC-0834 (<b>35</b>), GDC-0853 (<b>36</b>), and BMS-986142 (<b>37</b>). Pyridone <b>34</b> is comparably potent to ibrutinib in a competitive biochemical assay (IC<sub>50</sub> = 0.3 nM) with a high degree of selectivity (>100×) in a broad kinome panel.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> Excitingly, <b>34</b> demonstrated activity in a variety of cellular and in vivo models of inflammation and immunomodulation.<a onclick="showRef(event, 'ref83 ref84 ref85'); return false;" href="javascript:void(0);" class="ref ref83 ref84 ref85">(83−85)</a> These comprise BCR and FcR signaling blockade and inhibition of several disease-relevant cytokines in a cellular setting.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> In both mouse CIA and mannan-induced collagen antibody induced arthritis (mCAIA) models, <b>34</b> was able to inhibit inflammation and bone erosion as well as show additive effects upon co-dosing with methotrexate in a rat AIA model.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> Furthermore, the molecule inhibited progression of glomerular nephritis and SLE-prone NZB/W mouse model.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> Despite these promising results, no entry for clinical evaluation has been reported.</div><div class="NLM_p">Genentech has reported on multiple noncovalent BTK inhibitors including GDC-0834 (<b>35</b>) and the recently disclosed GDC-0853 (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a> and <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a> in orange, <b>36</b>). Like compound <b>34</b>, they feature a core 3-aminopyrazinone (<b>35</b>) or 3-aminopyridinone (<b>36</b>) for interaction with the hinge.<a onclick="showRef(event, 'ref61 ref84 ref85'); return false;" href="javascript:void(0);" class="ref ref61 ref84 ref85">(61,84,85)</a> The molecules also do not attempt to access the pocket filled by ibrutinib’s phenyl ether (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a> in pink). Like <b>34</b>, molecules <b>35</b> and <b>36</b> stabilize the inactive conformation resulting in the formation of a decidedly specific lipophilic pocket, referred to as the H3 pocket, leading to broad selectivity across the kinome.<a onclick="showRef(event, 'ref61 ref81 ref85'); return false;" href="javascript:void(0);" class="ref ref61 ref81 ref85">(61,81,85)</a> The pocket is flanked by Ser543, Val546, and Tyr551 which only occur as such in BTK.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a></div><div class="NLM_p">Despite promising preclinical efficacy, when GDC-0834 was advanced into the clinic, hydrolysis of the amide between the thiophene and the phenyl ring was seen in healthy volunteers.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> GDC-0853 prevents this by cyclizing the amide into a piperazinone reminiscent of the piperidinone seen in compound <b>34</b>.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> Overlay of the cocrystal structure of <b>36</b> with <b>27</b> in <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a> shows occupation of the deep lipophilic pocket by the piperazinone tricycle in orange.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> This pocket is absent in the ibrutinib cocrystal structure. Optimization of the tricycle, linker pyridine, and solvent front piperazine then allowed for superior potency and in vivo PK when evaluated in the clinic.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> GDC-0853 showed preclinical efficacy in both B and myeloid cell-dependent inflammatory arthritis models and in mouse models of SLE.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> GDC-0853 is currently undergoing clinical evaluation in phase II for SLE (NCT03407482, NCT02908100) and RA (NCT02983227, NCT02833350) after successfully showing suitable safety, PK and PD profiles in phase I.</div><div class="NLM_p">Bristol-Myers Squibb has also disclosed a clinical candidate, BMS-986142 (blue in <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>, <b>37</b> in <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>), that builds on earlier work identifying the carbazole motif as potent inhibitors of BTK and JAK2.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> In this series, the carbazole amide binds to the hinge region with the carbazole NH hydrogen-bonded to the backbone carbonyl of Met477. Much optimization of the phenyl ring and substituents was then undertaken to improve both oral exposure and kinase selectivity of the initial lead and then restrict the conformational flexibility to provide a single stable atropisomer, compound <b>37</b>.<a onclick="showRef(event, 'ref80 ref95'); return false;" href="javascript:void(0);" class="ref ref80 ref95">(80,95)</a> By overlaying this structure with ibrutinib in <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>, one can see the quinazolinone extending past the covalent warhead of ibrutinib in the active site that interacts with Cys481. Furthermore, the back pocket occupied by the phenyl ether of ibrutinib is not occupied by BMS-986142. BMS-986142 is now recruiting volunteers for a phase II study in RA (NCT02638948) after completing multiple phase I studies including three in RA or arthritis (NCT02456844, NCT02762123, NCT02880670).</div><div class="NLM_p last">The search for selective small molecule inhibitors of BTK is well underway. A number of potent kinase inhibitors have now been identified with a range of off-target kinase selectivity in both covalent and noncovalent scaffolds. Whether it is a covalent or noncovalent inhibitor that provides the best route for BTK signaling inhibition remains to be seen. It is possible that one method of inhibition will be better suited for different patients, co-dosing strategies, and/or dosing regimens. With selective covalent and noncovalent small molecule inhibitors of BTK kinase activity, these questions will be soon answered.</div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12">3.C.  Interleukin-2-Inducible T Cell Kinase (ITK)</h3><div class="NLM_p">ITK has been primarily associated with the regulation of T helper (Th) 2-driven immunological diseases as well as development of Th17 cells and their production of the proinflammatory cytokine IL17A.<a onclick="showRef(event, 'ref96 ref97 ref98 ref99 ref100'); return false;" href="javascript:void(0);" class="ref ref96 ref97 ref98 ref99 ref100">(96−100)</a> Both knockout and gene expression studies suggest that ITK has a dominant role in mediating TCR signaling, and there is potential therapeutic benefit to its inhibition in inflammatory and immunological disorders. Knockout studies with individual or combined T cell-expressed Tec family kinases have been generated. Loss of ITK leads to pronounced effects on the production of IL-2 and Th2 cytokines, while RLK knockout mice have a more mild phenotype, with loss predominantly affecting Th1 cytokines.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> In vivo studies have shown mice lacking ITK have diminished Th2 responses to various infectious agents while retaining Th1 responses. ITK-deficient mice challenged with ovalbumin exhibited drastically reduced airway hyper-responsiveness and lung inflammation in allergic asthma models, and T cells from these mice showed reduced IL-5 and IL-13 secretion.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> ITK gene expression is also upregulated in patients with atopic dermatitis.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> Together these studies suggest potential therapeutic benefits of inhibiting ITK in Th2-driven diseases like asthma and atopic dermatitis, and several organizations have set out to discover potent small molecule inhibitors of its kinase activity.<a onclick="showRef(event, 'ref96 ref100 ref102 ref103'); return false;" href="javascript:void(0);" class="ref ref96 ref100 ref102 ref103">(96,100,102,103)</a></div><div class="NLM_p">TCR activation triggers a signaling cascade involving three kinases: Zap-70, Lck, and ITK, with a simplified representation of that pathway shown in <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>.<a onclick="showRef(event, 'ref96 ref100'); return false;" href="javascript:void(0);" class="ref ref96 ref100">(96,100)</a> Activation of Src kinase Lck, shown in orange in <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a> leads to phosphorylation of the CD3 ITAM, resulting in ZAP-70 activation, phosphorylation, and subsequent phosphorylation of a complex comprising linker of activated T-cells (LAT, in brown in <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>) and Src homology 2 domain containing leukocyte protein of 76 kDa (SLP-76, in navy in <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>) by ZAP-70. Activation of this complex allows for ITK (in green) recruitment to the membrane where it becomes phosphorylated by Lck.<a onclick="showRef(event, 'ref96 ref100'); return false;" href="javascript:void(0);" class="ref ref96 ref100">(96,100)</a> Phosphorylation of ITK activates the kinase, and upon autophosphorylation of Tyr180 in the SH3 domain, ITK is primed for interaction with and phosphorylation of PLCγ1 lipase. PLCγ1 then hydrolyzes phosphoinositol diphosphate (PIP2) into inositol triphosphate (IP3) and diacyl glycerol (DAG), leading to stimulation of nuclear factor of activated T cells (NFAT) and NF-κB, respectively. Stimulation of these factors leads to multiple responses including production and release of proinflammatory cytokines, Erk activation, Ca<sup>2+</sup> flux, actin reorganization, and stimulation of T cell transcription factors. These in turn lead to cytokine production and T cell proliferation and differentiation in T cells, NK cells, and mast cells where ITK is predominantly expressed.<a onclick="showRef(event, 'ref96 ref99'); return false;" href="javascript:void(0);" class="ref ref96 ref99">(96,99)</a></div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/medium/jm-2018-00667b_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Role of ITK in TCR signaling.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00667&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Several noncovalent ITK inhibitors have been described in the patent and scientific literature, but only a few select molecules are mentioned here as the ITK inhibitor space has been well-covered in other reviews.<a onclick="showRef(event, 'ref97 ref98 ref104'); return false;" href="javascript:void(0);" class="ref ref97 ref98 ref104">(97,98,104)</a> Beginning with BMS-509744 (<b>38</b>), whose discovery predates public disclosure of the ITK structure, the aminothiazole was identified as a potent ATP-competitive inhibitor of ITK with >50-fold selectivity over a panel of 18 other protein kinases and >200-fold selectivity when compared to other Tec family tyrosine kinases (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>, parts A and B).<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> In the first preclinical demonstration of ITK inhibitor efficacy, this compound showed dose-dependent reduction in lung inflammation in a murine ovalbumin allergic asthma model.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> The discovery and cocrystal structures of two other noncovalent inhibitors followed suit with thienopyrazole <b>39</b> and tetrahydroindazole <b>40</b> (GNE-4997) (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>A).<a onclick="showRef(event, 'ref104 ref106 ref107'); return false;" href="javascript:void(0);" class="ref ref104 ref106 ref107">(104,106,107)</a> These two molecules are interesting in their similarity to each other and other known ITK inhibitors as well as for their differences from BMS-509744.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a></div><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/medium/jm-2018-00667b_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Noncovalent inhibitors of ITK. (A) Structures of noncovalent ITK inhibitors <b>38</b>–<b>42</b>. Areas of the molecule that participate in binding the hinge region are shown in red. (B) Cocrystal structure of BMS-509744, <b>38</b>, 3MJ2.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> (C) Cocrystal structure of <b>39</b>, 3V8T. (D) Cocrystal structure of GNE-4997, <b>40</b>, 4rfm.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00667&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As shown in <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>parts B, C, and D, all three molecules bind to the hinge region of the active site through Glu439 and Met438. Thiazole <b>38</b> and pyrazoles <b>39</b> and <b>40</b> adopt a hydrogen bond with the NH of Met438. The amide NH of <b>38</b> and <b>40</b> then forms a hydrogen bond with the backbone carbonyl of Glu439. The pyrrole moiety of <b>39</b> then mimics this same interaction. Diversion is then seen when the molecules approach gatekeeper residue Phe435. For thienopyrazole <b>39</b> and hexahydrocyclopropylindazole <b>40</b>, the molecules do not extend past the gatekeeper but either interact with residues near the gatekeeper or fill nearby hydrophobic pockets (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>, parts C and D). The difluoro moiety of <b>39</b> points away from the Phe toward the side chain of Lys391 (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>C).<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> The two fluorine atoms of GNE-4997 <b>40</b> occupy a hydrophobic pocket within the active site adjacent to Phe435 (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>D).</div><div class="NLM_p">BMS-509744 (<b>38</b>) takes a strikingly different approach with Phe435 (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>B) by constructing hydrophobic contacts with the gatekeeper via the sulfur atom and then progressing down the side of the active site with the adjacent methyl-benzamide moiety. The benzamide is in-plane to the aminothiazole, presumably through stabilizing interactions between the thiazole sulfur and the benzamide oxygen. Molecule binding leads to stabilization of the activation loop. Cocrystallization studies reveal the activation loop folded into a short helix blocking the protein substrate-binding site, giving an autoinhibited inactive conformation and improved kinase selectivity relative to other kinases outside the Src family.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a></div><div class="NLM_p">Molecules <b>38</b>, <b>39</b>, and <b>41</b> follow a similar path toward solvent along the hinge. Other recent scaffolds such as benzthiazole <b>41</b> and aminopyrazole <b>42</b> use elements of these core scaffolds while also filling the ribose pocket with a (1<i>R</i>,4<i>R</i>)-4-aminocyclohexanol moiety (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>A).<a onclick="showRef(event, 'ref109 ref110'); return false;" href="javascript:void(0);" class="ref ref109 ref110">(109,110)</a> Pyrazole <b>42</b> also makes a modified hinge interaction through Glu436 as opposed to Glu439. The branched alkyl chains of <b>38</b> and <b>39</b> are solvent exposed as are the phenyl and sulfone moieties of <b>40</b>.<a onclick="showRef(event, 'ref104 ref106 ref107 ref108'); return false;" href="javascript:void(0);" class="ref ref104 ref106 ref107 ref108">(104,106−108)</a> Both BMS-509744 and GNE-4997 extend past the opening to the active site with the alkane of <b>38</b> pointing perpendicular to the ligand core in a similar region to the phenyl of <b>40</b>.<a onclick="showRef(event, 'ref106 ref108'); return false;" href="javascript:void(0);" class="ref ref106 ref108">(106,108)</a> The cyclic sulfone helps to orient the phenyl ring for an edge-to-face interaction with Phe437.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a></div><div class="NLM_p">Thiazole <b>38</b> progressed into in vivo studies where it reduced anti-CD3-induced IL-2 production and ovalbumin-induced lung inflammation.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> Molecules related to pyrazolocyclohexane <b>40</b> have been reported to show inhibition of IL-2 and IL-13 upon dosing in an ITK PD model as well.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> Despite promising potency and selectivity, no clinical progress has been reported for BMS-509744 or GNE-4997 with both potentially hampered by metabolic instability.<a onclick="showRef(event, 'ref104 ref106'); return false;" href="javascript:void(0);" class="ref ref104 ref106">(104,106)</a> Insufficient target inhibition has been noted for <b>38</b> in a T cell prolymphocytic leukemia study focusing on TCR signaling when compared to dual ITK/RLK inhibitor PRN694 (<b>43</b>, <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>).<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a></div><figure id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/medium/jm-2018-00667b_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0015.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Selected covalent inhibitors of ITK kinase activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00667&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Imine <b>43</b> is interesting as it is both a dual Tec family kinase inhibitor and because it is a covalent inhibitor.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a> Other covalent irreversible inhibitors that have been developed for ITK include acrylamides <b>44</b> and PF-06465469 (<b>45</b>).<a onclick="showRef(event, 'ref111 ref112 ref113'); return false;" href="javascript:void(0);" class="ref ref111 ref112 ref113">(111−113)</a> BTK inhibitor ibrutinub (<b>27</b>) also inhibits ITK through covalent modification of Cys442 and targeted interaction with this residue has been a central focus of many ITK inhibitor programs seeking potency and potential broader kinome selectivity.<a onclick="showRef(event, 'ref111 ref112 ref113'); return false;" href="javascript:void(0);" class="ref ref111 ref112 ref113">(111−113)</a> Thiazolopyridine <b>44</b> was optimized for inhalation and selected for development but was not progressed into the clinic.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> Piperidine acrylamide <b>45</b>, which bears some structural similarity to <b>27</b>, was found to be a very potent irreversible covalent inhibitor of ITK.<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> This compound also inhibited BTK with similar biochemical potency. Compound <b>43</b> is reported to have greater than 50× selectivity over BTK though it does have a narrow window of selectivity in biochemical assays when compared to TEC and RLK.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a></div><div class="NLM_p">Despite much excitement and effort to discover novel ITK inhibitors, so far there has been little progress in the clinic. There are several potential challenges to ITK inhibition that may account for the apparent discrepancy between preclinical and clinical progress. First, both RLK and TEC are expressed in T cells and there may be some redundancy in roles of TEC kinases in TCR signaling.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> Combining knockouts of both RLK and ITK leads to a more pronounced phenotype further relaying its dominance among the Tec family in T cells, though RLK can compensate for loss of ITK function revealing challenges with selective Tec family member inhibition.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> Also, while downstream consequences of TCR activation are reduced upon ITK knockout, they are not completely ablated leading to altered development and differentiation of distinct T cell subsets.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a></div><div class="NLM_p">A disconnect in translatability may also exist between kinase knockout and kinase dead mouse models and human disease intervention. Many studies providing support for the hypothesis of ITK inhibition in Th2-driven inflammatory diseases were carried out in mice lacking ITK. Because of this, the results of these experiments may be complicated by T cell signaling and developmental differences in these mice.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> A recent study of rechallenge in an ovalbumin-induced mouse model of asthma highlighted the additional complexities of ITK biology.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> Unexpectedly, compound <b>40</b> resulted in an increase in Th2 cytokines in a murine ovalbumin rechallenge asthma model. This is the opposite of the intended outcome and suggests that ITK may have different roles in initial versus repeated exposure to stimuli.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a></div><div class="NLM_p last">There is currently only one ITK inhibitor under clinical evaluation, JTE-051, which is in phase II for RA (NCT02919475) and psoriasis (NCT03358290). While the chemical structure and discovery story have not been shared, the phase 2 study of JTE-051 in rheumatoid arthritis patients will be very informative. It remains to be determined what extent of kinase specificity would give optimal impact on an immune response. Redundancy among TEC kinases has led some to develop multi-Tec kinase inhibitors as mentioned for <b>43</b> and evaluation of a dual ITK/RLK inhibitor in patients will be informative if one enters clinical evaluation.<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a></div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">4.  Interleukin-1 Receptor Activated Kinase</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76714" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76714" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The inhibitors outlined above largely seek to stop the response of the adaptive immune system in autoimmune diseases by targeting key signaling kinases in B and T cells. In these cases, the adaptive immune system has already been engaged by the innate immune system to promote an inflammatory response to what is perceived as a nonself antigen.<a onclick="showRef(event, 'ref117 ref118'); return false;" href="javascript:void(0);" class="ref ref117 ref118">(117,118)</a> An alternative approach to blocking tissue damage is through targeting the innate immune system. The cells that comprise this system include natural killer cells, granulocytes such as neutrophils, basophils, eosinophils, and monocytes and macrophages which all play critical roles in this response. Macrophages and dendritic cells are particularly instrumental in both innate and adaptive immunity with dendritic cells comprising the most important antigen presenting cell, displaying antigens to T cells, forming a critical link between the innate and adaptive immune system.<a onclick="showRef(event, 'ref117 ref118'); return false;" href="javascript:void(0);" class="ref ref117 ref118">(117,118)</a> As the body’s first line of defense, the innate immune system must be sensitive and able to respond to immediate infections and injuries. Receptors that recognize pathogens are key regulators of innate immunity and either initiate signaling cascades themselves through kinase function or rely on other kinases to form critical nodes similar to examples above. One such example is the interleukin-1 receptor activated kinase (IRAK) family.</div><div class="NLM_p">The IRAK family is critical to the signaling transduction for the IL-1 receptor (IL-1R) family and for TLRs.<a onclick="showRef(event, 'ref6 ref119 ref120'); return false;" href="javascript:void(0);" class="ref ref6 ref119 ref120">(6,119,120)</a> TLRs are a family of transmembrane pattern recognition receptors (PPRs) that are critical in the detection of pathogen-associated molecular patterns (PAMPs) of foreign microbes such as lipopolysaccharide (LPS). Together with the IL-1R family, they enable cells to quickly respond to inflammatory cytokines by mounting the initial protective response through the activation and downstream function of IRAK. Recognition of PAMPs by the TLRs, either at the cell surface or in the endosomal compartment with the exception of TLR3, leads to recruitment of MyD88 to the Toll/IL-1R (TIR) domain followed by IRAK family members to form the myddosome complex, shown in <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>.<a onclick="showRef(event, 'ref121 ref122'); return false;" href="javascript:void(0);" class="ref ref121 ref122">(121,122)</a> The first IRAK family member involved is IRAK4. IRAK4 activation by autophosphorylation leads to IRAK1 phosphorylation which in turn leads to recruitment of TNF-receptor associated factor (TRAF), IRAK1:TRAF dissociation from the complex, and downstream signaling through multiple cascades leads to transcription and initiation of the inflammatory response. IL-1R also contains a TIR domain and is reliant on this pathway for signal transduction.</div><figure id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/medium/jm-2018-00667b_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0016.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. TLR and IL-1R signaling through IRAK family members to upregulate type I IFN genes leading to proinflammatory cytokine production.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00667&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Dysregulation of TLR signaling has been implicated in several inflammatory diseases including RA, SLE, gout, and Lyme disease.<a onclick="showRef(event, 'ref121 ref122'); return false;" href="javascript:void(0);" class="ref ref121 ref122">(121,122)</a> Multiple TLR family members are found to be more highly expressed in several cell types including macrophages, monocytes, synoviocytes, and certain dendritic cells in RA patients compared to healthy individuals. TLR7, an endosomal TLR family member, and its eliciting of type 1 interferon production have been heavily implicated in SLE pathophysiology. Inhibition of IL-1 signaling is already an approved therapy with anakinra, a recombinant human interleukin-1–receptor antagonist that blocks the proinflammatory effects of interleukin-1β, approved for patients with RA. As such, novel strategies for inhibiting TLR and IL-1R signaling are of therapeutic interest.</div><div class="NLM_p">The IRAK family comprises four members, IRAK1 and IRAK4 which both have kinase activity and IRAK2 and IRAK3 (also called IRAKm) which are catalytically inactive.<a onclick="showRef(event, 'ref119 ref123'); return false;" href="javascript:void(0);" class="ref ref119 ref123">(119,123)</a> Both IRAK4 and IRAK1 are serine–threonine kinases that act as active kinases with additional scaffolding functions.<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a> IRAK1 catalytic activity is required for IFNβ production, but not all IRAK4 signaling is dependent on IRAK1 catalytic activity. This includes IL-1 or TLR-agonist stimulated signal propagation.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Because of this, IRAK4 has been called the “master IRAK” as it is the only family indispensable in IL-1R and TLR signaling.<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> There are several reports of small molecule kinase inhibitor programs targeting the IRAK4 kinase domain.<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a></div><div class="NLM_p">The search for IRAK4-selective small molecule kinase inhibitors has endured since the early to mid-2000s and was recently comprehensively reviewed in this journal.<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> As such, this section will focus on only those recent examples where IRAK4 inhibition has been evaluated in vivo. Of the multitude of IRAK1/4 or IRAK4-specific molecules reported, only three are known to have entered into the clinic: molecules from Bayer and BMS and PF-06650833 (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>, <b>46</b>). Neither Bayer nor BMS has reported the chemical structures of the molecule(s) they advanced into human studies. However, they have reported on some structures including compounds (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>, <b>47</b>)<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> and BMS-986126 (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>, <b>48</b>),<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a> respectively. The discovery story of the Pfizer clinical candidate (PF-06650833, <b>46</b>) was recently disclosed.<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a></div><figure id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/medium/jm-2018-00667b_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0017.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Structures of IRAK4 kinase inhibitors PF-06650833 (<b>46</b>), pyridine <b>47</b>, and BMS-986126 (<b>48</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00667&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Briefly, compound <b>46</b> was derived from a carboxamide discovered during a fragment screening approach where binding to hinge residues is through the carboxamide moiety off the isoquinoline (<a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>). Advances in IRAK4 potency were then gained by growing into the space below the P-loop with the 5-hydroxymethyl pyrrolidinone. Displacement of a putative high-energy water molecule with the ethyl substituent off the pyrrolidinone then brings in further potency for the target. The IRAK family displays high structural similarity,<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> and compound <b>46</b> inhibits IRAK1 at 91% at a single 200 nM screening concentration. The molecule also inhibits four other kinases at greater than 70% when screened against a panel of 278 kinases at this same concentration. However, the carboxamide displays subnanomolar potency for its target (IC<sub>50</sub> = 0.2 nM) providing a potentially more than sufficient selectivity window.<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> Kinase selectivity may be further enhanced in a cellular setting based on the high <i>K</i><sub>M</sub> for ATP that IRAK4 displays.<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> Compound <b>46</b> showed modest stability and exposure in vivo but elicited dose-dependent reduction in LPS-induced TNF-β in rodent serum. This is of interest as compound <b>48</b> elicited little activity downstream of TLR4 upon LPS stimulation, which can also activate an MyD88-independent pathway.<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a> Compound <b>46</b> recently completed multiple phase I evaluations investigating modified release formulations and is currently recruiting RA patients with inadequate response to methotrexate in a phase II trial (NCT02996500).</div><figure id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/medium/jm-2018-00667b_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0018.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Cocrystal structure of PF-06650833, <b>46</b>, with IRAK4 (5UIU).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00667&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The question remains whether inhibition of such a critical component of innate immunity may cause too broad of an impact on sentinel innate immune function.<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> At the same time, other IRAK1/4 inhibitors have been shown to only inhibit response in certain cell types such as plasmacytoid dendritic cells (pDCs), the major systemic source of IFNα, though dispensable in other cells.<a onclick="showRef(event, 'ref6 ref124'); return false;" href="javascript:void(0);" class="ref ref6 ref124">(6,124)</a> Clinical outcome of patients with IRAK4 or MyD88 deficiencies, which are indistinguishable in the clinic, is poor largely due to recurrent life-threatening bacterial diseases in infancy and early childhood though no death or invasive infectious diseases were reported after 8 and 14 years of age, respectively.<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a> As such, the impact of IRAK1/4 inhibition in certain disease populations will be interesting to understand and the industry looks forward to the trial outcomes of these first IRAK4 inhibitors to enter human studies.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">5.  NF-κB Inducing Kinase (NIK)</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30284" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30284" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">As mentioned above with the IRAK family, the NF-κB family of transcription factors regulate the expression of specific genes involved in the inflammation response as well as proliferation, differentiation, cell adhesion, and apoptosis.<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> Transcription complexes comprise various homo- and heterodimeric subunits p50, p52, c-Rel, RelA (p65), and RelB. NF-κB signaling occurs through two distinct pathways: the canonical and noncanonical pathways. In the basal or resting state, the canonical pathway induces activation of an IκB-bound NF-κB species. Receptor activation leads to degradation of I-κB downstream of IKK α/β/γ complexes, which results in translocation of canonical NF-κB subunits, such as p65/p50, to the nucleus, where they trigger immune gene expression.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a></div><div class="NLM_p">The noncanonical NF-κB signaling requires NF-κB inducing kinase (NIK, also known as MAP3K14) as its central regulator (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>).<a onclick="showRef(event, 'ref129 ref130 ref131 ref132'); return false;" href="javascript:void(0);" class="ref ref129 ref130 ref131 ref132">(129−132)</a> In the basal or resting state, NIK signaling is constitutively tempered by the continuous degradation of NIK protein through its association with TRAF2, TRAF3, and cellular inhibitors of apoptosis (cIAP) (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>, left).<a onclick="showRef(event, 'ref132 ref133'); return false;" href="javascript:void(0);" class="ref ref132 ref133">(132,133)</a> This complex is responsible for mediating the ubiquitination and degradation of NIK. Once activated, though, the noncanonical pathway (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>, right) depends on activation of IKKα dimers only, activates NF-κB transcription factors p52 and RelB, and requires NIK for these functions.<a onclick="showRef(event, 'ref129 ref131 ref132'); return false;" href="javascript:void(0);" class="ref ref129 ref131 ref132">(129,131,132)</a></div><figure id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/medium/jm-2018-00667b_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0019.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Role of NIK in the noncanonical NF-κB pathway.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00667&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Pathway activation occurs upon ligand binding to a subset of TNF superfamily receptors including CD40 (as illustrated in <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>), lymphotoxin β receptor, BAFF receptor, and receptor activator of NF-κB (RANK). Binding and receptor activation triggers NIK dissociates from the complex. Without constitutive degradation, NIK accumulates in the cell and activates IKKα through phosphorylation. Once activated, IKKα phosphorylates p100, a precursor protein of NF-κB2 p52. Phosphorylation of p100 in turn leads to its ubiquitination and partial degradation to release mature p52. Transcription factor p52 heterodimerizes with RelB, and this complex translocates to the nucleus and initiates transcription of target genes leading to the release of chemokines and cytokines.<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a></div><div class="NLM_p">The noncanonical NF-κB pathway is thought to regulate important functions including lymphoid organogenesis, B cell maturation and survival and bone metabolism.<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a> Dysregulation leading to pathway activation is linked to both autoimmune and hematological disorders.<a onclick="showRef(event, 'ref132 ref133 ref134'); return false;" href="javascript:void(0);" class="ref ref132 ref133 ref134">(132−134)</a> For example, while BAFF is necessary for activation and maturation of B cells,<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a> high levels are associated with autoimmune and inflammatory diseases such as RA, SLE, and MS.<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a> Similarly, while RANK signaling under normal circumstances regulates osteoclastogenesis, hyperactivity is associated in bone erosion. RA patients in particular show high BAFF serum levels as well as high expression levels of NIK in synovial endothelial cells.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> These observations suggest that increased BAFF signaling through the noncanonical pathway may result in the increased survival of autoreactive B cells and autoimmune disease pathology as BAFF has a large contribution to diseases such as lupus. Insufficient efficacy has been noted for inhibitors targeting IKK,<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> and targeting the active NIK pathway may provide an alternative.</div><div class="NLM_p">Mice with a mutation in the <i>nik</i> gene (NIK<sup><i>aly</i>/<i>aly</i></sup>) that prevent NIK association with IKKα and NIK-knockout mice are unable to engage the noncanonical NF-κB pathway and show impaired B cell survival.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> NIK-knockout mice showed less bone erosion than wild-type mice in murine models of inflammatory arthritis.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> As NIK function is implicated in several autoimmune and inflammatory disorders and is positioned downstream of multiple receptors and upstream of proinflammatory gene expression, small molecule inhibition of NIK has been proposed as a therapeutic strategy. Despite recognition that NIK “may be an ideal target for clinical intervention”,<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a> there have only been a handful of reports describing discovery efforts and preclinical studies.<a onclick="showRef(event, 'ref140 ref141 ref142 ref143 ref144'); return false;" href="javascript:void(0);" class="ref ref140 ref141 ref142 ref143 ref144">(140−144)</a> This apparent discrepancy may have been in part due to an initial lack of protein structural information with early discovery efforts relying on virtual screens with homology models.<a onclick="showRef(event, 'ref142 ref143'); return false;" href="javascript:void(0);" class="ref ref142 ref143">(142,143)</a> Recently, however, both Amgen and Genentech identified stable protein constructs and reported crystal structures of the NIK kinase domain.<a onclick="showRef(event, 'ref141 ref145'); return false;" href="javascript:void(0);" class="ref ref141 ref145">(141,145)</a> The apo-NIK kinase domain was found to have an active “DFG-in” conformation without phosphorylation and a solvent-occupied back pocket behind the Met gatekeeper residue (<a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>A).</div><figure id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/medium/jm-2018-00667b_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0020.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. (A) Crystal structure of apo-murine NIK kinase domain where the pocket is filled by a sulfate (4G3C). (B) Overlay of inhibitors <b>51</b> and <b>53</b> in murine NIK kinase domain (4G3E, 5T8O).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00667&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Both groups then used structure-based drug design methods to discover potent NIK inhibitors.<a onclick="showRef(event, 'ref140 ref142'); return false;" href="javascript:void(0);" class="ref ref140 ref142">(140,142)</a> Beginning with a high throughput screening campaign hit and a CHK1-based homology model, scientists at Amgen identified a series of inhibitors that interact with the hinge through an imidazopyridinyl pyrimidinamine (compound <b>49</b>, <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>).<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a> After obtaining a cocrystal structure with an early lead, they found significant improvements in biochemical and cellular potency by appending a propargyl alcohol substituent to two indole-derived scaffolds (<b>50</b> and <b>51</b>, <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>).<a onclick="showRef(event, 'ref141 ref142'); return false;" href="javascript:void(0);" class="ref ref141 ref142">(141,142)</a> The alkyne functional group passes through the narrow channel adjacent to the gatekeeper Met471 residue and forms hydrogen bonding interactions with amino acids lining the back pocket (<a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>B, gold).</div><figure id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/medium/jm-2018-00667b_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0021.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. NIK inhibitors described by Amgen and Genentech. Areas of the molecule that participate in binding the hinge region of the active site are shown in red. Areas occupying the back pocket are shown in blue.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00667&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Genentech also described their NIK inhibitor discovery efforts beginning with tricyclic HTS hit <b>52</b>. This series of molecules takes advantage of the type I<sup>1</sup>/<sub>2</sub> binding mode seen in the Amgen molecules. The carboxamide moiety forms two hydrogen bonds with the hinge region via Leu474 and Glu472, and the tricyclic core provides the vector required to access the back pocket (<a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>B, salmon).<a onclick="showRef(event, 'ref140 ref141'); return false;" href="javascript:void(0);" class="ref ref140 ref141">(140,141)</a> Application of a propargyl alcohol moiety allows the molecule to extend past the gatekeeper into a deep back pocket and substitution with an isoxazole fills the space (<a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>). Although imidazolocarboxamide <b>53</b> showed acceptable kinase selectivity, the authors realized the tricyclic core could bind other kinases through an alternative hinge-binding motif through the benzoxepin oxygen based on reported inhibitors to PI3K family members. To preclude this binding mode, the authors investigated two modifications: substitution of the imidazole ring to clash with the PI3K active site (amide <b>54</b>) and removal of the oxygen atom (azabicyclo[4.1.1]octane <b>55</b>) (<a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>). Both compounds were found to be highly potent and selective NIK inhibitors, and in a cellular imaging study, amide <b>54</b> was shown to prevent nuclear translocation of p52 in HeLa cells.</div><div class="NLM_p last">Although NIK inhibitors have yet to enter the clinic, recent preclinical studies in inflammation models show encouraging results. Small molecule NIK inhibitors have reduced angiogenesis in an RA synovial inflammation model and decreased both levels of p52 protein in the liver and the expression of proinflammatory genes in a mouse carbon tetrachloride-induced acute liver inflammation model.<a onclick="showRef(event, 'ref144 ref146'); return false;" href="javascript:void(0);" class="ref ref144 ref146">(144,146)</a> Administration of <b>51</b> has been shown to protect mice from severe liver injury and death in a mouse model of liver inflammation. In a recent report, NIK inhibition by a small molecule kinase inhibitor mimicked the pharmacological effects of BAFF blockade both in vitro and in vivo in an experimental lupus model and demonstrated inhibition of BAFF-independent pathways and end points.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> With the recent advances in understanding NIK structure and function along with promising preclinical data, evaluation of NIK inhibitors in the clinical setting will be very interesting to see.</div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">6.  Receptor-Interacting Protein Kinase (RIPK)</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48783" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48783" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The receptor interacting protein (RIP) kinase family has recently received attention as potential targets for disease intervention in the innate immune system. Seven members have been identified within the RIP family, and all share a homologous kinase domain but have distinct functional domains.<a onclick="showRef(event, 'ref147 ref148'); return false;" href="javascript:void(0);" class="ref ref147 ref148">(147,148)</a> RIPK1 is the only family member to contain a C-terminal death domain, through which RIPK1 can be recruited to signaling complexes that initiate different pathways (<a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a></a>). It also possesses an intermediate domain containing a RIP homotypic interaction motif (RHIM) that likely mediates protein–protein interactions. RIPK2 bears a caspase activation and recruitment domain. This protein is essential in regulating signaling downstream of the Crohn’s disease susceptibility protein, NOD2. In this role, RIPK2 is part of the protein complex that recognizes intracellular bacterial infection and helps tailor the cytokine response to eradicate an offending pathogen.<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a> RIPK3 has a unique C-terminus and a RHIM motif like that found in RIPK1. RIPK4 and RIPK5 are characterized by the ankyrin repeats in their C-terminus. While less well studied, RIPK4 (also known as protein kinase C-associated kinase) is the causative gene in popliteal pterygium syndrome, a disease characterized by early lethality with multiple developmental abnormalities. RIPK6 and RIPK7 (also known as leucine-rich repeat kinases 1 and 2) contain potential recognition motifs for molecular patterns resulting from damage, stress, or pathogens as well as domains for stimulating kinase activity and have been associated with the pathogenesis of Parkinson’s disease.<a onclick="showRef(event, 'ref148 ref149'); return false;" href="javascript:void(0);" class="ref ref148 ref149">(148,149)</a></div><figure id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/medium/jm-2018-00667b_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0022.jpeg" id="gr22" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. RIPK1 regulation of multiple roles upon signaling by TNF. Abbreviations: TRADD, TNF-R1-associated death domain protein; TAK1, transforming growth factor β-activated kinase 1; IKK, IκB kinase; MLKL, mixed lineage kinase domain-like protein.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00667&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Molecular modeling and crystal structures have shown the kinase domains between at RIPK1, -2, and -3 are largely superimposable. However, there are subtle structural differences between these three kinases, which can help explain pharmacologic specificity as was elegantly reported by Abbott et al. in 2016.<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a> Furthermore, recent work has shown that, at least for RIPK2, Tyr474 can also be phosphorylated along with the previously known serine and threonine.<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a> RIPK1 and RIPK3 have well-established roles as central inducers of necrotic cell death (necroptosis) activation and apoptosis via caspase interaction.<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a> Emerging evidence now suggests additional roles for both RIPK1 and RIPK3 in the direct regulation of proinflammatory signaling as well with RIPK1 mediating the signaling switch between necroptosis and inflammatory gene expression.<a onclick="showRef(event, 'ref147 ref148 ref151'); return false;" href="javascript:void(0);" class="ref ref147 ref148 ref151">(147,148,151)</a></div><div class="NLM_p">A range of triggers including extracellular factors linked to innate immune regulation, such as ligands for TNF receptor (TNF-R), TNF-α, interferon-α receptor (IFNαR), and TLR families, as well as viral infection, genotoxic stressors, and T cell activation, have been associated with RIP activation and induction.<a onclick="showRef(event, 'ref148 ref150'); return false;" href="javascript:void(0);" class="ref ref148 ref150">(148,150)</a> These hallmarks of the proinflammatory response then lead to necroptosis that damages tissues and liberates DAMPS, further stimulating the inflammatory response and/or upregulating inflammatory signals.<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a> RIPK1 acts as a molecular switch to determine which path the cell will trigger (<a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a></a>).<a onclick="showRef(event, 'ref147 ref148'); return false;" href="javascript:void(0);" class="ref ref147 ref148">(147,148)</a> However, the mechanisms by which these and other RIPK functions are exerted, be it scaffolding or through catalytic activity, are still under investigation.<a onclick="showRef(event, 'ref150 ref151 ref152'); return false;" href="javascript:void(0);" class="ref ref150 ref151 ref152">(150−152)</a></div><div class="NLM_p">Given their key roles in inflammation, inhibitors of RIPK1, RIPK2, and RIPK3 have been discussed in the literature, though only molecules targeting RIPK1 and RIPK2 are currently known to be in the clinic. RIPK1 has effector functions downstream of multiple signaling events including TNFR-1 activation by TNF as shown in <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a></a>.<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a> These different pathways result from modification of RIP by ubiquitination, deubiquitination, or phosphorylation along with protein–protein interactions.<a onclick="showRef(event, 'ref147 ref148 ref151'); return false;" href="javascript:void(0);" class="ref ref147 ref148 ref151">(147,148,151)</a> Upon TNF stimulation of TNFR-1, RIPK1 and TRADD are recruited to TNFR-1. Ubiquitination of RIP1 leads to recognition by ubiquitin-binding domain containing proteins transforming growth factor β-activated kinase 1 (TAK1) and IKK. TAK1/IKK-mediated activation of NF-κB then leads to inflammation in one possible outcome.<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a> Deubiquitination results in the formation of the ripoptosome which leads to apoptosis via the caspase 8 cascade in another.<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a> Finally, autophosphorylation of RIPK1 and RIPK3 leads to formation of the necrosome. RIPK3 then interacts with mixed lineage kinase domain-like protein (MLKL). MLKL then can associate with other proteins leading to mitochondrial ROS production resulting in necroptosis or form oligomers leading to membrane rupture.<a onclick="showRef(event, 'ref147 ref151'); return false;" href="javascript:void(0);" class="ref ref147 ref151">(147,151)</a> With its role upstream of a number of inflammatory pathways, RIPK1 is positioned well within the innate immune response as a target for inhibition. Indeed, research by Najjar and others has shown RIPK1 activation by LPS in macrophages strongly increased expression of a broad range of inflammatory molecules while RIPK3’s functions were more contributory and context dependent.<a onclick="showRef(event, 'ref150 ref152'); return false;" href="javascript:void(0);" class="ref ref150 ref152">(150,152)</a></div><div class="NLM_p">The only known RIPK1 inhibitor in the clinic is GSK2982772 (<a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a>, <b>57</b>) which is undergoing evaluation in psoriasis (phase II NCT02776033), UC (NCT02903966), and RA (NCT02858492).<a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(153)</a> The discovery of <b>57</b> was recently disclosed and presents a very interesting story of an atypical kinase inhibitor.<a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(153)</a> The authors discussed in an earlier report the discovery of the highly novel and kinase selective benzoxazepinone pharmacophore <b>56</b> (<a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a>) using DNA-encoded libraries.<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a> Of particular interest with both <b>56</b> and <b>57</b> is the excellent selectivity among the kinome along with unique species selectivity for primate versus non-primate RIPK1.<a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(153)</a> While initially not structurally enabled, a cocrystal structure of GSK2982772 gave insights into both components by suggesting it functions as a type III binding inhibitor.</div><figure id="fig23" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/medium/jm-2018-00667b_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0023.jpeg" id="gr23" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. Development of RIPK1 clinical candidate GSK2982772 (compound <b>57</b>) from DNA-encoded library hit <b>56</b> showing significant shift in kinase activity across species.<a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(153)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00667&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>57</b> does not make interactions with the hinge but rather sits deep into the ATP binding pocket with the benzoxazepinone ring occupying the space normally occupied by the α phosphate of ATP. The binding mode leads to the single kinase specificity but also yields significant potency differences between primate and non-primate RIPK1 that was not seen in molecules using other binding modes. Specific mutations in mouse suggested that the loss in potency is a result of the inability of the activation loop in non-primate RIPK1 to adopt the required conformation to bind this template.<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a> While species differences contributed to poor potency in rodents, the molecule was able to prevent TNF-induced necrotic cell death and block spontaneous cytokine release in an UC explant assay.<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a> It will be very interesting to see how this first molecule targeting RIP signaling impacts disease progression in the clinic.</div><div class="NLM_p">Other RIPK inhibitors may not be far behind as selective inhibitors for RIPK1, RIPK2, and RIPK3 have been recently reported as well as RIPK1/RIPK3 inhibitors though their suitability as anti-inflammatory agents is unknown.<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a><a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">24</a></a> highlights the broad range of chemotypes able to inhibit kinase function of RIP family members. These include additional putative type III binders such as compound <b>58</b>,<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a> type II binders like the multikinase inhibitor ponatinib <b>59</b>,<a onclick="showRef(event, 'ref156'); return false;" href="javascript:void(0);" class="ref ref156">(156)</a> and smaller chemotypes like necrostatin-1 analog nec-1a (<b>60</b>).<a onclick="showRef(event, 'ref157'); return false;" href="javascript:void(0);" class="ref ref157">(157)</a> Compound <b>58</b> is hypothesized to be a type III binder based on molecular docking studies.<a onclick="showRef(event, 'ref156'); return false;" href="javascript:void(0);" class="ref ref156">(156)</a> In simulation studies, <b>58</b> may form hydrophobic interactions with RIPK1 through both the phenyl group and the branched alkane. In addition, two hydrogen bonds, one between the carbonyl oxygen and a backbone NH and the other between the N-OH and a Val residue, are hypothesized.<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a> Of note is compound <b>58</b>, a type III binder like <b>57</b>, which does not show the difference in potency between primates and non-primates. As such, researchers were able to assess the molecule in various murine models and found compound <b>58</b> efficiently protected mice from TNF-α-induced multiorgan damage and death.<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a> Type II binder <b>59</b> establishes a single hydrogen bond to hinge residue Met98 as well hydrophobic interactions with nearby residues. The central linker forms two additional hydrogen bonds, one with a side chain of a Glu residue and the other with a backbone NH. Upon binding to the inactive “DLG-out” conformation, the trifluoromethyl group fills the hydrophobic pocket vacated by the DLG. Structural determination with necrostatin <b>60</b> shows the molecule binding largely outside the ATP binding site and locks RIPK1 in an inactive conformation.<a onclick="showRef(event, 'ref157'); return false;" href="javascript:void(0);" class="ref ref157">(157)</a></div><figure id="fig24" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/medium/jm-2018-00667b_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0024.jpeg" id="gr24" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. Examples of recently reported inhibitors of RIPK1, RIPK2, and RIPK3 showing various chemotypes employed.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00667&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">More recent reports show type I binders of RIPK2 GSK583 (<b>61</b>),<a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a> imidazopyridine <b>62</b>,<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a> and pyrazolopyrimidine WEHI-345 (<b>63</b>).<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a> Quinoline <b>61</b> is an ATP competitive inhibitor that interacts with the hinge through a hydrogen bond between the quinolone N and the backbone of Met98. Other interactions include those by the 3-aminoindazole in a back pocket past the Thr gatekeeper and a hydrogen bond between the sulfone and the side chain of Ser25 side chain. The polar Ser25 residue is rare among protein kinases, with only three other kinases having a serine at this position, and is exploited in this case and by <b>62</b> for broader kinome selectivity.</div><div class="NLM_p">While <b>61</b> exhibits safety signals preventing advancement into the clinic, the molecule demonstrated inhibition of RIPK2 activity would modulate intestinal inflammation in both murine and human systems, supporting RIPK2 as an attractive therapeutic target for the treatment of IBD, and RIPK2 inhibitor GSK2983559 has just recently entered clinical evaluation (NCT03358407).<a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a> Like quinoline <b>61</b>, the pyridine of <b>62</b> forms a single hinge interaction with Met98 and there is a hydrogen bond interaction between the sulfone group and the side chain of Ser25 residue.<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a> In addition, compound <b>62</b> showed moderate but significant reduction in IL6 and TNF-α in PD studies designed to assess RIPK2 as a target for IBD treatment. Computational docking of compound <b>63</b> with a murine RIPK2 homology model hypothesizes interactions with hinge residues Glu96 and Met98 via pyrimidine N3 and the amine.<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a> The authors also provide evidence that in addition to blocking cytokine transcription and production, inhibition of RIPK2 is beneficial in a murine model for multiple sclerosis. Additional examples selected from the recent patent literature highlight the significant interest still in the RIP family. The discovery stories have yet to be shared and include pyridine <b>64</b>, isoxazolidinone <b>65</b> and 1,5-dihydro-4<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-4-one <b>66</b>, the lone RIPK3 inhibitor.<a onclick="showRef(event, 'ref161 ref162 ref163'); return false;" href="javascript:void(0);" class="ref ref161 ref162 ref163">(161−163)</a></div><div class="NLM_p last">There was initial hesitation in targeting RIPK1 as its expression is important to T cell survival and germline mice deficient in RIPK1 die within 3 days of birth due to multiorgan cell injury and inflammation.<a onclick="showRef(event, 'ref148 ref164'); return false;" href="javascript:void(0);" class="ref ref148 ref164">(148,164)</a> However, knock-in mice expressing kinase-inactive RIPK1 are viable and do not exhibit increased cell death and inflammation.<a onclick="showRef(event, 'ref164'); return false;" href="javascript:void(0);" class="ref ref164">(164)</a> Kaiser and others showed RIPK3-selective inhibition led to concentration-dependent induction of apoptosis, and there was growing concern that kinase intervention may lead to RHIM-driven apoptosis.<a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(165)</a> How inhibition of mediators in the signaling between necroptosis and inflammatory gene expression affect both efficacy and safety will be extremely interesting to learn.</div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">7.  Broadly Expressed Kinase Targets: MAPK/PI3K Families</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52405" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52405" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The previous kinases all focus on key cell members of the immune response, be it innate or adaptive. However, some kinase families are widely distributed and have been pursued for intervention in immune response as well as in other disease settings such as cancer. Two prime examples of this are the MAPK family and the PI3K family. Several of the kinases mentioned above signal through highly conserved MAPK and PI3K-mediated cascades, the cell’s chief mechanisms for regulating cell survival, proliferation, differentiation, metabolism, motility, and further amplification of signals in response to extracellular signals (<a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">25</a></a>).<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a> These have been extensively reviewed and are being actively pursued in a variety of therapeutic areas, in particular oncology along with cardiovascular, inflammatory, and autoimmune diseases.<a onclick="showRef(event, 'ref13 ref167 ref168 ref169'); return false;" href="javascript:void(0);" class="ref ref13 ref167 ref168 ref169">(13,167−169)</a> The two pathways are intertwined, as shown in <a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">25</a></a>, with both having mechanisms for activation and inhibition of the other.<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a> The MAPK signaling cascade will be highlighted first followed by the one PI3K family member of interest for immunological disease intervention, PI3Kδ.</div><figure id="fig25" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/medium/jm-2018-00667b_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0025.jpeg" id="gr25" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 25. Core components and cross-talk between PI3K and MAPK signaling pathways.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00667&amp;id=fig25"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div id="sec7_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17">7.A.  MAPK Family</h3><div class="NLM_p">The keen focus on the MAPK pathway is due to its far reaching roles within immune cell signaling. Following immune cell stimulation and signaling cascade initiation, members of the MAPK kinase kinases (MAP3Ks) are activated and phosphorylate MAPK kinases (MAP2Ks). MAP2Ks, MAPK/ERK kinases (MEKs), and mitogen-activated protein kinase kinase (MKKs) then phosphorylate the MAPK subfamilies, ERK, p38, and Jun N-terminal kinase (JNK), leading to their activation (<a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">26</a></a>).<a onclick="showRef(event, 'ref170'); return false;" href="javascript:void(0);" class="ref ref170">(170)</a> Different family members have distinct roles in translating the effects of stimulation into the correct physiological responses via the phosphorylation of a range of downstream substrates, including transcription factors, cytoskeletal proteins, and other signaling proteins.<a onclick="showRef(event, 'ref170'); return false;" href="javascript:void(0);" class="ref ref170">(170)</a></div><figure id="fig26" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Figure 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/medium/jm-2018-00667b_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0026.jpeg" id="gr26" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 26. Signaling cascade for MAPKs including ERKs, JNKs, and p38. Activation of MAP3Ks following receptor binding or stress induction leads to phosphorylation and activation of MAP2Ks such as MEKs and MKKs which in turn phosphorylate the MAPK family members. Activated MAPKs then translocate to the nucleus, where they phosphorylate transcription factors and modulate gene expression.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00667&amp;id=fig26"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Inhibitors of several MAPK kinases have shown efficacy in animal models such as collagen-induced arthritis models, acute inflammatory response in rat and cynomolgus monkeys, and robust anti-inflammatory activity in chronic disease models.<a onclick="showRef(event, 'ref170 ref171 ref172'); return false;" href="javascript:void(0);" class="ref ref170 ref171 ref172">(170−172)</a> However, of the multiple MAPK small molecule inhibitors discussed in a review by Arthur and Ley,<a onclick="showRef(event, 'ref170'); return false;" href="javascript:void(0);" class="ref ref170">(170)</a> none are currently being evaluated in the clinic for immunological disorders. In addition, of the well over 100 studies currently enrolling or active in the clinic with MAPK family member inhibitors, only one is for immune modulation: inhaled AZD7624 in corticosteroid resistant asthmatics (phase II, NCT02753764). This is after showing positive responses in humans on attenuation of lung and systemic inflammation upon LPS challenge.<a onclick="showRef(event, 'ref173'); return false;" href="javascript:void(0);" class="ref ref173">(173)</a></div><div class="NLM_p">The limited positive outcome for at least p38 MAPK inhibitors has been attributed to modest clinical efficacy and transient suppression of inflammation biomarkers observed in multiple studies.<a onclick="showRef(event, 'ref14 ref171'); return false;" href="javascript:void(0);" class="ref ref14 ref171">(14,171)</a> Hammaker et al. laid out a number of potential reasons behind this modest efficacy including isoform selection (p38α versus β), reliance on poorly translating animal models, and redundant signaling networks allowing for compensations.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> This may suggest that a more meaningful, sustained suppression of chronic inflammation is required. One potential mechanism for this is a new reported type I<sup>1</sup>/<sub>2</sub> inhibitor of p38 kinase that significantly extends the target residence time compared to classical type 1 inhibitors.<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a> An example is shown in <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>, panels A and B, where skepinone-L analog <b>67</b> has a target half-life of >15 h.<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a> Other examples in that report extend this to over 42 h.<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a> Compound <b>67</b> binds to the hinge via residues Met109 and Gly110 while also forming a hydrogen bond with Asp168 and an edge-to-face interaction with Phe169 of the DFG-motif (<a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">27</a></a>A).</div><figure id="fig27" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Figure 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/medium/jm-2018-00667b_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0027.jpeg" id="gr27" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 27. Different DFG orientations of p38α with DFG-out molecule PF-03715455 (<b>67</b>) and type 1<sup>1</sup>/<sub>2</sub> skepinone-L analog <b>68</b>: (A) X-ray cocrystal structure of <b>67</b> (5MTY); (B) chemical structures of <b>67</b> and <b>68</b> with reported binding kinetics;<a onclick="showRef(event, 'ref174 ref175'); return false;" href="javascript:void(0);" class="ref ref174 ref175">(174,175)</a> (C) X-ray cocrystal structure of <b>68</b> (2YIS); (D) overlay of p38α backbones showing different positions of D168 and F169 upon <b>67</b> and <b>68</b> binding.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00667&amp;id=fig27"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Pfizer has also reported a type II or DFG-out inhaled p38α inhibitor, PF-03715455 (<b>68</b>, <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">27</a></a>). In comparing binding kinetics of the two, the type II inhibitor showed even greater improvement in residence time, 80 h, as is expected for the DFG-out binding mode.<a onclick="showRef(event, 'ref175'); return false;" href="javascript:void(0);" class="ref ref175">(175)</a><a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">27</a></a> compares the conformation of the DFG residues with type I<sup>1</sup>/<sub>2</sub><b>67</b> (panel A), type II inhibitor <b>68</b> (panel C), and an overlay of the backbone of both showing the different positions of the DFG (panel D). While the increased residence time could lead to more meaningful suppression, development of <b>68</b> was halted in COPD and asthma due to business reasons, not safety and/or efficacy concerns (NCT02366637).</div></div><div id="sec7_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18">7.B.  Phosphoinositide 3-Kinase (PI3K)</h3><div class="NLM_p">Another critically important kinase within the immune system is phosphoinositide 3-kinase δ (PI3Kδ). PI3Kδ is a member of the class I PI3K family of lipid signaling kinases that phosphorylate phosphoinositides and is activated by receptor tyrosine kinases.<a onclick="showRef(event, 'ref167 ref168'); return false;" href="javascript:void(0);" class="ref ref167 ref168">(167,168)</a> While other PI3K members are ubiquitously expressed, PI3Kδ is predominantly found in leukocytes. There, it functions downstream of a number of receptors important to immune cell function including TCRs and FcRs as well as chemokine receptors in B cells and neutrophils. The heterodimeric kinase complex forming PI3Kδ, namely, the p85α regulatory subunit and the p110δ catalytic subunit, is acutely activated in B cells and T cells after exposure to antigens. This complex controls many aspects of lymphocyte development and differentiation, in part via the AKT/protein kinase B, forkhead box O1, and mechanistic target of rapamycin pathways.<a onclick="showRef(event, 'ref176'); return false;" href="javascript:void(0);" class="ref ref176">(176)</a> As such, PI3Kδ acts as a key signal transduction node in cells of the immune system where it is involved in cell survival, differentiation, activation, cellular senescence, and corticosteroid resistance.</div><div class="NLM_p">PI3Kδ had been a promising target in the pharmaceutical industry for over a decade. Driving this tremendous interest in PI3Kδ as a potential target for therapeutic intervention are the outcomes of its activation, deletion, and upregulation. Both PI3Kδ knockout and kinase dead mice show reduction in progenitor B cells. Activation and upregulation of PI3Kδ have been found in the lungs of COPD patients, in asthma animal models, and in the newly described activated PI3Kδ syndrome (APDS or PASLI disease). In APDS, hyperactivation of PI3Kδ signaling leads to T cell senescence and/or death among other symptoms.<a onclick="showRef(event, 'ref167 ref168 ref170 ref176 ref177'); return false;" href="javascript:void(0);" class="ref ref167 ref168 ref170 ref176 ref177">(167,168,170,176,177)</a> On the basis of these and other studies, several classes of PI3Kδ-isoform selective inhibitors have been described in the literature.<a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(167)</a> Examples are shown in <a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">28</a></a> including idelalisib (<b>69</b>) which is approved for chronic lymphocytic leukemia,<a onclick="showRef(event, 'ref178'); return false;" href="javascript:void(0);" class="ref ref178">(178)</a> clinical candidates GSK2269557 (<b>70</b>),<a onclick="showRef(event, 'ref179'); return false;" href="javascript:void(0);" class="ref ref179">(179)</a> and seletalisib (UCB5857, <b>71</b>)<a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(180)</a> along with recently disclosed preclinical molecule pyrrolotriazine <b>72</b>, which was found efficacious in a mouse arthritis model.<a onclick="showRef(event, 'ref181'); return false;" href="javascript:void(0);" class="ref ref181">(181)</a></div><figure id="fig28" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Figure 28</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/medium/jm-2018-00667b_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0028.jpeg" id="gr28" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 28. PI3Kδ-selective inhibitors recently described in the literature along with their important interactions where disclosed. Fold isoform selectivity is shown in parentheses. Participants in hinge residue binding are shown in red at the top of the molecule. Additional specific interactions are also shown.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00667&amp;id=fig28"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Critical interactions with the ATP binding site include hydrogen bonding with the backbone amine of hinge residue Val and the carbonyl of hinge residue Glu for those with bidentate interactions (<a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">28</a></a>: <b>69</b>, <b>70</b>, and <b>72</b>). In addition, indole <b>70</b> interacts with the Asp residue of the DFG loop.<a onclick="showRef(event, 'ref179'); return false;" href="javascript:void(0);" class="ref ref179">(179)</a> Previously disclosed series have also been identified that interact with a Lys in the affinity pocket.<a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(167)</a> Despite the tremendous effort placed on finding inhibitors, targeting PI3Kδ has not been without its challenges. Nonselective PI3K inhibitors have shown dose-limiting adverse events, some of which were hypothesized to be related to other family members.<a onclick="showRef(event, 'ref182'); return false;" href="javascript:void(0);" class="ref ref182">(182)</a> This led to the development of isoenzyme-selective inhibitors.</div><div class="NLM_p">Oral PI3Kδ inhibitors developed for the treatment of B cell leukemia include <b>69</b>, which exhibits >100× selectivity over other PI3K family isoforms. However, patients treated still suffer from considerable adverse effects. While <b>69</b> is efficacious in the lymphoma setting for which it is approved, unexpected autoimmune and infectious toxicities upon treatment demonstrate the need for careful development and monitoring, both alone and in combination.<a onclick="showRef(event, 'ref183'); return false;" href="javascript:void(0);" class="ref ref183">(183)</a> Clinical studies have shown high rates of autoimmune toxicities and increased rates of infection including opportunistic infections leading idelalisib to now carry a black-box warning. Phase I clinical evaluation of <b>71</b> in psoriasis patients and healthy volunteers (NCT02303509, NCT02207595) and the molecule was progressed to phase II in patients suffering from primary Sjögren’s syndrome (NCT02610543). However, this trial was terminated early this year due to enrollment challenges (<a href="http://www.clinicaltrials.gov" class="extLink">www.clinicaltrials.gov</a>). Noted safety findings were reported in the recent disclosure of <b>72</b>.<a onclick="showRef(event, 'ref181'); return false;" href="javascript:void(0);" class="ref ref181">(181)</a> Despite displaying >50% suppression of paw swelling in the mouse CIA efficacy model 2 and 5 mg/kg, QTc prolongation and hemodynamic effects were seen at doses down to 10 mg/kg to 20 mg/kg leaving a narrow safety margin for a chronic indication.<a onclick="showRef(event, 'ref181'); return false;" href="javascript:void(0);" class="ref ref181">(181)</a></div><div class="NLM_p last">Many of the autoimmune toxicities encountered are likely mediated through the on-target effects of inhibiting PI3Kδ in different lymphocyte subsets.<a onclick="showRef(event, 'ref167 ref168 ref176'); return false;" href="javascript:void(0);" class="ref ref167 ref168 ref176">(167,168,176)</a> These include T-regulatory lymphocytes which are critical in the maintenance of immune self-tolerance and downregulation and also appear to be instrumental in the mechanism of PI3K-associated autoimmune toxicities. A potential method for circumventing systemic exposure is being explored by indazole <b>70</b> (<a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">28</a></a>) which is being dosed as an inhaled inhibitor.<a onclick="showRef(event, 'ref176'); return false;" href="javascript:void(0);" class="ref ref176">(176)</a> Evaluation in asthma patients has been completed (NCT01462617), though results have not yet been disclosed. These and results from current clinical trials for APDS (NCT02593539) and COPD (NCT03345407, NCT02522299) will be informative around whether a PI3Kδ inhibitor can be successful in a chronic inflammation and immune setting.</div></div></div><div id="sec8" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">8.  Future Directions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68001" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68001" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Despite a lack of progress in terms of numbers of clinical approvals for small molecule kinase inhibitors for inflammatory and autoimmune diseases, there is much promise for continued pursuit in the field. First, only a relatively small subset of the human kinome has been studied with most of the focus being on tyrosine kinases.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> With the rapid advancement of our understanding of inflammatory pathways (guided by advanced genetics and CRIPR technologies), additional targets for therapeutic intervention are expected. There has also been a dramatic increase in the ability to achieve high levels of selectivity, decreasing the likelihood of off-target effect and broadening the window for improved safety. With these improvements, there has been an expansion in novel strategies for targeting these kinases. These include inducing pockets in the ATP-binding site (BTK), selecting for type I<sup>1</sup>/<sub>2</sub>, type II, and type III inhibitors (RIP, p38, NIK), targeting pseudokinase domains (JAK), and targeting kinase-unique cysteine residues (JAK, BTK). When systemic exposure may not be tolerated for even single-kinase selective inhibitors due to on-target toxicities or when localized exposure is critical, alternative modalities may provide relief. Indeed, these are being explored for several of the kinases mentioned including JAK family inhibitors and PI3Kδ inhibitors where both inhaled and topical applications are being pursued.</div><div class="NLM_p">There is also a growing appreciation for the redundancy and cross-talk involved in the immune system, and inhibiting more than one kinase may be needed to increase efficacy through additive or synergistic effects.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Toward this, specific combination therapies may prove highly beneficial due to the synergistic impact on multiple pathways and may allow for lower doses of different molecules giving better tolerability profiles and may avoid or delay the development of resistance or induction of broad immunosuppression.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> In cases where the level of inhibition for optimal impact is unknown, expected to be insufficient, or may come with tolerability challenges, either inhibiting multiple kinases with a single small molecule (e.g., dual ITK/RLK inhibitor <b>44</b>, dual SYK/JAK inhibitor <b>26</b>) or inhibiting multiple nodes via combination therapies (e.g., BTK/JAK inhibitors with SYK inhibitor GS-9876) may be more suitable.<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> In addition, they may prevent development of resistance as mentioned for JAK inhibitors. Certain diseases may be better suited for multikinase inhibitors including severe airway disease where treatment with inhaled, so-called narrow spectrum kinase inhibitors is more effective than p38α inhibitors alone at suppressing the release of inflammatory cytokines from macrophages in vitro and in rodent models.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a></div><div class="NLM_p last">Finally, other targets, including family members of those described above like IRAK1,<a onclick="showRef(event, 'ref6 ref119'); return false;" href="javascript:void(0);" class="ref ref6 ref119">(6,119)</a> other RIP family members, and other MAP2Ks like the mixed lineage kinases (MLKs),<a onclick="showRef(event, 'ref184'); return false;" href="javascript:void(0);" class="ref ref184">(184)</a> are actively being pursued and may hold significant benefit. Despite the challenges that targeting kinases for inflammatory and autoimmune diseases have faced, there remains a great deal of optimism for the strategy and for those small molecule inhibitors under clinical evaluation.</div></div><div class="NLM_back"><div class="NLM_notes" id="notes-1"><p class="first last">The authors declare the following competing financial interest(s): Authors are Genentech employees and have stock/shares in Genentech, Inc.</p></div><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.8b00667" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53455" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53455" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marian C. Bryan</span> - <span class="hlFld-Affiliation affiliation">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-3138-6888" title="Orcid link">http://orcid.org/0000-0002-3138-6888</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#6a0818130b0444070b18030b042a0d0f040f44090507"><span class="__cf_email__" data-cfemail="bfddcdc6ded191d2decdd6ded1ffd8dad1da91dcd0d2">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Naomi S. Rajapaksa</span> - <span class="hlFld-Affiliation affiliation">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><p>The authors declare the following competing financial interest(s): Authors are Genentech employees and have stock/shares in Genentech, Inc.<br /></br></p></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44155" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44155" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Marian C. Bryan</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00667&amp;id=BIO-d131e3213-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Marian C. Bryan</b> studied chemistry and biochemistry at Clemson University prior to pursuing her Ph.D. in Chemistry under the direction of Professor Chi-Huey Wong at The Scripps Research Institute. Following an American Cancer Society postdoctoral fellowship with Professor Linda Hsieh-Wilson at The California Institute of Technology, she joined the Department of Medicinal Chemistry at Amgen, Inc., in 2006. In 2012, she joined Genentech, Inc., where she is a team leader and Senior Scientist in Discovery Small Molecule Research.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Naomi S. Rajapaksa</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00667&amp;id=BIO-d131e3218-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Naomi S. Rajapaksa</b> received her Bachelor’s degree in Chemistry from Stanford University. She obtained her Ph.D. from Harvard University where she studied asymmetric catalysis and total synthesis under the direction of Professor Eric N. Jacobsen. She then joined the infectious diseases medicinal chemistry group at Novartis. In 2016, she joined Genentech, Inc., where she is a scientist in the Small Molecule Discovery Chemistry department.</p></figure></div><div class="ack" id="ACK-d131e3223-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53266" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53266" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors thank Dr. Brent McKenzie, Dr. Hans Brightbill, Swathi Sujatha-Bhaskar, and Dr. Tim Heffron for helpful discussions and feedback and Dr. James Kiefer for structural graphics support.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">APDS</td><td class="NLM_def"><p class="first last">activated PI3Kδ syndrome</p></td></tr><tr><td class="NLM_term">BAFF</td><td class="NLM_def"><p class="first last">B cell activating factor</p></td></tr><tr><td class="NLM_term">BCR</td><td class="NLM_def"><p class="first last">B cell receptor</p></td></tr><tr><td class="NLM_term">BMX</td><td class="NLM_def"><p class="first last">bone marrow kinase</p></td></tr><tr><td class="NLM_term">BTK</td><td class="NLM_def"><p class="first last">Bruton’s tyrosine kinase</p></td></tr><tr><td class="NLM_term">CIA</td><td class="NLM_def"><p class="first last">collagen-induced arthritis</p></td></tr><tr><td class="NLM_term">cIAP</td><td class="NLM_def"><p class="first last">cellular inhibitors of apoptosis</p></td></tr><tr><td class="NLM_term">CLE</td><td class="NLM_def"><p class="first last">cutaneous lupus erythematosus</p></td></tr><tr><td class="NLM_term">DAG</td><td class="NLM_def"><p class="first last">diacyl glycerol</p></td></tr><tr><td class="NLM_term">DMARD</td><td class="NLM_def"><p class="first last">disease-modifying antirheumatic drug treatment</p></td></tr><tr><td class="NLM_term">FcR</td><td class="NLM_def"><p class="first last">Fc receptor</p></td></tr><tr><td class="NLM_term">IFNαR</td><td class="NLM_def"><p class="first last">interferon-α receptor</p></td></tr><tr><td class="NLM_term">IgE</td><td class="NLM_def"><p class="first last">immunoglobulin E</p></td></tr><tr><td class="NLM_term">IKK</td><td class="NLM_def"><p class="first last">IκB kinase</p></td></tr><tr><td class="NLM_term">IL1R</td><td class="NLM_def"><p class="first last">IL-1 receptor</p></td></tr><tr><td class="NLM_term">IP3</td><td class="NLM_def"><p class="first last">inositol triphosphate</p></td></tr><tr><td class="NLM_term">IRAK</td><td class="NLM_def"><p class="first last">interleukin-1 receptor activated kinase</p></td></tr><tr><td class="NLM_term">ITAM</td><td class="NLM_def"><p class="first last">immunoreceptor tyrosine-based activation motif</p></td></tr><tr><td class="NLM_term">ITK</td><td class="NLM_def"><p class="first last">interleukin-2 inducible T cell kinase</p></td></tr><tr><td class="NLM_term">JAK</td><td class="NLM_def"><p class="first last">Janus kinase</p></td></tr><tr><td class="NLM_term">JNK</td><td class="NLM_def"><p class="first last">Jun N-terminal kinase</p></td></tr><tr><td class="NLM_term">mCAIA</td><td class="NLM_def"><p class="first last">mannan-induced collagen antibody induced arthritis</p></td></tr><tr><td class="NLM_term">LAT</td><td class="NLM_def"><p class="first last">linker of activated T-cells</p></td></tr><tr><td class="NLM_term">LPS</td><td class="NLM_def"><p class="first last">lipopolysaccharide</p></td></tr><tr><td class="NLM_term">MAP2K</td><td class="NLM_def"><p class="first last">MAPK kinase</p></td></tr><tr><td class="NLM_term">MAP3K</td><td class="NLM_def"><p class="first last">MAPK kinase kinase</p></td></tr><tr><td class="NLM_term">MEK</td><td class="NLM_def"><p class="first last">MAPK/ERK kinase</p></td></tr><tr><td class="NLM_term">MKK</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase kinase</p></td></tr><tr><td class="NLM_term">MLKL</td><td class="NLM_def"><p class="first last">mixed lineage kinase domain-like protein</p></td></tr><tr><td class="NLM_term">NFAT</td><td class="NLM_def"><p class="first last">nuclear factor of activated T cells</p></td></tr><tr><td class="NLM_term">NIK</td><td class="NLM_def"><p class="first last">NF-κB inducing kinase</p></td></tr><tr><td class="NLM_term">NK</td><td class="NLM_def"><p class="first last">natural killer</p></td></tr><tr><td class="NLM_term">PA</td><td class="NLM_def"><p class="first last">psoriatic arthritis</p></td></tr><tr><td class="NLM_term">PAMP</td><td class="NLM_def"><p class="first last">pathogen-associated molecular pattern</p></td></tr><tr><td class="NLM_term">pDC</td><td class="NLM_def"><p class="first last">plasmacytoid dendritic cell</p></td></tr><tr><td class="NLM_term">PIP2</td><td class="NLM_def"><p class="first last">phosphoinositol diphosphate</p></td></tr><tr><td class="NLM_term">PIP3</td><td class="NLM_def"><p class="first last">phosphatidylinositol 3,4,5-trisphosphate</p></td></tr><tr><td class="NLM_term">PLCγ2</td><td class="NLM_def"><p class="first last">phospholipase C γ 2</p></td></tr><tr><td class="NLM_term">PPR</td><td class="NLM_def"><p class="first last">pattern recognition receptor</p></td></tr><tr><td class="NLM_term">p-STAT</td><td class="NLM_def"><p class="first last">phosphorylated STAT</p></td></tr><tr><td class="NLM_term">RA</td><td class="NLM_def"><p class="first last">rheumatoid arthritis</p></td></tr><tr><td class="NLM_term">RANK</td><td class="NLM_def"><p class="first last">receptor activator of NF-κB</p></td></tr><tr><td class="NLM_term">RHIM</td><td class="NLM_def"><p class="first last">RIP homotypic interaction motif</p></td></tr><tr><td class="NLM_term">RIPK</td><td class="NLM_def"><p class="first last">receptor-interacting protein kinase</p></td></tr><tr><td class="NLM_term">RLK</td><td class="NLM_def"><p class="first last">resting lymphocyte kinase</p></td></tr><tr><td class="NLM_term">SLE</td><td class="NLM_def"><p class="first last">systemic lupus erythematosus</p></td></tr><tr><td class="NLM_term">STAT</td><td class="NLM_def"><p class="first last">signal transducers and activators of transcription</p></td></tr><tr><td class="NLM_term">SYK</td><td class="NLM_def"><p class="first last">spleen tyrosine kinase</p></td></tr><tr><td class="NLM_term">TAK1</td><td class="NLM_def"><p class="first last">transforming growth factor β-activated kinase 1</p></td></tr><tr><td class="NLM_term">TCR</td><td class="NLM_def"><p class="first last">T cell receptor</p></td></tr><tr><td class="NLM_term">TEC</td><td class="NLM_def"><p class="first last">tyrosine kinase expressed in hepatocellular carcinoma</p></td></tr><tr><td class="NLM_term">Th</td><td class="NLM_def"><p class="first last">T helper</p></td></tr><tr><td class="NLM_term">TIR</td><td class="NLM_def"><p class="first last">Toll/IL-1R</p></td></tr><tr><td class="NLM_term">TNF-R</td><td class="NLM_def"><p class="first last">TNF receptor</p></td></tr><tr><td class="NLM_term">TRAF</td><td class="NLM_def"><p class="first last">TNF-receptor associated factor</p></td></tr><tr><td class="NLM_term">TYK2</td><td class="NLM_def"><p class="first last">tyrosine kinase 2</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i24">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73766" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73766" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 184 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wekell, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlsson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fasth, A.</span></span> <span> </span><span class="NLM_article-title">Toward an inclusive, congruent, and precise definition of autoinflammatory diseases</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">497</span>, <span class="refDoi"> DOI: 10.3389/fimmu.2017.00497</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.3389%2Ffimmu.2017.00497" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=28496446" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVehsbzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=497&author=P.+Wekellauthor=S.+Bergauthor=A.+Karlssonauthor=A.+Fasth&title=Toward+an+inclusive%2C+congruent%2C+and+precise+definition+of+autoinflammatory+diseases&doi=10.3389%2Ffimmu.2017.00497"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Toward an inclusive, congruent, and precise definition of autoinflammatory diseases</span></div><div class="casAuthors">Wekell, Per; Berg, Stefan; Karlsson, Anna; Fasth, Anders</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Immunology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">497/1-497/5</span>CODEN:
                <span class="NLM_cas:coden">FIRMCW</span>;
        ISSN:<span class="NLM_cas:issn">1664-3224</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Autoinflammatory disease was introduced as a concept in 1999, demarcating an entirely new group of diseases in clin., immunol., and conceptual terms.  During recent years, the preconditions for the definition of autoinflammatory conditions have changed.  This includes the recent discovery of a no. of monogenic autoinflammatory conditions with complex phenotypes that combine autoinflammation with defects of the adaptive and/or innate immune system, resulting in the occurrence of infection, autoimmunity, and/or uncontrolled hyperinflammation in addn. to autoinflammation.  Further, there are strong indications that classical IL-1-driven autoinflammatory diseases are assocd. with activation of adaptive immunity.  As suggested by this development, we are of the opinion that an all-encompassing definition of autoinflammatory diseases should regard autoinflammatory conditions and innate dysregulation as inseparable and integral parts of the immune system as a whole.  Hence, in this article, we try to advance the conceptual understanding of autoinflammatory disease by, proposing a modification of the definition by Daniel Kastner et al., which allows for a congruent and precise description of conditions that expand the immunol. spectrum of autoinflammatory disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3AM5_YjQK0bVg90H21EOLACvtfcHk0lhlgEurYwx1ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVehsbzI&md5=d444df679f3bb90ab77362057b4ea1f5</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2017.00497&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2017.00497%26sid%3Dliteratum%253Aachs%26aulast%3DWekell%26aufirst%3DP.%26aulast%3DBerg%26aufirst%3DS.%26aulast%3DKarlsson%26aufirst%3DA.%26aulast%3DFasth%26aufirst%3DA.%26atitle%3DToward%2520an%2520inclusive%252C%2520congruent%252C%2520and%2520precise%2520definition%2520of%2520autoinflammatory%2520diseases%26jtitle%3DFront.%2520Immunol.%26date%3D2017%26volume%3D8%26spage%3D497%26doi%3D10.3389%2Ffimmu.2017.00497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, P. J.</span></span> <span> </span><span class="NLM_article-title">Kinases as novel therapeutic targets in asthma and chronic obstructive pulmonary disease</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">788</span>– <span class="NLM_lpage">815</span>, <span class="refDoi"> DOI: 10.1124/pr.116.012518</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1124%2Fpr.116.012518" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=27363440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkvFCrs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2016&pages=788-815&author=P.+J.+Barnes&title=Kinases+as+novel+therapeutic+targets+in+asthma+and+chronic+obstructive+pulmonary+disease&doi=10.1124%2Fpr.116.012518"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Kinases as novel therapeutic targets in asthma and chronic obstructive pulmonary disease</span></div><div class="casAuthors">Barnes, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">788-815</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">1521-0081</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Multiple kinases play a crit. role in orchestrating the chronic inflammation and structural changes in the respiratory tract of patients with asthma and chronic obstructive pulmonary disease (COPD).  Kinases activate signaling pathways that lead to contraction of airway smooth muscle and release of inflammatory mediators (such as cytokines, chemokines, growth factors) as well as cell migration, activation, and proliferation.  For this reason there has been great interest in the development of kinase inhibitors as anti-inflammatory therapies, particular where corticosteroids are less effective, as in severe asthma and COPD.  However, it has proven difficult to develop selective kinase inhibitors that are both effective and safe after oral administration and this has led to a search for inhaled kinase inhibitors, which would reduce systemic exposure.  Although many kinases have been implicated in inflammation and remodeling of airway disease, very few classes of drug have reached the stage of clin. studies in these diseases.  The most promisingdrugs arep38MAPkinases, isoenzyme-selective PI3-kinases, Janus-activated kinases, and Syk-kinases, and inhaled formulations of these drugs are now in development.  There has also been interest in developing inhibitors that block more than one kinase, because these drugs may be more effective and with less risk of losing efficacy with time.  No kinase inhibitors are yet on the market for the treatment of airway diseases, but as kinase inhibitors are improved from other therapeutic areas there is hope that these drugs may eventually prove useful in treating refractory asthma and COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpeztyKAL-brVg90H21EOLACvtfcHk0lgmLWhV2XwOiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkvFCrs7k%253D&md5=b1124d17b06af2c9577db2967d4914a9</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1124%2Fpr.116.012518&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.116.012518%26sid%3Dliteratum%253Aachs%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26atitle%3DKinases%2520as%2520novel%2520therapeutic%2520targets%2520in%2520asthma%2520and%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DPharmacol.%2520Rev.%26date%3D2016%26volume%3D68%26spage%3D788%26epage%3D815%26doi%3D10.1124%2Fpr.116.012518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bilsborough, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Targan, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snapper, S. B.</span></span> <span> </span><span class="NLM_article-title">Therapeutic targets in inflammatory bowel disease: current and future</span>. <i>Am. J. Gastroenterol. Suppl.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">37</span>, <span class="refDoi"> DOI: 10.1038/ajgsup.2016.18</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1038%2Fajgsup.2016.18" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVegtLzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2016&pages=27-37&author=J.+Bilsboroughauthor=S.+R.+Targanauthor=S.+B.+Snapper&title=Therapeutic+targets+in+inflammatory+bowel+disease%3A+current+and+future&doi=10.1038%2Fajgsup.2016.18"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic Targets in Inflammatory Bowel Disease: Current and Future</span></div><div class="casAuthors">Bilsborough, Janine; Targan, Stephan R.; Snapper, Scott B.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Gastroenterology Supplements</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">27-37</span>CODEN:
                <span class="NLM_cas:coden">AJGSAD</span>;
        ISSN:<span class="NLM_cas:issn">1948-9501</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The etiol. of inflammatory bowel disease (IBD) is not fully understood but is likely influenced by numerous factors such as genetic predisposition, environmental factors, like the microbiota, and social behaviors, including smoking and diet.  In addn. to anti-tumor necrosis factor therapy, we now have integrin inhibitors that target lymphocyte trafficking to the gastrointestinal tract (vedolizumab and natalizumab); however, unmet medical needs remain.  Although several immunol. pathways have been implicated in the pathogenesis of IBD, targeting these with drug therapy has produced mixed results.  Recent drug failures, particularly anti-interleukin-17 (anti-IL17) in Crohn's disease and anti-IL13 in ulcerative colitis, highlight our fundamental lack of understanding of the impact of pathogenic heterogeneity in the treatment of IBD.  In addn. to a "failure of mechanism," other reasons for drug failure may include issues with the drug itself-for example, insufficient activity, or lack of targeting, inadequate trial design or dosing, or potentially our inability to characterize patients who may be more (or less) responsive to a specific therapy.  This review summarizes some of the successes and failures and evaluates therapies currently under investigation for IBD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRauWR9GH_J7Vg90H21EOLACvtfcHk0lgmLWhV2XwOiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVegtLzF&md5=ba3de41ce55e58d7109e7367de403ac7</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fajgsup.2016.18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fajgsup.2016.18%26sid%3Dliteratum%253Aachs%26aulast%3DBilsborough%26aufirst%3DJ.%26aulast%3DTargan%26aufirst%3DS.%2BR.%26aulast%3DSnapper%26aufirst%3DS.%2BB.%26atitle%3DTherapeutic%2520targets%2520in%2520inflammatory%2520bowel%2520disease%253A%2520current%2520and%2520future%26jtitle%3DAm.%2520J.%2520Gastroenterol.%2520Suppl.%26date%3D2016%26volume%3D3%26spage%3D27%26epage%3D37%26doi%3D10.1038%2Fajgsup.2016.18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhari, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizvi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Syed, B. A.</span></span> <span> </span><span class="NLM_article-title">Rheumatoid arthritis: current and future trends</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">305</span>– <span class="NLM_lpage">306</span>, <span class="refDoi"> DOI: 10.1038/nrd.2016.21</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1038%2Fnrd.2016.21" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=27080040" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtVOqsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=305-306&author=K.+Chaudhariauthor=S.+Rizviauthor=B.+A.+Syed&title=Rheumatoid+arthritis%3A+current+and+future+trends&doi=10.1038%2Fnrd.2016.21"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Rheumatoid arthritis: current and future trends</span></div><div class="casAuthors">Chaudhari, Kritika; Rizvi, Salman; Syed, Basharut A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">305-306</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">This article analyses the market for rheumatoid arthritis therapies, which is growing rapidly, with a range of new disease-modifying drugs poised to enter in the next few years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoM2gpyG3Nq97Vg90H21EOLACvtfcHk0lgmLWhV2XwOiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtVOqsrw%253D&md5=2640f07d2a8e2a6191c900b6417164b0</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2016.21&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2016.21%26sid%3Dliteratum%253Aachs%26aulast%3DChaudhari%26aufirst%3DK.%26aulast%3DRizvi%26aufirst%3DS.%26aulast%3DSyed%26aufirst%3DB.%2BA.%26atitle%3DRheumatoid%2520arthritis%253A%2520current%2520and%2520future%2520trends%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2016%26volume%3D15%26spage%3D305%26epage%3D306%26doi%3D10.1038%2Fnrd.2016.21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J.-B.</span></span> <span> </span><span class="NLM_article-title">Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">5023</span>– <span class="NLM_lpage">5038</span>, <span class="refDoi"> DOI: 10.1021/jm401490p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401490p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotVCjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5023-5038&author=J.+D.+Clarkauthor=M.+E.+Flanaganauthor=J.-B.+Telliez&title=Discovery+and+development+of+Janus+kinase+%28JAK%29+inhibitors+for+inflammatory+diseases&doi=10.1021%2Fjm401490p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases</span></div><div class="casAuthors">Clark, James D.; Flanagan, Mark E.; Telliez, Jean-Baptiste</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5023-5038</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The Janus kinases (JAKs) are a family of intracellular tyrosine kinases that play an essential role in the signaling of numerous cytokines that have been implicated in the pathogenesis of inflammatory diseases.  As a consequence, the JAKs have received significant attention in recent years from the pharmaceutical and biotechnol. industries as therapeutic targets.  Here, we provide a review of the JAK pathways, the structure, function, and activation of the JAK enzymes followed by a detailed look at the JAK inhibitors currently in the clinic or approved for these indications.  Finally, a perspective is provided on what the past decade of research with JAK inhibitors for inflammatory indications has taught along with thoughts on what the future may hold in terms of addressing the opportunities and challenges that remain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3f7W5g8N6brVg90H21EOLACvtfcHk0lgbypm8skByfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotVCjsA%253D%253D&md5=6763ae2d46f52ddcda23e235a60634ae</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1021%2Fjm401490p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401490p%26sid%3Dliteratum%253Aachs%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DTelliez%26aufirst%3DJ.-B.%26atitle%3DDiscovery%2520and%2520development%2520of%2520Janus%2520kinase%2520%2528JAK%2529%2520inhibitors%2520for%2520inflammatory%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5023%26epage%3D5038%26doi%3D10.1021%2Fjm401490p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, P.</span></span> <span> </span><span class="NLM_article-title">The TLR and IL-1 signalling network at a glance</span>. <i>J. Cell Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">2383</span>– <span class="NLM_lpage">2390</span>, <span class="refDoi"> DOI: 10.1242/jcs.149831</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1242%2Fjcs.149831" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=24829146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVOgsrbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2014&pages=2383-2390&author=P.+Cohen&title=The+TLR+and+IL-1+signalling+network+at+a+glance&doi=10.1242%2Fjcs.149831"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The TLR and IL-1 signalling network at a glance</span></div><div class="casAuthors">Cohen, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2383-2390</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">A review.  Toll-like receptors (TLRs) and the receptors for interleukin (IL)-1, IL-18 and IL-33 are required for defense against microbial pathogens but, if hyper-activated or not switched off efficiently, can cause tissue damage and inflammatory and autoimmune diseases.  Understanding how the checks and balances in the system are integrated to fight infection without the network operating out of control will be crucial for the development of improved drugs to treat these diseases in the future.  In this Cell Science at a Glance article and the accompanying poster, I provide a brief overview of how one of these intricate networks is controlled by the interplay of protein phosphorylation and protein ubiquitylation events, and the mechanisms in myeloid cells that restrict and terminate its activation to prevent inflammatory and autoimmune diseases.  Finally, I suggest a few protein kinases that have been neglected as drug targets, but whose therapeutic potential should be explored in the light of recent advances in our understanding of their roles in the innate immune system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0Hfw28mAkmrVg90H21EOLACvtfcHk0lj1-zlPkKprng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVOgsrbK&md5=b86f588378be962309bad302139543c6</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1242%2Fjcs.149831&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fjcs.149831%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DP.%26atitle%3DThe%2520TLR%2520and%2520IL-1%2520signalling%2520network%2520at%2520a%2520glance%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2014%26volume%3D127%26spage%3D2383%26epage%3D2390%26doi%3D10.1242%2Fjcs.149831" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alessi, D. R.</span></span> <span> </span><span class="NLM_article-title">Kinase drug discovery – what’s next in the field?</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">96</span>– <span class="NLM_lpage">104</span>, <span class="refDoi"> DOI: 10.1021/cb300610s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb300610s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=96-104&author=P.+Cohenauthor=D.+R.+Alessi&title=Kinase+drug+discovery+%E2%80%93+what%E2%80%99s+next+in+the+field%3F&doi=10.1021%2Fcb300610s"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Fcb300610s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb300610s%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DP.%26aulast%3DAlessi%26aufirst%3DD.%2BR.%26atitle%3DKinase%2520drug%2520discovery%2520%25E2%2580%2593%2520what%25E2%2580%2599s%2520next%2520in%2520the%2520field%253F%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2013%26volume%3D8%26spage%3D96%26epage%3D104%26doi%3D10.1021%2Fcb300610s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Furumoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadina, M.</span></span> <span> </span><span class="NLM_article-title">The arrival of JAK inhibitors: advancing the treatment of immune and hematologic disorders</span>. <i>BioDrugs</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">431</span>– <span class="NLM_lpage">438</span>, <span class="refDoi"> DOI: 10.1007/s40259-013-0040-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1007%2Fs40259-013-0040-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=23743669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsl2nsbzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2013&pages=431-438&author=Y.+Furumotoauthor=M.+Gadina&title=The+arrival+of+JAK+inhibitors%3A+advancing+the+treatment+of+immune+and+hematologic+disorders&doi=10.1007%2Fs40259-013-0040-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The Arrival of JAK Inhibitors: Advancing the Treatment of Immune and Hematologic Disorders</span></div><div class="casAuthors">Furumoto, Yasuko; Gadina, Massimo</div><div class="citationInfo"><span class="NLM_cas:title">BioDrugs</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">431-438</span>CODEN:
                <span class="NLM_cas:coden">BIDRF4</span>;
        ISSN:<span class="NLM_cas:issn">1173-8804</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Altered prodn. of cytokines can result in pathologies ranging from autoimmune diseases to malignancies.  The Janus kinase family is a small group of receptor-assocd. signaling mols. that is essential to the signal cascade originating from type I and type II cytokine receptors.  Inhibition of tyrosine kinase enzymic activity using small mols. has recently become a powerful tool for treatment of several malignancies.  Twenty years after the discovery of these enzymes, two inhibitors for this class of kinases have been approved for clin. use and others are currently in the final stage of development.  Here we review the principles of cytokines signaling, summarize our current knowledge of the approved inhibitors, and briefly introduce some of the inhibitors that are currently under development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQNQJyHX0EDLVg90H21EOLACvtfcHk0lj1-zlPkKprng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsl2nsbzI&md5=a593c1f01565b3dc3bf3df8c424595a6</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1007%2Fs40259-013-0040-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40259-013-0040-7%26sid%3Dliteratum%253Aachs%26aulast%3DFurumoto%26aufirst%3DY.%26aulast%3DGadina%26aufirst%3DM.%26atitle%3DThe%2520arrival%2520of%2520JAK%2520inhibitors%253A%2520advancing%2520the%2520treatment%2520of%2520immune%2520and%2520hematologic%2520disorders%26jtitle%3DBioDrugs%26date%3D2013%26volume%3D27%26spage%3D431%26epage%3D438%26doi%3D10.1007%2Fs40259-013-0040-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mócsai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovács, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gergely, P.</span></span> <span> </span><span class="NLM_article-title">What is the future of targeted therapy in rheumatology: biologics or small molecules?</span>. <i>BMC Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">43</span>, <span class="refDoi"> DOI: 10.1186/1741-7015-12-43</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1186%2F1741-7015-12-43" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=24620738" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjsVWjtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2014&pages=43&author=A.+M%C3%B3csaiauthor=L.+Kov%C3%A1csauthor=P.+Gergely&title=What+is+the+future+of+targeted+therapy+in+rheumatology%3A+biologics+or+small+molecules%3F&doi=10.1186%2F1741-7015-12-43"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">What is the future of targeted therapy in rheumatology: biologics or small molecules?</span></div><div class="casAuthors">Mocsai, Attila; Kovacs, Laszlo; Gergely, Peter</div><div class="citationInfo"><span class="NLM_cas:title">BMC Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">43/1-43/9, 9</span>CODEN:
                <span class="NLM_cas:coden">BMMECZ</span>;
        ISSN:<span class="NLM_cas:issn">1741-7015</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Until late in the 20th century, the therapy of rheumatic diseases relied on the use of drugs that had been developed through empirical approaches without detailed understanding of the mol. mechanisms involved.  That approach changed with the introduction of biol. therapeutics at the end of the 20th century and by the recent development of small-mol. inhibitors of intracellular signal transduction pathways.  Here we compare and discuss the advantages and disadvantages of those two groups of targeted anti-inflammatory therapeutics.  Discussion: TNF-blocking biol. agents were introduced into the therapy of rheumatoid arthritis and other autoimmune and inflammatory diseases in the late 1990s.  Further biol. agents targeting cytokine networks or specific lymphocyte subsets have since been added to the armamentarium of anti-rheumatic therapy.  During the last few years, another wave of novel discoveries led to the development of a new class of small mol. anti-inflammatory compds. targeting intracellular signal transduction mols., such as tyrosine kinases.  In all those cases, the specific targets of the drugs are well defined and significant knowledge about their role in the disease pathomechanism is available, qualifying them for being targeted therapeutics for inflammatory rheumatic diseases.  While both groups of targeted therapeutics offer significant clin. benefit, they clearly differ in several aspects, such as the localization of their targets, their route of administration and target specificity, as well as tech. details such as manufg. procedures and cost basis.  In this debate paper, we compare the advantages and disadvantages of the two different approaches, aiming to shed light on the possible future of targeted therapies.  Summary: Biol. therapeutics and small-mol. inhibitors both have significant advantages and disadvantages in the therapy of rheumatic diseases.  The future of targeted therapies is one of the most exciting questions of current rheumatol. research and therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTONjip_IttLVg90H21EOLACvtfcHk0lhJNUs6IdGI8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjsVWjtrk%253D&md5=20ede05081b83e736ad5675afcffc21d</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1186%2F1741-7015-12-43&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1741-7015-12-43%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25B3csai%26aufirst%3DA.%26aulast%3DKov%25C3%25A1cs%26aufirst%3DL.%26aulast%3DGergely%26aufirst%3DP.%26atitle%3DWhat%2520is%2520the%2520future%2520of%2520targeted%2520therapy%2520in%2520rheumatology%253A%2520biologics%2520or%2520small%2520molecules%253F%26jtitle%3DBMC%2520Med.%26date%3D2014%26volume%3D12%26spage%3D43%26doi%3D10.1186%2F1741-7015-12-43" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Levin, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wildenberg, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van den Brink, G. R.</span></span> <span> </span><span class="NLM_article-title">Mechanism of action of anti-TNF therapy in inflammatory bowel disease</span>. <i>J. Crohn’s Colitis</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">989</span>– <span class="NLM_lpage">997</span>, <span class="refDoi"> DOI: 10.1093/ecco-jcc/jjw053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1093%2Fecco-jcc%2Fjjw053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=26896086" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A280%3ADC%252BC28jis1Smtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=989-997&author=A.+D.+Levinauthor=M.+E.+Wildenbergauthor=G.+R.+van+den+Brink&title=Mechanism+of+action+of+anti-TNF+therapy+in+inflammatory+bowel+disease&doi=10.1093%2Fecco-jcc%2Fjjw053"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of Action of Anti-TNF Therapy in Inflammatory Bowel Disease</span></div><div class="casAuthors">Levin Alon D; Wildenberg Manon E; van den Brink Gijs R</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Crohn's & colitis</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">989-97</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Several anti-tumour necrosis factor [TNF] blocking strategies have been evaluated in patients with Crohn's disease.  Compounds that have been tested included the full monoclonal IgG1 antibodies infliximab and adalimumab, the pegylated anti-TNF F[ab']2 fragment certolizumab, an IgG4 anti-TNF CDP571 with reduced affinity for the Fc receptor, the soluble TNF receptor I onercept, and the TNF receptor II-Fc fusion protein etanercept.  The endpoints of these studies suggest that not all methods of blocking TNF are equal.  Here we will review the differences in the clinical, biochemical, and endoscopic endpoints of the major clinical studies.  Collectively the data suggest that only IgG1 monoclonal antibodies have the ability to induce complete clinical, biochemical, and endoscopic remission.  We discuss the potential multiple modes of action that may contribute to the response to full IgG1 anti-TNFs, focusing on the rapid induction of lamina propria T cell apoptosis and Fc receptor-dependent induction of M2-type wound-healing macrophages.  We discuss how novel insights into the mechanism of action of anti-TNFs in Crohn's disease may contribute to the development of novel anti-TNFs with improved efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSGKvATnWdAPkwlCcfExbvbfW6udTcc2eYyisiZTI_Rh7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28jis1Smtg%253D%253D&md5=8b117377e55fae613c164a6756a64071</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1093%2Fecco-jcc%2Fjjw053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fecco-jcc%252Fjjw053%26sid%3Dliteratum%253Aachs%26aulast%3DLevin%26aufirst%3DA.%2BD.%26aulast%3DWildenberg%26aufirst%3DM.%2BE.%26aulast%3Dvan%2Bden%2BBrink%26aufirst%3DG.%2BR.%26atitle%3DMechanism%2520of%2520action%2520of%2520anti-TNF%2520therapy%2520in%2520inflammatory%2520bowel%2520disease%26jtitle%3DJ.%2520Crohn%25E2%2580%2599s%2520Colitis%26date%3D2016%26volume%3D10%26spage%3D989%26epage%3D997%26doi%3D10.1093%2Fecco-jcc%2Fjjw053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manoli, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaw, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frutoz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epstein, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khawli, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theil, F.-P.</span></span> <span> </span><span class="NLM_article-title">Unraveling the effect of immunogenicity on the PK/PD, efficacy, and safety of therapeutic proteins</span>. <i>J. Immunol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>2016</i></span>,  <span class="NLM_fpage">2342187</span>, <span class="refDoi"> DOI: 10.1155/2016/2342187</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1155%2F2016%2F2342187" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=27579329" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A280%3ADC%252BC2szmtlCitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2016&publication_year=2016&pages=2342187&author=A.+Smithauthor=H.+Manoliauthor=S.+Jawauthor=K.+Frutozauthor=A.+L.+Epsteinauthor=L.+A.+Khawliauthor=F.-P.+Theil&title=Unraveling+the+effect+of+immunogenicity+on+the+PK%2FPD%2C+efficacy%2C+and+safety+of+therapeutic+proteins&doi=10.1155%2F2016%2F2342187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Unraveling the Effect of Immunogenicity on the PK/PD, Efficacy, and Safety of Therapeutic Proteins</span></div><div class="casAuthors">Smith Alison; Manoli Hugh; Jaw Stacey; Frutoz Kimberley; Epstein Alan L; Khawli Leslie A; Theil Frank-Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of immunology research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">2016</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2342187</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Biologics have emerged as a powerful and diverse class of molecular and cell-based therapies that are capable of replacing enzymes, editing genomes, targeting tumors, and more.  As this complex array of tools arises a distinct set of challenges is rarely encountered in the development of small molecule therapies.  Biotherapeutics tend to be big, bulky, polar molecules comprised of protein and/or nucleic acids.  Compared to their small molecule counterparts, they are fragile, labile, and heterogeneous.  Their biodistribution is often limited by hydrophobic barriers which often restrict their administration to either intravenous or subcutaneous entry routes.  Additionally, their potential for immunogenicity has proven to be a challenge to developing safe and reliably efficacious drugs.  Our discussion will emphasize immunogenicity in the context of therapeutic proteins, a well-known class of biologics.  We set out to describe what is known and unknown about the mechanisms underlying the interplay between antigenicity and immune response and their effect on the safety, efficacy, pharmacokinetics, and pharmacodynamics of these therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSjz4uJE6F1CuWhZTslLrfffW6udTcc2eYyisiZTI_Rh7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2szmtlCitA%253D%253D&md5=79e4888ba27a004d9cbb69acc9643b7c</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1155%2F2016%2F2342187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2016%252F2342187%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DManoli%26aufirst%3DH.%26aulast%3DJaw%26aufirst%3DS.%26aulast%3DFrutoz%26aufirst%3DK.%26aulast%3DEpstein%26aufirst%3DA.%2BL.%26aulast%3DKhawli%26aufirst%3DL.%2BA.%26aulast%3DTheil%26aufirst%3DF.-P.%26atitle%3DUnraveling%2520the%2520effect%2520of%2520immunogenicity%2520on%2520the%2520PK%252FPD%252C%2520efficacy%252C%2520and%2520safety%2520of%2520therapeutic%2520proteins%26jtitle%3DJ.%2520Immunol.%2520Res.%26date%3D2016%26volume%3D2016%26spage%3D2342187%26doi%3D10.1155%2F2016%2F2342187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clausen, M. H.</span></span> <span> </span><span class="NLM_article-title">Small-molecule kinase inhibitors: an analysis of FDA-approved drugs</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">5</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2015.07.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1016%2Fj.drudis.2015.07.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=26210956" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Gru73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2016&pages=5-10&author=P.+Wuauthor=T.+E.+Nielsenauthor=M.+H.+Clausen&title=Small-molecule+kinase+inhibitors%3A+an+analysis+of+FDA-approved+drugs&doi=10.1016%2Fj.drudis.2015.07.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule kinase inhibitors: an analysis of FDA-approved drugs</span></div><div class="casAuthors">Wu, Peng; Nielsen, Thomas E.; Clausen, Mads H.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5-10</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Small-mol. kinase inhibitors (SMKIs), 28 of which are approved by the US Food and Drug Administration (FDA), have been actively pursued as promising targeted therapeutics.  Here, we assess the key structural and physicochem. properties, target selectivity and mechanism of function, and therapeutic indications of these approved inhibitors.  Our anal. showed that >30% of approved SMKIs have a mol. wt. (MW) exceeding 500 and all have a total ring count of between three and five.  The assumption that type II inhibitors tend to be more selective than type I inhibitors has been proved to be unreliable.  Although previous SMKI research was concd. on tyrosine kinase inhibitors for cancer treatment, recent progress indicates diversification of SMKI research in terms of new targets, mechanistic types, and therapeutic indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZrY68ZOI2xLVg90H21EOLACvtfcHk0li4S14GudSvFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Gru73P&md5=228524fa464393053ecbfac19e994929</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2015.07.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2015.07.008%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DP.%26aulast%3DNielsen%26aufirst%3DT.%2BE.%26aulast%3DClausen%26aufirst%3DM.%2BH.%26atitle%3DSmall-molecule%2520kinase%2520inhibitors%253A%2520an%2520analysis%2520of%2520FDA-approved%2520drugs%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2016%26volume%3D21%26spage%3D5%26epage%3D10%26doi%3D10.1016%2Fj.drudis.2015.07.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nibbs, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McInnes, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siebert, S.</span></span> <span> </span><span class="NLM_article-title">Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases</span>. <i>Clin. Exp. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>176</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.1111/cei.12248</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1111%2Fcei.12248" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=24313320" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktVylurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=176&publication_year=2014&pages=1-10&author=H.+Pattersonauthor=R.+Nibbsauthor=I.+McInnesauthor=S.+Siebert&title=Protein+kinase+inhibitors+in+the+treatment+of+inflammatory+and+autoimmune+diseases&doi=10.1111%2Fcei.12248"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases</span></div><div class="casAuthors">Patterson, H.; Nibbs, R.; McInnes, I.; Siebert, S.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Experimental Immunology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">176</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-10</span>CODEN:
                <span class="NLM_cas:coden">CEXIAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-9104</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Summary : Protein kinases mediate protein phosphorylation, which is a fundamental component of cell signalling, with crucial roles in most signal transduction cascades: from controlling cell growth and proliferation to the initiation and regulation of immunol. responses.  Aberrant kinase activity is implicated in an increasing no. of diseases, with more than 400 human diseases now linked either directly or indirectly to protein kinases.  Protein kinases are therefore regarded as highly important drug targets, and are the subject of intensive research activity.  The success of small mol. kinase inhibitors in the treatment of cancer, coupled with a greater understanding of inflammatory signalling cascades, has led to kinase inhibitors taking center stage in the pursuit for new anti-inflammatory agents for the treatment of immune-mediated diseases.  Herein we discuss the main classes of kinase inhibitors; namely Janus kinase (JAK), mitogen-activated protein kinase (MAPK) and spleen tyrosine kinase (Syk) inhibitors.  We provide a mechanistic insight into how these inhibitors interfere with kinase signalling pathways and discuss the clin. successes and failures in the implementation of kinase-directed therapeutics in the context of inflammatory and autoimmune disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro6xmLNBP2V7Vg90H21EOLACvtfcHk0li4S14GudSvFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktVylurw%253D&md5=fb65f5c7ee7086383ddbc95c787da2b4</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1111%2Fcei.12248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcei.12248%26sid%3Dliteratum%253Aachs%26aulast%3DPatterson%26aufirst%3DH.%26aulast%3DNibbs%26aufirst%3DR.%26aulast%3DMcInnes%26aufirst%3DI.%26aulast%3DSiebert%26aufirst%3DS.%26atitle%3DProtein%2520kinase%2520inhibitors%2520in%2520the%2520treatment%2520of%2520inflammatory%2520and%2520autoimmune%2520diseases%26jtitle%3DClin.%2520Exp.%2520Immunol.%26date%3D2014%26volume%3D176%26spage%3D1%26epage%3D10%26doi%3D10.1111%2Fcei.12248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hammaker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firestein, G. S.</span></span> <span> </span><span class="NLM_article-title">“Go upstream, young man”: lessons learned from the p38 saga</span>. <i>Ann. Rheum. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">i77</span>– <span class="NLM_lpage">i82</span>, <span class="refDoi"> DOI: 10.1136/ard.2009.119479</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1136%2Fard.2009.119479" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=19995751" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFOltrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2010&pages=i77-i82&author=D.+Hammakerauthor=G.+S.+Firestein&title=%E2%80%9CGo+upstream%2C+young+man%E2%80%9D%3A+lessons+learned+from+the+p38+saga&doi=10.1136%2Fard.2009.119479"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">"Go upstream, young man": lessons learned from the p38 saga</span></div><div class="casAuthors">Hammaker, D.; Firestein, G. S.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the Rheumatic Diseases</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">Suppl. 1</span>),
    <span class="NLM_cas:pages">i77-i82</span>CODEN:
                <span class="NLM_cas:coden">ARDIAO</span>;
        ISSN:<span class="NLM_cas:issn">0003-4967</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">A review.  Despite the success of biol. therapies in rheumatoid arthritis (RA), orally active small-mol. drugs are desirable.  Signal transduction inhibitors have been the focus of intense efforts, with some recent notable successes and failures.  P38α is a signalling mol. that regulates proinflammatory cytokines, which makes it a logical target for RA.  Unfortunately, selective p38α inhibitors have limited efficacy.  An attempt is made here to put these studies into perspective and offer possible explanations for the failure of p38α blockers.  Alternative strategies, such as targeting kinases higher in the signalling cascade or using less selective compds., might be more successful as suggested by the efficacy seen with Syk and JAK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8J_h8eiP0BLVg90H21EOLACvtfcHk0li4S14GudSvFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFOltrs%253D&md5=5f571d0d4a87adc3477921a928f9d78e</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1136%2Fard.2009.119479&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fard.2009.119479%26sid%3Dliteratum%253Aachs%26aulast%3DHammaker%26aufirst%3DD.%26aulast%3DFirestein%26aufirst%3DG.%2BS.%26atitle%3D%25E2%2580%259CGo%2520upstream%252C%2520young%2520man%25E2%2580%259D%253A%2520lessons%2520learned%2520from%2520the%2520p38%2520saga%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2010%26volume%3D69%26spage%3Di77%26epage%3Di82%26doi%3D10.1136%2Fard.2009.119479" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grothe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flechsenhar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paehler, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritzeler, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beninga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudolphi, K.</span></span> <span> </span><span class="NLM_article-title">IκB kinase inhibition as a potential treatment of osteoarthritis – results of a clinical proof-of-concept study</span>. <i>Osteoarthr. Cartil.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">46</span>– <span class="NLM_lpage">52</span>, <span class="refDoi"> DOI: 10.1016/j.joca.2016.08.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1016%2Fj.joca.2016.08.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=27592041" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=46-52&author=K.+Grotheauthor=K.+Flechsenharauthor=T.+Paehlerauthor=O.+Ritzelerauthor=J.+Beningaauthor=J.+Saasauthor=M.+Herrmannauthor=K.+Rudolphi&title=I%CE%BAB+kinase+inhibition+as+a+potential+treatment+of+osteoarthritis+%E2%80%93+results+of+a+clinical+proof-of-concept+study&doi=10.1016%2Fj.joca.2016.08.010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.joca.2016.08.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.joca.2016.08.010%26sid%3Dliteratum%253Aachs%26aulast%3DGrothe%26aufirst%3DK.%26aulast%3DFlechsenhar%26aufirst%3DK.%26aulast%3DPaehler%26aufirst%3DT.%26aulast%3DRitzeler%26aufirst%3DO.%26aulast%3DBeninga%26aufirst%3DJ.%26aulast%3DSaas%26aufirst%3DJ.%26aulast%3DHerrmann%26aufirst%3DM.%26aulast%3DRudolphi%26aufirst%3DK.%26atitle%3DI%25CE%25BAB%2520kinase%2520inhibition%2520as%2520a%2520potential%2520treatment%2520of%2520osteoarthritis%2520%25E2%2580%2593%2520results%2520of%2520a%2520clinical%2520proof-of-concept%2520study%26jtitle%3DOsteoarthr.%2520Cartil.%26date%3D2017%26volume%3D25%26spage%3D46%26epage%3D52%26doi%3D10.1016%2Fj.joca.2016.08.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, R. L.</span></span> <span> </span><span class="NLM_article-title">Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">2051</span>– <span class="NLM_lpage">2059</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-0279</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1158%2F1078-0432.CCR-13-0279" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=24583800" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtl2ms78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=2051-2059&author=S.+C.+Meyerauthor=R.+L.+Levine&title=Molecular+pathways%3A+molecular+basis+for+sensitivity+and+resistance+to+JAK+kinase+inhibitors&doi=10.1158%2F1078-0432.CCR-13-0279"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Pathways: Molecular Basis for Sensitivity and Resistance to JAK Kinase Inhibitors</span></div><div class="casAuthors">Meyer, Sara C.; Levine, Ross L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2051-2059</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Janus-activated kinases (JAK) are the mediators of a variety of cytokine signals via their cognate receptors that result in activation of intracellular signaling pathways.  Alterations in JAK1, JAK2, JAK3, and TYK2 signaling contribute to different disease states, and dysregulated JAK-STAT signaling is assocd. with hematol. malignancies, autoimmune disorders, and immune-deficient conditions.  Genetic alterations of JAK2 occur in the majority of patients with myeloproliferative neoplasms and occur in a subset of patients with acute leukemias.  JAK-mediated signaling critically relies on STAT transcription factors, and on activation of the MAPK and PI3K/Akt signaling axes.  Hyperactive JAK at the apex of these potent oncogenic signaling pathways therefore represents an important target for small-mol. kinase inhibitors in different disease states.  The JAK1/2 inhibitor ruxolitinib and the JAK3 inhibitor tofacitinib were recently approved for the treatment of myelofibrosis and rheumatoid arthritis, resp., and addnl. ATP-competitive JAK inhibitors are in clin. development.  Although these agents show clin. activity, the ability of these JAK inhibitors to induce clin./mol. remissions in hematol. malignancies seems limited and resistance upon chronic drug exposure is seen.  Alternative modes of targeting JAK2 such as allosteric kinase inhibition or HSP90 inhibition are under evaluation, as is the use of histone deacetylase inhibitors.  Combination therapy approaches integrating inhibition of STAT, PI3K/Akt, and MAPK pathways with JAK kinase inhibitors might be crit. to overcome malignancies characterized by dysregulated JAK signaling.  Clin Cancer Res; 20(8); 2051-9. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKgmYqhJDI07Vg90H21EOLACvtfcHk0liKL-NGI0_3Fg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtl2ms78%253D&md5=7c7ad00b5c8020fd660d86c057827eb2</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-0279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-0279%26sid%3Dliteratum%253Aachs%26aulast%3DMeyer%26aufirst%3DS.%2BC.%26aulast%3DLevine%26aufirst%3DR.%2BL.%26atitle%3DMolecular%2520pathways%253A%2520molecular%2520basis%2520for%2520sensitivity%2520and%2520resistance%2520to%2520JAK%2520kinase%2520inhibitors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26spage%3D2051%26epage%3D2059%26doi%3D10.1158%2F1078-0432.CCR-13-0279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kontzias, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaoka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurence, A.</span></span> <span> </span><span class="NLM_article-title">Janus kinase inhibitors in autoimmune diseases</span>. <i>Ann. Rheum. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">ii111</span>– <span class="NLM_lpage">ii115</span>, <span class="refDoi"> DOI: 10.1136/annrheumdis-2012-202576</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1136%2Fannrheumdis-2012-202576" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=23532440" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2013&pages=ii111-ii115&author=J.+J.+O%E2%80%99Sheaauthor=A.+Kontziasauthor=K.+Yamaokaauthor=Y.+Tanakaauthor=A.+Laurence&title=Janus+kinase+inhibitors+in+autoimmune+diseases&doi=10.1136%2Fannrheumdis-2012-202576"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1136%2Fannrheumdis-2012-202576&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fannrheumdis-2012-202576%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26aulast%3DKontzias%26aufirst%3DA.%26aulast%3DYamaoka%26aufirst%3DK.%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DLaurence%26aufirst%3DA.%26atitle%3DJanus%2520kinase%2520inhibitors%2520in%2520autoimmune%2520diseases%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2013%26volume%3D72%26spage%3Dii111%26epage%3Dii115%26doi%3D10.1136%2Fannrheumdis-2012-202576" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghoreschi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurence, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span> <span> </span><span class="NLM_article-title">Janus kinases in immune cell signaling</span>. <i>Immunol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>228</i></span>,  <span class="NLM_fpage">273</span>– <span class="NLM_lpage">287</span>, <span class="refDoi"> DOI: 10.1111/j.1600-065X.2008.00754.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1111%2Fj.1600-065X.2008.00754.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=19290934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=228&publication_year=2009&pages=273-287&author=K.+Ghoreschiauthor=A.+Laurenceauthor=J.+J.+O%E2%80%99Shea&title=Janus+kinases+in+immune+cell+signaling&doi=10.1111%2Fj.1600-065X.2008.00754.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Janus kinases in immune cell signaling</span></div><div class="casAuthors">Ghoreschi, Kamran; Laurence, Arian; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">228</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">273-287</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">1600-065X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  The Janus family kinases (Jaks), Jak1, Jak2, Jak3, and Tyk2, form one subgroup of the non-receptor protein tyrosine kinases.  They are involved in cell growth, survival, development, and differentiation of a variety of cells but are critically important for immune cells and hematopoietic cells.  Data from exptl. mice and clin. observations have unraveled multiple signaling events mediated by Jaks in innate and adaptive immunity.  Deficiency of Jak3 or Tyk2 results in defined clin. disorders, which are also evident in mouse models.  A striking phenotype assocd. with inactivating Jak3 mutations is severe combined immunodeficiency syndrome, whereas mutation of Tyk2 results in another primary immunodeficiency termed autosomal recessive hyperimmunoglobulin E syndrome.  By contrast, complete deletion of Jak1 or Jak2 in the mouse are not compatible with life and, unsurprisingly, do not have counterparts in human disease.  However, activating mutations of each of the Jaks are found in assocn. with malignant transformation, the most common being gain-of-function mutations of Jak2 in polycythemia vera and other myeloproliferative disorders.  Our existing knowledge on Jak signaling pathways and fundamental work on their biochem. structure and intracellular interactions allow us to develop new strategies for controlling autoimmune diseases or malignancies by developing selective Jak inhibitors, which are now coming into clin. use.  Despite the fact that Jaks were discovered only a little more than a decade ago, at the time of writing there are 20 clin. trials underway testing the safely and efficacy of Jak inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp23ncK0nYqpbVg90H21EOLACvtfcHk0liKL-NGI0_3Fg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7vJ&md5=adc282a9ad381ee18abe57a82c921f65</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-065X.2008.00754.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-065X.2008.00754.x%26sid%3Dliteratum%253Aachs%26aulast%3DGhoreschi%26aufirst%3DK.%26aulast%3DLaurence%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DJanus%2520kinases%2520in%2520immune%2520cell%2520signaling%26jtitle%3DImmunol.%2520Rev.%26date%3D2009%26volume%3D228%26spage%3D273%26epage%3D287%26doi%3D10.1111%2Fj.1600-065X.2008.00754.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurence, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McInnes, I. B.</span></span> <span> </span><span class="NLM_article-title">Back to the future: oral targeted therapy for RA and other autoimmune diseases</span>. <i>Nat. Rev. Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">173</span>– <span class="NLM_lpage">182</span>, <span class="refDoi"> DOI: 10.1038/nrrheum.2013.7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1038%2Fnrrheum.2013.7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=23419429" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A280%3ADC%252BC3szpsFGiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=173-182&author=J.+J.+O%E2%80%99Sheaauthor=A.+Laurenceauthor=I.+B.+McInnes&title=Back+to+the+future%3A+oral+targeted+therapy+for+RA+and+other+autoimmune+diseases&doi=10.1038%2Fnrrheum.2013.7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Back to the future: oral targeted therapy for RA and other autoimmune diseases</span></div><div class="casAuthors">O'Shea John J; Laurence Arian; McInnes Iain B</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Rheumatology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">173-82</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The molecular biology revolution coupled with the development of monoclonal antibody technology enabled remarkable progress in rheumatology therapy, comprising an array of highly effective biologic agents.  With advances in understanding of the molecular nature of immune cell receptors came elucidation of intracellular signalling pathways downstream of these receptors.  These discoveries raise the question of whether selective targeting of key intracellular factors with small molecules would add to the rheumatologic armamentarium.  In this Review, we discuss several examples of this therapeutic strategy that seem to be successful, and consider their implications for the future of immune-targeted treatments.  We focus on kinase inhibitors, primarily those targeting Janus kinase family members and spleen tyrosine kinase, given their advanced status in clinical development and application.  We also summarize other targets involved in signalling pathways that might offer promise for therapeutic intervention in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQmTYwNff3DeTjk2McQZ6XmfW6udTcc2ebZyj7UBG9OIrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3szpsFGiug%253D%253D&md5=92218e154d717c374bbe42e1f0a0f34f</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnrrheum.2013.7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrrheum.2013.7%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26aulast%3DLaurence%26aufirst%3DA.%26aulast%3DMcInnes%26aufirst%3DI.%2BB.%26atitle%3DBack%2520to%2520the%2520future%253A%2520oral%2520targeted%2520therapy%2520for%2520RA%2520and%2520other%2520autoimmune%2520diseases%26jtitle%3DNat.%2520Rev.%2520Rheumatol.%26date%3D2013%26volume%3D9%26spage%3D173%26epage%3D182%26doi%3D10.1038%2Fnrrheum.2013.7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villarino, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McInnes, I. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurence, A.</span></span> <span> </span><span class="NLM_article-title">The JAK-STAT pathway: impact on human disease and therapeutic intervention</span>. <i>Annu. Rev. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">311</span>– <span class="NLM_lpage">328</span>, <span class="refDoi"> DOI: 10.1146/annurev-med-051113-024537</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1146%2Fannurev-med-051113-024537" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=25587654" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjvFyhsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2015&pages=311-328&author=J.+J.+O%E2%80%99Sheaauthor=D.+M.+Schwartzauthor=A.+V.+Villarinoauthor=M.+Gadinaauthor=I.+B.+McInnesauthor=A.+Laurence&title=The+JAK-STAT+pathway%3A+impact+on+human+disease+and+therapeutic+intervention&doi=10.1146%2Fannurev-med-051113-024537"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">The JAK-STAT pathway: impact on human disease and therapeutic intervention</span></div><div class="casAuthors">O'Shea, John J.; Schwartz, Daniella M.; Villarino, Alejandro V.; Gadina, Massimo; McInnes, Iain B.; Laurence, Arian</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">311-328</span>CODEN:
                <span class="NLM_cas:coden">ARMCAH</span>;
        ISSN:<span class="NLM_cas:issn">0066-4219</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">A review.  The Janus kinase (JAK)-signal transducer of activators of transcription (STAT) pathway is now recognized as an evolutionarily conserved signaling pathway employed by diverse cytokines, interferons, growth factors, and related mols.  This pathway provides an elegant and remarkably straightforward mechanism whereby extracellular factors control gene expression.  It thus serves as a fundamental paradigm for how cells sense environmental cues and interpret these signals to regulate cell growth and differentiation.  Genetic mutations and polymorphisms are functionally relevant to a variety of human diseases, esp. cancer and immune-related conditions.  The clin. relevance of the pathway has been confirmed by the emergence of a new class of therapeutics that targets JAKs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMxvQCRiTbL7Vg90H21EOLACvtfcHk0liGDeYWJSzurQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjvFyhsLY%253D&md5=19182154f1a046df039eb4a37b66bf78</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1146%2Fannurev-med-051113-024537&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-med-051113-024537%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26aulast%3DSchwartz%26aufirst%3DD.%2BM.%26aulast%3DVillarino%26aufirst%3DA.%2BV.%26aulast%3DGadina%26aufirst%3DM.%26aulast%3DMcInnes%26aufirst%3DI.%2BB.%26aulast%3DLaurence%26aufirst%3DA.%26atitle%3DThe%2520JAK-STAT%2520pathway%253A%2520impact%2520on%2520human%2520disease%2520and%2520therapeutic%2520intervention%26jtitle%3DAnnu.%2520Rev.%2520Med.%26date%3D2015%26volume%3D66%26spage%3D311%26epage%3D328%26doi%3D10.1146%2Fannurev-med-051113-024537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chrencik, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patny, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, I. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korniski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emmons, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinberg, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gormley, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsch, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiefer, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leone, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sommers, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobsen, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tenbrink, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomasselli, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benson, T. E.</span></span> <span> </span><span class="NLM_article-title">Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>400</i></span>,  <span class="NLM_fpage">413</span>– <span class="NLM_lpage">433</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2010.05.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1016%2Fj.jmb.2010.05.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=20478313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1ylt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=400&publication_year=2010&pages=413-433&author=J.+E.+Chrencikauthor=A.+Patnyauthor=I.+K.+Leungauthor=B.+Korniskiauthor=T.+L.+Emmonsauthor=T.+Hallauthor=R.+A.+Weinbergauthor=J.+A.+Gormleyauthor=J.+M.+Williamsauthor=J.+E.+Dayauthor=J.+L.+Hirschauthor=J.+R.+Kieferauthor=J.+W.+Leoneauthor=H.+D.+Fischerauthor=C.+D.+Sommersauthor=H.-C.+Huangauthor=E.+J.+Jacobsenauthor=R.+E.+Tenbrinkauthor=A.+G.+Tomasselliauthor=T.+E.+Benson&title=Structural+and+thermodynamic+characterization+of+the+TYK2+and+JAK3+kinase+domains+in+complex+with+CP-690550+and+CMP-6&doi=10.1016%2Fj.jmb.2010.05.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and Thermodynamic Characterization of the TYK2 and JAK3 Kinase Domains in Complex with CP-690550 and CMP-6</span></div><div class="casAuthors">Chrencik, Jill E.; Patny, Akshay; Leung, Iris K.; Korniski, Brian; Emmons, Thomas L.; Hall, Troii; Weinberg, Robin A.; Gormley, Jennifer A.; Williams, Jennifer M.; Day, Jacqueline E.; Hirsch, Jeffrey L.; Kiefer, James R.; Leone, Joseph W.; Fischer, H. David; Sommers, Cynthia D.; Huang, Horng-Chih; Jacobsen, E. J.; Tenbrink, Ruth E.; Tomasselli, Alfredo G.; Benson, Timothy E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">400</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">413-433</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Janus kinases (JAKs) are crit. regulators of cytokine pathways and attractive targets of therapeutic value in both inflammatory and myeloproliferative diseases.  Although the crystal structures of active JAK1 and JAK2 kinase domains have been reported recently with the clin. compd. CP-690550, the structures of both TYK2 and JAK3 with CP-690550 have remained outstanding.  Here, we report the crystal structures of TYK2, a first in class structure, and JAK3 in complex with PAN-JAK inhibitors CP-690550 ((3R,4R)-3-[4-methyl-3-[N-methyl-N-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropionitrile) and CMP-6 (tetracyclic pyridone 2-t-butyl-9-fluoro-3,6-dihydro-7H-benz[h]-imidaz[4,5-f]isoquinoline-7-one), both of which bind in the ATP-binding cavities of both JAK isoenzymes in orientations similar to that obsd. in crystal structures of JAK1 and JAK2.  Addnl., a complete thermodn. characterization of JAK/CP-690550 complex formation was completed by isothermal titrn. calorimetry, indicating the crit. role of the nitrile group from the CP-690550 compd.  Finally, computational anal. using WaterMap further highlights the crit. positioning of the CP-690550 nitrile group in the displacement of an unfavorable water mol. beneath the glycine-rich loop.  Taken together, the data emphasize the outstanding properties of the kinome-selective JAK inhibitor CP-690550, as well as the challenges in obtaining JAK isoenzyme-selective inhibitors due to the overall structural and sequence similarities between the TYK2, JAK1, JAK2 and JAK3 isoenzymes.  Nevertheless, subtle amino acid variations of residues lining the ligand-binding cavity of the JAK enzymes, as well as the global positioning of the glycine-rich loop, might provide the initial clues to obtaining JAK-isoenzyme selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5dnGkvq0jPbVg90H21EOLACvtfcHk0liGDeYWJSzurQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1ylt7g%253D&md5=1b1efc3d6f913143dc9113e4ac1c4c60</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2010.05.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2010.05.020%26sid%3Dliteratum%253Aachs%26aulast%3DChrencik%26aufirst%3DJ.%2BE.%26aulast%3DPatny%26aufirst%3DA.%26aulast%3DLeung%26aufirst%3DI.%2BK.%26aulast%3DKorniski%26aufirst%3DB.%26aulast%3DEmmons%26aufirst%3DT.%2BL.%26aulast%3DHall%26aufirst%3DT.%26aulast%3DWeinberg%26aufirst%3DR.%2BA.%26aulast%3DGormley%26aufirst%3DJ.%2BA.%26aulast%3DWilliams%26aufirst%3DJ.%2BM.%26aulast%3DDay%26aufirst%3DJ.%2BE.%26aulast%3DHirsch%26aufirst%3DJ.%2BL.%26aulast%3DKiefer%26aufirst%3DJ.%2BR.%26aulast%3DLeone%26aufirst%3DJ.%2BW.%26aulast%3DFischer%26aufirst%3DH.%2BD.%26aulast%3DSommers%26aufirst%3DC.%2BD.%26aulast%3DHuang%26aufirst%3DH.-C.%26aulast%3DJacobsen%26aufirst%3DE.%2BJ.%26aulast%3DTenbrink%26aufirst%3DR.%2BE.%26aulast%3DTomasselli%26aufirst%3DA.%2BG.%26aulast%3DBenson%26aufirst%3DT.%2BE.%26atitle%3DStructural%2520and%2520thermodynamic%2520characterization%2520of%2520the%2520TYK2%2520and%2520JAK3%2520kinase%2520domains%2520in%2520complex%2520with%2520CP-690550%2520and%2520CMP-6%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2010%26volume%3D400%26spage%3D413%26epage%3D433%26doi%3D10.1016%2Fj.jmb.2010.05.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wiegman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adcock, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothaul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Main, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, F.</span></span> <span> </span><span class="NLM_article-title">In-vitro evaluation of a new potent, selective pan-Janus kinase (JAK) inhibitor VR588</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">PA2130</span>, <span class="refDoi"> DOI: 10.1183/13993003.congress-2015.PA2130</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1183%2F13993003.congress-2015.PA2130" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2015&pages=PA2130&author=C.+Wiegmanauthor=I.+Adcockauthor=A.+Rothaulauthor=M.+Mainauthor=F.+Morgan&title=In-vitro+evaluation+of+a+new+potent%2C+selective+pan-Janus+kinase+%28JAK%29+inhibitor+VR588&doi=10.1183%2F13993003.congress-2015.PA2130"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1183%2F13993003.congress-2015.PA2130&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F13993003.congress-2015.PA2130%26sid%3Dliteratum%253Aachs%26aulast%3DWiegman%26aufirst%3DC.%26aulast%3DAdcock%26aufirst%3DI.%26aulast%3DRothaul%26aufirst%3DA.%26aulast%3DMain%26aufirst%3DM.%26aulast%3DMorgan%26aufirst%3DF.%26atitle%3DIn-vitro%2520evaluation%2520of%2520a%2520new%2520potent%252C%2520selective%2520pan-Janus%2520kinase%2520%2528JAK%2529%2520inhibitor%2520VR588%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2015%26volume%3D46%26spage%3DPA2130%26doi%3D10.1183%2F13993003.congress-2015.PA2130" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumenkopf, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brissette, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casavant, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shang-Poa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doty, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hines, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kent, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kudlacz, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lillie, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnuson, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCurdy, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munchhof, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawyer, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strelevitz, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanyam, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whipple, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Changelian, P. S.</span></span> <span> </span><span class="NLM_article-title">Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">8468</span>– <span class="NLM_lpage">8484</span>, <span class="refDoi"> DOI: 10.1021/jm1004286</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1004286" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8468-8484&author=M.+E.+Flanaganauthor=T.+A.+Blumenkopfauthor=W.+H.+Brissetteauthor=M.+F.+Brownauthor=J.+M.+Casavantauthor=C.+Shang-Poaauthor=J.+L.+Dotyauthor=E.+A.+Elliottauthor=M.+B.+Fisherauthor=M.+Hinesauthor=C.+Kentauthor=E.+M.+Kudlaczauthor=B.+M.+Lillieauthor=K.+S.+Magnusonauthor=S.+P.+McCurdyauthor=M.+J.+Munchhofauthor=B.+D.+Perryauthor=P.+S.+Sawyerauthor=T.+J.+Strelevitzauthor=C.+Subramanyamauthor=J.+Sunauthor=D.+A.+Whippleauthor=P.+S.+Changelian&title=Discovery+of+CP-690%2C550%3A+a+potent+and+selective+Janus+kinase+%28JAK%29+inhibitor+for+the+treatment+of+autoimmune+diseases+and+organ+transplant+rejection&doi=10.1021%2Fjm1004286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection</span></div><div class="casAuthors">Flanagan, Mark E.; Blumenkopf, Todd A.; Brissette, William H.; Brown, Matthew F.; Casavant, Jeffrey M.; Chang, Shang-Poa; Doty, Jonathan L.; Elliott, Eileen A.; Fisher, Michael B.; Hines, Michael; Kent, Craig; Kudlacz, Elizabeth M.; Lillie, Brett M.; Magnuson, Kelly S.; McCurdy, Sandra P.; Munchhof, Michael J.; Perry, Bret D.; Sawyer, Perry S.; Strelevitz, Timothy J.; Subramanyam, Chakrapani; Sun, Jianmin; Whipple, David A.; Changelian, Paul S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8468-8484</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There is a crit. need for safer and more convenient treatments for organ transplant rejection and autoimmune disorders such as rheumatoid arthritis.  Janus tyrosine kinases (JAK1, JAK3) are expressed in lymphoid cells and are involved in the signaling of multiple cytokines important for various T cell functions.  Blockade of the JAK1/JAK3-STAT pathway with a small mol. was anticipated to provide therapeutic immunosuppression/immunomodulation.  The Pfizer compd. library was screened against the catalytic domain of JAK3 resulting in the identification of a pyrrolopyrimidine-based series of inhibitors represented by the hexahydrocarbazolyl pyrrolopyrimidine CP-352,664.  Synthetic analogs of CP-352,664 were screened against the JAK enzymes and evaluated in an IL-2 induced T cell blast proliferation assay.  Select compds. were evaluated in rodent efficacy models of allograft rejection and destructive inflammatory arthritis.  Optimization within this chem. series led to identification of the cyanoacetylpiperidinylamino pyrrolopyrimidine CP-690,550, a potential first-in-class JAK inhibitor for treatment of autoimmune diseases and organ transplant rejection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbFS_8DSHkDbVg90H21EOLACvtfcHk0lgwBvrqQDCOsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP&md5=c1d31ce42ab3f1c1f3029c6f4f48df1a</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm1004286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1004286%26sid%3Dliteratum%253Aachs%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DBlumenkopf%26aufirst%3DT.%2BA.%26aulast%3DBrissette%26aufirst%3DW.%2BH.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DShang-Poa%26aufirst%3DC.%26aulast%3DDoty%26aufirst%3DJ.%2BL.%26aulast%3DElliott%26aufirst%3DE.%2BA.%26aulast%3DFisher%26aufirst%3DM.%2BB.%26aulast%3DHines%26aufirst%3DM.%26aulast%3DKent%26aufirst%3DC.%26aulast%3DKudlacz%26aufirst%3DE.%2BM.%26aulast%3DLillie%26aufirst%3DB.%2BM.%26aulast%3DMagnuson%26aufirst%3DK.%2BS.%26aulast%3DMcCurdy%26aufirst%3DS.%2BP.%26aulast%3DMunchhof%26aufirst%3DM.%2BJ.%26aulast%3DPerry%26aufirst%3DB.%2BD.%26aulast%3DSawyer%26aufirst%3DP.%2BS.%26aulast%3DStrelevitz%26aufirst%3DT.%2BJ.%26aulast%3DSubramanyam%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DWhipple%26aufirst%3DD.%2BA.%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26atitle%3DDiscovery%2520of%2520CP-690%252C550%253A%2520a%2520potent%2520and%2520selective%2520Janus%2520kinase%2520%2528JAK%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520autoimmune%2520diseases%2520and%2520organ%2520transplant%2520rejection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D8468%26epage%3D8484%26doi%3D10.1021%2Fjm1004286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wollenhaupt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverfield, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtis, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nduaka, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benda, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruben, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komuro, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zwillich, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riese, R. J.</span></span> <span> </span><span class="NLM_article-title">Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies</span>. <i>J. Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">837</span>– <span class="NLM_lpage">852</span>, <span class="refDoi"> DOI: 10.3899/jrheum.130683</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.3899%2Fjrheum.130683" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=24692527" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVyiurbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2014&pages=837-852&author=J.+Wollenhauptauthor=J.+Silverfieldauthor=E.+B.+Leeauthor=J.+R.+Curtisauthor=S.+P.+Woodauthor=K.+Somaauthor=C.+I.+Nduakaauthor=B.+Bendaauthor=D.+Grubenauthor=H.+Nakamuraauthor=Y.+Komuroauthor=S.+H.+Zwillichauthor=L.+Wangauthor=R.+J.+Riese&title=Safety+and+efficacy+of+tofacitinib%2C+an+oral+Janus+kinase+inhibitor%2C+for+the+treatment+of+rheumatoid+arthritis+in+open-label%2C+longterm+extension+studies&doi=10.3899%2Fjrheum.130683"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies</span></div><div class="casAuthors">Wollenhaupt, Juergen; Silverfield, Joel; Lee, Eun Bong; Curtis, Jeffrey R.; Wood, Susan P.; Soma, Koshika; Nduaka, Chudy I.; Benda, Birgitta; Gruben, David; Nakamura, Hiroyuki; Komuro, Yoshihiro; Zwillich, Samuel H.; Wang, Lisy; Riese, Richard J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Rheumatology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">837-852</span>CODEN:
                <span class="NLM_cas:coden">JRHUA9</span>;
        ISSN:<span class="NLM_cas:issn">0315-162X</span>.
    
            (<span class="NLM_cas:orgname">Journal of Rheumatology Publishing Co. Ltd.</span>)
        </div><div class="casAbstract">Objective: To describe the longterm safety and efficacy profile of tofacitinib in patients with moderate to severe active rheumatoid arthritis (RA).  Methods: Data were pooled from 2 open-label studies (NCT00413699, NCT00661661) involving patients who had participated in qualifying phase I, II, or III index studies of tofacitinib.  Safety data included over 60 mo of observation; efficacy data are reported up to Month 48.  Treatment was initiated with tofacitinib 5 or 10 mg twice daily.  Primary endpoints were adverse events (AE) and lab. safety data.  Secondary endpoints included American College of Rheumatol. (ACR) response rates, and Disease Activity Score (28 joints) (DAS28)-4[erythrocyte sedimentation rate (ESR)] and Health Assessment Questionnaire-Disability Index (HAQ-DI) assessments.  Results: Overall, 4102 patients were treated for 5963 patient-years; mean (max.) treatment duration was 531 (1844) days; 20.8% of patients discontinued treatment over 60 mo.  The most common AE were nasopharyngitis (12.7%) and upper respiratory tract infection (10.5%).  Serious AE were reported in 15.4% of patients with an exposure-estd. incidence rate of 11.1 events/100 patient-years.  Serious infections were reported in 4.5% of patients with an exposure-estd. incidence rate of 3.1 events/100 patient-years (95% CI: 2.66-3.55).  Mean values for lab. variables were stable over time and consistent with phase II and III studies.  Persistent efficacy was demonstrated through Month 48, as measured by ACR response rate (ACR20/50/70) DAS28-4-ESR, and HAQ-DI.  Safety and efficacy were similar for patients receiving tofacitinib as monotherapy or with background nonbiol. disease-modifying antirheumatic drugs.  Conclusion: Tofacitinib demonstrated consistent safety and persistent efficacy over 48 mo in patients with RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-Scjk1FOYMrVg90H21EOLACvtfcHk0lgwBvrqQDCOsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVyiurbJ&md5=0c8cf68569627b3948b6c275ec69d8df</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.3899%2Fjrheum.130683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3899%252Fjrheum.130683%26sid%3Dliteratum%253Aachs%26aulast%3DWollenhaupt%26aufirst%3DJ.%26aulast%3DSilverfield%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DE.%2BB.%26aulast%3DCurtis%26aufirst%3DJ.%2BR.%26aulast%3DWood%26aufirst%3DS.%2BP.%26aulast%3DSoma%26aufirst%3DK.%26aulast%3DNduaka%26aufirst%3DC.%2BI.%26aulast%3DBenda%26aufirst%3DB.%26aulast%3DGruben%26aufirst%3DD.%26aulast%3DNakamura%26aufirst%3DH.%26aulast%3DKomuro%26aufirst%3DY.%26aulast%3DZwillich%26aufirst%3DS.%2BH.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DRiese%26aufirst%3DR.%2BJ.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520tofacitinib%252C%2520an%2520oral%2520Janus%2520kinase%2520inhibitor%252C%2520for%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%2520in%2520open-label%252C%2520longterm%2520extension%2520studies%26jtitle%3DJ.%2520Rheumatol.%26date%3D2014%26volume%3D41%26spage%3D837%26epage%3D852%26doi%3D10.3899%2Fjrheum.130683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zerbini, C. A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lomonte, A. B. V.</span></span> <span> </span><span class="NLM_article-title">Tofacitinib for the treatment of rheumatoid arthritis</span>. <i>Expert Rev. Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">319</span>– <span class="NLM_lpage">331</span>, <span class="refDoi"> DOI: 10.1586/eci.12.19</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1586%2Feci.12.19" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=22607178" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC38Xnt1yqs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=319-331&author=C.+A.+F.+Zerbiniauthor=A.+B.+V.+Lomonte&title=Tofacitinib+for+the+treatment+of+rheumatoid+arthritis&doi=10.1586%2Feci.12.19"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Tofacitinib for the treatment of rheumatoid arthritis</span></div><div class="casAuthors">Zerbini, Cristiano A. F.; Lomonte, Andrea Barranjard Vannucci</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Clinical Immunology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">319-331</span>CODEN:
                <span class="NLM_cas:coden">ERCIBU</span>;
        ISSN:<span class="NLM_cas:issn">1744-666X</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  Rheumatoid arthritis (RA) is a chronic inflammatory disease that affects approx. 1% of the worldwide population.  It primarily targets the synovial membrane of joints, leading to a synovial proliferation, joint cartilage lesion and erosions in the adjacent bone tissue.  The disease is usually progressive and if the inflammatory process is not adequately suppressed, joint deformity takes place, leading to a significant functional disability and work incapacity.  Over the last decade, biol. therapy was established as a major step towards disease control in those patients who experienced failure after treatment with disease-modifying antirheumatic drugs.  Despite the growing no. of biol. agents with different immunol. targets, a significant no. of patients do not receive appropriate disease control, or have the use of these agents limited because of adverse events.  As such, the search for new mols. with a higher efficacy and better safety profile is ongoing.  This article focuses on a new drug, tofacitinib, which is a synthetic disease-modifying antirheumatic drug for treatment of RA.  Preclin. studies in arthritis and transplantation animal models are reviewed as a background for the possible use of tofacitinib treatment in humans.  Four Phase II (one A and three B dose-ranging) trials lasting from 6 to 24 wk in RA patients showed significant American College of Rheumatol. 20 improvements as early as week 2 and sustained at week 24 in two studies.  Tofacitinib Phase III studies in RA are included in a clin. program called ORAL Trials'.  Long-term follow-up from ongoing studies will contribute to a more accurate tofacitinib efficacy and safety profile.  Trials in other illness such as psoriasis, psoriatic arthritis, renal transplant rejection prevention, inflammatory bowel diseases and dry eye are underway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHpLt7-aROnLVg90H21EOLACvtfcHk0lg2SAUbCEOyHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xnt1yqs78%253D&md5=ad557fe321ab93878f9eace579afcadf</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1586%2Feci.12.19&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252Feci.12.19%26sid%3Dliteratum%253Aachs%26aulast%3DZerbini%26aufirst%3DC.%2BA.%2BF.%26aulast%3DLomonte%26aufirst%3DA.%2BB.%2BV.%26atitle%3DTofacitinib%2520for%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%26jtitle%3DExpert%2520Rev.%2520Clin.%2520Immunol.%26date%3D2012%26volume%3D8%26spage%3D319%26epage%3D331%26doi%3D10.1586%2Feci.12.19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamagami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuno, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okuma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chida, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inami, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirakami, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higashi, Y.</span></span> <span> </span><span class="NLM_article-title">A novel JAK inhibitor, peficitinib, demonstrates potent efficacy in a rat adjuvant-induced arthritis model</span>. <i>J. Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>133</i></span>,  <span class="NLM_fpage">25</span>– <span class="NLM_lpage">33</span>, <span class="refDoi"> DOI: 10.1016/j.jphs.2016.12.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1016%2Fj.jphs.2016.12.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=28117214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFKru7zK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2017&pages=25-33&author=M.+Itoauthor=S.+Yamazakiauthor=K.+Yamagamiauthor=M.+Kunoauthor=Y.+Moritaauthor=K.+Okumaauthor=K.+Nakamuraauthor=N.+Chidaauthor=M.+Inamiauthor=T.+Inoueauthor=S.+Shirakamiauthor=Y.+Higashi&title=A+novel+JAK+inhibitor%2C+peficitinib%2C+demonstrates+potent+efficacy+in+a+rat+adjuvant-induced+arthritis+model&doi=10.1016%2Fj.jphs.2016.12.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">A novel JAK inhibitor, peficitinib, demonstrates potent efficacy in a rat adjuvant-induced arthritis model</span></div><div class="casAuthors">Ito, Misato; Yamazaki, Shunji; Yamagami, Kaoru; Kuno, Masako; Morita, Yoshiaki; Okuma, Kenji; Nakamura, Koji; Chida, Noboru; Inami, Masamichi; Inoue, Takayuki; Shirakami, Shohei; Higashi, Yasuyuki</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacological Sciences (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-33</span>CODEN:
                <span class="NLM_cas:coden">JPSTGJ</span>;
        ISSN:<span class="NLM_cas:issn">1347-8613</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The Janus kinase (JAK) family of tyrosine kinases is assocd. with various cytokine receptors.  JAK1 and JAK3 play particularly important roles in the immune response, and their inhibition is expected to provide targeted immune modulation.  Several oral JAK inhibitors have recently been developed for treating autoimmune diseases, including rheumatoid arthritis (RA).  Here, we investigated the pharmacol. effects of peficitinib (formerly known as ASP015K), a novel, chem. synthesized JAK inhibitor.  We found that peficitinib inhibited JAK1 and JAK3 with 50% inhibitory concns. of 3.9 and 0.7 nM, resp.  Peficitinib also inhibited IL-2-dependent T cell proliferation in vitro and STAT5 phosphorylation in vitro and ex vivo.  Furthermore, peficitinib dose-dependently suppressed bone destruction and paw swelling in an adjuvant-induced arthritis model in rats via prophylactic or therapeutic oral dosing regimens.  Peficitinib also showed efficacy in the model by continuous i.p. infusion.  Area under the concn. vs. time curve (AUC) at 50% inhibition of paw swelling via i.p. infusion was similar to exposure levels of AUC at 50% inhibition via oral administration, implying that AUC might be important for detg. the therapeutic efficacy of peficitinib.  These data suggest that peficitinib has therapeutic potential for the oral treatment of RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXCuMIThrVN7Vg90H21EOLACvtfcHk0lg2SAUbCEOyHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFKru7zK&md5=1d5bf4c2d40ccf8209e24684d53dbfe8</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.jphs.2016.12.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jphs.2016.12.001%26sid%3Dliteratum%253Aachs%26aulast%3DIto%26aufirst%3DM.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DYamagami%26aufirst%3DK.%26aulast%3DKuno%26aufirst%3DM.%26aulast%3DMorita%26aufirst%3DY.%26aulast%3DOkuma%26aufirst%3DK.%26aulast%3DNakamura%26aufirst%3DK.%26aulast%3DChida%26aufirst%3DN.%26aulast%3DInami%26aufirst%3DM.%26aulast%3DInoue%26aufirst%3DT.%26aulast%3DShirakami%26aufirst%3DS.%26aulast%3DHigashi%26aufirst%3DY.%26atitle%3DA%2520novel%2520JAK%2520inhibitor%252C%2520peficitinib%252C%2520demonstrates%2520potent%2520efficacy%2520in%2520a%2520rat%2520adjuvant-induced%2520arthritis%2520model%26jtitle%3DJ.%2520Pharmacol.%2520Sci.%26date%3D2017%26volume%3D133%26spage%3D25%26epage%3D33%26doi%3D10.1016%2Fj.jphs.2016.12.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wernig, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kharas, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okabe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leeman, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cullen, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gozo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDowell, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doukas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mak, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noronha, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, Y. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soll, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tefferi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hood, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilliland, D. G.</span></span> <span> </span><span class="NLM_article-title">Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">311</span>– <span class="NLM_lpage">320</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2008.02.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1016%2Fj.ccr.2008.02.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=18394554" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BD1cXkslSjtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2008&pages=311-320&author=G.+Wernigauthor=M.+G.+Kharasauthor=R.+Okabeauthor=S.+A.+Mooreauthor=D.+S.+Leemanauthor=D.+E.+Cullenauthor=M.+Gozoauthor=E.+P.+McDowellauthor=R.+L.+Levineauthor=J.+Doukasauthor=C.+C.+Makauthor=G.+Noronhaauthor=M.+Martinauthor=Y.+D.+Koauthor=B.+H.+Leeauthor=R.+M.+Sollauthor=A.+Tefferiauthor=J.+D.+Hoodauthor=D.+G.+Gilliland&title=Efficacy+of+TG101348%2C+a+selective+JAK2+inhibitor%2C+in+treatment+of+a+murine+model+of+JAK2V617F-induced+polycythemia+vera&doi=10.1016%2Fj.ccr.2008.02.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera</span></div><div class="casAuthors">Wernig, Gerlinde; Kharas, Michael G.; Okabe, Rachel; Moore, Sandra A.; Leeman, Dena S.; Cullen, Dana E.; Gozo, Maricel; McDowell, Elizabeth P.; Levine, Ross L.; Doukas, John; Mak, Chi Ching; Noronha, Glenn; Martin, Michael; Ko, Yon D.; Lee, Benjamin H.; Soll, Richard M.; Tefferi, Ayalew; Hood, John D.; Gilliland, D. Gary</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">311-320</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">We report that TG101348, a selective small-mol. inhibitor of JAK2 with an in vitro IC50 of ∼3 nM, shows therapeutic efficacy in a murine model of myeloproliferative disease induced by the JAK2V617F mutation.  In treated animals, there was a statistically significant redn. in hematocrit and leukocyte count, a dose-dependent redn./elimination of extramedullary hematopoiesis, and, at least in some instances, evidence for attenuation of myelofibrosis.  There were no apparent toxicities and no effect on T cell no.  In vivo responses were correlated with surrogate endpoints, including redn./elimination of JAK2V617F disease burden assessed by quant. genomic PCR, suppression of endogenous erythroid colony formation, and in vivo inhibition of JAK-STAT signal transduction as assessed by flow cytometric measurement of phosphorylated Stat5.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSJOc4cS_lO7Vg90H21EOLACvtfcHk0lg2SAUbCEOyHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXkslSjtrs%253D&md5=3dd923595cafebb6439dd67f026735be</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2008.02.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2008.02.009%26sid%3Dliteratum%253Aachs%26aulast%3DWernig%26aufirst%3DG.%26aulast%3DKharas%26aufirst%3DM.%2BG.%26aulast%3DOkabe%26aufirst%3DR.%26aulast%3DMoore%26aufirst%3DS.%2BA.%26aulast%3DLeeman%26aufirst%3DD.%2BS.%26aulast%3DCullen%26aufirst%3DD.%2BE.%26aulast%3DGozo%26aufirst%3DM.%26aulast%3DMcDowell%26aufirst%3DE.%2BP.%26aulast%3DLevine%26aufirst%3DR.%2BL.%26aulast%3DDoukas%26aufirst%3DJ.%26aulast%3DMak%26aufirst%3DC.%2BC.%26aulast%3DNoronha%26aufirst%3DG.%26aulast%3DMartin%26aufirst%3DM.%26aulast%3DKo%26aufirst%3DY.%2BD.%26aulast%3DLee%26aufirst%3DB.%2BH.%26aulast%3DSoll%26aufirst%3DR.%2BM.%26aulast%3DTefferi%26aufirst%3DA.%26aulast%3DHood%26aufirst%3DJ.%2BD.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26atitle%3DEfficacy%2520of%2520TG101348%252C%2520a%2520selective%2520JAK2%2520inhibitor%252C%2520in%2520treatment%2520of%2520a%2520murine%2520model%2520of%2520JAK2V617F-induced%2520polycythemia%2520vera%26jtitle%3DCancer%2520Cell%26date%3D2008%26volume%3D13%26spage%3D311%26epage%3D320%26doi%3D10.1016%2Fj.ccr.2008.02.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inghrim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grebinski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokarski, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenzi, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDevitt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penhallow, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vuppugalla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trainor, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruepp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blat, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sack, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefanski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sleczka, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arunachalam, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pragalathan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayanan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">K.C., N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuppusamy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purandare, A. V.</span></span> <span> </span><span class="NLM_article-title">Discovery of a highly selective JAK2 inhibitor, BMS-911543, for the treatment of myeloproliferative neoplasms</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">850</span>– <span class="NLM_lpage">855</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00226</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00226" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFGitbvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=850-855&author=H.+Wanauthor=G.+M.+Schroederauthor=A.+C.+Hartauthor=J.+Inghrimauthor=J.+Grebinskiauthor=J.+S.+Tokarskiauthor=M.+V.+Lorenziauthor=D.+Youauthor=T.+McDevittauthor=B.+Penhallowauthor=R.+Vuppugallaauthor=Y.+Zhangauthor=X.+Guauthor=R.+Iyerauthor=L.+J.+Lombardoauthor=G.+L.+Trainorauthor=S.+Rueppauthor=J.+Lippyauthor=Y.+Blatauthor=J.+S.+Sackauthor=J.+A.+Khanauthor=K.+Stefanskiauthor=B.+Sleczkaauthor=A.+Mathurauthor=J.-H.+Sunauthor=M.+K.+Wongauthor=D.-R.+Wuauthor=P.+Liauthor=A.+Guptaauthor=P.+N.+Arunachalamauthor=B.+Pragalathanauthor=S.+Narayananauthor=N.+K.C.author=P.+Kuppusamyauthor=A.+V.+Purandare&title=Discovery+of+a+highly+selective+JAK2+inhibitor%2C+BMS-911543%2C+for+the+treatment+of+myeloproliferative+neoplasms&doi=10.1021%2Facsmedchemlett.5b00226"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Highly Selective JAK2 Inhibitor, BMS-911543, for the Treatment of Myeloproliferative Neoplasms</span></div><div class="casAuthors">Wan, Honghe; Schroeder, Gretchen M.; Hart, Amy C.; Inghrim, Jennifer; Grebinski, James; Tokarski, John S.; Lorenzi, Matthew V.; You, Dan; McDevitt, Theresa; Penhallow, Becky; Vuppugalla, Ragini; Zhang, Yueping; Gu, Xiaomei; Iyer, Ramaswamy; Lombardo, Louis J.; Trainor, George L.; Ruepp, Stefan; Lippy, Jonathan; Blat, Yuval; Sack, John S.; Khan, Javed A.; Stefanski, Kevin; Sleczka, Bogdan; Mathur, Arvind; Sun, Jung-Hui; Wong, Michael K.; Wu, Dauh-Rurng; Li, Peng; Gupta, Anuradha; Arunachalam, P. N.; Pragalathan, Bala; Narayanan, Sankara; Nanjundaswamy, K. C.; Kuppusamy, Prakasam; Purandare, Ashok V.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">850-855</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">JAK2 kinase inhibitors are a promising new class of agents for the treatment of myeloproliferative neoplasms and have potential for the treatment of other diseases possessing a deregulated JAK2-STAT pathway.  X-ray structure and ADME guided refinement of C-4 heterocycles to address metabolic liability present in dialkylthiazole (I) led to the discovery of a clin. candidate, BMS-911543 (11), with excellent kinome selectivity, in vivo PD activity, and safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7LTsDfjeehLVg90H21EOLACvtfcHk0lgOEhIHnWHjNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFGitbvF&md5=d6bdb9b070a8f7492352600ea1222a8f</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00226%26sid%3Dliteratum%253Aachs%26aulast%3DWan%26aufirst%3DH.%26aulast%3DSchroeder%26aufirst%3DG.%2BM.%26aulast%3DHart%26aufirst%3DA.%2BC.%26aulast%3DInghrim%26aufirst%3DJ.%26aulast%3DGrebinski%26aufirst%3DJ.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DLorenzi%26aufirst%3DM.%2BV.%26aulast%3DYou%26aufirst%3DD.%26aulast%3DMcDevitt%26aufirst%3DT.%26aulast%3DPenhallow%26aufirst%3DB.%26aulast%3DVuppugalla%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DGu%26aufirst%3DX.%26aulast%3DIyer%26aufirst%3DR.%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26aulast%3DTrainor%26aufirst%3DG.%2BL.%26aulast%3DRuepp%26aufirst%3DS.%26aulast%3DLippy%26aufirst%3DJ.%26aulast%3DBlat%26aufirst%3DY.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DKhan%26aufirst%3DJ.%2BA.%26aulast%3DStefanski%26aufirst%3DK.%26aulast%3DSleczka%26aufirst%3DB.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DWong%26aufirst%3DM.%2BK.%26aulast%3DWu%26aufirst%3DD.-R.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DArunachalam%26aufirst%3DP.%2BN.%26aulast%3DPragalathan%26aufirst%3DB.%26aulast%3DNarayanan%26aufirst%3DS.%26aulast%3DK.C.%26aufirst%3DN.%26aulast%3DKuppusamy%26aufirst%3DP.%26aulast%3DPurandare%26aufirst%3DA.%2BV.%26atitle%3DDiscovery%2520of%2520a%2520highly%2520selective%2520JAK2%2520inhibitor%252C%2520BMS-911543%252C%2520for%2520the%2520treatment%2520of%2520myeloproliferative%2520neoplasms%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D850%26epage%3D855%26doi%3D10.1021%2Facsmedchemlett.5b00226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vazquez, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaila, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strohbach, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trzupek, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitton-Fry, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">TenBrink, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heasley, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langille, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parikh, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casavant, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duclos, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenwick, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caspers, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banker, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symanowicz, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jussif, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unwalla, R.</span></span> <span> </span><span class="NLM_article-title">Identification of N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): a selective JAK1 clinical candidate for the treatment of autoimmune diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">1130</span>– <span class="NLM_lpage">1152</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01598</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01598" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1Wnsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=1130-1152&author=M.+L.+Vazquezauthor=N.+Kailaauthor=J.+W.+Strohbachauthor=J.+D.+Trzupekauthor=M.+F.+Brownauthor=M.+E.+Flanaganauthor=M.+J.+Mitton-Fryauthor=T.+A.+Johnsonauthor=R.+E.+TenBrinkauthor=E.+P.+Arnoldauthor=A.+Basakauthor=S.+E.+Heasleyauthor=S.+Kwonauthor=J.+Langilleauthor=M.+D.+Parikhauthor=S.+H.+Griffinauthor=J.+M.+Casavantauthor=B.+A.+Duclosauthor=A.+E.+Fenwickauthor=T.+M.+Harrisauthor=S.+Hanauthor=N.+Caspersauthor=M.+E.+Dowtyauthor=X.+Yangauthor=M.+E.+Bankerauthor=M.+Hegenauthor=P.+T.+Symanowiczauthor=L.+Liauthor=L.+Wangauthor=T.+H.+Linauthor=J.+Jussifauthor=J.+D.+Clarkauthor=J.-B.+Telliezauthor=R.+P.+Robinsonauthor=R.+Unwalla&title=Identification+of+N-%7Bcis-3-%5Bmethyl%287H-pyrrolo%5B2%2C3-d%5Dpyrimidin-4-yl%29amino%5Dcyclobutyl%7Dpropane-1-sulfonamide+%28PF-04965842%29%3A+a+selective+JAK1+clinical+candidate+for+the+treatment+of+autoimmune+diseases&doi=10.1021%2Facs.jmedchem.7b01598"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases</span></div><div class="casAuthors">Vazquez, Michael L.; Kaila, Neelu; Strohbach, Joseph W.; Trzupek, John D.; Brown, Matthew F.; Flanagan, Mark E.; Mitton-Fry, Mark J.; Johnson, Timothy A.; TenBrink, Ruth E.; Arnold, Eric P.; Basak, Arindrajit; Heasley, Steven E.; Kwon, Soojin; Langille, Jonathan; Parikh, Mihir D.; Griffin, Sarah H.; Casavant, Jeffrey M.; Duclos, Brian A.; Fenwick, Ashley E.; Harris, Thomas M.; Han, Seungil; Caspers, Nicole; Dowty, Martin E.; Yang, Xin; Banker, Mary Ellen; Hegen, Martin; Symanowicz, Peter T.; Li, Li; Wang, Lu; Lin, Tsung H.; Jussif, Jason; Clark, James D.; Telliez, Jean-Baptiste; Robinson, Ralph P.; Unwalla, Ray</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1130-1152</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Janus kinases (JAKs) are intracellular tyrosine kinases that mediate the signaling of numerous cytokines and growth factors involved in the regulation of immunity, inflammation, and hematopoiesis.  As JAK1 pairs with JAK2, JAK3, and TYK2, a JAK1-selective inhibitor would be expected to inhibit many cytokines involved in inflammation and immune function while avoiding inhibition of the JAK2 homodimer regulating erythropoietin and thrombopoietin signaling.  The authors' efforts began with tofacitinib, an oral JAK inhibitor approved for the treatment of rheumatoid arthritis.  Through modification of the 3-aminopiperidine linker in tofacitinib, the authors discovered highly selective JAK1 inhibitors with nanomolar potency in a human whole blood assay.  Improvements in JAK1 potency and selectivity were achieved via structural modifications suggested by x-ray crystallog. anal.  After demonstrating efficacy in a rat adjuvant-induced arthritis (rAIA) model, PF-04965842 (25) was nominated as a clin. candidate for the treatment of JAK1-mediated autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNdiJFIHI-YLVg90H21EOLACvtfcHk0lgOEhIHnWHjNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1Wnsw%253D%253D&md5=45c6d1b0eee7ab9d5dfc8ea168607a8b</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01598%26sid%3Dliteratum%253Aachs%26aulast%3DVazquez%26aufirst%3DM.%2BL.%26aulast%3DKaila%26aufirst%3DN.%26aulast%3DStrohbach%26aufirst%3DJ.%2BW.%26aulast%3DTrzupek%26aufirst%3DJ.%2BD.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DMitton-Fry%26aufirst%3DM.%2BJ.%26aulast%3DJohnson%26aufirst%3DT.%2BA.%26aulast%3DTenBrink%26aufirst%3DR.%2BE.%26aulast%3DArnold%26aufirst%3DE.%2BP.%26aulast%3DBasak%26aufirst%3DA.%26aulast%3DHeasley%26aufirst%3DS.%2BE.%26aulast%3DKwon%26aufirst%3DS.%26aulast%3DLangille%26aufirst%3DJ.%26aulast%3DParikh%26aufirst%3DM.%2BD.%26aulast%3DGriffin%26aufirst%3DS.%2BH.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DDuclos%26aufirst%3DB.%2BA.%26aulast%3DFenwick%26aufirst%3DA.%2BE.%26aulast%3DHarris%26aufirst%3DT.%2BM.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DCaspers%26aufirst%3DN.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DBanker%26aufirst%3DM.%2BE.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DSymanowicz%26aufirst%3DP.%2BT.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DT.%2BH.%26aulast%3DJussif%26aufirst%3DJ.%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DTelliez%26aufirst%3DJ.-B.%26aulast%3DRobinson%26aufirst%3DR.%2BP.%26aulast%3DUnwalla%26aufirst%3DR.%26atitle%3DIdentification%2520of%2520N-%257Bcis-3-%255Bmethyl%25287H-pyrrolo%255B2%252C3-d%255Dpyrimidin-4-yl%2529amino%255Dcyclobutyl%257Dpropane-1-sulfonamide%2520%2528PF-04965842%2529%253A%2520a%2520selective%2520JAK1%2520clinical%2520candidate%2520for%2520the%2520treatment%2520of%2520autoimmune%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D1130%26epage%3D1152%26doi%3D10.1021%2Facs.jmedchem.7b01598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Voss, J. W.</span>; <span class="NLM_string-name">Camp, H. S.</span>; <span class="NLM_string-name">Padley, R. J.</span></span> <span> </span><span class="NLM_article-title">JAK1 Selective Inhibitors and Uses Thereof</span>. <span class="NLM_patent">WO2015061665</span>, April 30, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=J.+W.+Voss&author=H.+S.+Camp&author=R.+J.+Padley&title=JAK1+Selective+Inhibitors+and+Uses+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DVoss%26aufirst%3DJ.%2BW.%26atitle%3DJAK1%2520Selective%2520Inhibitors%2520and%2520Uses%2520Thereof%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurley, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergeron, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balazs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blair, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bull, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakravarty, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crackett, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshmukh, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVoss, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dragovich, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellwood, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaines, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghilardi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbons, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gradl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gribling, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harstad, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hewitt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenny, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koehler, M. F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bir
Kohli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labadie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liimatta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendonca, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narukulla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulk, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reeve, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savage, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steffek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ubhayakar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Abbema, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aliagas, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avitabile-Woo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulagowski, J. J.</span></span> <span> </span><span class="NLM_article-title">Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">4764</span>– <span class="NLM_lpage">4785</span>, <span class="refDoi"> DOI: 10.1021/jm4004895</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4004895" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnsVWit74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=4764-4785&author=M.+Zakauthor=C.+A.+Hurleyauthor=S.+I.+Wardauthor=P.+Bergeronauthor=K.+Barrettauthor=M.+Balazsauthor=W.+S.+Blairauthor=R.+Bullauthor=P.+Chakravartyauthor=C.+Changauthor=P.+Crackettauthor=G.+Deshmukhauthor=J.+DeVossauthor=P.+S.+Dragovichauthor=C.+Eigenbrotauthor=C.+Ellwoodauthor=S.+Gainesauthor=N.+Ghilardiauthor=P.+Gibbonsauthor=S.+Gradlauthor=P.+Griblingauthor=C.+Hammanauthor=E.+Harstadauthor=P.+Hewittauthor=A.+Johnsonauthor=T.+Johnsonauthor=J.+R.+Kennyauthor=M.+F.+T.+Koehlerauthor=P.+Bir%0AKohliauthor=S.+Labadieauthor=W.+P.+Leeauthor=J.+Liaoauthor=M.+Liimattaauthor=R.+Mendoncaauthor=R.+Narukullaauthor=R.+Pulkauthor=A.+Reeveauthor=S.+Savageauthor=S.+Shiaauthor=M.+Steffekauthor=S.+Ubhayakarauthor=A.+van+Abbemaauthor=I.+Aliagasauthor=B.+Avitabile-Wooauthor=Y.+Xiaoauthor=J.+Yangauthor=J.+J.+Kulagowski&title=Identification+of+C-2+hydroxyethyl+imidazopyrrolopyridines+as+potent+JAK1+inhibitors+with+favorable+physicochemical+properties+and+high+selectivity+over+JAK2&doi=10.1021%2Fjm4004895"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of C-2 Hydroxyethyl Imidazopyrrolopyridines as Potent JAK1 Inhibitors with Favorable Physicochemical Properties and High Selectivity over JAK2</span></div><div class="casAuthors">Zak, Mark; Hurley, Christopher A.; Ward, Stuart I.; Bergeron, Philippe; Barrett, Kathy; Balazs, Mercedesz; Blair, Wade S.; Bull, Richard; Chakravarty, Paroma; Chang, Christine; Crackett, Peter; Deshmukh, Gauri; DeVoss, Jason; Dragovich, Peter S.; Eigenbrot, Charles; Ellwood, Charles; Gaines, Simon; Ghilardi, Nico; Gibbons, Paul; Gradl, Stefan; Gribling, Peter; Hamman, Chris; Harstad, Eric; Hewitt, Peter; Johnson, Adam; Johnson, Tony; Kenny, Jane R.; Koehler, Michael F. T.; Bir Kohli, Pawan; Labadie, Sharada; Lee, Wyne P.; Liao, Jiangpeng; Liimatta, Marya; Mendonca, Rohan; Narukulla, Raman; Pulk, Rebecca; Reeve, Austin; Savage, Scott; Shia, Steven; Steffek, Micah; Ubhayakar, Savita; van Abbema, Anne; Aliagas, Ignacio; Avitabile-Woo, Barbara; Xiao, Yisong; Yang, Jing; Kulagowski, Janusz J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4764-4785</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein we report on the structure-based discovery of a C-2 hydroxyethyl moiety which provided consistently high levels of selectivity for JAK1 over JAK2 to the imidazopyrrolopyridine series of JAK1 inhibitors.  X-ray structures of a C-2 hydroxyethyl analog in complex with both JAK1 and JAK2 revealed differential ligand/protein interactions between the two isoforms and offered an explanation for the obsd. selectivity.  Anal. of historical data from related mols. was used to develop a set of physicochem. compd. design parameters to impart desirable properties such as acceptable membrane permeability, potent whole blood activity, and a high degree of metabolic stability.  This work culminated in the identification of a highly JAK1 selective compd. (31) exhibiting favorable oral bioavailability across a range of preclin. species and robust efficacy in a rat CIA model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrP0DlLtJCYq7Vg90H21EOLACvtfcHk0lgji8c3VUl-EA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnsVWit74%253D&md5=0b0d1950adebf325cc434344f57ca139</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm4004895&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4004895%26sid%3Dliteratum%253Aachs%26aulast%3DZak%26aufirst%3DM.%26aulast%3DHurley%26aufirst%3DC.%2BA.%26aulast%3DWard%26aufirst%3DS.%2BI.%26aulast%3DBergeron%26aufirst%3DP.%26aulast%3DBarrett%26aufirst%3DK.%26aulast%3DBalazs%26aufirst%3DM.%26aulast%3DBlair%26aufirst%3DW.%2BS.%26aulast%3DBull%26aufirst%3DR.%26aulast%3DChakravarty%26aufirst%3DP.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DCrackett%26aufirst%3DP.%26aulast%3DDeshmukh%26aufirst%3DG.%26aulast%3DDeVoss%26aufirst%3DJ.%26aulast%3DDragovich%26aufirst%3DP.%2BS.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DEllwood%26aufirst%3DC.%26aulast%3DGaines%26aufirst%3DS.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DGibbons%26aufirst%3DP.%26aulast%3DGradl%26aufirst%3DS.%26aulast%3DGribling%26aufirst%3DP.%26aulast%3DHamman%26aufirst%3DC.%26aulast%3DHarstad%26aufirst%3DE.%26aulast%3DHewitt%26aufirst%3DP.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DT.%26aulast%3DKenny%26aufirst%3DJ.%2BR.%26aulast%3DKoehler%26aufirst%3DM.%2BF.%2BT.%26aulast%3DBir%2BKohli%26aufirst%3DP.%26aulast%3DLabadie%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DW.%2BP.%26aulast%3DLiao%26aufirst%3DJ.%26aulast%3DLiimatta%26aufirst%3DM.%26aulast%3DMendonca%26aufirst%3DR.%26aulast%3DNarukulla%26aufirst%3DR.%26aulast%3DPulk%26aufirst%3DR.%26aulast%3DReeve%26aufirst%3DA.%26aulast%3DSavage%26aufirst%3DS.%26aulast%3DShia%26aufirst%3DS.%26aulast%3DSteffek%26aufirst%3DM.%26aulast%3DUbhayakar%26aufirst%3DS.%26aulast%3Dvan%2BAbbema%26aufirst%3DA.%26aulast%3DAliagas%26aufirst%3DI.%26aulast%3DAvitabile-Woo%26aufirst%3DB.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DKulagowski%26aufirst%3DJ.%2BJ.%26atitle%3DIdentification%2520of%2520C-2%2520hydroxyethyl%2520imidazopyrrolopyridines%2520as%2520potent%2520JAK1%2520inhibitors%2520with%2520favorable%2520physicochemical%2520properties%2520and%2520high%2520selectivity%2520over%2520JAK2%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D4764%26epage%3D4785%26doi%3D10.1021%2Fjm4004895" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Abbema, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balazs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berezhkovsky, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blair, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delarosa, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVoss, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driscoll, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodacre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghilardi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacLeod, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bir Kohli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantik, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menghrajani, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sambrone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sohn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsui, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ultsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnuson, S.</span></span> <span> </span><span class="NLM_article-title">Identification of an imidazopyridine scaffold to generate potent and selective TYK2 inhibitors that demonstrate activity in an in vivo psoriasis model</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">4370</span>– <span class="NLM_lpage">4376</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.08.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1016%2Fj.bmcl.2017.08.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=28830649" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlOku7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=4370-4376&author=J.+Liangauthor=A.+Van+Abbemaauthor=M.+Balazsauthor=K.+Barrettauthor=L.+Berezhkovskyauthor=W.+S.+Blairauthor=C.+Changauthor=D.+Delarosaauthor=J.+DeVossauthor=J.+Driscollauthor=C.+Eigenbrotauthor=S.+Goodacreauthor=N.+Ghilardiauthor=C.+MacLeodauthor=A.+Johnsonauthor=P.+Bir+Kohliauthor=Y.+Laiauthor=Z.+Linauthor=P.+Mantikauthor=K.+Menghrajaniauthor=H.+Nguyenauthor=I.+Pengauthor=A.+Sambroneauthor=S.+Shiaauthor=J.+Smithauthor=S.+Sohnauthor=V.+Tsuiauthor=M.+Ultschauthor=K.+Williamsauthor=L.+C.+Wuauthor=W.+Yangauthor=B.+Zhangauthor=S.+Magnuson&title=Identification+of+an+imidazopyridine+scaffold+to+generate+potent+and+selective+TYK2+inhibitors+that+demonstrate+activity+in+an+in+vivo+psoriasis+model&doi=10.1016%2Fj.bmcl.2017.08.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of an imidazopyridine scaffold to generate potent and selective TYK2 inhibitors that demonstrate activity in an in vivo psoriasis model</span></div><div class="casAuthors">Liang, Jun; Van Abbema, Anne; Balazs, Mercedesz; Barrett, Kathy; Berezhkovsky, Leo; Blair, Wade S.; Chang, Christine; Delarosa, Donnie; De Voss, Jason; Driscoll, Jim; Eigenbrot, Charles; Goodacre, Simon; Ghilardi, Nico; MacLeod, Calum; Johnson, Adam; Bir Kohli, Pawan; Lai, Yingjie; Lin, Zhonghua; Mantik, Priscilla; Menghrajani, Kapil; Nguyen, Hieu; Peng, Ivan; Sambrone, Amy; Shia, Steven; Smith, Jan; Sohn, Sue; Tsui, Vickie; Ultsch, Mark; Williams, Karen; Wu, Lawren C.; Yang, Wenqian; Zhang, Birong; Magnuson, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4370-4376</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Herein we report identification of an imidazopyridine class of potent and selective TYK2 inhibitors, exemplified by prototype 6, through constraint of the rotatable amide bond connecting the pyridine and aryl rings of compd. 1.  Further optimization led to generation of compd. 30 that potently inhibits the TYK2 enzyme and the IL-23 pathway in cells, exhibits selectivity against cellular JAK2 activity, and has good pharmacokinetic properties.  In mice, compd. 30 demonstrated dose-dependent redn. of IL-17 prodn. in a PK/PD model as well as in an imiquimod-induced psoriasis model.  In this efficacy model, the IL-17 decrease was accompanied by a redn. of ear thickness indicating the potential of TYK2 inhibition as a therapeutic approach for psoriasis patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoe2FqArjLnebVg90H21EOLACvtfcHk0liGleeeErqGog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlOku7bJ&md5=d132566f504626660c52c680399c9a09</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.08.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.08.022%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DJ.%26aulast%3DVan%2BAbbema%26aufirst%3DA.%26aulast%3DBalazs%26aufirst%3DM.%26aulast%3DBarrett%26aufirst%3DK.%26aulast%3DBerezhkovsky%26aufirst%3DL.%26aulast%3DBlair%26aufirst%3DW.%2BS.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DDelarosa%26aufirst%3DD.%26aulast%3DDeVoss%26aufirst%3DJ.%26aulast%3DDriscoll%26aufirst%3DJ.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DGoodacre%26aufirst%3DS.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DMacLeod%26aufirst%3DC.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DBir%2BKohli%26aufirst%3DP.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DLin%26aufirst%3DZ.%26aulast%3DMantik%26aufirst%3DP.%26aulast%3DMenghrajani%26aufirst%3DK.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DPeng%26aufirst%3DI.%26aulast%3DSambrone%26aufirst%3DA.%26aulast%3DShia%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DJ.%26aulast%3DSohn%26aufirst%3DS.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DUltsch%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DK.%26aulast%3DWu%26aufirst%3DL.%2BC.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DMagnuson%26aufirst%3DS.%26atitle%3DIdentification%2520of%2520an%2520imidazopyridine%2520scaffold%2520to%2520generate%2520potent%2520and%2520selective%2520TYK2%2520inhibitors%2520that%2520demonstrate%2520activity%2520in%2520an%2520in%2520vivo%2520psoriasis%2520model%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26spage%3D4370%26epage%3D4376%26doi%3D10.1016%2Fj.bmcl.2017.08.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williams, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bamert, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walden, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilks, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fantino, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossjohn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucet, I. S.</span></span> <span> </span><span class="NLM_article-title">Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>387</i></span>,  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">232</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2009.01.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1016%2Fj.jmb.2009.01.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=19361440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivVegtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=387&publication_year=2009&pages=219-232&author=N.+K.+Williamsauthor=R.+S.+Bamertauthor=O.+Patelauthor=C.+Wangauthor=P.+M.+Waldenauthor=A.+F.+Wilksauthor=E.+Fantinoauthor=J.+Rossjohnauthor=I.+S.+Lucet&title=Dissecting+specificity+in+the+Janus+kinases%3A+the+structures+of+JAK-specific+inhibitors+complexed+to+the+JAK1+and+JAK2+protein+tyrosine+kinase+domains&doi=10.1016%2Fj.jmb.2009.01.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Dissecting Specificity in the Janus Kinases: The Structures of JAK-Specific Inhibitors Complexed to the JAK1 and JAK2 Protein Tyrosine Kinase Domains</span></div><div class="casAuthors">Williams, Neal K.; Bamert, Rebecca S.; Patel, Onisha; Wang, Christina; Walden, Patricia M.; Wilks, Andrew F.; Fantino, Emmanuelle; Rossjohn, Jamie; Lucet, Isabelle S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">387</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">219-232</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The Janus kinases (JAKs) are a pivotal family of protein tyrosine kinases (PTKs) that play prominent roles in numerous cytokine signaling pathways, with aberrant JAK activity assocd. with a variety of hematopoietic malignancies, cardiovascular diseases and immune-related disorders.  Whereas the structures of the JAK2 and JAK3 PTK domains have been detd., the structure of the JAK1 PTK domain is unknown.  Here, we report the high-resoln. crystal structures of the "active form" of the JAK1 PTK domain in complex with two JAK inhibitors, a tetracyclic pyridone 2-t-butyl-9-fluoro-3,6-dihydro-7H-benz[h]-imidaz[4,5-f]isoquinoline-7-one (CMP6) and (3R,4R)-3-[4-methyl-3-[N-methyl-N-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropionitrile (CP-690,550), and compare them with the corresponding JAK2 PTK inhibitor complexes.  Both inhibitors bound in a similar manner to JAK1, namely buried deep within a constricted ATP-binding site, thereby providing a basis for the potent inhibition of JAK1.  As expected, the mode of inhibitor binding in JAK1 was very similar to that obsd. in JAK2, highlighting the challenges in developing JAK-specific inhibitors that target the ATP-binding site.  Nevertheless, differences surrounding the JAK1 and JAK2 ATP-binding sites were apparent, thereby providing a platform for the rational design of JAK2- and JAK1-specific inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQDLkMkCgiLbVg90H21EOLACvtfcHk0liGleeeErqGog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivVegtbo%253D&md5=79957755d04323057b5acf7e9d2c56ca</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2009.01.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2009.01.041%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DN.%2BK.%26aulast%3DBamert%26aufirst%3DR.%2BS.%26aulast%3DPatel%26aufirst%3DO.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DWalden%26aufirst%3DP.%2BM.%26aulast%3DWilks%26aufirst%3DA.%2BF.%26aulast%3DFantino%26aufirst%3DE.%26aulast%3DRossjohn%26aufirst%3DJ.%26aulast%3DLucet%26aufirst%3DI.%2BS.%26atitle%3DDissecting%2520specificity%2520in%2520the%2520Janus%2520kinases%253A%2520the%2520structures%2520of%2520JAK-specific%2520inhibitors%2520complexed%2520to%2520the%2520JAK1%2520and%2520JAK2%2520protein%2520tyrosine%2520kinase%2520domains%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2009%26volume%3D387%26spage%3D219%26epage%3D232%26doi%3D10.1016%2Fj.jmb.2009.01.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, K.-s.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chong, Y.</span></span> <span> </span><span class="NLM_article-title">Benzimidazole derivatives as potent JAK1-selective inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">7596</span>– <span class="NLM_lpage">7602</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01263</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01263" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=7596-7602&author=M.+K.+Kimauthor=H.+Shinauthor=K.-s.+Parkauthor=H.+Kimauthor=J.+Parkauthor=K.+Kimauthor=J.+Namauthor=H.+Chooauthor=Y.+Chong&title=Benzimidazole+derivatives+as+potent+JAK1-selective+inhibitors&doi=10.1021%2Facs.jmedchem.5b01263"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01263%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DM.%2BK.%26aulast%3DShin%26aufirst%3DH.%26aulast%3DPark%26aufirst%3DK.-s.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DK.%26aulast%3DNam%26aufirst%3DJ.%26aulast%3DChoo%26aufirst%3DH.%26aulast%3DChong%26aufirst%3DY.%26atitle%3DBenzimidazole%2520derivatives%2520as%2520potent%2520JAK1-selective%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D7596%26epage%3D7602%26doi%3D10.1021%2Facs.jmedchem.5b01263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Renert-Yuval, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guttman-Yassky, E.</span></span> <span> </span><span class="NLM_article-title">The changing landscape of alopecia areata: the therapeutic paradigm</span>. <i>Adv. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">1594</span>– <span class="NLM_lpage">1609</span>, <span class="refDoi"> DOI: 10.1007/s12325-017-0542-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1007%2Fs12325-017-0542-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2017&pages=1594-1609&author=Y.+Renert-Yuvalauthor=E.+Guttman-Yassky&title=The+changing+landscape+of+alopecia+areata%3A+the+therapeutic+paradigm&doi=10.1007%2Fs12325-017-0542-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1007%2Fs12325-017-0542-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12325-017-0542-7%26sid%3Dliteratum%253Aachs%26aulast%3DRenert-Yuval%26aufirst%3DY.%26aulast%3DGuttman-Yassky%26aufirst%3DE.%26atitle%3DThe%2520changing%2520landscape%2520of%2520alopecia%2520areata%253A%2520the%2520therapeutic%2520paradigm%26jtitle%3DAdv.%2520Ther.%26date%3D2017%26volume%3D34%26spage%3D1594%26epage%3D1609%26doi%3D10.1007%2Fs12325-017-0542-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Genovese, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kremer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamani, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludivico, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krogulec, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beattie, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardillo, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rooney, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macias, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Bono, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlichting, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smolen, J. S.</span></span> <span> </span><span class="NLM_article-title">Baricitinib in patients with refractory rheumatoid arthritis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>374</i></span>,  <span class="NLM_fpage">1243</span>– <span class="NLM_lpage">1252</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1507247</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1056%2FNEJMoa1507247" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=27028914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Kisr3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=2016&pages=1243-1252&author=M.+C.+Genoveseauthor=J.+Kremerauthor=O.+Zamaniauthor=C.+Ludivicoauthor=M.+Krogulecauthor=L.+Xieauthor=S.+D.+Beattieauthor=A.+E.+Kochauthor=T.+E.+Cardilloauthor=T.+P.+Rooneyauthor=W.+L.+Maciasauthor=S.+de+Bonoauthor=D.+E.+Schlichtingauthor=J.+S.+Smolen&title=Baricitinib+in+patients+with+refractory+rheumatoid+arthritis&doi=10.1056%2FNEJMoa1507247"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Baricitinib in patients with refractory rheumatoid arthritis</span></div><div class="casAuthors">Genovese, Mark C.; Kremer, Joel; Zamani, Omid; Ludivico, Charles; Krogulec, Marek; Xie, Li; Beattie, Scott D.; Koch, Alisa E.; Cardillo, Tracy E.; Rooney, Terence P.; Macias, William L.; de Bono, Stephanie; Schlichting, Douglas E.; Smolen, Josef S.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">374</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1243-1252</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND In phase 2 studies, baricitinib, an oral Janus kinase 1 and 2 inhibitor, reduced disease activity in patients with rheumatoid arthritis who had not previously received treatment with biol. disease-modifying antirheumatic drugs (DMARDs).  METHODS In this phase 3 study involving 527 patients with an inadequate response to or unacceptable side effects assocd. with one or more tumor necrosis factor inhibitors, other biol. DMARDs, or both, we randomly assigned the patients in a 1:1:1 ratio to baricitinib at a dose of 2 or 4 mg daily or placebo for 24 wk.  End points, tested hierarchically at week 12 to control type 1 error, were the American College of Rheumatol. 20% (ACR20) response (primary end point), the Health Assessment Questionnaire-Disability Index (HAQ-DI) score, the 28-joint Disease Activity Score based on C-reactive protein level (DAS28-CRP), and a Simplified Disease Activity Index (SDAI) score of 3.3 or less (on a scale of 0.1 to 86.0, with a score of 3.3 or less indicating remission).  Comparisons with placebo were made first with the 4-mg dose of baricitinib and then with the 2-mg dose.  RESULTS Significantly more patients receiving baricitinib at the 4-mg dose than those receiving placebo had an ACR20 response at week 12 (55% vs. 27%, P<0.001).  Differences between the higher-dose baricitinib group and the placebo group were also significant for the HAQ-DI score and the DAS28-CRP but not for an SDAI score of 3.3 or less.  Adverse-event rates through 24 wk were higher for patients receiving the 2-mg dose of baricitinib and those receiving the 4-mg dose than for patients receiving placebo (71% and 77%, resp., vs. 64%), including infections (44% and 40%, vs. 31%).  The rates of serious adverse events were 4%, 10%, and 7% in the three groups, resp.  Two nonmelanoma skin cancers and two major adverse cardiovascular events, including a fatal stroke, occurred in the higher-dose group.  Baricitinib was assocd. with a small redn. in neutrophil levels and increases in serum creatinine and low-d. lipoprotein cholesterol levels.  CONCLUSIONS In patients with rheumatoid arthritis and an inadequate response to biol. DMARDs, baricitinib at a daily dose of 4 mg was assocd. with clin. improvement at 12 wk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqj72FQTLOsQLVg90H21EOLACvtfcHk0lgf6UYpn34MOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Kisr3E&md5=d7d317ee88fae38379b3b07c420349f6</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1507247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1507247%26sid%3Dliteratum%253Aachs%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26aulast%3DKremer%26aufirst%3DJ.%26aulast%3DZamani%26aufirst%3DO.%26aulast%3DLudivico%26aufirst%3DC.%26aulast%3DKrogulec%26aufirst%3DM.%26aulast%3DXie%26aufirst%3DL.%26aulast%3DBeattie%26aufirst%3DS.%2BD.%26aulast%3DKoch%26aufirst%3DA.%2BE.%26aulast%3DCardillo%26aufirst%3DT.%2BE.%26aulast%3DRooney%26aufirst%3DT.%2BP.%26aulast%3DMacias%26aufirst%3DW.%2BL.%26aulast%3Dde%2BBono%26aufirst%3DS.%26aulast%3DSchlichting%26aufirst%3DD.%2BE.%26aulast%3DSmolen%26aufirst%3DJ.%2BS.%26atitle%3DBaricitinib%2520in%2520patients%2520with%2520refractory%2520rheumatoid%2520arthritis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D374%26spage%3D1243%26epage%3D1252%26doi%3D10.1056%2FNEJMoa1507247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vannucchi, A. M.</span></span> <span> </span><span class="NLM_article-title">Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians</span>. <i>Ther. Adv. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">341</span>– <span class="NLM_lpage">354</span>, <span class="refDoi"> DOI: 10.1177/2040620712459746</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1177%2F2040620712459746" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=23606937" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnslWntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=341-354&author=C.+Harrisonauthor=A.+M.+Vannucchi&title=Ruxolitinib%3A+a+potent+and+selective+Janus+kinase+1+and+2+inhibitor+in+patients+with+myelofibrosis.+An+update+for+clinicians&doi=10.1177%2F2040620712459746"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians</span></div><div class="casAuthors">Harrison, Claire; Vannucchi, Alessandro N.</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutic Advances in Hematology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">341-354</span>CODEN:
                <span class="NLM_cas:coden">TAHHAT</span>;
        ISSN:<span class="NLM_cas:issn">2040-6207</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Ruxolitinib became the first US Food and Drug Administration approved therapy for myelofibrosis in 2011 and EU approval is anticipated in summer 2012.  Two large phase III trials (known as the COMFORT studies) were the basis for this approval and were published recently.  In this review article we discuss the challenges in managing myelofibrosis, the information to date about ruxolitinib and speculate as to the future direction with this and similar agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-1M-lwEgpCrVg90H21EOLACvtfcHk0lgf6UYpn34MOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnslWntA%253D%253D&md5=6c88ade9fb3df126e6b0188b69a68d3c</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1177%2F2040620712459746&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F2040620712459746%26sid%3Dliteratum%253Aachs%26aulast%3DHarrison%26aufirst%3DC.%26aulast%3DVannucchi%26aufirst%3DA.%2BM.%26atitle%3DRuxolitinib%253A%2520a%2520potent%2520and%2520selective%2520Janus%2520kinase%25201%2520and%25202%2520inhibitor%2520in%2520patients%2520with%2520myelofibrosis.%2520An%2520update%2520for%2520clinicians%26jtitle%3DTher.%2520Adv.%2520Hematol.%26date%3D2012%26volume%3D3%26spage%3D341%26epage%3D354%26doi%3D10.1177%2F2040620712459746" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pardanani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tefferi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamieson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabrail, N. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebedinsky, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talpaz, M.</span></span> <span> </span><span class="NLM_article-title">A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis</span>. <i>Blood Cancer J.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">e335</span>, <span class="refDoi"> DOI: 10.1038/bcj.2015.63</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1038%2Fbcj.2015.63" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=26252788" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=e335&author=A.+Pardananiauthor=A.+Tefferiauthor=C.+Jamiesonauthor=N.+Y.+Gabrailauthor=C.+Lebedinskyauthor=G.+Gaoauthor=F.+Liuauthor=C.+Xuauthor=H.+Caoauthor=M.+Talpaz&title=A+phase+2+randomized+dose-ranging+study+of+the+JAK2-selective+inhibitor+fedratinib+%28SAR302503%29+in+patients+with+myelofibrosis&doi=10.1038%2Fbcj.2015.63"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fbcj.2015.63&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbcj.2015.63%26sid%3Dliteratum%253Aachs%26aulast%3DPardanani%26aufirst%3DA.%26aulast%3DTefferi%26aufirst%3DA.%26aulast%3DJamieson%26aufirst%3DC.%26aulast%3DGabrail%26aufirst%3DN.%2BY.%26aulast%3DLebedinsky%26aufirst%3DC.%26aulast%3DGao%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DXu%26aufirst%3DC.%26aulast%3DCao%26aufirst%3DH.%26aulast%3DTalpaz%26aufirst%3DM.%26atitle%3DA%2520phase%25202%2520randomized%2520dose-ranging%2520study%2520of%2520the%2520JAK2-selective%2520inhibitor%2520fedratinib%2520%2528SAR302503%2529%2520in%2520patients%2520with%2520myelofibrosis%26jtitle%3DBlood%2520Cancer%2520J.%26date%3D2015%26volume%3D5%26spage%3De335%26doi%3D10.1038%2Fbcj.2015.63" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, A. W.</span></span> <span> </span><span class="NLM_article-title">JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis</span>. <i>J. Immunol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>2014</i></span>,  <span class="NLM_fpage">283617</span>, <span class="refDoi"> DOI: 10.1155/2014/283617</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1155%2F2014%2F283617" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=24883332" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A280%3ADC%252BC2cfot1ehtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2014&publication_year=2014&pages=283617&author=L.+Hsuauthor=A.+W.+Armstrong&title=JAK+inhibitors%3A+treatment+efficacy+and+safety+profile+in+patients+with+psoriasis&doi=10.1155%2F2014%2F283617"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis</span></div><div class="casAuthors">Hsu Leeyen; Armstrong April W</div><div class="citationInfo"><span class="NLM_cas:title">Journal of immunology research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">2014</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">283617</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Janus kinase (JAK) pathways are key mediators in the immunopathogenesis of psoriasis.  Psoriasis treatment has evolved with the advent of targeted therapies, which inhibit specific components of the psoriasis proinflammatory cascade.  JAK inhibitors have been studied in early phase trials for psoriasis patients, and the data are promising for these agents as potential treatment options.  Tofacitinib, an oral or topically administered JAK1 and JAK3 inhibitor, and ruxolitinib, a topical JAK1 and JAK2 inhibitor, have been most extensively studied in psoriasis, and both improved clinical symptoms of psoriasis.  Additional JAK1 or JAK3 inhibitors are being studied in clinical trials.  In phase III trials for rheumatoid arthritis, tofacitinib was efficacious in patients with inadequate responses to tumor necrosis factor inhibitors, methotrexate monotherapy, or disease-modifying antirheumatic drugs.  The results of phase III trials are pending for these therapies in psoriasis, and these agents may represent important alternatives for patients with inadequate responses to currently available agents.  Further investigations with long-term clinical trials are necessary to verify their utility in psoriasis treatment and assess their safety in this patient population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS8NFwIZodl1tTiMd2aNQVUfW6udTcc2ea1xLLDS8JRiLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cfot1ehtw%253D%253D&md5=241b16e23f36ea06d03b49fa4c53104f</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1155%2F2014%2F283617&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2014%252F283617%26sid%3Dliteratum%253Aachs%26aulast%3DHsu%26aufirst%3DL.%26aulast%3DArmstrong%26aufirst%3DA.%2BW.%26atitle%3DJAK%2520inhibitors%253A%2520treatment%2520efficacy%2520and%2520safety%2520profile%2520in%2520patients%2520with%2520psoriasis%26jtitle%3DJ.%2520Immunol.%2520Res.%26date%3D2014%26volume%3D2014%26spage%3D283617%26doi%3D10.1155%2F2014%2F283617" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moslin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santella, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duncia, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokarski, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strnad, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedicord, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blat, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zupa-Fernandez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sack, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muckelbauer, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tredup, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aranibar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, D. S.</span></span> <span> </span><span class="NLM_article-title">Identification of imidazo[1,2-b]pyridazine TYK2 pseudokinase ligands as potent and selective allosteric inhibitors of TYK2 signalling</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">700</span>– <span class="NLM_lpage">712</span>, <span class="refDoi"> DOI: 10.1039/C6MD00560H</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1039%2FC6MD00560H" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=30108788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVyru7jN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=700-712&author=R.+Moslinauthor=D.+Gardnerauthor=J.+Santellaauthor=Y.+Zhangauthor=J.+V.+Dunciaauthor=C.+Liuauthor=J.+Linauthor=J.+S.+Tokarskiauthor=J.+Strnadauthor=D.+Pedicordauthor=J.+Chenauthor=Y.+Blatauthor=A.+Zupa-Fernandezauthor=L.+Chengauthor=H.+Sunauthor=C.+Chaudhryauthor=C.+Huangauthor=C.+D%E2%80%99Arienzoauthor=J.+S.+Sackauthor=J.+K.+Muckelbauerauthor=C.+Changauthor=J.+Tredupauthor=D.+Xieauthor=N.+Aranibarauthor=J.+R.+Burkeauthor=P.+H.+Carterauthor=D.+S.+Weinstein&title=Identification+of+imidazo%5B1%2C2-b%5Dpyridazine+TYK2+pseudokinase+ligands+as+potent+and+selective+allosteric+inhibitors+of+TYK2+signalling&doi=10.1039%2FC6MD00560H"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of imidazo[1,2-b]pyridazine TYK2 pseudokinase ligands as potent and selective allosteric inhibitors of TYK2 signalling</span></div><div class="casAuthors">Moslin, R.; Gardner, D.; Santella, J.; Zhang, Y.; Duncia, J. V.; Liu, C.; Lin, J.; Tokarski, J. S.; Strnad, J.; Pedicord, D.; Chen, J.; Blat, Y.; Zupa-Fernandez, A.; Cheng, L.; Sun, H.; Chaudhry, C.; Huang, C.; D'Arienzo, C.; Sack, J. S.; Muckelbauer, J. K.; Chang, C.; Tredup, J.; Xie, D.; Aranibar, N.; Burke, J. R.; Carter, P. H.; Weinstein, D. S.</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">700-712</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">As a member of the Janus (JAK) family of non-receptor tyrosine kinases, TYK2 mediates the signaling of pro-inflammatory cytokines including IL-12, IL-23 and type 1 interferon (IFN), and therefore represents an attractive potential target for treating the various immuno-inflammatory diseases in which these cytokines have been shown to play a role.  Following up on our previous report that ligands to the pseudokinase domain (JH2) of TYK2 suppress cytokine-mediated receptor activation of the catalytic (JH1) domain, the imidazo[1,2-b]pyridazine (IZP) 7 was identified as a promising hit compd.  Through iterative modification of each of the substituents of the IZP scaffold, the cellular potency was improved while maintaining selectivity over the JH1 domain.  These studies led to the discovery of the JH2-selective TYK2 inhibitor 29, which provided encouraging systemic exposures after oral dosing in mice.  Phosphodiesterase 4 (PDE4) was identified as an off-target and potential liability of the IZP ligands, and selectivity for TYK2 JH2 over this enzyme was obtained by elaborating along selectivity vectors detd. from analyses of X-ray co-crystal structures of representative ligands of the IZP class bound to both proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobX5_XfvLHsLVg90H21EOLACvtfcHk0ljUHVbjOiIZPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVyru7jN&md5=67b06413866ee6096810903f62edd901</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1039%2FC6MD00560H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6MD00560H%26sid%3Dliteratum%253Aachs%26aulast%3DMoslin%26aufirst%3DR.%26aulast%3DGardner%26aufirst%3DD.%26aulast%3DSantella%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DDuncia%26aufirst%3DJ.%2BV.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DStrnad%26aufirst%3DJ.%26aulast%3DPedicord%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DBlat%26aufirst%3DY.%26aulast%3DZupa-Fernandez%26aufirst%3DA.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DChaudhry%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DC.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DMuckelbauer%26aufirst%3DJ.%2BK.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DTredup%26aufirst%3DJ.%26aulast%3DXie%26aufirst%3DD.%26aulast%3DAranibar%26aufirst%3DN.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DWeinstein%26aufirst%3DD.%2BS.%26atitle%3DIdentification%2520of%2520imidazo%255B1%252C2-b%255Dpyridazine%2520TYK2%2520pseudokinase%2520ligands%2520as%2520potent%2520and%2520selective%2520allosteric%2520inhibitors%2520of%2520TYK2%2520signalling%26jtitle%3DMedChemComm%26date%3D2017%26volume%3D8%26spage%3D700%26epage%3D712%26doi%3D10.1039%2FC6MD00560H" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sohn, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Abbema, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohli, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macleod, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurley, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulagowski, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewin-Koh, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dengler, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghilardi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blair, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnuson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L. C.</span></span> <span> </span><span class="NLM_article-title">A restricted role for TYK2 catalytic activity in human cytokine responses revealed by novel TYK2-selective inhibitors</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>191</i></span>,  <span class="NLM_fpage">2205</span>– <span class="NLM_lpage">2216</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1202859</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.4049%2Fjimmunol.1202859" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=23894201" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlSgtL%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2013&pages=2205-2216&author=S.+J.+Sohnauthor=K.+Barrettauthor=A.+Van+Abbemaauthor=C.+Changauthor=P.+B.+Kohliauthor=H.+Kandaauthor=J.+Smithauthor=Y.+Laiauthor=A.+Zhouauthor=B.+Zhangauthor=W.+Yangauthor=K.+Williamsauthor=C.+Macleodauthor=C.+A.+Hurleyauthor=J.+J.+Kulagowskiauthor=N.+Lewin-Kohauthor=H.+S.+Denglerauthor=A.+R.+Johnsonauthor=N.+Ghilardiauthor=M.+Zakauthor=J.+Liangauthor=W.+S.+Blairauthor=S.+Magnusonauthor=L.+C.+Wu&title=A+restricted+role+for+TYK2+catalytic+activity+in+human+cytokine+responses+revealed+by+novel+TYK2-selective+inhibitors&doi=10.4049%2Fjimmunol.1202859"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">A Restricted Role for TYK2 Catalytic Activity in Human Cytokine Responses Revealed by Novel TYK2-Selective Inhibitors</span></div><div class="casAuthors">Sohn, Sue J.; Barrett, Kathy; Van Abbema, Anne; Chang, Christine; Kohli, Pawan Bir; Kanda, Hidenobu; Smith, Janice; Lai, Yingjie; Zhou, Aihe; Zhang, Birong; Yang, Wenqian; Williams, Karen; MacLeod, Calum; Hurley, Christopher A.; Kulagowski, Janusz J.; Lewin-Koh, Nicholas; Dengler, Hart S.; Johnson, Adam R.; Ghilardi, Nico; Zak, Mark; Liang, Jun; Blair, Wade S.; Magnuson, Steven; Wu, Lawren C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">191</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2205-2216</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">TYK2 is a JAK family protein tyrosine kinase activated in response to multiple cytokines, including type I IFNs, IL-6, IL-10, IL-12, and IL-23.  Extensive studies of mice that lack TYK2 expression indicate that the IFN-α, IL-12, and IL-23 pathways, but not the IL-6 or IL-10 pathways, are compromised.  In contrast, there have been few studies of the role of TYK2 in primary human cells.  A genetic mutation at the tyk2 locus that results in a lack of TYK2 protein in a single human patient has been linked to defects in the IFN-α, IL-6, IL-10, IL-12, and IL-23 pathways, suggesting a broad role for TYK2 protein in human cytokine responses.  In this article, we have used a panel of novel potent TYK2 small-mol. inhibitors with varying degrees of selectivity against other JAK kinases to address the requirement for TYK2 catalytic activity in cytokine pathways in primary human cells.  Our results indicate that the biol. processes that require TYK2 catalytic function in humans are restricted to the IL-12 and IL-23 pathways, and suggest that inhibition of TYK2 catalytic activity may be an efficacious approach for the treatment of select autoimmune diseases without broad immunosuppression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgACYZYW8b07Vg90H21EOLACvtfcHk0ljUHVbjOiIZPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlSgtL%252FP&md5=527289e055e91fe2dfb15d3de7faa894</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1202859&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1202859%26sid%3Dliteratum%253Aachs%26aulast%3DSohn%26aufirst%3DS.%2BJ.%26aulast%3DBarrett%26aufirst%3DK.%26aulast%3DVan%2BAbbema%26aufirst%3DA.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DKohli%26aufirst%3DP.%2BB.%26aulast%3DKanda%26aufirst%3DH.%26aulast%3DSmith%26aufirst%3DJ.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DWilliams%26aufirst%3DK.%26aulast%3DMacleod%26aufirst%3DC.%26aulast%3DHurley%26aufirst%3DC.%2BA.%26aulast%3DKulagowski%26aufirst%3DJ.%2BJ.%26aulast%3DLewin-Koh%26aufirst%3DN.%26aulast%3DDengler%26aufirst%3DH.%2BS.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DZak%26aufirst%3DM.%26aulast%3DLiang%26aufirst%3DJ.%26aulast%3DBlair%26aufirst%3DW.%2BS.%26aulast%3DMagnuson%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DL.%2BC.%26atitle%3DA%2520restricted%2520role%2520for%2520TYK2%2520catalytic%2520activity%2520in%2520human%2520cytokine%2520responses%2520revealed%2520by%2520novel%2520TYK2-selective%2520inhibitors%26jtitle%3DJ.%2520Immunol.%26date%3D2013%26volume%3D191%26spage%3D2205%26epage%3D2216%26doi%3D10.4049%2Fjimmunol.1202859" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Menet, C. J.</span></span> <span> </span><span class="NLM_article-title">Toward selective TYK2 inhibitors as therapeutic agents for the treatment of inflammatory diseases</span>. <i>Pharm. Pat. Anal.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">449</span>– <span class="NLM_lpage">466</span>, <span class="refDoi"> DOI: 10.4155/ppa.14.23</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.4155%2Fppa.14.23" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=25291316" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslSkurjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2014&pages=449-466&author=C.+J.+Menet&title=Toward+selective+TYK2+inhibitors+as+therapeutic+agents+for+the+treatment+of+inflammatory+diseases&doi=10.4155%2Fppa.14.23"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Toward selective TYK2 inhibitors as therapeutic agents for the treatment of inflammatory diseases</span></div><div class="casAuthors">Menet, Christel J.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Patent Analyst</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">449-466</span>CODEN:
                <span class="NLM_cas:coden">PPAHCN</span>;
        ISSN:<span class="NLM_cas:issn">2046-8954</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">The family of JAK comprises four members and has received significant attention in recent years from the pharmaceutical industry as a therapeutic target.  The role of JAK is central to cytokine signaling pathways.  It is believed that selective modulation of one specific JAK can lead to the inhibition of a restricted set of cytokines, which should avoid undesired side effects and get closer to the profile of biol. therapies.  Consequently, selective JAK inhibition has become a major focus area of drug discovery research.  A review of the TYK2 patents indicates that industry attention has recently turned toward the development of specific inhibitors.  Importantly, despite the increasing no. of published patents, none of these drugs have yet made it to the clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcmMgH3Z8Ff7Vg90H21EOLACvtfcHk0lgrpEB7TYO5Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslSkurjF&md5=0a79df697117246c840c559260d8e7ba</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.4155%2Fppa.14.23&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Fppa.14.23%26sid%3Dliteratum%253Aachs%26aulast%3DMenet%26aufirst%3DC.%2BJ.%26atitle%3DToward%2520selective%2520TYK2%2520inhibitors%2520as%2520therapeutic%2520agents%2520for%2520the%2520treatment%2520of%2520inflammatory%2520diseases%26jtitle%3DPharm.%2520Pat.%2520Anal.%26date%3D2014%26volume%3D3%26spage%3D449%26epage%3D466%26doi%3D10.4155%2Fppa.14.23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Welsch, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holstein, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurence, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghoreschi, K.</span></span> <span> </span><span class="NLM_article-title">Targeting JAK/STAT signalling in inflammatory skin diseases with small molecule inhibitors</span>. <i>Eur. J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">1096</span>– <span class="NLM_lpage">1107</span>, <span class="refDoi"> DOI: 10.1002/eji.201646680</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1002%2Feji.201646680" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2017&pages=1096-1107&author=K.+Welschauthor=J.+Holsteinauthor=A.+Laurenceauthor=K.+Ghoreschi&title=Targeting+JAK%2FSTAT+signalling+in+inflammatory+skin+diseases+with+small+molecule+inhibitors&doi=10.1002%2Feji.201646680"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1002%2Feji.201646680&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Feji.201646680%26sid%3Dliteratum%253Aachs%26aulast%3DWelsch%26aufirst%3DK.%26aulast%3DHolstein%26aufirst%3DJ.%26aulast%3DLaurence%26aufirst%3DA.%26aulast%3DGhoreschi%26aufirst%3DK.%26atitle%3DTargeting%2520JAK%252FSTAT%2520signalling%2520in%2520inflammatory%2520skin%2520diseases%2520with%2520small%2520molecule%2520inhibitors%26jtitle%3DEur.%2520J.%2520Immunol.%26date%3D2017%26volume%3D47%26spage%3D1096%26epage%3D1107%26doi%3D10.1002%2Feji.201646680" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Farmer, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ledeboer, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoock, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnost, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bethiel, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennani, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brummel, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakilam, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorsch, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cochran, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrington, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogan, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laitinen, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahajan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marone, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Botella, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messersmith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namchuk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penney, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raybuck, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rugg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salituro, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saxena, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shannon, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shlyakter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swenson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, S.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Town, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wannamaker, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winquist, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuccola, H. J.</span></span> <span> </span><span class="NLM_article-title">Discovery of VX-509 (decernotinib): a potent and selective Janus kinase 3 inhibitor for the treatment of autoimmune diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">7195</span>– <span class="NLM_lpage">7216</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00301</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00301" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1KmsbbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=7195-7216&author=L.+J.+Farmerauthor=M.+W.+Ledeboerauthor=T.+Hoockauthor=M.+J.+Arnostauthor=R.+S.+Bethielauthor=Y.+L.+Bennaniauthor=J.+J.+Blackauthor=C.+L.+Brummelauthor=A.+Chakilamauthor=W.+A.+Dorschauthor=B.+Fanauthor=J.+E.+Cochranauthor=S.+Halasauthor=E.+M.+Harringtonauthor=J.+K.+Hoganauthor=D.+Howeauthor=H.+Huangauthor=D.+H.+Jacobsauthor=L.+M.+Laitinenauthor=S.+Liaoauthor=S.+Mahajanauthor=V.+Maroneauthor=G.+Martinez-Botellaauthor=P.+McCarthyauthor=D.+Messersmithauthor=M.+Namchukauthor=L.+Ohauthor=M.+S.+Penneyauthor=A.+C.+Pierceauthor=S.+A.+Raybuckauthor=A.+Ruggauthor=F.+G.+Salituroauthor=K.+Saxenaauthor=D.+Shannonauthor=D.+Shlyakterauthor=L.+Swensonauthor=S.-K.+Tianauthor=C.+Townauthor=J.+Wangauthor=T.+Wangauthor=M.+W.+Wannamakerauthor=R.+J.+Winquistauthor=H.+J.+Zuccola&title=Discovery+of+VX-509+%28decernotinib%29%3A+a+potent+and+selective+Janus+kinase+3+inhibitor+for+the+treatment+of+autoimmune+diseases&doi=10.1021%2Facs.jmedchem.5b00301"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases</span></div><div class="casAuthors">Farmer, Luc J.; Ledeboer, Mark W.; Hoock, Thomas; Arnost, Michael J.; Bethiel, Randy S.; Bennani, Youssef L.; Black, James J.; Brummel, Christopher L.; Chakilam, Ananthsrinivas; Dorsch, Warren A.; Fan, Bin; Cochran, John E.; Halas, Summer; Harrington, Edmund M.; Hogan, James K.; Howe, David; Huang, Hui; Jacobs, Dylan H.; Laitinen, Leena M.; Liao, Shengkai; Mahajan, Sudipta; Marone, Valerie; Martinez-Botella, Gabriel; McCarthy, Pamela; Messersmith, David; Namchuk, Mark; Oh, Luke; Penney, Marina S.; Pierce, Albert C.; Raybuck, Scott A.; Rugg, Arthur; Salituro, Francesco G.; Saxena, Kumkum; Shannon, Dean; Shlyakter, Dina; Swenson, Lora; Tian, Shi-Kai; Town, Christopher; Wang, Jian; Wang, Tiansheng; Wannamaker, M. Woods; Winquist, Raymond J.; Zuccola, Harmon J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7195-7216</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">While several therapeutic options exist, the need for more effective, safe, and convenient treatment for a variety of autoimmune diseases persists.  Targeting the Janus tyrosine kinases (JAKs), which play essential roles in cell signaling responses and can contribute to aberrant immune function assocd. with disease, has emerged as a novel and attractive approach for the development of new autoimmune disease therapies.  We screened our compd. library against JAK3, a key signaling kinase in immune cells, and identified multiple scaffolds showing good inhibitory activity for this kinase.  A particular scaffold of interest, the 1H-pyrrolo[2,3-b]pyridine series (7-azaindoles), was selected for further optimization in part on the basis of binding affinity (Ki) as well as on the basis of cellular potency.  Optimization of this chem. series led to the identification of VX-509 (decernotinib), a novel, potent, and selective JAK3 inhibitor, which demonstrates good efficacy in vivo in the rat host vs. graft model (HvG).  On the basis of these findings, it appears that VX-509 offers potential for the treatment of a variety of autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-CrqEc481PLVg90H21EOLACvtfcHk0lgrpEB7TYO5Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1KmsbbO&md5=8ba1e0beb7570baaf68fd5f20b54f9f9</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00301%26sid%3Dliteratum%253Aachs%26aulast%3DFarmer%26aufirst%3DL.%2BJ.%26aulast%3DLedeboer%26aufirst%3DM.%2BW.%26aulast%3DHoock%26aufirst%3DT.%26aulast%3DArnost%26aufirst%3DM.%2BJ.%26aulast%3DBethiel%26aufirst%3DR.%2BS.%26aulast%3DBennani%26aufirst%3DY.%2BL.%26aulast%3DBlack%26aufirst%3DJ.%2BJ.%26aulast%3DBrummel%26aufirst%3DC.%2BL.%26aulast%3DChakilam%26aufirst%3DA.%26aulast%3DDorsch%26aufirst%3DW.%2BA.%26aulast%3DFan%26aufirst%3DB.%26aulast%3DCochran%26aufirst%3DJ.%2BE.%26aulast%3DHalas%26aufirst%3DS.%26aulast%3DHarrington%26aufirst%3DE.%2BM.%26aulast%3DHogan%26aufirst%3DJ.%2BK.%26aulast%3DHowe%26aufirst%3DD.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DJacobs%26aufirst%3DD.%2BH.%26aulast%3DLaitinen%26aufirst%3DL.%2BM.%26aulast%3DLiao%26aufirst%3DS.%26aulast%3DMahajan%26aufirst%3DS.%26aulast%3DMarone%26aufirst%3DV.%26aulast%3DMartinez-Botella%26aufirst%3DG.%26aulast%3DMcCarthy%26aufirst%3DP.%26aulast%3DMessersmith%26aufirst%3DD.%26aulast%3DNamchuk%26aufirst%3DM.%26aulast%3DOh%26aufirst%3DL.%26aulast%3DPenney%26aufirst%3DM.%2BS.%26aulast%3DPierce%26aufirst%3DA.%2BC.%26aulast%3DRaybuck%26aufirst%3DS.%2BA.%26aulast%3DRugg%26aufirst%3DA.%26aulast%3DSalituro%26aufirst%3DF.%2BG.%26aulast%3DSaxena%26aufirst%3DK.%26aulast%3DShannon%26aufirst%3DD.%26aulast%3DShlyakter%26aufirst%3DD.%26aulast%3DSwenson%26aufirst%3DL.%26aulast%3DTian%26aufirst%3DS.-K.%26aulast%3DTown%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DWannamaker%26aufirst%3DM.%2BW.%26aulast%3DWinquist%26aufirst%3DR.%2BJ.%26aulast%3DZuccola%26aufirst%3DH.%2BJ.%26atitle%3DDiscovery%2520of%2520VX-509%2520%2528decernotinib%2529%253A%2520a%2520potent%2520and%2520selective%2520Janus%2520kinase%25203%2520inhibitor%2520for%2520the%2520treatment%2520of%2520autoimmune%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D7195%26epage%3D7216%26doi%3D10.1021%2Facs.jmedchem.5b00301" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thorarensen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banker, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fensome, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juba, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czerwinski, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casimiro-Garcia, A.</span></span> <span> </span><span class="NLM_article-title">ATP-mediated kinome selectivity: the missing link in understanding the contribution of individual JAK kinase isoforms to cellular signaling</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1552</span>– <span class="NLM_lpage">1558</span>, <span class="refDoi"> DOI: 10.1021/cb5002125</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb5002125" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnslart7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1552-1558&author=A.+Thorarensenauthor=M.+E.+Bankerauthor=A.+Fensomeauthor=J.-B.+Telliezauthor=B.+Jubaauthor=F.+Vincentauthor=R.+M.+Czerwinskiauthor=A.+Casimiro-Garcia&title=ATP-mediated+kinome+selectivity%3A+the+missing+link+in+understanding+the+contribution+of+individual+JAK+kinase+isoforms+to+cellular+signaling&doi=10.1021%2Fcb5002125"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">ATP-Mediated Kinome Selectivity: The Missing Link in Understanding the Contribution of Individual JAK Kinase Isoforms to Cellular Signaling</span></div><div class="casAuthors">Thorarensen, Atli; Banker, Mary Ellen; Fensome, Andrew; Telliez, Jean-Baptiste; Juba, Brian; Vincent, Fabien; Czerwinski, Robert M.; Casimiro-Garcia, Agustin</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1552-1558</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Kinases constitute an important class of therapeutic targets being explored both by academia and the pharmaceutical industry.  The major focus of this effort was directed toward the identification of ATP competitive inhibitors.  Although it has long been recognized that the intracellular concn. of ATP is very different from the concns. utilized in biochem. enzyme assays, little thought has been devoted to incorporating this discrepancy into our understanding of translation from enzyme inhibition to cellular function.  Significant work has been dedicated to the discovery of JAK kinase inhibitors; however, a disconnect between enzyme and cellular function is prominently displayed in the literature for this class of inhibitors.  Herein, we demonstrate utilizing the four JAK family members (JAK1, JAK2, JAK3, and TYK2) that the difference in the ATP Km of each individual kinase has a significant impact on the enzyme to cell inhibition translation.  We evaluated a large no. of JAK inhibitors in enzymic assays utilizing either 1 mM ATP or Km ATP for the four isoforms as well as in primary cell assays.  This data set provided the opportunity to examine individual kinase contributions to the heterodimeric kinase complexes mediating cellular signaling.  In contrast to a recent study, we demonstrate that for IL-15 cytokine signaling it is sufficient to inhibit either JAK1 or JAK3 to fully inhibit downstream STAT5 phosphorylation.  This addnl. data thus provides a crit. piece of information explaining why JAK1 has incorrectly been thought to have a dominant role over JAK3.  Beyond enabling a deeper understanding of JAK signaling, conducting similar analyses for other kinases by taking into account potency at high ATP rather than Km ATP may provide crucial insights into a compd.'s activity and selectivity in cellular contexts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYiMVl7OpPFLVg90H21EOLACvtfcHk0livZsyOSCioJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnslart7s%253D&md5=c87874cb1748e13eef2aa241ecef3e79</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fcb5002125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb5002125%26sid%3Dliteratum%253Aachs%26aulast%3DThorarensen%26aufirst%3DA.%26aulast%3DBanker%26aufirst%3DM.%2BE.%26aulast%3DFensome%26aufirst%3DA.%26aulast%3DTelliez%26aufirst%3DJ.-B.%26aulast%3DJuba%26aufirst%3DB.%26aulast%3DVincent%26aufirst%3DF.%26aulast%3DCzerwinski%26aufirst%3DR.%2BM.%26aulast%3DCasimiro-Garcia%26aufirst%3DA.%26atitle%3DATP-mediated%2520kinome%2520selectivity%253A%2520the%2520missing%2520link%2520in%2520understanding%2520the%2520contribution%2520of%2520individual%2520JAK%2520kinase%2520isoforms%2520to%2520cellular%2520signaling%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2014%26volume%3D9%26spage%3D1552%26epage%3D1558%26doi%3D10.1021%2Fcb5002125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Genovese, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Østergaard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinnman, N.</span></span> <span> </span><span class="NLM_article-title">Efficacy of VX-509 (decernotinib) in combination with a disease-modifying antirheumatic drug in patients with rheumatoid arthritis: clinical and MRI findings</span>. <i>Ann. Rheum. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">1979</span>– <span class="NLM_lpage">1983</span>, <span class="refDoi"> DOI: 10.1136/annrheumdis-2015-208901</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1136%2Fannrheumdis-2015-208901" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=27084959" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFahs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2016&pages=1979-1983&author=M.+C.+Genoveseauthor=F.+Yangauthor=M.+%C3%98stergaardauthor=N.+Kinnman&title=Efficacy+of+VX-509+%28decernotinib%29+in+combination+with+a+disease-modifying+antirheumatic+drug+in+patients+with+rheumatoid+arthritis%3A+clinical+and+MRI+findings&doi=10.1136%2Fannrheumdis-2015-208901"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of VX-509 (decernotinib) in combination with a disease-modifying antirheumatic drug in patients with rheumatoid arthritis: clinical and MRI findings</span></div><div class="casAuthors">Genovese, Mark C.; Yang, Fang; Oestergaard, Mikkel; Kinnman, Nils</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the Rheumatic Diseases</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1979-1983</span>CODEN:
                <span class="NLM_cas:coden">ARDIAO</span>;
        ISSN:<span class="NLM_cas:issn">0003-4967</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Objective: To assess early effects on joint structures of VX-509 in combination with stable disease-modifying antirheumatic drug (DMARD) therapy using MRI in adults with rheumatoid arthritis (RA).  Methods: This phase II, placebo-controlled, double blind, dose-ranging study randomised patients with RA and inadequate DMARD response to VX-509 100 mg (n=11), 200 mg (n=10) or 300 mg (n=10) or placebo (n=12) once daily for 12 wk.  Outcome measures included American College of Rheumatol. score (ACR20; improvement of ≥20% ) and disease activity score (DAS28) using C reactive protein (CRP), and the RA MRI scoring (RAMRIS) system.  Results: ACR20 response at week 12 was 63.6%, 60.0% and 60.0% in the VX-509 100-mg, 200-mg and 300-mg groups, resp., compared with 25.0% in the placebo group.  DAS28-CRP scores decreased in a dose-dependent manner with increasing VX-509 doses.  Decreases in RAMRIS synovitis scores were significantly different from placebo for all VX-509 doses ( p<0.01) and for RAMRIS osteitis scores ( p<0.01) for VX-509 300 mg.  Treatment was generally well tolerated.  Conclusions: VX-509 plus a DMARD reduced the signs and symptoms of RA in patients with an inadequate response to a DMARD alone.  MRI responses were detected at week 12.  Treatment was generally well tolerated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgpFXc2bfqZLVg90H21EOLACvtfcHk0livZsyOSCioJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFahs7c%253D&md5=b88684b8a805901d4836d3c8d7cce219</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1136%2Fannrheumdis-2015-208901&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fannrheumdis-2015-208901%26sid%3Dliteratum%253Aachs%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26aulast%3DYang%26aufirst%3DF.%26aulast%3D%25C3%2598stergaard%26aufirst%3DM.%26aulast%3DKinnman%26aufirst%3DN.%26atitle%3DEfficacy%2520of%2520VX-509%2520%2528decernotinib%2529%2520in%2520combination%2520with%2520a%2520disease-modifying%2520antirheumatic%2520drug%2520in%2520patients%2520with%2520rheumatoid%2520arthritis%253A%2520clinical%2520and%2520MRI%2520findings%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2016%26volume%3D75%26spage%3D1979%26epage%3D1983%26doi%3D10.1136%2Fannrheumdis-2015-208901" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Menet, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Lommen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geney, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanc, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smits, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jouannigot, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deprez, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Aar, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clement-Lacroix, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lepescheux, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galien, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vayssiere, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelles, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christophe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brys, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uhring, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciesielski, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Rompaey, L.</span></span> <span> </span><span class="NLM_article-title">Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">9323</span>– <span class="NLM_lpage">9342</span>, <span class="refDoi"> DOI: 10.1021/jm501262q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501262q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVGls7nN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=9323-9342&author=C.+J.+Menetauthor=S.+R.+Fletcherauthor=G.+Van+Lommenauthor=R.+Geneyauthor=J.+Blancauthor=K.+Smitsauthor=N.+Jouannigotauthor=P.+Deprezauthor=E.+M.+van+der%0AAarauthor=P.+Clement-Lacroixauthor=L.+Lepescheuxauthor=R.+Galienauthor=B.+Vayssiereauthor=L.+Nellesauthor=T.+Christopheauthor=R.+Brysauthor=M.+Uhringauthor=F.+Ciesielskiauthor=L.+Van+Rompaey&title=Triazolopyridines+as+selective+JAK1+inhibitors%3A+from+hit+identification+to+GLPG0634&doi=10.1021%2Fjm501262q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Triazolopyridines as Selective JAK1 Inhibitors: From Hit Identification to GLPG0634</span></div><div class="casAuthors">Menet, Christel J.; Fletcher, Stephen R.; Van Lommen, Guy; Geney, Raphael; Blanc, Javier; Smits, Koen; Jouannigot, Nolwenn; Deprez, Pierre; van der Aar, Ellen M.; Clement-Lacroix, Philippe; Lepescheux, Lien; Galien, Rene; Vayssiere, Beatrice; Nelles, Luc; Christophe, Thierry; Brys, Reginald; Uhring, Muriel; Ciesielski, Fabrice; Van Rompaey, Luc</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9323-9342</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Janus kinases (JAK1, JAK2, JAK3, and TYK2) are involved in the signaling of multiple cytokines important in cellular function.  Blockade of the JAK-STAT pathway with a small mol. has been shown to provide therapeutic immunomodulation.  Having identified JAK1 as a possible new target for arthritis at Galapagos, the compd. library was screened against JAK1, resulting in the identification of a triazolopyridine-based series of inhibitors represented by I.  Optimization within this chem. series led to identification of II (GLPG0634, filgotinib), a selective JAK1 inhibitor currently in phase 2B development for RA and phase 2A development for Crohn's disease (CD).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBHELw4zQ5QLVg90H21EOLACvtfcHk0livZsyOSCioJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVGls7nN&md5=756f687dc30e6fd34004deb672fe8b23</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fjm501262q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501262q%26sid%3Dliteratum%253Aachs%26aulast%3DMenet%26aufirst%3DC.%2BJ.%26aulast%3DFletcher%26aufirst%3DS.%2BR.%26aulast%3DVan%2BLommen%26aufirst%3DG.%26aulast%3DGeney%26aufirst%3DR.%26aulast%3DBlanc%26aufirst%3DJ.%26aulast%3DSmits%26aufirst%3DK.%26aulast%3DJouannigot%26aufirst%3DN.%26aulast%3DDeprez%26aufirst%3DP.%26aulast%3Dvan%2Bder%2BAar%26aufirst%3DE.%2BM.%26aulast%3DClement-Lacroix%26aufirst%3DP.%26aulast%3DLepescheux%26aufirst%3DL.%26aulast%3DGalien%26aufirst%3DR.%26aulast%3DVayssiere%26aufirst%3DB.%26aulast%3DNelles%26aufirst%3DL.%26aulast%3DChristophe%26aufirst%3DT.%26aulast%3DBrys%26aufirst%3DR.%26aulast%3DUhring%26aufirst%3DM.%26aulast%3DCiesielski%26aufirst%3DF.%26aulast%3DVan%2BRompaey%26aufirst%3DL.%26atitle%3DTriazolopyridines%2520as%2520selective%2520JAK1%2520inhibitors%253A%2520from%2520hit%2520identification%2520to%2520GLPG0634%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D9323%26epage%3D9342%26doi%3D10.1021%2Fjm501262q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu-Farseeva, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, L.</span></span> <span> </span><span class="NLM_article-title">Selective JAK inhibitors</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1439</span>– <span class="NLM_lpage">1471</span>, <span class="refDoi"> DOI: 10.4155/fmc.14.92</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.4155%2Ffmc.14.92" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=25329199" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslOhu7jI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=1439-1471&author=B.+W.+Dymockauthor=E.+G.+Yangauthor=Y.+Chu-Farseevaauthor=L.+Yao&title=Selective+JAK+inhibitors&doi=10.4155%2Ffmc.14.92"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Selective JAK inhibitors</span></div><div class="casAuthors">Dymock, Brian W.; Yang, Eugene Guorong; Chu-Farseeva, Yuyi; Yao, Lianbin</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1439-1471</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Consisting of four members, JAK1, JAK2, JAK3 and TYK2, the JAK kinases have emerged as important targets for proliferative and immune-inflammatory disorders.  Recent progress in the discovery of selective inhibitors has been significant, with selective compds. now reported for each isoform.  This article summarizes the current state-of-the-art with a discussion of the most recently described selective compds.  X-ray co-crystal structures reveal the mol. reasons for the obsd. biochem. selectivity.  A concluding anal. of JAK inhibitors in the clinic highlights increased clin. trial activity and diversity of indications.  Selective JAK inhibitors, as single agents or in combination regimens, have a very promising future in the treatment of oncol., immune and inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6G9eFT7Ww27Vg90H21EOLACvtfcHk0lhiC4-Egwi1rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslOhu7jI&md5=343aa75228918e6e4e063adb1fed96f1</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.4155%2Ffmc.14.92&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.14.92%26sid%3Dliteratum%253Aachs%26aulast%3DDymock%26aufirst%3DB.%2BW.%26aulast%3DYang%26aufirst%3DE.%2BG.%26aulast%3DChu-Farseeva%26aufirst%3DY.%26aulast%3DYao%26aufirst%3DL.%26atitle%3DSelective%2520JAK%2520inhibitors%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2014%26volume%3D6%26spage%3D1439%26epage%3D1471%26doi%3D10.4155%2Ffmc.14.92" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Namour, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diderichsen, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vayssière, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der Aa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tasset, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van’t Klooster, G.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics and pharmacokinetic/pharmacodynamic modeling of filgotinib (GLPG0634), a selective JAK1 inhibitor, in support of phase IIB dose selection</span>. <i>Clin. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">859</span>– <span class="NLM_lpage">874</span>, <span class="refDoi"> DOI: 10.1007/s40262-015-0240-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1007%2Fs40262-015-0240-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=25681059" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2MXivFWktro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2015&pages=859-874&author=F.+Namourauthor=P.+M.+Diderichsenauthor=E.+Coxauthor=B.+Vayssi%C3%A8reauthor=A.+Van+der+Aaauthor=C.+Tassetauthor=G.+Van%E2%80%99t+Klooster&title=Pharmacokinetics+and+pharmacokinetic%2Fpharmacodynamic+modeling+of+filgotinib+%28GLPG0634%29%2C+a+selective+JAK1+inhibitor%2C+in+support+of+phase+IIB+dose+selection&doi=10.1007%2Fs40262-015-0240-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection</span></div><div class="casAuthors">Namour, Florence; Diderichsen, Paul Matthias; Cox, Eugene; Vayssiere, Beatrice; Van der Aa, Annegret; Tasset, Chantal; Van't Klooster, Gerben</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">859-874</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Background and Objectives: Filgotinib (GLPG0634) is a selective inhibitor of Janus kinase 1 (JAK1) currently in development for the treatment of rheumatoid arthritis and Crohn's disease.  While less selective JAK inhibitors have shown long-term efficacy in treating inflammatory conditions, this was accompanied by dose-limiting side effects.  Here, we describe the pharmacokinetics of filgotinib and its active metabolite in healthy volunteers and the use of pharmacokinetic-pharmacodynamic modeling and simulation to support dose selection for phase IIB in patients with rheumatoid arthritis.  Methods: Two trials were conducted in healthy male volunteers.  In the first trial, filgotinib was administered as single doses from 10 mg up to multiple daily doses of 200 mg.  In the second trial, daily doses of 300 and 450 mg for 10 days were evaluated.  Non-compartmental anal. was used to det. individual pharmacokinetic parameters for filgotinib and its metabolite.  The overall pharmacodynamic activity for the two moieties was assessed in whole blood using interleukin-6-induced phosphorylation of signal-transducer and activator of transcription 1 as a biomarker for JAK1 activity.  These data were used to conduct non-linear mixed-effects modeling to investigate a pharmacokinetic/pharmacodynamic relationship.  Results: Modeling and simulation on the basis of early clin. data suggest that the pharmacokinetics of filgotinib are dose proportional up to 200 mg, in agreement with obsd. data, and support that both filgotinib and its metabolite contribute to its pharmacodynamic effects.  Simulation of biomarker response supports that the max. pharmacodynamic effect is reached at a daily dose of 200 mg filgotinib.  Conclusion: Based on these results, a daily dose range up to 200 mg has been selected for phase IIB dose-finding studies in patients with rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqa_k98wV2QwLVg90H21EOLACvtfcHk0lhiC4-Egwi1rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXivFWktro%253D&md5=fe06dc0e772239f0493601364273857f</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1007%2Fs40262-015-0240-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40262-015-0240-z%26sid%3Dliteratum%253Aachs%26aulast%3DNamour%26aufirst%3DF.%26aulast%3DDiderichsen%26aufirst%3DP.%2BM.%26aulast%3DCox%26aufirst%3DE.%26aulast%3DVayssi%25C3%25A8re%26aufirst%3DB.%26aulast%3DVan%2Bder%2BAa%26aufirst%3DA.%26aulast%3DTasset%26aufirst%3DC.%26aulast%3DVan%25E2%2580%2599t%2BKlooster%26aufirst%3DG.%26atitle%3DPharmacokinetics%2520and%2520pharmacokinetic%252Fpharmacodynamic%2520modeling%2520of%2520filgotinib%2520%2528GLPG0634%2529%252C%2520a%2520selective%2520JAK1%2520inhibitor%252C%2520in%2520support%2520of%2520phase%2520IIB%2520dose%2520selection%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2015%26volume%3D54%26spage%3D859%26epage%3D874%26doi%3D10.1007%2Fs40262-015-0240-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vanhoutte, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazur, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voloshyn, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanislavchuk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der Aa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namour, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galien, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meuleners, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van’t Klooster, G.</span></span> <span> </span><span class="NLM_article-title">Efficacy, safety, pharmacokinetics, and pharmacodynamics of filgotinib, a selective Janus kinase 1 inhibitor, after short-term treatment of rheumatoid arthritis: Results of two randomized Phase IIA trials</span>. <i>Arthritis Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">1949</span>– <span class="NLM_lpage">1959</span>, <span class="refDoi"> DOI: 10.1002/art.40186</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1002%2Fart.40186" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=28622463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFyrurjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2017&pages=1949-1959&author=F.+Vanhoutteauthor=M.+Mazurauthor=O.+Voloshynauthor=M.+Stanislavchukauthor=A.+Van+der+Aaauthor=F.+Namourauthor=R.+Galienauthor=L.+Meulenersauthor=G.+van%E2%80%99t+Klooster&title=Efficacy%2C+safety%2C+pharmacokinetics%2C+and+pharmacodynamics+of+filgotinib%2C+a+selective+Janus+kinase+1+inhibitor%2C+after+short-term+treatment+of+rheumatoid+arthritis%3A+Results+of+two+randomized+Phase+IIA+trials&doi=10.1002%2Fart.40186"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK-1 Inhibitor, After Short-Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials</span></div><div class="casAuthors">Vanhoutte, Frederic; Mazur, Minodora; Voloshyn, Oleksandr; Stanislavchuk, Mykola; Van der Aa, Annegret; Namour, Florence; Galien, Rene; Meuleners, Luc; van 't Klooster, Gerben</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1949-1959</span>CODEN:
                <span class="NLM_cas:coden">ARRHBO</span>;
        ISSN:<span class="NLM_cas:issn">2326-5191</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective : JAK inhibitors have shown efficacy in rheumatoid arthritis (RA).  We undertook this study to test our hypothesis that selective inhibition of JAK-1 would combine good efficacy with a better safety profile compared with less selective JAK inhibitors.  Methods : In two 4-wk exploratory, double-blind, placebo-controlled phase IIa trials, 127 RA patients with an insufficient response to methotrexate (MTX) received filgotinib (GLPG0634, GS-6034) oral capsules (100 mg twice daily or 30, 75, 150, 200, or 300 mg once daily) or placebo, added onto a stable regimen of MTX, to evaluate safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of filgotinib.  The primary efficacy end point was the no. and percentage of patients in each treatment group meeting the American College of Rheumatol. 20% improvement criteria (achieving an ACR20 response) at week 4.  Results : Treatment with filgotinib at 75-300 mg met the primary end point and showed early onset of efficacy.  ACR20 response rates progressively increased to week 4, and the Disease Activity Score in 28 joints using the C-reactive protein (CRP) level decreased.  Marked and sustained improvements were obsd. in serum CRP level and other PD markers.  The PK of filgotinib and its major metabolite was dose proportional over the 30-300 mg range.  Early side effects seen with other less selective JAK inhibitors were not obsd. (e.g., there was no worsening of anemia [JAK-2 inhibition related], no effects on liver transaminases, and no increase in low-d. lipoprotein or total cholesterol).  A limited decrease in neutrophils without neutropenia was consistent with immunomodulatory effects through JAK-1 inhibition.  There were no infections.  Overall, filgotinib was well tolerated.  Events related to study drug were mild or moderate and transient during therapy, and the most common such event was nausea.  Conclusion : Selective inhibition of JAK-1 with filgotinib shows initial efficacy in RA with an encouraging safety profile in these exploratory studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7oTo2cM5so7Vg90H21EOLACvtfcHk0lhiC4-Egwi1rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFyrurjP&md5=b704bd2b69231f1aa95815120b8cf922</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1002%2Fart.40186&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.40186%26sid%3Dliteratum%253Aachs%26aulast%3DVanhoutte%26aufirst%3DF.%26aulast%3DMazur%26aufirst%3DM.%26aulast%3DVoloshyn%26aufirst%3DO.%26aulast%3DStanislavchuk%26aufirst%3DM.%26aulast%3DVan%2Bder%2BAa%26aufirst%3DA.%26aulast%3DNamour%26aufirst%3DF.%26aulast%3DGalien%26aufirst%3DR.%26aulast%3DMeuleners%26aufirst%3DL.%26aulast%3Dvan%25E2%2580%2599t%2BKlooster%26aufirst%3DG.%26atitle%3DEfficacy%252C%2520safety%252C%2520pharmacokinetics%252C%2520and%2520pharmacodynamics%2520of%2520filgotinib%252C%2520a%2520selective%2520Janus%2520kinase%25201%2520inhibitor%252C%2520after%2520short-term%2520treatment%2520of%2520rheumatoid%2520arthritis%253A%2520Results%2520of%2520two%2520randomized%2520Phase%2520IIA%2520trials%26jtitle%3DArthritis%2520Rheumatol.%26date%3D2017%26volume%3D69%26spage%3D1949%26epage%3D1959%26doi%3D10.1002%2Fart.40186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mascarenhas, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talpaz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foltz, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savona, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paquette, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coughlin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winton, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burn, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Assad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verstovsek, S.</span></span> <span> </span><span class="NLM_article-title">Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis</span>. <i>Haematologica</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">327</span>– <span class="NLM_lpage">335</span>, <span class="refDoi"> DOI: 10.3324/haematol.2016.151126</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.3324%2Fhaematol.2016.151126" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2017&pages=327-335&author=J.+O.+Mascarenhasauthor=M.+Talpazauthor=V.+Guptaauthor=L.+M.+Foltzauthor=M.+R.+Savonaauthor=R.+Paquetteauthor=A.+R.+Turnerauthor=P.+Coughlinauthor=E.+Wintonauthor=T.+C.+Burnauthor=P.+O%E2%80%99Neillauthor=J.+Clarkauthor=D.+Hunterauthor=A.+Assadauthor=R.+Hoffmanauthor=S.+Verstovsek&title=Primary+analysis+of+a+phase+II+open-label+trial+of+INCB039110%2C+a+selective+JAK1+inhibitor%2C+in+patients+with+myelofibrosis&doi=10.3324%2Fhaematol.2016.151126"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.3324%2Fhaematol.2016.151126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3324%252Fhaematol.2016.151126%26sid%3Dliteratum%253Aachs%26aulast%3DMascarenhas%26aufirst%3DJ.%2BO.%26aulast%3DTalpaz%26aufirst%3DM.%26aulast%3DGupta%26aufirst%3DV.%26aulast%3DFoltz%26aufirst%3DL.%2BM.%26aulast%3DSavona%26aufirst%3DM.%2BR.%26aulast%3DPaquette%26aufirst%3DR.%26aulast%3DTurner%26aufirst%3DA.%2BR.%26aulast%3DCoughlin%26aufirst%3DP.%26aulast%3DWinton%26aufirst%3DE.%26aulast%3DBurn%26aufirst%3DT.%2BC.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DP.%26aulast%3DClark%26aufirst%3DJ.%26aulast%3DHunter%26aufirst%3DD.%26aulast%3DAssad%26aufirst%3DA.%26aulast%3DHoffman%26aufirst%3DR.%26aulast%3DVerstovsek%26aufirst%3DS.%26atitle%3DPrimary%2520analysis%2520of%2520a%2520phase%2520II%2520open-label%2520trial%2520of%2520INCB039110%252C%2520a%2520selective%2520JAK1%2520inhibitor%252C%2520in%2520patients%2520with%2520myelofibrosis%26jtitle%3DHaematologica%26date%3D2017%26volume%3D102%26spage%3D327%26epage%3D335%26doi%3D10.3324%2Fhaematol.2016.151126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmieder, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Draelos, Z. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pariser, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banfield, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kieras, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parsons-Rich, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salganik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peeva, E.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: phase II, randomized, double-blind, placebo-controlled study</span>. <i>Br. J. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>, <span class="refDoi"> DOI: 10.1111/bjd.16004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1111%2Fbjd.16004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=28949012" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=G.+J.+Schmiederauthor=Z.+D.+Draelosauthor=D.+M.+Pariserauthor=C.+Banfieldauthor=L.+Coxauthor=M.+Hodgeauthor=E.+Kierasauthor=D.+Parsons-Richauthor=S.+Menonauthor=M.+Salganikauthor=K.+Pageauthor=E.+Peeva&title=Efficacy+and+safety+of+the+Janus+kinase+1+inhibitor+PF-04965842+in+patients+with+moderate-to-severe+psoriasis%3A+phase+II%2C+randomized%2C+double-blind%2C+placebo-controlled+study&doi=10.1111%2Fbjd.16004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1111%2Fbjd.16004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjd.16004%26sid%3Dliteratum%253Aachs%26aulast%3DSchmieder%26aufirst%3DG.%2BJ.%26aulast%3DDraelos%26aufirst%3DZ.%2BD.%26aulast%3DPariser%26aufirst%3DD.%2BM.%26aulast%3DBanfield%26aufirst%3DC.%26aulast%3DCox%26aufirst%3DL.%26aulast%3DHodge%26aufirst%3DM.%26aulast%3DKieras%26aufirst%3DE.%26aulast%3DParsons-Rich%26aufirst%3DD.%26aulast%3DMenon%26aufirst%3DS.%26aulast%3DSalganik%26aufirst%3DM.%26aulast%3DPage%26aufirst%3DK.%26aulast%3DPeeva%26aufirst%3DE.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520the%2520Janus%2520kinase%25201%2520inhibitor%2520PF-04965842%2520in%2520patients%2520with%2520moderate-to-severe%2520psoriasis%253A%2520phase%2520II%252C%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520study%26jtitle%3DBr.%2520J.%2520Dermatol.%26date%3D2018%26doi%3D10.1111%2Fbjd.16004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kettle, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Åstrand, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimster, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woessner, R.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of JAK-family kinases: an update on the patent literature 2013–2015, Part 2</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">145</span>– <span class="NLM_lpage">161</span>, <span class="refDoi"> DOI: 10.1080/13543776.2017.1252754</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1080%2F13543776.2017.1252754" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=27774822" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhsl2htrnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=145-161&author=J.+G.+Kettleauthor=A.+%C3%85strandauthor=M.+Catleyauthor=N.+P.+Grimsterauthor=M.+Nilssonauthor=Q.+Suauthor=R.+Woessner&title=Inhibitors+of+JAK-family+kinases%3A+an+update+on+the+patent+literature+2013%E2%80%932015%2C+Part+2&doi=10.1080%2F13543776.2017.1252754"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2</span></div><div class="casAuthors">Kettle, Jason G.; Astrand, Annika; Catley, Matthew; Grimster, Neil P.; Nilsson, Magnus; Su, Qibin; Woessner, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">145-161</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Janus kinases (JAKs) are a family of four enzymes; JAK1, JAK2, JAK3 and tyrosine kinase 2 (TYK2) that are crit. in cytokine signalling and are strongly linked to both cancer and inflammatory diseases.  There are currently two launched JAK inhibitors for the treatment of human conditions: tofacitinib for Rheumatoid arthritis (RA) and ruxolitinib for myeloproliferative neoplasms including intermediate or high risk myelofibrosis and polycythemia vera.  This review covers patents claiming activity against one or more JAK family members in the period 2013-2015 inclusive, and covers 95 patents from 42 applicants, split over two parts.  The authors have ordered recent patents according to the primary applicant's name, with part 2 covering J through Z.  Inhibition of JAK-family kinases is an area of growing interest, catalyzed by the maturity of data on marketed inhibitors ruxolitinib and tofacitinib in late stage clin. trials.  Many applicants are pursuing traditional fast-follower strategies around these inhibitors, with a range of chem. strategies adopted.  The challenge will be to show sufficient differentiation to the originator compds., since dose limiting toxicities with such agents appear to be on target and mechanism-related and also considering that such agents may be available as generic compds. by the time follower agents reach market.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3xWVX0ADy67Vg90H21EOLACvtfcHk0liLwKWO5gkFZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhsl2htrnI&md5=c75e5d123fd35306665e0713f801320c</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1080%2F13543776.2017.1252754&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2017.1252754%26sid%3Dliteratum%253Aachs%26aulast%3DKettle%26aufirst%3DJ.%2BG.%26aulast%3D%25C3%2585strand%26aufirst%3DA.%26aulast%3DCatley%26aufirst%3DM.%26aulast%3DGrimster%26aufirst%3DN.%2BP.%26aulast%3DNilsson%26aufirst%3DM.%26aulast%3DSu%26aufirst%3DQ.%26aulast%3DWoessner%26aufirst%3DR.%26atitle%3DInhibitors%2520of%2520JAK-family%2520kinases%253A%2520an%2520update%2520on%2520the%2520patent%2520literature%25202013%25E2%2580%25932015%252C%2520Part%25202%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2017%26volume%3D27%26spage%3D145%26epage%3D161%26doi%3D10.1080%2F13543776.2017.1252754" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storer, R. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabnis, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakenhut, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitlock, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">England, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukaiyama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dehnhardt, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coe, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kortum, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chrencik, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeoh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilty, I.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of a pan-Janus kinase inhibitor clinical candidate (PF-06263276) suitable for inhaled and topical delivery for the treatment of inflammatory diseases of the lungs and skin</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">767</span>– <span class="NLM_lpage">786</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01634</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01634" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFSnsr3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=767-786&author=P.+Jonesauthor=R.+I.+Storerauthor=Y.+A.+Sabnisauthor=F.+M.+Wakenhutauthor=G.+A.+Whitlockauthor=K.+S.+Englandauthor=T.+Mukaiyamaauthor=C.+M.+Dehnhardtauthor=J.+W.+Coeauthor=S.+W.+Kortumauthor=J.+E.+Chrencikauthor=D.+G.+Brownauthor=R.+M.+Jonesauthor=J.+R.+Murphyauthor=T.+Yeohauthor=P.+Morganauthor=I.+Kilty&title=Design+and+synthesis+of+a+pan-Janus+kinase+inhibitor+clinical+candidate+%28PF-06263276%29+suitable+for+inhaled+and+topical+delivery+for+the+treatment+of+inflammatory+diseases+of+the+lungs+and+skin&doi=10.1021%2Facs.jmedchem.6b01634"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of a Pan-Janus Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin</span></div><div class="casAuthors">Jones, Peter; Storer, R. Ian; Sabnis, Yogesh A.; Wakenhut, Florian M.; Whitlock, Gavin A.; England, Katherine S.; Mukaiyama, Takasuke; Dehnhardt, Christoph M.; Coe, Jotham W.; Kortum, Steve W.; Chrencik, Jill E.; Brown, David G.; Jones, Rhys M.; Murphy, John R.; Yeoh, Thean; Morgan, Paul; Kilty, Iain</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">767-786</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Using a structure-based computational method for identification of structurally novel JAK inhibitors predicted to bind beyond the ATP binding site, a potent series of indazoles was identified as selective pan-JAK inhibitors with a type 1.5 binding mode.  Optimization of the series for potency and increased duration of action commensurate with inhaled or topical delivery resulted in PF-06263276 which was advanced into clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEt2oMBlGsBbVg90H21EOLACvtfcHk0ljE1C4e990qDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFSnsr3J&md5=a69247c21ff53a3b7d9c63cf0af72101</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01634%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DP.%26aulast%3DStorer%26aufirst%3DR.%2BI.%26aulast%3DSabnis%26aufirst%3DY.%2BA.%26aulast%3DWakenhut%26aufirst%3DF.%2BM.%26aulast%3DWhitlock%26aufirst%3DG.%2BA.%26aulast%3DEngland%26aufirst%3DK.%2BS.%26aulast%3DMukaiyama%26aufirst%3DT.%26aulast%3DDehnhardt%26aufirst%3DC.%2BM.%26aulast%3DCoe%26aufirst%3DJ.%2BW.%26aulast%3DKortum%26aufirst%3DS.%2BW.%26aulast%3DChrencik%26aufirst%3DJ.%2BE.%26aulast%3DBrown%26aufirst%3DD.%2BG.%26aulast%3DJones%26aufirst%3DR.%2BM.%26aulast%3DMurphy%26aufirst%3DJ.%2BR.%26aulast%3DYeoh%26aufirst%3DT.%26aulast%3DMorgan%26aufirst%3DP.%26aulast%3DKilty%26aufirst%3DI.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520a%2520pan-Janus%2520kinase%2520inhibitor%2520clinical%2520candidate%2520%2528PF-06263276%2529%2520suitable%2520for%2520inhaled%2520and%2520topical%2520delivery%2520for%2520the%2520treatment%2520of%2520inflammatory%2520diseases%2520of%2520the%2520lungs%2520and%2520skin%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D767%26epage%3D786%26doi%3D10.1021%2Facs.jmedchem.6b01634" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Elwood, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witter, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piesvaux, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraybill, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bays, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alpert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldenblatt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivanovska, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, C.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshmukh, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zielstorff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byford, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakravarthy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorosh, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivkin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klappenbach, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, B.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kariv, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinsmore, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slipetz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dandliker, P. J.</span></span> <span> </span><span class="NLM_article-title">Evaluation of JAK3 biology in autoimmune disease using a highly selective, irreversible JAK3 inhibitor</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>361</i></span>,  <span class="NLM_fpage">229</span>– <span class="NLM_lpage">244</span>, <span class="refDoi"> DOI: 10.1124/jpet.116.239723</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1124%2Fjpet.116.239723" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=28193636" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtV2js7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2017&pages=229-244&author=F.+Elwoodauthor=D.+J.+Witterauthor=J.+Piesvauxauthor=B.+Kraybillauthor=N.+Baysauthor=C.+Alpertauthor=P.+Goldenblattauthor=Y.+Quauthor=I.+Ivanovskaauthor=H.-H.+Leeauthor=C.-S.+Chiuauthor=H.+Tangauthor=M.+E.+Scottauthor=S.+V.+Deshmukhauthor=M.+Zielstorffauthor=A.+Byfordauthor=K.+Chakravarthyauthor=L.+Doroshauthor=A.+Rivkinauthor=J.+Klappenbachauthor=B.-S.+Panauthor=I.+Karivauthor=C.+Dinsmoreauthor=D.+Slipetzauthor=P.+J.+Dandliker&title=Evaluation+of+JAK3+biology+in+autoimmune+disease+using+a+highly+selective%2C+irreversible+JAK3+inhibitor&doi=10.1124%2Fjpet.116.239723"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of JAK3 biology in autoimmune disease using a highly selective, irreversible JAK3 inhibitor</span></div><div class="casAuthors">Elwood, Fiona; Witter, David J.; Piesvaux, Jennifer; Kraybill, Brian; Bays, Nathan; Alpert, Carla; Goldenblatt, Peter; Qu, Yujie; Ivanovska, Irena; Lee, Hyun-Hee; Chiu, Chi-Sung; Tang, Hao; Scott, Mark E.; Deshmukh, Sujal V.; Zielstorff, Mark; Byford, Alan; Chakravarthy, Kalyan; Dorosh, Lauren; Rivkin, Alexey; Klappenbach, Joel; Pan, Bo-Sheng; Kariv, Ilona; Dinsmore, Christopher; Slipetz, Deborah; Dandliker, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">361</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">229-244</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Reversible janus assocd. kinase (JAK) inhibitors such as tofacitinib and decernotinib block cytokine signaling and are efficacious in treating autoimmune diseases.  However, therapeutic doses are limited due to inhibition of other JAK/signal transducer and activator of transcription pathways assocd. with hematopoiesis, lipid biogenesis, infection, and immune responses.  A selective JAK3 inhibitor may have a better therapeutic index; however, until recently, no compds. have been described that maintain JAK3 selectivity in cells, as well as against the kinome, with good physicochem. properties to test the JAK3 hypothesis in vivo.  To quantify the biochem. basis for JAK isoenzyme selectivity, we detd. that the apparent Km value for each JAK isoenzyme ranged from 31.8 to 2.9 μM for JAK1 and JAK3, resp.  To confirm compd. activity in cells, we developed a novel enzyme complementation assay that read activity of single JAK isoenzymes in a cellular context.  Reversible JAK3 inhibitors cannot achieve sufficient selectivity against other isoenzymes in the cellular context due to inherent differences in enzyme ATP Km values.  Therefore, we developed irreversible JAK3 compds. that are potent and highly selective in vitro in cells and against the kinome.  Compd. 2, a potent inhibitor of JAK3 (0.15 nM) was 4300-fold selective for JAK3 over JAK1 in enzyme assays, 67-fold [interleukin (IL)-2 vs. IL-6] or 140-fold [IL-2 vs. erythropoietin or granulocyte-macrophage colony-stimulating factor (GMCSF)] selective in cellular reporter assays and >35-fold selective in human peripheral blood mononuclear cell assays (IL-7 vs. IL-6 or GMCSF).  In vivo, selective JAK3 inhibition was sufficient to block the development of inflammation in a rat model of rheumatoid arthritis, while sparing hematopoiesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpp6-yK4H1dDbVg90H21EOLACvtfcHk0lg8JKfQlR2x6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtV2js7vL&md5=942ec024e9681b696dfbfeaf22f5acb2</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1124%2Fjpet.116.239723&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.116.239723%26sid%3Dliteratum%253Aachs%26aulast%3DElwood%26aufirst%3DF.%26aulast%3DWitter%26aufirst%3DD.%2BJ.%26aulast%3DPiesvaux%26aufirst%3DJ.%26aulast%3DKraybill%26aufirst%3DB.%26aulast%3DBays%26aufirst%3DN.%26aulast%3DAlpert%26aufirst%3DC.%26aulast%3DGoldenblatt%26aufirst%3DP.%26aulast%3DQu%26aufirst%3DY.%26aulast%3DIvanovska%26aufirst%3DI.%26aulast%3DLee%26aufirst%3DH.-H.%26aulast%3DChiu%26aufirst%3DC.-S.%26aulast%3DTang%26aufirst%3DH.%26aulast%3DScott%26aufirst%3DM.%2BE.%26aulast%3DDeshmukh%26aufirst%3DS.%2BV.%26aulast%3DZielstorff%26aufirst%3DM.%26aulast%3DByford%26aufirst%3DA.%26aulast%3DChakravarthy%26aufirst%3DK.%26aulast%3DDorosh%26aufirst%3DL.%26aulast%3DRivkin%26aufirst%3DA.%26aulast%3DKlappenbach%26aufirst%3DJ.%26aulast%3DPan%26aufirst%3DB.-S.%26aulast%3DKariv%26aufirst%3DI.%26aulast%3DDinsmore%26aufirst%3DC.%26aulast%3DSlipetz%26aufirst%3DD.%26aulast%3DDandliker%26aufirst%3DP.%2BJ.%26atitle%3DEvaluation%2520of%2520JAK3%2520biology%2520in%2520autoimmune%2520disease%2520using%2520a%2520highly%2520selective%252C%2520irreversible%2520JAK3%2520inhibitor%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2017%26volume%3D361%26spage%3D229%26epage%3D244%26doi%3D10.1124%2Fjpet.116.239723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jussif, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balbo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crouse, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickinson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symanowicz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banker, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unwalla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayward, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montgomery, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trujillo, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casimiro-Garcia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vajdos, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geoghegan, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xuan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hett, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorarensen, A.</span></span> <span> </span><span class="NLM_article-title">Discovery of a JAK3-selective inhibitor: functional differentiation of JAK3-selective inhibition over pan-JAK or JAK1-selective inhibition</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">3442</span>– <span class="NLM_lpage">3451</span>, <span class="refDoi"> DOI: 10.1021/acschembio.6b00677</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.6b00677" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslGku7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=3442-3451&author=J.-B.+Telliezauthor=M.+E.+Dowtyauthor=L.+Wangauthor=J.+Jussifauthor=T.+Linauthor=L.+Liauthor=E.+Moyauthor=P.+Balboauthor=W.+Liauthor=Y.+Zhaoauthor=K.+Crouseauthor=C.+Dickinsonauthor=P.+Symanowiczauthor=M.+Hegenauthor=M.+E.+Bankerauthor=F.+Vincentauthor=R.+Unwallaauthor=S.+Liangauthor=A.+M.+Gilbertauthor=M.+F.+Brownauthor=M.+Haywardauthor=J.+Montgomeryauthor=X.+Yangauthor=J.+Baumanauthor=J.+I.+Trujilloauthor=A.+Casimiro-Garciaauthor=F.+F.+Vajdosauthor=L.+Leungauthor=K.+F.+Geogheganauthor=A.+Quaziauthor=D.+Xuanauthor=L.+Jonesauthor=E.+Hettauthor=K.+Wrightauthor=J.+D.+Clarkauthor=A.+Thorarensen&title=Discovery+of+a+JAK3-selective+inhibitor%3A+functional+differentiation+of+JAK3-selective+inhibition+over+pan-JAK+or+JAK1-selective+inhibition&doi=10.1021%2Facschembio.6b00677"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition</span></div><div class="casAuthors">Telliez, Jean-Baptiste; Dowty, Martin E.; Wang, Lu; Jussif, Jason; Lin, Tsung; Li, Li; Moy, Erick; Balbo, Paul; Li, Wei; Zhao, Yajuan; Crouse, Kimberly; Dickinson, Caitlyn; Symanowicz, Peter; Hegen, Martin; Banker, Mary Ellen; Vincent, Fabien; Unwalla, Ray; Liang, Sidney; Gilbert, Adam M.; Brown, Matthew F.; Hayward, Matthew; Montgomery, Justin; Yang, Xin; Bauman, Jonathan; Trujillo, John I.; Casimiro-Garcia, Agustin; Vajdos, Felix F.; Leung, Louis; Geoghegan, Kieran F.; Quazi, Amira; Xuan, Dejun; Jones, Lyn; Hett, Erik; Wright, Katherine; Clark, James D.; Thorarensen, Atli</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3442-3451</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">PF-06651600, a newly discovered potent JAK3-selective inhibitor is highly efficacious at inhibiting γc cytokine signaling which is dependent on both JAK1 and JAK3.  PF-06651600 allowed the comparison of JAK3-selective inhibition to pan-JAK or JAK1-selective inhibition, in relevant immune cells to a level that couldn't be achieved previously without such potency and selectivity.  In vitro, PF-06651600 inhibits Th1 and Th17 cell differentiation and function, and in vivo it reduces disease pathol. in the rat adjuvant-induced arthritis as well as in the mouse exptl. autoimmune encephalomyelitis models.  Importantly, by sparing JAK1 function, PF-06651600 selectively targets γc cytokine pathways while preserving JAK1-dependent anti-inflammatory signaling such as the IL-10 suppressive functions following LPS treatment in macrophages and the suppression of TNFα and IL-1β prodn. in IL-27-primed macrophages.  Thus, JAK3-selective inhibition differentiates from pan-JAK or JAK1 inhibition in various immune cellular responses which could potentially translate to advantageous clin. outcomes in inflammatory and autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNLk0mtStNSrVg90H21EOLACvtfcHk0lg8JKfQlR2x6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslGku7nK&md5=dd83978cf9ac22947f4a3f07c5eed8ab</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Facschembio.6b00677&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.6b00677%26sid%3Dliteratum%253Aachs%26aulast%3DTelliez%26aufirst%3DJ.-B.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DJussif%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DMoy%26aufirst%3DE.%26aulast%3DBalbo%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DCrouse%26aufirst%3DK.%26aulast%3DDickinson%26aufirst%3DC.%26aulast%3DSymanowicz%26aufirst%3DP.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DBanker%26aufirst%3DM.%2BE.%26aulast%3DVincent%26aufirst%3DF.%26aulast%3DUnwalla%26aufirst%3DR.%26aulast%3DLiang%26aufirst%3DS.%26aulast%3DGilbert%26aufirst%3DA.%2BM.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DHayward%26aufirst%3DM.%26aulast%3DMontgomery%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DBauman%26aufirst%3DJ.%26aulast%3DTrujillo%26aufirst%3DJ.%2BI.%26aulast%3DCasimiro-Garcia%26aufirst%3DA.%26aulast%3DVajdos%26aufirst%3DF.%2BF.%26aulast%3DLeung%26aufirst%3DL.%26aulast%3DGeoghegan%26aufirst%3DK.%2BF.%26aulast%3DQuazi%26aufirst%3DA.%26aulast%3DXuan%26aufirst%3DD.%26aulast%3DJones%26aufirst%3DL.%26aulast%3DHett%26aufirst%3DE.%26aulast%3DWright%26aufirst%3DK.%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DThorarensen%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520a%2520JAK3-selective%2520inhibitor%253A%2520functional%2520differentiation%2520of%2520JAK3-selective%2520inhibition%2520over%2520pan-JAK%2520or%2520JAK1-selective%2520inhibition%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2016%26volume%3D11%26spage%3D3442%26epage%3D3451%26doi%3D10.1021%2Facschembio.6b00677" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roskoski, R.</span></span> <span> </span><span class="NLM_article-title">Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">784</span>– <span class="NLM_lpage">803</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2016.07.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1016%2Fj.phrs.2016.07.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=27473820" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht12jurzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2016&pages=784-803&author=R.+Roskoski&title=Janus+kinase+%28JAK%29+inhibitors+in+the+treatment+of+inflammatory+and+neoplastic+diseases&doi=10.1016%2Fj.phrs.2016.07.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases</span></div><div class="casAuthors">Roskoski, Robert, Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">784-803</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The Janus kinase (JAK) family of non-receptor protein-tyrosine kinases consists of JAK1, JAK2, JAK3, and TYK2 (tyrosine kinase-2).  Each of these proteins contains a JAK homol. pseudokinase (JH2) domain that regulates the adjacent protein kinase domain (JH1).  JAK1/2 and TYK2 are ubiquitously expressed whereas JAK3 is found predominantly in hematopoietic cells.  The Janus kinase family is regulated by numerous cytokines including interleukins, interferons, and hormones such as erythropoietin, thrombopoietin, and growth hormone.  Ligand binding to cytokine and hormone receptors leads to the activation of assocd. Janus kinases, which then mediate the phosphorylation of the receptors.  The SH2 domain of STATs (signal transducers and activators of transcription) binds to the receptor phosphotyrosines thereby promoting STAT phosphorylation by the Janus kinases and consequent activation.  STAT dimers are translocated to the nucleus where they participate in the regulation of the expression of thousands of proteins.  JAK-STAT dysregulation results in autoimmune disorders such as rheumatoid arthritis, ulcerative colitis, and Crohn disease.  JAK-STAT dysregulation also plays a role in the pathogenesis of myelofibrosis, polycythemia vera, and other myeloproliferative illnesses.  An activating JAK2 V617F mutation occurs in 95% of people with polycythemia vera and in a lower percentage of people with other neoplasms.  JAK1/3 signaling participates in the pathogenesis of inflammatory afflictions while JAK1/2 signaling participates in the development of several malignancies including leukemias and lymphomas as well as myeloproliferative neoplasms.  Tofacitinib is a pan-JAK inhibitor that is approved by the FDA for the treatment of rheumatoid arthritis and ruxolitinib is a JAK1/2 inhibitor that is approved for the treatment of polycythemia vera and myelofibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGov32m4UjOrv7Vg90H21EOLACvtfcHk0lg8JKfQlR2x6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht12jurzJ&md5=a45fba1bb110eff4d5c1b31b78c1b3ac</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2016.07.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2016.07.038%26sid%3Dliteratum%253Aachs%26aulast%3DRoskoski%26aufirst%3DR.%26atitle%3DJanus%2520kinase%2520%2528JAK%2529%2520inhibitors%2520in%2520the%2520treatment%2520of%2520inflammatory%2520and%2520neoplastic%2520diseases%26jtitle%3DPharmacol.%2520Res.%26date%3D2016%26volume%3D111%26spage%3D784%26epage%3D803%26doi%3D10.1016%2Fj.phrs.2016.07.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lupardus, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ultsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallweber, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bir Kohli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span> <span> </span><span class="NLM_article-title">Structure of the pseudokinase–kinase domains from protein kinase TYK2 reveals a mechanism for Janus Kinase (JAK) autoinhibition</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">8025</span>– <span class="NLM_lpage">8030</span>, <span class="refDoi"> DOI: 10.1073/pnas.1401180111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1073%2Fpnas.1401180111" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=8025-8030&author=P.+J.+Lupardusauthor=M.+Ultschauthor=H.+Wallweberauthor=P.+Bir+Kohliauthor=A.+R.+Johnsonauthor=C.+Eigenbrot&title=Structure+of+the+pseudokinase%E2%80%93kinase+domains+from+protein+kinase+TYK2+reveals+a+mechanism+for+Janus+Kinase+%28JAK%29+autoinhibition&doi=10.1073%2Fpnas.1401180111"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1401180111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1401180111%26sid%3Dliteratum%253Aachs%26aulast%3DLupardus%26aufirst%3DP.%2BJ.%26aulast%3DUltsch%26aufirst%3DM.%26aulast%3DWallweber%26aufirst%3DH.%26aulast%3DBir%2BKohli%26aufirst%3DP.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DEigenbrot%26aufirst%3DC.%26atitle%3DStructure%2520of%2520the%2520pseudokinase%25E2%2580%2593kinase%2520domains%2520from%2520protein%2520kinase%2520TYK2%2520reveals%2520a%2520mechanism%2520for%2520Janus%2520Kinase%2520%2528JAK%2529%2520autoinhibition%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2014%26volume%3D111%26spage%3D8025%26epage%3D8030%26doi%3D10.1073%2Fpnas.1401180111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Puleo, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kucera, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammarén, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ungureanu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newton, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvennoinen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorgensen, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, J.</span></span> <span> </span><span class="NLM_article-title">Identification and characterization of JAK2 pseudokinase domain small molecule binders</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">618</span>– <span class="NLM_lpage">621</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00153</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00153" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnvFClsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=618-621&author=D.+E.+Puleoauthor=K.+Kuceraauthor=H.+M.+Hammar%C3%A9nauthor=D.+Ungureanuauthor=A.+S.+Newtonauthor=O.+Silvennoinenauthor=W.+L.+Jorgensenauthor=J.+Schlessinger&title=Identification+and+characterization+of+JAK2+pseudokinase+domain+small+molecule+binders&doi=10.1021%2Facsmedchemlett.7b00153"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and Characterization of JAK2 Pseudokinase Domain Small Molecule Binders</span></div><div class="casAuthors">Puleo, David E.; Kucera, Kaury; Hammaren, Henrik M.; Ungureanu, Daniela; Newton, Ana S.; Silvennoinen, Olli; Jorgensen, William L.; Schlessinger, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">618-621</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Janus kinases (JAKs) regulate hematopoiesis via the cytokine-mediated JAK-STAT signaling pathway.  JAKs contain tandem C-terminal pseudokinase (JH2) and tyrosine kinase (JH1) domains.  The JAK2 pseudokinase domain adopts a protein kinase fold and, despite its pseudokinase designation, binds ATP with micromolar affinity.  Recent evidence shows that displacing ATP from the JAK2 JH2 domain alters the hyperactivation state of the oncogenic JAK2 V617F protein while sparing the wild type JAK2 protein.  In this study, small mol. binders of JAK2 JH2 were identified via an in vitro screen.  Top hits were characterized using biophys. and structural approaches.  Development of pseudokinase-selective compds. may offer novel pharmacol. opportunities for treating cancers driven by JAK2 V617F and other oncogenic JAK mutants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmtcoH5qmUWrVg90H21EOLACvtfcHk0liSEfSlz1ZERw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnvFClsr4%253D&md5=a3f1f6e10a8a1d3b64bb5691d246f5d0</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00153%26sid%3Dliteratum%253Aachs%26aulast%3DPuleo%26aufirst%3DD.%2BE.%26aulast%3DKucera%26aufirst%3DK.%26aulast%3DHammar%25C3%25A9n%26aufirst%3DH.%2BM.%26aulast%3DUngureanu%26aufirst%3DD.%26aulast%3DNewton%26aufirst%3DA.%2BS.%26aulast%3DSilvennoinen%26aufirst%3DO.%26aulast%3DJorgensen%26aufirst%3DW.%2BL.%26aulast%3DSchlessinger%26aufirst%3DJ.%26atitle%3DIdentification%2520and%2520characterization%2520of%2520JAK2%2520pseudokinase%2520domain%2520small%2520molecule%2520binders%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D618%26epage%3D621%26doi%3D10.1021%2Facsmedchemlett.7b00153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leroy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Constantinescu, S. N.</span></span> <span> </span><span class="NLM_article-title">Rethinking JAK2 inhibition: towards novel strategies of more specific and versatile Janus kinase inhibition</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">1023</span>– <span class="NLM_lpage">1038</span>, <span class="refDoi"> DOI: 10.1038/leu.2017.43</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1038%2Fleu.2017.43" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=28119526" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2sXislyms7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=1023-1038&author=E.+Leroyauthor=S.+N.+Constantinescu&title=Rethinking+JAK2+inhibition%3A+towards+novel+strategies+of+more+specific+and+versatile+Janus+kinase+inhibition&doi=10.1038%2Fleu.2017.43"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Rethinking JAK2 inhibition: towards novel strategies of more specific and versatile janus kinase inhibition</span></div><div class="casAuthors">Leroy, E.; Constantinescu, S. N.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1023-1038</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Janus kinases (JAKs) are required for cytokine receptor signaling.  Since the discovery of the highly prevalent JAK2 V617F mutation in myeloproliferative neoplasms (MPNs), JAK2 became a prime target for inhibition.  Only one approved JAK2 inhibitor exists, with pos., but not curative effects in MPNs, and promising effects in autoimmune diseases and cancer.  On the basis of recent advances in the structural features regulating both normal and mutant JAKs, as well as in small-mol. targeting, we review the current state of JAK2 inhibitor development and present novel avenues of selecting JAK2 inhibitors, with broad and narrow specificities and extend these approaches to other JAKs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLVJS8PwHOlbVg90H21EOLACvtfcHk0liSEfSlz1ZERw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXislyms7w%253D&md5=0dc333d94e27daad1d32110dee26e637</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1038%2Fleu.2017.43&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2017.43%26sid%3Dliteratum%253Aachs%26aulast%3DLeroy%26aufirst%3DE.%26aulast%3DConstantinescu%26aufirst%3DS.%2BN.%26atitle%3DRethinking%2520JAK2%2520inhibition%253A%2520towards%2520novel%2520strategies%2520of%2520more%2520specific%2520and%2520versatile%2520Janus%2520kinase%2520inhibition%26jtitle%3DLeukemia%26date%3D2017%26volume%3D31%26spage%3D1023%26epage%3D1038%26doi%3D10.1038%2Fleu.2017.43" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misner, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belmont, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castanedo, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coraggio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erickson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghilardi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katewa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohli, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubach, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenzie, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortwine, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schutt, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tay, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span> <span> </span><span class="NLM_article-title">Discovery of GDC-0853, a potent, selective, and non-covalent Bruton’s tyrosine kinase inhibitor in early clinical development</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">2227</span>– <span class="NLM_lpage">2245</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01712</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01712" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=2227-2245&author=J.+J.+Crawfordauthor=A.+R.+Johnsonauthor=D.+L.+Misnerauthor=L.+D.+Belmontauthor=G.+M.+Castanedoauthor=R.+Choyauthor=M.+Coraggioauthor=L.+Dongauthor=C.+Eigenbrotauthor=R.+Ericksonauthor=N.+Ghilardiauthor=J.+Hauauthor=A.+Katewaauthor=P.+B.+Kohliauthor=W.+Leeauthor=J.+W.+Lubachauthor=B.+S.+McKenzieauthor=D.+F.+Ortwineauthor=L.+Schuttauthor=S.+Tayauthor=B.+Weiauthor=K.+Reifauthor=L.+Liuauthor=H.+Wongauthor=W.+B.+Young&title=Discovery+of+GDC-0853%2C+a+potent%2C+selective%2C+and+non-covalent+Bruton%E2%80%99s+tyrosine+kinase+inhibitor+in+early+clinical+development&doi=10.1021%2Facs.jmedchem.7b01712"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01712%26sid%3Dliteratum%253Aachs%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DMisner%26aufirst%3DD.%2BL.%26aulast%3DBelmont%26aufirst%3DL.%2BD.%26aulast%3DCastanedo%26aufirst%3DG.%2BM.%26aulast%3DChoy%26aufirst%3DR.%26aulast%3DCoraggio%26aufirst%3DM.%26aulast%3DDong%26aufirst%3DL.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DErickson%26aufirst%3DR.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DHau%26aufirst%3DJ.%26aulast%3DKatewa%26aufirst%3DA.%26aulast%3DKohli%26aufirst%3DP.%2BB.%26aulast%3DLee%26aufirst%3DW.%26aulast%3DLubach%26aufirst%3DJ.%2BW.%26aulast%3DMcKenzie%26aufirst%3DB.%2BS.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DSchutt%26aufirst%3DL.%26aulast%3DTay%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26atitle%3DDiscovery%2520of%2520GDC-0853%252C%2520a%2520potent%252C%2520selective%252C%2520and%2520non-covalent%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitor%2520in%2520early%2520clinical%2520development%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D2227%26epage%3D2245%26doi%3D10.1021%2Facs.jmedchem.7b01712" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mócsai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruland, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tybulewicz, V. L.</span></span> <span> </span><span class="NLM_article-title">The SYK tyrosine kinase: a crucial player in diverse biological functions</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">387</span>– <span class="NLM_lpage">402</span>, <span class="refDoi"> DOI: 10.1038/nri2765</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1038%2Fnri2765" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=20467426" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlvFOkurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=387-402&author=A.+M%C3%B3csaiauthor=J.+Rulandauthor=V.+L.+Tybulewicz&title=The+SYK+tyrosine+kinase%3A+a+crucial+player+in+diverse+biological+functions&doi=10.1038%2Fnri2765"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">The SYK tyrosine kinase: a crucial player in diverse biological functions</span></div><div class="casAuthors">Mocsai, Attila; Ruland, Jurgen; Tybulewicz, Victor L. J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">387-402</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Spleen tyrosine kinase (SYK) is known to have a crucial role in adaptive immune receptor signalling.  However, recent reports indicate that SYK also mediates other, unexpectedly diverse biol. functions, including cellular adhesion, innate immune recognition, osteoclast maturation, platelet activation and vascular development.  SYK is activated by C-type lectins and integrins, and activates new targets, including the CARD9-BCL-10-MALT1 pathway and the NLRP3 inflammasome.  Studies using Drosophila melanogaster suggest that there is an evolutionarily ancient origin of SYK-mediated signalling.  Moreover, SYK has a crucial role in autoimmune diseases and haematol. malignancies.  This Review summarizes our current understanding of the diverse functions of SYK and how this is being translated for therapeutic purposes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3YO5BcMqrf7Vg90H21EOLACvtfcHk0lhjgiEp0mh15g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlvFOkurk%253D&md5=85857a2b9beb84e0fe74263a90fa8a53</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1038%2Fnri2765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri2765%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25B3csai%26aufirst%3DA.%26aulast%3DRuland%26aufirst%3DJ.%26aulast%3DTybulewicz%26aufirst%3DV.%2BL.%26atitle%3DThe%2520SYK%2520tyrosine%2520kinase%253A%2520a%2520crucial%2520player%2520in%2520diverse%2520biological%2520functions%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2010%26volume%3D10%26spage%3D387%26epage%3D402%26doi%3D10.1038%2Fnri2765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Geahlen, R. L.</span></span> <span> </span><span class="NLM_article-title">Getting Syk: spleen tyrosine kinase as a therapeutic target</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">414</span>– <span class="NLM_lpage">422</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2014.05.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1016%2Fj.tips.2014.05.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=24975478" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVKhtbvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2014&pages=414-422&author=R.+L.+Geahlen&title=Getting+Syk%3A+spleen+tyrosine+kinase+as+a+therapeutic+target&doi=10.1016%2Fj.tips.2014.05.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Getting Syk: spleen tyrosine kinase as a therapeutic target</span></div><div class="casAuthors">Geahlen, Robert L.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">414-422</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Spleen tyrosine kinase (Syk) is a cytoplasmic protein tyrosine kinase well known for its ability to couple immune cell receptors to intracellular signaling pathways that regulate cellular responses to extracellular antigens and antigen-Ig (Ig) complexes of particular importance to the initiation of inflammatory responses.  Thus, Syk is an attractive target for therapeutic kinase inhibitors designed to ameliorate the symptoms and consequences of acute and chronic inflammation.  Its more recently recognized role as a promoter of cell survival in numerous cancer cell types ranging from leukemia to retinoblastoma has attracted considerable interest as a target for a new generation of anticancer drugs.  This review discusses the biol. processes in which Syk participates that have made this kinase such a compelling drug target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoE5Tut36Cq0LVg90H21EOLACvtfcHk0lhjgiEp0mh15g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVKhtbvK&md5=8b161de626d96f82c754eff4c5ef078f</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2014.05.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2014.05.007%26sid%3Dliteratum%253Aachs%26aulast%3DGeahlen%26aufirst%3DR.%2BL.%26atitle%3DGetting%2520Syk%253A%2520spleen%2520tyrosine%2520kinase%2520as%2520a%2520therapeutic%2520target%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2014%26volume%3D35%26spage%3D414%26epage%3D422%26doi%3D10.1016%2Fj.tips.2014.05.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silakari, O.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of switch kinase ‘spleen tyrosine kinase’ in inflammation and immune-mediated disorders: a review</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">434</span>– <span class="NLM_lpage">446</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2013.04.070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1016%2Fj.ejmech.2013.04.070" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2013&pages=434-446&author=M.+Kaurauthor=M.+Singhauthor=O.+Silakari&title=Inhibitors+of+switch+kinase+%E2%80%98spleen+tyrosine+kinase%E2%80%99+in+inflammation+and+immune-mediated+disorders%3A+a+review&doi=10.1016%2Fj.ejmech.2013.04.070"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.04.070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.04.070%26sid%3Dliteratum%253Aachs%26aulast%3DKaur%26aufirst%3DM.%26aulast%3DSingh%26aufirst%3DM.%26aulast%3DSilakari%26aufirst%3DO.%26atitle%3DInhibitors%2520of%2520switch%2520kinase%2520%25E2%2580%2598spleen%2520tyrosine%2520kinase%25E2%2580%2599%2520in%2520inflammation%2520and%2520immune-mediated%2520disorders%253A%2520a%2520review%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D67%26spage%3D434%26epage%3D446%26doi%3D10.1016%2Fj.ejmech.2013.04.070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuda, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Payan, D. G.</span></span> <span> </span><span class="NLM_article-title">Discovery and development of spleen tyrosine kinase (SYK) inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">3614</span>– <span class="NLM_lpage">3643</span>, <span class="refDoi"> DOI: 10.1021/jm201271b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201271b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC38XpsVOntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=3614-3643&author=R.+Singhauthor=E.+S.+Masudaauthor=D.+G.+Payan&title=Discovery+and+development+of+spleen+tyrosine+kinase+%28SYK%29+inhibitors&doi=10.1021%2Fjm201271b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Development of Spleen Tyrosine Kinase (SYK) Inhibitors</span></div><div class="casAuthors">Singh, Rajinder; Masuda, Esteban S.; Payan, Donald G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3614-3643</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Spleen tyrosine kinase (SYK) is a member of the cytoplasmic protein tyrosine kinase (PTK) family and has been identified as an important target for the development of therapeutics for the treatment of allergic and autoimmune diseases.  Maladies resulting from chronic inflammation and autoimmune dysfunction include, asthma, rheumatoid arthritis (RA), Crohn's disease, systemic lupus erythematosus (SLE) and idiopathic thrombocytopenia purpura (ITP).  SYK has garnered substantial attention because of its importance as a key signal transduction regulator through antigen and Fc receptors in hematopoietic cells.  Recently SYK has entered the mainstream of potential pharmaceutical targets with a no. of inhibitor classes being reported in the literature.  The true potential as a validated target for inhibition by small mols. has been investigated in the last few years, with the emergence of advanced clin. trial data.  Structurally SYK possesses a tandem N-terminal Src homol. 2 domains (SH2), referred to as N-SH2 and C-SH2 domains, followed by a C-terminal kinase domain and most closely related to ZAP-70.  The multiple phosphorylation sites on SYK are fundamental structural prerequisites for its diverse functional activity.  Overall, these phosphorylation sites contribute to maintaining the kinase in an inactivated state.  In addn., they are implicated in events leading to primary activation of the kinase catalytic domain, amplification of this activity, and the orchestrated phosphorylation of multiple substrates.  Utilization of the numerous sites of phosphorylation on SYK leads to the activation of a multitude of signaling networks relevant to immune and autoimmune maladies.  SYK serves as a master regulator of inflammatory responses in a multitude of immune cells and as a result, inhibiting SYK activity dampens inflammation broadly and comprehensively.  The validation of SYK as an effective target for therapeutic intervention in autoimmune and inflammatory disorders has picked up pace over the last decade.  In particular, this has been attributable to the recognition of key biol. findings, coupled with successful small mol. inhibitors of SYK that have shown early indications of clin. efficacy in diverse autoimmune and inflammatory diseases.  SYK as a target has gained reinforcement with the successful completion of several Phase 2 clin. studies in RA, ITP and B-cell lymphoma.  Addnl. clin. studies are under way that may further emphasize the position of SYK as a therapeutically relevant target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp363qA4V4g-rVg90H21EOLACvtfcHk0lhjgiEp0mh15g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpsVOntw%253D%253D&md5=1b51e1b658842f2b562d533edb05e685</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1021%2Fjm201271b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201271b%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DMasuda%26aufirst%3DE.%2BS.%26aulast%3DPayan%26aufirst%3DD.%2BG.%26atitle%3DDiscovery%2520and%2520development%2520of%2520spleen%2520tyrosine%2520kinase%2520%2528SYK%2529%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D3614%26epage%3D3643%26doi%3D10.1021%2Fjm201271b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Turner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph Mee, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costello, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duddy, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furlong, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geahlen, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tybulewicz, V. L. J.</span></span> <span> </span><span class="NLM_article-title">Perinatal lethality and blocked B-cell development in mice lacking the tyrosine kinase Syk</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>378</i></span>,  <span class="NLM_fpage">298</span>– <span class="NLM_lpage">302</span>, <span class="refDoi"> DOI: 10.1038/378298a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1038%2F378298a0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=378&publication_year=1995&pages=298-302&author=M.+Turnerauthor=P.+Joseph+Meeauthor=P.+S.+Costelloauthor=O.+Williamsauthor=A.+A.+Priceauthor=L.+P.+Duddyauthor=M.+T.+Furlongauthor=R.+L.+Geahlenauthor=V.+L.+J.+Tybulewicz&title=Perinatal+lethality+and+blocked+B-cell+development+in+mice+lacking+the+tyrosine+kinase+Syk&doi=10.1038%2F378298a0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1038%2F378298a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F378298a0%26sid%3Dliteratum%253Aachs%26aulast%3DTurner%26aufirst%3DM.%26aulast%3DJoseph%2BMee%26aufirst%3DP.%26aulast%3DCostello%26aufirst%3DP.%2BS.%26aulast%3DWilliams%26aufirst%3DO.%26aulast%3DPrice%26aufirst%3DA.%2BA.%26aulast%3DDuddy%26aufirst%3DL.%2BP.%26aulast%3DFurlong%26aufirst%3DM.%2BT.%26aulast%3DGeahlen%26aufirst%3DR.%2BL.%26aulast%3DTybulewicz%26aufirst%3DV.%2BL.%2BJ.%26atitle%3DPerinatal%2520lethality%2520and%2520blocked%2520B-cell%2520development%2520in%2520mice%2520lacking%2520the%2520tyrosine%2520kinase%2520Syk%26jtitle%3DNature%26date%3D1995%26volume%3D378%26spage%3D298%26epage%3D302%26doi%3D10.1038%2F378298a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jakus, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balázs, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mócsai, A.</span></span> <span> </span><span class="NLM_article-title">Genetic deficiency of Syk protects mice from autoantibody-induced arthritis</span>. <i>Arthritis Rheum.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">1899</span>– <span class="NLM_lpage">1910</span>, <span class="refDoi"> DOI: 10.1002/art.27438</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1002%2Fart.27438" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=20201079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1aqsL%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2010&pages=1899-1910&author=Z.+Jakusauthor=E.+Simonauthor=B.+Bal%C3%A1zsauthor=A.+M%C3%B3csai&title=Genetic+deficiency+of+Syk+protects+mice+from+autoantibody-induced+arthritis&doi=10.1002%2Fart.27438"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic deficiency of Syk protects mice from autoantibody-induced arthritis</span></div><div class="casAuthors">Jakus, Zoltan; Simon, Edina; Balazs, Balint; Mocsai, Attila</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1899-1910</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective: The Syk tyrosine kinase plays an important role in diverse functions in hematopoietic lineage cells.  Although previous in vitro and pharmacol. analyses suggested Syk to be a possible player in the development of autoimmune arthritis, no in vivo genetic studies addressing that issue have yet been reported.  The aim of the present study was to test whether genetic deficiency of Syk affects autoantibody-induced exptl. arthritis in the K/BxN serumtransfer model.  Methods: Syk-/- bone marrow chimeras carrying a Syk-deficient hematopoietic system were generated by transplanting Syk-/- fetal liver cells into lethally irradiated wild-type recipients.  After complete repopulation of the hematopoietic compartment, autoantibody-mediated arthritis was induced by injection of arthritogenic K/BxN serum.  Arthritis development was monitored by macroscopic and microscopic observation of the ankle joints, micro-computed tomog. of bone morphol., as well as joint function assay.  Results: Genetic deficiency of Syk in the hematopoietic compartment completely blocked the development of all macroscopic and microscopic signs of arthritis.  The Syk-/- mutation also prevented the appearance of periarticular bone erosions.  Finally, Syk-/- bone marrow chimeras were completely protected from arthritis-induced loss of articular function.  Conclusion: Our results indicate that Syk is critically involved in the development of all clin. relevant aspects of autoantibody-mediated K/BxN serumtransfer arthritis in exptl. mice.  These results provide the first in vivo genetic evidence of the role of Syk in the development of autoimmune arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMg3hF7NyGgrVg90H21EOLACvtfcHk0ljthagrEW36Rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1aqsL%252FO&md5=0dfab55caa648c3c556fcc8a63ba9a4f</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1002%2Fart.27438&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.27438%26sid%3Dliteratum%253Aachs%26aulast%3DJakus%26aufirst%3DZ.%26aulast%3DSimon%26aufirst%3DE.%26aulast%3DBal%25C3%25A1zs%26aufirst%3DB.%26aulast%3DM%25C3%25B3csai%26aufirst%3DA.%26atitle%3DGenetic%2520deficiency%2520of%2520Syk%2520protects%2520mice%2520from%2520autoantibody-induced%2520arthritis%26jtitle%3DArthritis%2520Rheum.%26date%3D2010%26volume%3D62%26spage%3D1899%26epage%3D1910%26doi%3D10.1002%2Fart.27438" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yi, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Son, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sung, G.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, J. Y.</span></span> <span> </span><span class="NLM_article-title">Functional roles of Syk in macrophage-mediated inflammatory responses</span>. <i>Mediators Inflammation</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>2014</i></span>,  <span class="NLM_fpage">270302</span>, <span class="refDoi"> DOI: 10.1155/2014/270302</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1155%2F2014%2F270302" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=25045209" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A280%3ADC%252BC2cbpslylsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2014&publication_year=2014&pages=270302&author=Y.-S.+Yiauthor=Y.-J.+Sonauthor=C.+Ryouauthor=G.-H.+Sungauthor=J.-H.+Kimauthor=J.+Y.+Cho&title=Functional+roles+of+Syk+in+macrophage-mediated+inflammatory+responses&doi=10.1155%2F2014%2F270302"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Functional roles of Syk in macrophage-mediated inflammatory responses</span></div><div class="casAuthors">Yi Young-Su; Cho Jae Youl; Son Young-Jin; Ryou Chongsuk; Sung Gi-Ho; Kim Jong-Hoon</div><div class="citationInfo"><span class="NLM_cas:title">Mediators of inflammation</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">2014</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">270302</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Inflammation is a series of complex biological responses to protect the host from pathogen invasion.  Chronic inflammation is considered a major cause of diseases, such as various types of inflammatory/autoimmune diseases and cancers.  Spleen tyrosine kinase (Syk) was initially found to be highly expressed in hematopoietic cells and has been known to play crucial roles in adaptive immune responses.  However, recent studies have reported that Syk is also involved in other biological functions, especially in innate immune responses.  Although Syk has been extensively studied in adaptive immune responses, numerous studies have recently presented evidence that Syk has critical functions in macrophage-mediated inflammatory responses and is closely related to innate immune response.  This review describes the characteristics of Syk-mediated signaling pathways, summarizes the recent findings supporting the crucial roles of Syk in macrophage-mediated inflammatory responses and diseases, and discusses Syk-targeted drug development for the therapy of inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSfGd8CCEOs1GZyxfu64m4ffW6udTcc2eai_nuQLE4vubntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cbpslylsQ%253D%253D&md5=35476f2963c8eeb92d14e2a55a6375e1</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1155%2F2014%2F270302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2014%252F270302%26sid%3Dliteratum%253Aachs%26aulast%3DYi%26aufirst%3DY.-S.%26aulast%3DSon%26aufirst%3DY.-J.%26aulast%3DRyou%26aufirst%3DC.%26aulast%3DSung%26aufirst%3DG.-H.%26aulast%3DKim%26aufirst%3DJ.-H.%26aulast%3DCho%26aufirst%3DJ.%2BY.%26atitle%3DFunctional%2520roles%2520of%2520Syk%2520in%2520macrophage-mediated%2520inflammatory%2520responses%26jtitle%3DMediators%2520Inflammation%26date%3D2014%26volume%3D2014%26spage%3D270302%26doi%3D10.1155%2F2014%2F270302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Braselmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sylvain, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baluom, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herlaar, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argade, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jurcevic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pine, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grossbard, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Payan, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuda, E. S.</span></span> <span> </span><span class="NLM_article-title">R406, an orally available spleen tyrosine kinase inhibitor blocks Fc receptor signaling and reduces immune complex-mediated inflammation</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>319</i></span>,  <span class="NLM_fpage">998</span>– <span class="NLM_lpage">1008</span>, <span class="refDoi"> DOI: 10.1124/jpet.106.109058</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1124%2Fjpet.106.109058" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=16946104" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1yltL7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=319&publication_year=2006&pages=998-1008&author=S.+Braselmannauthor=V.+Taylorauthor=H.+Zhaoauthor=S.+Wangauthor=C.+Sylvainauthor=M.+Baluomauthor=K.+Quauthor=E.+Herlaarauthor=A.+Lauauthor=C.+Youngauthor=B.+R.+Wongauthor=S.+Lovellauthor=T.+Sunauthor=G.+Parkauthor=A.+Argadeauthor=S.+Jurcevicauthor=P.+Pineauthor=R.+Singhauthor=E.+B.+Grossbardauthor=D.+G.+Payanauthor=E.+S.+Masuda&title=R406%2C+an+orally+available+spleen+tyrosine+kinase+inhibitor+blocks+Fc+receptor+signaling+and+reduces+immune+complex-mediated+inflammation&doi=10.1124%2Fjpet.106.109058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">R406, an orally available spleen tyrosine kinase inhibitor blocks Fc receptor signaling and reduces immune complex-mediated inflammation</span></div><div class="casAuthors">Braselmann, Sylvia; Taylor, Vanessa; Zhao, Haoran; Wang, Su; Sylvain, Catherine; Baluom, Muhammad; Qu, Kunbin; Herlaar, Ellen; Lau, Angela; Young, Chi; Wong, Brian R.; Lovell, Scott; Sun, Thomas; Park, Gary; Argade, Ankush; Jurcevic, Stipo; Pine, Polly; Singh, Rajinder; Grossbard, Elliott B.; Payan, Donald G.; Masuda, Esteban S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">319</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">998-1008</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Recent compelling evidence has lead to renewed interest in the role of antibodies and immune complexes in the pathogenesis of several autoimmune disorders, such as rheumatoid arthritis.  These immune complexes, consisting of autoantibodies to self-antigens, can mediate inflammatory responses largely through binding and activating the Ig Fc receptors (FcRs).  Using cell-based structure activity relationships with cultured human mast cells, we have identified the small mol. R406 [N4-(2,2-dimethyl-3-oxo-4H-pyrid[1,4]oxazin-6-yl)-5-fluoro-N2- (3,4,5-trimethoxyphenyl)-2,4-pyrimidinediamine] as a potent inhibitor of IgE (IgE)- and IgG-mediated activation of Fc receptor signaling (EC50 for degranulation = 56-64 nM).  Here we show that the primary target for R406 is the spleen tyrosine kinase (Syk), which plays a key role in the signaling of activating Fc receptors and the B-cell receptor (BCR).  R406 inhibited phosphorylation of Syk substrate linker for activation of T cells in mast cells and B-cell linker protein/SLP65 in B cells.  R406 bound to the ATP binding pocket of Syk and inhibited its kinase activity as an ATP-competitive inhibitor (Ki = 30 nM).  Furthermore, R406 blocked Syk-dependent FcR-mediated activation of monocytes/macrophages and neutrophils and BCR-mediated activation of B lymphocytes.  R406 was selective as assessed using a large panel of Syk-independent cell-based assays representing both specific and general signaling pathways.  Consistent with Syk inhibition, oral administration of R406 to mice reduced immune complex-mediated inflammation in a reverse-passive Arthus reaction and two antibody-induced arthritis models.  Finally, we report a first-in-human study showing that R406 is orally bioavailable, achieving exposures capable of inhibiting Syk-dependent IgE-mediated basophil activation.  Collectively, the results show R406 potential for modulating Syk activity in human disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohoeT9BJQAyLVg90H21EOLACvtfcHk0ljYHj_rEgWhLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1yltL7P&md5=18fea516041ea075d2123158f321a186</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1124%2Fjpet.106.109058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.106.109058%26sid%3Dliteratum%253Aachs%26aulast%3DBraselmann%26aufirst%3DS.%26aulast%3DTaylor%26aufirst%3DV.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DSylvain%26aufirst%3DC.%26aulast%3DBaluom%26aufirst%3DM.%26aulast%3DQu%26aufirst%3DK.%26aulast%3DHerlaar%26aufirst%3DE.%26aulast%3DLau%26aufirst%3DA.%26aulast%3DYoung%26aufirst%3DC.%26aulast%3DWong%26aufirst%3DB.%2BR.%26aulast%3DLovell%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DT.%26aulast%3DPark%26aufirst%3DG.%26aulast%3DArgade%26aufirst%3DA.%26aulast%3DJurcevic%26aufirst%3DS.%26aulast%3DPine%26aufirst%3DP.%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DGrossbard%26aufirst%3DE.%2BB.%26aulast%3DPayan%26aufirst%3DD.%2BG.%26aulast%3DMasuda%26aufirst%3DE.%2BS.%26atitle%3DR406%252C%2520an%2520orally%2520available%2520spleen%2520tyrosine%2520kinase%2520inhibitor%2520blocks%2520Fc%2520receptor%2520signaling%2520and%2520reduces%2520immune%2520complex-mediated%2520inflammation%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2006%26volume%3D319%26spage%3D998%26epage%3D1008%26doi%3D10.1124%2Fjpet.106.109058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baluom, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grossbard, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mant, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, D. T. W.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics of fostamatinib, a spleen tyrosine kinase (SYK) inhibitor, in healthy human subjects following single and multiple oral dosing in three phase I studies</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">78</span>– <span class="NLM_lpage">88</span>, <span class="refDoi"> DOI: 10.1111/bcp.12048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1111%2Fbcp.12048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=23190017" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpvFeksLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2013&pages=78-88&author=M.+Baluomauthor=E.+B.+Grossbardauthor=T.+Mantauthor=D.+T.+W.+Lau&title=Pharmacokinetics+of+fostamatinib%2C+a+spleen+tyrosine+kinase+%28SYK%29+inhibitor%2C+in+healthy+human+subjects+following+single+and+multiple+oral+dosing+in+three+phase+I+studies&doi=10.1111%2Fbcp.12048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics of fostamatinib, a spleen tyrosine kinase (SYK) inhibitor, in healthy human subjects following single and multiple oral dosing in three phase I studies</span></div><div class="casAuthors">Baluom, Muhammad; Grossbard, Elliott B.; Mant, Tim; Lau, David T. W.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">78-88</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">1365-2125</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Aim : Fostamatinib (R788) is an orally dosed prodrug designed to deliver the active metabolite R940406 (R406), a spleen tyrosine kinase (SYK) inhibitor, for the treatment of rheumatoid arthritis.  The objectives were to evaluate the human pharmacokinetic properties of fostamatinib and R406.  Method : Three clin. studies were conducted in healthy subjects: (A) A single ascending dose study for R406 with doses ranging from 80-600mg, (B) a single- and multiple-dose study of fostamatinib in aq. suspension, with single doses ranging from 80-400mg and multiple doses at 160mg twice daily and (C) a study comparing suspension and tablet of fostamatinib, with the latter tested in both fed and fasted states.  Results : These studies demonstrated that when administered as a soln., R406 was rapidly absorbed.  Increases in exposure were obsd. with doses up to 400mg.  A terminal half-life of 12-21h was obsd.  Similar R406 exposure could be achieved with fostamatinib suspension and steady-state was achieved after 3-4 days following twice daily administration.  Fostamatinib tablet and suspension exhibited similar R406 exposure.  Upon co-administration with food, a delay in peak time and lower peak concns. of R406 were obsd. but at the same time the overall exposure did not change.  Conclusion : Fostamatinib demonstrates rapid and extensive conversion to R406, an inhibitor of SYK.  Solid dosage forms of fostamatinib overcome the challenge of low aq. soly. of R406.  The PK profile of R406 could potentially allow once daily or twice daily oral administration of fostamatinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpely6sKuO98LVg90H21EOLACvtfcHk0ljYHj_rEgWhLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpvFeksLw%253D&md5=1096322f44f8dcdd3ea408f1e0619298</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1111%2Fbcp.12048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcp.12048%26sid%3Dliteratum%253Aachs%26aulast%3DBaluom%26aufirst%3DM.%26aulast%3DGrossbard%26aufirst%3DE.%2BB.%26aulast%3DMant%26aufirst%3DT.%26aulast%3DLau%26aufirst%3DD.%2BT.%2BW.%26atitle%3DPharmacokinetics%2520of%2520fostamatinib%252C%2520a%2520spleen%2520tyrosine%2520kinase%2520%2528SYK%2529%2520inhibitor%252C%2520in%2520healthy%2520human%2520subjects%2520following%2520single%2520and%2520multiple%2520oral%2520dosing%2520in%2520three%2520phase%2520I%2520studies%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2013%26volume%3D76%26spage%3D78%26epage%3D88%26doi%3D10.1111%2Fbcp.12048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weinblatt, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genovese, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosiak-Jedrychowicz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kavanaugh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millson, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Heijde, D.</span></span> <span> </span><span class="NLM_article-title">Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study</span>. <i>Arthritis Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">3255</span>– <span class="NLM_lpage">3264</span>, <span class="refDoi"> DOI: 10.1002/art.38851</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1002%2Fart.38851" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=25223724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2MXislWmtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2014&pages=3255-3264&author=M.+E.+Weinblattauthor=M.+C.+Genoveseauthor=M.+Hoauthor=S.+Hollisauthor=K.+Rosiak-Jedrychowiczauthor=A.+Kavanaughauthor=D.+S.+Millsonauthor=G.+Leonauthor=M.+Wangauthor=D.+van+der+Heijde&title=Effects+of+fostamatinib%2C+an+oral+spleen+tyrosine+kinase+inhibitor%2C+in+rheumatoid+arthritis+patients+with+an+inadequate+response+to+methotrexate%3A+results+from+a+phase+III%2C+multicenter%2C+randomized%2C+double-blind%2C+placebo-controlled%2C+parallel-group+study&doi=10.1002%2Fart.38851"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel group study</span></div><div class="casAuthors">Weinblatt, Michael E.; Genovese, Mark C.; Ho, Meilien; Hollis, Sally; Rosiak-Jedrychowicz, Krystyna; Kavanaugh, Arthur; Millson, David S.; Leon, Gustavo; Wang, Millie; van der Heijde, Desiree</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3255-3264</span>CODEN:
                <span class="NLM_cas:coden">ARRHBO</span>;
        ISSN:<span class="NLM_cas:issn">2326-5191</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective. This phase III, 52-wk study compared fostamatinib with placebo (for 24 wk) in patients with active rheumatoid arthritis (RA) and an inadequate response to methotrexate (MTX) therapy.  Methods. Patients taking MTX were randomized (1:1:1) to receive fostamatinib 100 mg twice daily for 52 wk (group A), fostamatinib 100 mg twice daily for 4 wk and then 150 mg once daily (group B), or placebo for 24 wk and then fostamatinib 100 mg twice daily (group C).  At week 24, the co-primary end points were change from baseline in the American College of Rheumatol. 20% (ACR20) improvement response rates and change in the modified total Sharp/van der Heijde score of radiog. damage (SHS).  Results. In this study, 918 patients were randomized and received ≥1 dose of study drug (fostamatinib or placebo); the demog. and baseline clin. characteristics were well balanced.  Following treatment with both fostamatinib regimens, a statistically significant difference in the ACR20 improvement response was achieved at week 24 as compared with that in patients receiving placebo (49.0% [group A] and 44.4%, [group B] vs. 34.2%; P < 0.001 and P = 0.006, resp.), but there was no statistically significant difference in the SHS between either fostamatinib group and placebo (P = 0.25 and P = 0.17, resp.).  The most common adverse events in patients in groups A, B, and C were hypertension (15.8%, 15.1%, and 3.9%, resp.) and diarrhea (13.9%, 15.1%, and 3.9%, resp.).  Elevated blood pressure (≥140/90 mm Hg) occurred at ≥1 visit in 44.2%, 41.6%, and 19.3% of patients in each resp. group.  Conclusion. With the use of either fostamatinib regimen in patients with RA, statistically significant, but not clin. significant, improvements in the ACR20 improvement response over placebo were achieved at 24 wk, whereas a significant difference in the SHS was not seen.  The overall level of response to treatment with fostamatinib was lower than had been obsd. in the phase II program, but similar adverse events were reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwksjH3b98S7Vg90H21EOLACvtfcHk0ljYHj_rEgWhLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXislWmtw%253D%253D&md5=dd477eceb0e92b09422be73161307b2a</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1002%2Fart.38851&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.38851%26sid%3Dliteratum%253Aachs%26aulast%3DWeinblatt%26aufirst%3DM.%2BE.%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26aulast%3DHo%26aufirst%3DM.%26aulast%3DHollis%26aufirst%3DS.%26aulast%3DRosiak-Jedrychowicz%26aufirst%3DK.%26aulast%3DKavanaugh%26aufirst%3DA.%26aulast%3DMillson%26aufirst%3DD.%2BS.%26aulast%3DLeon%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DM.%26aulast%3Dvan%2Bder%2BHeijde%26aufirst%3DD.%26atitle%3DEffects%2520of%2520fostamatinib%252C%2520an%2520oral%2520spleen%2520tyrosine%2520kinase%2520inhibitor%252C%2520in%2520rheumatoid%2520arthritis%2520patients%2520with%2520an%2520inadequate%2520response%2520to%2520methotrexate%253A%2520results%2520from%2520a%2520phase%2520III%252C%2520multicenter%252C%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%252C%2520parallel-group%2520study%26jtitle%3DArthritis%2520Rheumatol.%26date%3D2014%26volume%3D66%26spage%3D3255%26epage%3D3264%26doi%3D10.1002%2Fart.38851" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genovese, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenwood, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nasonov, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oemar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoilov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vencovsky, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinblatt, M.</span></span> <span> </span><span class="NLM_article-title">OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy</span>. <i>Ann. Rheum. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">2123</span>– <span class="NLM_lpage">2129</span>, <span class="refDoi"> DOI: 10.1136/annrheumdis-2014-205361</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1136%2Fannrheumdis-2014-205361" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=25074688" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC28XntVWis7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2015&pages=2123-2129&author=P.+C.+Taylorauthor=M.+C.+Genoveseauthor=M.+Greenwoodauthor=M.+Hoauthor=E.+Nasonovauthor=B.+Oemarauthor=R.+Stoilovauthor=J.+Vencovskyauthor=M.+Weinblatt&title=OSKIRA-4%3A+a+phase+IIb+randomised%2C+placebo-controlled+study+of+the+efficacy+and+safety+of+fostamatinib+monotherapy&doi=10.1136%2Fannrheumdis-2014-205361"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy</span></div><div class="casAuthors">Taylor, Peter C.; Genovese, Mark C.; Greenwood, Mike; Ho, Meilien; Nasonov, Evgeny; Oemar, Barry; Stoilov, Rumen; Vencovsky, Jiri; Weinblatt, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the Rheumatic Diseases</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2123-2129</span>CODEN:
                <span class="NLM_cas:coden">ARDIAO</span>;
        ISSN:<span class="NLM_cas:issn">0003-4967</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Objectives OSKIRA-4 evaluated the efficacy of fostamatinib monotherapy vs. placebo on the signs and symptoms of rheumatoid arthritis over 6 wk by Disease Activity Score C reactive protein (DAS-28(CRP)) and assessed non-inferiority to adalimumab monotherapy at Week 24 by DAS-28(CRP).  Methods Overall, 279 patients not currently taking disease-modifying antirheumatic drugs were randomised to: (A) fostamatinib 100 mg twice daily for 24 wk plus placebo injection every 2 wk (PBOI); (B) fostamatinib 100 mg twice daily for 4 wk, then 150 mg once daily up to Week 24, plus PBOI; (C) fostamatinib 100 mg twice daily for 4 wk, then 100 mg once daily up to Week 24, plus PBOI; (D) adalimumab 40 mg every 2 wk for 24 wk, plus oral placebo twice daily; or (E) oral placebo twice daily for 6 wk, plus PBOI, then a switch to arm A or B.  Results Fostamatinib demonstrated a significant improvement in DAS-28(CRP) score from baseline vs. placebo at Week 6 for arms A and B, but not C.  Fostamatinib was significantly less effective than adalimumab at Week 24 based on DAS-28(CRP).  Adverse events obsd. with fostamatinib treatment were consistent with those reported in previous studies, including hypertension and diarrhoea.  Conclusions Fostamatinib demonstrated efficacy as monotherapy, showing superior DAS-28(CRP) score changes between baseline and 6 wk when compared with placebo in treatment arms A and B.  However, all fostamatinib regimens demonstrated inferior responses compared with adalimumab at Week 24.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUtupT8ZIrf7Vg90H21EOLACvtfcHk0lj9sai8gHH5PQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntVWis7s%253D&md5=7cd74465eaed6bc5692c448f5f0fb1c4</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1136%2Fannrheumdis-2014-205361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fannrheumdis-2014-205361%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DP.%2BC.%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26aulast%3DGreenwood%26aufirst%3DM.%26aulast%3DHo%26aufirst%3DM.%26aulast%3DNasonov%26aufirst%3DE.%26aulast%3DOemar%26aufirst%3DB.%26aulast%3DStoilov%26aufirst%3DR.%26aulast%3DVencovsky%26aufirst%3DJ.%26aulast%3DWeinblatt%26aufirst%3DM.%26atitle%3DOSKIRA-4%253A%2520a%2520phase%2520IIb%2520randomised%252C%2520placebo-controlled%2520study%2520of%2520the%2520efficacy%2520and%2520safety%2520of%2520fostamatinib%2520monotherapy%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2015%26volume%3D74%26spage%3D2123%26epage%3D2129%26doi%3D10.1136%2Fannrheumdis-2014-205361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Genovese, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Heijde, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keystone, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spindler, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benhamou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kavanaugh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fudman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lampl, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffield, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poiley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinblatt, M. E.</span></span> <span> </span><span class="NLM_article-title">A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of 2 dosing regimens of fostamatinib in patients with rheumatoid arthritis with an inadequate response to a tumor necrosis factor-α antagonist</span>. <i>J. Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">2120</span>– <span class="NLM_lpage">2128</span>, <span class="refDoi"> DOI: 10.3899/jrheum.140238</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.3899%2Fjrheum.140238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=25225285" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVyltLfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2014&pages=2120-2128&author=M.+C.+Genoveseauthor=D.+M.+van+der+Heijdeauthor=E.+C.+Keystoneauthor=A.+J.+Spindlerauthor=C.+Benhamouauthor=A.+Kavanaughauthor=E.+Fudmanauthor=K.+Lamplauthor=C.+O%E2%80%99Brienauthor=E.+L.+Duffieldauthor=J.+Poileyauthor=M.+E.+Weinblatt&title=A+phase+III%2C+multicenter%2C+randomized%2C+double-blind%2C+placebo-controlled%2C+parallel-group+study+of+2+dosing+regimens+of+fostamatinib+in+patients+with+rheumatoid+arthritis+with+an+inadequate+response+to+a+tumor+necrosis+factor-%CE%B1+antagonist&doi=10.3899%2Fjrheum.140238"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of 2 dosing regimens of fostamatinib in patients with rheumatoid arthritis with an inadequate response to a tumor necrosis factor-α antagonist</span></div><div class="casAuthors">Genovese, Mark C.; van der Heijde, Desiree M.; Keystone, Edward C.; Spindler, Alberto J.; Benhamou, Claude; Kavanaugh, Arthur; Fudman, Edward; Lampl, Kathy; O'Brien, Chris; Duffield, Emma L.; Poiley, Jeffrey; Weinblatt, Michael E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Rheumatology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2120-2128</span>CODEN:
                <span class="NLM_cas:coden">JRHUA9</span>;
        ISSN:<span class="NLM_cas:issn">0315-162X</span>.
    
            (<span class="NLM_cas:orgname">Journal of Rheumatology Publishing Co. Ltd.</span>)
        </div><div class="casAbstract">Objective. Our 24-wk study (NCT01197755; OSKIRA-3) compared the efficacy and safety of fostamatinib vs. placebo in patients taking background methotrexate treatment with active rheumatoid arthritis (RA) and an inadequate response to a single tumor necrosis factor-α antagonist.  Methods. Adult patients were randomized (1:1:1) to fostamatinib [100 mg bid for 24 wk (n = 105; Group A)], or 100 mg bid for 4 wk, then 150 mg qd (n = 108; Group B), or to placebo (n = 110; Group C) for 24 wk.  Nonresponders at Week 12 could enter a longterm extension study.  The primary endpoint was the proportion of patients achieving an American College of Rheumatol. 20% (ACR20) response at Week 24.  Results. Baseline characteristics were well balanced.  Significantly more patients in fostamatinib Group A (36.2%; p = 0.004), but not B (27.8%; p = 0.168), achieved ACR20 at Week 24 vs. placebo (21.1%).  Frequently reported adverse events were diarrhea, hypertension, and headache.  Elevated blood pressure (≥ 140/90 mm Hg) at ≥ 1 visit was obsd. in 46.7%, 51.9%, and 26.6% of patients, resp.  There were 2 deaths in the study, 1 in Group B and 1 in the placebo group.  Conclusion. Fostamatinib 100 mg bid, but not fostamatinib 100 mg bid for 4 wk then 150 mg qd, achieved statistical improvements in ACR20 at 24 wk vs. placebo.  Because of efficacy and safety results from the phase III clin. program, the companies developing fostamatinib have decided not to study it further in RA at this time.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqU3UHjiwj-cbVg90H21EOLACvtfcHk0lj9sai8gHH5PQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVyltLfI&md5=6fbb8ff3ec66561f2fd5c8d066ce814b</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.3899%2Fjrheum.140238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3899%252Fjrheum.140238%26sid%3Dliteratum%253Aachs%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26aulast%3Dvan%2Bder%2BHeijde%26aufirst%3DD.%2BM.%26aulast%3DKeystone%26aufirst%3DE.%2BC.%26aulast%3DSpindler%26aufirst%3DA.%2BJ.%26aulast%3DBenhamou%26aufirst%3DC.%26aulast%3DKavanaugh%26aufirst%3DA.%26aulast%3DFudman%26aufirst%3DE.%26aulast%3DLampl%26aufirst%3DK.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DC.%26aulast%3DDuffield%26aufirst%3DE.%2BL.%26aulast%3DPoiley%26aufirst%3DJ.%26aulast%3DWeinblatt%26aufirst%3DM.%2BE.%26atitle%3DA%2520phase%2520III%252C%2520multicenter%252C%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%252C%2520parallel-group%2520study%2520of%25202%2520dosing%2520regimens%2520of%2520fostamatinib%2520in%2520patients%2520with%2520rheumatoid%2520arthritis%2520with%2520an%2520inadequate%2520response%2520to%2520a%2520tumor%2520necrosis%2520factor-%25CE%25B1%2520antagonist%26jtitle%3DJ.%2520Rheumatol.%26date%3D2014%26volume%3D41%26spage%3D2120%26epage%3D2128%26doi%3D10.3899%2Fjrheum.140238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Currie, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kropf, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blomgren, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallion, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitney, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maclin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lansdon, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maciejewski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macaluso, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbosa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Paolo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, S. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">3856</span>– <span class="NLM_lpage">3873</span>, <span class="refDoi"> DOI: 10.1021/jm500228a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500228a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2cXls1CrsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=3856-3873&author=K.+S.+Currieauthor=J.+E.+Kropfauthor=T.+Leeauthor=P.+Blomgrenauthor=J.+Xuauthor=Z.+Zhaoauthor=S.+Gallionauthor=J.+A.+Whitneyauthor=D.+Maclinauthor=E.+B.+Lansdonauthor=P.+Maciejewskiauthor=A.+M.+Rossiauthor=H.+Rongauthor=J.+Macalusoauthor=J.+Barbosaauthor=J.+A.+Di+Paoloauthor=S.+A.+Mitchell&title=Discovery+of+GS-9973%2C+a+selective+and+orally+efficacious+inhibitor+of+spleen+tyrosine+kinase&doi=10.1021%2Fjm500228a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of GS-9973, a Selective and Orally Efficacious Inhibitor of Spleen Tyrosine Kinase</span></div><div class="casAuthors">Currie, Kevin S.; Kropf, Jeffrey E.; Lee, Tony; Blomgren, Peter; Xu, Jianjun; Zhao, Zhongdong; Gallion, Steve; Whitney, J. Andrew; Maclin, Deborah; Lansdon, Eric B.; Maciejewski, Patricia; Rossi, Ann Marie; Rong, Hong; Macaluso, Jennifer; Barbosa, James; Di Paolo, Julie A.; Mitchell, Scott A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3856-3873</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Spleen tyrosine kinase (Syk) is an attractive drug target in autoimmune, inflammatory, and oncol. disease indications.  The most advanced Syk inhibitor, R406, (or its prodrug form fostamatinib), has shown efficacy in multiple therapeutic indications, but its clin. progress has been hampered by dose-limiting adverse effects that have been attributed, at least in part, to the off-target activities of R406.  It is expected that a more selective Syk inhibitor would provide a greater therapeutic window.  Herein the authors report the discovery and optimization of a novel series of imidazo[1,2-a]pyrazine Syk inhibitors.  This work culminated in the identification of GS-9973, a highly selective and orally efficacious Syk inhibitor which is currently undergoing clin. evaluation for autoimmune and oncol. indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRyEcx9jKxCbVg90H21EOLACvtfcHk0lj9sai8gHH5PQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXls1CrsL4%253D&md5=fc53448de1f5416f2c6600876f8c6385</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1021%2Fjm500228a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500228a%26sid%3Dliteratum%253Aachs%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26aulast%3DKropf%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DT.%26aulast%3DBlomgren%26aufirst%3DP.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DGallion%26aufirst%3DS.%26aulast%3DWhitney%26aufirst%3DJ.%2BA.%26aulast%3DMaclin%26aufirst%3DD.%26aulast%3DLansdon%26aufirst%3DE.%2BB.%26aulast%3DMaciejewski%26aufirst%3DP.%26aulast%3DRossi%26aufirst%3DA.%2BM.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DMacaluso%26aufirst%3DJ.%26aulast%3DBarbosa%26aufirst%3DJ.%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%2BA.%26aulast%3DMitchell%26aufirst%3DS.%2BA.%26atitle%3DDiscovery%2520of%2520GS-9973%252C%2520a%2520selective%2520and%2520orally%2520efficacious%2520inhibitor%2520of%2520spleen%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D3856%26epage%3D3873%26doi%3D10.1021%2Fjm500228a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tam, F. W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAdoo, S. P.</span></span> <span> </span><span class="NLM_article-title">Fostamatinib disodium</span>. <i>Drugs Future</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">273</span>, <span class="refDoi"> DOI: 10.1358/dof.2011.036.04.1588554</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1358%2Fdof.2011.036.04.1588554" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=23284223" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpt1ylurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2011&pages=273&author=F.+W.+K.+Tamauthor=S.+P.+McAdoo&title=Fostamatinib+disodium&doi=10.1358%2Fdof.2011.036.04.1588554"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Fostamatinib disodium: tyrosine-protein kinase SYK/FLT3 inhibitor treatment of rheumatoid arthritis oncolytic</span></div><div class="casAuthors">McAdoo, S. P.; Tam, F. W. K.; Pandian, R.; Bolos, J.; Castaner, R.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of the Future</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">273-280</span>CODEN:
                <span class="NLM_cas:coden">DRFUD4</span>;
        ISSN:<span class="NLM_cas:issn">0377-8282</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  The non-receptor tyrosine-protein kinase SYK (spleen tyrosine kinase) has a diverse range of biol. functions, including a crit. role in the intracellular signaling cascade for the surface Ig receptor on B lymphocytes and the Fc receptor expressed on numerous immune effector cells.  It is therefore seen as a potential therapeutic target in a variety of conditions, including autoimmune, allergic and malignant diseases.  Fostamatinib disodium is the orally bioavailable prodrug of R-406, a relatively selective small-mol. inhibitor of SYK, that has accordingly shown activity in numerous cell types in vitro, and efficacy in a remarkable range of animal models in vivo, including rodent models of asthma, inflammatory arthritis, lupus, glomerulonephritis, diabetes and lymphoma.  Success in these models has translated to phase II clin. trials in autoimmune thrombocytopenia, lymphoma and, most notably, rheumatoid arthritis, in which larger phase III trials are currently in progress.  While the diverse biol. functions of SYK coupled with the potential off-target effects of this kinase inhibitor are a source of possible toxicity, the available data thus far augur well for future clin. use of fostamatinib in a wide range of human diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1UBbKHhezKrVg90H21EOLACvtfcHk0lgrzSCxLXEZeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpt1ylurs%253D&md5=762da3b1321b7eadbe9ae531221b5593</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1358%2Fdof.2011.036.04.1588554&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdof.2011.036.04.1588554%26sid%3Dliteratum%253Aachs%26aulast%3DTam%26aufirst%3DF.%2BW.%2BK.%26aulast%3DMcAdoo%26aufirst%3DS.%2BP.%26atitle%3DFostamatinib%2520disodium%26jtitle%3DDrugs%2520Future%26date%3D2011%26volume%3D36%26spage%3D273%26doi%3D10.1358%2Fdof.2011.036.04.1588554" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vollenhoven, R. v.</span>; <span class="NLM_string-name">Cohen, S. B.</span>; <span class="NLM_string-name">Mease, P. J.</span>; <span class="NLM_string-name">Peterfy, C. G.</span>; <span class="NLM_string-name">Spieler, W.</span>; <span class="NLM_string-name">Boice, J.</span>; <span class="NLM_string-name">Curtis, S.</span>; <span class="NLM_string-name">Li, Q.</span>; <span class="NLM_string-name">Yao, R.</span>; <span class="NLM_string-name">Baumgartner, R.</span>; <span class="NLM_string-name">Weng, H.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety of MK-8457, a novel SYK inhibitor for the treatment of rheumatoid arthritis in two randomized, controlled, phase 2 studies</span>. Presented at the 2014 ACR/ARHP Annual Meeting, Boston MA, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=R.+v.+Vollenhoven&author=S.+B.+Cohen&author=P.+J.+Mease&author=C.+G.+Peterfy&author=W.+Spieler&author=J.+Boice&author=S.+Curtis&author=Q.+Li&author=R.+Yao&author=R.+Baumgartner&author=H.+Weng&title=Efficacy+and+safety+of+MK-8457%2C+a+novel+SYK+inhibitor+for+the+treatment+of+rheumatoid+arthritis+in+two+randomized%2C+controlled%2C+phase+2+studies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DVollenhoven%26aufirst%3DR.%2Bv.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520MK-8457%252C%2520a%2520novel%2520SYK%2520inhibitor%2520for%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%2520in%2520two%2520randomized%252C%2520controlled%252C%2520phase%25202%2520studies%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coffey, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pak, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haberstock-Debic, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollenbach, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gretler, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mant, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jurcevic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinha, U.</span></span> <span> </span><span class="NLM_article-title">PRT062607 achieves complete inhibition of the spleen tyrosine kinase at tolerated exposures following oral dosing in healthy volunteers</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">194</span>– <span class="NLM_lpage">210</span>, <span class="refDoi"> DOI: 10.1002/jcph.794</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1002%2Fjcph.794" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=27406873" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2sXotlSrtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2017&pages=194-210&author=G.+Coffeyauthor=A.+Raniauthor=A.+Betzauthor=Y.+Pakauthor=H.+Haberstock-Debicauthor=A.+Pandeyauthor=S.+Hollenbachauthor=D.+D.+Gretlerauthor=T.+Mantauthor=S.+Jurcevicauthor=U.+Sinha&title=PRT062607+achieves+complete+inhibition+of+the+spleen+tyrosine+kinase+at+tolerated+exposures+following+oral+dosing+in+healthy+volunteers&doi=10.1002%2Fjcph.794"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">PRT062607 Achieves Complete Inhibition of the Spleen Tyrosine Kinase at Tolerated Exposures Following Oral Dosing in Healthy Volunteers</span></div><div class="casAuthors">Coffey, Greg; Rani, Aradhana; Betz, Andreas; Pak, Yvonne; Haberstock-Debic, Helena; Pandey, Anjali; Hollenbach, Stanley; Gretler, Daniel D.; Mant, Tim; Jurcevic, Stipo; Sinha, Uma</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">194-210</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The spleen tyrosine kinase (SYK) regulates immune cell activation in response to engagement of a variety of receptors, making it an intriguing target for the treatment of inflammatory and autoimmune disorders as well as certain B-cell malignancies.  We have previously reported on the discovery and preclin. characterization of PRT062607, a potent and highly selective inhibitor of SYK that exhibits robust anti-inflammatory activity in a variety of animal models.  Here we present data from our first human studies aimed at characterizing the pharmacokinetics (PK), pharmacodynamics (PD), and safety of PRT062607 in healthy volunteers following single and multiple oral administrations.  PRT062607 demonstrated a favorable PK profile and the ability to completely inhibit SYK activity in multiple whole-blood assays.  The PD half-life in the more sensitive assays was approx. 24 h and returned to predose levels by 72 h.  Selectivity for SYK was obsd. at all dose levels tested.  Anal. of the PK/PD relationship indicated an IC50 of 324 nM for inhibition of B-cell antigen receptor-mediated B-cell activation and 205 nM for inhibition of FcεRI-mediated basophil degranulation.  PRT062607 was safe and well tolerated across the entire range of doses.  Clin. PK/PD was related to in vivo anti-inflammatory activity of PRT062607 in the rat collagen-induced arthritis model, which predicts that therapeutic concns. may be safely achieved in humans for the treatment of autoimmune disease.  PRT062607 has a desirable PK profile and is capable of safely, potently, and selectively suppressing SYK kinase function in humans following once-daily oral dosing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCmfMLrtasGbVg90H21EOLACvtfcHk0lgrzSCxLXEZeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXotlSrtw%253D%253D&md5=93d8c5128dbd3d21a51335941f06a8c1</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1002%2Fjcph.794&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcph.794%26sid%3Dliteratum%253Aachs%26aulast%3DCoffey%26aufirst%3DG.%26aulast%3DRani%26aufirst%3DA.%26aulast%3DBetz%26aufirst%3DA.%26aulast%3DPak%26aufirst%3DY.%26aulast%3DHaberstock-Debic%26aufirst%3DH.%26aulast%3DPandey%26aufirst%3DA.%26aulast%3DHollenbach%26aufirst%3DS.%26aulast%3DGretler%26aufirst%3DD.%2BD.%26aulast%3DMant%26aufirst%3DT.%26aulast%3DJurcevic%26aufirst%3DS.%26aulast%3DSinha%26aufirst%3DU.%26atitle%3DPRT062607%2520achieves%2520complete%2520inhibition%2520of%2520the%2520spleen%2520tyrosine%2520kinase%2520at%2520tolerated%2520exposures%2520following%2520oral%2520dosing%2520in%2520healthy%2520volunteers%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2017%26volume%3D57%26spage%3D194%26epage%3D210%26doi%3D10.1002%2Fjcph.794" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di Paolo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blomgren, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kropf, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suekawa-Pirrone, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wise, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, K.</span></span> <span> </span><span class="NLM_article-title">Preclinical characterization of GS-9876, a novel, oral SYK inhibitor that shows efficacy in multiple established rat models of collagen-induced arthritis</span>. <i>Ann. Rheum. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">443</span>– <span class="NLM_lpage">444</span>, <span class="refDoi"> DOI: 10.1136/annrheumdis-2016-eular.2209</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1136%2Fannrheumdis-2016-eular.2209" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2016&pages=443-444&author=J.+Di+Paoloauthor=P.+Blomgrenauthor=M.+Doltonauthor=R.+Jonesauthor=J.+Kropfauthor=T.+Leeauthor=S.+Mitchellauthor=B.+Murrayauthor=K.+Suekawa-Pirroneauthor=S.+Wiseauthor=J.+Xuauthor=Z.+Zhaoauthor=K.+Currie&title=Preclinical+characterization+of+GS-9876%2C+a+novel%2C+oral+SYK+inhibitor+that+shows+efficacy+in+multiple+established+rat+models+of+collagen-induced+arthritis&doi=10.1136%2Fannrheumdis-2016-eular.2209"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1136%2Fannrheumdis-2016-eular.2209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fannrheumdis-2016-eular.2209%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%26aulast%3DBlomgren%26aufirst%3DP.%26aulast%3DDolton%26aufirst%3DM.%26aulast%3DJones%26aufirst%3DR.%26aulast%3DKropf%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DT.%26aulast%3DMitchell%26aufirst%3DS.%26aulast%3DMurray%26aufirst%3DB.%26aulast%3DSuekawa-Pirrone%26aufirst%3DK.%26aulast%3DWise%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DCurrie%26aufirst%3DK.%26atitle%3DPreclinical%2520characterization%2520of%2520GS-9876%252C%2520a%2520novel%252C%2520oral%2520SYK%2520inhibitor%2520that%2520shows%2520efficacy%2520in%2520multiple%2520established%2520rat%2520models%2520of%2520collagen-induced%2520arthritis%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2016%26volume%3D75%26spage%3D443%26epage%3D444%26doi%3D10.1136%2Fannrheumdis-2016-eular.2209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zammit, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denis, L.</span></span> <span> </span><span class="NLM_article-title">A novel dual SYK/JAK inhibitor with strong antitumor activity in both hematological and solid tumor xenograft models</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">4204</span>– <span class="NLM_lpage">4204</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2017-4204</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1158%2F1538-7445.AM2017-4204" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=4204-4204&author=S.+P.+Reddyauthor=N.+Raoauthor=D.+Zammitauthor=S.+K.+Thompsonauthor=R.+A.+Smithauthor=L.+Denis&title=A+novel+dual+SYK%2FJAK+inhibitor+with+strong+antitumor+activity+in+both+hematological+and+solid+tumor+xenograft+models&doi=10.1158%2F1538-7445.AM2017-4204"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2017-4204&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2017-4204%26sid%3Dliteratum%253Aachs%26aulast%3DReddy%26aufirst%3DS.%2BP.%26aulast%3DRao%26aufirst%3DN.%26aulast%3DZammit%26aufirst%3DD.%26aulast%3DThompson%26aufirst%3DS.%2BK.%26aulast%3DSmith%26aufirst%3DR.%2BA.%26aulast%3DDenis%26aufirst%3DL.%26atitle%3DA%2520novel%2520dual%2520SYK%252FJAK%2520inhibitor%2520with%2520strong%2520antitumor%2520activity%2520in%2520both%2520hematological%2520and%2520solid%2520tumor%2520xenograft%2520models%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26spage%3D4204%26epage%3D4204%26doi%3D10.1158%2F1538-7445.AM2017-4204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Lucca, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langevine, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batt, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaudoin
Bertrand, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yip, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traeger, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattoli, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obermeier, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vickery, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Discenza, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimrich, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulicicchio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galella, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebben, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muckelbauer, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rampulla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-Cid, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrish, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tino, J. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of 6-fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): a reversible inhibitor of Bruton’s tyrosine kinase (BTK) conformationally constrained by two locked atropisomers</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">9173</span>– <span class="NLM_lpage">9200</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01088</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01088" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVKjsrfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=9173-9200&author=S.+H.+Wattersonauthor=G.+V.+De+Luccaauthor=Q.+Shiauthor=C.+M.+Langevineauthor=Q.+Liuauthor=D.+G.+Battauthor=M.+Beaudoin%0ABertrandauthor=H.+Gongauthor=J.+Daiauthor=S.+Yipauthor=P.+Liauthor=D.+Sunauthor=D.-R.+Wuauthor=C.+Wangauthor=Y.+Zhangauthor=S.+C.+Traegerauthor=M.+A.+Pattoliauthor=S.+Skalaauthor=L.+Chengauthor=M.+T.+Obermeierauthor=R.+Vickeryauthor=L.+N.+Discenzaauthor=C.+J.+D%E2%80%99Arienzoauthor=Y.+Zhangauthor=E.+Heimrichauthor=K.+M.+Gilloolyauthor=T.+L.+Taylorauthor=C.+Pulicicchioauthor=K.+W.+McIntyreauthor=M.+A.+Galellaauthor=A.+J.+Tebbenauthor=J.+K.+Muckelbauerauthor=C.+Changauthor=R.+Rampullaauthor=A.+Mathurauthor=L.+Salter-Cidauthor=J.+C.+Barrishauthor=P.+H.+Carterauthor=A.+Furaauthor=J.+R.+Burkeauthor=J.+A.+Tino&title=Discovery+of+6-fluoro-5-%28R%29-%283-%28S%29-%288-fluoro-1-methyl-2%2C4-dioxo-1%2C2-dihydroquinazolin-3%284H%29-yl%29-2-methylphenyl%29-2-%28S%29-%282-hydroxypropan-2-yl%29-2%2C3%2C4%2C9-tetrahydro-1H-carbazole-8-carboxamide+%28BMS-986142%29%3A+a+reversible+inhibitor+of+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29+conformationally+constrained+by+two+locked+atropisomers&doi=10.1021%2Facs.jmedchem.6b01088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton's Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers</span></div><div class="casAuthors">Watterson, Scott H.; De Lucca, George V.; Shi, Qing; Langevine, Charles M.; Liu, Qingjie; Batt, Douglas G.; Beaudoin Bertrand, Myra; Gong, Hua; Dai, Jun; Yip, Shiuhang; Li, Peng; Sun, Dawn; Wu, Dauh-Rurng; Wang, Chunlei; Zhang, Yingru; Traeger, Sarah C.; Pattoli, Mark A.; Skala, Stacey; Cheng, Lihong; Obermeier, Mary T.; Vickery, Rodney; Discenza, Lorell N.; D'Arienzo, Celia J.; Zhang, Yifan; Heimrich, Elizabeth; Gillooly, Kathleen M.; Taylor, Tracy L.; Pulicicchio, Claudine; McIntyre, Kim W.; Galella, Michael A.; Tebben, Andy J.; Muckelbauer, Jodi K.; Chang, ChiehYing; Rampulla, Richard; Mathur, Arvind; Salter-Cid, Luisa; Barrish, Joel C.; Carter, Percy H.; Fura, Aberra; Burke, James R.; Tino, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">9173-9200</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK), a nonreceptor tyrosine kinase, is a member of the Tec family of kinases.  BTK plays an essential role in B cell receptor (BCR)-mediated signaling as well as Fcγ receptor signaling in monocytes and Fcε receptor signaling in mast cells and basophils, all of which have been implicated in the pathophysiol. of autoimmune disease.  As a result, inhibition of BTK is anticipated to provide an effective strategy for the clin. treatment of autoimmune diseases such as lupus and rheumatoid arthritis.  This article details the structure-activity relationships (SAR) leading to a novel series of highly potent and selective carbazole and tetrahydrocarbazole based, reversible inhibitors of BTK.  Of particular interest is that two atropisomeric centers were rotationally locked to provide a single, stable atropisomer, resulting in enhanced potency and selectivity as well as a redn. in safety liabilities.  With significantly enhanced potency and selectivity, excellent in vivo properties and efficacy, and a very desirable tolerability and safety profile, 14f (BMS-986142) was advanced into clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmpBAygRAsYrVg90H21EOLACvtfcHk0lherrkwojkC_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVKjsrfF&md5=91098abc802521b9ad91563d20ac5893</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01088%26sid%3Dliteratum%253Aachs%26aulast%3DWatterson%26aufirst%3DS.%2BH.%26aulast%3DDe%2BLucca%26aufirst%3DG.%2BV.%26aulast%3DShi%26aufirst%3DQ.%26aulast%3DLangevine%26aufirst%3DC.%2BM.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DBatt%26aufirst%3DD.%2BG.%26aulast%3DBeaudoin%2BBertrand%26aufirst%3DM.%26aulast%3DGong%26aufirst%3DH.%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DYip%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DD.-R.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DTraeger%26aufirst%3DS.%2BC.%26aulast%3DPattoli%26aufirst%3DM.%2BA.%26aulast%3DSkala%26aufirst%3DS.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DObermeier%26aufirst%3DM.%2BT.%26aulast%3DVickery%26aufirst%3DR.%26aulast%3DDiscenza%26aufirst%3DL.%2BN.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%2BJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHeimrich%26aufirst%3DE.%26aulast%3DGillooly%26aufirst%3DK.%2BM.%26aulast%3DTaylor%26aufirst%3DT.%2BL.%26aulast%3DPulicicchio%26aufirst%3DC.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DGalella%26aufirst%3DM.%2BA.%26aulast%3DTebben%26aufirst%3DA.%2BJ.%26aulast%3DMuckelbauer%26aufirst%3DJ.%2BK.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DRampulla%26aufirst%3DR.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DSalter-Cid%26aufirst%3DL.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DFura%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DTino%26aufirst%3DJ.%2BA.%26atitle%3DDiscovery%2520of%25206-fluoro-5-%2528R%2529-%25283-%2528S%2529-%25288-fluoro-1-methyl-2%252C4-dioxo-1%252C2-dihydroquinazolin-3%25284H%2529-yl%2529-2-methylphenyl%2529-2-%2528S%2529-%25282-hydroxypropan-2-yl%2529-2%252C3%252C4%252C9-tetrahydro-1H-carbazole-8-carboxamide%2520%2528BMS-986142%2529%253A%2520a%2520reversible%2520inhibitor%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%2520conformationally%2520constrained%2520by%2520two%2520locked%2520atropisomers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D9173%26epage%3D9200%26doi%3D10.1021%2Facs.jmedchem.6b01088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohli, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katewa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gogol, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belmont, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penuel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burton, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortwine, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franke, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estevez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergeron, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span> <span> </span><span class="NLM_article-title">Battling Btk mutants with noncovalent inhibitors that overcome Cys481 and Thr474 mutations</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">2897</span>– <span class="NLM_lpage">2907</span>, <span class="refDoi"> DOI: 10.1021/acschembio.6b00480</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.6b00480" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVWltr3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=2897-2907&author=A.+R.+Johnsonauthor=P.+B.+Kohliauthor=A.+Katewaauthor=E.+Gogolauthor=L.+D.+Belmontauthor=R.+Choyauthor=E.+Penuelauthor=L.+Burtonauthor=C.+Eigenbrotauthor=C.+Yuauthor=D.+F.+Ortwineauthor=K.+Bowmanauthor=Y.+Frankeauthor=C.+Tamauthor=A.+Estevezauthor=K.+Mortaraauthor=J.+Wuauthor=H.+Liauthor=M.+Linauthor=P.+Bergeronauthor=J.+J.+Crawfordauthor=W.+B.+Young&title=Battling+Btk+mutants+with+noncovalent+inhibitors+that+overcome+Cys481+and+Thr474+mutations&doi=10.1021%2Facschembio.6b00480"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations</span></div><div class="casAuthors">Johnson, Adam R.; Kohli, Pawan Bir; Katewa, Arna; Gogol, Emily; Belmont, Lisa D.; Choy, Regina; Penuel, Elicia; Burton, Luciana; Eigenbrot, Charles; Yu, Christine; Ortwine, Daniel F.; Bowman, Krista; Franke, Yvonne; Tam, Christine; Estevez, Alberto; Mortara, Kyle; Wu, Jiansheng; Li, Hong; Lin, May; Bergeron, Philippe; Crawford, James J.; Young, Wendy B.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2897-2907</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The Bruton's tyrosine kinase (Btk) inhibitor ibrutinib has shown impressive clin. efficacy in a range of B-cell malignancies, however acquired resistance has emerged and second generation therapies are now being sought.  Ibrutinib is a covalent, irreversible inhibitor that modifies Cys481 in the ATP binding site of Btk and renders the enzyme inactive, thereby blocking B-cell receptor signal transduction.  Not surprisingly, Cys481 is the most commonly mutated Btk residue in cases of acquired resistance to ibrutinib.  Mutations at other sites, including Thr474, a gatekeeper residue, have also been detected.  Herein the authors describe noncovalent Btk inhibitors that differ from covalent inhibitors like ibrutinib in that they do not interact with Cys481, they potently inhibit the ibrutinib-resistant Btk C481S mutant in vitro and in cells, and they are exquisitely selective for Btk.  Noncovalent inhibitors such as GNE-431 also show excellent potency against the C481R, T474I, and T474M mutants.  X-ray crystallog. anal. of Btk provides insight into the unique mode of binding of these inhibitors that explains their high selectivity for Btk and their retained activity against mutant forms of Btk.  This class of noncovalent Btk inhibitors may provide a treatment option to patients, esp. those who have acquired resistance to ibrutinib by mutation of Cys481 or Thr474.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkuzaMmxhJ67Vg90H21EOLACvtfcHk0lg6_Cripn6zFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVWltr3E&md5=1e0458160f967ed01c259751cc2118e1</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1021%2Facschembio.6b00480&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.6b00480%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DKohli%26aufirst%3DP.%2BB.%26aulast%3DKatewa%26aufirst%3DA.%26aulast%3DGogol%26aufirst%3DE.%26aulast%3DBelmont%26aufirst%3DL.%2BD.%26aulast%3DChoy%26aufirst%3DR.%26aulast%3DPenuel%26aufirst%3DE.%26aulast%3DBurton%26aufirst%3DL.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DBowman%26aufirst%3DK.%26aulast%3DFranke%26aufirst%3DY.%26aulast%3DTam%26aufirst%3DC.%26aulast%3DEstevez%26aufirst%3DA.%26aulast%3DMortara%26aufirst%3DK.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DLin%26aufirst%3DM.%26aulast%3DBergeron%26aufirst%3DP.%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26atitle%3DBattling%2520Btk%2520mutants%2520with%2520noncovalent%2520inhibitors%2520that%2520overcome%2520Cys481%2520and%2520Thr474%2520mutations%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2016%26volume%3D11%26spage%3D2897%26epage%3D2907%26doi%3D10.1021%2Facschembio.6b00480" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dougan, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komandla, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanouni, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knight, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawson, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabat, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyrick, C.</span></span> <span> </span><span class="NLM_article-title">Fragment-based discovery of a small molecule inhibitor of Bruton’s tyrosine kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">5437</span>– <span class="NLM_lpage">5444</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00734</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00734" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVans7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=5437-5444&author=C.+R.+Smithauthor=D.+R.+Douganauthor=M.+Komandlaauthor=T.+Kanouniauthor=B.+Knightauthor=J.+D.+Lawsonauthor=M.+Sabatauthor=E.+R.+Taylorauthor=P.+Vuauthor=C.+Wyrick&title=Fragment-based+discovery+of+a+small+molecule+inhibitor+of+Bruton%E2%80%99s+tyrosine+kinase&doi=10.1021%2Facs.jmedchem.5b00734"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment-Based Discovery of a Small Molecule Inhibitor of Bruton's Tyrosine Kinase</span></div><div class="casAuthors">Smith, Christopher R.; Dougan, Douglas R.; Komandla, Mallareddy; Kanouni, Toufike; Knight, Beverly; Lawson, J. David; Sabat, Mark; Taylor, Ewan R.; Vu, Phong; Wyrick, Corey</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5437-5444</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery and optimization of a series of 4-aminocinnoline-3-carboxamide inhibitors of Bruton's tyrosine kinase are reported.  A fragment-based screening approach incorporating x-ray cocrystallog. was used to identify a cinnoline fragment and characterize its binding mode in the ATP binding site of Btk.  Optimization of the fragment hit resulted in the identification of a lead compd. I which reduced paw swelling in a dose- and exposure-dependent fashion in a rat model of collagen-induced arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozENTW7pHlFrVg90H21EOLACvtfcHk0lg6_Cripn6zFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVans7rF&md5=d6626fabcc3e2aa6a9180dc702a5030c</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00734&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00734%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DC.%2BR.%26aulast%3DDougan%26aufirst%3DD.%2BR.%26aulast%3DKomandla%26aufirst%3DM.%26aulast%3DKanouni%26aufirst%3DT.%26aulast%3DKnight%26aufirst%3DB.%26aulast%3DLawson%26aufirst%3DJ.%2BD.%26aulast%3DSabat%26aufirst%3DM.%26aulast%3DTaylor%26aufirst%3DE.%2BR.%26aulast%3DVu%26aufirst%3DP.%26aulast%3DWyrick%26aufirst%3DC.%26atitle%3DFragment-based%2520discovery%2520of%2520a%2520small%2520molecule%2520inhibitor%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D5437%26epage%3D5444%26doi%3D10.1021%2Facs.jmedchem.5b00734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuglstatter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondru, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, D. M.</span></span> <span> </span><span class="NLM_article-title">Bruton’s tyrosine kinase inhibitors: approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and B cell malignancies</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">4539</span>– <span class="NLM_lpage">4550</span>, <span class="refDoi"> DOI: 10.1021/jm300035p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300035p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC38XjsVChsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=4539-4550&author=Y.+Louauthor=T.+D.+Owensauthor=A.+Kuglstatterauthor=R.+K.+Kondruauthor=D.+M.+Goldstein&title=Bruton%E2%80%99s+tyrosine+kinase+inhibitors%3A+approaches+to+potent+and+selective+inhibition%2C+preclinical+and+clinical+evaluation+for+inflammatory+diseases+and+B+cell+malignancies&doi=10.1021%2Fjm300035p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton's Tyrosine Kinase Inhibitors: Approaches to Potent and Selective Inhibition, Preclinical and Clinical Evaluation for Inflammatory Diseases and B Cell Malignancies</span></div><div class="casAuthors">Lou, Yan; Owens, Timothy D.; Kuglstatter, Andreas; Kondru, Rama K.; Goldstein, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4539-4550</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRzAwa4gtFprVg90H21EOLACvtfcHk0lg6_Cripn6zFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjsVChsb8%253D&md5=b470ba4ec4867e4bfb8d1cfa92b1cc6d</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1021%2Fjm300035p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300035p%26sid%3Dliteratum%253Aachs%26aulast%3DLou%26aufirst%3DY.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26aulast%3DKuglstatter%26aufirst%3DA.%26aulast%3DKondru%26aufirst%3DR.%2BK.%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26atitle%3DBruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitors%253A%2520approaches%2520to%2520potent%2520and%2520selective%2520inhibition%252C%2520preclinical%2520and%2520clinical%2520evaluation%2520for%2520inflammatory%2520diseases%2520and%2520B%2520cell%2520malignancies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D4539%26epage%3D4550%26doi%3D10.1021%2Fjm300035p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Akinleye, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukhi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span> <span> </span><span class="NLM_article-title">Ibrutinib and novel BTK inhibitors in clinical development</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">59</span>– <span class="NLM_lpage">67</span>, <span class="refDoi"> DOI: 10.1186/1756-8722-6-59</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1186%2F1756-8722-6-59" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=23958373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVagtrjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2013&pages=59-67&author=A.+Akinleyeauthor=Y.+Chenauthor=N.+Mukhiauthor=Y.+Songauthor=D.+Liu&title=Ibrutinib+and+novel+BTK+inhibitors+in+clinical+development&doi=10.1186%2F1756-8722-6-59"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Ibrutinib and novel BTK inhibitors in clinical development</span></div><div class="casAuthors">Akinleye, Akintunde; Chen, Yamei; Mukhi, Nikhil; Song, Yongping; Liu, Delong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">59</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Small mol. inhibitors targeting dysregulated pathways (RAS/RAF/MEK, PI3K/AKT/mTOR, JAK/STAT) have significantly improved clin. outcomes in cancer patients.  Recently Bruton's tyrosine kinase (BTK), a crucial terminal kinase enzyme in the B-cell antigen receptor (BCR) signaling pathway, has emerged as an attractive target for therapeutic intervention in human malignancies and autoimmune disorders.  Ibrutinib, a novel first-in-human BTK inhibitor, has demonstrated clin. effectiveness and tolerability in early clin. trials and has progressed into phase III trials.  However, addnl. research is necessary to identify the optimal dosing schedule, as well as patients most likely to benefit from BTK inhibition.  This review summarizes preclin. and clin. development of ibrutinib and other novel BTK inhibitors (GDC-0834, CGI-560, CGI-1746, HM-71224, CC-292 and ONO-4059, CNX-774, LFM-A13) in the treatment of B-cell malignancies and autoimmune disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-fz7_rhCHvbVg90H21EOLACvtfcHk0lghBlwFcKAlNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVagtrjI&md5=e5067b998c61818e2efbb62da935b490</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1186%2F1756-8722-6-59&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1756-8722-6-59%26sid%3Dliteratum%253Aachs%26aulast%3DAkinleye%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DMukhi%26aufirst%3DN.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DD.%26atitle%3DIbrutinib%2520and%2520novel%2520BTK%2520inhibitors%2520in%2520clinical%2520development%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2013%26volume%3D6%26spage%3D59%26epage%3D67%26doi%3D10.1186%2F1756-8722-6-59" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Musumeci, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanna, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greco, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giacchello, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fallacara, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amato, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schenone, S.</span></span> <span> </span><span class="NLM_article-title">Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1305</span>– <span class="NLM_lpage">1318</span>, <span class="refDoi"> DOI: 10.1080/13543776.2017.1355908</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1080%2F13543776.2017.1355908" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=28705083" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1Sgt7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=1305-1318&author=F.+Musumeciauthor=M.+Sannaauthor=C.+Grecoauthor=I.+Giacchelloauthor=A.+L.+Fallacaraauthor=R.+Amatoauthor=S.+Schenone&title=Pyrrolo%5B2%2C3-d%5Dpyrimidines+active+as+Btk+inhibitors&doi=10.1080%2F13543776.2017.1355908"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors</span></div><div class="casAuthors">Musumeci, Francesca; Sanna, Monica; Greco, Chiara; Giacchello, Ilaria; Fallacara, Anna Lucia; Amato, Rosario; Schenone, Silvia</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1305-1318</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Introduction: Btk is a tyrosine kinase dysregulated in several B-cell malignancies and autoimmune diseases, and this has given rise to a search for Btk inhibitors.  Nevertheless, only one Btk inhibitor, ibrutinib, has been approved to date, although other compds. are currently being evaluated in clin. trials or in preclinal stages.  Area covered: This review, after a brief introduction on Btk and its inhibitors already in clin. trials, focusses on pyrrolo[2,3-d]pyrimidine derivs. patented in the last five years as Btk inhibitors.  Indeed, the pyrrolo[2,3-d]pyrimidine scaffold, being a deaza-isostere of adenine, the nitrogenous base of ATP, is an actively pursued target for Btk inhibitors.  The patent literature since 2012 have been extensively investigated, pointing out the general features of the patented compds. and, when it is possible, their mechanism of action.  Expert opinion: The recently patented pyrrolo[2,3-d]pyrimidines, acting as reversible or irreversible inhibitors, showed a very interesting in vitro activity.  For this reason, the development of compds. endowed with this scaffold could afford a significant impact in the search for drug candidates for the treatment of immune diseases or B-cell malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPT0s7eVqXebVg90H21EOLACvtfcHk0lghBlwFcKAlNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1Sgt7vK&md5=294c9b8bcafe6f7831187cb963f2f072</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1080%2F13543776.2017.1355908&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2017.1355908%26sid%3Dliteratum%253Aachs%26aulast%3DMusumeci%26aufirst%3DF.%26aulast%3DSanna%26aufirst%3DM.%26aulast%3DGreco%26aufirst%3DC.%26aulast%3DGiacchello%26aufirst%3DI.%26aulast%3DFallacara%26aufirst%3DA.%2BL.%26aulast%3DAmato%26aufirst%3DR.%26aulast%3DSchenone%26aufirst%3DS.%26atitle%3DPyrrolo%255B2%252C3-d%255Dpyrimidines%2520active%2520as%2520Btk%2520inhibitors%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2017%26volume%3D27%26spage%3D1305%26epage%3D1318%26doi%3D10.1080%2F13543776.2017.1355908" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lanning, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitby, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dix, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douhan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hett, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joslyn, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kath, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niessen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnute, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hulce, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whiteley, L. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayward, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span> <span> </span><span class="NLM_article-title">A roadmap to evaluate the proteome-wide selectivity of covalent kinase inhibitors</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">760</span>– <span class="NLM_lpage">767</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1582</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1038%2Fnchembio.1582" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=25038787" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFygs7nO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=760-767&author=B.+R.+Lanningauthor=L.+R.+Whitbyauthor=M.+M.+Dixauthor=J.+Douhanauthor=A.+M.+Gilbertauthor=E.+C.+Hettauthor=T.+O.+Johnsonauthor=C.+Joslynauthor=J.+C.+Kathauthor=S.+Niessenauthor=L.+R.+Robertsauthor=M.+E.+Schnuteauthor=C.+Wangauthor=J.+J.+Hulceauthor=B.+Weiauthor=L.+O.+Whiteleyauthor=M.+M.+Haywardauthor=B.+F.+Cravatt&title=A+roadmap+to+evaluate+the+proteome-wide+selectivity+of+covalent+kinase+inhibitors&doi=10.1038%2Fnchembio.1582"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors</span></div><div class="casAuthors">Lanning, Bryan R.; Whitby, Landon R.; Dix, Melissa M.; Douhan, John; Gilbert, Adam M.; Hett, Erik C.; Johnson, Theodore O.; Joslyn, Chris; Kath, John C.; Niessen, Sherry; Roberts, Lee R.; Schnute, Mark E.; Wang, Chu; Hulce, Jonathan J.; Wei, Baoxian; Whiteley, Laurence O.; Hayward, Matthew M.; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">760-767</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinases are principal components of signal transduction pathways and the focus of intense basic and drug discovery research.  Irreversible inhibitors that covalently modify non-catalytic cysteines in kinase active sites have emerged as valuable probes and approved drugs.  Many protein classes, however, have functional cysteines, and therefore understanding the proteome-wide selectivity of covalent kinase inhibitors is imperative.  Here, we accomplish this objective using activity-based protein profiling coupled with quant. MS to globally map the targets, both specific and nonspecific, of covalent kinase inhibitors in human cells.  Many of the specific off-targets represent nonkinase proteins that, notably, have conserved active site cysteines.  We define windows of selectivity for covalent kinase inhibitors and show that, when these windows are exceeded, rampant proteome-wide reactivity and kinase target-independent cell death conjointly occur.  Our findings, taken together, provide an exptl. road map to illuminate opportunities and surmount challenges for the development of covalent kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMAiUlEg9R5rVg90H21EOLACvtfcHk0lghBlwFcKAlNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFygs7nO&md5=6f17b0d1b00e088f37c511eea577d290</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1582&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1582%26sid%3Dliteratum%253Aachs%26aulast%3DLanning%26aufirst%3DB.%2BR.%26aulast%3DWhitby%26aufirst%3DL.%2BR.%26aulast%3DDix%26aufirst%3DM.%2BM.%26aulast%3DDouhan%26aufirst%3DJ.%26aulast%3DGilbert%26aufirst%3DA.%2BM.%26aulast%3DHett%26aufirst%3DE.%2BC.%26aulast%3DJohnson%26aufirst%3DT.%2BO.%26aulast%3DJoslyn%26aufirst%3DC.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DNiessen%26aufirst%3DS.%26aulast%3DRoberts%26aufirst%3DL.%2BR.%26aulast%3DSchnute%26aufirst%3DM.%2BE.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DHulce%26aufirst%3DJ.%2BJ.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DWhiteley%26aufirst%3DL.%2BO.%26aulast%3DHayward%26aufirst%3DM.%2BM.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DA%2520roadmap%2520to%2520evaluate%2520the%2520proteome-wide%2520selectivity%2520of%2520covalent%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2014%26volume%3D10%26spage%3D760%26epage%3D767%26doi%3D10.1038%2Fnchembio.1582" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Owens, T. D.</span></span> <span> </span><span class="NLM_article-title">Discovery of PRN1008: A reversible covalent BTK inhibitor for treatment of autoimmune diseases</span>. Presented at the 255th American Chemical Society National Meeting & Exposition, New Orleans, LA, March 21, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Owens%2C+T.+D.+Discovery+of+PRN1008%3A+A+reversible+covalent+BTK+inhibitor+for+treatment+of+autoimmune+diseases.+Presented+at+the+255th+American+Chemical+Society+National+Meeting+%26+Exposition%2C+New+Orleans%2C+LA%2C+March+21%2C+2018."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DOwens%26aufirst%3DT.%2BD.%26atitle%3DDiscovery%2520of%2520PRN1008%253A%2520A%2520reversible%2520covalent%2520BTK%2520inhibitor%2520for%2520treatment%2520of%2520autoimmune%2520diseases%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byun, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Son, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suh, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. B.</span></span> <span> </span><span class="NLM_article-title">HM71224, a novel Bruton’s tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: a potential drug for rheumatoid arthritis</span>. <i>Arthritis Res. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">91</span>– <span class="NLM_lpage">99</span>, <span class="refDoi"> DOI: 10.1186/s13075-016-0988-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1186%2Fs13075-016-0988-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=27090981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2sXivV2msLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2016&pages=91-99&author=J.+K.+Parkauthor=J.-Y.+Byunauthor=J.+A.+Parkauthor=Y.-Y.+Kimauthor=Y.+J.+Leeauthor=J.+I.+Ohauthor=S.+Y.+Jangauthor=Y.+H.+Kimauthor=Y.+W.+Songauthor=J.+Sonauthor=K.+H.+Suhauthor=Y.-M.+Leeauthor=E.+B.+Lee&title=HM71224%2C+a+novel+Bruton%E2%80%99s+tyrosine+kinase+inhibitor%2C+suppresses+B+cell+and+monocyte+activation+and+ameliorates+arthritis+in+a+mouse+model%3A+a+potential+drug+for+rheumatoid+arthritis&doi=10.1186%2Fs13075-016-0988-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">HM71224, a novel Bruton's tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: a potential drug for rheumatoid arthritis</span></div><div class="casAuthors">Park, Jin Kyun; Byun, Joo-Yun; Park, Ji Ah; Kim, Yu-Yon; Lee, Ye Ji; Oh, Jeong In; Jang, Sun Young; Kim, Young Hoon; Song, Yeong Wook; Son, Jeewoong; Suh, Kwee Hyun; Lee, Young-Mi; Lee, Eun Bong</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis Research & Therapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">91/1-91/9</span>CODEN:
                <span class="NLM_cas:coden">ARTRCV</span>;
        ISSN:<span class="NLM_cas:issn">1478-6362</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Bruton's tyrosine kinase (Btk) is crit. for activation of B cells and myeloid cells.  This study aimed to characterize the effects of HM71224, a novel Btk inhibitor, both in vitro and in a mouse model of exptl. arthritis.  Methods: The kinase inhibition profile of HM71224 was analyzed.  The in vitro effects of HM71224 on B cells and monocytes were analyzed by examg. phosphorylation of Btk and its downstream signaling mols., along with cytokine prodn. and osteoclast formation.  The in vivo effects of HM71224 were investigated in a mouse model of collagen-induced arthritis (CIA).  Results: HM71224 irreversibly bound to and inhibited Btk (IC50 = 1.95 nM).  The compd. also inhibited the phosphorylation of Btk and its downstream mols. such as PLCγ2, in activated Ramos B lymphoma cells and primary human B cells in a dose-dependent manner.  Furthermore, HM71224 effectively inhibited the prodn. of tumor necrosis factor (TNF)-α, interleukin (IL)-6, and IL-1β by human monocytes, and osteoclast formation by human monocytes.  Finally, HM71224 improved exptl. arthritis and prevented joint destruction in a murine model of CIA.  Conclusions: HM71224 inhibits Btk in B cells and monocytes and ameliorates exptl. arthritis in a mouse model.  Thus, HM71224 is a potential novel therapeutic agent for rheumatoid arthritis in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIE3CGRUJef7Vg90H21EOLACvtfcHk0lippVALxY-R4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXivV2msLY%253D&md5=80eab623ff968690ba8f92bcd26301b7</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1186%2Fs13075-016-0988-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13075-016-0988-z%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DJ.%2BK.%26aulast%3DByun%26aufirst%3DJ.-Y.%26aulast%3DPark%26aufirst%3DJ.%2BA.%26aulast%3DKim%26aufirst%3DY.-Y.%26aulast%3DLee%26aufirst%3DY.%2BJ.%26aulast%3DOh%26aufirst%3DJ.%2BI.%26aulast%3DJang%26aufirst%3DS.%2BY.%26aulast%3DKim%26aufirst%3DY.%2BH.%26aulast%3DSong%26aufirst%3DY.%2BW.%26aulast%3DSon%26aufirst%3DJ.%26aulast%3DSuh%26aufirst%3DK.%2BH.%26aulast%3DLee%26aufirst%3DY.-M.%26aulast%3DLee%26aufirst%3DE.%2BB.%26atitle%3DHM71224%252C%2520a%2520novel%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitor%252C%2520suppresses%2520B%2520cell%2520and%2520monocyte%2520activation%2520and%2520ameliorates%2520arthritis%2520in%2520a%2520mouse%2520model%253A%2520a%2520potential%2520drug%2520for%2520rheumatoid%2520arthritis%26jtitle%3DArthritis%2520Res.%2520Ther.%26date%3D2016%26volume%3D18%26spage%3D91%26epage%3D99%26doi%3D10.1186%2Fs13075-016-0988-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, S. H.</span></span> <span> </span><span class="NLM_article-title">Discovery of BMS-986195: A strategy for identifying a highly potent and selective covalent inhibitor providing rapid inactivation of Bruton’s tyrosine kinase (BTK)</span>. Presented at the 255th American Chemical Society National Meeting & Exposition, New Orleans, LA, March 21, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Watterson%2C+S.+H.+Discovery+of+BMS-986195%3A+A+strategy+for+identifying+a+highly+potent+and+selective+covalent+inhibitor+providing+rapid+inactivation+of+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29.+Presented+at+the+255th+American+Chemical+Society+National+Meeting+%26+Exposition%2C+New+Orleans%2C+LA%2C+March+21%2C+2018."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DWatterson%26aufirst%3DS.%2BH.%26atitle%3DDiscovery%2520of%2520BMS-986195%253A%2520A%2520strategy%2520for%2520identifying%2520a%2520highly%2520potent%2520and%2520selective%2520covalent%2520inhibitor%2520providing%2520rapid%2520inactivation%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barf, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covey, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izumi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Kar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulrajani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Lith, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Hoek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Zwart, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittag, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demont, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verkaik, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krantz, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulrich, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaptein, A.</span></span> <span> </span><span class="NLM_article-title">Acalabrutinib: a differentiated covalent BTK inhibitor</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>363</i></span>,  <span class="NLM_fpage">240</span>– <span class="NLM_lpage">252</span>, <span class="refDoi"> DOI: 10.1124/jpet.117.242909</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1124%2Fjpet.117.242909" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=28882879" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtleltrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2017&pages=240-252&author=T.+Barfauthor=T.+Coveyauthor=R.+Izumiauthor=B.+van+de+Karauthor=M.+Gulrajaniauthor=B.+van+Lithauthor=M.+van+Hoekauthor=E.+de+Zwartauthor=D.+Mittagauthor=D.+Demontauthor=S.+Verkaikauthor=F.+Krantzauthor=P.+G.+Pearsonauthor=R.+Ulrichauthor=A.+Kaptein&title=Acalabrutinib%3A+a+differentiated+covalent+BTK+inhibitor&doi=10.1124%2Fjpet.117.242909"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Acalabrutinib (ACP-196): a covalent Bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile</span></div><div class="casAuthors">Barf, Tjeerd; Covey, Todd; Izumi, Raquel; van de Kar, Bas; Gulrajani, Michael; van Lith, Bart; van Hoek, Maaike; de Zwart, Edwin; Mittag, Diana; Demont, Dennis; Verkaik, Saskia; Krantz, Fanny; Pearson, Paul G.; Ulrich, Roger; Kaptein, Allard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">240-252</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Several small-mol. Bruton tyrosine kinase (BTK) inhibitors are in development for B cell malignancies and autoimmune disorders, each characterized by distinct potency and selectivity patterns.  Herein we describe the pharmacol. characterization of BTK inhibitor acalabrutinib [compd. 1, ACP-196 (4-[8- amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin1-yl]-N-(2-pyridyl)benzamide)].  Acalabrutinib possesses a reactive butynamide group that binds covalently to Cys481 in BTK.  Relative to the other BTK inhibitors described here, the reduced intrinsic reactivity of acalabrutinib helps to limit inhibition of off-target kinases having cysteine-mediated covalent binding potential.  Acalabrutinib demonstrated higher biochem. and cellular selectivity than ibrutinib and spebrutinib (compds. 2 and 3, resp.).  Importantly, off-target kinases, such as epidermal growth factor receptor (EGFR) and interleukin 2-inducible T cell kinase (ITK), were not inhibited.  Detn. of the inhibitory potential of anti-IgM-induced CD69 expression in human peripheral blood mononuclear cells and whole blood demonstrated that acalabrutinib is a potent functional BTK inhibitor.  In vivo evaluation in mice revealed that acalabrutinib is more potent than ibrutinib and spebrutinib.  Preclin. and clin. studies showed that the level and duration of BTK occupancy correlates with in vivo efficacy.  Evaluation of the pharmacokinetic properties of acalabrutinib in healthy adult volunteers demonstrated rapid absorption and fast elimination.  In these healthy individuals, a single oral dose of 100 mg showed approx. 99% median target coverage at 3 and 12 h and around 90% at 24 h in peripheral B cells.  In conclusion, acalabrutinib is a BTK inhibitor with key pharmacol. differentiators vs. ibrutinib and spebrutinib and is currently being evaluated in clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGol9xhDmwvup7Vg90H21EOLACvtfcHk0lippVALxY-R4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtleltrnO&md5=73cbd3a87396abbf8cb20e4361f96f64</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1124%2Fjpet.117.242909&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.117.242909%26sid%3Dliteratum%253Aachs%26aulast%3DBarf%26aufirst%3DT.%26aulast%3DCovey%26aufirst%3DT.%26aulast%3DIzumi%26aufirst%3DR.%26aulast%3Dvan%2Bde%2BKar%26aufirst%3DB.%26aulast%3DGulrajani%26aufirst%3DM.%26aulast%3Dvan%2BLith%26aufirst%3DB.%26aulast%3Dvan%2BHoek%26aufirst%3DM.%26aulast%3Dde%2BZwart%26aufirst%3DE.%26aulast%3DMittag%26aufirst%3DD.%26aulast%3DDemont%26aufirst%3DD.%26aulast%3DVerkaik%26aufirst%3DS.%26aulast%3DKrantz%26aufirst%3DF.%26aulast%3DPearson%26aufirst%3DP.%2BG.%26aulast%3DUlrich%26aufirst%3DR.%26aulast%3DKaptein%26aufirst%3DA.%26atitle%3DAcalabrutinib%253A%2520a%2520differentiated%2520covalent%2520BTK%2520inhibitor%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2017%26volume%3D363%26spage%3D240%26epage%3D252%26doi%3D10.1124%2Fjpet.117.242909" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheerens, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sprengeler, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrill, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendonca, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, K. C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grothaus, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffery, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spoerke, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honigberg, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalrymple, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, J. T.</span></span> <span> </span><span class="NLM_article-title">Discovery of selective irreversible inhibitors for Bruton’s tyrosine kinase</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">58</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1002/cmdc.200600221</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1002%2Fcmdc.200600221" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=17154430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsVWjsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=58-61&author=Z.+Panauthor=H.+Scheerensauthor=S.-J.+Liauthor=B.+E.+Schultzauthor=P.+A.+Sprengelerauthor=L.+C.+Burrillauthor=R.+V.+Mendoncaauthor=M.+D.+Sweeneyauthor=K.+C.+K.+Scottauthor=P.+G.+Grothausauthor=D.+A.+Jefferyauthor=J.+M.+Spoerkeauthor=L.+A.+Honigbergauthor=P.+R.+Youngauthor=S.+A.+Dalrympleauthor=J.+T.+Palmer&title=Discovery+of+selective+irreversible+inhibitors+for+Bruton%E2%80%99s+tyrosine+kinase&doi=10.1002%2Fcmdc.200600221"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of selective irreversible inhibitors for bruton's tyrosine kinase</span></div><div class="casAuthors">Pan, Zhengying; Scheerens, Heleen; Li, Shyr-Jiann; Schultz, Brian E.; Sprengeler, Paul A.; Burrill, L. Chuck; Mendonca, Rohan V.; Sweeney, Michael D.; Scott, Keana C. K.; Grothaus, Paul G.; Jeffery, Douglas A.; Spoerke, Jill M.; Honigberg, Lee A.; Young, Peter R.; Dalrymple, Stacie A.; Palmer, James T.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-61</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Synthesis and pharmacol. evaluation of a series of peptidomimetic quinoline derivs. was undertaken to evaluate their efficacy in acting as selective irreversible inhibitors of Bruton's tyrosine kinase (Btk).  With the relative scarcity of knowledge on the inhibition of Btk it is crucial to discover a potent and selective tool compd. for this kinase.  Herein is described the discovery of selective irreversible Btk inhibitors and their efficacy in a mouse RA model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovT3kBCYECdbVg90H21EOLACvtfcHk0lippVALxY-R4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsVWjsbg%253D&md5=023ba8bca9942ad0127d7cf32293e9d2</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200600221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200600221%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DZ.%26aulast%3DScheerens%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DS.-J.%26aulast%3DSchultz%26aufirst%3DB.%2BE.%26aulast%3DSprengeler%26aufirst%3DP.%2BA.%26aulast%3DBurrill%26aufirst%3DL.%2BC.%26aulast%3DMendonca%26aufirst%3DR.%2BV.%26aulast%3DSweeney%26aufirst%3DM.%2BD.%26aulast%3DScott%26aufirst%3DK.%2BC.%2BK.%26aulast%3DGrothaus%26aufirst%3DP.%2BG.%26aulast%3DJeffery%26aufirst%3DD.%2BA.%26aulast%3DSpoerke%26aufirst%3DJ.%2BM.%26aulast%3DHonigberg%26aufirst%3DL.%2BA.%26aulast%3DYoung%26aufirst%3DP.%2BR.%26aulast%3DDalrymple%26aufirst%3DS.%2BA.%26aulast%3DPalmer%26aufirst%3DJ.%2BT.%26atitle%3DDiscovery%2520of%2520selective%2520irreversible%2520inhibitors%2520for%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%26jtitle%3DChemMedChem%26date%3D2007%26volume%3D2%26spage%3D58%26epage%3D61%26doi%3D10.1002%2Fcmdc.200600221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnarajah, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunn, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karr, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masjedizadeh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funk, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gourlay, S. G.</span></span> <span> </span><span class="NLM_article-title">A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton’s tyrosine kinase, in healthy volunteers</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">2367</span>– <span class="NLM_lpage">2376</span>, <span class="refDoi"> DOI: 10.1111/bcp.13351</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1111%2Fbcp.13351" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=28636208" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslWrsLnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2017&pages=2367-2376&author=P.+F.+Smithauthor=J.+Krishnarajahauthor=P.+A.+Nunnauthor=R.+J.+Hillauthor=D.+Karrauthor=D.+Tamauthor=M.+Masjedizadehauthor=J.+O.+Funkauthor=S.+G.+Gourlay&title=A+phase+I+trial+of+PRN1008%2C+a+novel+reversible+covalent+inhibitor+of+Bruton%E2%80%99s+tyrosine+kinase%2C+in+healthy+volunteers&doi=10.1111%2Fbcp.13351"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers</span></div><div class="casAuthors">Smith, Patrick F.; Krishnarajah, Janakan; Nunn, Philip A.; Hill, Ron J.; Karr, Dane; Tam, D.; Masjedizadeh, Mohammad; Funk, Jens O.; Gourlay, Steve G.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2367-2376</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">1365-2125</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">To evaluate the safety, tolerability, and pharmacokinetics/pharmacodynamics of PRN1008, a novel Bruton's tyrosine kinase (BTK) inhibitor, in healthy volunteers, and thus det. the dose range for future clin. studies.  This was a two-part randomized, placebo controlled study in healthy volunteers using a liq. formulation.  Part I was a single ascending dose design with dose levels of 50-1200 mg (n = 6 active, two placebos per cohort); Part II was a multiple ascending dose design, with dose regimens ranging from 300 to 900 mg daily, either four times or twice daily for 10 days.  Plasma pharmacokinetics, adverse events, vital signs, electrocardiograms and lab. parameters were assessed.  BTK occupancy in peripheral blood mononuclear cells was evaluated as a marker of target engagement.  PRN1008 was rapidly absorbed following oral administration, and was safe and well tolerated in all dose regimens evaluated in both single and multiple doses.  PRN1008 demonstrated a large vol. of distribution, and a half-life of approx. 3-4 h.  BTK occupancy of >90% was obsd. within 4 h after dosing in both single and multiple dose regimens, and was closely linked to max. plasma concn.  BTK occupancy decay was slow (-1.6% h-1), and occupancy was sustained despite drug concns. being undetectable.  No severe or serious adverse events occurred, and the most common adverse events were gastrointestinal in nature.  PRN1008 was safe and well-tolerated following oral administration, and achieved high, sustained levels of BTK occupancy in peripheral blood mononuclear cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDCmAr26_VXLVg90H21EOLACvtfcHk0lhtaPSLLWzEIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslWrsLnE&md5=8da03545b8beec4c50cdd95854bcad8f</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1111%2Fbcp.13351&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcp.13351%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DP.%2BF.%26aulast%3DKrishnarajah%26aufirst%3DJ.%26aulast%3DNunn%26aufirst%3DP.%2BA.%26aulast%3DHill%26aufirst%3DR.%2BJ.%26aulast%3DKarr%26aufirst%3DD.%26aulast%3DTam%26aufirst%3DD.%26aulast%3DMasjedizadeh%26aufirst%3DM.%26aulast%3DFunk%26aufirst%3DJ.%2BO.%26aulast%3DGourlay%26aufirst%3DS.%2BG.%26atitle%3DA%2520phase%2520I%2520trial%2520of%2520PRN1008%252C%2520a%2520novel%2520reversible%2520covalent%2520inhibitor%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%252C%2520in%2520healthy%2520volunteers%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2017%26volume%3D83%26spage%3D2367%26epage%3D2376%26doi%3D10.1111%2Fbcp.13351" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bradshaw, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McFarland, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paavilainen, V. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bisconte, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phan, V. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romanov, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finkle, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ton, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loughhead, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunn, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karr, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerritsen, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funk, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brameld, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taunton, J.</span></span> <span> </span><span class="NLM_article-title">Prolonged and tunable residence time using reversible covalent kinase inhibitors</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">525</span>– <span class="NLM_lpage">531</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1817</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1038%2Fnchembio.1817" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=26006010" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFeju7%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=525-531&author=J.+M.+Bradshawauthor=J.+M.+McFarlandauthor=V.+O.+Paavilainenauthor=A.+Bisconteauthor=D.+Tamauthor=V.+T.+Phanauthor=S.+Romanovauthor=D.+Finkleauthor=J.+Shuauthor=V.+Patelauthor=T.+Tonauthor=X.+Liauthor=D.+G.+Loughheadauthor=P.+A.+Nunnauthor=D.+E.+Karrauthor=M.+E.+Gerritsenauthor=J.+O.+Funkauthor=T.+D.+Owensauthor=E.+Vernerauthor=K.+A.+Brameldauthor=R.+J.+Hillauthor=D.+M.+Goldsteinauthor=J.+Taunton&title=Prolonged+and+tunable+residence+time+using+reversible+covalent+kinase+inhibitors&doi=10.1038%2Fnchembio.1817"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Prolonged and tunable residence time using reversible covalent kinase inhibitors</span></div><div class="casAuthors">Bradshaw, J. Michael; McFarland, Jesse M.; Paavilainen, Ville O.; Bisconte, Angelina; Tam, Danny; Phan, Vernon T.; Romanov, Sergei; Finkle, David; Shu, Jin; Patel, Vaishali; Ton, Tony; Li, Xiaoyan; Loughhead, David G.; Nunn, Philip A.; Karr, Dane E.; Gerritsen, Mary E.; Funk, Jens Oliver; Owens, Timothy D.; Verner, Erik; Brameld, Ken A.; Hill, Ronald J.; Goldstein, David M.; Taunton, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">525-531</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Drugs with prolonged on-target residence times often show superior efficacy, yet general strategies for optimizing drug-target residence time are lacking.  Here the authors made progress toward this elusive goal by targeting a noncatalytic cysteine in Bruton's tyrosine kinase (BTK) with reversible covalent inhibitors.  Using an inverted orientation of the cysteine-reactive cyanoacrylamide electrophile, the authors identified potent and selective BTK inhibitors that demonstrated biochem. residence times spanning from minutes to 7 d.  An inverted cyanoacrylamide with prolonged residence time in vivo remained bound to BTK for more than 18 h after clearance from the circulation.  The inverted cyanoacrylamide strategy was further used to discover fibroblast growth factor receptor (FGFR) kinase inhibitors with residence times of several days, demonstrating the generalizability of the approach.  Targeting of noncatalytic cysteines with inverted cyanoacrylamides may serve as a broadly applicable platform that facilitates 'residence time by design', the ability to modulate and improve the duration of target engagement in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXCpNprhn6kLVg90H21EOLACvtfcHk0lhtaPSLLWzEIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFeju7%252FE&md5=85a73d9ecd62695d03166f7009c68dd8</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1817&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1817%26sid%3Dliteratum%253Aachs%26aulast%3DBradshaw%26aufirst%3DJ.%2BM.%26aulast%3DMcFarland%26aufirst%3DJ.%2BM.%26aulast%3DPaavilainen%26aufirst%3DV.%2BO.%26aulast%3DBisconte%26aufirst%3DA.%26aulast%3DTam%26aufirst%3DD.%26aulast%3DPhan%26aufirst%3DV.%2BT.%26aulast%3DRomanov%26aufirst%3DS.%26aulast%3DFinkle%26aufirst%3DD.%26aulast%3DShu%26aufirst%3DJ.%26aulast%3DPatel%26aufirst%3DV.%26aulast%3DTon%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLoughhead%26aufirst%3DD.%2BG.%26aulast%3DNunn%26aufirst%3DP.%2BA.%26aulast%3DKarr%26aufirst%3DD.%2BE.%26aulast%3DGerritsen%26aufirst%3DM.%2BE.%26aulast%3DFunk%26aufirst%3DJ.%2BO.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26aulast%3DVerner%26aufirst%3DE.%26aulast%3DBrameld%26aufirst%3DK.%2BA.%26aulast%3DHill%26aufirst%3DR.%2BJ.%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26aulast%3DTaunton%26aufirst%3DJ.%26atitle%3DProlonged%2520and%2520tunable%2520residence%2520time%2520using%2520reversible%2520covalent%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2015%26volume%3D11%26spage%3D525%26epage%3D531%26doi%3D10.1038%2Fnchembio.1817" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petter, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitty, A.</span></span> <span> </span><span class="NLM_article-title">The resurgence of covalent drugs</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">307</span>, <span class="refDoi"> DOI: 10.1038/nrd3410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1038%2Fnrd3410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=21455239" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=307&author=J.+Singhauthor=R.+C.+Petterauthor=T.+A.+Baillieauthor=A.+Whitty&title=The+resurgence+of+covalent+drugs&doi=10.1038%2Fnrd3410"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">The resurgence of covalent drugs</span></div><div class="casAuthors">Singh, Juswinder; Petter, Russell C.; Baillie, Thomas A.; Whitty, Adrian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">307-317</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Covalent drugs haveproved to be successful therapies for various indications, but largely owing to safety concerns, they are rarely considered when initiating a target-directed drug discovery project.  There is a need to reassess this important class of drugs, and to reconcile the discordance between the historic success of covalent drugs and the reluctance of most drug discovery teams to include them in their armamentarium.  This Review surveys the prevalence and pharmacol. advantages of covalent drugs, discusses how potential risks and challenges may be addressed through innovative design, and presents the broad opportunities provided by targeted covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreDCEmORV_NbVg90H21EOLACvtfcHk0lguNAR4yQPISQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D&md5=2190289081e151416c097be4a5b04460</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1038%2Fnrd3410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3410%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26aulast%3DWhitty%26aufirst%3DA.%26atitle%3DThe%2520resurgence%2520of%2520covalent%2520drugs%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D307%26doi%3D10.1038%2Fnrd3410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Lucca, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batt, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaudoin Bertrand, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rampulla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Discenza, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obermeier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vickery, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marathe, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebben, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muckelbauer, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattoli, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kukral, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-Cid, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrish, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tino, J. A.</span></span> <span> </span><span class="NLM_article-title">Small molecule reversible inhibitors of Bruton’s tyrosine kinase (BTK): Structure–activity relationships leading to the identification of 7-(2-hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide (BMS-935177)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">7915</span>– <span class="NLM_lpage">7935</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00722</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00722" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlCrsL3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7915-7935&author=G.+V.+De+Luccaauthor=Q.+Shiauthor=Q.+Liuauthor=D.+G.+Battauthor=M.+Beaudoin+Bertrandauthor=R.+Rampullaauthor=A.+Mathurauthor=L.+Discenzaauthor=C.+D%E2%80%99Arienzoauthor=J.+Daiauthor=M.+Obermeierauthor=R.+Vickeryauthor=Y.+Zhangauthor=Z.+Yangauthor=P.+Maratheauthor=A.+J.+Tebbenauthor=J.+K.+Muckelbauerauthor=C.+J.+Changauthor=H.+Zhangauthor=K.+Gilloolyauthor=T.+Taylorauthor=M.+A.+Pattoliauthor=S.+Skalaauthor=D.+W.+Kukralauthor=K.+W.+McIntyreauthor=L.+Salter-Cidauthor=A.+Furaauthor=J.+R.+Burkeauthor=J.+C.+Barrishauthor=P.+H.+Carterauthor=J.+A.+Tino&title=Small+molecule+reversible+inhibitors+of+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29%3A+Structure%E2%80%93activity+relationships+leading+to+the+identification+of+7-%282-hydroxypropan-2-yl%29-4-%5B2-methyl-3-%284-oxo-3%2C4-dihydroquinazolin-3-yl%29phenyl%5D-9H-carbazole-1-carboxamide+%28BMS-935177%29&doi=10.1021%2Facs.jmedchem.6b00722"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Reversible Inhibitors of Bruton's Tyrosine Kinase (BTK): Structure-Activity Relationships Leading to the Identification of 7-(2-Hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide (BMS-935177)</span></div><div class="casAuthors">De Lucca, George V.; Shi, Qing; Liu, Qingjie; Batt, Douglas G.; Beaudoin Bertrand, Myra; Rampulla, Rick; Mathur, Arvind; Discenza, Lorell; D'Arienzo, Celia; Dai, Jun; Obermeier, Mary; Vickery, Rodney; Zhang, Yingru; Yang, Zheng; Marathe, Punit; Tebben, Andrew J.; Muckelbauer, Jodi K.; Chang, ChiehYing J.; Zhang, Huiping; Gillooly, Kathleen; Taylor, Tracy; Pattoli, Mark A.; Skala, Stacey; Kukral, Daniel W.; McIntyre, Kim W.; Salter-Cid, Luisa; Fura, Aberra; Burke, James R.; Barrish, Joel C.; Carter, Percy H.; Tino, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7915-7935</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK) belongs to the TEC family of nonreceptor tyrosine kinases and plays a crit. role in multiple cell types responsible for numerous autoimmune diseases.  This article will detail the structure-activity relationships (SARs) leading to a novel second generation series of potent and selective reversible carbazole inhibitors of BTK.  With an excellent pharmacokinetic profile as well as demonstrated in vivo activity and an acceptable safety profile, 7-(2-hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide 6 (BMS-935177) was selected to advance into clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1HUwZaRn_w7Vg90H21EOLACvtfcHk0lguNAR4yQPISQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlCrsL3M&md5=7c7ec1a52121c541753c045c1cbf758b</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00722%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BLucca%26aufirst%3DG.%2BV.%26aulast%3DShi%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DBatt%26aufirst%3DD.%2BG.%26aulast%3DBeaudoin%2BBertrand%26aufirst%3DM.%26aulast%3DRampulla%26aufirst%3DR.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DDiscenza%26aufirst%3DL.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DObermeier%26aufirst%3DM.%26aulast%3DVickery%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DTebben%26aufirst%3DA.%2BJ.%26aulast%3DMuckelbauer%26aufirst%3DJ.%2BK.%26aulast%3DChang%26aufirst%3DC.%2BJ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DGillooly%26aufirst%3DK.%26aulast%3DTaylor%26aufirst%3DT.%26aulast%3DPattoli%26aufirst%3DM.%2BA.%26aulast%3DSkala%26aufirst%3DS.%26aulast%3DKukral%26aufirst%3DD.%2BW.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DSalter-Cid%26aufirst%3DL.%26aulast%3DFura%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DTino%26aufirst%3DJ.%2BA.%26atitle%3DSmall%2520molecule%2520reversible%2520inhibitors%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%253A%2520Structure%25E2%2580%2593activity%2520relationships%2520leading%2520to%2520the%2520identification%2520of%25207-%25282-hydroxypropan-2-yl%2529-4-%255B2-methyl-3-%25284-oxo-3%252C4-dihydroquinazolin-3-yl%2529phenyl%255D-9H-carbazole-1-carboxamide%2520%2528BMS-935177%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D7915%26epage%3D7935%26doi%3D10.1021%2Facs.jmedchem.6b00722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahia, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silakari, O.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of interleukin-2 inducible T-cell kinase as potential therapeutic candidates for the treatment of various inflammatory disease conditions</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">574</span>– <span class="NLM_lpage">588</span>, <span class="refDoi"> DOI: 10.1016/j.ejps.2012.07.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1016%2Fj.ejps.2012.07.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=22820564" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhtl2kurrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2012&pages=574-588&author=M.+Kaurauthor=M.+S.+Bahiaauthor=O.+Silakari&title=Inhibitors+of+interleukin-2+inducible+T-cell+kinase+as+potential+therapeutic+candidates+for+the+treatment+of+various+inflammatory+disease+conditions&doi=10.1016%2Fj.ejps.2012.07.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of interleukin-2 inducible T-cell kinase as potential therapeutic candidates for the treatment of various inflammatory disease conditions</span></div><div class="casAuthors">Kaur, Maninder; Bahia, Malkeet Singh; Silakari, Om</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">574-588</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Interleukin-2 inducible T-cell kinase (ITK), a member of Tec family of non-receptor protein tyrosine kinases plays a domineering role in the T-cell development, differentiation and prodn. of pro-inflammatory cytokines such as IL-2, IL-4, IL-5, IL-10, IL-13 and IL-17.  This kinase is also an important contributor in Th 2 cells mediated autoimmune and allergic disease conditions, e.g. psoriasis, atopic dermatitis and allergic asthma.  ITK modulates T-cell signaling by activating PLCγ1 and regulating the extent of Ca2+ flux.  It contributes in prolific T-cell responses by maintaining cellular adhesion and cytoskeleton reorganization via actin polymn. and integrin binding.  This review article describes the structure of ITK and its role in T-cell signaling.  In addn. to this, data regarding small mol. inhibitors of ITK has also been reviewed from different papers and patents published.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZRRvOoVByI7Vg90H21EOLACvtfcHk0lguNAR4yQPISQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhtl2kurrO&md5=5944bca7430769906289d96b3b067498</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2012.07.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2012.07.013%26sid%3Dliteratum%253Aachs%26aulast%3DKaur%26aufirst%3DM.%26aulast%3DBahia%26aufirst%3DM.%2BS.%26aulast%3DSilakari%26aufirst%3DO.%26atitle%3DInhibitors%2520of%2520interleukin-2%2520inducible%2520T-cell%2520kinase%2520as%2520potential%2520therapeutic%2520candidates%2520for%2520the%2520treatment%2520of%2520various%2520inflammatory%2520disease%2520conditions%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2012%26volume%3D47%26spage%3D574%26epage%3D588%26doi%3D10.1016%2Fj.ejps.2012.07.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lo, H. Y.</span></span> <span> </span><span class="NLM_article-title">Itk inhibitors: a patent review</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">459</span>– <span class="NLM_lpage">469</span>, <span class="refDoi"> DOI: 10.1517/13543771003674409</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1517%2F13543771003674409" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=20218931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjslamu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=459-469&author=H.+Y.+Lo&title=Itk+inhibitors%3A+a+patent+review&doi=10.1517%2F13543771003674409"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Itk inhibitors: a patent review</span></div><div class="casAuthors">Lo, Ho Yin</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">459-469</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Importance of field: IL-2 inducible T-cell kinase (Itk) is a non-receptor tyrosine kinase of the Tec family.  It plays an important role in T cell signaling and the prodn. of various pro-inflammatory cytokines such as IL-2, IL-4, IL-5, IL-10 and IL-13.  Inhibition of Itk has been a target for the treatment of diseases related to inflammation disorders such as psoriasis and allergic asthma.  Rich resources on the structural information for Itk made discovery of novel selective Itk inhibitors blossom in the past decade.  Areas covered in this review: In this report, distinct structural classes of specific Itk inhibitors are summarized and their in vitro/in vivo properties are discussed.  What the reader will gain: A summary of 21 patents including 16 different chem. structure classes of Itk inhibitors.  The in vivo efficacies of some of the inhibitors in animal models are also discussed.  Take home message: Although some of the inhibitors show efficacy in different animal models, which implies potential for therapeutic use in human, there is not yet a chem. entity reported in clin. trials.  The prospects for Itk inhibitors will rely on the quality of the compd. and the validity of the target in patients within the selected therapeutic area.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKrKjXoATESLVg90H21EOLACvtfcHk0lgXP7CFY7AEBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjslamu7g%253D&md5=48ab6a3192e5805860d9f97a7d97de94</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1517%2F13543771003674409&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543771003674409%26sid%3Dliteratum%253Aachs%26aulast%3DLo%26aufirst%3DH.%2BY.%26atitle%3DItk%2520inhibitors%253A%2520a%2520patent%2520review%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2010%26volume%3D20%26spage%3D459%26epage%3D469%26doi%3D10.1517%2F13543771003674409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Norman, P.</span></span> <span> </span><span class="NLM_article-title">Inducible tyrosine kinase inhibitors: a review of the patent literature (2010 – 2013)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">979</span>– <span class="NLM_lpage">991</span>, <span class="refDoi"> DOI: 10.1517/13543776.2014.936381</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1517%2F13543776.2014.936381" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=24990480" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlKjtb3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=979-991&author=P.+Norman&title=Inducible+tyrosine+kinase+inhibitors%3A+a+review+of+the+patent+literature+%282010+%E2%80%93+2013%29&doi=10.1517%2F13543776.2014.936381"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Inducible tyrosine kinase inhibitors: a review of the patent literature (2010 - 2013)</span></div><div class="casAuthors">Norman, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">979-991</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: The non-receptor tyrosine kinase, inducible tyrosine kinase (Itk), plays an important role in thymus(T)-cell signalling and the prodn. of pro-inflammatory cytokines.  Itk, and the other Tec family members, Rlk and Tec, are viewed as attractive drug targets for new agents for the treatment of autoimmune and inflammatory diseases.  Interest in Itk inhibitors is still modest compared to other kinases such as the Janus kinase (JAK) family or Syk.  Areas covered: This article reviews the patent filings published from Jan. 2010 to Apr. 2014 that claim Itk inhibitors.  It first considers those applications that claim selective, or apparently selective, Itk inhibitors.  It then considers those applications that claim less-selective Itk inhibitors.  The recent interest in irreversible Itk inhibitors is also discussed.  Expert opinion: There is a difference of opinion as to the preferred utility for Itk inhibitors.  Progress has been made in designing selective Itk inhibitors but little clin. progress.  Until clin. data are available, it remains difficult to assess how well Itk inhibitors compare with JAK inhibitors as potential treatments for rheumatoid arthritis.  However, animal data suggest that irreversible Itk inhibitors could be useful in treating asthma, whereas dual Itk inhibitors may have more utility in treating rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWRBj5BlBRoLVg90H21EOLACvtfcHk0lgXP7CFY7AEBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlKjtb3I&md5=b48c10504c7bb8958c5519b1397b496a</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1517%2F13543776.2014.936381&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2014.936381%26sid%3Dliteratum%253Aachs%26aulast%3DNorman%26aufirst%3DP.%26atitle%3DInducible%2520tyrosine%2520kinase%2520inhibitors%253A%2520a%2520review%2520of%2520the%2520patent%2520literature%2520%25282010%2520%25E2%2580%2593%25202013%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2014%26volume%3D24%26spage%3D979%26epage%3D991%26doi%3D10.1517%2F13543776.2014.936381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sahu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">August, A.</span></span> <span> </span><span class="NLM_article-title">ITK inhibitors in inflammation and immune-mediated disorders</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">690</span>– <span class="NLM_lpage">703</span>, <span class="refDoi"> DOI: 10.2174/156802609789044443</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.2174%2F156802609789044443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=19689375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFehsLnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=690-703&author=N.+Sahuauthor=A.+August&title=ITK+inhibitors+in+inflammation+and+immune-mediated+disorders&doi=10.2174%2F156802609789044443"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">ITK inhibitors in inflammation and immune-mediated disorders</span></div><div class="casAuthors">Sahu, Nisebita; August, Avery</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">690-703</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Interleukin-2-inducible T cell kinase (ITK) is a non-receptor tyrosine kinase expressed in T cells, NKT cells and mast cells which plays a crucial role in regulating the T cell receptor (TCR), CD28, CD2, chemokine receptor CXCR4, and FcεR-mediated signaling pathways.  In T cells, ITK is an important mediator for actin reorganization, activation of PLCγ, mobilization of calcium, and activation of the NFAT transcription factor.  ITK plays an important role in the secretion of IL-2, but more critically, also has a pivotal role in the secretion of Th2 cytokines, IL-4, IL-5 and IL-13.  As such, ITK has been shown to regulate the development of effective Th2 response during allergic asthma as well as infections by parasitic worms.  This ability of ITK to regulate Th2 responses, along with its pattern of expression, has led to the proposal that it would represent an excellent target for Th2-mediated inflammation.  We discuss here the possibilities and pitfalls of targeting ITK for inflammatory disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQ4v3nHF04CLVg90H21EOLACvtfcHk0lgXP7CFY7AEBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFehsLnM&md5=75c4ecb794cfa96eda65b6ed8841571e</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.2174%2F156802609789044443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802609789044443%26sid%3Dliteratum%253Aachs%26aulast%3DSahu%26aufirst%3DN.%26aulast%3DAugust%26aufirst%3DA.%26atitle%3DITK%2520inhibitors%2520in%2520inflammation%2520and%2520immune-mediated%2520disorders%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2009%26volume%3D9%26spage%3D690%26epage%3D703%26doi%3D10.2174%2F156802609789044443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andreotti, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartzberg, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berg, L. J.</span></span> <span> </span><span class="NLM_article-title">T-cell signaling regulated by the Tec family kinase, Itk</span>. <i>Cold Spring Harbor Perspect. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">a002287</span>, <span class="refDoi"> DOI: 10.1101/cshperspect.a002287</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1101%2Fcshperspect.a002287" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2010&pages=a002287&author=A.+H.+Andreottiauthor=P.+L.+Schwartzbergauthor=R.+E.+Josephauthor=L.+J.+Berg&title=T-cell+signaling+regulated+by+the+Tec+family+kinase%2C+Itk&doi=10.1101%2Fcshperspect.a002287"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1101%2Fcshperspect.a002287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fcshperspect.a002287%26sid%3Dliteratum%253Aachs%26aulast%3DAndreotti%26aufirst%3DA.%2BH.%26aulast%3DSchwartzberg%26aufirst%3DP.%2BL.%26aulast%3DJoseph%26aufirst%3DR.%2BE.%26aulast%3DBerg%26aufirst%3DL.%2BJ.%26atitle%3DT-cell%2520signaling%2520regulated%2520by%2520the%2520Tec%2520family%2520kinase%252C%2520Itk%26jtitle%3DCold%2520Spring%2520Harbor%2520Perspect.%2520Biol.%26date%3D2010%26volume%3D2%26spage%3Da002287%26doi%3D10.1101%2Fcshperspect.a002287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senger, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collier, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burch, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eastham-Anderson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staton, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Havnar, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaochico, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riol-Blanco, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choy, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arron, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenzie, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghilardi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ismaili, M. H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVoss, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrin, A. A.</span></span> <span> </span><span class="NLM_article-title">Inhibition of the kinase ITK in a mouse model of asthma reduces cell death and fails to inhibit the inflammatory response</span>. <i>Sci. Signaling</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">ra122</span>– <span class="NLM_lpage">ra122</span>, <span class="refDoi"> DOI: 10.1126/scisignal.aab0949</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1126%2Fscisignal.aab0949" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=26628680" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2015&pages=ra122-ra122&author=Y.+Sunauthor=I.+Pengauthor=J.+D.+Websterauthor=E.+Sutoauthor=J.+Leschauthor=X.+Wuauthor=K.+Sengerauthor=G.+Francisauthor=K.+Barrettauthor=J.+L.+Collierauthor=J.+D.+Burchauthor=M.+Zhouauthor=Y.+Chenauthor=C.+Chanauthor=J.+Eastham-Andersonauthor=H.+Nguauthor=O.+Liauthor=T.+Statonauthor=C.+Havnarauthor=A.+Jaochicoauthor=J.+Jackmanauthor=S.+Jeetauthor=L.+Riol-Blancoauthor=L.+C.+Wuauthor=D.+F.+Choyauthor=J.+R.+Arronauthor=B.+S.+McKenzieauthor=N.+Ghilardiauthor=M.+H.+A.+Ismailiauthor=Z.+Peiauthor=J.+DeVossauthor=C.+D.+Austinauthor=W.+P.+Leeauthor=A.+A.+Zarrin&title=Inhibition+of+the+kinase+ITK+in+a+mouse+model+of+asthma+reduces+cell+death+and+fails+to+inhibit+the+inflammatory+response&doi=10.1126%2Fscisignal.aab0949"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1126%2Fscisignal.aab0949&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscisignal.aab0949%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DY.%26aulast%3DPeng%26aufirst%3DI.%26aulast%3DWebster%26aufirst%3DJ.%2BD.%26aulast%3DSuto%26aufirst%3DE.%26aulast%3DLesch%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DSenger%26aufirst%3DK.%26aulast%3DFrancis%26aufirst%3DG.%26aulast%3DBarrett%26aufirst%3DK.%26aulast%3DCollier%26aufirst%3DJ.%2BL.%26aulast%3DBurch%26aufirst%3DJ.%2BD.%26aulast%3DZhou%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DChan%26aufirst%3DC.%26aulast%3DEastham-Anderson%26aufirst%3DJ.%26aulast%3DNgu%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DO.%26aulast%3DStaton%26aufirst%3DT.%26aulast%3DHavnar%26aufirst%3DC.%26aulast%3DJaochico%26aufirst%3DA.%26aulast%3DJackman%26aufirst%3DJ.%26aulast%3DJeet%26aufirst%3DS.%26aulast%3DRiol-Blanco%26aufirst%3DL.%26aulast%3DWu%26aufirst%3DL.%2BC.%26aulast%3DChoy%26aufirst%3DD.%2BF.%26aulast%3DArron%26aufirst%3DJ.%2BR.%26aulast%3DMcKenzie%26aufirst%3DB.%2BS.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DIsmaili%26aufirst%3DM.%2BH.%2BA.%26aulast%3DPei%26aufirst%3DZ.%26aulast%3DDeVoss%26aufirst%3DJ.%26aulast%3DAustin%26aufirst%3DC.%2BD.%26aulast%3DLee%26aufirst%3DW.%2BP.%26aulast%3DZarrin%26aufirst%3DA.%2BA.%26atitle%3DInhibition%2520of%2520the%2520kinase%2520ITK%2520in%2520a%2520mouse%2520model%2520of%2520asthma%2520reduces%2520cell%2520death%2520and%2520fails%2520to%2520inhibit%2520the%2520inflammatory%2520response%26jtitle%3DSci.%2520Signaling%26date%3D2015%26volume%3D8%26spage%3Dra122%26epage%3Dra122%26doi%3D10.1126%2Fscisignal.aab0949" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferrara, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ben-Jebria, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">August, A.</span></span> <span> </span><span class="NLM_article-title">Reduced airway hyperresponsiveness and tracheal responses during allergic asthma in mice lacking tyrosine kinase inducible T-cell kinase</span>. <i>J. Allergy Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">780</span>– <span class="NLM_lpage">786</span>, <span class="refDoi"> DOI: 10.1016/j.jaci.2005.12.1330</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1016%2Fj.jaci.2005.12.1330" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=16630934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BD28Xjslels7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2006&pages=780-786&author=T.+J.+Ferraraauthor=C.+Muellerauthor=N.+Sahuauthor=A.+Ben-Jebriaauthor=A.+August&title=Reduced+airway+hyperresponsiveness+and+tracheal+responses+during+allergic+asthma+in+mice+lacking+tyrosine+kinase+inducible+T-cell+kinase&doi=10.1016%2Fj.jaci.2005.12.1330"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Reduced airway hyperresponsiveness and tracheal responses during allergic asthma in mice lacking tyrosine kinase inducible T-cell kinase</span></div><div class="casAuthors">Ferrara, Tanna J.; Mueller, Cynthia; Sahu, Nisebita; Ben-Jebria, Abdellaziz; August, Avery</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Allergy and Clinical Immunology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">780-786</span>CODEN:
                <span class="NLM_cas:coden">JACIBY</span>;
        ISSN:<span class="NLM_cas:issn">0091-6749</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Background: Patients with allergic asthma have symptoms of a predominant TH2 response, including airway eosinophilic inflammation and increased mucous prodn. in the lungs.  This accompanies increased airways responsiveness, which can be life threatening.  Because TH2 cells and cytokines have been implicated in contributing to these symptoms, pathways that control the development of these cells or that regulate their cytokine prodn. represent good targets for controlling this disease.  Objective: We have previously shown that mice lacking the tyrosine kinase inducible T-cell kinase (ITK) have drastically reduced airway inflammation in a model of allergic asthma.  However, it was not clear whether this translated into reduced airways hyperresponsiveness.  We have analyzed tracheal responsiveness and airways hyperresponsiveness of wild-type (WT) and ITK null mice during induction of exptl. allergic asthma.  Methods: Exptl. allergic asthma was induced in WT and ITK knockout mice.  Tracheal responses to carbachol, acetylcholine, and potassium chloride were analyzed.  Airways hyperresponsiveness to methacholine challenge was also analyzed in allergen-challenged mice, along with lung and bronchoalveolar lavage fluid TH2 cytokine message and protein.  Results: ITK null mice have reduced tracheal responses to cholinergic challenge in vitro before as well as after allergen challenge.  These mice also have reduced airways hyperresponsiveness in response to allergen challenge, which could be rescued by transferring WT splenocytes or purified WT CD4+ T cells.  This reduced airways response was preferentially accompanied by reduced expression of TH2 cytokines in the lungs.  Conclusion: Our results indicate that the tyrosine kinase ITK and its function in T cells represent an attractive target for antiasthmatic drugs.  Clin. implications: Modulating the expression or activity of ITK may be a novel strategy to block allergic airway inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq64IqAG_bfV7Vg90H21EOLACvtfcHk0ljd_O8eMHZJVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xjslels7k%253D&md5=2f1f14c05770b2c0eee0ffcd8fd1610b</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1016%2Fj.jaci.2005.12.1330&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaci.2005.12.1330%26sid%3Dliteratum%253Aachs%26aulast%3DFerrara%26aufirst%3DT.%2BJ.%26aulast%3DMueller%26aufirst%3DC.%26aulast%3DSahu%26aufirst%3DN.%26aulast%3DBen-Jebria%26aufirst%3DA.%26aulast%3DAugust%26aufirst%3DA.%26atitle%3DReduced%2520airway%2520hyperresponsiveness%2520and%2520tracheal%2520responses%2520during%2520allergic%2520asthma%2520in%2520mice%2520lacking%2520tyrosine%2520kinase%2520inducible%2520T-cell%2520kinase%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%26date%3D2006%26volume%3D117%26spage%3D780%26epage%3D786%26doi%3D10.1016%2Fj.jaci.2005.12.1330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oshida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obayashi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsui, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagata, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obayashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashiwabara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunji, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsujimoto, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katsunuma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akasawa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, H.</span></span> <span> </span><span class="NLM_article-title">Identification of highly expressed genes in peripheral blood T cells from patients with atopic dermatitis</span>. <i>Int. Arch. Allergy Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">327</span>– <span class="NLM_lpage">340</span>, <span class="refDoi"> DOI: 10.1159/000067589</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1159%2F000067589" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=12483038" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BD38XpsFKrsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2002&pages=327-340&author=Y.+Matsumotoauthor=T.+Oshidaauthor=I.+Obayashiauthor=Y.+Imaiauthor=K.+Matsuiauthor=N.+L.+Yoshidaauthor=N.+Nagataauthor=K.+Ogawaauthor=M.+Obayashiauthor=T.+Kashiwabaraauthor=S.+Gunjiauthor=T.+Nagasuauthor=Y.+Sugitaauthor=T.+Tanakaauthor=G.+Tsujimotoauthor=T.+Katsunumaauthor=A.+Akasawaauthor=H.+Saito&title=Identification+of+highly+expressed+genes+in+peripheral+blood+T+cells+from+patients+with+atopic+dermatitis&doi=10.1159%2F000067589"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Highly Expressed Genes in Peripheral Blood T cells from Patients with Atopic Dermatitis</span></div><div class="casAuthors">Matsumoto, Yoshiko; Oshida, Tadahilo; Obayashi, Izumi; Imai, Yukiho; Matsui, Keiko; Yoshida, Ning Lu; Nagata, Naoko; Ogawa, Kaoru; Obayashi, Masaya; Kashiwabara, Tomoko; Gunji, Shigemichi; Nagasu, Takeshi; Sugita, Yuji; Tanaka, Toshio; Tsujimoto, Gozoh; Katsunuma, Toshio; Akasawa, Akira; Saito, Hirohisa</div><div class="citationInfo"><span class="NLM_cas:title">International Archives of Allergy and Immunology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">327-340</span>CODEN:
                <span class="NLM_cas:coden">IAAIEG</span>;
        ISSN:<span class="NLM_cas:issn">1018-2438</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">Background: Anal. of genes that are differentially expressed in patients with atopic dermatitis (AD) and normal individuals will provide important information on the underlying mol. pathogenetic mechanisms of AD.  Methods: Transcript of freshly isolated peripheral blood T cells from 59 individuals were analyzed with a fluorescent differential display (FDD) method.  Ninety-two differentially expressed genes were identified in this manner.  Addnl., real-time quant. RT-PCR was employed to investigate the expression of the FDD-selected genes and also genes related to T cell function.  Results: A no. of genes, including CC chemokine receptor 4, T cell-specific tyrosine kinase (Emt/Itk), integrin β1, integrin α6, IQGAP1 and MAR/SAR DNA-binding protein (SATB1), were shown to be more highly expressed in patients with moderate and/or severe AD than in controls or patients with mild AD.  Because the products of these upregulated genes influence chemotaxis, adhesion, migration and Th2 polarization, it is suggested that in more severe AD, circulating T cells may function differently in this regard.  Several other genes, the role of which in T cell function is currently unknown, were also found to be differentially expressed in AD.  These included the heat shock protein 40 and vasopressin-activated calcium-mobilizing receptor 1.  Conclusion: The upregulated genes identified in this work may serve as useful markers for moderate to severe AD as opposed to normal or mild AD and also as markers indicating progression to more severe AD.  Further functional characterization will provide a better understanding of the pathophysiol. of circulating T cells in AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcEc0xdnxw7bVg90H21EOLACvtfcHk0ljd_O8eMHZJVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XpsFKrsbY%253D&md5=3a8769c4279651610c56109905809c7d</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1159%2F000067589&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000067589%26sid%3Dliteratum%253Aachs%26aulast%3DMatsumoto%26aufirst%3DY.%26aulast%3DOshida%26aufirst%3DT.%26aulast%3DObayashi%26aufirst%3DI.%26aulast%3DImai%26aufirst%3DY.%26aulast%3DMatsui%26aufirst%3DK.%26aulast%3DYoshida%26aufirst%3DN.%2BL.%26aulast%3DNagata%26aufirst%3DN.%26aulast%3DOgawa%26aufirst%3DK.%26aulast%3DObayashi%26aufirst%3DM.%26aulast%3DKashiwabara%26aufirst%3DT.%26aulast%3DGunji%26aufirst%3DS.%26aulast%3DNagasu%26aufirst%3DT.%26aulast%3DSugita%26aufirst%3DY.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DTsujimoto%26aufirst%3DG.%26aulast%3DKatsunuma%26aufirst%3DT.%26aulast%3DAkasawa%26aufirst%3DA.%26aulast%3DSaito%26aufirst%3DH.%26atitle%3DIdentification%2520of%2520highly%2520expressed%2520genes%2520in%2520peripheral%2520blood%2520T%2520cells%2520from%2520patients%2520with%2520atopic%2520dermatitis%26jtitle%3DInt.%2520Arch.%2520Allergy%2520Immunol.%26date%3D2002%26volume%3D129%26spage%3D327%26epage%3D340%26doi%3D10.1159%2F000067589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Charrier, J.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knegtel, R. M. A.</span></span> <span> </span><span class="NLM_article-title">Advances in the design of ITK inhibitors</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">369</span>– <span class="NLM_lpage">381</span>, <span class="refDoi"> DOI: 10.1517/17460441.2013.769520</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1517%2F17460441.2013.769520" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=369-381&author=J.-D.+Charrierauthor=R.+M.+A.+Knegtel&title=Advances+in+the+design+of+ITK+inhibitors&doi=10.1517%2F17460441.2013.769520"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1517%2F17460441.2013.769520&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2013.769520%26sid%3Dliteratum%253Aachs%26aulast%3DCharrier%26aufirst%3DJ.-D.%26aulast%3DKnegtel%26aufirst%3DR.%2BM.%2BA.%26atitle%3DAdvances%2520in%2520the%2520design%2520of%2520ITK%2520inhibitors%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2013%26volume%3D8%26spage%3D369%26epage%3D381%26doi%3D10.1517%2F17460441.2013.769520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Das, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moquin, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spergel, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuster, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Day, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penhallow, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doweyko, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamath, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marathe, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanner, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodd, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrish, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wityak, J.</span></span> <span> </span><span class="NLM_article-title">Discovery and SAR of 2-amino-5-(thioaryl)thiazoles as potent and selective Itk inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">3706</span>– <span class="NLM_lpage">3712</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2006.04.060</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1016%2Fj.bmcl.2006.04.060" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=3706-3712&author=J.+Dasauthor=J.+A.+Furchauthor=C.+Liuauthor=R.+V.+Moquinauthor=J.+Linauthor=S.+H.+Spergelauthor=K.+W.+McIntyreauthor=D.+J.+Shusterauthor=K.+D.+O%E2%80%99Dayauthor=B.+Penhallowauthor=C.-Y.+Hungauthor=A.+M.+Doweykoauthor=A.+Kamathauthor=H.+Zhangauthor=P.+Maratheauthor=S.+B.+Kannerauthor=T.-A.+Linauthor=J.+H.+Doddauthor=J.+C.+Barrishauthor=J.+Wityak&title=Discovery+and+SAR+of+2-amino-5-%28thioaryl%29thiazoles+as+potent+and+selective+Itk+inhibitors&doi=10.1016%2Fj.bmcl.2006.04.060"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.04.060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.04.060%26sid%3Dliteratum%253Aachs%26aulast%3DDas%26aufirst%3DJ.%26aulast%3DFurch%26aufirst%3DJ.%2BA.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DMoquin%26aufirst%3DR.%2BV.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DSpergel%26aufirst%3DS.%2BH.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DShuster%26aufirst%3DD.%2BJ.%26aulast%3DO%25E2%2580%2599Day%26aufirst%3DK.%2BD.%26aulast%3DPenhallow%26aufirst%3DB.%26aulast%3DHung%26aufirst%3DC.-Y.%26aulast%3DDoweyko%26aufirst%3DA.%2BM.%26aulast%3DKamath%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DKanner%26aufirst%3DS.%2BB.%26aulast%3DLin%26aufirst%3DT.-A.%26aulast%3DDodd%26aufirst%3DJ.%2BH.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DWityak%26aufirst%3DJ.%26atitle%3DDiscovery%2520and%2520SAR%2520of%25202-amino-5-%2528thioaryl%2529thiazoles%2520as%2520potent%2520and%2520selective%2520Itk%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D3706%26epage%3D3712%26doi%3D10.1016%2Fj.bmcl.2006.04.060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burch, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVoss, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldsmith, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ismaili, M. H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortwine, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrin, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEwan, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barker, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellebrandt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kordt, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuen, P.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, Z.</span></span> <span> </span><span class="NLM_article-title">Tetrahydroindazoles as interleukin-2 inducible T-Cell kinase inhibitors. part II. Second-generation analogues with enhanced potency, selectivity, and pharmacodynamic modulation in vivo</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">3806</span>– <span class="NLM_lpage">3816</span>, <span class="refDoi"> DOI: 10.1021/jm501998m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501998m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlvVaktbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=3806-3816&author=J.+D.+Burchauthor=K.+Barrettauthor=Y.+Chenauthor=J.+DeVossauthor=C.+Eigenbrotauthor=R.+Goldsmithauthor=M.+H.+A.+Ismailiauthor=K.+Lauauthor=Z.+Linauthor=D.+F.+Ortwineauthor=A.+A.+Zarrinauthor=P.+A.+McEwanauthor=J.+J.+Barkerauthor=C.+Ellebrandtauthor=D.+Kordtauthor=D.+B.+Steinauthor=X.+Wangauthor=Y.+Chenauthor=B.+Huauthor=X.+Xuauthor=P.-W.+Yuenauthor=Y.+Zhangauthor=Z.+Pei&title=Tetrahydroindazoles+as+interleukin-2+inducible+T-Cell+kinase+inhibitors.+part+II.+Second-generation+analogues+with+enhanced+potency%2C+selectivity%2C+and+pharmacodynamic+modulation+in+vivo&doi=10.1021%2Fjm501998m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Tetrahydroindazoles as Interleukin-2 Inducible T-Cell Kinase Inhibitors. Part II. Second-Generation Analogues with Enhanced Potency, Selectivity, and Pharmacodynamic Modulation in Vivo</span></div><div class="casAuthors">Burch, Jason D.; Barrett, Kathy; Chen, Yuan; DeVoss, Jason; Eigenbrot, Charles; Goldsmith, Richard; Ismaili, M. Hicham A.; Lau, Kevin; Lin, Zhonghua; Ortwine, Daniel F.; Zarrin, Ali A.; McEwan, Paul A.; Barker, John J.; Ellebrandt, Claire; Kordt, Daniel; Stein, Daniel B.; Wang, Xiaolu; Chen, Yong; Hu, Baihua; Xu, Xiaofeng; Yuen, Po-Wai; Zhang, Yamin; Pei, Zhonghua</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3806-3816</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The medicinal chem. community has directed considerable efforts toward the discovery of selective inhibitors of interleukin-2 inducible T-cell kinase (ITK), given its role in T-cell signaling downstream of the T-cell receptor (TCR) and the implications of this target for inflammatory disorders such as asthma.  The authors have previously disclosed a structure- and property-guided lead optimization effort which resulted in the discovery of a new series of tetrahydroindazole-contg. selective ITK inhibitors.  Herein the authors disclose further optimization of this series that resulted in further potency improvements, reduced off-target receptor binding liabilities, and reduced cytotoxicity.  Specifically, the authors have identified a correlation between the basicity of solubilizing elements in the ITK inhibitors and off-target antiproliferative effects, which was exploited to reduce cytotoxicity while maintaining kinase selectivity.  Optimized analogs, e.g. I, were shown to reduce IL-2 and IL-13 prodn. in vivo following oral or i.p. dosing in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9z-34VWYnsbVg90H21EOLACvtfcHk0lhbmYSbmnKgSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlvVaktbo%253D&md5=59a2cd1c2c9d368f9b49344af9b75545</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1021%2Fjm501998m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501998m%26sid%3Dliteratum%253Aachs%26aulast%3DBurch%26aufirst%3DJ.%2BD.%26aulast%3DBarrett%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DDeVoss%26aufirst%3DJ.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DGoldsmith%26aufirst%3DR.%26aulast%3DIsmaili%26aufirst%3DM.%2BH.%2BA.%26aulast%3DLau%26aufirst%3DK.%26aulast%3DLin%26aufirst%3DZ.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DZarrin%26aufirst%3DA.%2BA.%26aulast%3DMcEwan%26aufirst%3DP.%2BA.%26aulast%3DBarker%26aufirst%3DJ.%2BJ.%26aulast%3DEllebrandt%26aufirst%3DC.%26aulast%3DKordt%26aufirst%3DD.%26aulast%3DStein%26aufirst%3DD.%2BB.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DB.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DYuen%26aufirst%3DP.-W.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DPei%26aufirst%3DZ.%26atitle%3DTetrahydroindazoles%2520as%2520interleukin-2%2520inducible%2520T-Cell%2520kinase%2520inhibitors.%2520part%2520II.%2520Second-generation%2520analogues%2520with%2520enhanced%2520potency%252C%2520selectivity%252C%2520and%2520pharmacodynamic%2520modulation%2520in%2520vivo%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D3806%26epage%3D3816%26doi%3D10.1021%2Fjm501998m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McLean, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaidi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dharanipragada, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jurcak, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillespy, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musick, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrague, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peppard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smicker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duguid, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parkar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fordham, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kominos, D.</span></span> <span> </span><span class="NLM_article-title">X-ray crystallographic structure-based design of selective thienopyrazole inhibitors for interleukin-2-inducible tyrosine kinase</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">3296</span>– <span class="NLM_lpage">3300</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.03.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1016%2Fj.bmcl.2012.03.016" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=3296-3300&author=L.+R.+McLeanauthor=Y.+Zhangauthor=N.+Zaidiauthor=X.+Biauthor=R.+Wangauthor=R.+Dharanipragadaauthor=J.+G.+Jurcakauthor=T.+A.+Gillespyauthor=Z.+Zhaoauthor=K.+Y.+Musickauthor=Y.-M.+Choiauthor=M.+Barragueauthor=J.+Peppardauthor=M.+Smickerauthor=M.+Duguidauthor=A.+Parkarauthor=J.+Fordhamauthor=D.+Kominos&title=X-ray+crystallographic+structure-based+design+of+selective+thienopyrazole+inhibitors+for+interleukin-2-inducible+tyrosine+kinase&doi=10.1016%2Fj.bmcl.2012.03.016"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.03.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.03.016%26sid%3Dliteratum%253Aachs%26aulast%3DMcLean%26aufirst%3DL.%2BR.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZaidi%26aufirst%3DN.%26aulast%3DBi%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DDharanipragada%26aufirst%3DR.%26aulast%3DJurcak%26aufirst%3DJ.%2BG.%26aulast%3DGillespy%26aufirst%3DT.%2BA.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DMusick%26aufirst%3DK.%2BY.%26aulast%3DChoi%26aufirst%3DY.-M.%26aulast%3DBarrague%26aufirst%3DM.%26aulast%3DPeppard%26aufirst%3DJ.%26aulast%3DSmicker%26aufirst%3DM.%26aulast%3DDuguid%26aufirst%3DM.%26aulast%3DParkar%26aufirst%3DA.%26aulast%3DFordham%26aufirst%3DJ.%26aulast%3DKominos%26aufirst%3DD.%26atitle%3DX-ray%2520crystallographic%2520structure-based%2520design%2520of%2520selective%2520thienopyrazole%2520inhibitors%2520for%2520interleukin-2-inducible%2520tyrosine%2520kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D3296%26epage%3D3300%26doi%3D10.1016%2Fj.bmcl.2012.03.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kutach, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villaseñor, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belunis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lok, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, L.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deval, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novak, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnett, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuglstatter, A.</span></span> <span> </span><span class="NLM_article-title">Crystal Structures of IL-2-inducible T cell Kinase Complexed with Inhibitors: Insights into Rational Drug Design and Activity Regulation</span>. <i>Chem. Biol. Drug Des.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">154</span>– <span class="NLM_lpage">163</span>, <span class="refDoi"> DOI: 10.1111/j.1747-0285.2010.00993.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1111%2Fj.1747-0285.2010.00993.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=20545945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptleqs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2010&pages=154-163&author=A.+K.+Kutachauthor=A.+G.+Villase%C3%B1orauthor=D.+Lamauthor=C.+Belunisauthor=C.+Jansonauthor=S.+Lokauthor=L.-N.+Hongauthor=C.-M.+Liuauthor=J.+Devalauthor=T.+J.+Novakauthor=J.+W.+Barnettauthor=W.+Chuauthor=D.+Shawauthor=A.+Kuglstatter&title=Crystal+Structures+of+IL-2-inducible+T+cell+Kinase+Complexed+with+Inhibitors%3A+Insights+into+Rational+Drug+Design+and+Activity+Regulation&doi=10.1111%2Fj.1747-0285.2010.00993.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structures of IL-2-inducible T cell kinase complexed with inhibitors: insights into rational drug design and activity regulation</span></div><div class="casAuthors">Kutach, Alan K.; Villasenor, Armando G.; Lam, Diana; Belunis, Charles; Janson, Cheryl; Lok, Stephen; Hong, Li-Na; Liu, Chao-Min; Deval, Jerome; Novak, Thomas J.; Barnett, Jim W.; Chu, Wei; Shaw, David; Kuglstatter, Andreas</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">154-163</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">IL-2-inducible T cell kinase plays an essential role in T cell receptor signaling and is considered a drug target for the treatment of Th2-mediated inflammatory diseases.  By applying high-throughput protein engineering and crystn., we have detd. the x-ray crystal structures of IL-2-inducible T cell kinase in complex with its selective inhibitor BMS-509744 and the broad-spectrum kinase inhibitors sunitinib and RO5191614.  Sunitinib uniquely stabilizes IL-2-inducible T cell kinase in the helix C-in conformation by inducing side chain conformational changes in the ATP-binding site.  This preference of sunitinib to bind to an active kinase conformation is reflective of its broad-spectrum kinase activity.  BMS-509744 uniquely stabilizes the activation loop in a substrate-blocking inactive conformation, indicating that structural changes described for Src family kinases are also involved in the regulation of IL-2-inducible T cell kinase activity.  The obsd. BMS-509744 binding mode allows rationalization of structure-activity relationships reported for this inhibitor class and facilitates further structure-based drug design.  Sequence-based anal. of this binding mode provides guidance for the rational design of inhibitor selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXxFkkRUV7B7Vg90H21EOLACvtfcHk0lgAPleS7EobLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptleqs7Y%253D&md5=24b9225c52eff5cca4e295dad1c554c3</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1111%2Fj.1747-0285.2010.00993.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1747-0285.2010.00993.x%26sid%3Dliteratum%253Aachs%26aulast%3DKutach%26aufirst%3DA.%2BK.%26aulast%3DVillase%25C3%25B1or%26aufirst%3DA.%2BG.%26aulast%3DLam%26aufirst%3DD.%26aulast%3DBelunis%26aufirst%3DC.%26aulast%3DJanson%26aufirst%3DC.%26aulast%3DLok%26aufirst%3DS.%26aulast%3DHong%26aufirst%3DL.-N.%26aulast%3DLiu%26aufirst%3DC.-M.%26aulast%3DDeval%26aufirst%3DJ.%26aulast%3DNovak%26aufirst%3DT.%2BJ.%26aulast%3DBarnett%26aufirst%3DJ.%2BW.%26aulast%3DChu%26aufirst%3DW.%26aulast%3DShaw%26aufirst%3DD.%26aulast%3DKuglstatter%26aufirst%3DA.%26atitle%3DCrystal%2520Structures%2520of%2520IL-2-inducible%2520T%2520cell%2520Kinase%2520Complexed%2520with%2520Inhibitors%253A%2520Insights%2520into%2520Rational%2520Drug%2520Design%2520and%2520Activity%2520Regulation%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2010%26volume%3D76%26spage%3D154%26epage%3D163%26doi%3D10.1111%2Fj.1747-0285.2010.00993.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heifetz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aldeghi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacKinnon, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEwan, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brookfield, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chudyk, E. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bodkin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burch, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortwine, D. F.</span></span> <span> </span><span class="NLM_article-title">Fragment molecular orbital method applied to lead optimization of novel interleukin-2 inducible T-cell kinase (ITK) inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">4352</span>– <span class="NLM_lpage">4363</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00045</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00045" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjs12jt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=4352-4363&author=A.+Heifetzauthor=G.+Traniauthor=M.+Aldeghiauthor=C.+H.+MacKinnonauthor=P.+A.+McEwanauthor=F.+A.+Brookfieldauthor=E.+I.+Chudykauthor=M.+Bodkinauthor=Z.+Peiauthor=J.+D.+Burchauthor=D.+F.+Ortwine&title=Fragment+molecular+orbital+method+applied+to+lead+optimization+of+novel+interleukin-2+inducible+T-cell+kinase+%28ITK%29+inhibitors&doi=10.1021%2Facs.jmedchem.6b00045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment Molecular Orbital Method Applied to Lead Optimization of Novel Interleukin-2 Inducible T-Cell Kinase (ITK) Inhibitors</span></div><div class="casAuthors">Heifetz, Alexander; Trani, Giancarlo; Aldeghi, Matteo; MacKinnon, Colin H.; McEwan, Paul A.; Brookfield, Frederick A.; Chudyk, Ewa I.; Bodkin, Mike; Pei, Zhonghua; Burch, Jason D.; Ortwine, Daniel F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4352-4363</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of inducible T-cell kinase (ITK), a nonreceptor tyrosine kinase, may represent a novel treatment for allergic asthma.  In our previous reports, we described the discovery of sulfonylpyridine (SAP), benzothiazole (BZT), indazole (IND), and tetrahydroindazole (THI) series as novel ITK inhibitors and how computational tools such as dihedral scans and docking were used to support this process.  X-ray crystallog. and modeling were applied to provide essential insight into ITK-ligand interactions.  However, "visual inspection" traditionally used for the rationalization of protein-ligand affinity cannot always explain the full complexity of the mol. interactions.  The fragment MO (FMO) quantum-mech. (QM) method provides a complete list of the interactions formed between the ligand and protein that are often omitted from traditional structure-based descriptions.  FMO methodol. was successfully used as part of a rational structure-based drug design effort to improve the ITK potency of high-throughput screening hits, ultimately delivering ligands with potency in the subnanomolar range.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTGF0Bo-GJM7Vg90H21EOLACvtfcHk0lgAPleS7EobLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjs12jt70%253D&md5=b0958d9c29f7d61aadcc730ac00e8f90</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00045%26sid%3Dliteratum%253Aachs%26aulast%3DHeifetz%26aufirst%3DA.%26aulast%3DTrani%26aufirst%3DG.%26aulast%3DAldeghi%26aufirst%3DM.%26aulast%3DMacKinnon%26aufirst%3DC.%2BH.%26aulast%3DMcEwan%26aufirst%3DP.%2BA.%26aulast%3DBrookfield%26aufirst%3DF.%2BA.%26aulast%3DChudyk%26aufirst%3DE.%2BI.%26aulast%3DBodkin%26aufirst%3DM.%26aulast%3DPei%26aufirst%3DZ.%26aulast%3DBurch%26aufirst%3DJ.%2BD.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26atitle%3DFragment%2520molecular%2520orbital%2520method%2520applied%2520to%2520lead%2520optimization%2520of%2520novel%2520interleukin-2%2520inducible%2520T-cell%2520kinase%2520%2528ITK%2529%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D4352%26epage%3D4363%26doi%3D10.1021%2Facs.jmedchem.6b00045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alder, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Champigny, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deakin, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harling, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longstaff, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maxwell, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mooney, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scullion, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, O. M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, I. E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somers, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tame, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wayne, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woolven, J. M.</span></span> <span> </span><span class="NLM_article-title">Identification of a novel and selective series of Itk inhibitors via a template-hopping strategy</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">948</span>– <span class="NLM_lpage">952</span>, <span class="refDoi"> DOI: 10.1021/ml400206q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml400206q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=948-952&author=C.+M.+Alderauthor=M.+Amblerauthor=A.+J.+Campbellauthor=A.+C.+Champignyauthor=A.+M.+Deakinauthor=J.+D.+Harlingauthor=C.+A.+Harrisauthor=T.+Longstaffauthor=S.+Lynnauthor=A.+C.+Maxwellauthor=C.+J.+Mooneyauthor=C.+Scullionauthor=O.+M.+P.+Singhauthor=I.+E.+D.+Smithauthor=D.+O.+Somersauthor=C.+J.+Tameauthor=G.+Wayneauthor=C.+Wilsonauthor=J.+M.+Woolven&title=Identification+of+a+novel+and+selective+series+of+Itk+inhibitors+via+a+template-hopping+strategy&doi=10.1021%2Fml400206q"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1021%2Fml400206q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml400206q%26sid%3Dliteratum%253Aachs%26aulast%3DAlder%26aufirst%3DC.%2BM.%26aulast%3DAmbler%26aufirst%3DM.%26aulast%3DCampbell%26aufirst%3DA.%2BJ.%26aulast%3DChampigny%26aufirst%3DA.%2BC.%26aulast%3DDeakin%26aufirst%3DA.%2BM.%26aulast%3DHarling%26aufirst%3DJ.%2BD.%26aulast%3DHarris%26aufirst%3DC.%2BA.%26aulast%3DLongstaff%26aufirst%3DT.%26aulast%3DLynn%26aufirst%3DS.%26aulast%3DMaxwell%26aufirst%3DA.%2BC.%26aulast%3DMooney%26aufirst%3DC.%2BJ.%26aulast%3DScullion%26aufirst%3DC.%26aulast%3DSingh%26aufirst%3DO.%2BM.%2BP.%26aulast%3DSmith%26aufirst%3DI.%2BE.%2BD.%26aulast%3DSomers%26aufirst%3DD.%2BO.%26aulast%3DTame%26aufirst%3DC.%2BJ.%26aulast%3DWayne%26aufirst%3DG.%26aulast%3DWilson%26aufirst%3DC.%26aulast%3DWoolven%26aufirst%3DJ.%2BM.%26atitle%3DIdentification%2520of%2520a%2520novel%2520and%2520selective%2520series%2520of%2520Itk%2520inhibitors%2520via%2520a%2520template-hopping%2520strategy%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D948%26epage%3D952%26doi%3D10.1021%2Fml400206q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strattan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butchar, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thornton, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porcu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradshaw, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bisconte, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brameld, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funk, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubovsky, J. A.</span></span> <span> </span><span class="NLM_article-title">Targeting interleukin-2-inducible T-cell kinase (ITK) and resting lymphocyte kinase (RLK) using a novel covalent inhibitor PRN694</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>290</i></span>,  <span class="NLM_fpage">5960</span>– <span class="NLM_lpage">5978</span>, <span class="refDoi"> DOI: 10.1074/jbc.M114.614891</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1074%2Fjbc.M114.614891" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=290&publication_year=2015&pages=5960-5978&author=Y.+Zhongauthor=S.+Dongauthor=E.+Strattanauthor=L.+Renauthor=J.+P.+Butcharauthor=K.+Thorntonauthor=A.+Mishraauthor=P.+Porcuauthor=J.+M.+Bradshawauthor=A.+Bisconteauthor=T.+D.+Owensauthor=E.+Vernerauthor=K.+A.+Brameldauthor=J.+O.+Funkauthor=R.+J.+Hillauthor=A.+J.+Johnsonauthor=J.+A.+Dubovsky&title=Targeting+interleukin-2-inducible+T-cell+kinase+%28ITK%29+and+resting+lymphocyte+kinase+%28RLK%29+using+a+novel+covalent+inhibitor+PRN694&doi=10.1074%2Fjbc.M114.614891"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M114.614891&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M114.614891%26sid%3Dliteratum%253Aachs%26aulast%3DZhong%26aufirst%3DY.%26aulast%3DDong%26aufirst%3DS.%26aulast%3DStrattan%26aufirst%3DE.%26aulast%3DRen%26aufirst%3DL.%26aulast%3DButchar%26aufirst%3DJ.%2BP.%26aulast%3DThornton%26aufirst%3DK.%26aulast%3DMishra%26aufirst%3DA.%26aulast%3DPorcu%26aufirst%3DP.%26aulast%3DBradshaw%26aufirst%3DJ.%2BM.%26aulast%3DBisconte%26aufirst%3DA.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26aulast%3DVerner%26aufirst%3DE.%26aulast%3DBrameld%26aufirst%3DK.%2BA.%26aulast%3DFunk%26aufirst%3DJ.%2BO.%26aulast%3DHill%26aufirst%3DR.%2BJ.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DDubovsky%26aufirst%3DJ.%2BA.%26atitle%3DTargeting%2520interleukin-2-inducible%2520T-cell%2520kinase%2520%2528ITK%2529%2520and%2520resting%2520lymphocyte%2520kinase%2520%2528RLK%2529%2520using%2520a%2520novel%2520covalent%2520inhibitor%2520PRN694%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2015%26volume%3D290%26spage%3D5960%26epage%3D5978%26doi%3D10.1074%2Fjbc.M114.614891" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harling, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deakin, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimley, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudry, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nye, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polyakova, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bessant, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barton, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somers, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graves, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanns, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerr, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solari, R.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel irreversible inhibitors of interleukin (IL)-2-inducible tyrosine kinase (Itk) by targeting cysteine 442 in the ATP pocket</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>288</i></span>,  <span class="NLM_fpage">28195</span>– <span class="NLM_lpage">28206</span>, <span class="refDoi"> DOI: 10.1074/jbc.M113.474114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1074%2Fjbc.M113.474114" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2013&pages=28195-28206&author=J.+D.+Harlingauthor=A.+M.+Deakinauthor=S.+Camposauthor=R.+Grimleyauthor=L.+Chaudryauthor=C.+Nyeauthor=O.+Polyakovaauthor=C.+M.+Bessantauthor=N.+Bartonauthor=D.+Somersauthor=J.+Barrettauthor=R.+H.+Gravesauthor=L.+Hannsauthor=W.+J.+Kerrauthor=R.+Solari&title=Discovery+of+novel+irreversible+inhibitors+of+interleukin+%28IL%29-2-inducible+tyrosine+kinase+%28Itk%29+by+targeting+cysteine+442+in+the+ATP+pocket&doi=10.1074%2Fjbc.M113.474114"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M113.474114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M113.474114%26sid%3Dliteratum%253Aachs%26aulast%3DHarling%26aufirst%3DJ.%2BD.%26aulast%3DDeakin%26aufirst%3DA.%2BM.%26aulast%3DCampos%26aufirst%3DS.%26aulast%3DGrimley%26aufirst%3DR.%26aulast%3DChaudry%26aufirst%3DL.%26aulast%3DNye%26aufirst%3DC.%26aulast%3DPolyakova%26aufirst%3DO.%26aulast%3DBessant%26aufirst%3DC.%2BM.%26aulast%3DBarton%26aufirst%3DN.%26aulast%3DSomers%26aufirst%3DD.%26aulast%3DBarrett%26aufirst%3DJ.%26aulast%3DGraves%26aufirst%3DR.%2BH.%26aulast%3DHanns%26aufirst%3DL.%26aulast%3DKerr%26aufirst%3DW.%2BJ.%26aulast%3DSolari%26aufirst%3DR.%26atitle%3DDiscovery%2520of%2520novel%2520irreversible%2520inhibitors%2520of%2520interleukin%2520%2528IL%2529-2-inducible%2520tyrosine%2520kinase%2520%2528Itk%2529%2520by%2520targeting%2520cysteine%2520442%2520in%2520the%2520ATP%2520pocket%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2013%26volume%3D288%26spage%3D28195%26epage%3D28206%26doi%3D10.1074%2Fjbc.M113.474114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zapf, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerstenberger, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Limburg, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caspers, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aulabaugh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurumbail, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spaulding, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czerwinski, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seth, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medley, Q. G.</span></span> <span> </span><span class="NLM_article-title">Covalent inhibitors of interleukin-2 inducible T cell kinase (Itk) with nanomolar potency in a whole-blood assay</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">10047</span>– <span class="NLM_lpage">10063</span>, <span class="refDoi"> DOI: 10.1021/jm301190s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301190s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFOlsbnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=10047-10063&author=C.+W.+Zapfauthor=B.+S.+Gerstenbergerauthor=L.+Xingauthor=D.+C.+Limburgauthor=D.+R.+Andersonauthor=N.+Caspersauthor=S.+Hanauthor=A.+Aulabaughauthor=R.+Kurumbailauthor=S.+Shakyaauthor=X.+Liauthor=V.+Spauldingauthor=R.+M.+Czerwinskiauthor=N.+Sethauthor=Q.+G.+Medley&title=Covalent+inhibitors+of+interleukin-2+inducible+T+cell+kinase+%28Itk%29+with+nanomolar+potency+in+a+whole-blood+assay&doi=10.1021%2Fjm301190s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent Inhibitors of Interleukin-2 Inducible T Cell Kinase (Itk) with Nanomolar Potency in a Whole-Blood Assay</span></div><div class="casAuthors">Zapf, Christoph W.; Gerstenberger, Brian S.; Xing, Li; Limburg, David C.; Anderson, David R.; Caspers, Nicole; Han, Seungil; Aulabaugh, Ann; Kurumbail, Ravi; Shakya, Subarna; Li, Xin; Spaulding, Vikki; Czerwinski, Robert M.; Seth, Nilufer; Medley, Quintus G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10047-10063</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We wish to report a strategy that targets interleukin-2 inducible T cell kinase (Itk) with covalent inhibitors.  Thus far, covalent inhibition of Itk has not been disclosed in the literature.  Structure-based drug design was utilized to achieve low nanomolar potency of the disclosed series even at high ATP concns.  Kinetic measurements confirmed an irreversible binding mode with off-rate half-lives exceeding 24 h and moderate on-rates.  The analogs are highly potent in a cellular IP1 assay as well as in a human whole-blood (hWB) assay.  Despite a half-life of approx. 2 h in resting primary T cells, the covalent inhibition of Itk resulted in functional silencing of the TCR pathway for more than 24 h.  This prolonged effect indicates that covalent inhibition is a viable strategy to target the inactivation of Itk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnh9j28SM8jbVg90H21EOLACvtfcHk0ljM2KWhdlDqqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFOlsbnP&md5=7e39a17151dc9493d13439bc48fa83a3</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1021%2Fjm301190s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301190s%26sid%3Dliteratum%253Aachs%26aulast%3DZapf%26aufirst%3DC.%2BW.%26aulast%3DGerstenberger%26aufirst%3DB.%2BS.%26aulast%3DXing%26aufirst%3DL.%26aulast%3DLimburg%26aufirst%3DD.%2BC.%26aulast%3DAnderson%26aufirst%3DD.%2BR.%26aulast%3DCaspers%26aufirst%3DN.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DAulabaugh%26aufirst%3DA.%26aulast%3DKurumbail%26aufirst%3DR.%26aulast%3DShakya%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DSpaulding%26aufirst%3DV.%26aulast%3DCzerwinski%26aufirst%3DR.%2BM.%26aulast%3DSeth%26aufirst%3DN.%26aulast%3DMedley%26aufirst%3DQ.%2BG.%26atitle%3DCovalent%2520inhibitors%2520of%2520interleukin-2%2520inducible%2520T%2520cell%2520kinase%2520%2528Itk%2529%2520with%2520nanomolar%2520potency%2520in%2520a%2520whole-blood%2520assay%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D10047%26epage%3D10063%26doi%3D10.1021%2Fjm301190s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schaeffer, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debnath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yap, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McVicar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, X. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Littman, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varmus, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenardo, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartzberg, P. L.</span></span> <span> </span><span class="NLM_article-title">Requirement for Tec kinases Rlk and Itk in T cell receptor signaling and immunity</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>284</i></span>,  <span class="NLM_fpage">638</span>– <span class="NLM_lpage">641</span>, <span class="refDoi"> DOI: 10.1126/science.284.5414.638</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1126%2Fscience.284.5414.638" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=284&publication_year=1999&pages=638-641&author=E.+M.+Schaefferauthor=J.+Debnathauthor=G.+Yapauthor=D.+McVicarauthor=X.+C.+Liaoauthor=D.+R.+Littmanauthor=A.+Sherauthor=H.+E.+Varmusauthor=M.+J.+Lenardoauthor=P.+L.+Schwartzberg&title=Requirement+for+Tec+kinases+Rlk+and+Itk+in+T+cell+receptor+signaling+and+immunity&doi=10.1126%2Fscience.284.5414.638"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1126%2Fscience.284.5414.638&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.284.5414.638%26sid%3Dliteratum%253Aachs%26aulast%3DSchaeffer%26aufirst%3DE.%2BM.%26aulast%3DDebnath%26aufirst%3DJ.%26aulast%3DYap%26aufirst%3DG.%26aulast%3DMcVicar%26aufirst%3DD.%26aulast%3DLiao%26aufirst%3DX.%2BC.%26aulast%3DLittman%26aufirst%3DD.%2BR.%26aulast%3DSher%26aufirst%3DA.%26aulast%3DVarmus%26aufirst%3DH.%2BE.%26aulast%3DLenardo%26aufirst%3DM.%2BJ.%26aulast%3DSchwartzberg%26aufirst%3DP.%2BL.%26atitle%3DRequirement%2520for%2520Tec%2520kinases%2520Rlk%2520and%2520Itk%2520in%2520T%2520cell%2520receptor%2520signaling%2520and%2520immunity%26jtitle%3DScience%26date%3D1999%26volume%3D284%26spage%3D638%26epage%3D641%26doi%3D10.1126%2Fscience.284.5414.638" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deakin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duddy, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latcham, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fulleylove, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fung, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedrick, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKevitt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felton, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quint, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fattah, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gough, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solari, R.</span></span> <span> </span><span class="NLM_article-title">Characterisation of a K390R ITK kinase dead transgenic mouse – implications for ITK as a therapeutic target</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">e107490</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0107490</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1371%2Fjournal.pone.0107490" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=e107490&author=A.+Deakinauthor=G.+Duddyauthor=S.+Wilsonauthor=S.+Harrisonauthor=J.+Latchamauthor=M.+Fulleyloveauthor=S.+Fungauthor=J.+Smithauthor=M.+Pedrickauthor=T.+McKevittauthor=L.+Feltonauthor=J.+Morleyauthor=D.+Quintauthor=D.+Fattahauthor=B.+Hayesauthor=J.+Goughauthor=R.+Solari&title=Characterisation+of+a+K390R+ITK+kinase+dead+transgenic+mouse+%E2%80%93+implications+for+ITK+as+a+therapeutic+target&doi=10.1371%2Fjournal.pone.0107490"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0107490&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0107490%26sid%3Dliteratum%253Aachs%26aulast%3DDeakin%26aufirst%3DA.%26aulast%3DDuddy%26aufirst%3DG.%26aulast%3DWilson%26aufirst%3DS.%26aulast%3DHarrison%26aufirst%3DS.%26aulast%3DLatcham%26aufirst%3DJ.%26aulast%3DFulleylove%26aufirst%3DM.%26aulast%3DFung%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DJ.%26aulast%3DPedrick%26aufirst%3DM.%26aulast%3DMcKevitt%26aufirst%3DT.%26aulast%3DFelton%26aufirst%3DL.%26aulast%3DMorley%26aufirst%3DJ.%26aulast%3DQuint%26aufirst%3DD.%26aulast%3DFattah%26aufirst%3DD.%26aulast%3DHayes%26aufirst%3DB.%26aulast%3DGough%26aufirst%3DJ.%26aulast%3DSolari%26aufirst%3DR.%26atitle%3DCharacterisation%2520of%2520a%2520K390R%2520ITK%2520kinase%2520dead%2520transgenic%2520mouse%2520%25E2%2580%2593%2520implications%2520for%2520ITK%2520as%2520a%2520therapeutic%2520target%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26spage%3De107490%26doi%3D10.1371%2Fjournal.pone.0107490" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cho, H.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haberstock-Debic, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funk, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradshaw, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berg, L. J.</span></span> <span> </span><span class="NLM_article-title">A small molecule inhibitor of ITK and RLK impairs Th1 differentiation and prevents colitis disease progression</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>195</i></span>,  <span class="NLM_fpage">4822</span>– <span class="NLM_lpage">4831</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1501828</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.4049%2Fjimmunol.1501828" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=195&publication_year=2015&pages=4822-4831&author=H.-S.+Choauthor=H.+M.+Shinauthor=H.+Haberstock-Debicauthor=Y.+Xingauthor=T.+D.+Owensauthor=J.+O.+Funkauthor=R.+J.+Hillauthor=J.+M.+Bradshawauthor=L.+J.+Berg&title=A+small+molecule+inhibitor+of+ITK+and+RLK+impairs+Th1+differentiation+and+prevents+colitis+disease+progression&doi=10.4049%2Fjimmunol.1501828"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1501828&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1501828%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DH.-S.%26aulast%3DShin%26aufirst%3DH.%2BM.%26aulast%3DHaberstock-Debic%26aufirst%3DH.%26aulast%3DXing%26aufirst%3DY.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26aulast%3DFunk%26aufirst%3DJ.%2BO.%26aulast%3DHill%26aufirst%3DR.%2BJ.%26aulast%3DBradshaw%26aufirst%3DJ.%2BM.%26aulast%3DBerg%26aufirst%3DL.%2BJ.%26atitle%3DA%2520small%2520molecule%2520inhibitor%2520of%2520ITK%2520and%2520RLK%2520impairs%2520Th1%2520differentiation%2520and%2520prevents%2520colitis%2520disease%2520progression%26jtitle%3DJ.%2520Immunol.%26date%3D2015%26volume%3D195%26spage%3D4822%26epage%3D4831%26doi%3D10.4049%2Fjimmunol.1501828" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coico, R.</span>; <span class="NLM_string-name">Sunshine, G.</span></span> <i>Immunology: A Short Course</i>, <span class="NLM_edition">6</span>th ed.; <span class="NLM_publisher-name">John Wiley & Sons</span>, <span class="NLM_year">2009</span>; p  <span class="NLM_fpage">391</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&pages=391&author=R.+Coico&author=G.+Sunshine&title=Immunology%3A+A+Short+Course"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DCoico%26aufirst%3DR.%26btitle%3DImmunology%253A%2520A%2520Short%2520Course%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%26date%3D2009%26spage%3D391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, K.</span></span> <i>Janeway’s Immunobiology</i>, <span class="NLM_edition">8</span>th ed.; <span class="NLM_publisher-name">Garland Science, Taylor & Francis Group, LLC</span>: <span class="NLM_publisher-loc">New York, NY</span>, <span class="NLM_year">2012</span>; p  <span class="NLM_fpage">888</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=888&author=K.+Murphy&title=Janeway%E2%80%99s+Immunobiology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DMurphy%26aufirst%3DK.%26btitle%3DJaneway%25E2%2580%2599s%2520Immunobiology%26pub%3DGarland%2520Science%252C%2520Taylor%2520%2526%2520Francis%2520Group%252C%2520LLC%26date%3D2012%26spage%3D888" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rokosz, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beasley, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appell, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, M. L.</span></span> <span> </span><span class="NLM_article-title">Kinase inhibitors as drugs for chronic inflammatory and immunological diseases: progress and challenges</span>. <i>Expert Opin. Ther. Targets</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">883</span>– <span class="NLM_lpage">903</span>, <span class="refDoi"> DOI: 10.1517/14728222.12.7.883</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1517%2F14728222.12.7.883" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=18554156" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BD1cXntFylsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2008&pages=883-903&author=L.+L.+Rokoszauthor=J.+R.+Beasleyauthor=C.+D.+Carrollauthor=T.+Linauthor=J.+Zhaoauthor=K.+C.+Appellauthor=M.+L.+Webb&title=Kinase+inhibitors+as+drugs+for+chronic+inflammatory+and+immunological+diseases%3A+progress+and+challenges&doi=10.1517%2F14728222.12.7.883"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase inhibitors as drugs for chronic inflammatory and immunological diseases: progress and challenges</span></div><div class="casAuthors">Rokosz, Laura L.; Beasley, James R.; Carroll, Carolyn DiIanni; Lin, Tsung; Zhao, Jiuqiao; Appell, Kenneth C.; Webb, Maria L.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">883-903</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  At the time of writing, there are seven marketed kinase inhibitor drugs.  The first kinase inhibitor, imatinib mesilate (Gleevec, Novartis), came to market in 2001, an inhibitor of the breakpoint cluster region (BCR)/Abelson murine leukemia oncogene homolog (ABL) fusion, platelet-derived growth factor (PDGF) receptor, and c-kit kinases.  The most recent kinase inhibitor to come to market, disatinib (Sprycel, Bristol-Myers Squibb), acts on c-SRC, ABL and Bruton's tyrosine kinase.  To date, kinase inhibitor drugs are approved for oncol. and demonstrate that it is possible to develop compds. with relative selectivity for the target kinase against the broader kinome.  However, the use of kinase inhibitors in chronic inflammatory and immunol. diseases may require greater selectivity for the target kinase.  This review addresses the opportunities and challenges of kinase inhibition as a therapeutic approach in chronic immune and inflammatory disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq458NGQKTbcbVg90H21EOLACvtfcHk0lgWgpRauGoUwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXntFylsLY%253D&md5=6db3fdcc34b3ec97394c9dc6cdca8b99</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1517%2F14728222.12.7.883&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728222.12.7.883%26sid%3Dliteratum%253Aachs%26aulast%3DRokosz%26aufirst%3DL.%2BL.%26aulast%3DBeasley%26aufirst%3DJ.%2BR.%26aulast%3DCarroll%26aufirst%3DC.%2BD.%26aulast%3DLin%26aufirst%3DT.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DAppell%26aufirst%3DK.%2BC.%26aulast%3DWebb%26aufirst%3DM.%2BL.%26atitle%3DKinase%2520inhibitors%2520as%2520drugs%2520for%2520chronic%2520inflammatory%2520and%2520immunological%2520diseases%253A%2520progress%2520and%2520challenges%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2008%26volume%3D12%26spage%3D883%26epage%3D903%26doi%3D10.1517%2F14728222.12.7.883" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wesche, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, W.-C.</span></span> <span> </span><span class="NLM_article-title">IRAK-4 inhibitors for inflammation</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">724</span>– <span class="NLM_lpage">737</span>, <span class="refDoi"> DOI: 10.2174/156802609789044407</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.2174%2F156802609789044407" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=19689377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFehsLnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=724-737&author=Z.+Wangauthor=H.+Wescheauthor=T.+Stevensauthor=N.+Walkerauthor=W.-C.+Yeh&title=IRAK-4+inhibitors+for+inflammation&doi=10.2174%2F156802609789044407"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">IRAK-4 inhibitors for inflammation</span></div><div class="casAuthors">Wang, Zhulun; Wesche, Holger; Stevens, Tracey; Walker, Nigel; Yeh, Wen-Chen</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">724-737</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Interleukin-1 receptor-assocd. kinases (IRAKs) are key components in the signal transduction pathways utilized by interleukin-1 receptor (IL-1R), interleukin-18 receptor (IL-18R), and Toll-like receptors (TLRs).  Out of four members in the mammalian IRAK family, IRAK-4 is considered to be the "master IRAK", the only family member indispensable for IL-1R/TLR signaling.  In humans, mutations resulting in IRAK-4 deficiency have been linked to susceptibility to bacterial infections, esp. recurrent pyogenic bacterial infections.  Furthermore, knock-in expts. by several groups have clearly demonstrated that IRAK-4 requires its kinase activity for its function.  Given the crit. role of IRAK-4 in inflammatory processes, modulation of IRAK-4 kinase activity presents an attractive therapeutic approach for the treatment of immune and inflammatory diseases.  The recent success in the detn. of the 3-dimensional structure of the IRAK-4 kinase domain in complex with inhibitors has facilitated the understanding of the mechanistic role of IRAK-4 in immunity and inflammation as well as the development of specific IRAK-4 kinase inhibitors.  In this article, we review the biol. function of IRAK-4, the structural characteristics of the kinase domain, and the development of small mol. inhibitors targeting the kinase activity.  We also review the key pharmacophores required for several classes of inhibitors as well as important features for optimal protein/inhibitor interactions.  Lastly, we summarize how these insights can be translated into strategies to develop potent IRAK-4 inhibitors with desired properties as new anti-inflammatory therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRhyk3FnIbSrVg90H21EOLACvtfcHk0liZXjyLSUPYHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFehsLnO&md5=c6a1278c9b9647aa8ce21edac373ddaa</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.2174%2F156802609789044407&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802609789044407%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DWesche%26aufirst%3DH.%26aulast%3DStevens%26aufirst%3DT.%26aulast%3DWalker%26aufirst%3DN.%26aulast%3DYeh%26aufirst%3DW.-C.%26atitle%3DIRAK-4%2520inhibitors%2520for%2520inflammation%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2009%26volume%3D9%26spage%3D724%26epage%3D737%26doi%3D10.2174%2F156802609789044407" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dudhgaonkar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranade, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasad, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karunanithi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatesh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selvam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnamurthy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mariappan, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saxena, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stetsko, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holloway, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruepp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santella, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duncia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hynes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carman, J. A.</span></span> <span> </span><span class="NLM_article-title">Selective IRAK4 inhibition attenuates disease in murine lupus models and demonstrates steroid sparing activity</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>198</i></span>,  <span class="NLM_fpage">1308</span>– <span class="NLM_lpage">1319</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1600583</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.4049%2Fjimmunol.1600583" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=28003376" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlaitb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=198&publication_year=2017&pages=1308-1319&author=S.+Dudhgaonkarauthor=S.+Ranadeauthor=J.+Nagarauthor=S.+Subramaniauthor=D.+S.+Prasadauthor=P.+Karunanithiauthor=R.+Srivastavaauthor=K.+Venkateshauthor=S.+Selvamauthor=P.+Krishnamurthyauthor=T.+T.+Mariappanauthor=A.+Saxenaauthor=L.+Fanauthor=D.+K.+Stetskoauthor=D.+A.+Hollowayauthor=X.+Liauthor=J.+Zhuauthor=W.-P.+Yangauthor=S.+Rueppauthor=S.+Nairauthor=J.+Santellaauthor=J.+Dunciaauthor=J.+Hynesauthor=K.+W.+McIntyreauthor=J.+A.+Carman&title=Selective+IRAK4+inhibition+attenuates+disease+in+murine+lupus+models+and+demonstrates+steroid+sparing+activity&doi=10.4049%2Fjimmunol.1600583"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Selective IRAK4 Inhibition Attenuates Disease in Murine Lupus Models and Demonstrates Steroid Sparing Activity</span></div><div class="casAuthors">Dudhgaonkar, Shailesh; Ranade, Sourabh; Nagar, Jignesh; Subramani, Siva; Prasad, Durga Shiv; Karunanithi, Preethi; Srivastava, Ratika; Venkatesh, Kamala; Selvam, Sabariya; Krishnamurthy, Prasad; Mariappan, T. Thanga; Saxena, Ajay; Fan, Li; Stetsko, Dawn K.; Holloway, Deborah A.; Li, Xin; Zhu, Jun; Yang, Wen-Pin; Ruepp, Stefan; Nair, Satheesh; Santella, Joseph; Duncia, John; Hynes, John; McIntyre, Kim W.; Carman, Julie A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">198</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1308-1319</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">The serine/threonine kinase IL-1R-assocd. kinase (IRAK)4 is a crit. regulator of innate immunity.  We have identified BMS-986126, a potent, highly selective inhibitor of IRAK4 kinase activity that demonstrates equipotent activity against multiple MyD88-dependent responses both in vitro and in vivo.  BMS-986126 failed to inhibit assays downstream of MyD88-independent receptors, including the TNF receptor and TLR3.  Very little activity was seen downstream of TLR4, which can also activate an MyD88-independent pathway.  In mice, the compd. inhibited cytokine prodn. induced by injection of several different TLR agonists, including those for TLR2, TLR7, and TLR9.  The compd. also significantly suppressed skin inflammation induced by topical administration of the TLR7 agonist imiquimod.  BMS-986126 demonstrated robust activity in the MRL/lpr and NZB/NZW models of lupus, inhibiting multiple pathogenic responses.  In the MRL/lpr model, robust activity was obsd. with the combination of suboptimal doses of BMS-986126 and prednisolone, suggesting the potential for steroid sparing activity.  BMS-986126 also demonstrated synergy with prednisolone in assays of TLR7- and TLR9-induced IFN target gene expression using human PBMCs.  Lastly, BMS-986126 inhibited TLR7- and TLR9-dependent responses using cells derived from lupus patients, suggesting that inhibition of IRAK4 has the potential for therapeutic benefit in treating lupus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrs4ZWIchaO6rVg90H21EOLACvtfcHk0liZXjyLSUPYHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlaitb8%253D&md5=340ba834510cd04eb0e984e212731e17</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1600583&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1600583%26sid%3Dliteratum%253Aachs%26aulast%3DDudhgaonkar%26aufirst%3DS.%26aulast%3DRanade%26aufirst%3DS.%26aulast%3DNagar%26aufirst%3DJ.%26aulast%3DSubramani%26aufirst%3DS.%26aulast%3DPrasad%26aufirst%3DD.%2BS.%26aulast%3DKarunanithi%26aufirst%3DP.%26aulast%3DSrivastava%26aufirst%3DR.%26aulast%3DVenkatesh%26aufirst%3DK.%26aulast%3DSelvam%26aufirst%3DS.%26aulast%3DKrishnamurthy%26aufirst%3DP.%26aulast%3DMariappan%26aufirst%3DT.%2BT.%26aulast%3DSaxena%26aufirst%3DA.%26aulast%3DFan%26aufirst%3DL.%26aulast%3DStetsko%26aufirst%3DD.%2BK.%26aulast%3DHolloway%26aufirst%3DD.%2BA.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DW.-P.%26aulast%3DRuepp%26aufirst%3DS.%26aulast%3DNair%26aufirst%3DS.%26aulast%3DSantella%26aufirst%3DJ.%26aulast%3DDuncia%26aufirst%3DJ.%26aulast%3DHynes%26aufirst%3DJ.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DCarman%26aufirst%3DJ.%2BA.%26atitle%3DSelective%2520IRAK4%2520inhibition%2520attenuates%2520disease%2520in%2520murine%2520lupus%2520models%2520and%2520demonstrates%2520steroid%2520sparing%2520activity%26jtitle%3DJ.%2520Immunol.%26date%3D2017%26volume%3D198%26spage%3D1308%26epage%3D1319%26doi%3D10.4049%2Fjimmunol.1600583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Joosten, L. A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdollahi-Roodsaz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinarello, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Netea, M. G.</span></span> <span> </span><span class="NLM_article-title">Toll-like receptors and chronic inflammation in rheumatic diseases: new developments</span>. <i>Nat. Rev. Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">344</span>– <span class="NLM_lpage">357</span>, <span class="refDoi"> DOI: 10.1038/nrrheum.2016.61</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1038%2Fnrrheum.2016.61" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=27170508" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC28XnvV2ntb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=344-357&author=L.+A.+B.+Joostenauthor=S.+Abdollahi-Roodsazauthor=C.+A.+Dinarelloauthor=L.+O%E2%80%99Neillauthor=M.+G.+Netea&title=Toll-like+receptors+and+chronic+inflammation+in+rheumatic+diseases%3A+new+developments&doi=10.1038%2Fnrrheum.2016.61"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Toll-like receptors and chronic inflammation in rheumatic diseases: new developments</span></div><div class="casAuthors">Joosten, Leo A. B.; Abdollahi-Roodsaz, Shahla; Dinarello, Charles A.; O'Neill, Luke; Netea, Mihai G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Rheumatology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">344-357</span>CODEN:
                <span class="NLM_cas:coden">NRRACB</span>;
        ISSN:<span class="NLM_cas:issn">1759-4790</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In the past few years, new developments have been reported on the role of Toll-like receptors (TLRs) in chronic inflammation in rheumatic diseases.  The inhibitory function of TLR10 has been demonstrated.  Receptors that enhance the function of TLRs, and several TLR inhibitors, have been identified.  In addn., the role of the microbiome and TLRs in the onset of rheumatic diseases has been reported.  We review novel insights on the role of TLRs in several inflammatory joint diseases, including rheumatoid arthritis, systemic lupus erythematosus, gout and Lyme arthritis, with a focus on the signalling mechanisms mediated by the Toll-IL-1 receptor (TIR) domain, the exogenous and endogenous ligands of TLRs, and the current and future therapeutic strategies to target TLR signalling in rheumatic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBPDFqhEIq1rVg90H21EOLACvtfcHk0liZXjyLSUPYHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnvV2ntb8%253D&md5=a561bbe778204e8e57d599efdbec093a</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1038%2Fnrrheum.2016.61&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrrheum.2016.61%26sid%3Dliteratum%253Aachs%26aulast%3DJoosten%26aufirst%3DL.%2BA.%2BB.%26aulast%3DAbdollahi-Roodsaz%26aufirst%3DS.%26aulast%3DDinarello%26aufirst%3DC.%2BA.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DL.%26aulast%3DNetea%26aufirst%3DM.%2BG.%26atitle%3DToll-like%2520receptors%2520and%2520chronic%2520inflammation%2520in%2520rheumatic%2520diseases%253A%2520new%2520developments%26jtitle%3DNat.%2520Rev.%2520Rheumatol.%26date%3D2016%26volume%3D12%26spage%3D344%26epage%3D357%26doi%3D10.1038%2Fnrrheum.2016.61" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhary, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, D. L.</span></span> <span> </span><span class="NLM_article-title">Recent advances in the discovery of small molecule inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4) as a therapeutic target for inflammation and oncology disorders</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">96</span>– <span class="NLM_lpage">110</span>, <span class="refDoi"> DOI: 10.1021/jm5016044</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5016044" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVCjsLzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=96-110&author=D.+Chaudharyauthor=S.+Robinsonauthor=D.+L.+Romero&title=Recent+advances+in+the+discovery+of+small+molecule+inhibitors+of+interleukin-1+receptor-associated+kinase+4+%28IRAK4%29+as+a+therapeutic+target+for+inflammation+and+oncology+disorders&doi=10.1021%2Fjm5016044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Advances in the Discovery of Small Molecule Inhibitors of Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) as a Therapeutic Target for Inflammation and Oncology Disorders</span></div><div class="casAuthors">Chaudhary, Divya; Robinson, Shaughnessy; Romero, Donna L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">96-110</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  IRAK4, a serine/threonine kinase, plays a key role in both inflammation and oncol. diseases.  Herein, we summarize the compelling biol. surrounding the IRAK4 signaling node in disease, review key structural features of IRAK4 including selectivity challenges, and describe efforts to discover clin. viable IRAK4 inhibitors.  Finally, a view of knowledge gained and remaining challenges is provided.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1K6ExwztfCLVg90H21EOLACvtfcHk0lhk6lNR8Jc7yw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVCjsLzL&md5=795797f7f3f07597ecd0b5899498804b</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1021%2Fjm5016044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5016044%26sid%3Dliteratum%253Aachs%26aulast%3DChaudhary%26aufirst%3DD.%26aulast%3DRobinson%26aufirst%3DS.%26aulast%3DRomero%26aufirst%3DD.%2BL.%26atitle%3DRecent%2520advances%2520in%2520the%2520discovery%2520of%2520small%2520molecule%2520inhibitors%2520of%2520interleukin-1%2520receptor-associated%2520kinase%25204%2520%2528IRAK4%2529%2520as%2520a%2520therapeutic%2520target%2520for%2520inflammation%2520and%2520oncology%2520disorders%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D96%26epage%3D110%26doi%3D10.1021%2Fjm5016044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grogan, J. L.</span></span> <span> </span><span class="NLM_article-title">Immune complex-mediated cell activation from systemic lupus erythematosus and rheumatoid arthritis patients elaborate different requirements for IRAK1/4 kinase activity across human cell types</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>186</i></span>,  <span class="NLM_fpage">1279</span>– <span class="NLM_lpage">1288</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1002821</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.4049%2Fjimmunol.1002821" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=186&publication_year=2011&pages=1279-1288&author=E.+Y.+Chiangauthor=X.+Yuauthor=J.+L.+Grogan&title=Immune+complex-mediated+cell+activation+from+systemic+lupus+erythematosus+and+rheumatoid+arthritis+patients+elaborate+different+requirements+for+IRAK1%2F4+kinase+activity+across+human+cell+types&doi=10.4049%2Fjimmunol.1002821"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1002821&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1002821%26sid%3Dliteratum%253Aachs%26aulast%3DChiang%26aufirst%3DE.%2BY.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DGrogan%26aufirst%3DJ.%2BL.%26atitle%3DImmune%2520complex-mediated%2520cell%2520activation%2520from%2520systemic%2520lupus%2520erythematosus%2520and%2520rheumatoid%2520arthritis%2520patients%2520elaborate%2520different%2520requirements%2520for%2520IRAK1%252F4%2520kinase%2520activity%2520across%2520human%2520cell%2520types%26jtitle%3DJ.%2520Immunol.%26date%3D2011%26volume%3D186%26spage%3D1279%26epage%3D1288%26doi%3D10.4049%2Fjimmunol.1002821" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bothe, U.</span>; <span class="NLM_string-name">Wengner, A. M.</span>; <span class="NLM_string-name">Siebeneicher, H.</span>; <span class="NLM_string-name">Schmidt, N.</span>; <span class="NLM_string-name">Nubbemeyer, R.</span>; <span class="NLM_string-name">Bomer, U.</span>; <span class="NLM_string-name">Gunther, J.</span>; <span class="NLM_string-name">Steuber, H.</span>; <span class="NLM_string-name">Lange, M.</span>; <span class="NLM_string-name">Stegmann, C.</span>; <span class="NLM_string-name">Sutter, A.</span>; <span class="NLM_string-name">Neuhaus, R.</span></span> <span> </span><span class="NLM_article-title">Combinations of Inhibitors of IRAK4 with Inhibitors of BTK</span>. <span class="NLM_patent">WO2016/174183 A1</span>, Nov 3, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=U.+Bothe&author=A.+M.+Wengner&author=H.+Siebeneicher&author=N.+Schmidt&author=R.+Nubbemeyer&author=U.+Bomer&author=J.+Gunther&author=H.+Steuber&author=M.+Lange&author=C.+Stegmann&author=A.+Sutter&author=R.+Neuhaus&title=Combinations+of+Inhibitors+of+IRAK4+with+Inhibitors+of+BTK"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBothe%26aufirst%3DU.%26atitle%3DCombinations%2520of%2520Inhibitors%2520of%2520IRAK4%2520with%2520Inhibitors%2520of%2520BTK%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambler, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boscoe, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bree, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodfuehrer, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curran, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dehnhardt, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dower, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drozda, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frisbie, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavrin, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hepworth, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hope, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamtekar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilty, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, L.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovering, F. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathias, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papaioannou, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patny, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saiah, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samardjiev, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samas, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, M. W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soutter, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strohbach, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symanowicz, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomason, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trzupek, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vargas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zapf, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, S. W.</span></span> <span> </span><span class="NLM_article-title">Discovery of clinical candidate 1-{[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a potent, selective inhibitor of interleukin-1 receptor associated kinase 4 (IRAK4), by fragment-based drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">5521</span>– <span class="NLM_lpage">5542</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00231</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00231" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnslGqu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5521-5542&author=K.+L.+Leeauthor=C.+M.+Amblerauthor=D.+R.+Andersonauthor=B.+P.+Boscoeauthor=A.+G.+Breeauthor=J.+I.+Brodfuehrerauthor=J.+S.+Changauthor=C.+Choiauthor=S.+Chungauthor=K.+J.+Curranauthor=J.+E.+Dayauthor=C.+M.+Dehnhardtauthor=K.+Dowerauthor=S.+E.+Drozdaauthor=R.+K.+Frisbieauthor=L.+K.+Gavrinauthor=J.+A.+Goldbergauthor=S.+Hanauthor=M.+Hegenauthor=D.+Hepworthauthor=H.+R.+Hopeauthor=S.+Kamtekarauthor=I.+C.+Kiltyauthor=A.+Leeauthor=L.-L.+Linauthor=F.+E.+Loveringauthor=M.+D.+Loweauthor=J.+P.+Mathiasauthor=H.+M.+Morganauthor=E.+A.+Murphyauthor=N.+Papaioannouauthor=A.+Patnyauthor=B.+S.+Pierceauthor=V.+R.+Raoauthor=E.+Saiahauthor=I.+J.+Samardjievauthor=B.+M.+Samasauthor=M.+W.+H.+Shenauthor=J.+H.+Shinauthor=H.+H.+Soutterauthor=J.+W.+Strohbachauthor=P.+T.+Symanowiczauthor=J.+R.+Thomasonauthor=J.+D.+Trzupekauthor=R.+Vargasauthor=F.+Vincentauthor=J.+Yanauthor=C.+W.+Zapfauthor=S.+W.+Wright&title=Discovery+of+clinical+candidate+1-%7B%5B%282S%2C3S%2C4S%29-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl%5Dmethoxy%7D-7-methoxyisoquinoline-6-carboxamide+%28PF-06650833%29%2C+a+potent%2C+selective+inhibitor+of+interleukin-1+receptor+associated+kinase+4+%28IRAK4%29%2C+by+fragment-based+drug+design&doi=10.1021%2Facs.jmedchem.7b00231"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Clinical Candidate 1-{[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design</span></div><div class="casAuthors">Lee, Katherine L.; Ambler, Catherine M.; Anderson, David R.; Boscoe, Brian P.; Bree, Andrea G.; Brodfuehrer, Joanne I.; Chang, Jeanne S.; Choi, Chulho; Chung, Seungwon; Curran, Kevin J.; Day, Jacqueline E.; Dehnhardt, Christoph M.; Dower, Ken; Drozda, Susan E.; Frisbie, Richard K.; Gavrin, Lori K.; Goldberg, Joel A.; Han, Seungil; Hegen, Martin; Hepworth, David; Hope, Heidi R.; Kamtekar, Satwik; Kilty, Iain C.; Lee, Arthur; Lin, Lih-Ling; Lovering, Frank E.; Lowe, Michael D.; Mathias, John P.; Morgan, Heidi M.; Murphy, Elizabeth A.; Papaioannou, Nikolaos; Patny, Akshay; Pierce, Betsy S.; Rao, Vikram R.; Saiah, Eddine; Samardjiev, Ivan J.; Samas, Brian M.; Shen, Marina W. H.; Shin, Julia H.; Soutter, Holly H.; Strohbach, Joseph W.; Symanowicz, Peter T.; Thomason, Jennifer R.; Trzupek, John D.; Vargas, Richard; Vincent, Fabien; Yan, Jiangli; Zapf, Christoph W.; Wright, Stephen W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5521-5542</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Through fragment-based drug design focused on engaging the active site of IRAK4 and leveraging three-dimensional topol. in a ligand-efficient manner, a micromolar hit identified from a screen of a Pfizer fragment library was optimized to afford IRAK4 inhibitors with nanomolar potency in cellular assays.  The medicinal chem. effort featured the judicious placement of lipophilicity, informed by cocrystal structures with IRAK4 and optimization of ADME properties to deliver clin. candidate I.  This compd. benefitted from a 5-unit increase in lipophilic efficiency from the fragment hit, excellent kinase selectivity, and pharmacokinetic properties suitable for oral administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYrCep64bhMbVg90H21EOLACvtfcHk0lhk6lNR8Jc7yw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnslGqu7c%253D&md5=9771ad2d33089f6ef3dba3556536ff1a</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00231&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00231%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DK.%2BL.%26aulast%3DAmbler%26aufirst%3DC.%2BM.%26aulast%3DAnderson%26aufirst%3DD.%2BR.%26aulast%3DBoscoe%26aufirst%3DB.%2BP.%26aulast%3DBree%26aufirst%3DA.%2BG.%26aulast%3DBrodfuehrer%26aufirst%3DJ.%2BI.%26aulast%3DChang%26aufirst%3DJ.%2BS.%26aulast%3DChoi%26aufirst%3DC.%26aulast%3DChung%26aufirst%3DS.%26aulast%3DCurran%26aufirst%3DK.%2BJ.%26aulast%3DDay%26aufirst%3DJ.%2BE.%26aulast%3DDehnhardt%26aufirst%3DC.%2BM.%26aulast%3DDower%26aufirst%3DK.%26aulast%3DDrozda%26aufirst%3DS.%2BE.%26aulast%3DFrisbie%26aufirst%3DR.%2BK.%26aulast%3DGavrin%26aufirst%3DL.%2BK.%26aulast%3DGoldberg%26aufirst%3DJ.%2BA.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DHepworth%26aufirst%3DD.%26aulast%3DHope%26aufirst%3DH.%2BR.%26aulast%3DKamtekar%26aufirst%3DS.%26aulast%3DKilty%26aufirst%3DI.%2BC.%26aulast%3DLee%26aufirst%3DA.%26aulast%3DLin%26aufirst%3DL.-L.%26aulast%3DLovering%26aufirst%3DF.%2BE.%26aulast%3DLowe%26aufirst%3DM.%2BD.%26aulast%3DMathias%26aufirst%3DJ.%2BP.%26aulast%3DMorgan%26aufirst%3DH.%2BM.%26aulast%3DMurphy%26aufirst%3DE.%2BA.%26aulast%3DPapaioannou%26aufirst%3DN.%26aulast%3DPatny%26aufirst%3DA.%26aulast%3DPierce%26aufirst%3DB.%2BS.%26aulast%3DRao%26aufirst%3DV.%2BR.%26aulast%3DSaiah%26aufirst%3DE.%26aulast%3DSamardjiev%26aufirst%3DI.%2BJ.%26aulast%3DSamas%26aufirst%3DB.%2BM.%26aulast%3DShen%26aufirst%3DM.%2BW.%2BH.%26aulast%3DShin%26aufirst%3DJ.%2BH.%26aulast%3DSoutter%26aufirst%3DH.%2BH.%26aulast%3DStrohbach%26aufirst%3DJ.%2BW.%26aulast%3DSymanowicz%26aufirst%3DP.%2BT.%26aulast%3DThomason%26aufirst%3DJ.%2BR.%26aulast%3DTrzupek%26aufirst%3DJ.%2BD.%26aulast%3DVargas%26aufirst%3DR.%26aulast%3DVincent%26aufirst%3DF.%26aulast%3DYan%26aufirst%3DJ.%26aulast%3DZapf%26aufirst%3DC.%2BW.%26aulast%3DWright%26aufirst%3DS.%2BW.%26atitle%3DDiscovery%2520of%2520clinical%2520candidate%25201-%257B%255B%25282S%252C3S%252C4S%2529-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl%255Dmethoxy%257D-7-methoxyisoquinoline-6-carboxamide%2520%2528PF-06650833%2529%252C%2520a%2520potent%252C%2520selective%2520inhibitor%2520of%2520interleukin-1%2520receptor%2520associated%2520kinase%25204%2520%2528IRAK4%2529%252C%2520by%2520fragment-based%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D5521%26epage%3D5542%26doi%3D10.1021%2Facs.jmedchem.7b00231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knight, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span> <span> </span><span class="NLM_article-title">Features of selective kinase inhibitors</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">621</span>– <span class="NLM_lpage">637</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2005.04.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1016%2Fj.chembiol.2005.04.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=15975507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlsFGhtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2005&pages=621-637&author=Z.+A.+Knightauthor=K.+M.+Shokat&title=Features+of+selective+kinase+inhibitors&doi=10.1016%2Fj.chembiol.2005.04.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Features of Selective Kinase Inhibitors</span></div><div class="casAuthors">Knight, Zachary A.; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">621-637</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Summary: Small-mol. inhibitors of protein and lipid kinases have emerged as indispensable tools for studying signal transduction.  Despite the widespread use of these reagents, there is little consensus about the biochem. criteria that define their potency and selectivity in cells.  We discuss some of the features that det. the cellular activity of kinase inhibitors and propose a framework for interpreting inhibitor selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAJWhVxtSrCLVg90H21EOLACvtfcHk0lgXOT6mCSwv5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlsFGhtrc%253D&md5=ce5b3505a0326b04479172ec05573152</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2005.04.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2005.04.011%26sid%3Dliteratum%253Aachs%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DFeatures%2520of%2520selective%2520kinase%2520inhibitors%26jtitle%3DChem.%2520Biol.%26date%3D2005%26volume%3D12%26spage%3D621%26epage%3D637%26doi%3D10.1016%2Fj.chembiol.2005.04.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Picard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Bernuth, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghandil, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chrabieh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arkwright, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geha, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krause, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creech, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ku, C.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maŕodi, Ĺ.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Muhsen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Hajjar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Ghonaium, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day-Good, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holland, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speert, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Gallego, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colino, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garty, B.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roifman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshikawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonoyama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domachowske, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Issekutz, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smart, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zitnik, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoarau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumararatne, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thrasher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bethune, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirvent, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Ricaud, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camcioglu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasconcelos, J. u.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guedes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitor, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almazán, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ḿendez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aŕostegui, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alsina, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortuny, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichenbach, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verbsky, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bossuyt, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doffinger, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casanova, J.-L.</span></span> <span> </span><span class="NLM_article-title">Clinical features and outcome of patients with IRAK-4 and MyD88 deficiency</span>. <i>Medicine</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">403</span>– <span class="NLM_lpage">425</span>, <span class="refDoi"> DOI: 10.1097/MD.0b013e3181fd8ec3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1097%2FMD.0b013e3181fd8ec3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=21057262" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtl2lt7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2010&pages=403-425&author=C.+Picardauthor=H.+von+Bernuthauthor=P.+Ghandilauthor=M.+Chrabiehauthor=O.+Levyauthor=P.+D.+Arkwrightauthor=D.+McDonaldauthor=R.+S.+Gehaauthor=H.+Takadaauthor=J.+C.+Krauseauthor=C.+B.+Creechauthor=C.-L.+Kuauthor=S.+Ehlauthor=%C4%B9.+Ma%C5%95odiauthor=S.+Al-Muhsenauthor=S.+Al-Hajjarauthor=A.+Al-Ghonaiumauthor=N.+K.+Day-Goodauthor=S.+M.+Hollandauthor=J.+Gallinauthor=H.+Chapelauthor=D.+P.+Speertauthor=C.+Rodriguez-Gallegoauthor=E.+Colinoauthor=B.-Z.+Gartyauthor=C.+Roifmanauthor=T.+Haraauthor=H.+Yoshikawaauthor=S.+Nonoyamaauthor=J.+Domachowskeauthor=A.+C.+Issekutzauthor=M.+Tangauthor=J.+Smartauthor=S.+E.+Zitnikauthor=C.+Hoarauauthor=D.+Kumararatneauthor=A.+Thrasherauthor=E.+G.+Daviesauthor=C.+Bethuneauthor=N.+Sirventauthor=D.+de+Ricaudauthor=Y.+Camciogluauthor=J.+u.+Vasconcelosauthor=M.+Guedesauthor=A.+B.+Vitorauthor=C.+Rodrigoauthor=F.+Almaz%C3%A1nauthor=M.+%E1%B8%BEendezauthor=J.+I.+A%C5%95osteguiauthor=L.+Alsinaauthor=C.+Fortunyauthor=J.+Reichenbachauthor=J.+W.+Verbskyauthor=X.+Bossuytauthor=R.+Doffingerauthor=L.+Abelauthor=A.+Puelauthor=J.-L.+Casanova&title=Clinical+features+and+outcome+of+patients+with+IRAK-4+and+MyD88+deficiency&doi=10.1097%2FMD.0b013e3181fd8ec3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical features and outcome of patients with IRAK-4 and MyD88 deficiency</span></div><div class="casAuthors">Picard, Capucine; von Bernuth, Horst; Ghandil, Pegah; Chrabieh, Maya; Levy, Ofer; Arkwright, Peter D.; McDonald, Douglas; Geha, Raif S.; Takada, Hidetoshi; Krause, Jens C.; Creech, C. Buddy; Ku, Cheng-Lung; Ehl, Stephan; Marodi, Laszlo; Al-Muhsen, Saleh; Al-Hajjar, Sami; Al-Ghonaium, Abdulaziz; Day-Good, Noorbibi K.; Holland, Steven M.; Gallin, John I.; Chapel, Helen; Speert, David P.; Rodriguez-Gallego, Carlos; Colino, Elena; Garty, Ben-Zion; Roifman, Chaim; Hara, Toshiro; Yoshikawa, Hideto; Nonoyama, Shigeaki; Domachowske, Joseph; Issekutz, Andrew C.; Tang, Mimi; Smart, Joanne; Zitnik, Simona Eva; Hoarau, Cyrille; Kumararatne, Dinakantha S.; Thrasher, Adrian J.; Davies, E. Graham; Bethune, Claire; Sirvent, Nicolas; de Ricaud, Dominique; Camcioglu, Yildiz; Vasconcelos, Julia; Guedes, Margarida; Vitor, Artur Bonito; Rodrigo, Carlos; Almazan, Francisco; Mendez, Maria; Arostegui, Juan Ignacio; Alsina, Laia; Fortuny, Claudia; Reichenbach, Janine; Verbsky, James W.; Bossuyt, Xavier; Doffinger, Rainer; Abel, Laurent; Puel, Anne; Casanova, Jean-Laurent</div><div class="citationInfo"><span class="NLM_cas:title">Medicine (Hagerstown, MD, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">403-425</span>CODEN:
                <span class="NLM_cas:coden">MEDIAV</span>;
        ISSN:<span class="NLM_cas:issn">0025-7974</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Autosomal recessive interleukin-1 receptor-assocd. kinase (IRAK)-4 and myeloid differentiation factor (MyD)88 deficiencies impair Toll-like receptor (TLR)- and interleukin-1 receptor-mediated immunity.  We documented the clin. features and outcome of 48 patients with IRAK-4 deficiency and 12 patients with MyD88 deficiency, from 37 kindreds in 15 countries.The clin. features of IRAK-4 and MyD88 deficiency were indistinguishable.  There were no severe viral, parasitic, and fungal diseases, and the range of bacterial infections was narrow.  Noninvasive bacterial infections occurred in 52 patients, with a high incidence of infections of the upper respiratory tract and the skin, mostly caused by Pseudomonas aeruginosa and Staphylococcus aureus, resp.  The leading threat was invasive pneumococcal disease, documented in 41 patients (68%) and causing 72 documented invasive infections (52.2%).  P. aeruginosa and Staph. aureus documented invasive infections also occurred (16.7% and 16%, resp., in 13 and 13 patients, resp.).  Systemic signs of inflammation were usually weak or delayed.  The first invasive infection occurred before the age of 2 years in 53 (88.3%) and in the neonatal period in 19 (32.7%) patients.  Multiple or recurrent invasive infections were obsd. in most survivors (n = 36/50, 72%).Clin. outcome was poor, with 24 deaths, in 10 cases during the first invasive episode and in 16 cases of invasive pneumococcal disease.  However, no death and invasive infectious disease were reported in patients after the age of 8 years and 14 years, resp.  Antibiotic prophylaxis (n = 34), antipneumococcal vaccination (n = 31), and/or IgG infusion (n = 19), when instituted, had a beneficial impact on patients until the teenage years, with no seemingly detectable impact thereafter.IRAK-4 and MyD88 deficiencies predispose patients to recurrent life-threatening bacterial diseases, such as invasive pneumococcal disease in particular, in infancy and early childhood, with weak signs of inflammation.  Patients and families should be informed of the risk of developing life-threatening infections; empiric antibacterial treatment and immediate medical consultation are strongly recommended in cases of suspected infection or moderate fever.  Prophylactic measures in childhood are beneficial, until spontaneous improvement occurs in adolescence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGaZKIOSMgkLVg90H21EOLACvtfcHk0lgXOT6mCSwv5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtl2lt7vI&md5=ed6d1e73355d1c7720c255073c999d9b</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1097%2FMD.0b013e3181fd8ec3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FMD.0b013e3181fd8ec3%26sid%3Dliteratum%253Aachs%26aulast%3DPicard%26aufirst%3DC.%26aulast%3Dvon%2BBernuth%26aufirst%3DH.%26aulast%3DGhandil%26aufirst%3DP.%26aulast%3DChrabieh%26aufirst%3DM.%26aulast%3DLevy%26aufirst%3DO.%26aulast%3DArkwright%26aufirst%3DP.%2BD.%26aulast%3DMcDonald%26aufirst%3DD.%26aulast%3DGeha%26aufirst%3DR.%2BS.%26aulast%3DTakada%26aufirst%3DH.%26aulast%3DKrause%26aufirst%3DJ.%2BC.%26aulast%3DCreech%26aufirst%3DC.%2BB.%26aulast%3DKu%26aufirst%3DC.-L.%26aulast%3DEhl%26aufirst%3DS.%26aulast%3DMa%25C5%2595odi%26aufirst%3D%25C4%25B9.%26aulast%3DAl-Muhsen%26aufirst%3DS.%26aulast%3DAl-Hajjar%26aufirst%3DS.%26aulast%3DAl-Ghonaium%26aufirst%3DA.%26aulast%3DDay-Good%26aufirst%3DN.%2BK.%26aulast%3DHolland%26aufirst%3DS.%2BM.%26aulast%3DGallin%26aufirst%3DJ.%26aulast%3DChapel%26aufirst%3DH.%26aulast%3DSpeert%26aufirst%3DD.%2BP.%26aulast%3DRodriguez-Gallego%26aufirst%3DC.%26aulast%3DColino%26aufirst%3DE.%26aulast%3DGarty%26aufirst%3DB.-Z.%26aulast%3DRoifman%26aufirst%3DC.%26aulast%3DHara%26aufirst%3DT.%26aulast%3DYoshikawa%26aufirst%3DH.%26aulast%3DNonoyama%26aufirst%3DS.%26aulast%3DDomachowske%26aufirst%3DJ.%26aulast%3DIssekutz%26aufirst%3DA.%2BC.%26aulast%3DTang%26aufirst%3DM.%26aulast%3DSmart%26aufirst%3DJ.%26aulast%3DZitnik%26aufirst%3DS.%2BE.%26aulast%3DHoarau%26aufirst%3DC.%26aulast%3DKumararatne%26aufirst%3DD.%26aulast%3DThrasher%26aufirst%3DA.%26aulast%3DDavies%26aufirst%3DE.%2BG.%26aulast%3DBethune%26aufirst%3DC.%26aulast%3DSirvent%26aufirst%3DN.%26aulast%3Dde%2BRicaud%26aufirst%3DD.%26aulast%3DCamcioglu%26aufirst%3DY.%26aulast%3DVasconcelos%26aufirst%3DJ.%2Bu.%26aulast%3DGuedes%26aufirst%3DM.%26aulast%3DVitor%26aufirst%3DA.%2BB.%26aulast%3DRodrigo%26aufirst%3DC.%26aulast%3DAlmaz%25C3%25A1n%26aufirst%3DF.%26aulast%3D%25E1%25B8%25BEendez%26aufirst%3DM.%26aulast%3DA%25C5%2595ostegui%26aufirst%3DJ.%2BI.%26aulast%3DAlsina%26aufirst%3DL.%26aulast%3DFortuny%26aufirst%3DC.%26aulast%3DReichenbach%26aufirst%3DJ.%26aulast%3DVerbsky%26aufirst%3DJ.%2BW.%26aulast%3DBossuyt%26aufirst%3DX.%26aulast%3DDoffinger%26aufirst%3DR.%26aulast%3DAbel%26aufirst%3DL.%26aulast%3DPuel%26aufirst%3DA.%26aulast%3DCasanova%26aufirst%3DJ.-L.%26atitle%3DClinical%2520features%2520and%2520outcome%2520of%2520patients%2520with%2520IRAK-4%2520and%2520MyD88%2520deficiency%26jtitle%3DMedicine%26date%3D2010%26volume%3D89%26spage%3D403%26epage%3D425%26doi%3D10.1097%2FMD.0b013e3181fd8ec3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Razani, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichardt, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, G.</span></span> <span> </span><span class="NLM_article-title">Non-canonical NF-κB signaling activation and regulation: principles and perspectives</span>. <i>Immunol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>244</i></span>,  <span class="NLM_fpage">44</span>– <span class="NLM_lpage">54</span>, <span class="refDoi"> DOI: 10.1111/j.1600-065X.2011.01059.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1111%2Fj.1600-065X.2011.01059.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=22017430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFagsL%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=244&publication_year=2011&pages=44-54&author=B.+Razaniauthor=A.+D.+Reichardtauthor=G.+Cheng&title=Non-canonical+NF-%CE%BAB+signaling+activation+and+regulation%3A+principles+and+perspectives&doi=10.1111%2Fj.1600-065X.2011.01059.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Non-canonical NF-κB signaling activation and regulation: principles and perspectives</span></div><div class="casAuthors">Razani, Bahram; Reichardt, Anna Devi; Cheng, Genhong</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">244</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">44-54</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">1600-065X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Nuclear-factor κB (NF-κB) transcription factors are activated by a wide variety of stimuli in diverse cell types and control key aspects of immune function and development.  Receptor-mediated activation of NF-κB appears to occur through two distinct signaling pathways termed as the canonical and non-canonical NF-κB pathways.  Although much work has demonstrated the physiol. importance of non-canonical NF-κB signaling to immunity and its involvement in diverse pathologies, such as cancers and autoimmune disease, the architecture and regulation of the pathway is only beginning to be understood.  The non-canonical pathway appears to be activated by a select set of receptors within the tumor necrosis factor superfamily, and we discuss the mol. mechanisms that connect ligation of these receptors to pathway activation.  It has become increasingly clear that the key regulatory step of the pathway involves modulation of the post-translational degrdn. of NF-κB-inducing kinase (NIK), the central activating kinase of non-canonical NF-κB signaling.  How NIK post-translational stability is controlled before and after receptor ligation is an important aspect of understanding non-canonical NF-κB signaling.  Furthermore, how release of NF-κB dimers downstream of the pathway's activation is actually connected to its identified physiol. and pathol. roles is a key remaining question in the field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxjtZ3BYUJjrVg90H21EOLACvtfcHk0lhJqf_jCtgnRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFagsL%252FK&md5=b4b7e40a5437602ea0a61aaa5577e1f3</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-065X.2011.01059.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-065X.2011.01059.x%26sid%3Dliteratum%253Aachs%26aulast%3DRazani%26aufirst%3DB.%26aulast%3DReichardt%26aufirst%3DA.%2BD.%26aulast%3DCheng%26aufirst%3DG.%26atitle%3DNon-canonical%2520NF-%25CE%25BAB%2520signaling%2520activation%2520and%2520regulation%253A%2520principles%2520and%2520perspectives%26jtitle%3DImmunol.%2520Rev.%26date%3D2011%26volume%3D244%26spage%3D44%26epage%3D54%26doi%3D10.1111%2Fj.1600-065X.2011.01059.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brightbill, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaquiere, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramamoorthi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sujatha-Bhaskar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gogol, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castanedo, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bents, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohli, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linge, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christian, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaochico, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berezhkovskiy, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modrusan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veliz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Townsend, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVoss, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godemann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenzie, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hackney, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staben, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alaoui Ismaili, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghilardi, N.</span></span> <span> </span><span class="NLM_article-title">NF-κB inducing kinase is a therapeutic target for systemic lupus erythematosus</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">179</span>– <span class="NLM_lpage">192</span>, <span class="refDoi"> DOI: 10.1038/s41467-017-02672-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1038%2Fs41467-017-02672-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=29330524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A280%3ADC%252BC1Mvgtlylug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=179-192&author=H.+D.+Brightbillauthor=E.+Sutoauthor=N.+Blaquiereauthor=N.+Ramamoorthiauthor=S.+Sujatha-Bhaskarauthor=E.+B.+Gogolauthor=G.+M.+Castanedoauthor=B.+T.+Jacksonauthor=Y.+C.+Kwonauthor=S.+Hallerauthor=J.+Leschauthor=K.+Bentsauthor=C.+Everettauthor=P.+B.+Kohliauthor=S.+Lingeauthor=L.+Christianauthor=K.+Barrettauthor=A.+Jaochicoauthor=L.+M.+Berezhkovskiyauthor=P.+W.+Fanauthor=Z.+Modrusanauthor=K.+Velizauthor=M.+J.+Townsendauthor=J.+DeVossauthor=A.+R.+Johnsonauthor=R.+Godemannauthor=W.+P.+Leeauthor=C.+D.+Austinauthor=B.+S.+McKenzieauthor=J.+A.+Hackneyauthor=J.+J.+Crawfordauthor=S.+T.+Stabenauthor=M.+H.+Alaoui+Ismailiauthor=L.+C.+Wuauthor=N.+Ghilardi&title=NF-%CE%BAB+inducing+kinase+is+a+therapeutic+target+for+systemic+lupus+erythematosus&doi=10.1038%2Fs41467-017-02672-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">NF-κB inducing kinase is a therapeutic target for systemic lupus erythematosus</span></div><div class="casAuthors">Brightbill Hans D; Sujatha-Bhaskar Swathi; Gogol Emily B; Jackson Benjamin T; Christian Laura; Wu Lawren C; Ghilardi Nico; Suto Eric; Kwon Youngsu C; Lesch Justin; DeVoss Jason; Lee Wyne P; McKenzie Brent S; Blaquiere Nicole; Castanedo Georgette M; Crawford James J; Staben Steven T; Ramamoorthi Nandhini; Townsend Michael J; Haller Susan; Austin Cary D; Bents Karin; Linge Sandra; Godemann Robert; Everett Christine; Kohli Pawan Bir; Barrett Kathy; Johnson Adam R; Alaoui Ismaili Moulay H; Jaochico Allan; Berezhkovskiy Leonid M; Fan Peter W; Modrusan Zora; Veliz Kelli; Hackney Jason A</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">179</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">NF-κB-inducing kinase (NIK) mediates non-canonical NF-κB signaling downstream of multiple TNF family members, including BAFF, TWEAK, CD40, and OX40, which are implicated in the pathogenesis of systemic lupus erythematosus (SLE).  Here, we show that experimental lupus in NZB/W F1 mice can be treated with a highly selective and potent NIK small molecule inhibitor.  Both in vitro as well as in vivo, NIK inhibition recapitulates the pharmacological effects of BAFF blockade, which is clinically efficacious in SLE.  Furthermore, NIK inhibition also affects T cell parameters in the spleen and proinflammatory gene expression in the kidney, which may be attributable to inhibition of OX40 and TWEAK signaling, respectively.  As a consequence, NIK inhibition results in improved survival, reduced renal pathology, and lower proteinuria scores.  Collectively, our data suggest that NIK inhibition is a potential therapeutic approach for SLE.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRSowPmlnIWxaqcneEtCi92fW6udTcc2ebko2N4UmP1n7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mvgtlylug%253D%253D&md5=41a91514e1f4e8b2b44912ba6d6a4788</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1038%2Fs41467-017-02672-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-017-02672-0%26sid%3Dliteratum%253Aachs%26aulast%3DBrightbill%26aufirst%3DH.%2BD.%26aulast%3DSuto%26aufirst%3DE.%26aulast%3DBlaquiere%26aufirst%3DN.%26aulast%3DRamamoorthi%26aufirst%3DN.%26aulast%3DSujatha-Bhaskar%26aufirst%3DS.%26aulast%3DGogol%26aufirst%3DE.%2BB.%26aulast%3DCastanedo%26aufirst%3DG.%2BM.%26aulast%3DJackson%26aufirst%3DB.%2BT.%26aulast%3DKwon%26aufirst%3DY.%2BC.%26aulast%3DHaller%26aufirst%3DS.%26aulast%3DLesch%26aufirst%3DJ.%26aulast%3DBents%26aufirst%3DK.%26aulast%3DEverett%26aufirst%3DC.%26aulast%3DKohli%26aufirst%3DP.%2BB.%26aulast%3DLinge%26aufirst%3DS.%26aulast%3DChristian%26aufirst%3DL.%26aulast%3DBarrett%26aufirst%3DK.%26aulast%3DJaochico%26aufirst%3DA.%26aulast%3DBerezhkovskiy%26aufirst%3DL.%2BM.%26aulast%3DFan%26aufirst%3DP.%2BW.%26aulast%3DModrusan%26aufirst%3DZ.%26aulast%3DVeliz%26aufirst%3DK.%26aulast%3DTownsend%26aufirst%3DM.%2BJ.%26aulast%3DDeVoss%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DGodemann%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DW.%2BP.%26aulast%3DAustin%26aufirst%3DC.%2BD.%26aulast%3DMcKenzie%26aufirst%3DB.%2BS.%26aulast%3DHackney%26aufirst%3DJ.%2BA.%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26aulast%3DStaben%26aufirst%3DS.%2BT.%26aulast%3DAlaoui%2BIsmaili%26aufirst%3DM.%2BH.%26aulast%3DWu%26aufirst%3DL.%2BC.%26aulast%3DGhilardi%26aufirst%3DN.%26atitle%3DNF-%25CE%25BAB%2520inducing%2520kinase%2520is%2520a%2520therapeutic%2520target%2520for%2520systemic%2520lupus%2520erythematosus%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26spage%3D179%26epage%3D192%26doi%3D10.1038%2Fs41467-017-02672-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vallabhapurapu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karin, M.</span></span> <span> </span><span class="NLM_article-title">Regulation and function of NF-κB transcription factors in the immune system</span>. <i>Annu. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">693</span>– <span class="NLM_lpage">733</span>, <span class="refDoi"> DOI: 10.1146/annurev.immunol.021908.132641</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1146%2Fannurev.immunol.021908.132641" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=19302050" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsFSlt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=693-733&author=S.+Vallabhapurapuauthor=M.+Karin&title=Regulation+and+function+of+NF-%CE%BAB+transcription+factors+in+the+immune+system&doi=10.1146%2Fannurev.immunol.021908.132641"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation and function of NF-κB transcription factors in the immune system</span></div><div class="casAuthors">Vallabhapurapu, Sivakumar; Karin, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Immunology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">693-733</span>CODEN:
                <span class="NLM_cas:coden">ARIMDU</span>;
        ISSN:<span class="NLM_cas:issn">0732-0582</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  The mammalian Rel/NF-κB family of transcription factors, including RelA, c-Rel, RelB, NF-κB1 (p50 and its precursor p105), and NF-κB2 (p52 and its precursor p100), plays a central role in the immune system by regulating several processes ranging from the development and survival of lymphocytes and lymphoid organs to the control of immune responses and malignant transformation.  The 5 members of the NF-κB family are normally kept inactive in the cytoplasm by interaction with inhibitors called IκBs or the unprocessed forms of NF-κB1 and NF-κB2.  A wide variety of signals emanating from antigen receptors, pattern-recognition receptors, receptors for the members of TNF and IL-1 cytokine families, and others induce differential activation of NF-κB heterodimers.  Although work over the past two decades has shed significant light on the regulation of NF-κB transcription factors and their functions, much progress has been made in the past two years revealing new insights into the regulation and functions of NF-κB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAbeMOsSfPT7Vg90H21EOLACvtfcHk0likTMOHBi4igA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsFSlt7o%253D&md5=9353fabd1673c6191220ef4acaf95c32</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1146%2Fannurev.immunol.021908.132641&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.immunol.021908.132641%26sid%3Dliteratum%253Aachs%26aulast%3DVallabhapurapu%26aufirst%3DS.%26aulast%3DKarin%26aufirst%3DM.%26atitle%3DRegulation%2520and%2520function%2520of%2520NF-%25CE%25BAB%2520transcription%2520factors%2520in%2520the%2520immune%2520system%26jtitle%3DAnnu.%2520Rev.%2520Immunol.%26date%3D2009%26volume%3D27%26spage%3D693%26epage%3D733%26doi%3D10.1146%2Fannurev.immunol.021908.132641" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, S.-C.</span></span> <span> </span><span class="NLM_article-title">The non-canonical NF-κB pathway in immunity and inflammation</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">545</span>– <span class="NLM_lpage">558</span>, <span class="refDoi"> DOI: 10.1038/nri.2017.52</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1038%2Fnri.2017.52" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=28580957" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpt1OgsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=545-558&author=S.-C.+Sun&title=The+non-canonical+NF-%CE%BAB+pathway+in+immunity+and+inflammation&doi=10.1038%2Fnri.2017.52"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">The non-canonical NF-κB pathway in immunity and inflammation</span></div><div class="casAuthors">Sun, Shao-Cong</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">545-558</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The nuclear factor-κB (NF-κB) family of transcription factors is activated by canonical and non-canonical signalling pathways, which differ in both signalling components and biol. functions.  Recent studies have revealed important roles for the non-canonical NF-κB pathway in regulating different aspects of immune functions.  Defects in non-canonical NF-κB signalling are assocd. with severe immune deficiencies, whereas dysregulated activation of this pathway contributes to the pathogenesis of various autoimmune and inflammatory diseases.  Here we review the signalling mechanisms and the biol. function of the non-canonical NF-κB pathway.  We also discuss recent progress in elucidating the mol. mechanisms regulating non-canonical NF-κB pathway activation, which may provide new opportunities for therapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpz7QEbrIECD7Vg90H21EOLACvtfcHk0likTMOHBi4igA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpt1OgsLw%253D&md5=b28dd6a87e76f3b61b5e108a24cf62f9</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1038%2Fnri.2017.52&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri.2017.52%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DS.-C.%26atitle%3DThe%2520non-canonical%2520NF-%25CE%25BAB%2520pathway%2520in%2520immunity%2520and%2520inflammation%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2017%26volume%3D17%26spage%3D545%26epage%3D558%26doi%3D10.1038%2Fnri.2017.52" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Madonna, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullman, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gentilcore, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmieri, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ascierto, P. A.</span></span> <span> </span><span class="NLM_article-title">NF-κB as potential target in the treatment of melanoma</span>. <i>J. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">53</span>– <span class="NLM_lpage">60</span>, <span class="refDoi"> DOI: 10.1186/1479-5876-10-53</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1186%2F1479-5876-10-53" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=22433222" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC38XosVelsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2012&pages=53-60&author=G.+Madonnaauthor=C.+D.+Ullmanauthor=G.+Gentilcoreauthor=G.+Palmieriauthor=P.+A.+Ascierto&title=NF-%CE%BAB+as+potential+target+in+the+treatment+of+melanoma&doi=10.1186%2F1479-5876-10-53"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">NF-κB as potential target in the treatment of melanoma</span></div><div class="casAuthors">Madonna, Gabriele; Dansky Ullman, Claudio; Gentilcore, Giusy; Palmieri, Giuseppe; Ascierto, Paolo Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Translational Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">53</span>CODEN:
                <span class="NLM_cas:coden">JTMOBV</span>;
        ISSN:<span class="NLM_cas:issn">1479-5876</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  The RAS/MAP kinase pathway has attracted attention because activating mutations of the BRAF serine/threonine kinase was described in over 50% of melanomas.  Very recently, selective and potent BRAF inhibitors have been developed.  Several other signal transduction pathways have been found to be constitutively active or mutated in other subsets of melanoma tumors that are potentially targetable with new agents.  Among these, NF-κB is another pathway that melanoma tumors use to achieve survival, proliferation and resistance to apoptosis.  Inhibition of NF-κB activation appears to be a very promising option for anti-cancer therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMWyr3R9S7XLVg90H21EOLACvtfcHk0likTMOHBi4igA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XosVelsLc%253D&md5=0b57ca0a874ebb02384f0e23e0a3474d</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1186%2F1479-5876-10-53&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1479-5876-10-53%26sid%3Dliteratum%253Aachs%26aulast%3DMadonna%26aufirst%3DG.%26aulast%3DUllman%26aufirst%3DC.%2BD.%26aulast%3DGentilcore%26aufirst%3DG.%26aulast%3DPalmieri%26aufirst%3DG.%26aulast%3DAscierto%26aufirst%3DP.%2BA.%26atitle%3DNF-%25CE%25BAB%2520as%2520potential%2520target%2520in%2520the%2520treatment%2520of%2520melanoma%26jtitle%3DJ.%2520Transl.%2520Med.%26date%3D2012%26volume%3D10%26spage%3D53%26epage%3D60%26doi%3D10.1186%2F1479-5876-10-53" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thu, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, A.</span></span> <span> </span><span class="NLM_article-title">NF-κB inducing kinase: a key regulator in the immune system and in cancer</span>. <i>Cytokine Growth Factor Rev.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">213</span>– <span class="NLM_lpage">226</span>, <span class="refDoi"> DOI: 10.1016/j.cytogfr.2010.06.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1016%2Fj.cytogfr.2010.06.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=20685151" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFGjsbbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2010&pages=213-226&author=Y.+M.+Thuauthor=A.+Richmond&title=NF-%CE%BAB+inducing+kinase%3A+a+key+regulator+in+the+immune+system+and+in+cancer&doi=10.1016%2Fj.cytogfr.2010.06.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">NF-κB inducing kinase: A key regulator in the immune system and in cancer</span></div><div class="casAuthors">Thu, Yee Mon; Richmond, Ann</div><div class="citationInfo"><span class="NLM_cas:title">Cytokine & Growth Factor Reviews</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">213-226</span>CODEN:
                <span class="NLM_cas:coden">CGFRFB</span>;
        ISSN:<span class="NLM_cas:issn">1359-6101</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  NF-κB inducing kinase (NIK) is a kinase that activates the canonical and non-canonical NF-κB pathways to control transcriptional expression of certain proteins such as cytokines, chemokines and NF-κB signaling mols.  Many advances have been made in understanding the mol. mechanisms by which the stability of NIK is regulated to affect downstream signaling.  Genetic mouse models suggest that NIK plays an essential role in the regulation of the immune system as well as in the bone microenvironment.  Increasing evidence links NIK to the tumorigenesis of hematol. cancers, such as multiple myeloma, and solid tumors, such as pancreatic carcinoma and melanoma.  Understanding the mechanism by which NIK is de-regulated will potentially provide therapeutic options for certain diseases such as autoimmunity and cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMtga85N1_7LVg90H21EOLACvtfcHk0lico56VUnW2kA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFGjsbbL&md5=5a8cebc7e8423336295544bcc4aab2d8</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1016%2Fj.cytogfr.2010.06.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cytogfr.2010.06.002%26sid%3Dliteratum%253Aachs%26aulast%3DThu%26aufirst%3DY.%2BM.%26aulast%3DRichmond%26aufirst%3DA.%26atitle%3DNF-%25CE%25BAB%2520inducing%2520kinase%253A%2520a%2520key%2520regulator%2520in%2520the%2520immune%2520system%2520and%2520in%2520cancer%26jtitle%3DCytokine%2520Growth%2520Factor%2520Rev.%26date%3D2010%26volume%3D21%26spage%3D213%26epage%3D226%26doi%3D10.1016%2Fj.cytogfr.2010.06.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kayagaki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seshasayee, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">French, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grewal, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cochran, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Starovasnik, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixit, V. M.</span></span> <span> </span><span class="NLM_article-title">BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-κB2</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">515</span>– <span class="NLM_lpage">524</span>, <span class="refDoi"> DOI: 10.1016/S1074-7613(02)00425-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1016%2FS1074-7613%2802%2900425-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2002&pages=515-524&author=N.+Kayagakiauthor=M.+Yanauthor=D.+Seshasayeeauthor=H.+Wangauthor=W.+Leeauthor=D.+M.+Frenchauthor=I.+S.+Grewalauthor=A.+G.+Cochranauthor=N.+C.+Gordonauthor=J.+Yinauthor=M.+A.+Starovasnikauthor=V.+M.+Dixit&title=BAFF%2FBLyS+receptor+3+binds+the+B+cell+survival+factor+BAFF+ligand+through+a+discrete+surface+loop+and+promotes+processing+of+NF-%CE%BAB2&doi=10.1016%2FS1074-7613%2802%2900425-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1016%2FS1074-7613%2802%2900425-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1074-7613%252802%252900425-9%26sid%3Dliteratum%253Aachs%26aulast%3DKayagaki%26aufirst%3DN.%26aulast%3DYan%26aufirst%3DM.%26aulast%3DSeshasayee%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DW.%26aulast%3DFrench%26aufirst%3DD.%2BM.%26aulast%3DGrewal%26aufirst%3DI.%2BS.%26aulast%3DCochran%26aufirst%3DA.%2BG.%26aulast%3DGordon%26aufirst%3DN.%2BC.%26aulast%3DYin%26aufirst%3DJ.%26aulast%3DStarovasnik%26aufirst%3DM.%2BA.%26aulast%3DDixit%26aufirst%3DV.%2BM.%26atitle%3DBAFF%252FBLyS%2520receptor%25203%2520binds%2520the%2520B%2520cell%2520survival%2520factor%2520BAFF%2520ligand%2520through%2520a%2520discrete%2520surface%2520loop%2520and%2520promotes%2520processing%2520of%2520NF-%25CE%25BAB2%26jtitle%3DImmunity%26date%3D2002%26volume%3D17%26spage%3D515%26epage%3D524%26doi%3D10.1016%2FS1074-7613%2802%2900425-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orrù, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Idda, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitzalis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pala, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zara, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sidore, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faà, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floris, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deiana, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asunis, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porcu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piras, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lobina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marongiu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serra, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marongiu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sole, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busonero, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maschio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cusano, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuccuru, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deidda, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poddie, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farina, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Virdis, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satta, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delitala, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cocco, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coghe, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorefice, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrigno, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ban, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barizzone, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerini, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piga, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firinu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kockum, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lima Bomfim, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfredsson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suarez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carreira, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castillo-Palma, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcus, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Congia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angius, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alarcón Riquelme, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">da Silva, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danieli, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Giacco, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathieu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montgomery, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosati, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawcer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Alfonso, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Todd, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novembre, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abecasis, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whalen, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marrosu, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meloni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanna, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorospe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiorillo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoledziewska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cucca, F.</span></span> <span> </span><span class="NLM_article-title">Overexpression of the cytokine BAFF and autoimmunity risk</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>376</i></span>,  <span class="NLM_fpage">1615</span>– <span class="NLM_lpage">1626</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1610528</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1056%2FNEJMoa1610528" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=28445677" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlOnsL%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=376&publication_year=2017&pages=1615-1626&author=M.+Steriauthor=V.+Orr%C3%B9author=M.+L.+Iddaauthor=M.+Pitzalisauthor=M.+Palaauthor=I.+Zaraauthor=C.+Sidoreauthor=V.+Fa%C3%A0author=M.+Florisauthor=M.+Deianaauthor=I.+Asunisauthor=E.+Porcuauthor=A.+Mulasauthor=M.+G.+Pirasauthor=M.+Lobinaauthor=S.+Laiauthor=M.+Marongiuauthor=V.+Serraauthor=M.+Marongiuauthor=G.+Soleauthor=F.+Busoneroauthor=A.+Maschioauthor=R.+Cusanoauthor=G.+Cuccuruauthor=F.+Deiddaauthor=F.+Poddieauthor=G.+Farinaauthor=M.+Deiauthor=F.+Virdisauthor=S.+Ollaauthor=M.+A.+Sattaauthor=M.+Paniauthor=A.+Delitalaauthor=E.+Coccoauthor=J.+Frauauthor=G.+Cogheauthor=L.+Loreficeauthor=G.+Fenuauthor=P.+Ferrignoauthor=M.+Banauthor=N.+Barizzoneauthor=M.+Leoneauthor=F.+R.+Gueriniauthor=M.+Pigaauthor=D.+Firinuauthor=I.+Kockumauthor=I.+Lima+Bomfimauthor=T.+Olssonauthor=L.+Alfredssonauthor=A.+Suarezauthor=P.+E.+Carreiraauthor=M.+J.+Castillo-Palmaauthor=J.+H.+Marcusauthor=M.+Congiaauthor=A.+Angiusauthor=M.+Melisauthor=A.+Gonzalezauthor=M.+E.+Alarc%C3%B3n+Riquelmeauthor=B.+M.+da+Silvaauthor=M.+Marchiniauthor=M.+G.+Danieliauthor=S.+Del+Giaccoauthor=A.+Mathieuauthor=A.+Paniauthor=S.+B.+Montgomeryauthor=G.+Rosatiauthor=J.+Hillertauthor=S.+Sawcerauthor=S.+D%E2%80%99Alfonsoauthor=J.+A.+Toddauthor=J.+Novembreauthor=G.+R.+Abecasisauthor=M.+B.+Whalenauthor=M.+G.+Marrosuauthor=A.+Meloniauthor=S.+Sannaauthor=M.+Gorospeauthor=D.+Schlessingerauthor=E.+Fiorilloauthor=M.+Zoledziewskaauthor=F.+Cucca&title=Overexpression+of+the+cytokine+BAFF+and+autoimmunity+risk&doi=10.1056%2FNEJMoa1610528"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Overexpression of the cytokine BAFF and autoimmunity risk</span></div><div class="casAuthors">Steri, M.; Orru, V.; Idda, M. L.; Pitzalis, M.; Pala, M.; Zara, I.; Sidore, C.; Faa, V.; Floris, M.; Deiana, M.; Asunis, I.; Porcu, E.; Mulas, A.; Piras, M. G.; Lobina, M.; Lai, S.; Marongiu, M.; Serra, V.; Sole, G.; Busonero, F.; Maschio, A.; Cusano, R.; Cuccuru, G.; Deidda, F.; Poddie, F.; Farina, G.; Dei, M.; Virdis, F.; Olla, S.; Satta, M. A.; Pani, M.; Delitala, A.; Cocco, E.; Frau, J.; Coghe, G.; Lorefice, L.; Fenu, G.; Ferrigno, P.; Ban, M.; Barizzone, N.; Leone, M.; Guerini, F. R.; Piga, M.; Firinu, D.; Kockum, I.; Lima Bomfim, I.; Olsson, T.; Alfredsson, L.; Suarez, A.; Carreira, P. E.; Castillo-Palma, M. J.; Marcus, J. H.; Congia, M.; Angius, A.; Melis, M.; Gonzalez, A.; Riquelme, M. E. A.; da Silva, B. M.; Marchini, M.; Danieli, M. G.; Del Giacco, S.; Mathieu, A.; Pani, A.; Montgomery, S. B.; Rosati, G.; Hillert, J.; Sawcer, S.; D'Alfonso, S.; Todd, J. A.; Novembre, J.; Abecasis, G. R.; Whalen, M. B.; Marrosu, M. G.; Meloni, A.; Sanna, S.; Gorospe, M.; Schlessinger, D.; Fiorillo, E.; Zoledziewska, M.; Cucca, F.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">376</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1615-1626</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Genomewide assocn. studies of autoimmune diseases have mapped hundreds of susceptibility regions in the genome.  However, only for a few assocn. signals has the causal gene been identified, and for even fewer have the causal variant and underlying mechanism been defined.  Coincident assocns. of DNA variants affecting both the risk of autoimmune disease and quant. immune variables provide an informative route to explore disease mechanisms and drug-targetable pathways.  METHODS Using case-control samples from Sardinia, Italy, we performed a genomewide assocn. study in multiple sclerosis followed by TNFSF13B locus-specific assocn. testing in systemic lupus erythematosus (SLE).  Extensive phenotyping of quant. immune variables, sequence-based fine mapping, cross-population and cross-phenotype analyses, and gene-expression studies were used to identify the causal variant and elucidate its mechanism of action.  Signatures of pos. selection were also investigated.  RESULTS A variant in TNFSF13B, encoding the cytokine and drug target B-cell activating factor (BAFF), was assocd. with multiple sclerosis as well as SLE.  The disease-risk allele was also assocd. with up-regulated humoral immunity through increased levels of sol. BAFF, B lymphocytes, and Igs.  The causal variant was identified: an insertion-deletion variant, GCTGT→A (in which A is the risk allele), yielded a shorter transcript that escaped microRNA inhibition and increased prodn. of sol. BAFF, which in turn up-regulated humoral immunity.  Population genetic signatures indicated that this autoimmunity variant has been evolutionarily advantageous, most likely by augmenting resistance to malaria.  CONCLUSIONS A TNFSF13B variant was assocd. with multiple sclerosis and SLE, and its effects were clarified at the population, cellular, and mol. levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqo_9hexYorUbVg90H21EOLACvtfcHk0lh6UUBzNgAxZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlOnsL%252FK&md5=acf28962ecdf6bdf4fbe65cfe88f9fb2</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1610528&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1610528%26sid%3Dliteratum%253Aachs%26aulast%3DSteri%26aufirst%3DM.%26aulast%3DOrr%25C3%25B9%26aufirst%3DV.%26aulast%3DIdda%26aufirst%3DM.%2BL.%26aulast%3DPitzalis%26aufirst%3DM.%26aulast%3DPala%26aufirst%3DM.%26aulast%3DZara%26aufirst%3DI.%26aulast%3DSidore%26aufirst%3DC.%26aulast%3DFa%25C3%25A0%26aufirst%3DV.%26aulast%3DFloris%26aufirst%3DM.%26aulast%3DDeiana%26aufirst%3DM.%26aulast%3DAsunis%26aufirst%3DI.%26aulast%3DPorcu%26aufirst%3DE.%26aulast%3DMulas%26aufirst%3DA.%26aulast%3DPiras%26aufirst%3DM.%2BG.%26aulast%3DLobina%26aufirst%3DM.%26aulast%3DLai%26aufirst%3DS.%26aulast%3DMarongiu%26aufirst%3DM.%26aulast%3DSerra%26aufirst%3DV.%26aulast%3DMarongiu%26aufirst%3DM.%26aulast%3DSole%26aufirst%3DG.%26aulast%3DBusonero%26aufirst%3DF.%26aulast%3DMaschio%26aufirst%3DA.%26aulast%3DCusano%26aufirst%3DR.%26aulast%3DCuccuru%26aufirst%3DG.%26aulast%3DDeidda%26aufirst%3DF.%26aulast%3DPoddie%26aufirst%3DF.%26aulast%3DFarina%26aufirst%3DG.%26aulast%3DDei%26aufirst%3DM.%26aulast%3DVirdis%26aufirst%3DF.%26aulast%3DOlla%26aufirst%3DS.%26aulast%3DSatta%26aufirst%3DM.%2BA.%26aulast%3DPani%26aufirst%3DM.%26aulast%3DDelitala%26aufirst%3DA.%26aulast%3DCocco%26aufirst%3DE.%26aulast%3DFrau%26aufirst%3DJ.%26aulast%3DCoghe%26aufirst%3DG.%26aulast%3DLorefice%26aufirst%3DL.%26aulast%3DFenu%26aufirst%3DG.%26aulast%3DFerrigno%26aufirst%3DP.%26aulast%3DBan%26aufirst%3DM.%26aulast%3DBarizzone%26aufirst%3DN.%26aulast%3DLeone%26aufirst%3DM.%26aulast%3DGuerini%26aufirst%3DF.%2BR.%26aulast%3DPiga%26aufirst%3DM.%26aulast%3DFirinu%26aufirst%3DD.%26aulast%3DKockum%26aufirst%3DI.%26aulast%3DLima%2BBomfim%26aufirst%3DI.%26aulast%3DOlsson%26aufirst%3DT.%26aulast%3DAlfredsson%26aufirst%3DL.%26aulast%3DSuarez%26aufirst%3DA.%26aulast%3DCarreira%26aufirst%3DP.%2BE.%26aulast%3DCastillo-Palma%26aufirst%3DM.%2BJ.%26aulast%3DMarcus%26aufirst%3DJ.%2BH.%26aulast%3DCongia%26aufirst%3DM.%26aulast%3DAngius%26aufirst%3DA.%26aulast%3DMelis%26aufirst%3DM.%26aulast%3DGonzalez%26aufirst%3DA.%26aulast%3DAlarc%25C3%25B3n%2BRiquelme%26aufirst%3DM.%2BE.%26aulast%3Dda%2BSilva%26aufirst%3DB.%2BM.%26aulast%3DMarchini%26aufirst%3DM.%26aulast%3DDanieli%26aufirst%3DM.%2BG.%26aulast%3DDel%2BGiacco%26aufirst%3DS.%26aulast%3DMathieu%26aufirst%3DA.%26aulast%3DPani%26aufirst%3DA.%26aulast%3DMontgomery%26aufirst%3DS.%2BB.%26aulast%3DRosati%26aufirst%3DG.%26aulast%3DHillert%26aufirst%3DJ.%26aulast%3DSawcer%26aufirst%3DS.%26aulast%3DD%25E2%2580%2599Alfonso%26aufirst%3DS.%26aulast%3DTodd%26aufirst%3DJ.%2BA.%26aulast%3DNovembre%26aufirst%3DJ.%26aulast%3DAbecasis%26aufirst%3DG.%2BR.%26aulast%3DWhalen%26aufirst%3DM.%2BB.%26aulast%3DMarrosu%26aufirst%3DM.%2BG.%26aulast%3DMeloni%26aufirst%3DA.%26aulast%3DSanna%26aufirst%3DS.%26aulast%3DGorospe%26aufirst%3DM.%26aulast%3DSchlessinger%26aufirst%3DD.%26aulast%3DFiorillo%26aufirst%3DE.%26aulast%3DZoledziewska%26aufirst%3DM.%26aulast%3DCucca%26aufirst%3DF.%26atitle%3DOverexpression%2520of%2520the%2520cytokine%2520BAFF%2520and%2520autoimmunity%2520risk%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2017%26volume%3D376%26spage%3D1615%26epage%3D1626%26doi%3D10.1056%2FNEJMoa1610528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Noort, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Zoest, K. P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weijers, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koolwijk, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maracle, C. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novack, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siemerink, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlingemann, R. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tak, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tas, S. W.</span></span> <span> </span><span class="NLM_article-title">NF-κB-inducing kinase is a key regulator of inflammation-induced and tumour-associated angiogenesis</span>. <i>J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>234</i></span>,  <span class="NLM_fpage">375</span>– <span class="NLM_lpage">385</span>, <span class="refDoi"> DOI: 10.1002/path.4403</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1002%2Fpath.4403" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=25043127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslCqtrnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=234&publication_year=2014&pages=375-385&author=A.+R.+Noortauthor=K.+P.+M.+van+Zoestauthor=E.+M.+Weijersauthor=P.+Koolwijkauthor=C.+X.+Maracleauthor=D.+V.+Novackauthor=M.+J.+Siemerinkauthor=R.+O.+Schlingemannauthor=P.+P.+Takauthor=S.+W.+Tas&title=NF-%CE%BAB-inducing+kinase+is+a+key+regulator+of+inflammation-induced+and+tumour-associated+angiogenesis&doi=10.1002%2Fpath.4403"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">NF-κB-inducing kinase is a key regulator of inflammation-induced and tumour-associated angiogenesis</span></div><div class="casAuthors">Noort, Ae R.; van Zoest, Katinka PM; Weijers, Ester M.; Koolwijk, Pieter; Maracle, Chrissta X.; Novack, Deborah V.; Siemerink, Martin J.; Schlingemann, Reinier O.; Tak, Paul P.; Tas, Sander W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pathology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">234</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">375-385</span>CODEN:
                <span class="NLM_cas:coden">JPTLAS</span>;
        ISSN:<span class="NLM_cas:issn">1096-9896</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Angiogenesis is essential during development and in pathol. conditions such as chronic inflammation and cancer progression.  Inhibition of angiogenesis by targeting vascular endothelial growth factor (VEGF) blocks disease progression, but most patients eventually develop resistance which may result from compensatory signalling pathways.  In endothelial cells (ECs), expression of the pro-angiogenic chemokine CXCL12 is regulated by non-canonical nuclear factor (NF)-κB signalling.  Here, we report that NF-κB-inducing kinase (NIK) and subsequent non-canonical NF-κB signalling regulate both inflammation-induced and tumor-assocd. angiogenesis.  NIK is highly expressed in endothelial cells (ECs) in tumor tissues and inflamed rheumatoid arthritis synovial tissue.  Furthermore, non-canonical NF-κB signalling in human microvascular ECs significantly enhanced vascular tube formation, which was completely blocked by siRNA targeting NIK.  Interestingly, Nik-/- mice exhibited normal angiogenesis during development and unaltered TNFα- or VEGF-induced angiogenic responses, whereas angiogenesis induced by non-canonical NF-κB stimuli was significantly reduced.  In addn., angiogenesis in exptl. arthritis and a murine tumor model was severely impaired in these mice.  These studies provide evidence for a role of non-canonical NF-κB signalling in pathol. angiogenesis, and identify NIK as a potential therapeutic target in chronic inflammatory diseases and tumor neoangiogenesis. © 2014 The Authors.  The Journal of Pathol. published by John Wiley & Sons Ltd on behalf of Pathol. Society of Great Britain and Ireland.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGmctnhHR1SrVg90H21EOLACvtfcHk0ljWLbqAUTdAHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslCqtrnE&md5=94bdaa642c3246981d16f79958dbc5d9</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1002%2Fpath.4403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpath.4403%26sid%3Dliteratum%253Aachs%26aulast%3DNoort%26aufirst%3DA.%2BR.%26aulast%3Dvan%2BZoest%26aufirst%3DK.%2BP.%2BM.%26aulast%3DWeijers%26aufirst%3DE.%2BM.%26aulast%3DKoolwijk%26aufirst%3DP.%26aulast%3DMaracle%26aufirst%3DC.%2BX.%26aulast%3DNovack%26aufirst%3DD.%2BV.%26aulast%3DSiemerink%26aufirst%3DM.%2BJ.%26aulast%3DSchlingemann%26aufirst%3DR.%2BO.%26aulast%3DTak%26aufirst%3DP.%2BP.%26aulast%3DTas%26aufirst%3DS.%2BW.%26atitle%3DNF-%25CE%25BAB-inducing%2520kinase%2520is%2520a%2520key%2520regulator%2520of%2520inflammation-induced%2520and%2520tumour-associated%2520angiogenesis%26jtitle%3DJ.%2520Pathol.%26date%3D2014%26volume%3D234%26spage%3D375%26epage%3D385%26doi%3D10.1002%2Fpath.4403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aya, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alhawagri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagen-Stapleton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitaura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanagawa, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veis Novack, D.</span></span> <span> </span><span class="NLM_article-title">NF-κB-inducing kinase controls lymphocyte and osteoclast activities in inflammatory arthritis</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">1848</span>– <span class="NLM_lpage">1854</span>, <span class="refDoi"> DOI: 10.1172/JCI23763</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1172%2FJCI23763" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2005&pages=1848-1854&author=K.+Ayaauthor=M.+Alhawagriauthor=A.+Hagen-Stapletonauthor=H.+Kitauraauthor=O.+Kanagawaauthor=D.+Veis+Novack&title=NF-%CE%BAB-inducing+kinase+controls+lymphocyte+and+osteoclast+activities+in+inflammatory+arthritis&doi=10.1172%2FJCI23763"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1172%2FJCI23763&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI23763%26sid%3Dliteratum%253Aachs%26aulast%3DAya%26aufirst%3DK.%26aulast%3DAlhawagri%26aufirst%3DM.%26aulast%3DHagen-Stapleton%26aufirst%3DA.%26aulast%3DKitaura%26aufirst%3DH.%26aulast%3DKanagawa%26aufirst%3DO.%26aulast%3DVeis%2BNovack%26aufirst%3DD.%26atitle%3DNF-%25CE%25BAB-inducing%2520kinase%2520controls%2520lymphocyte%2520and%2520osteoclast%2520activities%2520in%2520inflammatory%2520arthritis%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2005%26volume%3D115%26spage%3D1848%26epage%3D1854%26doi%3D10.1172%2FJCI23763" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Storz, P.</span></span> <span> </span><span class="NLM_article-title">Targeting the alternative NF-κB pathway in pancreatic cancer: a new direction for therapy?</span>. <i>Expert Rev. Anticancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">501</span>– <span class="NLM_lpage">504</span>, <span class="refDoi"> DOI: 10.1586/era.13.28</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1586%2Fera.13.28" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=23617340" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmsFWlsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=501-504&author=P.+Storz&title=Targeting+the+alternative+NF-%CE%BAB+pathway+in+pancreatic+cancer%3A+a+new+direction+for+therapy%3F&doi=10.1586%2Fera.13.28"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the alternative NF-κB pathway in pancreatic cancer: a new direction for therapy?</span></div><div class="casAuthors">Storz, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anticancer Therapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">501-504</span>CODEN:
                <span class="NLM_cas:coden">ERATBJ</span>;
        ISSN:<span class="NLM_cas:issn">1473-7140</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  Pancreatic cancer, due to its late diagnosis,is difficult to treat.  In addn., current therapy options are insufficient and new approaches for combination treatment are required.  Recent demonstration of the importance of constitutive signaling of NF-κB-inducing kinase (NIK,also named MAP3K14) in maintaining the high basal activity of the alternative NF-κB pathway in pancreatic cancer suggests novel possibilities for therapeutic intervention.  Strategies to target the alternative NF-κB pathway include not only the use of small mol. inhibitors for NIK and IκB kinase a (IKKa), but also broad spectrum approaches such as using proteasome inhibitors or combinatorial approaches targeting both alternative and canonical pathways.  These may also act synergistically with currently used drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkO5O_6UCQkrVg90H21EOLACvtfcHk0ljWLbqAUTdAHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmsFWlsL4%253D&md5=a4945c62cf71cb211141608f6790b853</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1586%2Fera.13.28&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252Fera.13.28%26sid%3Dliteratum%253Aachs%26aulast%3DStorz%26aufirst%3DP.%26atitle%3DTargeting%2520the%2520alternative%2520NF-%25CE%25BAB%2520pathway%2520in%2520pancreatic%2520cancer%253A%2520a%2520new%2520direction%2520for%2520therapy%253F%26jtitle%3DExpert%2520Rev.%2520Anticancer%2520Ther.%26date%3D2013%26volume%3D13%26spage%3D501%26epage%3D504%26doi%3D10.1586%2Fera.13.28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Castanedo, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaquiere, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beresini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bravo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brightbill, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, H.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godemann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gogol, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hymowitz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kayagaki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohli, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knüppel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraemer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krüger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loke, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEwan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montalbetti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinbacher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sujatha-Bhaskar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staben, S. T.</span></span> <span> </span><span class="NLM_article-title">Structure-based design of tricyclic NF-κB inducing kinase (NIK) inhibitors that have high selectivity over phosphoinositide-3-kinase (PI3K)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">627</span>– <span class="NLM_lpage">640</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01363</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01363" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFCgs7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=627-640&author=G.+M.+Castanedoauthor=N.+Blaquiereauthor=M.+Beresiniauthor=B.+Bravoauthor=H.+Brightbillauthor=J.+Chenauthor=H.-F.+Cuiauthor=C.+Eigenbrotauthor=C.+Everettauthor=J.+Fengauthor=R.+Godemannauthor=E.+Gogolauthor=S.+Hymowitzauthor=A.+Johnsonauthor=N.+Kayagakiauthor=P.+B.+Kohliauthor=K.+Kn%C3%BCppelauthor=J.+Kraemerauthor=S.+Kr%C3%BCgerauthor=P.+Lokeauthor=P.+McEwanauthor=C.+Montalbettiauthor=D.+A.+Robertsauthor=M.+Smithauthor=S.+Steinbacherauthor=S.+Sujatha-Bhaskarauthor=R.+Takahashiauthor=X.+Wangauthor=L.+C.+Wuauthor=Y.+Zhangauthor=S.+T.+Staben&title=Structure-based+design+of+tricyclic+NF-%CE%BAB+inducing+kinase+%28NIK%29+inhibitors+that+have+high+selectivity+over+phosphoinositide-3-kinase+%28PI3K%29&doi=10.1021%2Facs.jmedchem.6b01363"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design of Tricyclic NF-κB Inducing Kinase (NIK) Inhibitors That Have High Selectivity over Phosphoinositide-3-kinase (PI3K)</span></div><div class="casAuthors">Castanedo, Georgette M.; Blaquiere, Nicole; Beresini, Maureen; Bravo, Brandon; Brightbill, Hans; Chen, Jacob; Cui, Hai-Feng; Eigenbrot, Charles; Everett, Christine; Feng, Jianwen; Godemann, Robert; Gogol, Emily; Hymowitz, Sarah; Johnson, Adam; Kayagaki, Nobuhiko; Kohli, Pawan Bir; Knuppel, Kathleen; Kraemer, Joachim; Kruger, Susan; Loke, Pui; McEwan, Paul; Montalbetti, Christian; Roberts, David A.; Smith, Myron; Steinbacher, Stefan; Sujatha-Bhaskar, Swathi; Takahashi, Ryan; Wang, Xiaolu; Wu, Lawren C.; Zhang, Yamin; Staben, Steven T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">627-640</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors report a structure-guided optimization of a novel series of NF-κB inducing kinase (NIK) inhibitors.  Starting from a modestly potent, low mol. wt. lead, activity was improved by designing a type I1/2 binding mode that accessed a back pocket past the methionine-471 gatekeeper.  Divergent binding modes in NIK and PI3K were used to dampen PI3K-inhibition while maintaining NIK inhibition within these series.  Potent compds. were discovered that selectively inhibit the nuclear translocation of NF-kB2 (p52/REL-B) but not canonical NF-kB1 (REL-A/p50).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrws-sPXJiSfLVg90H21EOLACvtfcHk0ljpxowruMk4jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFCgs7bK&md5=316b70f51a5b800ba810082d0b3862da</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01363%26sid%3Dliteratum%253Aachs%26aulast%3DCastanedo%26aufirst%3DG.%2BM.%26aulast%3DBlaquiere%26aufirst%3DN.%26aulast%3DBeresini%26aufirst%3DM.%26aulast%3DBravo%26aufirst%3DB.%26aulast%3DBrightbill%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DCui%26aufirst%3DH.-F.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DEverett%26aufirst%3DC.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DGodemann%26aufirst%3DR.%26aulast%3DGogol%26aufirst%3DE.%26aulast%3DHymowitz%26aufirst%3DS.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DKayagaki%26aufirst%3DN.%26aulast%3DKohli%26aufirst%3DP.%2BB.%26aulast%3DKn%25C3%25BCppel%26aufirst%3DK.%26aulast%3DKraemer%26aufirst%3DJ.%26aulast%3DKr%25C3%25BCger%26aufirst%3DS.%26aulast%3DLoke%26aufirst%3DP.%26aulast%3DMcEwan%26aufirst%3DP.%26aulast%3DMontalbetti%26aufirst%3DC.%26aulast%3DRoberts%26aufirst%3DD.%2BA.%26aulast%3DSmith%26aufirst%3DM.%26aulast%3DSteinbacher%26aufirst%3DS.%26aulast%3DSujatha-Bhaskar%26aufirst%3DS.%26aulast%3DTakahashi%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DL.%2BC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DStaben%26aufirst%3DS.%2BT.%26atitle%3DStructure-based%2520design%2520of%2520tricyclic%2520NF-%25CE%25BAB%2520inducing%2520kinase%2520%2528NIK%2529%2520inhibitors%2520that%2520have%2520high%2520selectivity%2520over%2520phosphoinositide-3-kinase%2520%2528PI3K%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D627%26epage%3D640%26doi%3D10.1021%2Facs.jmedchem.6b01363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de Leon-Boenig, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franke, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staben, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Starovasnik, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallweber, H. J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hymowitz, S. G.</span></span> <span> </span><span class="NLM_article-title">The Crystal Structure of the Catalytic Domain of the NF-κB Inducing Kinase Reveals a Narrow but Flexible Active Site</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1704</span>– <span class="NLM_lpage">1714</span>, <span class="refDoi"> DOI: 10.1016/j.str.2012.07.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1016%2Fj.str.2012.07.013" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=1704-1714&author=G.+de+Leon-Boenigauthor=K.+K.+Bowmanauthor=J.+A.+Fengauthor=T.+Crawfordauthor=C.+Everettauthor=Y.+Frankeauthor=A.+Ohauthor=M.+Stanleyauthor=S.+T.+Stabenauthor=M.+A.+Starovasnikauthor=H.+J.+A.+Wallweberauthor=J.+Wuauthor=L.+C.+Wuauthor=A.+R.+Johnsonauthor=S.+G.+Hymowitz&title=The+Crystal+Structure+of+the+Catalytic+Domain+of+the+NF-%CE%BAB+Inducing+Kinase+Reveals+a+Narrow+but+Flexible+Active+Site&doi=10.1016%2Fj.str.2012.07.013"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2012.07.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2012.07.013%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BLeon-Boenig%26aufirst%3DG.%26aulast%3DBowman%26aufirst%3DK.%2BK.%26aulast%3DFeng%26aufirst%3DJ.%2BA.%26aulast%3DCrawford%26aufirst%3DT.%26aulast%3DEverett%26aufirst%3DC.%26aulast%3DFranke%26aufirst%3DY.%26aulast%3DOh%26aufirst%3DA.%26aulast%3DStanley%26aufirst%3DM.%26aulast%3DStaben%26aufirst%3DS.%2BT.%26aulast%3DStarovasnik%26aufirst%3DM.%2BA.%26aulast%3DWallweber%26aufirst%3DH.%2BJ.%2BA.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DL.%2BC.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DHymowitz%26aufirst%3DS.%2BG.%26atitle%3DThe%2520Crystal%2520Structure%2520of%2520the%2520Catalytic%2520Domain%2520of%2520the%2520NF-%25CE%25BAB%2520Inducing%2520Kinase%2520Reveals%2520a%2520Narrow%2520but%2520Flexible%2520Active%2520Site%26jtitle%3DStructure%26date%3D2012%26volume%3D20%26spage%3D1704%26epage%3D1714%26doi%3D10.1016%2Fj.str.2012.07.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGee, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sudom, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubenstein, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anwer, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cushing, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayres, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eksterowicz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faulder, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waszkowycz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plotnikova, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrelly, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span> <span> </span><span class="NLM_article-title">Inhibiting NF-κB-inducing kinase (NIK): Discovery, structure-based design, synthesis, structure–activity relationship, and co-crystal structures</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1238</span>– <span class="NLM_lpage">1244</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.01.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1016%2Fj.bmcl.2013.01.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=23374866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVGmt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=1238-1244&author=K.+Liauthor=L.+R.+McGeeauthor=B.+Fisherauthor=A.+Sudomauthor=J.+Liuauthor=S.+M.+Rubensteinauthor=M.+K.+Anwerauthor=T.+D.+Cushingauthor=Y.+Shinauthor=M.+Ayresauthor=F.+Leeauthor=J.+Eksterowiczauthor=P.+Faulderauthor=B.+Waszkowyczauthor=O.+Plotnikovaauthor=E.+Farrellyauthor=S.-H.+Xiaoauthor=G.+Chenauthor=Z.+Wang&title=Inhibiting+NF-%CE%BAB-inducing+kinase+%28NIK%29%3A+Discovery%2C+structure-based+design%2C+synthesis%2C+structure%E2%80%93activity+relationship%2C+and+co-crystal+structures&doi=10.1016%2Fj.bmcl.2013.01.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibiting NF-κB-inducing kinase (NIK): Discovery, structure-based design, synthesis, structure-activity relationship, and co-crystal structures</span></div><div class="casAuthors">Li, Kexue; McGee, Lawrence R.; Fisher, Ben; Sudom, Athena; Liu, Jinsong; Rubenstein, Steven M.; Anwer, Mohmed K.; Cushing, Timothy D.; Shin, Youngsook; Ayres, Merrill; Lee, Fei; Eksterowicz, John; Faulder, Paul; Waszkowycz, Bohdan; Plotnikova, Olga; Farrelly, Ellyn; Xiao, Shou-Hua; Chen, Guoqing; Wang, Zhulun</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1238-1244</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The discovery, structure-based design, synthesis, and optimization of NIK inhibitors are described.  Our work began with an HTS hit, imidazopyridinyl pyrimidinamine I.  We utilized homol. modeling and conformational anal. to optimize the indole scaffold leading to the discovery of novel and potent conformationally constrained inhibitors such as compds. II [R1 = Br, C≡CCMe2OH].  Compds. II [R1 = Br] and III were co-crystd. with NIK kinase domain to provide structural insights.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpm5WqvTIrBqrVg90H21EOLACvtfcHk0ljpxowruMk4jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVGmt7s%253D&md5=a382078cf3bf84a41749783be33a5988</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.01.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.01.012%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DK.%26aulast%3DMcGee%26aufirst%3DL.%2BR.%26aulast%3DFisher%26aufirst%3DB.%26aulast%3DSudom%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DRubenstein%26aufirst%3DS.%2BM.%26aulast%3DAnwer%26aufirst%3DM.%2BK.%26aulast%3DCushing%26aufirst%3DT.%2BD.%26aulast%3DShin%26aufirst%3DY.%26aulast%3DAyres%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DF.%26aulast%3DEksterowicz%26aufirst%3DJ.%26aulast%3DFaulder%26aufirst%3DP.%26aulast%3DWaszkowycz%26aufirst%3DB.%26aulast%3DPlotnikova%26aufirst%3DO.%26aulast%3DFarrelly%26aufirst%3DE.%26aulast%3DXiao%26aufirst%3DS.-H.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DZ.%26atitle%3DInhibiting%2520NF-%25CE%25BAB-inducing%2520kinase%2520%2528NIK%2529%253A%2520Discovery%252C%2520structure-based%2520design%252C%2520synthesis%252C%2520structure%25E2%2580%2593activity%2520relationship%252C%2520and%2520co-crystal%2520structures%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D1238%26epage%3D1244%26doi%3D10.1016%2Fj.bmcl.2013.01.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mortier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masereel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Remouchamps, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganeff, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piette, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">frederick, R.</span></span> <span> </span><span class="NLM_article-title">NF-κB inducing kinase (NIK) inhibitors: Identification of new scaffolds using virtual screening</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">4515</span>– <span class="NLM_lpage">4520</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.06.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1016%2Fj.bmcl.2010.06.027" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=4515-4520&author=J.+Mortierauthor=B.+Masereelauthor=C.+Remouchampsauthor=C.+Ganeffauthor=J.+Pietteauthor=R.+frederick&title=NF-%CE%BAB+inducing+kinase+%28NIK%29+inhibitors%3A+Identification+of+new+scaffolds+using+virtual+screening&doi=10.1016%2Fj.bmcl.2010.06.027"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.06.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.06.027%26sid%3Dliteratum%253Aachs%26aulast%3DMortier%26aufirst%3DJ.%26aulast%3DMasereel%26aufirst%3DB.%26aulast%3DRemouchamps%26aufirst%3DC.%26aulast%3DGaneff%26aufirst%3DC.%26aulast%3DPiette%26aufirst%3DJ.%26aulast%3Dfrederick%26aufirst%3DR.%26atitle%3DNF-%25CE%25BAB%2520inducing%2520kinase%2520%2528NIK%2529%2520inhibitors%253A%2520Identification%2520of%2520new%2520scaffolds%2520using%2520virtual%2520screening%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D4515%26epage%3D4520%26doi%3D10.1016%2Fj.bmcl.2010.06.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rui, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span> <span> </span><span class="NLM_article-title">A small-molecule inhibitor of NF-κB-inducing kinase (NIK) protects liver from toxin-induced inflammation, oxidative stress, and injury</span>. <i>FASEB J.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">711</span>– <span class="NLM_lpage">718</span>, <span class="refDoi"> DOI: 10.1096/fj.201600840R</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1096%2Ffj.201600840R" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=27871061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpsleit78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=711-718&author=X.+Renauthor=X.+Liauthor=L.+Jiaauthor=D.+Chenauthor=H.+Houauthor=L.+Ruiauthor=Y.+Zhaoauthor=Z.+Chen&title=A+small-molecule+inhibitor+of+NF-%CE%BAB-inducing+kinase+%28NIK%29+protects+liver+from+toxin-induced+inflammation%2C+oxidative+stress%2C+and+injury&doi=10.1096%2Ffj.201600840R"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">A small-molecule inhibitor of NF-κB-inducing kinase (NIK) protects liver from toxin-induced inflammation, oxidative stress, and injury</span></div><div class="casAuthors">Ren, Xiaomeng; Li, Xinzhi; Jia, Linna; Chen, Deheng; Hou, Hai; Rui, Liangyou; Zhao, Yujun; Chen, Zheng</div><div class="citationInfo"><span class="NLM_cas:title">FASEB Journal</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">711-718</span>CODEN:
                <span class="NLM_cas:coden">FAJOEC</span>;
        ISSN:<span class="NLM_cas:issn">0892-6638</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">Potent and selective chem. probes are valuable tools for discovery of novel treatments for human diseases.  NF-κB-inducing kinase (NIK) is a key trigger in the development of liver injury and fibrosis.  Whether inhibition of NIK activity by chem. probes ameliorates liver inflammation and injury is largely unknown.  In this study, a small-mol. inhibitor of NIK, B022, was found to be a potent and selective chem. probe for liver inflammation and injury.  B022 inhibited the NIK signaling pathway, including NIK-induced p100-to-p52 processing and inflammatory gene expression, both in vitro and in vivo.  Furthermore, in vivo administration of B022 protected against not only NIK but also CCl4-induced liver inflammation and injury.  Our data suggest that inhibition of NIK is a novel strategy for treatment of liver inflammation, oxidative stress, and injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAtVxDU8yQibVg90H21EOLACvtfcHk0li3Y8c8_q9a9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpsleit78%253D&md5=84f05fa8fdf2fcfe79d167827ceea738</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1096%2Ffj.201600840R&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.201600840R%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DJia%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DHou%26aufirst%3DH.%26aulast%3DRui%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DZ.%26atitle%3DA%2520small-molecule%2520inhibitor%2520of%2520NF-%25CE%25BAB-inducing%2520kinase%2520%2528NIK%2529%2520protects%2520liver%2520from%2520toxin-induced%2520inflammation%252C%2520oxidative%2520stress%252C%2520and%2520injury%26jtitle%3DFASEB%2520J.%26date%3D2017%26volume%3D31%26spage%3D711%26epage%3D718%26doi%3D10.1096%2Ffj.201600840R" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sudom, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Min, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayres, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plotnikova, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span> <span> </span><span class="NLM_article-title">Structure of the nuclear factor κB-inducing kinase (NIK) kinase domain reveals a constitutively active conformation</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>287</i></span>,  <span class="NLM_fpage">27326</span>– <span class="NLM_lpage">27334</span>, <span class="refDoi"> DOI: 10.1074/jbc.M112.366658</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1074%2Fjbc.M112.366658" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=287&publication_year=2012&pages=27326-27334&author=J.+Liuauthor=A.+Sudomauthor=X.+Minauthor=Z.+Caoauthor=X.+Gaoauthor=M.+Ayresauthor=F.+Leeauthor=P.+Caoauthor=S.+Johnstoneauthor=O.+Plotnikovaauthor=N.+Walkerauthor=G.+Chenauthor=Z.+Wang&title=Structure+of+the+nuclear+factor+%CE%BAB-inducing+kinase+%28NIK%29+kinase+domain+reveals+a+constitutively+active+conformation&doi=10.1074%2Fjbc.M112.366658"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M112.366658&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M112.366658%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DSudom%26aufirst%3DA.%26aulast%3DMin%26aufirst%3DX.%26aulast%3DCao%26aufirst%3DZ.%26aulast%3DGao%26aufirst%3DX.%26aulast%3DAyres%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DF.%26aulast%3DCao%26aufirst%3DP.%26aulast%3DJohnstone%26aufirst%3DS.%26aulast%3DPlotnikova%26aufirst%3DO.%26aulast%3DWalker%26aufirst%3DN.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DZ.%26atitle%3DStructure%2520of%2520the%2520nuclear%2520factor%2520%25CE%25BAB-inducing%2520kinase%2520%2528NIK%2529%2520kinase%2520domain%2520reveals%2520a%2520constitutively%2520active%2520conformation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2012%26volume%3D287%26spage%3D27326%26epage%3D27334%26doi%3D10.1074%2Fjbc.M112.366658" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maracle, C. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kucharzewska, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helder, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Horst, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correa de Sampaio, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noort, A.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Zoest, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffioen, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tas, S. W.</span></span> <span> </span><span class="NLM_article-title">Targeting non-canonical nuclear factor-κB signalling attenuates neovascularization in a novel 3D model of rheumatoid arthritis synovial angiogenesis</span>. <i>Rheumatology</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">294</span>– <span class="NLM_lpage">302</span>, <span class="refDoi"> DOI: 10.1093/rheumatology/kew393</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1093%2Frheumatology%2Fkew393" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=294-302&author=C.+X.+Maracleauthor=P.+Kucharzewskaauthor=B.+Helderauthor=C.+van+der%0AHorstauthor=P.+Correa+de+Sampaioauthor=A.-R.+Noortauthor=K.+van+Zoestauthor=A.+W.+Griffioenauthor=H.+Olssonauthor=S.+W.+Tas&title=Targeting+non-canonical+nuclear+factor-%CE%BAB+signalling+attenuates+neovascularization+in+a+novel+3D+model+of+rheumatoid+arthritis+synovial+angiogenesis&doi=10.1093%2Frheumatology%2Fkew393"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1093%2Frheumatology%2Fkew393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Frheumatology%252Fkew393%26sid%3Dliteratum%253Aachs%26aulast%3DMaracle%26aufirst%3DC.%2BX.%26aulast%3DKucharzewska%26aufirst%3DP.%26aulast%3DHelder%26aufirst%3DB.%26aulast%3Dvan%2Bder%2BHorst%26aufirst%3DC.%26aulast%3DCorrea%2Bde%2BSampaio%26aufirst%3DP.%26aulast%3DNoort%26aufirst%3DA.-R.%26aulast%3Dvan%2BZoest%26aufirst%3DK.%26aulast%3DGriffioen%26aufirst%3DA.%2BW.%26aulast%3DOlsson%26aufirst%3DH.%26aulast%3DTas%26aufirst%3DS.%2BW.%26atitle%3DTargeting%2520non-canonical%2520nuclear%2520factor-%25CE%25BAB%2520signalling%2520attenuates%2520neovascularization%2520in%2520a%2520novel%25203D%2520model%2520of%2520rheumatoid%2520arthritis%2520synovial%2520angiogenesis%26jtitle%3DRheumatology%26date%3D2017%26volume%3D56%26spage%3D294%26epage%3D302%26doi%3D10.1093%2Frheumatology%2Fkew393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Humphries, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moynagh, P. N.</span></span> <span> </span><span class="NLM_article-title">RIP kinases: key decision makers in cell death and innate immunity</span>. <i>Cell Death Differ.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">225</span>– <span class="NLM_lpage">236</span>, <span class="refDoi"> DOI: 10.1038/cdd.2014.126</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1038%2Fcdd.2014.126" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=25146926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVCrsLnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=225-236&author=F.+Humphriesauthor=S.+Yangauthor=B.+Wangauthor=P.+N.+Moynagh&title=RIP+kinases%3A+key+decision+makers+in+cell+death+and+innate+immunity&doi=10.1038%2Fcdd.2014.126"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">RIP kinases: key decision makers in cell death and innate immunity</span></div><div class="casAuthors">Humphries, F.; Yang, S.; Wang, B.; Moynagh, P. N.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Differentiation</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">225-236</span>CODEN:
                <span class="NLM_cas:coden">CDDIEK</span>;
        ISSN:<span class="NLM_cas:issn">1350-9047</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Innate immunity represents the first line of defense against invading pathogens.  It consists of an initial inflammatory response that recruits white blood cells to the site of infection in an effort to destroy and eliminate the pathogen.  Some pathogens replicate within host cells, and cell death by apoptosis is an important effector mechanism to remove the replication niche for such microbes.  However, some microbes have evolved evasive strategies to block apoptosis, and in these cases host cells may employ further countermeasures, including an inflammatory form of cell death know as necroptosis.  This review aims to highlight the importance of the RIP kinase family in controlling these various defense strategies.  RIP1 is initially discussed as a key component of death receptor signalling and in the context of dictating whether a cell triggers a pathway of pro-inflammatory gene expression or cell death by apoptosis.  The mol. and functional interplay of RIP1 and RIP3 is described, esp. with respect to mediating necroptosis and as key mediators of inflammation.  The function of RIP2, with particular emphasis on its role in NOD signalling, is also explored.  Special attention is given to emphasizing the physiol. and pathophysiol. contexts for these various functions of RIP kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPApofbdnkLLVg90H21EOLACvtfcHk0lgA3UREaC0JLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVCrsLnP&md5=f25195c56cf9a7553367a4eed0f1b34a</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1038%2Fcdd.2014.126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcdd.2014.126%26sid%3Dliteratum%253Aachs%26aulast%3DHumphries%26aufirst%3DF.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DMoynagh%26aufirst%3DP.%2BN.%26atitle%3DRIP%2520kinases%253A%2520key%2520decision%2520makers%2520in%2520cell%2520death%2520and%2520innate%2520immunity%26jtitle%3DCell%2520Death%2520Differ.%26date%3D2015%26volume%3D22%26spage%3D225%26epage%3D236%26doi%3D10.1038%2Fcdd.2014.126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, J.</span></span> <span> </span><span class="NLM_article-title">Receptor-interacting protein (RIP) kinase family</span>. <i>Cell. Mol. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">243</span>– <span class="NLM_lpage">249</span>, <span class="refDoi"> DOI: 10.1038/cmi.2010.10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1038%2Fcmi.2010.10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=20383176" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC3cXotlSms7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2010&pages=243-249&author=D.+Zhangauthor=J.+Linauthor=J.+Han&title=Receptor-interacting+protein+%28RIP%29+kinase+family&doi=10.1038%2Fcmi.2010.10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Receptor-interacting protein (RIP) kinase family</span></div><div class="casAuthors">Zhang, Duanwu; Lin, Juan; Han, Jiahuai</div><div class="citationInfo"><span class="NLM_cas:title">Cellular & Molecular Immunology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">243-249</span>CODEN:
                <span class="NLM_cas:coden">CMIEAO</span>;
        ISSN:<span class="NLM_cas:issn">1672-7681</span>.
    
            (<span class="NLM_cas:orgname">NPG Nature Asia-Pacific</span>)
        </div><div class="casAbstract">A review.  Receptor-interacting protein (RIP) kinases are a group of threonine/serine protein kinases with a relatively conserved kinase domain but distinct non-kinase regions.  A no. of different domain structures, such as death and caspase activation and recruitment domain (CARD) domains, were found in different RIP family members, and these domains should be keys in detg. the specific function of each RIP kinase.  It is known that RIP kinases participate in different biol. processes, including those in innate immunity, but their downstream substrates are largely unknown.  This review will give an overview of the structures and functions of RIP family members, and an update of recent progress in RIP kinase research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpICS9EnND6QLVg90H21EOLACvtfcHk0lgA3UREaC0JLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXotlSms7w%253D&md5=e110b4cbd223b7ddef4855830c7d4156</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1038%2Fcmi.2010.10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcmi.2010.10%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DHan%26aufirst%3DJ.%26atitle%3DReceptor-interacting%2520protein%2520%2528RIP%2529%2520kinase%2520family%26jtitle%3DCell.%2520Mol.%2520Immunol.%26date%3D2010%26volume%3D7%26spage%3D243%26epage%3D249%26doi%3D10.1038%2Fcmi.2010.10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chirieleison, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kertesy, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbott, D. W.</span></span> <span> </span><span class="NLM_article-title">Synthetic biology reveals the uniqueness of the RIP kinase domain</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>196</i></span>,  <span class="NLM_fpage">4291</span>– <span class="NLM_lpage">4297</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1502631</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.4049%2Fjimmunol.1502631" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=27045108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC28XntlCntLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=196&publication_year=2016&pages=4291-4297&author=S.+M.+Chirieleisonauthor=S.+B.+Kertesyauthor=D.+W.+Abbott&title=Synthetic+biology+reveals+the+uniqueness+of+the+RIP+kinase+domain&doi=10.4049%2Fjimmunol.1502631"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic Biology Reveals the Uniqueness of the RIP Kinase Domain</span></div><div class="casAuthors">Chirieleison, Steven M.; Kertesy, Sylvia B.; Abbott, Derek W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">196</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4291-4297</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">The RIP kinases (RIPKs) play an essential role in inflammatory signaling and inflammatory cell death.  However, the function of their kinase activity has been enigmatic, and only recently has kinase domain activity been shown to be crucial for their signal transduction capacity.  Despite this uncertainty, the RIPKs have been the subject of intense pharmaceutical development with a no. of compds. currently in preclin. testing.  In this work, we seek to det. the functional redundancy between the kinase domains of the four major RIPK family members.  We find that although RIPK1, RIPK2, and RIPK4 are similar in that they can all activate NF-κB and induce NF-κB essential modulator ubiquitination, only RIPK2 is a dual-specificity kinase.  Domain swapping expts. showed that the RIPK4 kinase domain could be converted to a dual-specificity kinase and is essentially indistinct from RIPK2 in biochem. and mol. activity.  Surprisingly, however, replacement of RIPK2's kinase domain with RIPK4's did not complement a nucleotide-binding oligomerization domain 2 signaling or gene expression induction defect in RIPK2-/- macrophages.  These findings suggest that RIPK2's kinase domain is functionally unique compared with other RIPK family members and that pharmacol. targeting of RIPK2 can be sepd. from the other RIPKs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI0BtYagqNBrVg90H21EOLACvtfcHk0lgA3UREaC0JLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntlCntLg%253D&md5=b5482ea6e9e0c17c8d097686d208430f</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1502631&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1502631%26sid%3Dliteratum%253Aachs%26aulast%3DChirieleison%26aufirst%3DS.%2BM.%26aulast%3DKertesy%26aufirst%3DS.%2BB.%26aulast%3DAbbott%26aufirst%3DD.%2BW.%26atitle%3DSynthetic%2520biology%2520reveals%2520the%2520uniqueness%2520of%2520the%2520RIP%2520kinase%2520domain%26jtitle%3DJ.%2520Immunol.%26date%3D2016%26volume%3D196%26spage%3D4291%26epage%3D4297%26doi%3D10.4049%2Fjimmunol.1502631" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Najjar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saleh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zelic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nogusa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finger, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polykratis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gough, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whalen, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasparakis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balachandran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelliher, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poltorak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degterev, A.</span></span> <span> </span><span class="NLM_article-title">RIPK1 and RIPK3 kinases promote cell-death-independent inflammation by toll-like receptor 4</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">46</span>– <span class="NLM_lpage">59</span>, <span class="refDoi"> DOI: 10.1016/j.immuni.2016.06.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1016%2Fj.immuni.2016.06.007" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2016&pages=46-59&author=M.+Najjarauthor=D.+Salehauthor=M.+Zelicauthor=S.+Nogusaauthor=S.+Shahauthor=A.+Taiauthor=J.+N.+Fingerauthor=A.+Polykratisauthor=P.+J.+Goughauthor=J.+Bertinauthor=M.+J.+Whalenauthor=M.+Pasparakisauthor=S.+Balachandranauthor=M.+Kelliherauthor=A.+Poltorakauthor=A.+Degterev&title=RIPK1+and+RIPK3+kinases+promote+cell-death-independent+inflammation+by+toll-like+receptor+4&doi=10.1016%2Fj.immuni.2016.06.007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1016%2Fj.immuni.2016.06.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.immuni.2016.06.007%26sid%3Dliteratum%253Aachs%26aulast%3DNajjar%26aufirst%3DM.%26aulast%3DSaleh%26aufirst%3DD.%26aulast%3DZelic%26aufirst%3DM.%26aulast%3DNogusa%26aufirst%3DS.%26aulast%3DShah%26aufirst%3DS.%26aulast%3DTai%26aufirst%3DA.%26aulast%3DFinger%26aufirst%3DJ.%2BN.%26aulast%3DPolykratis%26aufirst%3DA.%26aulast%3DGough%26aufirst%3DP.%2BJ.%26aulast%3DBertin%26aufirst%3DJ.%26aulast%3DWhalen%26aufirst%3DM.%2BJ.%26aulast%3DPasparakis%26aufirst%3DM.%26aulast%3DBalachandran%26aufirst%3DS.%26aulast%3DKelliher%26aufirst%3DM.%26aulast%3DPoltorak%26aufirst%3DA.%26aulast%3DDegterev%26aufirst%3DA.%26atitle%3DRIPK1%2520and%2520RIPK3%2520kinases%2520promote%2520cell-death-independent%2520inflammation%2520by%2520toll-like%2520receptor%25204%26jtitle%3DImmunity%26date%3D2016%26volume%3D45%26spage%3D46%26epage%3D59%26doi%3D10.1016%2Fj.immuni.2016.06.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Silke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rickard, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerlic, M.</span></span> <span> </span><span class="NLM_article-title">The diverse role of RIP kinases in necroptosis and inflammation</span>. <i>Nat. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">689</span>– <span class="NLM_lpage">697</span>, <span class="refDoi"> DOI: 10.1038/ni.3206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1038%2Fni.3206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=26086143" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1OmtL3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=689-697&author=J.+Silkeauthor=J.+A.+Rickardauthor=M.+Gerlic&title=The+diverse+role+of+RIP+kinases+in+necroptosis+and+inflammation&doi=10.1038%2Fni.3206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">The diverse role of RIP kinases in necroptosis and inflammation</span></div><div class="casAuthors">Silke, John; Rickard, James A.; Gerlic, Motti</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">689-697</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Inflammation is a healthy response to infection or danger and should be rapid, specific and terminated once the threat has passed.  Inflammatory diseases, where this regulation fails, cause considerable human suffering.  Treatments have successfully targeted pro-inflammatory cytokines, such as tumor-necrosis factor (TNF), that directly induce genes encoding inflammatory products.  Inflammatory signals, including TNF, may also directly induce caspase-independent cell death (necroptosis), which can also elicit inflammation.  Necroptosis was originally defined as being dependent on the kinase RIPK1 but is now known to be dependent on RIPK3 and the pseudo-kinase MLKL.  Therefore, RIPK1, RIPK3 and MLKL are potential therapeutic targets.  RIPK1 and RIPK3 also directly regulate inflammatory signaling, which complicates interpretation of their function but might alter their therapeutic utility.  This Review examines the role of cell death, particularly necroptosis, in inflammation, in the context of recent insights into the roles of the key necroptosis effector mols. RIPK1, RIPK3 and MLKL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQwQIKren3X7Vg90H21EOLACvtfcHk0ljsr_jAmCBvvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1OmtL3E&md5=124026d3c7caa25e1d416c6cb2bd8d87</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1038%2Fni.3206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni.3206%26sid%3Dliteratum%253Aachs%26aulast%3DSilke%26aufirst%3DJ.%26aulast%3DRickard%26aufirst%3DJ.%2BA.%26aulast%3DGerlic%26aufirst%3DM.%26atitle%3DThe%2520diverse%2520role%2520of%2520RIP%2520kinases%2520in%2520necroptosis%2520and%2520inflammation%26jtitle%3DNat.%2520Immunol.%26date%3D2015%26volume%3D16%26spage%3D689%26epage%3D697%26doi%3D10.1038%2Fni.3206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hildebrand, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, J. M.</span></span> <span> </span><span class="NLM_article-title">The highway to hell: a RIP kinase-directed shortcut to inflammatory cytokine production</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">3</span>, <span class="refDoi"> DOI: 10.1016/j.immuni.2016.06.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1016%2Fj.immuni.2016.06.029" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2016&pages=1-3&author=J.+M.+Hildebrandauthor=J.+M.+Murphy&title=The+highway+to+hell%3A+a+RIP+kinase-directed+shortcut+to+inflammatory+cytokine+production&doi=10.1016%2Fj.immuni.2016.06.029"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1016%2Fj.immuni.2016.06.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.immuni.2016.06.029%26sid%3Dliteratum%253Aachs%26aulast%3DHildebrand%26aufirst%3DJ.%2BM.%26aulast%3DMurphy%26aufirst%3DJ.%2BM.%26atitle%3DThe%2520highway%2520to%2520hell%253A%2520a%2520RIP%2520kinase-directed%2520shortcut%2520to%2520inflammatory%2520cytokine%2520production%26jtitle%3DImmunity%26date%3D2016%26volume%3D45%26spage%3D1%26epage%3D3%26doi%3D10.1016%2Fj.immuni.2016.06.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harris, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, J. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagilla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandyopadhyay, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campobasso, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capriotti, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dare, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eidam, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finger, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasparcova, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehr, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leister, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lich, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacDonald, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouellette, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reilly, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rendina, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaeffer, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sehon, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singhaus, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swift, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Totoritis, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vossenkämper, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wisnoski, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marquis, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gough, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertin, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of a first-in-class receptor interacting protein 1 (RIP1) kinase specific clinical candidate (GSK2982772) for the treatment of inflammatory diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1247</span>– <span class="NLM_lpage">1261</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01751</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01751" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVeksLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=1247-1261&author=P.+A.+Harrisauthor=S.+B.+Bergerauthor=J.+U.+Jeongauthor=R.+Nagillaauthor=D.+Bandyopadhyayauthor=N.+Campobassoauthor=C.+A.+Capriottiauthor=J.+A.+Coxauthor=L.+Dareauthor=X.+Dongauthor=P.+M.+Eidamauthor=J.+N.+Fingerauthor=S.+J.+Hoffmanauthor=J.+Kangauthor=V.+Kasparcovaauthor=B.+W.+Kingauthor=R.+Lehrauthor=Y.+Lanauthor=L.+K.+Leisterauthor=J.+D.+Lichauthor=T.+T.+MacDonaldauthor=N.+A.+Millerauthor=M.+T.+Ouelletteauthor=C.+S.+Paoauthor=A.+Rahmanauthor=M.+A.+Reillyauthor=A.+R.+Rendinaauthor=E.+J.+Riveraauthor=M.+C.+Schaefferauthor=C.+A.+Sehonauthor=R.+R.+Singhausauthor=H.+H.+Sunauthor=B.+A.+Swiftauthor=R.+D.+Totoritisauthor=A.+Vossenk%C3%A4mperauthor=P.+Wardauthor=D.+D.+Wisnoskiauthor=D.+Zhangauthor=R.+W.+Marquisauthor=P.+J.+Goughauthor=J.+Bertin&title=Discovery+of+a+first-in-class+receptor+interacting+protein+1+%28RIP1%29+kinase+specific+clinical+candidate+%28GSK2982772%29+for+the+treatment+of+inflammatory+diseases&doi=10.1021%2Facs.jmedchem.6b01751"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases</span></div><div class="casAuthors">Harris, Philip A.; Berger, Scott B.; Jeong, Jae U.; Nagilla, Rakesh; Bandyopadhyay, Deepak; Campobasso, Nino; Capriotti, Carol A.; Cox, Julie A.; Dare, Lauren; Dong, Xiaoyang; Eidam, Patrick M.; Finger, Joshua N.; Hoffman, Sandra J.; Kang, James; Kasparcova, Viera; King, Bryan W.; Lehr, Ruth; Lan, Yunfeng; Leister, Lara K.; Lich, John D.; MacDonald, Thomas T.; Miller, Nathan A.; Ouellette, Michael T.; Pao, Christina S.; Rahman, Attiq; Reilly, Michael A.; Rendina, Alan R.; Rivera, Elizabeth J.; Schaeffer, Michelle C.; Sehon, Clark A.; Singhaus, Robert R.; Sun, Helen H.; Swift, Barbara A.; Totoritis, Rachel D.; Vossenkamper, Anna; Ward, Paris; Wisnoski, David D.; Zhang, Daohua; Marquis, Robert W.; Gough, Peter J.; Bertin, John</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1247-1261</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">RIP1 regulates necroptosis and inflammation and may play an important role in contributing to a variety of human pathologies, including immune-mediated inflammatory diseases.  Small-mol. inhibitors of RIP1 kinase that are suitable for advancement into the clinic have yet to be described.  Herein, the authors report the lead optimization of a benzoxazepinone hit from a DNA-encoded library and the discovery and profile of clin. candidate GSK2982772 (compd. I), currently in phase 2a clin. studies for psoriasis, rheumatoid arthritis, and ulcerative colitis.  Compd. I potently binds to RIP1 with exquisite kinase specificity and has excellent activity in blocking many TNF-dependent cellular responses.  Highlighting its potential as a novel anti-inflammatory agent, the inhibitor was also able to reduce spontaneous prodn. of cytokines from human ulcerative colitis explants.  The highly favorable physicochem. and ADMET properties of I, combined with high potency, led to a predicted low oral dose in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZGRDTQv-vs7Vg90H21EOLACvtfcHk0lgipkmxvcCGVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVeksLk%253D&md5=ee0c3c60bb1351dff696490ac9edb1cc</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01751&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01751%26sid%3Dliteratum%253Aachs%26aulast%3DHarris%26aufirst%3DP.%2BA.%26aulast%3DBerger%26aufirst%3DS.%2BB.%26aulast%3DJeong%26aufirst%3DJ.%2BU.%26aulast%3DNagilla%26aufirst%3DR.%26aulast%3DBandyopadhyay%26aufirst%3DD.%26aulast%3DCampobasso%26aufirst%3DN.%26aulast%3DCapriotti%26aufirst%3DC.%2BA.%26aulast%3DCox%26aufirst%3DJ.%2BA.%26aulast%3DDare%26aufirst%3DL.%26aulast%3DDong%26aufirst%3DX.%26aulast%3DEidam%26aufirst%3DP.%2BM.%26aulast%3DFinger%26aufirst%3DJ.%2BN.%26aulast%3DHoffman%26aufirst%3DS.%2BJ.%26aulast%3DKang%26aufirst%3DJ.%26aulast%3DKasparcova%26aufirst%3DV.%26aulast%3DKing%26aufirst%3DB.%2BW.%26aulast%3DLehr%26aufirst%3DR.%26aulast%3DLan%26aufirst%3DY.%26aulast%3DLeister%26aufirst%3DL.%2BK.%26aulast%3DLich%26aufirst%3DJ.%2BD.%26aulast%3DMacDonald%26aufirst%3DT.%2BT.%26aulast%3DMiller%26aufirst%3DN.%2BA.%26aulast%3DOuellette%26aufirst%3DM.%2BT.%26aulast%3DPao%26aufirst%3DC.%2BS.%26aulast%3DRahman%26aufirst%3DA.%26aulast%3DReilly%26aufirst%3DM.%2BA.%26aulast%3DRendina%26aufirst%3DA.%2BR.%26aulast%3DRivera%26aufirst%3DE.%2BJ.%26aulast%3DSchaeffer%26aufirst%3DM.%2BC.%26aulast%3DSehon%26aufirst%3DC.%2BA.%26aulast%3DSinghaus%26aufirst%3DR.%2BR.%26aulast%3DSun%26aufirst%3DH.%2BH.%26aulast%3DSwift%26aufirst%3DB.%2BA.%26aulast%3DTotoritis%26aufirst%3DR.%2BD.%26aulast%3DVossenk%25C3%25A4mper%26aufirst%3DA.%26aulast%3DWard%26aufirst%3DP.%26aulast%3DWisnoski%26aufirst%3DD.%2BD.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DMarquis%26aufirst%3DR.%2BW.%26aulast%3DGough%26aufirst%3DP.%2BJ.%26aulast%3DBertin%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520a%2520first-in-class%2520receptor%2520interacting%2520protein%25201%2520%2528RIP1%2529%2520kinase%2520specific%2520clinical%2520candidate%2520%2528GSK2982772%2529%2520for%2520the%2520treatment%2520of%2520inflammatory%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D1247%26epage%3D1261%26doi%3D10.1021%2Facs.jmedchem.6b01751" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harris, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandyopadhyay, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campobasso, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capriotti, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dare, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finger, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grady, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, J. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasparcova, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakdawala, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehr, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNulty, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagilla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouellette, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rendina, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaeffer, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Summerfield, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swift, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Totoritis, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marquis, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gough, P. J.</span></span> <span> </span><span class="NLM_article-title">DNA-encoded library screening identifies benzo[b][1,4]oxazepin-4-ones as highly potent and monoselective receptor interacting protein 1 kinase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">2163</span>– <span class="NLM_lpage">2178</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01898</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01898" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC28Xit1Kqsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=2163-2178&author=P.+A.+Harrisauthor=B.+W.+Kingauthor=D.+Bandyopadhyayauthor=S.+B.+Bergerauthor=N.+Campobassoauthor=C.+A.+Capriottiauthor=J.+A.+Coxauthor=L.+Dareauthor=X.+Dongauthor=J.+N.+Fingerauthor=L.+C.+Gradyauthor=S.+J.+Hoffmanauthor=J.+U.+Jeongauthor=J.+Kangauthor=V.+Kasparcovaauthor=A.+S.+Lakdawalaauthor=R.+Lehrauthor=D.+E.+McNultyauthor=R.+Nagillaauthor=M.+T.+Ouelletteauthor=C.+S.+Paoauthor=A.+R.+Rendinaauthor=M.+C.+Schaefferauthor=J.+D.+Summerfieldauthor=B.+A.+Swiftauthor=R.+D.+Totoritisauthor=P.+Wardauthor=A.+Zhangauthor=D.+Zhangauthor=R.+W.+Marquisauthor=J.+Bertinauthor=P.+J.+Gough&title=DNA-encoded+library+screening+identifies+benzo%5Bb%5D%5B1%2C4%5Doxazepin-4-ones+as+highly+potent+and+monoselective+receptor+interacting+protein+1+kinase+inhibitors&doi=10.1021%2Facs.jmedchem.5b01898"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">DNA-Encoded Library Screening Identifies Benzo[b][1,4]oxazepin-4-ones as Highly Potent and Monoselective Receptor Interacting Protein 1 Kinase Inhibitors</span></div><div class="casAuthors">Harris, Philip A.; King, Bryan W.; Bandyopadhyay, Deepak; Berger, Scott B.; Campobasso, Nino; Capriotti, Carol A.; Cox, Julie A.; Dare, Lauren; Dong, Xiaoyang; Finger, Joshua N.; Grady, LaShadric C.; Hoffman, Sandra J.; Jeong, Jae U.; Kang, James; Kasparcova, Viera; Lakdawala, Ami S.; Lehr, Ruth; McNulty, Dean E.; Nagilla, Rakesh; Ouellette, Michael T.; Pao, Christina S.; Rendina, Alan R.; Schaeffer, Michelle C.; Summerfield, Jennifer D.; Swift, Barbara A.; Totoritis, Rachel D.; Ward, Paris; Zhang, Aming; Zhang, Daohua; Marquis, Robert W.; Bertin, John; Gough, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2163-2178</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The recent discovery of the role of receptor interacting protein 1 (RIP1) kinase in tumor necrosis factor (TNF)-mediated inflammation has led to its emergence as a highly promising target for the treatment of multiple inflammatory diseases.  The authors screened RIP1 against GSK's DNA-encoded small-mol. libraries and identified a novel highly potent benzoxazepinone inhibitor series.  The authors demonstrate that this template possesses complete monokinase selectivity for RIP1 plus unique species selectivity for primate vs. nonprimate RIP1.  The authors elucidate the conformation of RIP1 bound to this benzoxazepinone inhibitor driving its high kinase selectivity and design specific mutations in murine RIP1 to restore potency to levels similar to primate RIP1.  This series differentiates itself from known RIP1 inhibitors in combining high potency and kinase selectivity with good pharmacokinetic profiles in rodents.  The favorable developability profile of this benzoxazepinone template, as exemplified by compd. 14 (GSK'481), makes it an excellent starting point for further optimization into a RIP1 clin. candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4XvpziWGWg7Vg90H21EOLACvtfcHk0ljp74f-qaB74g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xit1Kqsr8%253D&md5=d6325dcaed97b7c339d1830ca041298c</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01898&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01898%26sid%3Dliteratum%253Aachs%26aulast%3DHarris%26aufirst%3DP.%2BA.%26aulast%3DKing%26aufirst%3DB.%2BW.%26aulast%3DBandyopadhyay%26aufirst%3DD.%26aulast%3DBerger%26aufirst%3DS.%2BB.%26aulast%3DCampobasso%26aufirst%3DN.%26aulast%3DCapriotti%26aufirst%3DC.%2BA.%26aulast%3DCox%26aufirst%3DJ.%2BA.%26aulast%3DDare%26aufirst%3DL.%26aulast%3DDong%26aufirst%3DX.%26aulast%3DFinger%26aufirst%3DJ.%2BN.%26aulast%3DGrady%26aufirst%3DL.%2BC.%26aulast%3DHoffman%26aufirst%3DS.%2BJ.%26aulast%3DJeong%26aufirst%3DJ.%2BU.%26aulast%3DKang%26aufirst%3DJ.%26aulast%3DKasparcova%26aufirst%3DV.%26aulast%3DLakdawala%26aufirst%3DA.%2BS.%26aulast%3DLehr%26aufirst%3DR.%26aulast%3DMcNulty%26aufirst%3DD.%2BE.%26aulast%3DNagilla%26aufirst%3DR.%26aulast%3DOuellette%26aufirst%3DM.%2BT.%26aulast%3DPao%26aufirst%3DC.%2BS.%26aulast%3DRendina%26aufirst%3DA.%2BR.%26aulast%3DSchaeffer%26aufirst%3DM.%2BC.%26aulast%3DSummerfield%26aufirst%3DJ.%2BD.%26aulast%3DSwift%26aufirst%3DB.%2BA.%26aulast%3DTotoritis%26aufirst%3DR.%2BD.%26aulast%3DWard%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DMarquis%26aufirst%3DR.%2BW.%26aulast%3DBertin%26aufirst%3DJ.%26aulast%3DGough%26aufirst%3DP.%2BJ.%26atitle%3DDNA-encoded%2520library%2520screening%2520identifies%2520benzo%255Bb%255D%255B1%252C4%255Doxazepin-4-ones%2520as%2520highly%2520potent%2520and%2520monoselective%2520receptor%2520interacting%2520protein%25201%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D2163%26epage%3D2178%26doi%3D10.1021%2Facs.jmedchem.5b01898" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span> <span> </span><span class="NLM_article-title">Discovery of a highly potent, selective, and metabolically stable inhibitor of receptor-interacting protein 1 (RIP1) for the treatment of systemic inflammatory response syndrome</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">972</span>– <span class="NLM_lpage">986</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01196</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01196" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFaitbfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=972-986&author=Y.+Renauthor=Y.+Suauthor=L.+Sunauthor=S.+Heauthor=L.+Mengauthor=D.+Liaoauthor=X.+Liuauthor=Y.+Maauthor=C.+Liuauthor=S.+Liauthor=H.+Ruanauthor=X.+Leiauthor=X.+Wangauthor=Z.+Zhang&title=Discovery+of+a+highly+potent%2C+selective%2C+and+metabolically+stable+inhibitor+of+receptor-interacting+protein+1+%28RIP1%29+for+the+treatment+of+systemic+inflammatory+response+syndrome&doi=10.1021%2Facs.jmedchem.6b01196"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Highly Potent, Selective, and Metabolically Stable Inhibitor of Receptor-Interacting Protein 1 (RIP1) for the Treatment of Systemic Inflammatory Response Syndrome</span></div><div class="casAuthors">Ren, Yan; Su, Yaning; Sun, Liming; He, Sudan; Meng, Lingjun; Liao, Daohong; Liu, Xiao; Ma, Yongfen; Liu, Chunyan; Li, Sisi; Ruan, Hanying; Lei, Xiaoguang; Wang, Xiaodong; Zhang, Zhiyuan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">972-986</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Based on its essential role in driving inflammation and disease pathol., cell necrosis has gradually been verified as a promising therapeutic target for treating atherosclerosis, systemic inflammatory response syndrome (SIRS), and ischemia injury, among other diseases.  Most necrosis inhibitors targeting receptor-interacting protein 1 (RIP1) still require further optimization because of weak potency or poor metabolic stability.  The authors conducted a phenotypic screen and identified a micromolar hit with novel amide structure.  Medicinal chem. efforts yielded a highly-potent, selective, and metabolically stable drug candidate - compd. 56 (RIPA-56, N-benzyl-N-hydroxy-2,2-dimethylbutanamide).  Biochem. studies and mol. docking revealed that RIP1 is the direct target of this new series of type III kinase inhibitors.  In the SIRS mice disease model, 56 efficiently reduced tumor necrosis factor alpha (TNFα)-induced mortality and multi-organ damage.  Compared to known RIP1 inhibitors, 56 is potent in both human and murine cells, is much more stable in vivo, and is efficacious in animal model studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqos-N-fJJ4vbVg90H21EOLACvtfcHk0ljp74f-qaB74g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFaitbfO&md5=6e7045a9646be5f9dc9559d90efe8aed</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01196&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01196%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DY.%26aulast%3DSu%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DHe%26aufirst%3DS.%26aulast%3DMeng%26aufirst%3DL.%26aulast%3DLiao%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DRuan%26aufirst%3DH.%26aulast%3DLei%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DZ.%26atitle%3DDiscovery%2520of%2520a%2520highly%2520potent%252C%2520selective%252C%2520and%2520metabolically%2520stable%2520inhibitor%2520of%2520receptor-interacting%2520protein%25201%2520%2528RIP1%2529%2520for%2520the%2520treatment%2520of%2520systemic%2520inflammatory%2520response%2520syndrome%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D972%26epage%3D986%26doi%3D10.1021%2Facs.jmedchem.6b01196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Canning, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwerd, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hrdinka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maki, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saleh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suebsuwong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennan, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuny, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uhlig, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gyrd-Hansen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degterev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, A. N.</span></span> <span> </span><span class="NLM_article-title">Inflammatory signaling by NOD-RIPK2 is inhibited by clinically relevant type II kinase inhibitors</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1174</span>– <span class="NLM_lpage">1184</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2015.07.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1016%2Fj.chembiol.2015.07.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=26320862" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVajs7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=1174-1184&author=P.+Canningauthor=Q.+Ruanauthor=T.+Schwerdauthor=M.+Hrdinkaauthor=J.+L.+Makiauthor=D.+Salehauthor=C.+Suebsuwongauthor=S.+Rayauthor=P.+E.+Brennanauthor=G.+D.+Cunyauthor=H.+H.+Uhligauthor=M.+Gyrd-Hansenauthor=A.+Degterevauthor=A.+N.+Bullock&title=Inflammatory+signaling+by+NOD-RIPK2+is+inhibited+by+clinically+relevant+type+II+kinase+inhibitors&doi=10.1016%2Fj.chembiol.2015.07.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Inflammatory Signaling by NOD-RIPK2 Is Inhibited by Clinically Relevant Type II Kinase Inhibitors</span></div><div class="casAuthors">Canning, Peter; Ruan, Qui; Schwerd, Tobias; Hrdinka, Matous; Maki, Jenny L.; Saleh, Danish; Suebsuwong, Chalada; Ray, Soumya; Brennan, Paul E.; Cuny, Gregory D.; Uhlig, Holm H.; Gyrd-Hansen, Mads; Degterev, Alexei; Bullock, Alex N.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1174-1184</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">RIPK2 mediates pro-inflammatory signaling from the bacterial sensors NOD1 and NOD2, and is an emerging therapeutic target in autoimmune and inflammatory diseases.  We obsd. that cellular RIPK2 can be potently inhibited by type II inhibitors that displace the kinase activation segment, whereas ATP-competitive type I inhibition was only poorly effective.  The most potent RIPK2 inhibitors were the US Food and Drug Administration-approved drugs ponatinib and regorafenib.  Their mechanism of action was independent of NOD2 interaction and involved loss of downstream kinase activation as evidenced by lack of RIPK2 autophosphorylation.  Notably, these mols. also blocked RIPK2 ubiquitination and, consequently, inflammatory nuclear factor κB signaling.  In monocytes, the inhibitors selectively blocked NOD-dependent tumor necrosis factor prodn. without affecting lipopolysaccharide-dependent pathways.  We also detd. the first crystal structure of RIPK2 bound to ponatinib, and identified an allosteric site for inhibitor development.  These results highlight the potential for type II inhibitors to treat indications of RIPK2 activation as well as inflammation-assocd. cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6MemkG2eHFLVg90H21EOLACvtfcHk0ljp74f-qaB74g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVajs7zP&md5=548df9cb0a629c1acdd831c9c716022c</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2015.07.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2015.07.017%26sid%3Dliteratum%253Aachs%26aulast%3DCanning%26aufirst%3DP.%26aulast%3DRuan%26aufirst%3DQ.%26aulast%3DSchwerd%26aufirst%3DT.%26aulast%3DHrdinka%26aufirst%3DM.%26aulast%3DMaki%26aufirst%3DJ.%2BL.%26aulast%3DSaleh%26aufirst%3DD.%26aulast%3DSuebsuwong%26aufirst%3DC.%26aulast%3DRay%26aufirst%3DS.%26aulast%3DBrennan%26aufirst%3DP.%2BE.%26aulast%3DCuny%26aufirst%3DG.%2BD.%26aulast%3DUhlig%26aufirst%3DH.%2BH.%26aulast%3DGyrd-Hansen%26aufirst%3DM.%26aulast%3DDegterev%26aufirst%3DA.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26atitle%3DInflammatory%2520signaling%2520by%2520NOD-RIPK2%2520is%2520inhibited%2520by%2520clinically%2520relevant%2520type%2520II%2520kinase%2520inhibitors%26jtitle%3DChem.%2520Biol.%26date%3D2015%26volume%3D22%26spage%3D1174%26epage%3D1184%26doi%3D10.1016%2Fj.chembiol.2015.07.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xie, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degterev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span> <span> </span><span class="NLM_article-title">Structural basis of RIP1 inhibition by necrostatins</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">493</span>– <span class="NLM_lpage">499</span>, <span class="refDoi"> DOI: 10.1016/j.str.2013.01.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1016%2Fj.str.2013.01.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=23473668" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktVOqsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=493-499&author=T.+Xieauthor=W.+Pengauthor=Y.+Liuauthor=C.+Yanauthor=J.+Makiauthor=A.+Degterevauthor=J.+Yuanauthor=Y.+Shi&title=Structural+basis+of+RIP1+inhibition+by+necrostatins&doi=10.1016%2Fj.str.2013.01.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis of RIP1 Inhibition by Necrostatins</span></div><div class="casAuthors">Xie, Tian; Peng, Wei; Liu, Yexing; Yan, Chuangye; Maki, Jenny; Degterev, Alexei; Yuan, Junying; Shi, Yigong</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">493-499</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Necroptosis is a cellular mechanism that mediates necrotic cell death.  The receptor-interacting serine/threonine protein kinase 1 (RIP1) is an essential upstream signaling mol. in tumor-necrosis-factor-α-induced necroptosis.  Necrostatins, a series of small-mol. inhibitors, suppress necroptosis by specifically inhibiting RIP1 kinase activity.  Both RIP1 structure and the mechanisms by which necrostatins inhibit RIP1 remain unknown.  Here, we report the crystal structures of the RIP1 kinase domain individually bound to necrostatin-1 analog, necrostatin-3 analog, and necrostatin-4.  Necrostatin, caged in a hydrophobic pocket between the N- and C-lobes of the kinase domain, stabilizes RIP1 in an inactive conformation through interactions with highly conserved amino acids in the activation loop and the surrounding structural elements.  Structural comparison of RIP1 with the inhibitor-bound oncogenic kinase B-RAF reveals partially overlapping binding sites for necrostatin and for the anticancer compd. PLX4032.  Our study provides a structural basis for RIP1 inhibition by necrostatins and offers insights into potential structure-based drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtw_1OVLFe4rVg90H21EOLACvtfcHk0lg47xAQoRHgAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktVOqsLk%253D&md5=42a3f8951b390358b9068bb1b885445e</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2013.01.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2013.01.016%26sid%3Dliteratum%253Aachs%26aulast%3DXie%26aufirst%3DT.%26aulast%3DPeng%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DYan%26aufirst%3DC.%26aulast%3DMaki%26aufirst%3DJ.%26aulast%3DDegterev%26aufirst%3DA.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DY.%26atitle%3DStructural%2520basis%2520of%2520RIP1%2520inhibition%2520by%2520necrostatins%26jtitle%3DStructure%26date%3D2013%26volume%3D21%26spage%3D493%26epage%3D499%26doi%3D10.1016%2Fj.str.2013.01.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haile, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Votta, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marquis, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bury, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehlmann, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singhaus, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charnley, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakdawala, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Convery, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipshutz, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swift, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capriotti, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahajan, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reilly, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagilla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beal, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finger, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouellette, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Totoritis, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierdomenico, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negroni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stronati, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cucchiara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziółkowski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vossenkämper, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacDonald, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gough, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casillas, L. N.</span></span> <span> </span><span class="NLM_article-title">The identification and pharmacological characterization of 6-(tert-butylsulfonyl)-N-(5-fluoro-1H-indazol-3-yl)quinolin-4-amine (GSK583), a highly potent and selective inhibitor of RIP2 kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">4867</span>– <span class="NLM_lpage">4880</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00211</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00211" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC28Xms1GqsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=4867-4880&author=P.+A.+Haileauthor=B.+J.+Vottaauthor=R.+W.+Marquisauthor=M.+J.+Buryauthor=J.+F.+Mehlmannauthor=R.+Singhausauthor=A.+K.+Charnleyauthor=A.+S.+Lakdawalaauthor=M.+A.+Converyauthor=D.+B.+Lipshutzauthor=B.+M.+Desaiauthor=B.+Swiftauthor=C.+A.+Capriottiauthor=S.+B.+Bergerauthor=M.+K.+Mahajanauthor=M.+A.+Reillyauthor=E.+J.+Riveraauthor=H.+H.+Sunauthor=R.+Nagillaauthor=A.+M.+Bealauthor=J.+N.+Fingerauthor=M.+N.+Cookauthor=B.+W.+Kingauthor=M.+T.+Ouelletteauthor=R.+D.+Totoritisauthor=M.+Pierdomenicoauthor=A.+Negroniauthor=L.+Stronatiauthor=S.+Cucchiaraauthor=B.+Zi%C3%B3%C5%82kowskiauthor=A.+Vossenk%C3%A4mperauthor=T.+T.+MacDonaldauthor=P.+J.+Goughauthor=J.+Bertinauthor=L.+N.+Casillas&title=The+identification+and+pharmacological+characterization+of+6-%28tert-butylsulfonyl%29-N-%285-fluoro-1H-indazol-3-yl%29quinolin-4-amine+%28GSK583%29%2C+a+highly+potent+and+selective+inhibitor+of+RIP2+kinase&doi=10.1021%2Facs.jmedchem.6b00211"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">The Identification and Pharmacological Characterization of 6-(tert-Butylsulfonyl)-N-(5-fluoro-1H-indazol-3-yl)quinolin-4-amine (GSK583), a Highly Potent and Selective Inhibitor of RIP2 Kinase</span></div><div class="casAuthors">Haile, Pamela A.; Votta, Bartholomew J.; Marquis, Robert W.; Bury, Michael J.; Mehlmann, John F.; Singhaus, Robert; Charnley, Adam K.; Lakdawala, Ami S.; Convery, Maire A.; Lipshutz, David B.; Desai, Biva M.; Swift, Barbara; Capriotti, Carol A.; Berger, Scott B.; Majahan, Mukesh K.; Reilly, Michael A.; Rivera, Elizabeth J.; Sun, Helen H.; Nagilla, Rakesh; Beal, Allison M.; Finger, Joshua N.; Cook, Michael N.; King, Bryan W.; Ouellette, Michael T.; Totoritis, Rachel D.; Pierdomenico, Maria; Negroni, Anna; Stronati, Laura; Cucchiara, Salvatore; Ziolkowski, Bartlomiej; Vossenkamper, Anna; MacDonald, Thomas T.; Gough, Peter J.; Bertin, John; Casillas, Linda N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4867-4880</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">RIP2 kinase is a central component of the innate immune system and enables downstream signaling following activation of the pattern recognition receptors NOD1 and NOD2, leading to the prodn. of inflammatory cytokines.  Recently, several inhibitors of RIP2 kinase have been disclosed that have contributed to the fundamental understanding of the role of RIP2 in this pathway.  However, because they lack either broad kinase selectivity or strong affinity for RIP2, these tools have only limited utility to assess the role of RIP2 in complex environments.  We present, herein, the discovery and pharmacol. characterization of GSK583 (I), a next-generation RIP2 inhibitor possessing exquisite selectivity and potency.  Having demonstrated the pharmacol. precision of this tool compd., we report its use in elucidating the role of RIP2 kinase in a variety of in vitro, in vivo, and ex vivo expts., further clarifying our understanding of the role of RIP2 in NOD1 and NOD2 mediated disease pathogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4OmfRRg6RHrVg90H21EOLACvtfcHk0lgaSkWTXlBMRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xms1GqsLs%253D&md5=74a178c9f055232de8a729bd254fce3e</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00211%26sid%3Dliteratum%253Aachs%26aulast%3DHaile%26aufirst%3DP.%2BA.%26aulast%3DVotta%26aufirst%3DB.%2BJ.%26aulast%3DMarquis%26aufirst%3DR.%2BW.%26aulast%3DBury%26aufirst%3DM.%2BJ.%26aulast%3DMehlmann%26aufirst%3DJ.%2BF.%26aulast%3DSinghaus%26aufirst%3DR.%26aulast%3DCharnley%26aufirst%3DA.%2BK.%26aulast%3DLakdawala%26aufirst%3DA.%2BS.%26aulast%3DConvery%26aufirst%3DM.%2BA.%26aulast%3DLipshutz%26aufirst%3DD.%2BB.%26aulast%3DDesai%26aufirst%3DB.%2BM.%26aulast%3DSwift%26aufirst%3DB.%26aulast%3DCapriotti%26aufirst%3DC.%2BA.%26aulast%3DBerger%26aufirst%3DS.%2BB.%26aulast%3DMahajan%26aufirst%3DM.%2BK.%26aulast%3DReilly%26aufirst%3DM.%2BA.%26aulast%3DRivera%26aufirst%3DE.%2BJ.%26aulast%3DSun%26aufirst%3DH.%2BH.%26aulast%3DNagilla%26aufirst%3DR.%26aulast%3DBeal%26aufirst%3DA.%2BM.%26aulast%3DFinger%26aufirst%3DJ.%2BN.%26aulast%3DCook%26aufirst%3DM.%2BN.%26aulast%3DKing%26aufirst%3DB.%2BW.%26aulast%3DOuellette%26aufirst%3DM.%2BT.%26aulast%3DTotoritis%26aufirst%3DR.%2BD.%26aulast%3DPierdomenico%26aufirst%3DM.%26aulast%3DNegroni%26aufirst%3DA.%26aulast%3DStronati%26aufirst%3DL.%26aulast%3DCucchiara%26aufirst%3DS.%26aulast%3DZi%25C3%25B3%25C5%2582kowski%26aufirst%3DB.%26aulast%3DVossenk%25C3%25A4mper%26aufirst%3DA.%26aulast%3DMacDonald%26aufirst%3DT.%2BT.%26aulast%3DGough%26aufirst%3DP.%2BJ.%26aulast%3DBertin%26aufirst%3DJ.%26aulast%3DCasillas%26aufirst%3DL.%2BN.%26atitle%3DThe%2520identification%2520and%2520pharmacological%2520characterization%2520of%25206-%2528tert-butylsulfonyl%2529-N-%25285-fluoro-1H-indazol-3-yl%2529quinolin-4-amine%2520%2528GSK583%2529%252C%2520a%2520highly%2520potent%2520and%2520selective%2520inhibitor%2520of%2520RIP2%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D4867%26epage%3D4880%26doi%3D10.1021%2Facs.jmedchem.6b00211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Da Ros, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okram, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michellys, P.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iskandar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espinola, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursulaya, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreusch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spraggon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baaten, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clemmer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meeusen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen-Tran, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fathman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuntland, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollenbeck, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bordone, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span> <span> </span><span class="NLM_article-title">Identification of potent and selective RIPK2 inhibitors for the treatment of inflammatory diseases</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1048</span>– <span class="NLM_lpage">1053</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00258</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00258" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFOjtLjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1048-1053&author=X.+Heauthor=S.+Da+Rosauthor=J.+Nelsonauthor=X.+Zhuauthor=T.+Jiangauthor=B.+Okramauthor=S.+Jiangauthor=P.-Y.+Michellysauthor=M.+Iskandarauthor=S.+Espinolaauthor=Y.+Jiaauthor=B.+Bursulayaauthor=A.+Kreuschauthor=M.-Y.+Gaoauthor=G.+Spraggonauthor=J.+Baatenauthor=L.+Clemmerauthor=S.+Meeusenauthor=D.+Huangauthor=R.+Hillauthor=V.+Nguyen-Tranauthor=J.+Fathmanauthor=B.+Liuauthor=T.+Tuntlandauthor=P.+Gordonauthor=T.+Hollenbeckauthor=K.+Ngauthor=J.+Shiauthor=L.+Bordoneauthor=H.+Liu&title=Identification+of+potent+and+selective+RIPK2+inhibitors+for+the+treatment+of+inflammatory+diseases&doi=10.1021%2Facsmedchemlett.7b00258"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Potent and Selective RIPK2 Inhibitors for the Treatment of Inflammatory Diseases</span></div><div class="casAuthors">He, Xiaohui; Da Ros, Sara; Nelson, John; Zhu, Xuefeng; Jiang, Tao; Okram, Barun; Jiang, Songchun; Michellys, Pierre-Yves; Iskandar, Maya; Espinola, Sheryll; Jia, Yong; Bursulaya, Badry; Kreusch, Andreas; Gao, Mu-Yun; Spraggon, Glen; Baaten, Janine; Clemmer, Leah; Meeusen, Shelly; Huang, David; Hill, Robert; Nguyen-Tran, Van; Fathman, John; Liu, Bo; Tuntland, Tove; Gordon, Perry; Hollenbeck, Thomas; Ng, Kenneth; Shi, Jian; Bordone, Laura; Liu, Hong</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1048-1053</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">NOD2 (nucleotide-binding oligomerization domain-contg. protein 2) is an internal pattern recognition receptor that recognizes bacterial peptidoglycan and stimulates host immune responses.  Dysfunction of NOD2 pathway has been assocd. with a no. of autoinflammatory disorders.  To date, direct inhibitors of NOD2 have not been described due to tech. challenges of targeting the oligomeric protein complex.  Receptor interacting protein kinase 2 (RIPK2) is an intracellular serine/threonine/tyrosine kinase, a key signaling partner, and an obligate kinase for NOD2.  As such, RIPK2 represents an attractive target to probe the pathol. roles of NOD2 pathway.  To search for selective RIPK2 inhibitors, the authors employed virtual library screening (VLS) and structure based design that eventually led to a potent and selective RIPK2 inhibitor 8 (4-(7-ethoxy-6-(isopropylsulfonyl)imidazo[1,2-a]pyridin-3-yl)-6-fluoropyridin-2-amine) with excellent oral bioavailability, which was used to evaluate the effects of inhibition of RIPK2 in various in vitro assays and ex vivo and in vivo pharmacodynamic models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVdc_tBhQU-7Vg90H21EOLACvtfcHk0lgaSkWTXlBMRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFOjtLjJ&md5=87e32df13c63a9cd16b20652ae96b36a</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00258%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DX.%26aulast%3DDa%2BRos%26aufirst%3DS.%26aulast%3DNelson%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DT.%26aulast%3DOkram%26aufirst%3DB.%26aulast%3DJiang%26aufirst%3DS.%26aulast%3DMichellys%26aufirst%3DP.-Y.%26aulast%3DIskandar%26aufirst%3DM.%26aulast%3DEspinola%26aufirst%3DS.%26aulast%3DJia%26aufirst%3DY.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DKreusch%26aufirst%3DA.%26aulast%3DGao%26aufirst%3DM.-Y.%26aulast%3DSpraggon%26aufirst%3DG.%26aulast%3DBaaten%26aufirst%3DJ.%26aulast%3DClemmer%26aufirst%3DL.%26aulast%3DMeeusen%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DD.%26aulast%3DHill%26aufirst%3DR.%26aulast%3DNguyen-Tran%26aufirst%3DV.%26aulast%3DFathman%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DGordon%26aufirst%3DP.%26aulast%3DHollenbeck%26aufirst%3DT.%26aulast%3DNg%26aufirst%3DK.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DBordone%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DH.%26atitle%3DIdentification%2520of%2520potent%2520and%2520selective%2520RIPK2%2520inhibitors%2520for%2520the%2520treatment%2520of%2520inflammatory%2520diseases%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D1048%26epage%3D1053%26doi%3D10.1021%2Facsmedchemlett.7b00258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nachbur, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stafford, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bankovacki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindqvist, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiil, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khakham, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandow, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falk, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holien, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chau, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hildebrand, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vince, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharp, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackman, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mühlen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowes, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gyrd-Hansen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartland, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lew, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, D. C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lessene, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silke, J.</span></span> <span> </span><span class="NLM_article-title">A RIPK2 inhibitor delays NOD signalling events yet prevents inflammatory cytokine production</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">6442</span>– <span class="NLM_lpage">6455</span>, <span class="refDoi"> DOI: 10.1038/ncomms7442</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1038%2Fncomms7442" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=25778803" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2MXosFeltr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=6442-6455&author=U.+Nachburauthor=C.+A.+Staffordauthor=A.+Bankovackiauthor=Y.+Zhanauthor=L.+M.+Lindqvistauthor=B.+K.+Fiilauthor=Y.+Khakhamauthor=H.-J.+Koauthor=J.+J.+Sandowauthor=H.+Falkauthor=J.+K.+Holienauthor=D.+Chauauthor=J.+Hildebrandauthor=J.+E.+Vinceauthor=P.+P.+Sharpauthor=A.+I.+Webbauthor=K.+A.+Jackmanauthor=S.+M%C3%BChlenauthor=C.+L.+Kennedyauthor=K.+N.+Lowesauthor=J.+M.+Murphyauthor=M.+Gyrd-Hansenauthor=M.+W.+Parkerauthor=E.+L.+Hartlandauthor=A.+M.+Lewauthor=D.+C.+S.+Huangauthor=G.+Lesseneauthor=J.+Silke&title=A+RIPK2+inhibitor+delays+NOD+signalling+events+yet+prevents+inflammatory+cytokine+production&doi=10.1038%2Fncomms7442"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">A RIPK2 inhibitor delays NOD signalling events yet prevents inflammatory cytokine production</span></div><div class="casAuthors">Nachbur, Ueli; Stafford, Che A.; Bankovacki, Aleksandra; Zhan, Yifan; Lindqvist, Lisa M.; Fiil, Berthe K.; Khakham, Yelena; Ko, Hyun-Ja; Sandow, Jarrod J.; Falk, Hendrik; Holien, Jessica K.; Chau, Diep; Hildebrand, Joanne; Vince, James E.; Sharp, Phillip P.; Webb, Andrew I.; Jackman, Katherine A.; Muhlen, Sabrina; Kennedy, Catherine L.; Lowes, Kym N.; Murphy, James M.; Gyrd-Hansen, Mads; Parker, Michael W.; Hartland, Elizabeth L.; Lew, Andrew M.; Huang, David C. S.; Lessene, Guillaume; Silke, John</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">6442</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Intracellular nucleotide binding and oligomerization domain (NOD) receptors recognize antigens including bacterial peptidoglycans and initiate immune responses by triggering the prodn. of pro-inflammatory cytokines through activating NF-κB and MAP kinases.  Receptor interacting protein kinase 2 (RIPK2) is crit. for NOD-mediated NF-κB activation and cytokine prodn.  Here we develop and characterize a selective RIPK2 kinase inhibitor, WEHI-345, which delays RIPK2 ubiquitylation and NF-κB activation downstream of NOD engagement.  Despite only delaying NF-κB activation on NOD stimulation, WEHI-345 prevents cytokine prodn. in vitro and in vivo and ameliorates exptl. autoimmune encephalomyelitis in mice.  Our study highlights the importance of the kinase activity of RIPK2 for proper immune responses and demonstrates the therapeutic potential of inhibiting RIPK2 in NOD-driven inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUTcBfWapFu7Vg90H21EOLACvtfcHk0lh-MkLBbTTs1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXosFeltr4%253D&md5=d3e10fa28b4c5187e75085abc9d4a01b</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1038%2Fncomms7442&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms7442%26sid%3Dliteratum%253Aachs%26aulast%3DNachbur%26aufirst%3DU.%26aulast%3DStafford%26aufirst%3DC.%2BA.%26aulast%3DBankovacki%26aufirst%3DA.%26aulast%3DZhan%26aufirst%3DY.%26aulast%3DLindqvist%26aufirst%3DL.%2BM.%26aulast%3DFiil%26aufirst%3DB.%2BK.%26aulast%3DKhakham%26aufirst%3DY.%26aulast%3DKo%26aufirst%3DH.-J.%26aulast%3DSandow%26aufirst%3DJ.%2BJ.%26aulast%3DFalk%26aufirst%3DH.%26aulast%3DHolien%26aufirst%3DJ.%2BK.%26aulast%3DChau%26aufirst%3DD.%26aulast%3DHildebrand%26aufirst%3DJ.%26aulast%3DVince%26aufirst%3DJ.%2BE.%26aulast%3DSharp%26aufirst%3DP.%2BP.%26aulast%3DWebb%26aufirst%3DA.%2BI.%26aulast%3DJackman%26aufirst%3DK.%2BA.%26aulast%3DM%25C3%25BChlen%26aufirst%3DS.%26aulast%3DKennedy%26aufirst%3DC.%2BL.%26aulast%3DLowes%26aufirst%3DK.%2BN.%26aulast%3DMurphy%26aufirst%3DJ.%2BM.%26aulast%3DGyrd-Hansen%26aufirst%3DM.%26aulast%3DParker%26aufirst%3DM.%2BW.%26aulast%3DHartland%26aufirst%3DE.%2BL.%26aulast%3DLew%26aufirst%3DA.%2BM.%26aulast%3DHuang%26aufirst%3DD.%2BC.%2BS.%26aulast%3DLessene%26aufirst%3DG.%26aulast%3DSilke%26aufirst%3DJ.%26atitle%3DA%2520RIPK2%2520inhibitor%2520delays%2520NOD%2520signalling%2520events%2520yet%2520prevents%2520inflammatory%2520cytokine%2520production%26jtitle%3DNat.%2520Commun.%26date%3D2015%26volume%3D6%26spage%3D6442%26epage%3D6455%26doi%3D10.1038%2Fncomms7442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Estrada, A. A.</span>; <span class="NLM_string-name">Feng, J. A.</span>; <span class="NLM_string-name">Fox, B.</span>; <span class="NLM_string-name">Leslie, C. P.</span>; <span class="NLM_string-name">Lyssikatos, J. P.</span>; <span class="NLM_string-name">Pozzan, A.</span>; <span class="NLM_string-name">Sweeney, Z. K.</span>; <span class="NLM_string-name">Fidalgo, J. D. V.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of Receptor-Interacting Protein Kinase 1</span>. <span class="NLM_patent">WO2017136727</span>, Feb 3, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=A.+A.+Estrada&author=J.+A.+Feng&author=B.+Fox&author=C.+P.+Leslie&author=J.+P.+Lyssikatos&author=A.+Pozzan&author=Z.+K.+Sweeney&author=J.+D.+V.+Fidalgo&title=Inhibitors+of+Receptor-Interacting+Protein+Kinase+1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DEstrada%26aufirst%3DA.%2BA.%26atitle%3DInhibitors%2520of%2520Receptor-Interacting%2520Protein%2520Kinase%25201%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hart, A. C.</span>; <span class="NLM_string-name">Pitts, W. J.</span>; <span class="NLM_string-name">Mastalerz, H.</span>; <span class="NLM_string-name">Guo, J.</span>; <span class="NLM_string-name">Brown, G. D.</span></span> <span> </span><span class="NLM_article-title">Substituted Dihydro-1H-pyrrolo[3,2-c]pyridin-4(5H)-ones as RIPK3 Inhibitors</span>. <span class="NLM_patent">WO2016100166</span>, Dec 14, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=A.+C.+Hart&author=W.+J.+Pitts&author=H.+Mastalerz&author=J.+Guo&author=G.+D.+Brown&title=Substituted+Dihydro-1H-pyrrolo%5B3%2C2-c%5Dpyridin-4%285H%29-ones+as+RIPK3+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHart%26aufirst%3DA.%2BC.%26atitle%3DSubstituted%2520Dihydro-1H-pyrrolo%255B3%252C2-c%255Dpyridin-4%25285H%2529-ones%2520as%2520RIPK3%2520Inhibitors%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bonanomi, G.</span>; <span class="NLM_string-name">Estrada, A. A.</span>; <span class="NLM_string-name">Feng, J. A.</span>; <span class="NLM_string-name">Fox, B.</span>; <span class="NLM_string-name">Leslie, C. P.</span>; <span class="NLM_string-name">Lyssikatos, J. P.</span>; <span class="NLM_string-name">Napolitano, C.</span>; <span class="NLM_string-name">Pozzan, A.</span>; <span class="NLM_string-name">Sudhakar, A.</span>; <span class="NLM_string-name">Sweeney, Z. K.</span>; <span class="NLM_string-name">Tonelli, F.</span>; <span class="NLM_string-name">Fidalgo, J. D. V.</span></span> <span> </span><span class="NLM_article-title">Isoxazolidine Derived Inhibitors of Receptor Interacting Protein Kinase 1 (RIPK 1)</span>. <span class="NLM_patent">WO2017096301</span>, Dec 2, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=G.+Bonanomi&author=A.+A.+Estrada&author=J.+A.+Feng&author=B.+Fox&author=C.+P.+Leslie&author=J.+P.+Lyssikatos&author=C.+Napolitano&author=A.+Pozzan&author=A.+Sudhakar&author=Z.+K.+Sweeney&author=F.+Tonelli&author=J.+D.+V.+Fidalgo&title=Isoxazolidine+Derived+Inhibitors+of+Receptor+Interacting+Protein+Kinase+1+%28RIPK+1%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBonanomi%26aufirst%3DG.%26atitle%3DIsoxazolidine%2520Derived%2520Inhibitors%2520of%2520Receptor%2520Interacting%2520Protein%2520Kinase%25201%2520%2528RIPK%25201%2529%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moriwaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, F. K.-M.</span></span> <span> </span><span class="NLM_article-title">Necroptosis-independent signaling by the RIP kinases in inflammation</span>. <i>Cell. Mol. Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">2325</span>– <span class="NLM_lpage">2334</span>, <span class="refDoi"> DOI: 10.1007/s00018-016-2203-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1007%2Fs00018-016-2203-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=27048814" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC28XlsValurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2016&pages=2325-2334&author=K.+Moriwakiauthor=F.+K.-M.+Chan&title=Necroptosis-independent+signaling+by+the+RIP+kinases+in+inflammation&doi=10.1007%2Fs00018-016-2203-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Necroptosis-independent signaling by the RIP kinases in inflammation</span></div><div class="casAuthors">Moriwaki, Kenta; Chan, Francis Ka-Ming</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">11-12</span>),
    <span class="NLM_cas:pages">2325-2334</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Basel</span>)
        </div><div class="casAbstract">Recent advances have identified a signaling cascade involving receptor interacting protein kinase 1 (RIPK1), RIPK3 and the pseudokinase mixed lineage kinase domain-like (MLKL) that is crucial for induction of necroptosis, a non-apoptotic form of cell death.  RIPK1-RIPK3-MLKL-mediated necroptosis has been attributed to cause many inflammatory diseases through the release of cellular damage-assocd. mol. patterns (DAMPs).  In addn. to necroptosis, emerging evidence suggests that these necroptosis signal adaptors can also facilitate inflammation independent of cell death.  In particular, the RIP kinases can drive NF-κB and inflammasome activation independent of cell death.  In this review, we will discuss recent discoveries that led to this realization and present arguments why cell death-independent signaling by the RIP kinases may have a more important role in inflammation than necroptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6wW0-uJ6xhbVg90H21EOLACvtfcHk0lhmVSvBLxDXkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlsValurs%253D&md5=8ba1cc7565ca54604626eb5d030dce48</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1007%2Fs00018-016-2203-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-016-2203-4%26sid%3Dliteratum%253Aachs%26aulast%3DMoriwaki%26aufirst%3DK.%26aulast%3DChan%26aufirst%3DF.%2BK.-M.%26atitle%3DNecroptosis-independent%2520signaling%2520by%2520the%2520RIP%2520kinases%2520in%2520inflammation%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2016%26volume%3D73%26spage%3D2325%26epage%3D2334%26doi%3D10.1007%2Fs00018-016-2203-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mandal, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pillay, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriwaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lich, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasparcova, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Votta, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouellette, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wisnoski, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakdawala, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMartino, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casillas, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haile, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sehon, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marquis, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Upton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daley-Bauer, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roback, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramia, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dovey, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carette, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gough, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mocarski, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaiser, W. J.</span></span> <span> </span><span class="NLM_article-title">RIP3 induces apoptosis independent of pro-necrotic kinase activity</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">481</span>– <span class="NLM_lpage">495</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2014.10.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1016%2Fj.molcel.2014.10.021" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2014&pages=481-495&author=P.+Mandalauthor=S.+B.+Bergerauthor=S.+Pillayauthor=K.+Moriwakiauthor=C.+Huangauthor=H.+Guoauthor=J.+D.+Lichauthor=J.+Fingerauthor=V.+Kasparcovaauthor=B.+Vottaauthor=M.+Ouelletteauthor=B.+W.+Kingauthor=D.+Wisnoskiauthor=A.+S.+Lakdawalaauthor=M.+P.+DeMartinoauthor=L.+N.+Casillasauthor=P.+A.+Haileauthor=C.+A.+Sehonauthor=R.+W.+Marquisauthor=J.+Uptonauthor=L.+P.+Daley-Bauerauthor=L.+Robackauthor=N.+Ramiaauthor=C.+M.+Doveyauthor=J.+E.+Caretteauthor=F.+Chanauthor=J.+Bertinauthor=P.+J.+Goughauthor=E.+S.+Mocarskiauthor=W.+J.+Kaiser&title=RIP3+induces+apoptosis+independent+of+pro-necrotic+kinase+activity&doi=10.1016%2Fj.molcel.2014.10.021"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2014.10.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2014.10.021%26sid%3Dliteratum%253Aachs%26aulast%3DMandal%26aufirst%3DP.%26aulast%3DBerger%26aufirst%3DS.%2BB.%26aulast%3DPillay%26aufirst%3DS.%26aulast%3DMoriwaki%26aufirst%3DK.%26aulast%3DHuang%26aufirst%3DC.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DLich%26aufirst%3DJ.%2BD.%26aulast%3DFinger%26aufirst%3DJ.%26aulast%3DKasparcova%26aufirst%3DV.%26aulast%3DVotta%26aufirst%3DB.%26aulast%3DOuellette%26aufirst%3DM.%26aulast%3DKing%26aufirst%3DB.%2BW.%26aulast%3DWisnoski%26aufirst%3DD.%26aulast%3DLakdawala%26aufirst%3DA.%2BS.%26aulast%3DDeMartino%26aufirst%3DM.%2BP.%26aulast%3DCasillas%26aufirst%3DL.%2BN.%26aulast%3DHaile%26aufirst%3DP.%2BA.%26aulast%3DSehon%26aufirst%3DC.%2BA.%26aulast%3DMarquis%26aufirst%3DR.%2BW.%26aulast%3DUpton%26aufirst%3DJ.%26aulast%3DDaley-Bauer%26aufirst%3DL.%2BP.%26aulast%3DRoback%26aufirst%3DL.%26aulast%3DRamia%26aufirst%3DN.%26aulast%3DDovey%26aufirst%3DC.%2BM.%26aulast%3DCarette%26aufirst%3DJ.%2BE.%26aulast%3DChan%26aufirst%3DF.%26aulast%3DBertin%26aufirst%3DJ.%26aulast%3DGough%26aufirst%3DP.%2BJ.%26aulast%3DMocarski%26aufirst%3DE.%2BS.%26aulast%3DKaiser%26aufirst%3DW.%2BJ.%26atitle%3DRIP3%2520induces%2520apoptosis%2520independent%2520of%2520pro-necrotic%2520kinase%2520activity%26jtitle%3DMol.%2520Cell%26date%3D2014%26volume%3D56%26spage%3D481%26epage%3D495%26doi%3D10.1016%2Fj.molcel.2014.10.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mendoza, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Er, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blenis, J.</span></span> <span> </span><span class="NLM_article-title">The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation</span>. <i>Trends Biochem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">320</span>– <span class="NLM_lpage">328</span>, <span class="refDoi"> DOI: 10.1016/j.tibs.2011.03.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1016%2Fj.tibs.2011.03.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=21531565" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnsVOqs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2011&pages=320-328&author=M.+C.+Mendozaauthor=E.+E.+Erauthor=J.+Blenis&title=The+Ras-ERK+and+PI3K-mTOR+pathways%3A+cross-talk+and+compensation&doi=10.1016%2Fj.tibs.2011.03.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation</span></div><div class="casAuthors">Mendoza, Michelle C.; Er, E. Emrah; Blenis, John</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Biochemical Sciences</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">320-328</span>CODEN:
                <span class="NLM_cas:coden">TBSCDB</span>;
        ISSN:<span class="NLM_cas:issn">0968-0004</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The Ras-extracellular signal-regulated kinase (Ras-ERK) and phosphatidylinositol 3-kinase-mammalian target of rapamycin (PI3K-mTOR) signaling pathways are the chief mechanisms for controlling cell survival, differentiation, proliferation, metab., and motility in response to extracellular cues.  Components of these pathways were among the first to be discovered when scientists began cloning proto-oncogenes and purifying cellular kinase activities in the 1980s.  Ras-ERK and PI3K-mTOR were originally modeled as linear signaling conduits activated by different stimuli, yet even early expts. hinted that they might intersect to regulate each other and co-regulate downstream functions.  The extent of this cross-talk and its significance in cancer therapeutics are now becoming clear.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-3LOfCYc7_bVg90H21EOLACvtfcHk0ljpt9XYtaisXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnsVOqs7k%253D&md5=d7d9938e5311b23932d23ef5379d6b12</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1016%2Fj.tibs.2011.03.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tibs.2011.03.006%26sid%3Dliteratum%253Aachs%26aulast%3DMendoza%26aufirst%3DM.%2BC.%26aulast%3DEr%26aufirst%3DE.%2BE.%26aulast%3DBlenis%26aufirst%3DJ.%26atitle%3DThe%2520Ras-ERK%2520and%2520PI3K-mTOR%2520pathways%253A%2520cross-talk%2520and%2520compensation%26jtitle%3DTrends%2520Biochem.%2520Sci.%26date%3D2011%26volume%3D36%26spage%3D320%26epage%3D328%26doi%3D10.1016%2Fj.tibs.2011.03.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sutherlin, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bisconte, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaney, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chantry, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castanedo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DePledge, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldsmith, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hancox, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knowles, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondru, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesnick, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadin, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonomiya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pegg, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safina, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salphati, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staben, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seward, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuttleworth, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sohal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, Z. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ultsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waszkowycz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B.</span></span> <span> </span><span class="NLM_article-title">Potent and selective inhibitors of PI3Kδ: Obtaining isoform selectivity from the affinity pocket and tryptophan shelf</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">4296</span>– <span class="NLM_lpage">4302</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.05.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1016%2Fj.bmcl.2012.05.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=22672799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC38XotVegur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=4296-4302&author=D.+P.+Sutherlinauthor=S.+Bakerauthor=A.+Bisconteauthor=P.+M.+Blaneyauthor=A.+Brownauthor=B.+K.+Chanauthor=D.+Chantryauthor=G.+Castanedoauthor=P.+DePledgeauthor=P.+Goldsmithauthor=D.+M.+Goldsteinauthor=T.+Hancoxauthor=J.+Kaurauthor=D.+Knowlesauthor=R.+Kondruauthor=J.+Lesnickauthor=M.+C.+Lucasauthor=C.+Lewisauthor=J.+Murrayauthor=A.+J.+Nadinauthor=J.+Nonomiyaauthor=J.+Pangauthor=N.+Peggauthor=S.+Priceauthor=K.+Reifauthor=B.+S.+Safinaauthor=L.+Salphatiauthor=S.+Stabenauthor=E.+M.+Sewardauthor=S.+Shuttleworthauthor=S.+Sohalauthor=Z.+K.+Sweeneyauthor=M.+Ultschauthor=B.+Waszkowyczauthor=B.+Wei&title=Potent+and+selective+inhibitors+of+PI3K%CE%B4%3A+Obtaining+isoform+selectivity+from+the+affinity+pocket+and+tryptophan+shelf&doi=10.1016%2Fj.bmcl.2012.05.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and selective inhibitors of PI3Kδ: Obtaining isoform selectivity from the affinity pocket and tryptophan shelf</span></div><div class="casAuthors">Sutherlin, Daniel P.; Baker, Stewart; Bisconte, Angelina; Blaney, Paul M.; Brown, Anthony; Chan, Bryan K.; Chantry, David; Castanedo, Georgette; DePledge, Paul; Goldsmith, Paul; Goldstein, David M.; Hancox, Timothy; Kaur, Jasmit; Knowles, David; Kondru, Rama; Lesnick, John; Lucas, Matthew C.; Lewis, Cristina; Murray, Jeremy; Nadin, Alan J.; Nonomiya, Jim; Pang, Jodie; Pegg, Neil; Price, Steve; Reif, Karin; Safina, Brian S.; Salphati, Laurent; Staben, Steven; Seward, Eileen M.; Shuttleworth, Stephen; Sohal, Sukhjit; Sweeney, Zachary K.; Ultsch, Mark; Waszkowycz, Bohdan; Wei, Binqing</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4296-4302</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A potent inhibitor of PI3Kδ that is ≥200 fold selective for the remaining three Class I PI3K isoforms and addnl. kinases is described.  The hypothesis for selectivity is illustrated through structure activity relationships and crystal structures of compds. bound to a K802T mutant of PI3Kγ.  Pharmacokinetic data in rats and mice support the use of 3 as a useful tool compd. to use for in vivo studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaSfg4K5zqbLVg90H21EOLACvtfcHk0ljpt9XYtaisXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XotVegur0%253D&md5=d15c7cd8ce626cc5e9a13ac355557ce8</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.05.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.05.027%26sid%3Dliteratum%253Aachs%26aulast%3DSutherlin%26aufirst%3DD.%2BP.%26aulast%3DBaker%26aufirst%3DS.%26aulast%3DBisconte%26aufirst%3DA.%26aulast%3DBlaney%26aufirst%3DP.%2BM.%26aulast%3DBrown%26aufirst%3DA.%26aulast%3DChan%26aufirst%3DB.%2BK.%26aulast%3DChantry%26aufirst%3DD.%26aulast%3DCastanedo%26aufirst%3DG.%26aulast%3DDePledge%26aufirst%3DP.%26aulast%3DGoldsmith%26aufirst%3DP.%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26aulast%3DHancox%26aufirst%3DT.%26aulast%3DKaur%26aufirst%3DJ.%26aulast%3DKnowles%26aufirst%3DD.%26aulast%3DKondru%26aufirst%3DR.%26aulast%3DLesnick%26aufirst%3DJ.%26aulast%3DLucas%26aufirst%3DM.%2BC.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DNadin%26aufirst%3DA.%2BJ.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPegg%26aufirst%3DN.%26aulast%3DPrice%26aufirst%3DS.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DSafina%26aufirst%3DB.%2BS.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DStaben%26aufirst%3DS.%26aulast%3DSeward%26aufirst%3DE.%2BM.%26aulast%3DShuttleworth%26aufirst%3DS.%26aulast%3DSohal%26aufirst%3DS.%26aulast%3DSweeney%26aufirst%3DZ.%2BK.%26aulast%3DUltsch%26aufirst%3DM.%26aulast%3DWaszkowycz%26aufirst%3DB.%26aulast%3DWei%26aufirst%3DB.%26atitle%3DPotent%2520and%2520selective%2520inhibitors%2520of%2520PI3K%25CE%25B4%253A%2520Obtaining%2520isoform%2520selectivity%2520from%2520the%2520affinity%2520pocket%2520and%2520tryptophan%2520shelf%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D4296%26epage%3D4302%26doi%3D10.1016%2Fj.bmcl.2012.05.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rommel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camps, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, H.</span></span> <span> </span><span class="NLM_article-title">PI3Kδ and PI3Kγ: partners in crime in inflammation in rheumatoid arthritis and beyond?</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">191</span>, <span class="refDoi"> DOI: 10.1038/nri2036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1038%2Fnri2036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=17290298" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitVGrtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=191&author=C.+Rommelauthor=M.+Campsauthor=H.+Ji&title=PI3K%CE%B4+and+PI3K%CE%B3%3A+partners+in+crime+in+inflammation+in+rheumatoid+arthritis+and+beyond%3F&doi=10.1038%2Fnri2036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">PI3Kδ and PI3Kγ: partners in crime in inflammation in rheumatoid arthritis and beyond?</span></div><div class="casAuthors">Rommel, Christian; Camps, Montserrat; Ji, Hong</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">191-201</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Dysregulated signal transduction in innate and adaptive immune cells is known to be assocd. with the development of various autoimmune and inflammatory diseases.  Consequently, targeting intracellular signaling of the pro-inflammatory cytokine network heralds hope for the next generation of anti-inflammatory drugs.  Phosphoinositide 3-kinases (PI3Ks) generate lipid-based second messengers that control an array of intracellular signaling pathways that are known to have important roles in leukocytes.  In light of the recent progress in the development of selective PI3K inhibitors, and the beneficial effects of these inhibitors in models of acute and chronic inflammatory disorders, the authors discuss the therapeutic potential of blocking PI3K isoforms for the treatment of rheumatoid arthritis and other immune-mediated diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKSAduhwUrPrVg90H21EOLACvtfcHk0lj3KlBfsxWuAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitVGrtbk%253D&md5=2fdb3507d06ddf7d5485185f4573790f</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1038%2Fnri2036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri2036%26sid%3Dliteratum%253Aachs%26aulast%3DRommel%26aufirst%3DC.%26aulast%3DCamps%26aufirst%3DM.%26aulast%3DJi%26aufirst%3DH.%26atitle%3DPI3K%25CE%25B4%2520and%2520PI3K%25CE%25B3%253A%2520partners%2520in%2520crime%2520in%2520inflammation%2520in%2520rheumatoid%2520arthritis%2520and%2520beyond%253F%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2007%26volume%3D7%26spage%3D191%26doi%3D10.1038%2Fnri2036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dienstmann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serra, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabernero, J.</span></span> <span> </span><span class="NLM_article-title">Picking the point of inhibition: A comparative review of PI3K/AKT/mTOR pathway inhibitors</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1021</span>– <span class="NLM_lpage">1031</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0639</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1158%2F1535-7163.MCT-13-0639" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=24748656" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnsFWjs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=1021-1031&author=R.+Dienstmannauthor=J.+Rodonauthor=V.+Serraauthor=J.+Tabernero&title=Picking+the+point+of+inhibition%3A+A+comparative+review+of+PI3K%2FAKT%2FmTOR+pathway+inhibitors&doi=10.1158%2F1535-7163.MCT-13-0639"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors</span></div><div class="casAuthors">Dienstmann, Rodrigo; Rodon, Jordi; Serra, Violeta; Tabernero, Josep</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1021-1031</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The frequent activation of the PI3K/AKT/mTOR pathway in cancer, and its crucial role in cell growth and survival, has made it a much desired target for pharmacol. intervention.  Following the regulatory approval of the rapamycin analogs everolimus and temsirolimus, recent years have seen an explosion in the no. of phosphoinositide 3-kinase (PI3K) pathway inhibitors under clin. investigation.  These include: ATP-competitive, dual inhibitors of class I PI3K and mTORC1/2; "pan-PI3K" inhibitors, which inhibit all four isoforms of class I PI3K (α, β, δ, γ); isoform-specific inhibitors of the various PI3K isoforms; allosteric and catalytic inhibitors of AKT; and ATP-competitive inhibitors of mTOR only (and thus mTORC1 and mTORC2).  With so many agents in development, clinicians are currently faced with a wide array of clin. trials investigating a multitude of inhibitors with different mechanisms of action, being used both as single agents and in combination with other therapies.  Here, we provide a review of the literature, with the aim of differentiating the genomic contexts in which these various types of inhibitors may potentially have superior activity.  Mol Cancer Ther; 13(5); 1021-31. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3McPbkS5dm7Vg90H21EOLACvtfcHk0lj3KlBfsxWuAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnsFWjs78%253D&md5=7b5ef12e83be522233ad403ce3040719</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0639&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0639%26sid%3Dliteratum%253Aachs%26aulast%3DDienstmann%26aufirst%3DR.%26aulast%3DRodon%26aufirst%3DJ.%26aulast%3DSerra%26aufirst%3DV.%26aulast%3DTabernero%26aufirst%3DJ.%26atitle%3DPicking%2520the%2520point%2520of%2520inhibition%253A%2520A%2520comparative%2520review%2520of%2520PI3K%252FAKT%252FmTOR%2520pathway%2520inhibitors%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D1021%26epage%3D1031%26doi%3D10.1158%2F1535-7163.MCT-13-0639" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref170"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref170'); return false;" data-citation="" class="refNumLink">170</a></strong><div class="NLM_citation" id="cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arthur, J. S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ley, S. C.</span></span> <span> </span><span class="NLM_article-title">Mitogen-activated protein kinases in innate immunity</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">679</span>– <span class="NLM_lpage">692</span>, <span class="refDoi"> DOI: 10.1038/nri3495</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1038%2Fnri3495" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=23954936" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1yltrjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=679-692&author=J.+S.+C.+Arthurauthor=S.+C.+Ley&title=Mitogen-activated+protein+kinases+in+innate+immunity&doi=10.1038%2Fnri3495"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Mitogen-activated protein kinases in innate immunity</span></div><div class="casAuthors">Arthur, J. Simon C.; Ley, Steven C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">679-692</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Following pathogen infection or tissue damage, the stimulation of pattern recognition receptors on the cell surface and in the cytoplasm of innate immune cells activates members of each of the major mitogen-activated protein kinase (MAPK) subfamilies - the extracellular signal-regulated kinase (ERK), p38 and Jun N-terminal kinase (JNK) subfamilies.  In conjunction with the activation of nuclear factor-κB and interferon-regulatory factor transcription factors, MAPK activation induces the expression of multiple genes that together regulate the inflammatory response.  In this Review, we discuss our current knowledge about the regulation and the function of MAPKs in innate immunity, as well as the importance of neg. feedback loops in limiting MAPK activity to prevent host tissue damage.  We also examine how pathogens have evolved complex mechanisms to manipulate MAPK activation to increase their virulence.  Finally, we consider the potential of the pharmacol. targeting of MAPK pathways to treat autoimmune and inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokaFaArJ0-rLVg90H21EOLACvtfcHk0lj3KlBfsxWuAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1yltrjI&md5=385a2fc463805b41ec03296345fb5d86</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1038%2Fnri3495&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri3495%26sid%3Dliteratum%253Aachs%26aulast%3DArthur%26aufirst%3DJ.%2BS.%2BC.%26aulast%3DLey%26aufirst%3DS.%2BC.%26atitle%3DMitogen-activated%2520protein%2520kinases%2520in%2520innate%2520immunity%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2013%26volume%3D13%26spage%3D679%26epage%3D692%26doi%3D10.1038%2Fnri3495" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref171"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref171'); return false;" data-citation="" class="refNumLink">171</a></strong><div class="NLM_citation" id="cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xing, L.</span></span> <span> </span><span class="NLM_article-title">Clinical candidates of small molecule p38 MAPK inhibitors for inflammatory diseases</span>. <i>MAP Kinase</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">24</span>– <span class="NLM_lpage">30</span>, <span class="refDoi"> DOI: 10.4081/mk.2015.5508</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.4081%2Fmk.2015.5508" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2015&pages=24-30&author=L.+Xing&title=Clinical+candidates+of+small+molecule+p38+MAPK+inhibitors+for+inflammatory+diseases&doi=10.4081%2Fmk.2015.5508"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.4081%2Fmk.2015.5508&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4081%252Fmk.2015.5508%26sid%3Dliteratum%253Aachs%26aulast%3DXing%26aufirst%3DL.%26atitle%3DClinical%2520candidates%2520of%2520small%2520molecule%2520p38%2520MAPK%2520inhibitors%2520for%2520inflammatory%2520diseases%26jtitle%3DMAP%2520Kinase%26date%3D2015%26volume%3D4%26spage%3D24%26epage%3D30%26doi%3D10.4081%2Fmk.2015.5508" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref172"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref172'); return false;" data-citation="" class="refNumLink">172</a></strong><div class="NLM_citation" id="cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hope, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burnette, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Compton, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devraj, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsch, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keith, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mbalaviele, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messing, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saabye, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schindler, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selness, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stillwell, L. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monahan, J. B.</span></span> <span> </span><span class="NLM_article-title">Anti-inflammatory properties of a novel N-phenyl pyridinone inhibitor of p38 mitogen-activated protein kinase: preclinical-to-clinical translation</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>331</i></span>,  <span class="NLM_fpage">882</span>– <span class="NLM_lpage">895</span>, <span class="refDoi"> DOI: 10.1124/jpet.109.158329</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1124%2Fjpet.109.158329" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=19720877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFaqsL3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=331&publication_year=2009&pages=882-895&author=H.+R.+Hopeauthor=G.+D.+Andersonauthor=B.+L.+Burnetteauthor=R.+P.+Comptonauthor=R.+V.+Devrajauthor=J.+L.+Hirschauthor=R.+H.+Keithauthor=X.+Liauthor=G.+Mbalavieleauthor=D.+M.+Messingauthor=M.+J.+Saabyeauthor=J.+F.+Schindlerauthor=S.+R.+Selnessauthor=L.+I.+Stillwellauthor=E.+G.+Webbauthor=J.+Zhangauthor=J.+B.+Monahan&title=Anti-inflammatory+properties+of+a+novel+N-phenyl+pyridinone+inhibitor+of+p38+mitogen-activated+protein+kinase%3A+preclinical-to-clinical+translation&doi=10.1124%2Fjpet.109.158329"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-inflammatory properties of a novel N-phenylpyridinone inhibitor of p38 mitogen-activated protein kinase: preclinical-to-clinical translation</span></div><div class="casAuthors">Hope, Heidi R.; Anderson, Gary D.; Burnette, Barry L.; Compton, Robert P.; Devraj, Rajesh V.; Hirsch, Jeffrey L.; Keith, Robert H.; Li, Xiong; Mbalaviele, Gabriel; Messing, Dean M.; Saabye, Matthew J.; Schindler, John F.; Selness, Shaun R.; Stillwell, Loreen I.; Webb, Elizabeth G.; Zhang, Jian; Monahan, Joseph B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">331</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">882-895</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Signal transduction through the p38 mitogen-activated protein (MAP) kinase pathway is central to the transcriptional and translational control of cytokine and inflammatory mediator prodn.  P38 MAP kinase inhibition hence constitutes a promising therapeutic strategy for treatment of chronic inflammatory diseases, based upon its potential to inhibit key pathways driving the inflammatory and destructive processes in these debilitating diseases.  The present study describes the pharmacol. properties of the N-phenylpyridinone p38 MAP kinase inhibitor benzamide [3-[3-bromo-4-[(2,4-difluorophenyl)methoxy]-6-methyl-2-oxo-1(2H)-pyridinyl]-N,4-dimethyl-, (-)-(9CI); PH-797804].  PH-797804 is an ATP-competitive, readily reversible inhibitor of the α isoform of human p38 MAP kinase, exhibiting a Ki = 5.8 nM.  In human monocyte and synovial fibroblast cell systems, PH-797804 blocks inflammation-induced prodn. of cytokines and proinflammatory mediators, such as prostaglandin E2, at concns. that parallel inhibition of cell-assocd. p38 MAP kinase.  After oral dosing, PH-797804 effectively inhibits acute inflammatory responses induced by systemically administered endotoxin in both rat and cynomolgus monkeys.  Furthermore, PH-797804 demonstrates robust anti-inflammatory activity in chronic disease models, significantly reducing both joint inflammation and assocd. bone loss in streptococcal cell wall-induced arthritis in rats and mouse collagen-induced arthritis.  Finally, PH-797804 reduced tumor necrosis factor-α and interleukin-6 prodn. in clin. studies after endotoxin administration in a dose-dependent manner, paralleling inhibition of the target enzyme.  Low-nanomolar biochem. enzyme inhibition potency correlated with p38 MAP kinase inhibition in human cells and in vivo studies.  In addn., a direct correspondence between p38 MAP kinase inhibition and anti-inflammatory activity was obsd. with PH-797804, thus providing confidence in dose projections for further human studies in chronic inflammatory disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr29aqHR77fj7Vg90H21EOLACvtfcHk0ligojyjvTgX3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFaqsL3K&md5=6b5455e9080767dd56b27d8a880f71c1</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1124%2Fjpet.109.158329&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.109.158329%26sid%3Dliteratum%253Aachs%26aulast%3DHope%26aufirst%3DH.%2BR.%26aulast%3DAnderson%26aufirst%3DG.%2BD.%26aulast%3DBurnette%26aufirst%3DB.%2BL.%26aulast%3DCompton%26aufirst%3DR.%2BP.%26aulast%3DDevraj%26aufirst%3DR.%2BV.%26aulast%3DHirsch%26aufirst%3DJ.%2BL.%26aulast%3DKeith%26aufirst%3DR.%2BH.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DMbalaviele%26aufirst%3DG.%26aulast%3DMessing%26aufirst%3DD.%2BM.%26aulast%3DSaabye%26aufirst%3DM.%2BJ.%26aulast%3DSchindler%26aufirst%3DJ.%2BF.%26aulast%3DSelness%26aufirst%3DS.%2BR.%26aulast%3DStillwell%26aufirst%3DL.%2BI.%26aulast%3DWebb%26aufirst%3DE.%2BG.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DMonahan%26aufirst%3DJ.%2BB.%26atitle%3DAnti-inflammatory%2520properties%2520of%2520a%2520novel%2520N-phenyl%2520pyridinone%2520inhibitor%2520of%2520p38%2520mitogen-activated%2520protein%2520kinase%253A%2520preclinical-to-clinical%2520translation%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2009%26volume%3D331%26spage%3D882%26epage%3D895%26doi%3D10.1124%2Fjpet.109.158329" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref173"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref173'); return false;" data-citation="" class="refNumLink">173</a></strong><div class="NLM_citation" id="cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunoosamy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegelund-Myrback, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pehrson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taib, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenaway, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siew, L.</span></span> <span> </span><span class="NLM_article-title">AZD7624, an inhaled p38 inhibitor for COPD, attenuates lung and systemic inflammation after LPS challenge in humans</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">OA483</span>, <span class="refDoi"> DOI: 10.1183/13993003.congress-2015.OA483</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1183%2F13993003.congress-2015.OA483" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2015&pages=OA483&author=N.+Patelauthor=D.+Cunoosamyauthor=T.+Hegelund-Myrbackauthor=R.+Pehrsonauthor=Z.+Taibauthor=P.+Janssonauthor=S.+Lundinauthor=S.+Greenawayauthor=G.+Clarkeauthor=L.+Siew&title=AZD7624%2C+an+inhaled+p38+inhibitor+for+COPD%2C+attenuates+lung+and+systemic+inflammation+after+LPS+challenge+in+humans&doi=10.1183%2F13993003.congress-2015.OA483"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1183%2F13993003.congress-2015.OA483&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F13993003.congress-2015.OA483%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DN.%26aulast%3DCunoosamy%26aufirst%3DD.%26aulast%3DHegelund-Myrback%26aufirst%3DT.%26aulast%3DPehrson%26aufirst%3DR.%26aulast%3DTaib%26aufirst%3DZ.%26aulast%3DJansson%26aufirst%3DP.%26aulast%3DLundin%26aufirst%3DS.%26aulast%3DGreenaway%26aufirst%3DS.%26aulast%3DClarke%26aufirst%3DG.%26aulast%3DSiew%26aufirst%3DL.%26atitle%3DAZD7624%252C%2520an%2520inhaled%2520p38%2520inhibitor%2520for%2520COPD%252C%2520attenuates%2520lung%2520and%2520systemic%2520inflammation%2520after%2520LPS%2520challenge%2520in%2520humans%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2015%26volume%3D46%26spage%3DOA483%26doi%3D10.1183%2F13993003.congress-2015.OA483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref174"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref174'); return false;" data-citation="" class="refNumLink">174</a></strong><div class="NLM_citation" id="cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walter, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wentsch, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bührmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Döring, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer-Wrangowski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sievers-Engler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willemsen-Seegers, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaman, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buijsman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lämmerhofer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S. A.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of novel type I1/2 p38α MAP kinase inhibitors with excellent selectivity, high potency, and prolonged target residence time by interfering with the R-spine</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">8027</span>– <span class="NLM_lpage">8054</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00745</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00745" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlOksb3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=8027-8054&author=N.+M.+Walterauthor=H.+K.+Wentschauthor=M.+B%C3%BChrmannauthor=S.+M.+Bauerauthor=E.+D%C3%B6ringauthor=S.+Mayer-Wrangowskiauthor=A.+Sievers-Englerauthor=N.+Willemsen-Seegersauthor=G.+Zamanauthor=R.+Buijsmanauthor=M.+L%C3%A4mmerhoferauthor=D.+Rauhauthor=S.+A.+Laufer&title=Design%2C+synthesis%2C+and+biological+evaluation+of+novel+type+I1%2F2+p38%CE%B1+MAP+kinase+inhibitors+with+excellent+selectivity%2C+high+potency%2C+and+prolonged+target+residence+time+by+interfering+with+the+R-spine&doi=10.1021%2Facs.jmedchem.7b00745"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Evaluation of Novel Type I1/2 p38α MAP Kinase Inhibitors with Excellent Selectivity, High Potency, and Prolonged Target Residence Time by Interfering with the R-Spine</span></div><div class="casAuthors">Walter, Niklas M.; Wentsch, Heike K.; Buehrmann, Mike; Bauer, Silke M.; Doering, Eva; Mayer-Wrangowski, Svenja; Sievers-Engler, Adrian; Willemsen-Seegers, Nicole; Zaman, Guido; Buijsman, Rogier; Laemmerhofer, Michael; Rauh, Daniel; Laufer, Stefan A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8027-8054</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We recently reported 1a (skepinone-L) as a type I p38α MAP kinase inhibitor with high potency and excellent selectivity in vitro and in vivo.  However, as a type I inhibitor, it is entirely ATP-competitive and shows just a moderate residence time.  Thus, the scope was to develop a new class of advanced compds. maintaining the structural binding features of skepinone-L scaffold like inducing a glycine flip at the hinge region and occupying both hydrophobic regions I and II.  Extending this scaffold with suitable residues resulted in an interference with the kinase's R-Spine.  By synthesizing 69 compds., we could significantly prolong the target residence time with one example to 3663 s, along with an excellent selectivity score of 0.006 and an outstanding potency of 1.0 nM.  This new binding mode was validated by cocrystn., showing all binding interactions typifying type I1/2 binding.  Moreover, microsomal studies showed convenient metabolic stability of the most potent, herein reported representatives.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAGz7uVuEJALVg90H21EOLACvtfcHk0ligojyjvTgX3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlOksb3M&md5=99afecb58a5cf1fff6d9a905eb9f3aca</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00745%26sid%3Dliteratum%253Aachs%26aulast%3DWalter%26aufirst%3DN.%2BM.%26aulast%3DWentsch%26aufirst%3DH.%2BK.%26aulast%3DB%25C3%25BChrmann%26aufirst%3DM.%26aulast%3DBauer%26aufirst%3DS.%2BM.%26aulast%3DD%25C3%25B6ring%26aufirst%3DE.%26aulast%3DMayer-Wrangowski%26aufirst%3DS.%26aulast%3DSievers-Engler%26aufirst%3DA.%26aulast%3DWillemsen-Seegers%26aufirst%3DN.%26aulast%3DZaman%26aufirst%3DG.%26aulast%3DBuijsman%26aufirst%3DR.%26aulast%3DL%25C3%25A4mmerhofer%26aufirst%3DM.%26aulast%3DRauh%26aufirst%3DD.%26aulast%3DLaufer%26aufirst%3DS.%2BA.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520novel%2520type%2520I1%252F2%2520p38%25CE%25B1%2520MAP%2520kinase%2520inhibitors%2520with%2520excellent%2520selectivity%252C%2520high%2520potency%252C%2520and%2520prolonged%2520target%2520residence%2520time%2520by%2520interfering%2520with%2520the%2520R-spine%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D8027%26epage%3D8054%26doi%3D10.1021%2Facs.jmedchem.7b00745" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref175"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref175'); return false;" data-citation="" class="refNumLink">175</a></strong><div class="NLM_citation" id="cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Millan, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunnage, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butcher, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodd, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairman, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilty, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemaitre, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewthwaite, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahnke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathias, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philip, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefaniak, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeadon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, C.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of inhaled p38 inhibitors for the treatment of chronic obstructive pulmonary disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">7797</span>– <span class="NLM_lpage">7814</span>, <span class="refDoi"> DOI: 10.1021/jm200677b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200677b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlOqu73E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7797-7814&author=D.+S.+Millanauthor=M.+E.+Bunnageauthor=J.+L.+Burrowsauthor=K.+J.+Butcherauthor=P.+G.+Doddauthor=T.+J.+Evansauthor=D.+A.+Fairmanauthor=S.+J.+Hughesauthor=I.+C.+Kiltyauthor=A.+Lemaitreauthor=R.+A.+Lewthwaiteauthor=A.+Mahnkeauthor=J.+P.+Mathiasauthor=J.+Philipauthor=R.+T.+Smithauthor=M.+H.+Stefaniakauthor=M.+Yeadonauthor=C.+Phillips&title=Design+and+synthesis+of+inhaled+p38+inhibitors+for+the+treatment+of+chronic+obstructive+pulmonary+disease&doi=10.1021%2Fjm200677b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Inhaled p38 Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease</span></div><div class="casAuthors">Millan, David S.; Bunnage, Mark E.; Burrows, Jane L.; Butcher, Kenneth J.; Dodd, Peter G.; Evans, Timothy J.; Fairman, David A.; Hughes, Samantha J.; Kilty, Iain C.; Lemaitre, Arnaud; Lewthwaite, Russell A.; Mahnke, Axel; Mathias, John P.; Philip, James; Smith, Robert T.; Stefaniak, Mark H.; Yeadon, Michael; Phillips, Christopher</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7797-7814</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This paper describes the identification and optimization of a novel series of DFG-out binding p38 inhibitors as inhaled agents for the treatment of chronic obstructive pulmonary disease.  Structure based drug design and "inhalation by design" principles have been applied to the optimization of the lead series exemplified by compd. I.  Analogs have been designed to be potent and selective for p38, with an emphasis on slow enzyme dissocn. kinetics to deliver prolonged lung p38 inhibition.  Pharmacokinetic properties were tuned with high intrinsic clearance and low oral bioavailability in mind, to minimize systemic exposure and reduce systemically driven adverse events.  High CYP mediated clearance and glucuronidation were targeted to achieve high intrinsic clearance coupled with multiple routes of clearance to minimize drug-drug interactions.  Furthermore, pharmaceutical properties such as stability, crystallinity, and soly. were considered to ensure compatibility with a dry powder inhaler.  P38 Inhibitor II (PF-03715455) was subsequently identified as a clin. candidate from this series with efficacy and safety profiles confirming its potential as an inhaled agent for the treatment of COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzy5ivwDBL6rVg90H21EOLACvtfcHk0ljj2OLxGbLsRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlOqu73E&md5=9bc6cccf04a78831f50fb402bf7cb4b1</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1021%2Fjm200677b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200677b%26sid%3Dliteratum%253Aachs%26aulast%3DMillan%26aufirst%3DD.%2BS.%26aulast%3DBunnage%26aufirst%3DM.%2BE.%26aulast%3DBurrows%26aufirst%3DJ.%2BL.%26aulast%3DButcher%26aufirst%3DK.%2BJ.%26aulast%3DDodd%26aufirst%3DP.%2BG.%26aulast%3DEvans%26aufirst%3DT.%2BJ.%26aulast%3DFairman%26aufirst%3DD.%2BA.%26aulast%3DHughes%26aufirst%3DS.%2BJ.%26aulast%3DKilty%26aufirst%3DI.%2BC.%26aulast%3DLemaitre%26aufirst%3DA.%26aulast%3DLewthwaite%26aufirst%3DR.%2BA.%26aulast%3DMahnke%26aufirst%3DA.%26aulast%3DMathias%26aufirst%3DJ.%2BP.%26aulast%3DPhilip%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DR.%2BT.%26aulast%3DStefaniak%26aufirst%3DM.%2BH.%26aulast%3DYeadon%26aufirst%3DM.%26aulast%3DPhillips%26aufirst%3DC.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520inhaled%2520p38%2520inhibitors%2520for%2520the%2520treatment%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7797%26epage%3D7814%26doi%3D10.1021%2Fjm200677b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref176"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref176'); return false;" data-citation="" class="refNumLink">176</a></strong><div class="NLM_citation" id="cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nejentsev, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Condliffe, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okkenhaug, K.</span></span> <span> </span><span class="NLM_article-title">PI3Kδ and primary immunodeficiencies</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">702</span>– <span class="NLM_lpage">714</span>, <span class="refDoi"> DOI: 10.1038/nri.2016.93</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1038%2Fnri.2016.93" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=27616589" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsV2isL3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=702-714&author=C.+L.+Lucasauthor=A.+Chandraauthor=S.+Nejentsevauthor=A.+M.+Condliffeauthor=K.+Okkenhaug&title=PI3K%CE%B4+and+primary+immunodeficiencies&doi=10.1038%2Fnri.2016.93"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">PI3Kδ and primary immunodeficiencies</span></div><div class="casAuthors">Lucas, Carrie L.; Chandra, Anita; Nejentsev, Sergey; Condliffe, Alison M.; Okkenhaug, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">702-714</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Primary immunodeficiencies are inherited disorders of the immune system, often caused by the mutation of genes required for lymphocyte development and activation.  Recently, several studies have identified gain-of-function mutations in the phosphoinositide 3-kinase (PI3K) genes PIK3CD (which encodes p110δ) and PIK3R1 (which encodes p85α) that cause a combined immunodeficiency syndrome, referred to as activated PI3Kδ syndrome (APDS; also known as p110δ-activating mutation causing senescent T cells, lymphadenopathy and immunodeficiency (PASLI)).  Paradoxically, both loss-of-function and gain-of-function mutations that affect these genes lead to immunosuppression, albeit via different mechanisms.  Here, we review the roles of PI3Kδ in adaptive immunity, describe the clin. manifestations and mechanisms of disease in APDS and highlight new insights into PI3Kδ gleaned from these patients, as well as implications of these findings for clin. therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqS1HjXfbEWt7Vg90H21EOLACvtfcHk0ljj2OLxGbLsRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsV2isL3O&md5=c10ce8e59ae67e476bccbefab52213b4</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1038%2Fnri.2016.93&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri.2016.93%26sid%3Dliteratum%253Aachs%26aulast%3DLucas%26aufirst%3DC.%2BL.%26aulast%3DChandra%26aufirst%3DA.%26aulast%3DNejentsev%26aufirst%3DS.%26aulast%3DCondliffe%26aufirst%3DA.%2BM.%26aulast%3DOkkenhaug%26aufirst%3DK.%26atitle%3DPI3K%25CE%25B4%2520and%2520primary%2520immunodeficiencies%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2016%26volume%3D16%26spage%3D702%26epage%3D714%26doi%3D10.1038%2Fnri.2016.93" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref177"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref177'); return false;" data-citation="" class="refNumLink">177</a></strong><div class="NLM_citation" id="cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gross, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, P. J.</span></span> <span> </span><span class="NLM_article-title">New therapies for asthma and chronic obstructive pulmonary disease</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>195</i></span>,  <span class="NLM_fpage">159</span>– <span class="NLM_lpage">166</span>, <span class="refDoi"> DOI: 10.1164/rccm.201610-2074PP</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1164%2Frccm.201610-2074PP" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=27922751" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjt1SltLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=195&publication_year=2017&pages=159-166&author=N.+J.+Grossauthor=P.+J.+Barnes&title=New+therapies+for+asthma+and+chronic+obstructive+pulmonary+disease&doi=10.1164%2Frccm.201610-2074PP"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">New therapies for asthma and chronic obstructive pulmonary disease</span></div><div class="casAuthors">Gross, Nicholas J.; Barnes, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">195</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">159-166</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">In this paper we discuss new therapies for asthma and chronic obstructive pulmonary disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXeDlu2KlgQrVg90H21EOLACvtfcHk0liVC5oE1OvcuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjt1SltLg%253D&md5=33192f02c8270268dd65b09e09f42568</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1164%2Frccm.201610-2074PP&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.201610-2074PP%26sid%3Dliteratum%253Aachs%26aulast%3DGross%26aufirst%3DN.%2BJ.%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26atitle%3DNew%2520therapies%2520for%2520asthma%2520and%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2017%26volume%3D195%26spage%3D159%26epage%3D166%26doi%3D10.1164%2Frccm.201610-2074PP" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref178"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref178'); return false;" data-citation="" class="refNumLink">178</a></strong><div class="NLM_citation" id="cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Somoza, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koditek, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villaseñor, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novikov, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liclican, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lagpacan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papalia, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samuel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lad, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGrath, M. E.</span></span> <span> </span><span class="NLM_article-title">Structural, biochemical, and biophysical characterization of idelalisib binding to phosphoinositide 3-kinase δ</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>290</i></span>,  <span class="NLM_fpage">8439</span>– <span class="NLM_lpage">8446</span>, <span class="refDoi"> DOI: 10.1074/jbc.M114.634683</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1074%2Fjbc.M114.634683" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=25631052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlsVSqtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=290&publication_year=2015&pages=8439-8446&author=J.+R.+Somozaauthor=D.+Koditekauthor=A.+G.+Villase%C3%B1orauthor=N.+Novikovauthor=M.+H.+Wongauthor=A.+Liclicanauthor=W.+Xingauthor=L.+Lagpacanauthor=R.+Wangauthor=B.+E.+Schultzauthor=G.+A.+Papaliaauthor=D.+Samuelauthor=L.+Ladauthor=M.+E.+McGrath&title=Structural%2C+biochemical%2C+and+biophysical+characterization+of+idelalisib+binding+to+phosphoinositide+3-kinase+%CE%B4&doi=10.1074%2Fjbc.M114.634683"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Structural, Biochemical, and Biophysical Characterization of Idelalisib Binding to Phosphoinositide 3-Kinase δ</span></div><div class="casAuthors">Somoza, John R.; Koditek, David; Villasenor, Armando G.; Novikov, Nikolai; Wong, Melanie H.; Liclican, Albert; Xing, Weimei; Lagpacan, Leanna; Wang, Ruth; Schultz, Brian E.; Papalia, Giuseppe A.; Samuel, Dharmaraj; Lad, Latesh; McGrath, Mary E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">290</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">8439-8446</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Idelalisib (also known as GS-1101, CAL-101, IC489666, and Zydelig) is a PI3Kδ inhibitor that has recently been approved for the treatment of several hematol. malignancies.  Given its use in human diseases, we needed a clear picture of how idelalisib binds to and inhibits PI3Kδ.  Our data show that idelalisib is a potent and selective inhibitor of the kinase activity of PI3Kδ.  A kinetic characterization clearly demonstrated ATP-competitive inhibition, and several addnl. biochem. and biophys. assays showed that the compd. binds reversibly and noncovalently to the kinase.  A crystal structure of idelalisib bound to the p110δ subunit of PI3Kδ furthers our understanding of the binding interactions that confer the potency and selectivity of idelalisib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnXZo8_qK79rVg90H21EOLACvtfcHk0liVC5oE1OvcuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlsVSqtrs%253D&md5=2969b7407f4edc367249215bbbf22a0e</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M114.634683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M114.634683%26sid%3Dliteratum%253Aachs%26aulast%3DSomoza%26aufirst%3DJ.%2BR.%26aulast%3DKoditek%26aufirst%3DD.%26aulast%3DVillase%25C3%25B1or%26aufirst%3DA.%2BG.%26aulast%3DNovikov%26aufirst%3DN.%26aulast%3DWong%26aufirst%3DM.%2BH.%26aulast%3DLiclican%26aufirst%3DA.%26aulast%3DXing%26aufirst%3DW.%26aulast%3DLagpacan%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DSchultz%26aufirst%3DB.%2BE.%26aulast%3DPapalia%26aufirst%3DG.%2BA.%26aulast%3DSamuel%26aufirst%3DD.%26aulast%3DLad%26aufirst%3DL.%26aulast%3DMcGrath%26aufirst%3DM.%2BE.%26atitle%3DStructural%252C%2520biochemical%252C%2520and%2520biophysical%2520characterization%2520of%2520idelalisib%2520binding%2520to%2520phosphoinositide%25203-kinase%2520%25CE%25B4%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2015%26volume%3D290%26spage%3D8439%26epage%3D8446%26doi%3D10.1074%2Fjbc.M114.634683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref179"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref179'); return false;" data-citation="" class="refNumLink">179</a></strong><div class="NLM_citation" id="cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Down, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amour, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldwin, I. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, A. W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deakin, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felton, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guntrip, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keeling, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Livia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lunniss, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parr, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowland, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitulli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Washio, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamblin, J. N.</span></span> <span> </span><span class="NLM_article-title">Optimization of novel indazoles as highly potent and selective inhibitors of phosphoinositide 3-kinase δ for the treatment of respiratory disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">7381</span>– <span class="NLM_lpage">7399</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00767</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00767" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlyjsrvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=7381-7399&author=K.+Downauthor=A.+Amourauthor=I.+R.+Baldwinauthor=A.+W.+J.+Cooperauthor=A.+M.+Deakinauthor=L.+M.+Feltonauthor=S.+B.+Guntripauthor=C.+Hardyauthor=Z.+A.+Harrisonauthor=K.+L.+Jonesauthor=P.+Jonesauthor=S.+E.+Keelingauthor=J.+Leauthor=S.+Liviaauthor=F.+Lucasauthor=C.+J.+Lunnissauthor=N.+J.+Parrauthor=E.+Robinsonauthor=P.+Rowlandauthor=S.+Smithauthor=D.+A.+Thomasauthor=G.+Vitulliauthor=Y.+Washioauthor=J.+N.+Hamblin&title=Optimization+of+novel+indazoles+as+highly+potent+and+selective+inhibitors+of+phosphoinositide+3-kinase+%CE%B4+for+the+treatment+of+respiratory+disease&doi=10.1021%2Facs.jmedchem.5b00767"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of Novel Indazoles as Highly Potent and Selective Inhibitors of Phosphoinositide 3-Kinase δ for the Treatment of Respiratory Disease</span></div><div class="casAuthors">Down, Kenneth; Amour, Augustin; Baldwin, Ian R.; Cooper, Anthony W. J.; Deakin, Angela M.; Felton, Leigh M.; Guntrip, Stephen B.; Hardy, Charlotte; Harrison, Zoe A.; Jones, Katherine L.; Jones, Paul; Keeling, Suzanne E.; Le, Joelle; Livia, Stefano; Lucas, Fiona; Lunniss, Christopher J.; Parr, Nigel J.; Robinson, Ed; Rowland, Paul; Smith, Sarah; Thomas, Daniel A.; Vitulli, Giovanni; Washio, Yoshiaki; Hamblin, J. Nicole</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7381-7399</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Optimization of lead compd., through extensive use of structure-based design and a focus on PI3Kδ potency, isoform selectivity, and inhaled PK properties, led to the discovery of clin. candidates I (GSK2269557) and II (GSK2292767) for the treatment of respiratory indications via inhalation.  Compds. I and II are both highly selective for PI3Kδ over the closely related isoforms and are active in a disease relevant brown Norway rat acute OVA model of Th2-driven lung inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUYzpPxn_ArbVg90H21EOLACvtfcHk0litHHMS8oayFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlyjsrvJ&md5=2fe8e51a64e6f7c798bdcb63781d02ad</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00767&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00767%26sid%3Dliteratum%253Aachs%26aulast%3DDown%26aufirst%3DK.%26aulast%3DAmour%26aufirst%3DA.%26aulast%3DBaldwin%26aufirst%3DI.%2BR.%26aulast%3DCooper%26aufirst%3DA.%2BW.%2BJ.%26aulast%3DDeakin%26aufirst%3DA.%2BM.%26aulast%3DFelton%26aufirst%3DL.%2BM.%26aulast%3DGuntrip%26aufirst%3DS.%2BB.%26aulast%3DHardy%26aufirst%3DC.%26aulast%3DHarrison%26aufirst%3DZ.%2BA.%26aulast%3DJones%26aufirst%3DK.%2BL.%26aulast%3DJones%26aufirst%3DP.%26aulast%3DKeeling%26aufirst%3DS.%2BE.%26aulast%3DLe%26aufirst%3DJ.%26aulast%3DLivia%26aufirst%3DS.%26aulast%3DLucas%26aufirst%3DF.%26aulast%3DLunniss%26aufirst%3DC.%2BJ.%26aulast%3DParr%26aufirst%3DN.%2BJ.%26aulast%3DRobinson%26aufirst%3DE.%26aulast%3DRowland%26aufirst%3DP.%26aulast%3DSmith%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DD.%2BA.%26aulast%3DVitulli%26aufirst%3DG.%26aulast%3DWashio%26aufirst%3DY.%26aulast%3DHamblin%26aufirst%3DJ.%2BN.%26atitle%3DOptimization%2520of%2520novel%2520indazoles%2520as%2520highly%2520potent%2520and%2520selective%2520inhibitors%2520of%2520phosphoinositide%25203-kinase%2520%25CE%25B4%2520for%2520the%2520treatment%2520of%2520respiratory%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D7381%26epage%3D7399%26doi%3D10.1021%2Facs.jmedchem.5b00767" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref180"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref180'); return false;" data-citation="" class="refNumLink">180</a></strong><div class="NLM_citation" id="cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Allen, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brookings, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delgado, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuttleworth, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merriman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fahy, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tewari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silva, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Healy, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, G. C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Twomey, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cutler, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crosby, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCluskey, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watt, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Payne, A.</span></span> <span> </span><span class="NLM_article-title">Seletalisib: characterization of a novel, potent, and selective inhibitor of PI3Kδ</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>361</i></span>,  <span class="NLM_fpage">429</span>– <span class="NLM_lpage">440</span>, <span class="refDoi"> DOI: 10.1124/jpet.116.237347</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1124%2Fjpet.116.237347" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=28442583" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFOqsLbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2017&pages=429-440&author=R.+A.+Allenauthor=D.+C.+Brookingsauthor=M.+J.+Powellauthor=J.+Delgadoauthor=L.+K.+Shuttleworthauthor=M.+Merrimanauthor=I.+J.+Fahyauthor=R.+Tewariauthor=J.+P.+Silvaauthor=L.+J.+Healyauthor=G.+C.+G.+Daviesauthor=B.+Twomeyauthor=R.+M.+Cutlerauthor=A.+Kotianauthor=A.+Crosbyauthor=G.+McCluskeyauthor=G.+F.+Wattauthor=A.+Payne&title=Seletalisib%3A+characterization+of+a+novel%2C+potent%2C+and+selective+inhibitor+of+PI3K%CE%B4&doi=10.1124%2Fjpet.116.237347"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Seletalisib: characterization of a novel, potent, and selective inhibitor of PI3Kδ</span></div><div class="casAuthors">Allen, Rodger A.; Brookings, Daniel C.; Powell, Mark J.; Delgado, Jean; Shuttleworth, Lindsay K.; Merriman, Mark; Fahy, Ian J.; Tewari, Roohi; Silva, John P.; Healy, Louise J.; Davies, Gareth C. G.; Twomey, Breda; Cutler, Rona M.; Kotian, Apoorva; Crosby, Andrea; McCluskey, Gillian; Watt, Gillian F.; Payne, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">361</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">429-440</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Phosphoinositide 3-kinases (PI3K) are key signaling enzymes regulating cellular survival, development, and function.  Expression of the PI3Kδ isoform is largely restricted to leukocytes and it plays a key role in immune cell development and function.  Seletalisib is a novel small-mol. inhibitor of PI3Kδ that was evaluated in biochem. assays, cellular assays of adaptive and innate immunity, and an in vivo rat model of inflammation.  Our findings show that seletalisib is a potent, ATP-competitive, and selective PI3Kδ inhibitor able to block protein kinase B (AKT) phosphorylation following activation of the B-cell receptor in a B-cell line.  Moreover, seletalisib inhibited N-formyl peptide-stimulated but not phorbol myristate acetate-stimulated superoxide release from human neutrophils, consistent with a PI3Kδ-specific activity.  No indications of cytotoxicity were obsd. in peripheral blood mononuclear cells (PBMCs) or other cell types treated with seletalisib.  Findings from cellular assays of adaptive immunity demonstrated that seletalisib blocks human T-cell prodn. of several cytokines from activated T-cells.  Addnl., seletalisib inhibited B-cell proliferation and cytokine release.  In human whole blood assays, seletalisib inhibited CD69 expression upon B-cell activation and anti-IgE-mediated basophil degranulation.  Seletalisib showed dose-dependent inhibition in an in vivo rat model of anti-CD3-antibody-induced interleukin 2 release.  Collectively, these data characterize seletalisib as a selective PI3Kδ inhibitor and potential therapeutic candidate for the treatment of B-cell malignancies and autoimmune diseases driven by dysregulated proinflammatory cytokine secretion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyxgOubZ1Ic7Vg90H21EOLACvtfcHk0litHHMS8oayFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFOqsLbI&md5=270c4866fe19b97aada323e9945715ab</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1124%2Fjpet.116.237347&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.116.237347%26sid%3Dliteratum%253Aachs%26aulast%3DAllen%26aufirst%3DR.%2BA.%26aulast%3DBrookings%26aufirst%3DD.%2BC.%26aulast%3DPowell%26aufirst%3DM.%2BJ.%26aulast%3DDelgado%26aufirst%3DJ.%26aulast%3DShuttleworth%26aufirst%3DL.%2BK.%26aulast%3DMerriman%26aufirst%3DM.%26aulast%3DFahy%26aufirst%3DI.%2BJ.%26aulast%3DTewari%26aufirst%3DR.%26aulast%3DSilva%26aufirst%3DJ.%2BP.%26aulast%3DHealy%26aufirst%3DL.%2BJ.%26aulast%3DDavies%26aufirst%3DG.%2BC.%2BG.%26aulast%3DTwomey%26aufirst%3DB.%26aulast%3DCutler%26aufirst%3DR.%2BM.%26aulast%3DKotian%26aufirst%3DA.%26aulast%3DCrosby%26aufirst%3DA.%26aulast%3DMcCluskey%26aufirst%3DG.%26aulast%3DWatt%26aufirst%3DG.%2BF.%26aulast%3DPayne%26aufirst%3DA.%26atitle%3DSeletalisib%253A%2520characterization%2520of%2520a%2520novel%252C%2520potent%252C%2520and%2520selective%2520inhibitor%2520of%2520PI3K%25CE%25B4%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2017%26volume%3D361%26spage%3D429%26epage%3D440%26doi%3D10.1124%2Fjpet.116.237347" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref181"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref181'); return false;" data-citation="" class="refNumLink">181</a></strong><div class="NLM_citation" id="cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcoux, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batt, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornelius, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, L.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neels, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaudoin-Bertrand, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherney, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weigelt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obermeier, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sleczka, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefanski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fancher, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padmanabhan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rp, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kundu, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajareddy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hennan, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levesque, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedicord, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yarde, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstine, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rampulla, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arunachalam, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sack, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muckelbauer, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cvijic, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-Cid, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhide, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poss, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hynes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macor, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruepp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schieven, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tino, J. A.</span></span> <span> </span><span class="NLM_article-title">Identification of a potent, selective, and efficacious phosphatidylinositol 3-kinase δ (PI3Kδ) inhibitor for the treatment of immunological disorders</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">5193</span>– <span class="NLM_lpage">5208</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00618</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00618" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2sXos1Sgtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5193-5208&author=Q.+Liuauthor=Q.+Shiauthor=D.+Marcouxauthor=D.+G.+Battauthor=L.+Corneliusauthor=L.-Y.+Qinauthor=Z.+Ruanauthor=J.+Neelsauthor=M.+Beaudoin-Bertrandauthor=A.+S.+Srivastavaauthor=L.+Liauthor=R.+J.+Cherneyauthor=H.+Gongauthor=S.+H.+Wattersonauthor=C.+Weigeltauthor=K.+M.+Gilloolyauthor=K.+W.+McIntyreauthor=J.+H.+Xieauthor=M.+T.+Obermeierauthor=A.+Furaauthor=B.+Sleczkaauthor=K.+Stefanskiauthor=R.+M.+Fancherauthor=S.+Padmanabhanauthor=T.+Rpauthor=I.+Kunduauthor=K.+Rajareddyauthor=R.+Smithauthor=J.+K.+Hennanauthor=D.+Xingauthor=J.+Fanauthor=P.+C.+Levesqueauthor=Q.+Ruanauthor=S.+Pittauthor=R.+Zhangauthor=D.+Pedicordauthor=J.+Panauthor=M.+Yardeauthor=H.+Luauthor=J.+Lippyauthor=C.+Goldstineauthor=S.+Skalaauthor=R.+A.+Rampullaauthor=A.+Mathurauthor=A.+Guptaauthor=P.+N.+Arunachalamauthor=J.+S.+Sackauthor=J.+K.+Muckelbauerauthor=M.+E.+Cvijicauthor=L.+M.+Salter-Cidauthor=R.+S.+Bhideauthor=M.+A.+Possauthor=J.+Hynesauthor=P.+H.+Carterauthor=J.+E.+Macorauthor=S.+Rueppauthor=G.+L.+Schievenauthor=J.+A.+Tino&title=Identification+of+a+potent%2C+selective%2C+and+efficacious+phosphatidylinositol+3-kinase+%CE%B4+%28PI3K%CE%B4%29+inhibitor+for+the+treatment+of+immunological+disorders&doi=10.1021%2Facs.jmedchem.7b00618"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a Potent, Selective, and Efficacious Phosphatidylinositol 3-Kinase δ (PI3Kδ) Inhibitor for the Treatment of Immunological Disorders</span></div><div class="casAuthors">Liu, Qingjie; Shi, Qing; Marcoux, David; Batt, Douglas G.; Cornelius, Lyndon; Qin, Lan-Ying; Ruan, Zheming; Neels, James; Beaudoin-Bertrand, Myra; Srivastava, Anurag S.; Li, Ling; Cherney, Robert J.; Gong, Hua; Watterson, Scott H.; Weigelt, Carolyn; Gillooly, Kathleen M.; McIntyre, Kim W.; Xie, Jenny H.; Obermeier, Mary T.; Fura, Aberra; Sleczka, Bogdan; Stefanski, Kevin; Fancher, R. M.; Padmanabhan, Shweta; Thatipamula, R. P.; Kundu, Ipsit; Rajareddy, Kallem; Smith, Rodney; Hennan, James K.; Xing, Dezhi; Fan, Jingsong; Levesque, Paul C.; Ruan, Qian; Pitt, Sidney; Zhang, Rosemary; Pedicord, Donna; Pan, Jie; Yarde, Melissa; Lu, Hao; Lippy, Jonathan; Goldstine, Christine; Skala, Stacey; Rampulla, Richard A.; Mathur, Arvind; Gupta, Anuradha; Arunachalam, Pirama Nayagam; Sack, John S.; Muckelbauer, Jodi K.; Cvijic, Mary Ellen; Salter-Cid, Luisa M.; Bhide, Rajeev S.; Poss, Michael A.; Hynes, John; Carter, Percy H.; Macor, John E.; Ruepp, Stefan; Schieven, Gary L.; Tino, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5193-5208</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">PI3Kδ plays an important role controlling immune cell function and has therefore been identified as a potential target for the treatment of immunol. disorders.  This article highlights the work toward the identification of a potent, selective, and efficacious PI3Kδ inhibitor.  Through careful SAR, the successful replacement of a polar pyrazole group by a simple chloro or trifluoromethyl group led to improved Caco-2 permeability, reduced Caco-2 efflux, reduced hERG PC activity, and increased selectivity profile while maintaining potency in the CD69 hWB assay.  The optimization of the aryl substitution then identified a 4'-CN group that improved the human/rodent correlation in microsomal metabolic stability.  The lead mol. is very potent in PK/PD assays and highly efficacious in a mouse collagen-induced arthritis model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCnrlN1J_ib7Vg90H21EOLACvtfcHk0litHHMS8oayFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXos1Sgtbc%253D&md5=4bcbe85e7b82c19e47065be4fbeccdc8</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00618%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DShi%26aufirst%3DQ.%26aulast%3DMarcoux%26aufirst%3DD.%26aulast%3DBatt%26aufirst%3DD.%2BG.%26aulast%3DCornelius%26aufirst%3DL.%26aulast%3DQin%26aufirst%3DL.-Y.%26aulast%3DRuan%26aufirst%3DZ.%26aulast%3DNeels%26aufirst%3DJ.%26aulast%3DBeaudoin-Bertrand%26aufirst%3DM.%26aulast%3DSrivastava%26aufirst%3DA.%2BS.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DCherney%26aufirst%3DR.%2BJ.%26aulast%3DGong%26aufirst%3DH.%26aulast%3DWatterson%26aufirst%3DS.%2BH.%26aulast%3DWeigelt%26aufirst%3DC.%26aulast%3DGillooly%26aufirst%3DK.%2BM.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DXie%26aufirst%3DJ.%2BH.%26aulast%3DObermeier%26aufirst%3DM.%2BT.%26aulast%3DFura%26aufirst%3DA.%26aulast%3DSleczka%26aufirst%3DB.%26aulast%3DStefanski%26aufirst%3DK.%26aulast%3DFancher%26aufirst%3DR.%2BM.%26aulast%3DPadmanabhan%26aufirst%3DS.%26aulast%3DRp%26aufirst%3DT.%26aulast%3DKundu%26aufirst%3DI.%26aulast%3DRajareddy%26aufirst%3DK.%26aulast%3DSmith%26aufirst%3DR.%26aulast%3DHennan%26aufirst%3DJ.%2BK.%26aulast%3DXing%26aufirst%3DD.%26aulast%3DFan%26aufirst%3DJ.%26aulast%3DLevesque%26aufirst%3DP.%2BC.%26aulast%3DRuan%26aufirst%3DQ.%26aulast%3DPitt%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DPedicord%26aufirst%3DD.%26aulast%3DPan%26aufirst%3DJ.%26aulast%3DYarde%26aufirst%3DM.%26aulast%3DLu%26aufirst%3DH.%26aulast%3DLippy%26aufirst%3DJ.%26aulast%3DGoldstine%26aufirst%3DC.%26aulast%3DSkala%26aufirst%3DS.%26aulast%3DRampulla%26aufirst%3DR.%2BA.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DArunachalam%26aufirst%3DP.%2BN.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DMuckelbauer%26aufirst%3DJ.%2BK.%26aulast%3DCvijic%26aufirst%3DM.%2BE.%26aulast%3DSalter-Cid%26aufirst%3DL.%2BM.%26aulast%3DBhide%26aufirst%3DR.%2BS.%26aulast%3DPoss%26aufirst%3DM.%2BA.%26aulast%3DHynes%26aufirst%3DJ.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DMacor%26aufirst%3DJ.%2BE.%26aulast%3DRuepp%26aufirst%3DS.%26aulast%3DSchieven%26aufirst%3DG.%2BL.%26aulast%3DTino%26aufirst%3DJ.%2BA.%26atitle%3DIdentification%2520of%2520a%2520potent%252C%2520selective%252C%2520and%2520efficacious%2520phosphatidylinositol%25203-kinase%2520%25CE%25B4%2520%2528PI3K%25CE%25B4%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520immunological%2520disorders%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D5193%26epage%3D5208%26doi%3D10.1021%2Facs.jmedchem.7b00618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref182"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref182'); return false;" data-citation="" class="refNumLink">182</a></strong><div class="NLM_citation" id="cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yap, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjerke, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, P.</span></span> <span> </span><span class="NLM_article-title">Drugging PI3K in cancer: refining targets and therapeutic strategies</span>. <i>Curr. Opin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">98</span>– <span class="NLM_lpage">107</span>, <span class="refDoi"> DOI: 10.1016/j.coph.2015.05.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1016%2Fj.coph.2015.05.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=26117819" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVWrt7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=98-107&author=T.+A.+Yapauthor=L.+Bjerkeauthor=P.+A.+Clarkeauthor=P.+Workman&title=Drugging+PI3K+in+cancer%3A+refining+targets+and+therapeutic+strategies&doi=10.1016%2Fj.coph.2015.05.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">Drugging PI3K in cancer: refining targets and therapeutic strategies</span></div><div class="casAuthors">Yap, Timothy A.; Bjerke, Lynn; Clarke, Paul A.; Workman, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">98-107</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The phosphatidylinositol-3 kinase (PI3K) pathway is one of the most frequently activated pathogenic signalling routes in human cancers, making it a rational and important target for innovative anticancer drug development and precision medicine.  The three main classes of PI3K inhibitors currently in clin. testing comprise dual pan-Class I PI3K/mTOR inhibitors, pan-Class I PI3K inhibitors lacking significant mTOR activity and isoform-selective PI3K inhibitors.  A major step forward in recent years is the progression of over 30 small mol. PI3K inhibitors into clin. trials and the first regulatory approval of the PI3Kδ inhibitor idelalisib for multiple B-cell malignancies.  This review article focuses on the progress made in the discovery and development of novel PI3K inhibitors, with an emphasis on antitumor activity and tolerability profiles for agents that have entered clin. trials.  We also discuss the key issues of drug resistance, patient selection approaches and rational targeted combinations.  Finally, we envision the future development and use of PI3K inhibitors for the treatment of patients with a range of malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDxyCAEREi_7Vg90H21EOLACvtfcHk0lh2uuGSJQkFFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVWrt7bJ&md5=9a0238f97d8ecdc54e0c5b9b6ce4fc76</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2015.05.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2015.05.016%26sid%3Dliteratum%253Aachs%26aulast%3DYap%26aufirst%3DT.%2BA.%26aulast%3DBjerke%26aufirst%3DL.%26aulast%3DClarke%26aufirst%3DP.%2BA.%26aulast%3DWorkman%26aufirst%3DP.%26atitle%3DDrugging%2520PI3K%2520in%2520cancer%253A%2520refining%2520targets%2520and%2520therapeutic%2520strategies%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2015%26volume%3D23%26spage%3D98%26epage%3D107%26doi%3D10.1016%2Fj.coph.2015.05.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref183"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref183'); return false;" data-citation="" class="refNumLink">183</a></strong><div class="NLM_citation" id="cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Greenwell, I. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ip, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, J. B.</span></span> <span> </span><span class="NLM_article-title">PI3K inhibitors: understanding toxicity mechanisms and management</span>. <i>Oncology (Williston Park)</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">821</span>– <span class="NLM_lpage">828</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=29179250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A280%3ADC%252BC1M3ltlGntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=821-828&author=I.+B.+Greenwellauthor=A.+Ipauthor=J.+B.+Cohen&title=PI3K+inhibitors%3A+understanding+toxicity+mechanisms+and+management"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">PI3K Inhibitors: Understanding Toxicity Mechanisms and Management</span></div><div class="casAuthors">Greenwell I Brian; Ip Andrew; Cohen Jonathon B</div><div class="citationInfo"><span class="NLM_cas:title">Oncology (Williston Park, N.Y.)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">821-8</span>
        ISSN:<span class="NLM_cas:issn">0890-9091</span>.
    </div><div class="casAbstract">The phosphatidylinositol 3-kinase (PI3K) pathway has attracted immense interest as a therapeutic target for cancer treatment.  Idelalisib was the first PI3K inhibitor approved by the US Food and Drug Administration and is utilized in the treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and follicular lymphoma.  Copanlisib has subsequently been approved for relapsed follicular lymphoma in patients who have received at least two prior systemic therapies.  There are multiple other PI3K agents currently in development; these target various combinations of PI3K isoforms.  Despite the therapeutic benefit, there have been concerns about the severe and sometimes fatal adverse effects of this class of drug.  Several side effects are unusual and have poorly understood mechanisms; these include autoimmune dysfunction, opportunistic infections, skin toxicity, hypertension, and hyperglycemia.  An understanding of these unusual toxicities, as well as a good grasp of management principles, will be important as more PI3K inhibitors are approved and become incorporated into routine practice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR5yvT6h5ErjpQHPYJuLg8TfW6udTcc2ebfpT07Io3SN7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M3ltlGntA%253D%253D&md5=6c477dd4ae70ee2393283cd0b43ec885</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGreenwell%26aufirst%3DI.%2BB.%26aulast%3DIp%26aufirst%3DA.%26aulast%3DCohen%26aufirst%3DJ.%2BB.%26atitle%3DPI3K%2520inhibitors%253A%2520understanding%2520toxicity%2520mechanisms%2520and%2520management%26jtitle%3DOncology%2520%2528Williston%2520Park%2529%26date%3D2017%26volume%3D31%26spage%3D821%26epage%3D828" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref184"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref184'); return false;" data-citation="" class="refNumLink">184</a></strong><div class="NLM_citation" id="cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Craige, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kant, S.</span></span> <span> </span><span class="NLM_article-title">Mixed-lineage protein kinases (MLKs) in inflammation, metabolism, and other disease states</span>. <i>Biochim. Biophys. Acta, Mol. Basis Dis.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>1862</i></span>,  <span class="NLM_fpage">1581</span>– <span class="NLM_lpage">1586</span>, <span class="refDoi"> DOI: 10.1016/j.bbadis.2016.05.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1016%2Fj.bbadis.2016.05.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=27259981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC28XptVWkt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1862&publication_year=2016&pages=1581-1586&author=S.+M.+Craigeauthor=M.+M.+Reifauthor=S.+Kant&title=Mixed-lineage+protein+kinases+%28MLKs%29+in+inflammation%2C+metabolism%2C+and+other+disease+states&doi=10.1016%2Fj.bbadis.2016.05.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">Mixed-lineage protein kinases (MLKs) in inflammation, metabolism, and other disease states</span></div><div class="casAuthors">Craige, Siobhan M.; Reif, Michaella M.; Kant, Shashi</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular Basis of Disease</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">1862</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1581-1586</span>CODEN:
                <span class="NLM_cas:coden">BBADEX</span>;
        ISSN:<span class="NLM_cas:issn">0925-4439</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">A review.  Mixed lineage kinases, or MLKs, are members of the MAP kinase kinase kinase (MAP3K) family, which were originally identified among the activators of the major stress-dependent mitogen activated protein kinases (MAPKs), JNK and p38.  During stress, the activation of JNK and p38 kinases targets several essential downstream substrates that react in a specific manner to the unique stressor and thus det. the fate of the cell in response to a particular challenge.  Recently, the MLK family was identified as a specific modulator of JNK and p38 signaling in metabolic syndrome.  Moreover, the MLK family of kinases appears to be involved in a very wide spectrum of disorders.  This review discusses the newly identified functions of MLKs in multiple diseases including metabolic disorders, inflammation, cancer, and neurol. diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvCjWSVZ3aH7Vg90H21EOLACvtfcHk0lh2uuGSJQkFFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XptVWkt7k%253D&md5=35fe462e637637958849af5dbbe6f542</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1016%2Fj.bbadis.2016.05.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbadis.2016.05.022%26sid%3Dliteratum%253Aachs%26aulast%3DCraige%26aufirst%3DS.%2BM.%26aulast%3DReif%26aufirst%3DM.%2BM.%26aulast%3DKant%26aufirst%3DS.%26atitle%3DMixed-lineage%2520protein%2520kinases%2520%2528MLKs%2529%2520in%2520inflammation%252C%2520metabolism%252C%2520and%2520other%2520disease%2520states%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Basis%2520Dis.%26date%3D2016%26volume%3D1862%26spage%3D1581%26epage%3D1586%26doi%3D10.1016%2Fj.bbadis.2016.05.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169'],'ref170':['cit170'],'ref171':['cit171'],'ref172':['cit172'],'ref173':['cit173'],'ref174':['cit174'],'ref175':['cit175'],'ref176':['cit176'],'ref177':['cit177'],'ref178':['cit178'],'ref179':['cit179'],'ref180':['cit180'],'ref181':['cit181'],'ref182':['cit182'],'ref183':['cit183'],'ref184':['cit184']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 27 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Andrew C. Flick, Carolyn A. Leverett, Hong X. Ding, Emma McInturff, Sarah J. Fink, Subham Mahapatra, Daniel W. Carney, Erick A. Lindsey, Jacob C. DeForest, Scott P. France, Simon Berritt, Simone V. Bigi-Botterill, Tony S. Gibson, Yiyang Liu, <span class="NLM_string-name hlFld-ContribAuthor">Christopher J. O’Donnell</span>. </span><span class="cited-content_cbyCitation_article-title">Synthetic Approaches to the New Drugs Approved during 2019. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (7)
                                     , 3604-3657. <a href="https://doi.org/10.1021/acs.jmedchem.1c00208" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00208</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00208%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthetic%252BApproaches%252Bto%252Bthe%252BNew%252BDrugs%252BApproved%252Bduring%252B2019%26aulast%3DFlick%26aufirst%3DAndrew%2BC.%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D03022021%26date%3D30032021%26volume%3D64%26issue%3D7%26spage%3D3604%26epage%3D3657" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Zhouling Xie, Xiaoxiao Yang, Yajun Duan, Jihong Han, <span class="NLM_string-name hlFld-ContribAuthor">Chenzhong Liao</span>. </span><span class="cited-content_cbyCitation_article-title">Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (3)
                                     , 1283-1345. <a href="https://doi.org/10.1021/acs.jmedchem.0c01511" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01511</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01511&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01511%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSmall-Molecule%252BKinase%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BNononcologic%252BDiseases%26aulast%3DXie%26aufirst%3DZhouling%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D29082020%26date%3D22012021%26volume%3D64%26issue%3D3%26spage%3D1283%26epage%3D1345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yuqin Zhu, Yuxiang Ma, Weidong Zu, Jianing Song, Hua Wang, You Zhong, Hongmei Li, Yanmin Zhang, Qianqian Gao, Bo Kong, Junyu Xu, Fei Jiang, Xinren Wang, Shuwen Li, Chenhe Liu, Haichun Liu, Tao Lu, <span class="NLM_string-name hlFld-ContribAuthor">Yadong Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of N-Phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine Derivatives as Novel, Potent, and Selective NF-κB Inducing Kinase (NIK) Inhibitors for the Treatment of Psoriasis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (13)
                                     , 6748-6773. <a href="https://doi.org/10.1021/acs.jmedchem.0c00055" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00055</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00055%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252BN-Phenyl-7H-pyrrolo%25255B2%25252C3-d%25255Dpyrimidin-4-amine%252BDerivatives%252Bas%252BNovel%25252C%252BPotent%25252C%252Band%252BSelective%252BNF-%2525CE%2525BAB%252BInducing%252BKinase%252B%252528NIK%252529%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BPsoriasis%26aulast%3DZhu%26aufirst%3DYuqin%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D12012020%26date%3D16062020%26date%3D01062020%26volume%3D63%26issue%3D13%26spage%3D6748%26epage%3D6773" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Amy C. Hart, Lynn Abell, Junqing Guo, Michael E. Mertzman, Ramesh Padmanabha, John E. Macor, Charu Chaudhry, Hao Lu, Kevin O’Malley, Patrick J. Shaw, Carolyn Weigelt, Matthew Pokross, Kevin Kish, Kyoung S. Kim, Lyndon Cornelius, Andrew E. Douglas, Deepa Calambur, Ping Zhang, Brian Carpenter, <span class="NLM_string-name hlFld-ContribAuthor">William J. Pitts</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of RIPK3 Type II Inhibitors Using High-Throughput Mechanistic Studies in Hit Triage. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (3)
                                     , 266-271. <a href="https://doi.org/10.1021/acsmedchemlett.9b00065" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.9b00065</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.9b00065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.9b00065%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DIdentification%252Bof%252BRIPK3%252BType%252BII%252BInhibitors%252BUsing%252BHigh-Throughput%252BMechanistic%252BStudies%252Bin%252BHit%252BTriage%26aulast%3DHart%26aufirst%3DAmy%2BC.%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D19022019%26date%3D06052019%26date%3D08052019%26date%3D06052019%26volume%3D11%26issue%3D3%26spage%3D266%26epage%3D271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Naomi S. Rajapaksa, Alberto Gobbi, Joy Drobnick, Steven Do, Aleksandr Kolesnikov, Jun Liang, Yongsheng Chen, Swathi Sujatha-Bhaskar, Zhiyu Huang, Hans Brightbill, Ross Francis, Christine Yu, Edna F. Choo, Kevin DeMent, Yingqing Ran, Le An, Claire Emson, Jonathan Maher, John Wai, Brent S. McKenzie, Patrick J. Lupardus, Ali A. Zarrin, James R. Kiefer, <span class="NLM_string-name hlFld-ContribAuthor">Marian C. Bryan</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Potent Benzolactam IRAK4 Inhibitors with Robust in Vivo Activity. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (3)
                                     , 327-333. <a href="https://doi.org/10.1021/acsmedchemlett.9b00380" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.9b00380</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.9b00380&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.9b00380%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BPotent%252BBenzolactam%252BIRAK4%252BInhibitors%252Bwith%252BRobust%252Bin%252BVivo%252BActivity%26aulast%3DRajapaksa%26aufirst%3DNaomi%2BS.%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D14082019%26date%3D11112019%26date%3D19112019%26date%3D11112019%26volume%3D11%26issue%3D3%26spage%3D327%26epage%3D333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Chunlin Zhuang, <span class="NLM_string-name hlFld-ContribAuthor">Fener Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Small-Molecule Inhibitors of Necroptosis: Current Status and Perspectives. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (4)
                                     , 1490-1510. <a href="https://doi.org/10.1021/acs.jmedchem.9b01317" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01317</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01317%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSmall-Molecule%252BInhibitors%252Bof%252BNecroptosis%25253A%252BCurrent%252BStatus%252Band%252BPerspectives%26aulast%3DZhuang%26aufirst%3DChunlin%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D11082019%26date%3D31102019%26date%3D17102019%26volume%3D63%26issue%3D4%26spage%3D1490%26epage%3D1510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Stephen T. Wrobleski, Ryan Moslin, Shuqun Lin, Yanlei Zhang, Steven Spergel, James Kempson, John S. Tokarski, Joann Strnad, Adriana Zupa-Fernandez, Lihong Cheng, David Shuster, Kathleen Gillooly, Xiaoxia Yang, Elizabeth Heimrich, Kim W. McIntyre, Charu Chaudhry, Javed Khan, Max Ruzanov, Jeffrey Tredup, Dawn Mulligan, Dianlin Xie, Huadong Sun, Christine Huang, Celia D’Arienzo, Nelly Aranibar, Manoj Chiney, Anjaneya Chimalakonda, William J. Pitts, Louis Lombardo, Percy H. Carter, James R. Burke, <span class="NLM_string-name hlFld-ContribAuthor">David S. Weinstein</span>. </span><span class="cited-content_cbyCitation_article-title">Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (20)
                                     , 8973-8995. <a href="https://doi.org/10.1021/acs.jmedchem.9b00444" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00444</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00444&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00444%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DHighly%252BSelective%252BInhibition%252Bof%252BTyrosine%252BKinase%252B2%252B%252528TYK2%252529%252Bfor%252Bthe%252BTreatment%252Bof%252BAutoimmune%252BDiseases%25253A%252BDiscovery%252Bof%252Bthe%252BAllosteric%252BInhibitor%252BBMS-986165%26aulast%3DWrobleski%26aufirst%3DStephen%2BT.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D14032019%26date%3D18072019%26volume%3D62%26issue%3D20%26spage%3D8973%26epage%3D8995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Marian C. Bryan, Joy Drobnick, Alberto Gobbi, Aleksandr Kolesnikov, Yongsheng Chen, Naomi Rajapaksa, Chudi Ndubaku, Jianwen Feng, Willy Chang, Ross Francis, Christine Yu, Edna F. Choo, Kevin DeMent, Yingqing Ran, Le An, Claire Emson, Zhiyu Huang, Swathi Sujatha-Bhaskar, Hans Brightbill, Antonio DiPasquale, Jonathan Maher, John Wai, Brent S. McKenzie, Patrick J. Lupardus, Ali A. Zarrin, <span class="NLM_string-name hlFld-ContribAuthor">James R. Kiefer</span>. </span><span class="cited-content_cbyCitation_article-title">Development of Potent and Selective Pyrazolopyrimidine IRAK4 Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (13)
                                     , 6223-6240. <a href="https://doi.org/10.1021/acs.jmedchem.9b00439" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00439</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00439&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00439%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDevelopment%252Bof%252BPotent%252Band%252BSelective%252BPyrazolopyrimidine%252BIRAK4%252BInhibitors%26aulast%3DBryan%26aufirst%3DMarian%2BC.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D26032019%26date%3D24052019%26date%3D13052019%26volume%3D62%26issue%3D13%26spage%3D6223%26epage%3D6240" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christopher W.  Pohlmeyer</span>, <span class="hlFld-ContribAuthor ">Ching  Shang</span>, <span class="hlFld-ContribAuthor ">Pei  Han</span>, <span class="hlFld-ContribAuthor ">Zhi-Hua  Cui</span>, <span class="hlFld-ContribAuthor ">Randall M.  Jones</span>, <span class="hlFld-ContribAuthor ">Astrid S.  Clarke</span>, <span class="hlFld-ContribAuthor ">Bernard P.  Murray</span>, <span class="hlFld-ContribAuthor ">David A.  Lopez</span>, <span class="hlFld-ContribAuthor ">David W.  Newstrom</span>, <span class="hlFld-ContribAuthor ">M. David  Inzunza</span>, <span class="hlFld-ContribAuthor ">Franziska G.  Matzkies</span>, <span class="hlFld-ContribAuthor ">Kevin S.  Currie</span>, <span class="hlFld-ContribAuthor ">Julie A.  Di Paolo</span>. </span><span class="cited-content_cbyCitation_article-title">Characterization of the mechanism of action of lanraplenib, a novel spleen tyrosine kinase inhibitor, in models of lupus nephritis. </span><span class="cited-content_cbyCitation_journal-name">BMC Rheumatology</span><span> <strong>2021,</strong> <em>5 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s41927-021-00178-3" title="DOI URL">https://doi.org/10.1186/s41927-021-00178-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s41927-021-00178-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs41927-021-00178-3%26sid%3Dliteratum%253Aachs%26jtitle%3DBMC%2520Rheumatology%26atitle%3DCharacterization%252Bof%252Bthe%252Bmechanism%252Bof%252Baction%252Bof%252Blanraplenib%25252C%252Ba%252Bnovel%252Bspleen%252Btyrosine%252Bkinase%252Binhibitor%25252C%252Bin%252Bmodels%252Bof%252Blupus%252Bnephritis%26aulast%3DPohlmeyer%26aufirst%3DChristopher%2BW.%26date%3D2021%26date%3D2021%26volume%3D5%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lei  Zhong</span>, <span class="hlFld-ContribAuthor ">Yueshan  Li</span>, <span class="hlFld-ContribAuthor ">Liang  Xiong</span>, <span class="hlFld-ContribAuthor ">Wenjing  Wang</span>, <span class="hlFld-ContribAuthor ">Ming  Wu</span>, <span class="hlFld-ContribAuthor ">Ting  Yuan</span>, <span class="hlFld-ContribAuthor ">Wei  Yang</span>, <span class="hlFld-ContribAuthor ">Chenyu  Tian</span>, <span class="hlFld-ContribAuthor ">Zhuang  Miao</span>, <span class="hlFld-ContribAuthor ">Tianqi  Wang</span>, <span class="hlFld-ContribAuthor ">Shengyong  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. </span><span class="cited-content_cbyCitation_journal-name">Signal Transduction and Targeted Therapy</span><span> <strong>2021,</strong> <em>6 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41392-021-00572-w" title="DOI URL">https://doi.org/10.1038/s41392-021-00572-w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41392-021-00572-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41392-021-00572-w%26sid%3Dliteratum%253Aachs%26jtitle%3DSignal%2520Transduction%2520and%2520Targeted%2520Therapy%26atitle%3DSmall%252Bmolecules%252Bin%252Btargeted%252Bcancer%252Btherapy%25253A%252Badvances%25252C%252Bchallenges%25252C%252Band%252Bfuture%252Bperspectives%26aulast%3DZhong%26aufirst%3DLei%26date%3D2021%26date%3D2021%26volume%3D6%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiamin  Zheng</span>, <span class="hlFld-ContribAuthor ">Jun  Wu</span>, <span class="hlFld-ContribAuthor ">Xiao  Ding</span>, <span class="hlFld-ContribAuthor ">Hong C.  Shen</span>, <span class="hlFld-ContribAuthor ">Ge  Zou</span>. </span><span class="cited-content_cbyCitation_article-title">Small molecule approaches to treat autoimmune and inflammatory diseases (Part I): Kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>38 </em>, 127862. <a href="https://doi.org/10.1016/j.bmcl.2021.127862" title="DOI URL">https://doi.org/10.1016/j.bmcl.2021.127862</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2021.127862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2021.127862%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSmall%252Bmolecule%252Bapproaches%252Bto%252Btreat%252Bautoimmune%252Band%252Binflammatory%252Bdiseases%252B%252528Part%252BI%252529%25253A%252BKinase%252Binhibitors%26aulast%3DZheng%26aufirst%3DJiamin%26date%3D2021%26volume%3D38%26spage%3D127862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dimitris  Korovesis</span>, <span class="hlFld-ContribAuthor ">Hester A.  Beard</span>, <span class="hlFld-ContribAuthor ">Christel  Mérillat</span>, <span class="hlFld-ContribAuthor ">Steven H. L.  Verhelst</span>. </span><span class="cited-content_cbyCitation_article-title">Probes for Photoaffinity Labelling of Kinases. </span><span class="cited-content_cbyCitation_journal-name">ChemBioChem</span><span> <strong>2021,</strong> <em>298 </em><a href="https://doi.org/10.1002/cbic.202000874" title="DOI URL">https://doi.org/10.1002/cbic.202000874</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cbic.202000874&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcbic.202000874%26sid%3Dliteratum%253Aachs%26jtitle%3DChemBioChem%26atitle%3DProbes%252Bfor%252BPhotoaffinity%252BLabelling%252Bof%252BKinases%26aulast%3DKorovesis%26aufirst%3DDimitris%26date%3D2021%26date%3D2021%26volume%3D298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Leonard  Sung</span>. </span><span class="cited-content_cbyCitation_article-title">Covalent drugs in development for immune-mediated diseases. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,<a href="https://doi.org/10.1016/bs.armc.2021.03.001" title="DOI URL">https://doi.org/10.1016/bs.armc.2021.03.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.armc.2021.03.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.armc.2021.03.001%26sid%3Dliteratum%253Aachs%26atitle%3DCovalent%252Bdrugs%252Bin%252Bdevelopment%252Bfor%252Bimmune-mediated%252Bdiseases%26aulast%3DSung%26aufirst%3DLeonard%26date%3D2021%26pub%3DElsevier%26date%3D2021%26volume%3D157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bernard  Barlaam</span>, <span class="hlFld-ContribAuthor ">Scott  Boiko</span>, <span class="hlFld-ContribAuthor ">Scott  Boyd</span>, <span class="hlFld-ContribAuthor ">Hannah  Dry</span>, <span class="hlFld-ContribAuthor ">Lakshmaiah  Gingipalli</span>, <span class="hlFld-ContribAuthor ">Timothy  Ikeda</span>, <span class="hlFld-ContribAuthor ">Tony  Johnson</span>, <span class="hlFld-ContribAuthor ">Sameer  Kawatkar</span>, <span class="hlFld-ContribAuthor ">Olivier  Lorthioir</span>, <span class="hlFld-ContribAuthor ">Andy  Pike</span>, <span class="hlFld-ContribAuthor ">Hannah  Pollard</span>, <span class="hlFld-ContribAuthor ">Jon  Read</span>, <span class="hlFld-ContribAuthor ">Qibin  Su</span>, <span class="hlFld-ContribAuthor ">Haiyun  Wang</span>, <span class="hlFld-ContribAuthor ">Huimin  Wang</span>, <span class="hlFld-ContribAuthor ">Lianghe  Wang</span>, <span class="hlFld-ContribAuthor ">Peng  Wang</span>, <span class="hlFld-ContribAuthor ">Scott D.  Edmondson</span>. </span><span class="cited-content_cbyCitation_article-title">Novel potent and selective pyrazolylpyrimidine-based SYK inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>30 </em>
                                    (22)
                                     , 127523. <a href="https://doi.org/10.1016/j.bmcl.2020.127523" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.127523</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.127523&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.127523%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DNovel%252Bpotent%252Band%252Bselective%252Bpyrazolylpyrimidine-based%252BSYK%252Binhibitors%26aulast%3DBarlaam%26aufirst%3DBernard%26date%3D2020%26volume%3D30%26issue%3D22%26spage%3D127523" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Prakash  Kannaboina</span>, <span class="hlFld-ContribAuthor ">Krishanu  Mondal</span>, <span class="hlFld-ContribAuthor ">Joydev K.  Laha</span>, <span class="hlFld-ContribAuthor ">Parthasarathi  Das</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in the global ring functionalization of 7-azaindoles. </span><span class="cited-content_cbyCitation_journal-name">Chemical Communications</span><span> <strong>2020,</strong> <em>56 </em>
                                    (79)
                                     , 11749-11762. <a href="https://doi.org/10.1039/D0CC04264A" title="DOI URL">https://doi.org/10.1039/D0CC04264A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0CC04264A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0CC04264A%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Communications%26atitle%3DRecent%252Badvances%252Bin%252Bthe%252Bglobal%252Bring%252Bfunctionalization%252Bof%252B7-azaindoles%26aulast%3DKannaboina%26aufirst%3DPrakash%26date%3D2020%26date%3D2020%26volume%3D56%26issue%3D79%26spage%3D11749%26epage%3D11762" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ben F.  Brian</span>, <span class="hlFld-ContribAuthor ">Candace R.  Guerrero</span>, <span class="hlFld-ContribAuthor ">Tanya S.  Freedman</span>. </span><span class="cited-content_cbyCitation_article-title">Immunopharmacology and Quantitative Analysis of Tyrosine Kinase Signaling. </span><span class="cited-content_cbyCitation_journal-name">Current Protocols in Immunology</span><span> <strong>2020,</strong> <em>130 </em>
                                    (1)
                                     <a href="https://doi.org/10.1002/cpim.104" title="DOI URL">https://doi.org/10.1002/cpim.104</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cpim.104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcpim.104%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Protocols%2520in%2520Immunology%26atitle%3DImmunopharmacology%252Band%252BQuantitative%252BAnalysis%252Bof%252BTyrosine%252BKinase%252BSignaling%26aulast%3DBrian%26aufirst%3DBen%2BF.%26date%3D2020%26date%3D2020%26volume%3D130%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Seung Chan  Kim</span>, <span class="hlFld-ContribAuthor ">Pulla Reddy  Boggu</span>, <span class="hlFld-ContribAuthor ">Ha Na  Yu</span>, <span class="hlFld-ContribAuthor ">So Young  Ki</span>, <span class="hlFld-ContribAuthor ">Jun Min  Jung</span>, <span class="hlFld-ContribAuthor ">Yeon Su  Kim</span>, <span class="hlFld-ContribAuthor ">Gi Min  Park</span>, <span class="hlFld-ContribAuthor ">Sang Ho  Ma</span>, <span class="hlFld-ContribAuthor ">In Su  Kim</span>, <span class="hlFld-ContribAuthor ">Young Hoon  Jung</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of quinoxaline derivatives as specific c-Met kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>30 </em>
                                    (13)
                                     , 127189. <a href="https://doi.org/10.1016/j.bmcl.2020.127189" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.127189</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.127189&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.127189%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bquinoxaline%252Bderivatives%252Bas%252Bspecific%252Bc-Met%252Bkinase%252Binhibitors%26aulast%3DKim%26aufirst%3DSeung%2BChan%26date%3D2020%26volume%3D30%26issue%3D13%26spage%3D127189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cesar A.  Corzo</span>, <span class="hlFld-ContribAuthor ">Eugene  Varfolomeev</span>, <span class="hlFld-ContribAuthor ">A. Francesca  Setiadi</span>, <span class="hlFld-ContribAuthor ">Ross  Francis</span>, <span class="hlFld-ContribAuthor ">Sha  Klabunde</span>, <span class="hlFld-ContribAuthor ">Kate  Senger</span>, <span class="hlFld-ContribAuthor ">Swathi  Sujatha-Bhaskar</span>, <span class="hlFld-ContribAuthor ">Joy  Drobnick</span>, <span class="hlFld-ContribAuthor ">Steven  Do</span>, <span class="hlFld-ContribAuthor ">Eric  Suto</span>, <span class="hlFld-ContribAuthor ">Zhiyu  Huang</span>, <span class="hlFld-ContribAuthor ">Jeffrey  Eastham-Anderson</span>, <span class="hlFld-ContribAuthor ">Arna  Katewa</span>, <span class="hlFld-ContribAuthor ">Jodie  Pang</span>, <span class="hlFld-ContribAuthor ">Melanie  Domeyer</span>, <span class="hlFld-ContribAuthor ">Christopher  Dela Cruz</span>, <span class="hlFld-ContribAuthor ">Andres  Paler-Martinez</span>, <span class="hlFld-ContribAuthor ">Vivian W. C.  Lau</span>, <span class="hlFld-ContribAuthor ">Azadeh  Hadadianpour</span>, <span class="hlFld-ContribAuthor ">Vladimir  Ramirez-Carrozi</span>, <span class="hlFld-ContribAuthor ">Yonglian  Sun</span>, <span class="hlFld-ContribAuthor ">Katherine  Bao</span>, <span class="hlFld-ContribAuthor ">Daqi  Xu</span>, <span class="hlFld-ContribAuthor ">Emily  Hunley</span>, <span class="hlFld-ContribAuthor ">Hans D.  Brightbill</span>, <span class="hlFld-ContribAuthor ">Soren  Warming</span>, <span class="hlFld-ContribAuthor ">Merone  Roose-Girma</span>, <span class="hlFld-ContribAuthor ">Alfred  Wong</span>, <span class="hlFld-ContribAuthor ">Lucinda  Tam</span>, <span class="hlFld-ContribAuthor ">Claire L.  Emson</span>, <span class="hlFld-ContribAuthor ">James J.  Crawford</span>, <span class="hlFld-ContribAuthor ">Wendy B.  Young</span>, <span class="hlFld-ContribAuthor ">Rajita  Pappu</span>, <span class="hlFld-ContribAuthor ">Brent S.  McKenzie</span>, <span class="hlFld-ContribAuthor ">Vida  Asghari</span>, <span class="hlFld-ContribAuthor ">Domagoj  Vucic</span>, <span class="hlFld-ContribAuthor ">Jason A.  Hackney</span>, <span class="hlFld-ContribAuthor ">Cary D.  Austin</span>, <span class="hlFld-ContribAuthor ">Wyne P.  Lee</span>, <span class="hlFld-ContribAuthor ">Annemarie  Lekkerkerker</span>, <span class="hlFld-ContribAuthor ">Nico  Ghilardi</span>, <span class="hlFld-ContribAuthor ">Marian C.  Bryan</span>, <span class="hlFld-ContribAuthor ">James R.  Kiefer</span>, <span class="hlFld-ContribAuthor ">Michael J.  Townsend</span>, <span class="hlFld-ContribAuthor ">Ali A.  Zarrin</span>. </span><span class="cited-content_cbyCitation_article-title">The kinase IRAK4 promotes endosomal TLR and immune complex signaling in B cells and plasmacytoid dendritic cells. </span><span class="cited-content_cbyCitation_journal-name">Science Signaling</span><span> <strong>2020,</strong> <em>13 </em>
                                    (634)
                                     , eaaz1053. <a href="https://doi.org/10.1126/scisignal.aaz1053" title="DOI URL">https://doi.org/10.1126/scisignal.aaz1053</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1126/scisignal.aaz1053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1126%2Fscisignal.aaz1053%26sid%3Dliteratum%253Aachs%26jtitle%3DScience%2520Signaling%26atitle%3DThe%252Bkinase%252BIRAK4%252Bpromotes%252Bendosomal%252BTLR%252Band%252Bimmune%252Bcomplex%252Bsignaling%252Bin%252BB%252Bcells%252Band%252Bplasmacytoid%252Bdendritic%252Bcells%26aulast%3DCorzo%26aufirst%3DCesar%2BA.%26date%3D2020%26date%3D2020%26volume%3D13%26issue%3D634%26spage%3Deaaz1053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lei  Pan</span>, <span class="hlFld-ContribAuthor ">Feng  Jin</span>, <span class="hlFld-ContribAuthor ">Rui  Fu</span>, <span class="hlFld-ContribAuthor ">Ke  Gao</span>, <span class="hlFld-ContribAuthor ">Shaofang  Zhou</span>, <span class="hlFld-ContribAuthor ">Xiaoguang  Bao</span>. </span><span class="cited-content_cbyCitation_article-title">Oxidative Ring-Opening of 1
              H
              -Pyrazol-5-amines and Its Application in Constructing Pyrazolo-Pyrrolo-Pyrazine Scaffolds by Domino Cyclization. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2020,</strong> <em>2020 </em>
                                    (19)
                                     , 2956-2961. <a href="https://doi.org/10.1002/ejoc.202000265" title="DOI URL">https://doi.org/10.1002/ejoc.202000265</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.202000265&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.202000265%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DOxidative%252BRing-Opening%252Bof%252B1%252BH%252B-Pyrazol-5-amines%252Band%252BIts%252BApplication%252Bin%252BConstructing%252BPyrazolo-Pyrrolo-Pyrazine%252BScaffolds%252Bby%252BDomino%252BCyclization%26aulast%3DPan%26aufirst%3DLei%26date%3D2020%26date%3D2020%26volume%3D2020%26issue%3D19%26spage%3D2956%26epage%3D2961" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cuining  Zhang</span>, <span class="hlFld-ContribAuthor ">Baohong  Tian</span>. </span><span class="cited-content_cbyCitation_article-title">Nonclinical Safety Assessment of Zanubrutinib: A Novel Irreversible BTK Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Toxicology</span><span> <strong>2020,</strong> <em>39 </em>
                                    (3)
                                     , 232-240. <a href="https://doi.org/10.1177/1091581820918511" title="DOI URL">https://doi.org/10.1177/1091581820918511</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/1091581820918511&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F1091581820918511%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Toxicology%26atitle%3DNonclinical%252BSafety%252BAssessment%252Bof%252BZanubrutinib%25253A%252BA%252BNovel%252BIrreversible%252BBTK%252BInhibitor%26aulast%3DZhang%26aufirst%3DCuining%26date%3D2020%26date%3D2020%26volume%3D39%26issue%3D3%26spage%3D232%26epage%3D240" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pengfei  Xu</span>, <span class="hlFld-ContribAuthor ">Pei  Shen</span>, <span class="hlFld-ContribAuthor ">Bin  Yu</span>, <span class="hlFld-ContribAuthor ">Xi  Xu</span>, <span class="hlFld-ContribAuthor ">Raoling  Ge</span>, <span class="hlFld-ContribAuthor ">Xinying  Cheng</span>, <span class="hlFld-ContribAuthor ">Qiuyu  Chen</span>, <span class="hlFld-ContribAuthor ">Jinlei  Bian</span>, <span class="hlFld-ContribAuthor ">Zhiyu  Li</span>, <span class="hlFld-ContribAuthor ">JuBo  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Janus kinases (JAKs): The efficient therapeutic targets for autoimmune diseases and myeloproliferative disorders. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>192 </em>, 112155. <a href="https://doi.org/10.1016/j.ejmech.2020.112155" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112155</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112155%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DJanus%252Bkinases%252B%252528JAKs%252529%25253A%252BThe%252Befficient%252Btherapeutic%252Btargets%252Bfor%252Bautoimmune%252Bdiseases%252Band%252Bmyeloproliferative%252Bdisorders%26aulast%3DXu%26aufirst%3DPengfei%26date%3D2020%26volume%3D192%26spage%3D112155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Monika  Adamczyk-Popławska</span>, <span class="hlFld-ContribAuthor ">Agnieszka  Kwiatek</span>. </span><span class="cited-content_cbyCitation_article-title">COVID-19 THERAPY: WHAT HAVE WE LEARNED IN 8 MONTHS?. </span><span class="cited-content_cbyCitation_journal-name">Postępy Mikrobiologii - Advancements of Microbiology</span><span> <strong>2020,</strong> <em>59 </em>
                                    (3)
                                     , 207-225. <a href="https://doi.org/10.21307/PM-2020.59.3.15" title="DOI URL">https://doi.org/10.21307/PM-2020.59.3.15</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.21307/PM-2020.59.3.15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.21307%2FPM-2020.59.3.15%26sid%3Dliteratum%253Aachs%26jtitle%3DPost%25C4%2599py%2520Mikrobiologii%2520-%2520Advancements%2520of%2520Microbiology%26atitle%3DCOVID-19%252BTHERAPY%25253A%252BWHAT%252BHAVE%252BWE%252BLEARNED%252BIN%252B8%252BMONTHS%25253F%26aulast%3DAdamczyk-Pop%25C5%2582awska%26aufirst%3DMonika%26date%3D2020%26date%3D2020%26volume%3D59%26issue%3D3%26spage%3D207%26epage%3D225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rie  Hantani</span>, <span class="hlFld-ContribAuthor ">Saya  Hanawa</span>, <span class="hlFld-ContribAuthor ">Shohei  Oie</span>, <span class="hlFld-ContribAuthor ">Kayo  Umetani</span>, <span class="hlFld-ContribAuthor ">Toshihiro  Sato</span>, <span class="hlFld-ContribAuthor ">Yoshiji  Hantani</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of a New Inhibitor That Stabilizes Interleukin-2-Inducible T-Cell Kinase in Its Inactive Conformation. </span><span class="cited-content_cbyCitation_journal-name">SLAS DISCOVERY: Advancing the Science of Drug Discovery</span><span> <strong>2019,</strong> <em>24 </em>
                                    (8)
                                     , 854-862. <a href="https://doi.org/10.1177/2472555219857542" title="DOI URL">https://doi.org/10.1177/2472555219857542</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/2472555219857542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F2472555219857542%26sid%3Dliteratum%253Aachs%26jtitle%3DSLAS%2520DISCOVERY%253A%2520Advancing%2520the%2520Science%2520of%2520Drug%2520Discovery%26atitle%3DIdentification%252Bof%252Ba%252BNew%252BInhibitor%252BThat%252BStabilizes%252BInterleukin-2-Inducible%252BT-Cell%252BKinase%252Bin%252BIts%252BInactive%252BConformation%26aulast%3DHantani%26aufirst%3DRie%26date%3D2019%26date%3D2019%26volume%3D24%26issue%3D8%26spage%3D854%26epage%3D862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Evelyne  Schaeffer</span>, <span class="hlFld-ContribAuthor ">Elena M.  Sánchez-Fernández</span>, <span class="hlFld-ContribAuthor ">Rita  Gonçalves-Pereira</span>, <span class="hlFld-ContribAuthor ">Vincent  Flacher</span>, <span class="hlFld-ContribAuthor ">Delphine  Lamon</span>, <span class="hlFld-ContribAuthor ">Monique  Duval</span>, <span class="hlFld-ContribAuthor ">Jean-Daniel  Fauny</span>, <span class="hlFld-ContribAuthor ">José M.  García Fernández</span>, <span class="hlFld-ContribAuthor ">Christopher G.  Mueller</span>, <span class="hlFld-ContribAuthor ">Carmen  Ortiz Mellet</span>. </span><span class="cited-content_cbyCitation_article-title">sp2-Iminosugar glycolipids as inhibitors of lipopolysaccharide-mediated human dendritic cell activation in vitro and of acute inflammation in mice in vivo. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>169 </em>, 111-120. <a href="https://doi.org/10.1016/j.ejmech.2019.02.078" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.02.078</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.02.078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.02.078%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3Dsp2-Iminosugar%252Bglycolipids%252Bas%252Binhibitors%252Bof%252Blipopolysaccharide-mediated%252Bhuman%252Bdendritic%252Bcell%252Bactivation%252Bin%2525C2%2525A0vitro%252Band%252Bof%252Bacute%252Binflammation%252Bin%252Bmice%252Bin%2525C2%2525A0vivo%26aulast%3DSchaeffer%26aufirst%3DEvelyne%26date%3D2019%26volume%3D169%26spage%3D111%26epage%3D120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">William T.  McElroy</span>. </span><span class="cited-content_cbyCitation_article-title">Interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors: an updated patent review (2016-2018). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2019,</strong> <em>29 </em>
                                    (4)
                                     , 243-259. <a href="https://doi.org/10.1080/13543776.2019.1597850" title="DOI URL">https://doi.org/10.1080/13543776.2019.1597850</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2019.1597850&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2019.1597850%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DInterleukin-1%252Breceptor-associated%252Bkinase%252B4%252B%252528IRAK4%252529%252Binhibitors%25253A%252Ban%252Bupdated%252Bpatent%252Breview%252B%2525282016-2018%252529%26aulast%3DMcElroy%26aufirst%3DWilliam%2BT.%26date%3D2019%26date%3D2019%26volume%3D29%26issue%3D4%26spage%3D243%26epage%3D259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xinrui  Yuan</span>, <span class="hlFld-ContribAuthor ">Hanshu  Wu</span>, <span class="hlFld-ContribAuthor ">Hong  Bu</span>, <span class="hlFld-ContribAuthor ">Jinpei  Zhou</span>, <span class="hlFld-ContribAuthor ">Huibin  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting the immunity protein kinases for immuno-oncology. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>163 </em>, 413-427. <a href="https://doi.org/10.1016/j.ejmech.2018.11.072" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.11.072</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.11.072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.11.072%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTargeting%252Bthe%252Bimmunity%252Bprotein%252Bkinases%252Bfor%252Bimmuno-oncology%26aulast%3DYuan%26aufirst%3DXinrui%26date%3D2019%26volume%3D163%26spage%3D413%26epage%3D427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Randy  Wouters</span>, <span class="hlFld-ContribAuthor ">Szu-Yuan  Pu</span>, <span class="hlFld-ContribAuthor ">Mathy  Froeyen</span>, <span class="hlFld-ContribAuthor ">Eveline  Lescrinier</span>, <span class="hlFld-ContribAuthor ">Shirit  Einav</span>, <span class="hlFld-ContribAuthor ">Piet  Herdewijn</span>, <span class="hlFld-ContribAuthor ">Steven  De Jonghe</span>. </span><span class="cited-content_cbyCitation_article-title">Cyclin G-associated kinase (GAK) affinity and antiviral activity studies of a series of 3-C-substituted isothiazolo[4,3-b]pyridines. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>163 </em>, 256-265. <a href="https://doi.org/10.1016/j.ejmech.2018.11.065" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.11.065</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.11.065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.11.065%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DCyclin%252BG-associated%252Bkinase%252B%252528GAK%252529%252Baffinity%252Band%252Bantiviral%252Bactivity%252Bstudies%252Bof%252Ba%252Bseries%252Bof%252B3-C-substituted%252Bisothiazolo%25255B4%25252C3-b%25255Dpyridines%26aulast%3DWouters%26aufirst%3DRandy%26date%3D2019%26volume%3D163%26spage%3D256%26epage%3D265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/medium/jm-2018-00667b_0029.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00667&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/medium/jm-2018-00667b_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. JAK/STAT pathway. Step 1: Cytokine binding, complex formation, activation, and phosphorylation of JAK. Step 2: Recruitment and phosphorylation of STAT. Step 3: Phosphorylated STAT (p-STAT) dimerization. Step 4: Nuclear translocation and DNA binding of p-STAT dimer. Step 5: Gene transcription.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00667&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/medium/jm-2018-00667b_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Example inhibitors of the JAK/STAT pathway in the clinic for the treatment of immunological diseases or approved by the FDA. Atoms participating in binding to the hinge region of the active site are shown in red with dashed lines for putative hydrogen bonds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00667&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/medium/jm-2018-00667b_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Tofacitinib (<b>1</b>) cocrystallized with JAK3 (3LXK).<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Hydrogen bonds to hinge residues Tyr904 and Glu903 and a conserved water are presented as black dashes. In addition, gatekeeper residue Met902 is highlighted.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00667&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/medium/jm-2018-00667b_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. X-ray cocrystal structures with sequence alignment for JAK1 (green, 3EYG), JAK2 (magenta, 3FUP), JAK3 (blue, 3LXK), and TYK2 (orange, 5WAL).<a onclick="showRef(event, 'ref5 ref21 ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref5 ref21 ref32 ref33">(5,21,32,33)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00667&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/medium/jm-2018-00667b_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Metabolism of JAK1-selective molecule filgotinib by carboxylesterase leads to active metabolite <b>13</b>. IC<sub>50</sub> values correspond to inhibition of cytokine-induced STAT phosphorylation in CD4<sup>+</sup> cells or CD33<sup>+</sup> cells in human whole blood.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00667&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/medium/jm-2018-00667b_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Chemical and cocrystal structures of pan-JAK inhibitor PF-06263276 (<b>14</b>) and JAK3 covalent inhibitor PF-06651600 (<b>15</b>).<a onclick="showRef(event, 'ref54 ref56'); return false;" href="javascript:void(0);" class="ref ref54 ref56">(54,56)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00667&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/medium/jm-2018-00667b_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Reported pseudokinase inhibitors of JAK family members.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00667&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/medium/jm-2018-00667b_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Role of SYK in BCR and FcγR1 signaling.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00667&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/medium/jm-2018-00667b_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Select clinical SYK inhibitors. Areas of the molecule that participate in binding the hinge region are shown in red with dashed lines for putative hydrogen bonds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00667&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/medium/jm-2018-00667b_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Overlay of first generation SYK inhibitor R406 (<b>21</b>, magenta, 3FQS) and entospletinib (<b>22</b>, blue, 4PUZ).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00667&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/medium/jm-2018-00667b_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Overlay of ATP-binding site inhibitors of BTK: (A) <b>27</b> (purple, 5P9J) and <b>36</b> (orange, 5VFI); (B) <b>27</b> (purple, 5P9J) and <b>37</b> (blue, 5T18).<a onclick="showRef(event, 'ref61 ref80'); return false;" href="javascript:void(0);" class="ref ref61 ref80">(61,80)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00667&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/medium/jm-2018-00667b_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Representative examples of BTK inhibitors including those disclosed and under clinical evaluation. Areas of the molecule that participate in binding the hinge region of the active site are shown in red with dashed lines for putative hydrogen bonds where crystallographic data are available.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00667&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/medium/jm-2018-00667b_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Role of ITK in TCR signaling.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00667&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/medium/jm-2018-00667b_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Noncovalent inhibitors of ITK. (A) Structures of noncovalent ITK inhibitors <b>38</b>–<b>42</b>. Areas of the molecule that participate in binding the hinge region are shown in red. (B) Cocrystal structure of BMS-509744, <b>38</b>, 3MJ2.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> (C) Cocrystal structure of <b>39</b>, 3V8T. (D) Cocrystal structure of GNE-4997, <b>40</b>, 4rfm.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00667&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/medium/jm-2018-00667b_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0015.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Selected covalent inhibitors of ITK kinase activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00667&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/medium/jm-2018-00667b_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0016.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. TLR and IL-1R signaling through IRAK family members to upregulate type I IFN genes leading to proinflammatory cytokine production.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00667&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/medium/jm-2018-00667b_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0017.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Structures of IRAK4 kinase inhibitors PF-06650833 (<b>46</b>), pyridine <b>47</b>, and BMS-986126 (<b>48</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00667&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/medium/jm-2018-00667b_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0018.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Cocrystal structure of PF-06650833, <b>46</b>, with IRAK4 (5UIU).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00667&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/medium/jm-2018-00667b_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0019.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Role of NIK in the noncanonical NF-κB pathway.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00667&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/medium/jm-2018-00667b_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0020.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. (A) Crystal structure of apo-murine NIK kinase domain where the pocket is filled by a sulfate (4G3C). (B) Overlay of inhibitors <b>51</b> and <b>53</b> in murine NIK kinase domain (4G3E, 5T8O).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00667&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/medium/jm-2018-00667b_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0021.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. NIK inhibitors described by Amgen and Genentech. Areas of the molecule that participate in binding the hinge region of the active site are shown in red. Areas occupying the back pocket are shown in blue.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00667&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/medium/jm-2018-00667b_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0022.jpeg" id="rightTab-gr22" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. RIPK1 regulation of multiple roles upon signaling by TNF. Abbreviations: TRADD, TNF-R1-associated death domain protein; TAK1, transforming growth factor β-activated kinase 1; IKK, IκB kinase; MLKL, mixed lineage kinase domain-like protein.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00667&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig23" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/medium/jm-2018-00667b_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0023.jpeg" id="rightTab-gr23" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. Development of RIPK1 clinical candidate GSK2982772 (compound <b>57</b>) from DNA-encoded library hit <b>56</b> showing significant shift in kinase activity across species.<a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(153)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00667&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig24" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/medium/jm-2018-00667b_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0024.jpeg" id="rightTab-gr24" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. Examples of recently reported inhibitors of RIPK1, RIPK2, and RIPK3 showing various chemotypes employed.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00667&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig25" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/medium/jm-2018-00667b_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0025.jpeg" id="rightTab-gr25" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 25. Core components and cross-talk between PI3K and MAPK signaling pathways.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00667&amp;id=fig25"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig26" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Figure 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/medium/jm-2018-00667b_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0026.jpeg" id="rightTab-gr26" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 26. Signaling cascade for MAPKs including ERKs, JNKs, and p38. Activation of MAP3Ks following receptor binding or stress induction leads to phosphorylation and activation of MAP2Ks such as MEKs and MKKs which in turn phosphorylate the MAPK family members. Activated MAPKs then translocate to the nucleus, where they phosphorylate transcription factors and modulate gene expression.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00667&amp;id=fig26"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig27" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Figure 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/medium/jm-2018-00667b_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0027.jpeg" id="rightTab-gr27" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 27. Different DFG orientations of p38α with DFG-out molecule PF-03715455 (<b>67</b>) and type 1<sup>1</sup>/<sub>2</sub> skepinone-L analog <b>68</b>: (A) X-ray cocrystal structure of <b>67</b> (5MTY); (B) chemical structures of <b>67</b> and <b>68</b> with reported binding kinetics;<a onclick="showRef(event, 'ref174 ref175'); return false;" href="javascript:void(0);" class="ref ref174 ref175">(174,175)</a> (C) X-ray cocrystal structure of <b>68</b> (2YIS); (D) overlay of p38α backbones showing different positions of D168 and F169 upon <b>67</b> and <b>68</b> binding.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00667&amp;id=fig27"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig28" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Figure 28</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/medium/jm-2018-00667b_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0028.jpeg" id="rightTab-gr28" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 28. PI3Kδ-selective inhibitors recently described in the literature along with their important interactions where disclosed. Fold isoform selectivity is shown in parentheses. Participants in hinge residue binding are shown in red at the top of the molecule. Additional specific interactions are also shown.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.8b00667/20181019/images/large/jm-2018-00667b_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00667&amp;id=fig28"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i24">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55611" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55611" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 184 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wekell, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlsson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fasth, A.</span></span> <span> </span><span class="NLM_article-title">Toward an inclusive, congruent, and precise definition of autoinflammatory diseases</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">497</span>, <span class="refDoi"> DOI: 10.3389/fimmu.2017.00497</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.3389%2Ffimmu.2017.00497" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=28496446" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVehsbzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=497&author=P.+Wekellauthor=S.+Bergauthor=A.+Karlssonauthor=A.+Fasth&title=Toward+an+inclusive%2C+congruent%2C+and+precise+definition+of+autoinflammatory+diseases&doi=10.3389%2Ffimmu.2017.00497"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Toward an inclusive, congruent, and precise definition of autoinflammatory diseases</span></div><div class="casAuthors">Wekell, Per; Berg, Stefan; Karlsson, Anna; Fasth, Anders</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Immunology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">497/1-497/5</span>CODEN:
                <span class="NLM_cas:coden">FIRMCW</span>;
        ISSN:<span class="NLM_cas:issn">1664-3224</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Autoinflammatory disease was introduced as a concept in 1999, demarcating an entirely new group of diseases in clin., immunol., and conceptual terms.  During recent years, the preconditions for the definition of autoinflammatory conditions have changed.  This includes the recent discovery of a no. of monogenic autoinflammatory conditions with complex phenotypes that combine autoinflammation with defects of the adaptive and/or innate immune system, resulting in the occurrence of infection, autoimmunity, and/or uncontrolled hyperinflammation in addn. to autoinflammation.  Further, there are strong indications that classical IL-1-driven autoinflammatory diseases are assocd. with activation of adaptive immunity.  As suggested by this development, we are of the opinion that an all-encompassing definition of autoinflammatory diseases should regard autoinflammatory conditions and innate dysregulation as inseparable and integral parts of the immune system as a whole.  Hence, in this article, we try to advance the conceptual understanding of autoinflammatory disease by, proposing a modification of the definition by Daniel Kastner et al., which allows for a congruent and precise description of conditions that expand the immunol. spectrum of autoinflammatory disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3AM5_YjQK0bVg90H21EOLACvtfcHk0li8_zuZGeMdig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVehsbzI&md5=d444df679f3bb90ab77362057b4ea1f5</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2017.00497&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2017.00497%26sid%3Dliteratum%253Aachs%26aulast%3DWekell%26aufirst%3DP.%26aulast%3DBerg%26aufirst%3DS.%26aulast%3DKarlsson%26aufirst%3DA.%26aulast%3DFasth%26aufirst%3DA.%26atitle%3DToward%2520an%2520inclusive%252C%2520congruent%252C%2520and%2520precise%2520definition%2520of%2520autoinflammatory%2520diseases%26jtitle%3DFront.%2520Immunol.%26date%3D2017%26volume%3D8%26spage%3D497%26doi%3D10.3389%2Ffimmu.2017.00497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, P. J.</span></span> <span> </span><span class="NLM_article-title">Kinases as novel therapeutic targets in asthma and chronic obstructive pulmonary disease</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">788</span>– <span class="NLM_lpage">815</span>, <span class="refDoi"> DOI: 10.1124/pr.116.012518</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1124%2Fpr.116.012518" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=27363440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkvFCrs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2016&pages=788-815&author=P.+J.+Barnes&title=Kinases+as+novel+therapeutic+targets+in+asthma+and+chronic+obstructive+pulmonary+disease&doi=10.1124%2Fpr.116.012518"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Kinases as novel therapeutic targets in asthma and chronic obstructive pulmonary disease</span></div><div class="casAuthors">Barnes, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">788-815</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">1521-0081</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Multiple kinases play a crit. role in orchestrating the chronic inflammation and structural changes in the respiratory tract of patients with asthma and chronic obstructive pulmonary disease (COPD).  Kinases activate signaling pathways that lead to contraction of airway smooth muscle and release of inflammatory mediators (such as cytokines, chemokines, growth factors) as well as cell migration, activation, and proliferation.  For this reason there has been great interest in the development of kinase inhibitors as anti-inflammatory therapies, particular where corticosteroids are less effective, as in severe asthma and COPD.  However, it has proven difficult to develop selective kinase inhibitors that are both effective and safe after oral administration and this has led to a search for inhaled kinase inhibitors, which would reduce systemic exposure.  Although many kinases have been implicated in inflammation and remodeling of airway disease, very few classes of drug have reached the stage of clin. studies in these diseases.  The most promisingdrugs arep38MAPkinases, isoenzyme-selective PI3-kinases, Janus-activated kinases, and Syk-kinases, and inhaled formulations of these drugs are now in development.  There has also been interest in developing inhibitors that block more than one kinase, because these drugs may be more effective and with less risk of losing efficacy with time.  No kinase inhibitors are yet on the market for the treatment of airway diseases, but as kinase inhibitors are improved from other therapeutic areas there is hope that these drugs may eventually prove useful in treating refractory asthma and COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpeztyKAL-brVg90H21EOLACvtfcHk0lgTpgwuYWuvNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkvFCrs7k%253D&md5=b1124d17b06af2c9577db2967d4914a9</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1124%2Fpr.116.012518&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.116.012518%26sid%3Dliteratum%253Aachs%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26atitle%3DKinases%2520as%2520novel%2520therapeutic%2520targets%2520in%2520asthma%2520and%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DPharmacol.%2520Rev.%26date%3D2016%26volume%3D68%26spage%3D788%26epage%3D815%26doi%3D10.1124%2Fpr.116.012518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bilsborough, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Targan, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snapper, S. B.</span></span> <span> </span><span class="NLM_article-title">Therapeutic targets in inflammatory bowel disease: current and future</span>. <i>Am. J. Gastroenterol. Suppl.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">37</span>, <span class="refDoi"> DOI: 10.1038/ajgsup.2016.18</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1038%2Fajgsup.2016.18" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVegtLzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2016&pages=27-37&author=J.+Bilsboroughauthor=S.+R.+Targanauthor=S.+B.+Snapper&title=Therapeutic+targets+in+inflammatory+bowel+disease%3A+current+and+future&doi=10.1038%2Fajgsup.2016.18"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic Targets in Inflammatory Bowel Disease: Current and Future</span></div><div class="casAuthors">Bilsborough, Janine; Targan, Stephan R.; Snapper, Scott B.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Gastroenterology Supplements</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">27-37</span>CODEN:
                <span class="NLM_cas:coden">AJGSAD</span>;
        ISSN:<span class="NLM_cas:issn">1948-9501</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The etiol. of inflammatory bowel disease (IBD) is not fully understood but is likely influenced by numerous factors such as genetic predisposition, environmental factors, like the microbiota, and social behaviors, including smoking and diet.  In addn. to anti-tumor necrosis factor therapy, we now have integrin inhibitors that target lymphocyte trafficking to the gastrointestinal tract (vedolizumab and natalizumab); however, unmet medical needs remain.  Although several immunol. pathways have been implicated in the pathogenesis of IBD, targeting these with drug therapy has produced mixed results.  Recent drug failures, particularly anti-interleukin-17 (anti-IL17) in Crohn's disease and anti-IL13 in ulcerative colitis, highlight our fundamental lack of understanding of the impact of pathogenic heterogeneity in the treatment of IBD.  In addn. to a "failure of mechanism," other reasons for drug failure may include issues with the drug itself-for example, insufficient activity, or lack of targeting, inadequate trial design or dosing, or potentially our inability to characterize patients who may be more (or less) responsive to a specific therapy.  This review summarizes some of the successes and failures and evaluates therapies currently under investigation for IBD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRauWR9GH_J7Vg90H21EOLACvtfcHk0lgTpgwuYWuvNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVegtLzF&md5=ba3de41ce55e58d7109e7367de403ac7</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fajgsup.2016.18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fajgsup.2016.18%26sid%3Dliteratum%253Aachs%26aulast%3DBilsborough%26aufirst%3DJ.%26aulast%3DTargan%26aufirst%3DS.%2BR.%26aulast%3DSnapper%26aufirst%3DS.%2BB.%26atitle%3DTherapeutic%2520targets%2520in%2520inflammatory%2520bowel%2520disease%253A%2520current%2520and%2520future%26jtitle%3DAm.%2520J.%2520Gastroenterol.%2520Suppl.%26date%3D2016%26volume%3D3%26spage%3D27%26epage%3D37%26doi%3D10.1038%2Fajgsup.2016.18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhari, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizvi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Syed, B. A.</span></span> <span> </span><span class="NLM_article-title">Rheumatoid arthritis: current and future trends</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">305</span>– <span class="NLM_lpage">306</span>, <span class="refDoi"> DOI: 10.1038/nrd.2016.21</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1038%2Fnrd.2016.21" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=27080040" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtVOqsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=305-306&author=K.+Chaudhariauthor=S.+Rizviauthor=B.+A.+Syed&title=Rheumatoid+arthritis%3A+current+and+future+trends&doi=10.1038%2Fnrd.2016.21"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Rheumatoid arthritis: current and future trends</span></div><div class="casAuthors">Chaudhari, Kritika; Rizvi, Salman; Syed, Basharut A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">305-306</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">This article analyses the market for rheumatoid arthritis therapies, which is growing rapidly, with a range of new disease-modifying drugs poised to enter in the next few years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoM2gpyG3Nq97Vg90H21EOLACvtfcHk0lgTpgwuYWuvNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtVOqsrw%253D&md5=2640f07d2a8e2a6191c900b6417164b0</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2016.21&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2016.21%26sid%3Dliteratum%253Aachs%26aulast%3DChaudhari%26aufirst%3DK.%26aulast%3DRizvi%26aufirst%3DS.%26aulast%3DSyed%26aufirst%3DB.%2BA.%26atitle%3DRheumatoid%2520arthritis%253A%2520current%2520and%2520future%2520trends%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2016%26volume%3D15%26spage%3D305%26epage%3D306%26doi%3D10.1038%2Fnrd.2016.21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J.-B.</span></span> <span> </span><span class="NLM_article-title">Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">5023</span>– <span class="NLM_lpage">5038</span>, <span class="refDoi"> DOI: 10.1021/jm401490p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401490p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotVCjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5023-5038&author=J.+D.+Clarkauthor=M.+E.+Flanaganauthor=J.-B.+Telliez&title=Discovery+and+development+of+Janus+kinase+%28JAK%29+inhibitors+for+inflammatory+diseases&doi=10.1021%2Fjm401490p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases</span></div><div class="casAuthors">Clark, James D.; Flanagan, Mark E.; Telliez, Jean-Baptiste</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5023-5038</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The Janus kinases (JAKs) are a family of intracellular tyrosine kinases that play an essential role in the signaling of numerous cytokines that have been implicated in the pathogenesis of inflammatory diseases.  As a consequence, the JAKs have received significant attention in recent years from the pharmaceutical and biotechnol. industries as therapeutic targets.  Here, we provide a review of the JAK pathways, the structure, function, and activation of the JAK enzymes followed by a detailed look at the JAK inhibitors currently in the clinic or approved for these indications.  Finally, a perspective is provided on what the past decade of research with JAK inhibitors for inflammatory indications has taught along with thoughts on what the future may hold in terms of addressing the opportunities and challenges that remain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3f7W5g8N6brVg90H21EOLACvtfcHk0li_fakQ7g3zgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotVCjsA%253D%253D&md5=6763ae2d46f52ddcda23e235a60634ae</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1021%2Fjm401490p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401490p%26sid%3Dliteratum%253Aachs%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DTelliez%26aufirst%3DJ.-B.%26atitle%3DDiscovery%2520and%2520development%2520of%2520Janus%2520kinase%2520%2528JAK%2529%2520inhibitors%2520for%2520inflammatory%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5023%26epage%3D5038%26doi%3D10.1021%2Fjm401490p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, P.</span></span> <span> </span><span class="NLM_article-title">The TLR and IL-1 signalling network at a glance</span>. <i>J. Cell Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">2383</span>– <span class="NLM_lpage">2390</span>, <span class="refDoi"> DOI: 10.1242/jcs.149831</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1242%2Fjcs.149831" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=24829146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVOgsrbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2014&pages=2383-2390&author=P.+Cohen&title=The+TLR+and+IL-1+signalling+network+at+a+glance&doi=10.1242%2Fjcs.149831"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The TLR and IL-1 signalling network at a glance</span></div><div class="casAuthors">Cohen, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2383-2390</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">A review.  Toll-like receptors (TLRs) and the receptors for interleukin (IL)-1, IL-18 and IL-33 are required for defense against microbial pathogens but, if hyper-activated or not switched off efficiently, can cause tissue damage and inflammatory and autoimmune diseases.  Understanding how the checks and balances in the system are integrated to fight infection without the network operating out of control will be crucial for the development of improved drugs to treat these diseases in the future.  In this Cell Science at a Glance article and the accompanying poster, I provide a brief overview of how one of these intricate networks is controlled by the interplay of protein phosphorylation and protein ubiquitylation events, and the mechanisms in myeloid cells that restrict and terminate its activation to prevent inflammatory and autoimmune diseases.  Finally, I suggest a few protein kinases that have been neglected as drug targets, but whose therapeutic potential should be explored in the light of recent advances in our understanding of their roles in the innate immune system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0Hfw28mAkmrVg90H21EOLACvtfcHk0li_fakQ7g3zgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVOgsrbK&md5=b86f588378be962309bad302139543c6</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1242%2Fjcs.149831&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fjcs.149831%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DP.%26atitle%3DThe%2520TLR%2520and%2520IL-1%2520signalling%2520network%2520at%2520a%2520glance%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2014%26volume%3D127%26spage%3D2383%26epage%3D2390%26doi%3D10.1242%2Fjcs.149831" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alessi, D. R.</span></span> <span> </span><span class="NLM_article-title">Kinase drug discovery – what’s next in the field?</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">96</span>– <span class="NLM_lpage">104</span>, <span class="refDoi"> DOI: 10.1021/cb300610s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb300610s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=96-104&author=P.+Cohenauthor=D.+R.+Alessi&title=Kinase+drug+discovery+%E2%80%93+what%E2%80%99s+next+in+the+field%3F&doi=10.1021%2Fcb300610s"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Fcb300610s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb300610s%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DP.%26aulast%3DAlessi%26aufirst%3DD.%2BR.%26atitle%3DKinase%2520drug%2520discovery%2520%25E2%2580%2593%2520what%25E2%2580%2599s%2520next%2520in%2520the%2520field%253F%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2013%26volume%3D8%26spage%3D96%26epage%3D104%26doi%3D10.1021%2Fcb300610s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Furumoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadina, M.</span></span> <span> </span><span class="NLM_article-title">The arrival of JAK inhibitors: advancing the treatment of immune and hematologic disorders</span>. <i>BioDrugs</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">431</span>– <span class="NLM_lpage">438</span>, <span class="refDoi"> DOI: 10.1007/s40259-013-0040-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1007%2Fs40259-013-0040-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=23743669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsl2nsbzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2013&pages=431-438&author=Y.+Furumotoauthor=M.+Gadina&title=The+arrival+of+JAK+inhibitors%3A+advancing+the+treatment+of+immune+and+hematologic+disorders&doi=10.1007%2Fs40259-013-0040-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The Arrival of JAK Inhibitors: Advancing the Treatment of Immune and Hematologic Disorders</span></div><div class="casAuthors">Furumoto, Yasuko; Gadina, Massimo</div><div class="citationInfo"><span class="NLM_cas:title">BioDrugs</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">431-438</span>CODEN:
                <span class="NLM_cas:coden">BIDRF4</span>;
        ISSN:<span class="NLM_cas:issn">1173-8804</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Altered prodn. of cytokines can result in pathologies ranging from autoimmune diseases to malignancies.  The Janus kinase family is a small group of receptor-assocd. signaling mols. that is essential to the signal cascade originating from type I and type II cytokine receptors.  Inhibition of tyrosine kinase enzymic activity using small mols. has recently become a powerful tool for treatment of several malignancies.  Twenty years after the discovery of these enzymes, two inhibitors for this class of kinases have been approved for clin. use and others are currently in the final stage of development.  Here we review the principles of cytokines signaling, summarize our current knowledge of the approved inhibitors, and briefly introduce some of the inhibitors that are currently under development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQNQJyHX0EDLVg90H21EOLACvtfcHk0li_fakQ7g3zgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsl2nsbzI&md5=a593c1f01565b3dc3bf3df8c424595a6</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1007%2Fs40259-013-0040-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40259-013-0040-7%26sid%3Dliteratum%253Aachs%26aulast%3DFurumoto%26aufirst%3DY.%26aulast%3DGadina%26aufirst%3DM.%26atitle%3DThe%2520arrival%2520of%2520JAK%2520inhibitors%253A%2520advancing%2520the%2520treatment%2520of%2520immune%2520and%2520hematologic%2520disorders%26jtitle%3DBioDrugs%26date%3D2013%26volume%3D27%26spage%3D431%26epage%3D438%26doi%3D10.1007%2Fs40259-013-0040-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mócsai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovács, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gergely, P.</span></span> <span> </span><span class="NLM_article-title">What is the future of targeted therapy in rheumatology: biologics or small molecules?</span>. <i>BMC Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">43</span>, <span class="refDoi"> DOI: 10.1186/1741-7015-12-43</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1186%2F1741-7015-12-43" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=24620738" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjsVWjtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2014&pages=43&author=A.+M%C3%B3csaiauthor=L.+Kov%C3%A1csauthor=P.+Gergely&title=What+is+the+future+of+targeted+therapy+in+rheumatology%3A+biologics+or+small+molecules%3F&doi=10.1186%2F1741-7015-12-43"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">What is the future of targeted therapy in rheumatology: biologics or small molecules?</span></div><div class="casAuthors">Mocsai, Attila; Kovacs, Laszlo; Gergely, Peter</div><div class="citationInfo"><span class="NLM_cas:title">BMC Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">43/1-43/9, 9</span>CODEN:
                <span class="NLM_cas:coden">BMMECZ</span>;
        ISSN:<span class="NLM_cas:issn">1741-7015</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Until late in the 20th century, the therapy of rheumatic diseases relied on the use of drugs that had been developed through empirical approaches without detailed understanding of the mol. mechanisms involved.  That approach changed with the introduction of biol. therapeutics at the end of the 20th century and by the recent development of small-mol. inhibitors of intracellular signal transduction pathways.  Here we compare and discuss the advantages and disadvantages of those two groups of targeted anti-inflammatory therapeutics.  Discussion: TNF-blocking biol. agents were introduced into the therapy of rheumatoid arthritis and other autoimmune and inflammatory diseases in the late 1990s.  Further biol. agents targeting cytokine networks or specific lymphocyte subsets have since been added to the armamentarium of anti-rheumatic therapy.  During the last few years, another wave of novel discoveries led to the development of a new class of small mol. anti-inflammatory compds. targeting intracellular signal transduction mols., such as tyrosine kinases.  In all those cases, the specific targets of the drugs are well defined and significant knowledge about their role in the disease pathomechanism is available, qualifying them for being targeted therapeutics for inflammatory rheumatic diseases.  While both groups of targeted therapeutics offer significant clin. benefit, they clearly differ in several aspects, such as the localization of their targets, their route of administration and target specificity, as well as tech. details such as manufg. procedures and cost basis.  In this debate paper, we compare the advantages and disadvantages of the two different approaches, aiming to shed light on the possible future of targeted therapies.  Summary: Biol. therapeutics and small-mol. inhibitors both have significant advantages and disadvantages in the therapy of rheumatic diseases.  The future of targeted therapies is one of the most exciting questions of current rheumatol. research and therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTONjip_IttLVg90H21EOLACvtfcHk0liEpFPh8BHPZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjsVWjtrk%253D&md5=20ede05081b83e736ad5675afcffc21d</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1186%2F1741-7015-12-43&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1741-7015-12-43%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25B3csai%26aufirst%3DA.%26aulast%3DKov%25C3%25A1cs%26aufirst%3DL.%26aulast%3DGergely%26aufirst%3DP.%26atitle%3DWhat%2520is%2520the%2520future%2520of%2520targeted%2520therapy%2520in%2520rheumatology%253A%2520biologics%2520or%2520small%2520molecules%253F%26jtitle%3DBMC%2520Med.%26date%3D2014%26volume%3D12%26spage%3D43%26doi%3D10.1186%2F1741-7015-12-43" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Levin, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wildenberg, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van den Brink, G. R.</span></span> <span> </span><span class="NLM_article-title">Mechanism of action of anti-TNF therapy in inflammatory bowel disease</span>. <i>J. Crohn’s Colitis</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">989</span>– <span class="NLM_lpage">997</span>, <span class="refDoi"> DOI: 10.1093/ecco-jcc/jjw053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1093%2Fecco-jcc%2Fjjw053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=26896086" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A280%3ADC%252BC28jis1Smtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=989-997&author=A.+D.+Levinauthor=M.+E.+Wildenbergauthor=G.+R.+van+den+Brink&title=Mechanism+of+action+of+anti-TNF+therapy+in+inflammatory+bowel+disease&doi=10.1093%2Fecco-jcc%2Fjjw053"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of Action of Anti-TNF Therapy in Inflammatory Bowel Disease</span></div><div class="casAuthors">Levin Alon D; Wildenberg Manon E; van den Brink Gijs R</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Crohn's & colitis</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">989-97</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Several anti-tumour necrosis factor [TNF] blocking strategies have been evaluated in patients with Crohn's disease.  Compounds that have been tested included the full monoclonal IgG1 antibodies infliximab and adalimumab, the pegylated anti-TNF F[ab']2 fragment certolizumab, an IgG4 anti-TNF CDP571 with reduced affinity for the Fc receptor, the soluble TNF receptor I onercept, and the TNF receptor II-Fc fusion protein etanercept.  The endpoints of these studies suggest that not all methods of blocking TNF are equal.  Here we will review the differences in the clinical, biochemical, and endoscopic endpoints of the major clinical studies.  Collectively the data suggest that only IgG1 monoclonal antibodies have the ability to induce complete clinical, biochemical, and endoscopic remission.  We discuss the potential multiple modes of action that may contribute to the response to full IgG1 anti-TNFs, focusing on the rapid induction of lamina propria T cell apoptosis and Fc receptor-dependent induction of M2-type wound-healing macrophages.  We discuss how novel insights into the mechanism of action of anti-TNFs in Crohn's disease may contribute to the development of novel anti-TNFs with improved efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSGKvATnWdAPkwlCcfExbvbfW6udTcc2eZIJSEN-PuZU7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28jis1Smtg%253D%253D&md5=8b117377e55fae613c164a6756a64071</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1093%2Fecco-jcc%2Fjjw053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fecco-jcc%252Fjjw053%26sid%3Dliteratum%253Aachs%26aulast%3DLevin%26aufirst%3DA.%2BD.%26aulast%3DWildenberg%26aufirst%3DM.%2BE.%26aulast%3Dvan%2Bden%2BBrink%26aufirst%3DG.%2BR.%26atitle%3DMechanism%2520of%2520action%2520of%2520anti-TNF%2520therapy%2520in%2520inflammatory%2520bowel%2520disease%26jtitle%3DJ.%2520Crohn%25E2%2580%2599s%2520Colitis%26date%3D2016%26volume%3D10%26spage%3D989%26epage%3D997%26doi%3D10.1093%2Fecco-jcc%2Fjjw053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manoli, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaw, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frutoz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epstein, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khawli, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theil, F.-P.</span></span> <span> </span><span class="NLM_article-title">Unraveling the effect of immunogenicity on the PK/PD, efficacy, and safety of therapeutic proteins</span>. <i>J. Immunol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>2016</i></span>,  <span class="NLM_fpage">2342187</span>, <span class="refDoi"> DOI: 10.1155/2016/2342187</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1155%2F2016%2F2342187" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=27579329" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A280%3ADC%252BC2szmtlCitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2016&publication_year=2016&pages=2342187&author=A.+Smithauthor=H.+Manoliauthor=S.+Jawauthor=K.+Frutozauthor=A.+L.+Epsteinauthor=L.+A.+Khawliauthor=F.-P.+Theil&title=Unraveling+the+effect+of+immunogenicity+on+the+PK%2FPD%2C+efficacy%2C+and+safety+of+therapeutic+proteins&doi=10.1155%2F2016%2F2342187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Unraveling the Effect of Immunogenicity on the PK/PD, Efficacy, and Safety of Therapeutic Proteins</span></div><div class="casAuthors">Smith Alison; Manoli Hugh; Jaw Stacey; Frutoz Kimberley; Epstein Alan L; Khawli Leslie A; Theil Frank-Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of immunology research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">2016</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2342187</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Biologics have emerged as a powerful and diverse class of molecular and cell-based therapies that are capable of replacing enzymes, editing genomes, targeting tumors, and more.  As this complex array of tools arises a distinct set of challenges is rarely encountered in the development of small molecule therapies.  Biotherapeutics tend to be big, bulky, polar molecules comprised of protein and/or nucleic acids.  Compared to their small molecule counterparts, they are fragile, labile, and heterogeneous.  Their biodistribution is often limited by hydrophobic barriers which often restrict their administration to either intravenous or subcutaneous entry routes.  Additionally, their potential for immunogenicity has proven to be a challenge to developing safe and reliably efficacious drugs.  Our discussion will emphasize immunogenicity in the context of therapeutic proteins, a well-known class of biologics.  We set out to describe what is known and unknown about the mechanisms underlying the interplay between antigenicity and immune response and their effect on the safety, efficacy, pharmacokinetics, and pharmacodynamics of these therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSjz4uJE6F1CuWhZTslLrfffW6udTcc2eZIJSEN-PuZU7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2szmtlCitA%253D%253D&md5=79e4888ba27a004d9cbb69acc9643b7c</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1155%2F2016%2F2342187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2016%252F2342187%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DManoli%26aufirst%3DH.%26aulast%3DJaw%26aufirst%3DS.%26aulast%3DFrutoz%26aufirst%3DK.%26aulast%3DEpstein%26aufirst%3DA.%2BL.%26aulast%3DKhawli%26aufirst%3DL.%2BA.%26aulast%3DTheil%26aufirst%3DF.-P.%26atitle%3DUnraveling%2520the%2520effect%2520of%2520immunogenicity%2520on%2520the%2520PK%252FPD%252C%2520efficacy%252C%2520and%2520safety%2520of%2520therapeutic%2520proteins%26jtitle%3DJ.%2520Immunol.%2520Res.%26date%3D2016%26volume%3D2016%26spage%3D2342187%26doi%3D10.1155%2F2016%2F2342187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clausen, M. H.</span></span> <span> </span><span class="NLM_article-title">Small-molecule kinase inhibitors: an analysis of FDA-approved drugs</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">5</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2015.07.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1016%2Fj.drudis.2015.07.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=26210956" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Gru73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2016&pages=5-10&author=P.+Wuauthor=T.+E.+Nielsenauthor=M.+H.+Clausen&title=Small-molecule+kinase+inhibitors%3A+an+analysis+of+FDA-approved+drugs&doi=10.1016%2Fj.drudis.2015.07.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule kinase inhibitors: an analysis of FDA-approved drugs</span></div><div class="casAuthors">Wu, Peng; Nielsen, Thomas E.; Clausen, Mads H.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5-10</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Small-mol. kinase inhibitors (SMKIs), 28 of which are approved by the US Food and Drug Administration (FDA), have been actively pursued as promising targeted therapeutics.  Here, we assess the key structural and physicochem. properties, target selectivity and mechanism of function, and therapeutic indications of these approved inhibitors.  Our anal. showed that >30% of approved SMKIs have a mol. wt. (MW) exceeding 500 and all have a total ring count of between three and five.  The assumption that type II inhibitors tend to be more selective than type I inhibitors has been proved to be unreliable.  Although previous SMKI research was concd. on tyrosine kinase inhibitors for cancer treatment, recent progress indicates diversification of SMKI research in terms of new targets, mechanistic types, and therapeutic indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZrY68ZOI2xLVg90H21EOLACvtfcHk0lgm-AaFPrhTVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Gru73P&md5=228524fa464393053ecbfac19e994929</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2015.07.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2015.07.008%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DP.%26aulast%3DNielsen%26aufirst%3DT.%2BE.%26aulast%3DClausen%26aufirst%3DM.%2BH.%26atitle%3DSmall-molecule%2520kinase%2520inhibitors%253A%2520an%2520analysis%2520of%2520FDA-approved%2520drugs%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2016%26volume%3D21%26spage%3D5%26epage%3D10%26doi%3D10.1016%2Fj.drudis.2015.07.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nibbs, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McInnes, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siebert, S.</span></span> <span> </span><span class="NLM_article-title">Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases</span>. <i>Clin. Exp. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>176</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.1111/cei.12248</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1111%2Fcei.12248" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=24313320" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktVylurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=176&publication_year=2014&pages=1-10&author=H.+Pattersonauthor=R.+Nibbsauthor=I.+McInnesauthor=S.+Siebert&title=Protein+kinase+inhibitors+in+the+treatment+of+inflammatory+and+autoimmune+diseases&doi=10.1111%2Fcei.12248"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases</span></div><div class="casAuthors">Patterson, H.; Nibbs, R.; McInnes, I.; Siebert, S.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Experimental Immunology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">176</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-10</span>CODEN:
                <span class="NLM_cas:coden">CEXIAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-9104</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Summary : Protein kinases mediate protein phosphorylation, which is a fundamental component of cell signalling, with crucial roles in most signal transduction cascades: from controlling cell growth and proliferation to the initiation and regulation of immunol. responses.  Aberrant kinase activity is implicated in an increasing no. of diseases, with more than 400 human diseases now linked either directly or indirectly to protein kinases.  Protein kinases are therefore regarded as highly important drug targets, and are the subject of intensive research activity.  The success of small mol. kinase inhibitors in the treatment of cancer, coupled with a greater understanding of inflammatory signalling cascades, has led to kinase inhibitors taking center stage in the pursuit for new anti-inflammatory agents for the treatment of immune-mediated diseases.  Herein we discuss the main classes of kinase inhibitors; namely Janus kinase (JAK), mitogen-activated protein kinase (MAPK) and spleen tyrosine kinase (Syk) inhibitors.  We provide a mechanistic insight into how these inhibitors interfere with kinase signalling pathways and discuss the clin. successes and failures in the implementation of kinase-directed therapeutics in the context of inflammatory and autoimmune disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro6xmLNBP2V7Vg90H21EOLACvtfcHk0lgm-AaFPrhTVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktVylurw%253D&md5=fb65f5c7ee7086383ddbc95c787da2b4</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1111%2Fcei.12248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcei.12248%26sid%3Dliteratum%253Aachs%26aulast%3DPatterson%26aufirst%3DH.%26aulast%3DNibbs%26aufirst%3DR.%26aulast%3DMcInnes%26aufirst%3DI.%26aulast%3DSiebert%26aufirst%3DS.%26atitle%3DProtein%2520kinase%2520inhibitors%2520in%2520the%2520treatment%2520of%2520inflammatory%2520and%2520autoimmune%2520diseases%26jtitle%3DClin.%2520Exp.%2520Immunol.%26date%3D2014%26volume%3D176%26spage%3D1%26epage%3D10%26doi%3D10.1111%2Fcei.12248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hammaker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firestein, G. S.</span></span> <span> </span><span class="NLM_article-title">“Go upstream, young man”: lessons learned from the p38 saga</span>. <i>Ann. Rheum. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">i77</span>– <span class="NLM_lpage">i82</span>, <span class="refDoi"> DOI: 10.1136/ard.2009.119479</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1136%2Fard.2009.119479" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=19995751" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFOltrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2010&pages=i77-i82&author=D.+Hammakerauthor=G.+S.+Firestein&title=%E2%80%9CGo+upstream%2C+young+man%E2%80%9D%3A+lessons+learned+from+the+p38+saga&doi=10.1136%2Fard.2009.119479"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">"Go upstream, young man": lessons learned from the p38 saga</span></div><div class="casAuthors">Hammaker, D.; Firestein, G. S.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the Rheumatic Diseases</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">Suppl. 1</span>),
    <span class="NLM_cas:pages">i77-i82</span>CODEN:
                <span class="NLM_cas:coden">ARDIAO</span>;
        ISSN:<span class="NLM_cas:issn">0003-4967</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">A review.  Despite the success of biol. therapies in rheumatoid arthritis (RA), orally active small-mol. drugs are desirable.  Signal transduction inhibitors have been the focus of intense efforts, with some recent notable successes and failures.  P38α is a signalling mol. that regulates proinflammatory cytokines, which makes it a logical target for RA.  Unfortunately, selective p38α inhibitors have limited efficacy.  An attempt is made here to put these studies into perspective and offer possible explanations for the failure of p38α blockers.  Alternative strategies, such as targeting kinases higher in the signalling cascade or using less selective compds., might be more successful as suggested by the efficacy seen with Syk and JAK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8J_h8eiP0BLVg90H21EOLACvtfcHk0lig4kaI6sRsdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFOltrs%253D&md5=5f571d0d4a87adc3477921a928f9d78e</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1136%2Fard.2009.119479&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fard.2009.119479%26sid%3Dliteratum%253Aachs%26aulast%3DHammaker%26aufirst%3DD.%26aulast%3DFirestein%26aufirst%3DG.%2BS.%26atitle%3D%25E2%2580%259CGo%2520upstream%252C%2520young%2520man%25E2%2580%259D%253A%2520lessons%2520learned%2520from%2520the%2520p38%2520saga%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2010%26volume%3D69%26spage%3Di77%26epage%3Di82%26doi%3D10.1136%2Fard.2009.119479" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grothe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flechsenhar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paehler, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritzeler, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beninga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudolphi, K.</span></span> <span> </span><span class="NLM_article-title">IκB kinase inhibition as a potential treatment of osteoarthritis – results of a clinical proof-of-concept study</span>. <i>Osteoarthr. Cartil.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">46</span>– <span class="NLM_lpage">52</span>, <span class="refDoi"> DOI: 10.1016/j.joca.2016.08.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1016%2Fj.joca.2016.08.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=27592041" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=46-52&author=K.+Grotheauthor=K.+Flechsenharauthor=T.+Paehlerauthor=O.+Ritzelerauthor=J.+Beningaauthor=J.+Saasauthor=M.+Herrmannauthor=K.+Rudolphi&title=I%CE%BAB+kinase+inhibition+as+a+potential+treatment+of+osteoarthritis+%E2%80%93+results+of+a+clinical+proof-of-concept+study&doi=10.1016%2Fj.joca.2016.08.010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.joca.2016.08.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.joca.2016.08.010%26sid%3Dliteratum%253Aachs%26aulast%3DGrothe%26aufirst%3DK.%26aulast%3DFlechsenhar%26aufirst%3DK.%26aulast%3DPaehler%26aufirst%3DT.%26aulast%3DRitzeler%26aufirst%3DO.%26aulast%3DBeninga%26aufirst%3DJ.%26aulast%3DSaas%26aufirst%3DJ.%26aulast%3DHerrmann%26aufirst%3DM.%26aulast%3DRudolphi%26aufirst%3DK.%26atitle%3DI%25CE%25BAB%2520kinase%2520inhibition%2520as%2520a%2520potential%2520treatment%2520of%2520osteoarthritis%2520%25E2%2580%2593%2520results%2520of%2520a%2520clinical%2520proof-of-concept%2520study%26jtitle%3DOsteoarthr.%2520Cartil.%26date%3D2017%26volume%3D25%26spage%3D46%26epage%3D52%26doi%3D10.1016%2Fj.joca.2016.08.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, R. L.</span></span> <span> </span><span class="NLM_article-title">Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">2051</span>– <span class="NLM_lpage">2059</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-0279</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1158%2F1078-0432.CCR-13-0279" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=24583800" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtl2ms78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=2051-2059&author=S.+C.+Meyerauthor=R.+L.+Levine&title=Molecular+pathways%3A+molecular+basis+for+sensitivity+and+resistance+to+JAK+kinase+inhibitors&doi=10.1158%2F1078-0432.CCR-13-0279"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Pathways: Molecular Basis for Sensitivity and Resistance to JAK Kinase Inhibitors</span></div><div class="casAuthors">Meyer, Sara C.; Levine, Ross L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2051-2059</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Janus-activated kinases (JAK) are the mediators of a variety of cytokine signals via their cognate receptors that result in activation of intracellular signaling pathways.  Alterations in JAK1, JAK2, JAK3, and TYK2 signaling contribute to different disease states, and dysregulated JAK-STAT signaling is assocd. with hematol. malignancies, autoimmune disorders, and immune-deficient conditions.  Genetic alterations of JAK2 occur in the majority of patients with myeloproliferative neoplasms and occur in a subset of patients with acute leukemias.  JAK-mediated signaling critically relies on STAT transcription factors, and on activation of the MAPK and PI3K/Akt signaling axes.  Hyperactive JAK at the apex of these potent oncogenic signaling pathways therefore represents an important target for small-mol. kinase inhibitors in different disease states.  The JAK1/2 inhibitor ruxolitinib and the JAK3 inhibitor tofacitinib were recently approved for the treatment of myelofibrosis and rheumatoid arthritis, resp., and addnl. ATP-competitive JAK inhibitors are in clin. development.  Although these agents show clin. activity, the ability of these JAK inhibitors to induce clin./mol. remissions in hematol. malignancies seems limited and resistance upon chronic drug exposure is seen.  Alternative modes of targeting JAK2 such as allosteric kinase inhibition or HSP90 inhibition are under evaluation, as is the use of histone deacetylase inhibitors.  Combination therapy approaches integrating inhibition of STAT, PI3K/Akt, and MAPK pathways with JAK kinase inhibitors might be crit. to overcome malignancies characterized by dysregulated JAK signaling.  Clin Cancer Res; 20(8); 2051-9. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKgmYqhJDI07Vg90H21EOLACvtfcHk0lig4kaI6sRsdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtl2ms78%253D&md5=7c7ad00b5c8020fd660d86c057827eb2</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-0279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-0279%26sid%3Dliteratum%253Aachs%26aulast%3DMeyer%26aufirst%3DS.%2BC.%26aulast%3DLevine%26aufirst%3DR.%2BL.%26atitle%3DMolecular%2520pathways%253A%2520molecular%2520basis%2520for%2520sensitivity%2520and%2520resistance%2520to%2520JAK%2520kinase%2520inhibitors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26spage%3D2051%26epage%3D2059%26doi%3D10.1158%2F1078-0432.CCR-13-0279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kontzias, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaoka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurence, A.</span></span> <span> </span><span class="NLM_article-title">Janus kinase inhibitors in autoimmune diseases</span>. <i>Ann. Rheum. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">ii111</span>– <span class="NLM_lpage">ii115</span>, <span class="refDoi"> DOI: 10.1136/annrheumdis-2012-202576</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1136%2Fannrheumdis-2012-202576" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=23532440" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2013&pages=ii111-ii115&author=J.+J.+O%E2%80%99Sheaauthor=A.+Kontziasauthor=K.+Yamaokaauthor=Y.+Tanakaauthor=A.+Laurence&title=Janus+kinase+inhibitors+in+autoimmune+diseases&doi=10.1136%2Fannrheumdis-2012-202576"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1136%2Fannrheumdis-2012-202576&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fannrheumdis-2012-202576%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26aulast%3DKontzias%26aufirst%3DA.%26aulast%3DYamaoka%26aufirst%3DK.%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DLaurence%26aufirst%3DA.%26atitle%3DJanus%2520kinase%2520inhibitors%2520in%2520autoimmune%2520diseases%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2013%26volume%3D72%26spage%3Dii111%26epage%3Dii115%26doi%3D10.1136%2Fannrheumdis-2012-202576" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghoreschi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurence, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span> <span> </span><span class="NLM_article-title">Janus kinases in immune cell signaling</span>. <i>Immunol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>228</i></span>,  <span class="NLM_fpage">273</span>– <span class="NLM_lpage">287</span>, <span class="refDoi"> DOI: 10.1111/j.1600-065X.2008.00754.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1111%2Fj.1600-065X.2008.00754.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=19290934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=228&publication_year=2009&pages=273-287&author=K.+Ghoreschiauthor=A.+Laurenceauthor=J.+J.+O%E2%80%99Shea&title=Janus+kinases+in+immune+cell+signaling&doi=10.1111%2Fj.1600-065X.2008.00754.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Janus kinases in immune cell signaling</span></div><div class="casAuthors">Ghoreschi, Kamran; Laurence, Arian; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">228</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">273-287</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">1600-065X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  The Janus family kinases (Jaks), Jak1, Jak2, Jak3, and Tyk2, form one subgroup of the non-receptor protein tyrosine kinases.  They are involved in cell growth, survival, development, and differentiation of a variety of cells but are critically important for immune cells and hematopoietic cells.  Data from exptl. mice and clin. observations have unraveled multiple signaling events mediated by Jaks in innate and adaptive immunity.  Deficiency of Jak3 or Tyk2 results in defined clin. disorders, which are also evident in mouse models.  A striking phenotype assocd. with inactivating Jak3 mutations is severe combined immunodeficiency syndrome, whereas mutation of Tyk2 results in another primary immunodeficiency termed autosomal recessive hyperimmunoglobulin E syndrome.  By contrast, complete deletion of Jak1 or Jak2 in the mouse are not compatible with life and, unsurprisingly, do not have counterparts in human disease.  However, activating mutations of each of the Jaks are found in assocn. with malignant transformation, the most common being gain-of-function mutations of Jak2 in polycythemia vera and other myeloproliferative disorders.  Our existing knowledge on Jak signaling pathways and fundamental work on their biochem. structure and intracellular interactions allow us to develop new strategies for controlling autoimmune diseases or malignancies by developing selective Jak inhibitors, which are now coming into clin. use.  Despite the fact that Jaks were discovered only a little more than a decade ago, at the time of writing there are 20 clin. trials underway testing the safely and efficacy of Jak inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp23ncK0nYqpbVg90H21EOLACvtfcHk0ljfX50XIRGrqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7vJ&md5=adc282a9ad381ee18abe57a82c921f65</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-065X.2008.00754.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-065X.2008.00754.x%26sid%3Dliteratum%253Aachs%26aulast%3DGhoreschi%26aufirst%3DK.%26aulast%3DLaurence%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DJanus%2520kinases%2520in%2520immune%2520cell%2520signaling%26jtitle%3DImmunol.%2520Rev.%26date%3D2009%26volume%3D228%26spage%3D273%26epage%3D287%26doi%3D10.1111%2Fj.1600-065X.2008.00754.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurence, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McInnes, I. B.</span></span> <span> </span><span class="NLM_article-title">Back to the future: oral targeted therapy for RA and other autoimmune diseases</span>. <i>Nat. Rev. Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">173</span>– <span class="NLM_lpage">182</span>, <span class="refDoi"> DOI: 10.1038/nrrheum.2013.7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1038%2Fnrrheum.2013.7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=23419429" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A280%3ADC%252BC3szpsFGiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=173-182&author=J.+J.+O%E2%80%99Sheaauthor=A.+Laurenceauthor=I.+B.+McInnes&title=Back+to+the+future%3A+oral+targeted+therapy+for+RA+and+other+autoimmune+diseases&doi=10.1038%2Fnrrheum.2013.7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Back to the future: oral targeted therapy for RA and other autoimmune diseases</span></div><div class="casAuthors">O'Shea John J; Laurence Arian; McInnes Iain B</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Rheumatology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">173-82</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The molecular biology revolution coupled with the development of monoclonal antibody technology enabled remarkable progress in rheumatology therapy, comprising an array of highly effective biologic agents.  With advances in understanding of the molecular nature of immune cell receptors came elucidation of intracellular signalling pathways downstream of these receptors.  These discoveries raise the question of whether selective targeting of key intracellular factors with small molecules would add to the rheumatologic armamentarium.  In this Review, we discuss several examples of this therapeutic strategy that seem to be successful, and consider their implications for the future of immune-targeted treatments.  We focus on kinase inhibitors, primarily those targeting Janus kinase family members and spleen tyrosine kinase, given their advanced status in clinical development and application.  We also summarize other targets involved in signalling pathways that might offer promise for therapeutic intervention in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQmTYwNff3DeTjk2McQZ6XmfW6udTcc2ebYZmP0DhSOr7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3szpsFGiug%253D%253D&md5=92218e154d717c374bbe42e1f0a0f34f</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnrrheum.2013.7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrrheum.2013.7%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26aulast%3DLaurence%26aufirst%3DA.%26aulast%3DMcInnes%26aufirst%3DI.%2BB.%26atitle%3DBack%2520to%2520the%2520future%253A%2520oral%2520targeted%2520therapy%2520for%2520RA%2520and%2520other%2520autoimmune%2520diseases%26jtitle%3DNat.%2520Rev.%2520Rheumatol.%26date%3D2013%26volume%3D9%26spage%3D173%26epage%3D182%26doi%3D10.1038%2Fnrrheum.2013.7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villarino, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McInnes, I. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurence, A.</span></span> <span> </span><span class="NLM_article-title">The JAK-STAT pathway: impact on human disease and therapeutic intervention</span>. <i>Annu. Rev. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">311</span>– <span class="NLM_lpage">328</span>, <span class="refDoi"> DOI: 10.1146/annurev-med-051113-024537</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1146%2Fannurev-med-051113-024537" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=25587654" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjvFyhsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2015&pages=311-328&author=J.+J.+O%E2%80%99Sheaauthor=D.+M.+Schwartzauthor=A.+V.+Villarinoauthor=M.+Gadinaauthor=I.+B.+McInnesauthor=A.+Laurence&title=The+JAK-STAT+pathway%3A+impact+on+human+disease+and+therapeutic+intervention&doi=10.1146%2Fannurev-med-051113-024537"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">The JAK-STAT pathway: impact on human disease and therapeutic intervention</span></div><div class="casAuthors">O'Shea, John J.; Schwartz, Daniella M.; Villarino, Alejandro V.; Gadina, Massimo; McInnes, Iain B.; Laurence, Arian</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">311-328</span>CODEN:
                <span class="NLM_cas:coden">ARMCAH</span>;
        ISSN:<span class="NLM_cas:issn">0066-4219</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">A review.  The Janus kinase (JAK)-signal transducer of activators of transcription (STAT) pathway is now recognized as an evolutionarily conserved signaling pathway employed by diverse cytokines, interferons, growth factors, and related mols.  This pathway provides an elegant and remarkably straightforward mechanism whereby extracellular factors control gene expression.  It thus serves as a fundamental paradigm for how cells sense environmental cues and interpret these signals to regulate cell growth and differentiation.  Genetic mutations and polymorphisms are functionally relevant to a variety of human diseases, esp. cancer and immune-related conditions.  The clin. relevance of the pathway has been confirmed by the emergence of a new class of therapeutics that targets JAKs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMxvQCRiTbL7Vg90H21EOLACvtfcHk0ljfX50XIRGrqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjvFyhsLY%253D&md5=19182154f1a046df039eb4a37b66bf78</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1146%2Fannurev-med-051113-024537&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-med-051113-024537%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26aulast%3DSchwartz%26aufirst%3DD.%2BM.%26aulast%3DVillarino%26aufirst%3DA.%2BV.%26aulast%3DGadina%26aufirst%3DM.%26aulast%3DMcInnes%26aufirst%3DI.%2BB.%26aulast%3DLaurence%26aufirst%3DA.%26atitle%3DThe%2520JAK-STAT%2520pathway%253A%2520impact%2520on%2520human%2520disease%2520and%2520therapeutic%2520intervention%26jtitle%3DAnnu.%2520Rev.%2520Med.%26date%3D2015%26volume%3D66%26spage%3D311%26epage%3D328%26doi%3D10.1146%2Fannurev-med-051113-024537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chrencik, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patny, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, I. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korniski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emmons, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinberg, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gormley, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsch, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiefer, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leone, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sommers, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobsen, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tenbrink, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomasselli, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benson, T. E.</span></span> <span> </span><span class="NLM_article-title">Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>400</i></span>,  <span class="NLM_fpage">413</span>– <span class="NLM_lpage">433</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2010.05.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1016%2Fj.jmb.2010.05.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=20478313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1ylt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=400&publication_year=2010&pages=413-433&author=J.+E.+Chrencikauthor=A.+Patnyauthor=I.+K.+Leungauthor=B.+Korniskiauthor=T.+L.+Emmonsauthor=T.+Hallauthor=R.+A.+Weinbergauthor=J.+A.+Gormleyauthor=J.+M.+Williamsauthor=J.+E.+Dayauthor=J.+L.+Hirschauthor=J.+R.+Kieferauthor=J.+W.+Leoneauthor=H.+D.+Fischerauthor=C.+D.+Sommersauthor=H.-C.+Huangauthor=E.+J.+Jacobsenauthor=R.+E.+Tenbrinkauthor=A.+G.+Tomasselliauthor=T.+E.+Benson&title=Structural+and+thermodynamic+characterization+of+the+TYK2+and+JAK3+kinase+domains+in+complex+with+CP-690550+and+CMP-6&doi=10.1016%2Fj.jmb.2010.05.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and Thermodynamic Characterization of the TYK2 and JAK3 Kinase Domains in Complex with CP-690550 and CMP-6</span></div><div class="casAuthors">Chrencik, Jill E.; Patny, Akshay; Leung, Iris K.; Korniski, Brian; Emmons, Thomas L.; Hall, Troii; Weinberg, Robin A.; Gormley, Jennifer A.; Williams, Jennifer M.; Day, Jacqueline E.; Hirsch, Jeffrey L.; Kiefer, James R.; Leone, Joseph W.; Fischer, H. David; Sommers, Cynthia D.; Huang, Horng-Chih; Jacobsen, E. J.; Tenbrink, Ruth E.; Tomasselli, Alfredo G.; Benson, Timothy E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">400</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">413-433</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Janus kinases (JAKs) are crit. regulators of cytokine pathways and attractive targets of therapeutic value in both inflammatory and myeloproliferative diseases.  Although the crystal structures of active JAK1 and JAK2 kinase domains have been reported recently with the clin. compd. CP-690550, the structures of both TYK2 and JAK3 with CP-690550 have remained outstanding.  Here, we report the crystal structures of TYK2, a first in class structure, and JAK3 in complex with PAN-JAK inhibitors CP-690550 ((3R,4R)-3-[4-methyl-3-[N-methyl-N-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropionitrile) and CMP-6 (tetracyclic pyridone 2-t-butyl-9-fluoro-3,6-dihydro-7H-benz[h]-imidaz[4,5-f]isoquinoline-7-one), both of which bind in the ATP-binding cavities of both JAK isoenzymes in orientations similar to that obsd. in crystal structures of JAK1 and JAK2.  Addnl., a complete thermodn. characterization of JAK/CP-690550 complex formation was completed by isothermal titrn. calorimetry, indicating the crit. role of the nitrile group from the CP-690550 compd.  Finally, computational anal. using WaterMap further highlights the crit. positioning of the CP-690550 nitrile group in the displacement of an unfavorable water mol. beneath the glycine-rich loop.  Taken together, the data emphasize the outstanding properties of the kinome-selective JAK inhibitor CP-690550, as well as the challenges in obtaining JAK isoenzyme-selective inhibitors due to the overall structural and sequence similarities between the TYK2, JAK1, JAK2 and JAK3 isoenzymes.  Nevertheless, subtle amino acid variations of residues lining the ligand-binding cavity of the JAK enzymes, as well as the global positioning of the glycine-rich loop, might provide the initial clues to obtaining JAK-isoenzyme selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5dnGkvq0jPbVg90H21EOLACvtfcHk0ljfX50XIRGrqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1ylt7g%253D&md5=1b1efc3d6f913143dc9113e4ac1c4c60</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2010.05.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2010.05.020%26sid%3Dliteratum%253Aachs%26aulast%3DChrencik%26aufirst%3DJ.%2BE.%26aulast%3DPatny%26aufirst%3DA.%26aulast%3DLeung%26aufirst%3DI.%2BK.%26aulast%3DKorniski%26aufirst%3DB.%26aulast%3DEmmons%26aufirst%3DT.%2BL.%26aulast%3DHall%26aufirst%3DT.%26aulast%3DWeinberg%26aufirst%3DR.%2BA.%26aulast%3DGormley%26aufirst%3DJ.%2BA.%26aulast%3DWilliams%26aufirst%3DJ.%2BM.%26aulast%3DDay%26aufirst%3DJ.%2BE.%26aulast%3DHirsch%26aufirst%3DJ.%2BL.%26aulast%3DKiefer%26aufirst%3DJ.%2BR.%26aulast%3DLeone%26aufirst%3DJ.%2BW.%26aulast%3DFischer%26aufirst%3DH.%2BD.%26aulast%3DSommers%26aufirst%3DC.%2BD.%26aulast%3DHuang%26aufirst%3DH.-C.%26aulast%3DJacobsen%26aufirst%3DE.%2BJ.%26aulast%3DTenbrink%26aufirst%3DR.%2BE.%26aulast%3DTomasselli%26aufirst%3DA.%2BG.%26aulast%3DBenson%26aufirst%3DT.%2BE.%26atitle%3DStructural%2520and%2520thermodynamic%2520characterization%2520of%2520the%2520TYK2%2520and%2520JAK3%2520kinase%2520domains%2520in%2520complex%2520with%2520CP-690550%2520and%2520CMP-6%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2010%26volume%3D400%26spage%3D413%26epage%3D433%26doi%3D10.1016%2Fj.jmb.2010.05.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wiegman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adcock, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothaul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Main, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, F.</span></span> <span> </span><span class="NLM_article-title">In-vitro evaluation of a new potent, selective pan-Janus kinase (JAK) inhibitor VR588</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">PA2130</span>, <span class="refDoi"> DOI: 10.1183/13993003.congress-2015.PA2130</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1183%2F13993003.congress-2015.PA2130" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2015&pages=PA2130&author=C.+Wiegmanauthor=I.+Adcockauthor=A.+Rothaulauthor=M.+Mainauthor=F.+Morgan&title=In-vitro+evaluation+of+a+new+potent%2C+selective+pan-Janus+kinase+%28JAK%29+inhibitor+VR588&doi=10.1183%2F13993003.congress-2015.PA2130"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1183%2F13993003.congress-2015.PA2130&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F13993003.congress-2015.PA2130%26sid%3Dliteratum%253Aachs%26aulast%3DWiegman%26aufirst%3DC.%26aulast%3DAdcock%26aufirst%3DI.%26aulast%3DRothaul%26aufirst%3DA.%26aulast%3DMain%26aufirst%3DM.%26aulast%3DMorgan%26aufirst%3DF.%26atitle%3DIn-vitro%2520evaluation%2520of%2520a%2520new%2520potent%252C%2520selective%2520pan-Janus%2520kinase%2520%2528JAK%2529%2520inhibitor%2520VR588%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2015%26volume%3D46%26spage%3DPA2130%26doi%3D10.1183%2F13993003.congress-2015.PA2130" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumenkopf, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brissette, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casavant, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shang-Poa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doty, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hines, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kent, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kudlacz, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lillie, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnuson, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCurdy, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munchhof, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawyer, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strelevitz, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanyam, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whipple, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Changelian, P. S.</span></span> <span> </span><span class="NLM_article-title">Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">8468</span>– <span class="NLM_lpage">8484</span>, <span class="refDoi"> DOI: 10.1021/jm1004286</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1004286" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8468-8484&author=M.+E.+Flanaganauthor=T.+A.+Blumenkopfauthor=W.+H.+Brissetteauthor=M.+F.+Brownauthor=J.+M.+Casavantauthor=C.+Shang-Poaauthor=J.+L.+Dotyauthor=E.+A.+Elliottauthor=M.+B.+Fisherauthor=M.+Hinesauthor=C.+Kentauthor=E.+M.+Kudlaczauthor=B.+M.+Lillieauthor=K.+S.+Magnusonauthor=S.+P.+McCurdyauthor=M.+J.+Munchhofauthor=B.+D.+Perryauthor=P.+S.+Sawyerauthor=T.+J.+Strelevitzauthor=C.+Subramanyamauthor=J.+Sunauthor=D.+A.+Whippleauthor=P.+S.+Changelian&title=Discovery+of+CP-690%2C550%3A+a+potent+and+selective+Janus+kinase+%28JAK%29+inhibitor+for+the+treatment+of+autoimmune+diseases+and+organ+transplant+rejection&doi=10.1021%2Fjm1004286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection</span></div><div class="casAuthors">Flanagan, Mark E.; Blumenkopf, Todd A.; Brissette, William H.; Brown, Matthew F.; Casavant, Jeffrey M.; Chang, Shang-Poa; Doty, Jonathan L.; Elliott, Eileen A.; Fisher, Michael B.; Hines, Michael; Kent, Craig; Kudlacz, Elizabeth M.; Lillie, Brett M.; Magnuson, Kelly S.; McCurdy, Sandra P.; Munchhof, Michael J.; Perry, Bret D.; Sawyer, Perry S.; Strelevitz, Timothy J.; Subramanyam, Chakrapani; Sun, Jianmin; Whipple, David A.; Changelian, Paul S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8468-8484</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There is a crit. need for safer and more convenient treatments for organ transplant rejection and autoimmune disorders such as rheumatoid arthritis.  Janus tyrosine kinases (JAK1, JAK3) are expressed in lymphoid cells and are involved in the signaling of multiple cytokines important for various T cell functions.  Blockade of the JAK1/JAK3-STAT pathway with a small mol. was anticipated to provide therapeutic immunosuppression/immunomodulation.  The Pfizer compd. library was screened against the catalytic domain of JAK3 resulting in the identification of a pyrrolopyrimidine-based series of inhibitors represented by the hexahydrocarbazolyl pyrrolopyrimidine CP-352,664.  Synthetic analogs of CP-352,664 were screened against the JAK enzymes and evaluated in an IL-2 induced T cell blast proliferation assay.  Select compds. were evaluated in rodent efficacy models of allograft rejection and destructive inflammatory arthritis.  Optimization within this chem. series led to identification of the cyanoacetylpiperidinylamino pyrrolopyrimidine CP-690,550, a potential first-in-class JAK inhibitor for treatment of autoimmune diseases and organ transplant rejection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbFS_8DSHkDbVg90H21EOLACvtfcHk0lgDpWvAJe1SaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP&md5=c1d31ce42ab3f1c1f3029c6f4f48df1a</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm1004286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1004286%26sid%3Dliteratum%253Aachs%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DBlumenkopf%26aufirst%3DT.%2BA.%26aulast%3DBrissette%26aufirst%3DW.%2BH.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DShang-Poa%26aufirst%3DC.%26aulast%3DDoty%26aufirst%3DJ.%2BL.%26aulast%3DElliott%26aufirst%3DE.%2BA.%26aulast%3DFisher%26aufirst%3DM.%2BB.%26aulast%3DHines%26aufirst%3DM.%26aulast%3DKent%26aufirst%3DC.%26aulast%3DKudlacz%26aufirst%3DE.%2BM.%26aulast%3DLillie%26aufirst%3DB.%2BM.%26aulast%3DMagnuson%26aufirst%3DK.%2BS.%26aulast%3DMcCurdy%26aufirst%3DS.%2BP.%26aulast%3DMunchhof%26aufirst%3DM.%2BJ.%26aulast%3DPerry%26aufirst%3DB.%2BD.%26aulast%3DSawyer%26aufirst%3DP.%2BS.%26aulast%3DStrelevitz%26aufirst%3DT.%2BJ.%26aulast%3DSubramanyam%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DWhipple%26aufirst%3DD.%2BA.%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26atitle%3DDiscovery%2520of%2520CP-690%252C550%253A%2520a%2520potent%2520and%2520selective%2520Janus%2520kinase%2520%2528JAK%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520autoimmune%2520diseases%2520and%2520organ%2520transplant%2520rejection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D8468%26epage%3D8484%26doi%3D10.1021%2Fjm1004286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wollenhaupt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverfield, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtis, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nduaka, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benda, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruben, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komuro, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zwillich, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riese, R. J.</span></span> <span> </span><span class="NLM_article-title">Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies</span>. <i>J. Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">837</span>– <span class="NLM_lpage">852</span>, <span class="refDoi"> DOI: 10.3899/jrheum.130683</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.3899%2Fjrheum.130683" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=24692527" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVyiurbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2014&pages=837-852&author=J.+Wollenhauptauthor=J.+Silverfieldauthor=E.+B.+Leeauthor=J.+R.+Curtisauthor=S.+P.+Woodauthor=K.+Somaauthor=C.+I.+Nduakaauthor=B.+Bendaauthor=D.+Grubenauthor=H.+Nakamuraauthor=Y.+Komuroauthor=S.+H.+Zwillichauthor=L.+Wangauthor=R.+J.+Riese&title=Safety+and+efficacy+of+tofacitinib%2C+an+oral+Janus+kinase+inhibitor%2C+for+the+treatment+of+rheumatoid+arthritis+in+open-label%2C+longterm+extension+studies&doi=10.3899%2Fjrheum.130683"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies</span></div><div class="casAuthors">Wollenhaupt, Juergen; Silverfield, Joel; Lee, Eun Bong; Curtis, Jeffrey R.; Wood, Susan P.; Soma, Koshika; Nduaka, Chudy I.; Benda, Birgitta; Gruben, David; Nakamura, Hiroyuki; Komuro, Yoshihiro; Zwillich, Samuel H.; Wang, Lisy; Riese, Richard J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Rheumatology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">837-852</span>CODEN:
                <span class="NLM_cas:coden">JRHUA9</span>;
        ISSN:<span class="NLM_cas:issn">0315-162X</span>.
    
            (<span class="NLM_cas:orgname">Journal of Rheumatology Publishing Co. Ltd.</span>)
        </div><div class="casAbstract">Objective: To describe the longterm safety and efficacy profile of tofacitinib in patients with moderate to severe active rheumatoid arthritis (RA).  Methods: Data were pooled from 2 open-label studies (NCT00413699, NCT00661661) involving patients who had participated in qualifying phase I, II, or III index studies of tofacitinib.  Safety data included over 60 mo of observation; efficacy data are reported up to Month 48.  Treatment was initiated with tofacitinib 5 or 10 mg twice daily.  Primary endpoints were adverse events (AE) and lab. safety data.  Secondary endpoints included American College of Rheumatol. (ACR) response rates, and Disease Activity Score (28 joints) (DAS28)-4[erythrocyte sedimentation rate (ESR)] and Health Assessment Questionnaire-Disability Index (HAQ-DI) assessments.  Results: Overall, 4102 patients were treated for 5963 patient-years; mean (max.) treatment duration was 531 (1844) days; 20.8% of patients discontinued treatment over 60 mo.  The most common AE were nasopharyngitis (12.7%) and upper respiratory tract infection (10.5%).  Serious AE were reported in 15.4% of patients with an exposure-estd. incidence rate of 11.1 events/100 patient-years.  Serious infections were reported in 4.5% of patients with an exposure-estd. incidence rate of 3.1 events/100 patient-years (95% CI: 2.66-3.55).  Mean values for lab. variables were stable over time and consistent with phase II and III studies.  Persistent efficacy was demonstrated through Month 48, as measured by ACR response rate (ACR20/50/70) DAS28-4-ESR, and HAQ-DI.  Safety and efficacy were similar for patients receiving tofacitinib as monotherapy or with background nonbiol. disease-modifying antirheumatic drugs.  Conclusion: Tofacitinib demonstrated consistent safety and persistent efficacy over 48 mo in patients with RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-Scjk1FOYMrVg90H21EOLACvtfcHk0lgDpWvAJe1SaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVyiurbJ&md5=0c8cf68569627b3948b6c275ec69d8df</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.3899%2Fjrheum.130683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3899%252Fjrheum.130683%26sid%3Dliteratum%253Aachs%26aulast%3DWollenhaupt%26aufirst%3DJ.%26aulast%3DSilverfield%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DE.%2BB.%26aulast%3DCurtis%26aufirst%3DJ.%2BR.%26aulast%3DWood%26aufirst%3DS.%2BP.%26aulast%3DSoma%26aufirst%3DK.%26aulast%3DNduaka%26aufirst%3DC.%2BI.%26aulast%3DBenda%26aufirst%3DB.%26aulast%3DGruben%26aufirst%3DD.%26aulast%3DNakamura%26aufirst%3DH.%26aulast%3DKomuro%26aufirst%3DY.%26aulast%3DZwillich%26aufirst%3DS.%2BH.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DRiese%26aufirst%3DR.%2BJ.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520tofacitinib%252C%2520an%2520oral%2520Janus%2520kinase%2520inhibitor%252C%2520for%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%2520in%2520open-label%252C%2520longterm%2520extension%2520studies%26jtitle%3DJ.%2520Rheumatol.%26date%3D2014%26volume%3D41%26spage%3D837%26epage%3D852%26doi%3D10.3899%2Fjrheum.130683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zerbini, C. A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lomonte, A. B. V.</span></span> <span> </span><span class="NLM_article-title">Tofacitinib for the treatment of rheumatoid arthritis</span>. <i>Expert Rev. Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">319</span>– <span class="NLM_lpage">331</span>, <span class="refDoi"> DOI: 10.1586/eci.12.19</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1586%2Feci.12.19" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=22607178" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC38Xnt1yqs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=319-331&author=C.+A.+F.+Zerbiniauthor=A.+B.+V.+Lomonte&title=Tofacitinib+for+the+treatment+of+rheumatoid+arthritis&doi=10.1586%2Feci.12.19"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Tofacitinib for the treatment of rheumatoid arthritis</span></div><div class="casAuthors">Zerbini, Cristiano A. F.; Lomonte, Andrea Barranjard Vannucci</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Clinical Immunology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">319-331</span>CODEN:
                <span class="NLM_cas:coden">ERCIBU</span>;
        ISSN:<span class="NLM_cas:issn">1744-666X</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  Rheumatoid arthritis (RA) is a chronic inflammatory disease that affects approx. 1% of the worldwide population.  It primarily targets the synovial membrane of joints, leading to a synovial proliferation, joint cartilage lesion and erosions in the adjacent bone tissue.  The disease is usually progressive and if the inflammatory process is not adequately suppressed, joint deformity takes place, leading to a significant functional disability and work incapacity.  Over the last decade, biol. therapy was established as a major step towards disease control in those patients who experienced failure after treatment with disease-modifying antirheumatic drugs.  Despite the growing no. of biol. agents with different immunol. targets, a significant no. of patients do not receive appropriate disease control, or have the use of these agents limited because of adverse events.  As such, the search for new mols. with a higher efficacy and better safety profile is ongoing.  This article focuses on a new drug, tofacitinib, which is a synthetic disease-modifying antirheumatic drug for treatment of RA.  Preclin. studies in arthritis and transplantation animal models are reviewed as a background for the possible use of tofacitinib treatment in humans.  Four Phase II (one A and three B dose-ranging) trials lasting from 6 to 24 wk in RA patients showed significant American College of Rheumatol. 20 improvements as early as week 2 and sustained at week 24 in two studies.  Tofacitinib Phase III studies in RA are included in a clin. program called ORAL Trials'.  Long-term follow-up from ongoing studies will contribute to a more accurate tofacitinib efficacy and safety profile.  Trials in other illness such as psoriasis, psoriatic arthritis, renal transplant rejection prevention, inflammatory bowel diseases and dry eye are underway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHpLt7-aROnLVg90H21EOLACvtfcHk0lhJU94a2EZ3sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xnt1yqs78%253D&md5=ad557fe321ab93878f9eace579afcadf</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1586%2Feci.12.19&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252Feci.12.19%26sid%3Dliteratum%253Aachs%26aulast%3DZerbini%26aufirst%3DC.%2BA.%2BF.%26aulast%3DLomonte%26aufirst%3DA.%2BB.%2BV.%26atitle%3DTofacitinib%2520for%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%26jtitle%3DExpert%2520Rev.%2520Clin.%2520Immunol.%26date%3D2012%26volume%3D8%26spage%3D319%26epage%3D331%26doi%3D10.1586%2Feci.12.19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamagami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuno, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okuma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chida, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inami, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirakami, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higashi, Y.</span></span> <span> </span><span class="NLM_article-title">A novel JAK inhibitor, peficitinib, demonstrates potent efficacy in a rat adjuvant-induced arthritis model</span>. <i>J. Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>133</i></span>,  <span class="NLM_fpage">25</span>– <span class="NLM_lpage">33</span>, <span class="refDoi"> DOI: 10.1016/j.jphs.2016.12.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1016%2Fj.jphs.2016.12.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=28117214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFKru7zK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2017&pages=25-33&author=M.+Itoauthor=S.+Yamazakiauthor=K.+Yamagamiauthor=M.+Kunoauthor=Y.+Moritaauthor=K.+Okumaauthor=K.+Nakamuraauthor=N.+Chidaauthor=M.+Inamiauthor=T.+Inoueauthor=S.+Shirakamiauthor=Y.+Higashi&title=A+novel+JAK+inhibitor%2C+peficitinib%2C+demonstrates+potent+efficacy+in+a+rat+adjuvant-induced+arthritis+model&doi=10.1016%2Fj.jphs.2016.12.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">A novel JAK inhibitor, peficitinib, demonstrates potent efficacy in a rat adjuvant-induced arthritis model</span></div><div class="casAuthors">Ito, Misato; Yamazaki, Shunji; Yamagami, Kaoru; Kuno, Masako; Morita, Yoshiaki; Okuma, Kenji; Nakamura, Koji; Chida, Noboru; Inami, Masamichi; Inoue, Takayuki; Shirakami, Shohei; Higashi, Yasuyuki</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacological Sciences (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-33</span>CODEN:
                <span class="NLM_cas:coden">JPSTGJ</span>;
        ISSN:<span class="NLM_cas:issn">1347-8613</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The Janus kinase (JAK) family of tyrosine kinases is assocd. with various cytokine receptors.  JAK1 and JAK3 play particularly important roles in the immune response, and their inhibition is expected to provide targeted immune modulation.  Several oral JAK inhibitors have recently been developed for treating autoimmune diseases, including rheumatoid arthritis (RA).  Here, we investigated the pharmacol. effects of peficitinib (formerly known as ASP015K), a novel, chem. synthesized JAK inhibitor.  We found that peficitinib inhibited JAK1 and JAK3 with 50% inhibitory concns. of 3.9 and 0.7 nM, resp.  Peficitinib also inhibited IL-2-dependent T cell proliferation in vitro and STAT5 phosphorylation in vitro and ex vivo.  Furthermore, peficitinib dose-dependently suppressed bone destruction and paw swelling in an adjuvant-induced arthritis model in rats via prophylactic or therapeutic oral dosing regimens.  Peficitinib also showed efficacy in the model by continuous i.p. infusion.  Area under the concn. vs. time curve (AUC) at 50% inhibition of paw swelling via i.p. infusion was similar to exposure levels of AUC at 50% inhibition via oral administration, implying that AUC might be important for detg. the therapeutic efficacy of peficitinib.  These data suggest that peficitinib has therapeutic potential for the oral treatment of RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXCuMIThrVN7Vg90H21EOLACvtfcHk0lhJU94a2EZ3sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFKru7zK&md5=1d5bf4c2d40ccf8209e24684d53dbfe8</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.jphs.2016.12.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jphs.2016.12.001%26sid%3Dliteratum%253Aachs%26aulast%3DIto%26aufirst%3DM.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DYamagami%26aufirst%3DK.%26aulast%3DKuno%26aufirst%3DM.%26aulast%3DMorita%26aufirst%3DY.%26aulast%3DOkuma%26aufirst%3DK.%26aulast%3DNakamura%26aufirst%3DK.%26aulast%3DChida%26aufirst%3DN.%26aulast%3DInami%26aufirst%3DM.%26aulast%3DInoue%26aufirst%3DT.%26aulast%3DShirakami%26aufirst%3DS.%26aulast%3DHigashi%26aufirst%3DY.%26atitle%3DA%2520novel%2520JAK%2520inhibitor%252C%2520peficitinib%252C%2520demonstrates%2520potent%2520efficacy%2520in%2520a%2520rat%2520adjuvant-induced%2520arthritis%2520model%26jtitle%3DJ.%2520Pharmacol.%2520Sci.%26date%3D2017%26volume%3D133%26spage%3D25%26epage%3D33%26doi%3D10.1016%2Fj.jphs.2016.12.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wernig, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kharas, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okabe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leeman, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cullen, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gozo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDowell, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doukas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mak, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noronha, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, Y. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soll, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tefferi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hood, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilliland, D. G.</span></span> <span> </span><span class="NLM_article-title">Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">311</span>– <span class="NLM_lpage">320</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2008.02.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1016%2Fj.ccr.2008.02.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=18394554" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BD1cXkslSjtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2008&pages=311-320&author=G.+Wernigauthor=M.+G.+Kharasauthor=R.+Okabeauthor=S.+A.+Mooreauthor=D.+S.+Leemanauthor=D.+E.+Cullenauthor=M.+Gozoauthor=E.+P.+McDowellauthor=R.+L.+Levineauthor=J.+Doukasauthor=C.+C.+Makauthor=G.+Noronhaauthor=M.+Martinauthor=Y.+D.+Koauthor=B.+H.+Leeauthor=R.+M.+Sollauthor=A.+Tefferiauthor=J.+D.+Hoodauthor=D.+G.+Gilliland&title=Efficacy+of+TG101348%2C+a+selective+JAK2+inhibitor%2C+in+treatment+of+a+murine+model+of+JAK2V617F-induced+polycythemia+vera&doi=10.1016%2Fj.ccr.2008.02.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera</span></div><div class="casAuthors">Wernig, Gerlinde; Kharas, Michael G.; Okabe, Rachel; Moore, Sandra A.; Leeman, Dena S.; Cullen, Dana E.; Gozo, Maricel; McDowell, Elizabeth P.; Levine, Ross L.; Doukas, John; Mak, Chi Ching; Noronha, Glenn; Martin, Michael; Ko, Yon D.; Lee, Benjamin H.; Soll, Richard M.; Tefferi, Ayalew; Hood, John D.; Gilliland, D. Gary</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">311-320</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">We report that TG101348, a selective small-mol. inhibitor of JAK2 with an in vitro IC50 of ∼3 nM, shows therapeutic efficacy in a murine model of myeloproliferative disease induced by the JAK2V617F mutation.  In treated animals, there was a statistically significant redn. in hematocrit and leukocyte count, a dose-dependent redn./elimination of extramedullary hematopoiesis, and, at least in some instances, evidence for attenuation of myelofibrosis.  There were no apparent toxicities and no effect on T cell no.  In vivo responses were correlated with surrogate endpoints, including redn./elimination of JAK2V617F disease burden assessed by quant. genomic PCR, suppression of endogenous erythroid colony formation, and in vivo inhibition of JAK-STAT signal transduction as assessed by flow cytometric measurement of phosphorylated Stat5.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSJOc4cS_lO7Vg90H21EOLACvtfcHk0lhJU94a2EZ3sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXkslSjtrs%253D&md5=3dd923595cafebb6439dd67f026735be</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2008.02.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2008.02.009%26sid%3Dliteratum%253Aachs%26aulast%3DWernig%26aufirst%3DG.%26aulast%3DKharas%26aufirst%3DM.%2BG.%26aulast%3DOkabe%26aufirst%3DR.%26aulast%3DMoore%26aufirst%3DS.%2BA.%26aulast%3DLeeman%26aufirst%3DD.%2BS.%26aulast%3DCullen%26aufirst%3DD.%2BE.%26aulast%3DGozo%26aufirst%3DM.%26aulast%3DMcDowell%26aufirst%3DE.%2BP.%26aulast%3DLevine%26aufirst%3DR.%2BL.%26aulast%3DDoukas%26aufirst%3DJ.%26aulast%3DMak%26aufirst%3DC.%2BC.%26aulast%3DNoronha%26aufirst%3DG.%26aulast%3DMartin%26aufirst%3DM.%26aulast%3DKo%26aufirst%3DY.%2BD.%26aulast%3DLee%26aufirst%3DB.%2BH.%26aulast%3DSoll%26aufirst%3DR.%2BM.%26aulast%3DTefferi%26aufirst%3DA.%26aulast%3DHood%26aufirst%3DJ.%2BD.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26atitle%3DEfficacy%2520of%2520TG101348%252C%2520a%2520selective%2520JAK2%2520inhibitor%252C%2520in%2520treatment%2520of%2520a%2520murine%2520model%2520of%2520JAK2V617F-induced%2520polycythemia%2520vera%26jtitle%3DCancer%2520Cell%26date%3D2008%26volume%3D13%26spage%3D311%26epage%3D320%26doi%3D10.1016%2Fj.ccr.2008.02.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inghrim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grebinski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokarski, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenzi, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDevitt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penhallow, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vuppugalla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trainor, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruepp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blat, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sack, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefanski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sleczka, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arunachalam, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pragalathan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayanan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">K.C., N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuppusamy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purandare, A. V.</span></span> <span> </span><span class="NLM_article-title">Discovery of a highly selective JAK2 inhibitor, BMS-911543, for the treatment of myeloproliferative neoplasms</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">850</span>– <span class="NLM_lpage">855</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00226</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00226" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFGitbvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=850-855&author=H.+Wanauthor=G.+M.+Schroederauthor=A.+C.+Hartauthor=J.+Inghrimauthor=J.+Grebinskiauthor=J.+S.+Tokarskiauthor=M.+V.+Lorenziauthor=D.+Youauthor=T.+McDevittauthor=B.+Penhallowauthor=R.+Vuppugallaauthor=Y.+Zhangauthor=X.+Guauthor=R.+Iyerauthor=L.+J.+Lombardoauthor=G.+L.+Trainorauthor=S.+Rueppauthor=J.+Lippyauthor=Y.+Blatauthor=J.+S.+Sackauthor=J.+A.+Khanauthor=K.+Stefanskiauthor=B.+Sleczkaauthor=A.+Mathurauthor=J.-H.+Sunauthor=M.+K.+Wongauthor=D.-R.+Wuauthor=P.+Liauthor=A.+Guptaauthor=P.+N.+Arunachalamauthor=B.+Pragalathanauthor=S.+Narayananauthor=N.+K.C.author=P.+Kuppusamyauthor=A.+V.+Purandare&title=Discovery+of+a+highly+selective+JAK2+inhibitor%2C+BMS-911543%2C+for+the+treatment+of+myeloproliferative+neoplasms&doi=10.1021%2Facsmedchemlett.5b00226"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Highly Selective JAK2 Inhibitor, BMS-911543, for the Treatment of Myeloproliferative Neoplasms</span></div><div class="casAuthors">Wan, Honghe; Schroeder, Gretchen M.; Hart, Amy C.; Inghrim, Jennifer; Grebinski, James; Tokarski, John S.; Lorenzi, Matthew V.; You, Dan; McDevitt, Theresa; Penhallow, Becky; Vuppugalla, Ragini; Zhang, Yueping; Gu, Xiaomei; Iyer, Ramaswamy; Lombardo, Louis J.; Trainor, George L.; Ruepp, Stefan; Lippy, Jonathan; Blat, Yuval; Sack, John S.; Khan, Javed A.; Stefanski, Kevin; Sleczka, Bogdan; Mathur, Arvind; Sun, Jung-Hui; Wong, Michael K.; Wu, Dauh-Rurng; Li, Peng; Gupta, Anuradha; Arunachalam, P. N.; Pragalathan, Bala; Narayanan, Sankara; Nanjundaswamy, K. C.; Kuppusamy, Prakasam; Purandare, Ashok V.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">850-855</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">JAK2 kinase inhibitors are a promising new class of agents for the treatment of myeloproliferative neoplasms and have potential for the treatment of other diseases possessing a deregulated JAK2-STAT pathway.  X-ray structure and ADME guided refinement of C-4 heterocycles to address metabolic liability present in dialkylthiazole (I) led to the discovery of a clin. candidate, BMS-911543 (11), with excellent kinome selectivity, in vivo PD activity, and safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7LTsDfjeehLVg90H21EOLACvtfcHk0lhk-mJI9LBUlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFGitbvF&md5=d6bdb9b070a8f7492352600ea1222a8f</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00226%26sid%3Dliteratum%253Aachs%26aulast%3DWan%26aufirst%3DH.%26aulast%3DSchroeder%26aufirst%3DG.%2BM.%26aulast%3DHart%26aufirst%3DA.%2BC.%26aulast%3DInghrim%26aufirst%3DJ.%26aulast%3DGrebinski%26aufirst%3DJ.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DLorenzi%26aufirst%3DM.%2BV.%26aulast%3DYou%26aufirst%3DD.%26aulast%3DMcDevitt%26aufirst%3DT.%26aulast%3DPenhallow%26aufirst%3DB.%26aulast%3DVuppugalla%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DGu%26aufirst%3DX.%26aulast%3DIyer%26aufirst%3DR.%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26aulast%3DTrainor%26aufirst%3DG.%2BL.%26aulast%3DRuepp%26aufirst%3DS.%26aulast%3DLippy%26aufirst%3DJ.%26aulast%3DBlat%26aufirst%3DY.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DKhan%26aufirst%3DJ.%2BA.%26aulast%3DStefanski%26aufirst%3DK.%26aulast%3DSleczka%26aufirst%3DB.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DWong%26aufirst%3DM.%2BK.%26aulast%3DWu%26aufirst%3DD.-R.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DArunachalam%26aufirst%3DP.%2BN.%26aulast%3DPragalathan%26aufirst%3DB.%26aulast%3DNarayanan%26aufirst%3DS.%26aulast%3DK.C.%26aufirst%3DN.%26aulast%3DKuppusamy%26aufirst%3DP.%26aulast%3DPurandare%26aufirst%3DA.%2BV.%26atitle%3DDiscovery%2520of%2520a%2520highly%2520selective%2520JAK2%2520inhibitor%252C%2520BMS-911543%252C%2520for%2520the%2520treatment%2520of%2520myeloproliferative%2520neoplasms%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D850%26epage%3D855%26doi%3D10.1021%2Facsmedchemlett.5b00226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vazquez, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaila, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strohbach, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trzupek, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitton-Fry, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">TenBrink, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heasley, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langille, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parikh, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casavant, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duclos, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenwick, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caspers, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banker, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symanowicz, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jussif, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unwalla, R.</span></span> <span> </span><span class="NLM_article-title">Identification of N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): a selective JAK1 clinical candidate for the treatment of autoimmune diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">1130</span>– <span class="NLM_lpage">1152</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01598</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01598" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1Wnsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=1130-1152&author=M.+L.+Vazquezauthor=N.+Kailaauthor=J.+W.+Strohbachauthor=J.+D.+Trzupekauthor=M.+F.+Brownauthor=M.+E.+Flanaganauthor=M.+J.+Mitton-Fryauthor=T.+A.+Johnsonauthor=R.+E.+TenBrinkauthor=E.+P.+Arnoldauthor=A.+Basakauthor=S.+E.+Heasleyauthor=S.+Kwonauthor=J.+Langilleauthor=M.+D.+Parikhauthor=S.+H.+Griffinauthor=J.+M.+Casavantauthor=B.+A.+Duclosauthor=A.+E.+Fenwickauthor=T.+M.+Harrisauthor=S.+Hanauthor=N.+Caspersauthor=M.+E.+Dowtyauthor=X.+Yangauthor=M.+E.+Bankerauthor=M.+Hegenauthor=P.+T.+Symanowiczauthor=L.+Liauthor=L.+Wangauthor=T.+H.+Linauthor=J.+Jussifauthor=J.+D.+Clarkauthor=J.-B.+Telliezauthor=R.+P.+Robinsonauthor=R.+Unwalla&title=Identification+of+N-%7Bcis-3-%5Bmethyl%287H-pyrrolo%5B2%2C3-d%5Dpyrimidin-4-yl%29amino%5Dcyclobutyl%7Dpropane-1-sulfonamide+%28PF-04965842%29%3A+a+selective+JAK1+clinical+candidate+for+the+treatment+of+autoimmune+diseases&doi=10.1021%2Facs.jmedchem.7b01598"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases</span></div><div class="casAuthors">Vazquez, Michael L.; Kaila, Neelu; Strohbach, Joseph W.; Trzupek, John D.; Brown, Matthew F.; Flanagan, Mark E.; Mitton-Fry, Mark J.; Johnson, Timothy A.; TenBrink, Ruth E.; Arnold, Eric P.; Basak, Arindrajit; Heasley, Steven E.; Kwon, Soojin; Langille, Jonathan; Parikh, Mihir D.; Griffin, Sarah H.; Casavant, Jeffrey M.; Duclos, Brian A.; Fenwick, Ashley E.; Harris, Thomas M.; Han, Seungil; Caspers, Nicole; Dowty, Martin E.; Yang, Xin; Banker, Mary Ellen; Hegen, Martin; Symanowicz, Peter T.; Li, Li; Wang, Lu; Lin, Tsung H.; Jussif, Jason; Clark, James D.; Telliez, Jean-Baptiste; Robinson, Ralph P.; Unwalla, Ray</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1130-1152</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Janus kinases (JAKs) are intracellular tyrosine kinases that mediate the signaling of numerous cytokines and growth factors involved in the regulation of immunity, inflammation, and hematopoiesis.  As JAK1 pairs with JAK2, JAK3, and TYK2, a JAK1-selective inhibitor would be expected to inhibit many cytokines involved in inflammation and immune function while avoiding inhibition of the JAK2 homodimer regulating erythropoietin and thrombopoietin signaling.  The authors' efforts began with tofacitinib, an oral JAK inhibitor approved for the treatment of rheumatoid arthritis.  Through modification of the 3-aminopiperidine linker in tofacitinib, the authors discovered highly selective JAK1 inhibitors with nanomolar potency in a human whole blood assay.  Improvements in JAK1 potency and selectivity were achieved via structural modifications suggested by x-ray crystallog. anal.  After demonstrating efficacy in a rat adjuvant-induced arthritis (rAIA) model, PF-04965842 (25) was nominated as a clin. candidate for the treatment of JAK1-mediated autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNdiJFIHI-YLVg90H21EOLACvtfcHk0lhk-mJI9LBUlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1Wnsw%253D%253D&md5=45c6d1b0eee7ab9d5dfc8ea168607a8b</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01598%26sid%3Dliteratum%253Aachs%26aulast%3DVazquez%26aufirst%3DM.%2BL.%26aulast%3DKaila%26aufirst%3DN.%26aulast%3DStrohbach%26aufirst%3DJ.%2BW.%26aulast%3DTrzupek%26aufirst%3DJ.%2BD.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DMitton-Fry%26aufirst%3DM.%2BJ.%26aulast%3DJohnson%26aufirst%3DT.%2BA.%26aulast%3DTenBrink%26aufirst%3DR.%2BE.%26aulast%3DArnold%26aufirst%3DE.%2BP.%26aulast%3DBasak%26aufirst%3DA.%26aulast%3DHeasley%26aufirst%3DS.%2BE.%26aulast%3DKwon%26aufirst%3DS.%26aulast%3DLangille%26aufirst%3DJ.%26aulast%3DParikh%26aufirst%3DM.%2BD.%26aulast%3DGriffin%26aufirst%3DS.%2BH.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DDuclos%26aufirst%3DB.%2BA.%26aulast%3DFenwick%26aufirst%3DA.%2BE.%26aulast%3DHarris%26aufirst%3DT.%2BM.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DCaspers%26aufirst%3DN.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DBanker%26aufirst%3DM.%2BE.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DSymanowicz%26aufirst%3DP.%2BT.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DT.%2BH.%26aulast%3DJussif%26aufirst%3DJ.%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DTelliez%26aufirst%3DJ.-B.%26aulast%3DRobinson%26aufirst%3DR.%2BP.%26aulast%3DUnwalla%26aufirst%3DR.%26atitle%3DIdentification%2520of%2520N-%257Bcis-3-%255Bmethyl%25287H-pyrrolo%255B2%252C3-d%255Dpyrimidin-4-yl%2529amino%255Dcyclobutyl%257Dpropane-1-sulfonamide%2520%2528PF-04965842%2529%253A%2520a%2520selective%2520JAK1%2520clinical%2520candidate%2520for%2520the%2520treatment%2520of%2520autoimmune%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D1130%26epage%3D1152%26doi%3D10.1021%2Facs.jmedchem.7b01598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Voss, J. W.</span>; <span class="NLM_string-name">Camp, H. S.</span>; <span class="NLM_string-name">Padley, R. J.</span></span> <span> </span><span class="NLM_article-title">JAK1 Selective Inhibitors and Uses Thereof</span>. <span class="NLM_patent">WO2015061665</span>, April 30, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=J.+W.+Voss&author=H.+S.+Camp&author=R.+J.+Padley&title=JAK1+Selective+Inhibitors+and+Uses+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DVoss%26aufirst%3DJ.%2BW.%26atitle%3DJAK1%2520Selective%2520Inhibitors%2520and%2520Uses%2520Thereof%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurley, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergeron, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balazs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blair, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bull, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakravarty, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crackett, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshmukh, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVoss, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dragovich, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellwood, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaines, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghilardi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbons, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gradl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gribling, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harstad, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hewitt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenny, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koehler, M. F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bir
Kohli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labadie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liimatta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendonca, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narukulla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulk, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reeve, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savage, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steffek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ubhayakar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Abbema, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aliagas, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avitabile-Woo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulagowski, J. J.</span></span> <span> </span><span class="NLM_article-title">Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">4764</span>– <span class="NLM_lpage">4785</span>, <span class="refDoi"> DOI: 10.1021/jm4004895</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4004895" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnsVWit74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=4764-4785&author=M.+Zakauthor=C.+A.+Hurleyauthor=S.+I.+Wardauthor=P.+Bergeronauthor=K.+Barrettauthor=M.+Balazsauthor=W.+S.+Blairauthor=R.+Bullauthor=P.+Chakravartyauthor=C.+Changauthor=P.+Crackettauthor=G.+Deshmukhauthor=J.+DeVossauthor=P.+S.+Dragovichauthor=C.+Eigenbrotauthor=C.+Ellwoodauthor=S.+Gainesauthor=N.+Ghilardiauthor=P.+Gibbonsauthor=S.+Gradlauthor=P.+Griblingauthor=C.+Hammanauthor=E.+Harstadauthor=P.+Hewittauthor=A.+Johnsonauthor=T.+Johnsonauthor=J.+R.+Kennyauthor=M.+F.+T.+Koehlerauthor=P.+Bir%0AKohliauthor=S.+Labadieauthor=W.+P.+Leeauthor=J.+Liaoauthor=M.+Liimattaauthor=R.+Mendoncaauthor=R.+Narukullaauthor=R.+Pulkauthor=A.+Reeveauthor=S.+Savageauthor=S.+Shiaauthor=M.+Steffekauthor=S.+Ubhayakarauthor=A.+van+Abbemaauthor=I.+Aliagasauthor=B.+Avitabile-Wooauthor=Y.+Xiaoauthor=J.+Yangauthor=J.+J.+Kulagowski&title=Identification+of+C-2+hydroxyethyl+imidazopyrrolopyridines+as+potent+JAK1+inhibitors+with+favorable+physicochemical+properties+and+high+selectivity+over+JAK2&doi=10.1021%2Fjm4004895"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of C-2 Hydroxyethyl Imidazopyrrolopyridines as Potent JAK1 Inhibitors with Favorable Physicochemical Properties and High Selectivity over JAK2</span></div><div class="casAuthors">Zak, Mark; Hurley, Christopher A.; Ward, Stuart I.; Bergeron, Philippe; Barrett, Kathy; Balazs, Mercedesz; Blair, Wade S.; Bull, Richard; Chakravarty, Paroma; Chang, Christine; Crackett, Peter; Deshmukh, Gauri; DeVoss, Jason; Dragovich, Peter S.; Eigenbrot, Charles; Ellwood, Charles; Gaines, Simon; Ghilardi, Nico; Gibbons, Paul; Gradl, Stefan; Gribling, Peter; Hamman, Chris; Harstad, Eric; Hewitt, Peter; Johnson, Adam; Johnson, Tony; Kenny, Jane R.; Koehler, Michael F. T.; Bir Kohli, Pawan; Labadie, Sharada; Lee, Wyne P.; Liao, Jiangpeng; Liimatta, Marya; Mendonca, Rohan; Narukulla, Raman; Pulk, Rebecca; Reeve, Austin; Savage, Scott; Shia, Steven; Steffek, Micah; Ubhayakar, Savita; van Abbema, Anne; Aliagas, Ignacio; Avitabile-Woo, Barbara; Xiao, Yisong; Yang, Jing; Kulagowski, Janusz J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4764-4785</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein we report on the structure-based discovery of a C-2 hydroxyethyl moiety which provided consistently high levels of selectivity for JAK1 over JAK2 to the imidazopyrrolopyridine series of JAK1 inhibitors.  X-ray structures of a C-2 hydroxyethyl analog in complex with both JAK1 and JAK2 revealed differential ligand/protein interactions between the two isoforms and offered an explanation for the obsd. selectivity.  Anal. of historical data from related mols. was used to develop a set of physicochem. compd. design parameters to impart desirable properties such as acceptable membrane permeability, potent whole blood activity, and a high degree of metabolic stability.  This work culminated in the identification of a highly JAK1 selective compd. (31) exhibiting favorable oral bioavailability across a range of preclin. species and robust efficacy in a rat CIA model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrP0DlLtJCYq7Vg90H21EOLACvtfcHk0lhTMhVIeGgkKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnsVWit74%253D&md5=0b0d1950adebf325cc434344f57ca139</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm4004895&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4004895%26sid%3Dliteratum%253Aachs%26aulast%3DZak%26aufirst%3DM.%26aulast%3DHurley%26aufirst%3DC.%2BA.%26aulast%3DWard%26aufirst%3DS.%2BI.%26aulast%3DBergeron%26aufirst%3DP.%26aulast%3DBarrett%26aufirst%3DK.%26aulast%3DBalazs%26aufirst%3DM.%26aulast%3DBlair%26aufirst%3DW.%2BS.%26aulast%3DBull%26aufirst%3DR.%26aulast%3DChakravarty%26aufirst%3DP.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DCrackett%26aufirst%3DP.%26aulast%3DDeshmukh%26aufirst%3DG.%26aulast%3DDeVoss%26aufirst%3DJ.%26aulast%3DDragovich%26aufirst%3DP.%2BS.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DEllwood%26aufirst%3DC.%26aulast%3DGaines%26aufirst%3DS.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DGibbons%26aufirst%3DP.%26aulast%3DGradl%26aufirst%3DS.%26aulast%3DGribling%26aufirst%3DP.%26aulast%3DHamman%26aufirst%3DC.%26aulast%3DHarstad%26aufirst%3DE.%26aulast%3DHewitt%26aufirst%3DP.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DT.%26aulast%3DKenny%26aufirst%3DJ.%2BR.%26aulast%3DKoehler%26aufirst%3DM.%2BF.%2BT.%26aulast%3DBir%2BKohli%26aufirst%3DP.%26aulast%3DLabadie%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DW.%2BP.%26aulast%3DLiao%26aufirst%3DJ.%26aulast%3DLiimatta%26aufirst%3DM.%26aulast%3DMendonca%26aufirst%3DR.%26aulast%3DNarukulla%26aufirst%3DR.%26aulast%3DPulk%26aufirst%3DR.%26aulast%3DReeve%26aufirst%3DA.%26aulast%3DSavage%26aufirst%3DS.%26aulast%3DShia%26aufirst%3DS.%26aulast%3DSteffek%26aufirst%3DM.%26aulast%3DUbhayakar%26aufirst%3DS.%26aulast%3Dvan%2BAbbema%26aufirst%3DA.%26aulast%3DAliagas%26aufirst%3DI.%26aulast%3DAvitabile-Woo%26aufirst%3DB.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DKulagowski%26aufirst%3DJ.%2BJ.%26atitle%3DIdentification%2520of%2520C-2%2520hydroxyethyl%2520imidazopyrrolopyridines%2520as%2520potent%2520JAK1%2520inhibitors%2520with%2520favorable%2520physicochemical%2520properties%2520and%2520high%2520selectivity%2520over%2520JAK2%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D4764%26epage%3D4785%26doi%3D10.1021%2Fjm4004895" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Abbema, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balazs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berezhkovsky, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blair, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delarosa, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVoss, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driscoll, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodacre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghilardi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacLeod, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bir Kohli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantik, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menghrajani, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sambrone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sohn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsui, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ultsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnuson, S.</span></span> <span> </span><span class="NLM_article-title">Identification of an imidazopyridine scaffold to generate potent and selective TYK2 inhibitors that demonstrate activity in an in vivo psoriasis model</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">4370</span>– <span class="NLM_lpage">4376</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.08.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1016%2Fj.bmcl.2017.08.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=28830649" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlOku7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=4370-4376&author=J.+Liangauthor=A.+Van+Abbemaauthor=M.+Balazsauthor=K.+Barrettauthor=L.+Berezhkovskyauthor=W.+S.+Blairauthor=C.+Changauthor=D.+Delarosaauthor=J.+DeVossauthor=J.+Driscollauthor=C.+Eigenbrotauthor=S.+Goodacreauthor=N.+Ghilardiauthor=C.+MacLeodauthor=A.+Johnsonauthor=P.+Bir+Kohliauthor=Y.+Laiauthor=Z.+Linauthor=P.+Mantikauthor=K.+Menghrajaniauthor=H.+Nguyenauthor=I.+Pengauthor=A.+Sambroneauthor=S.+Shiaauthor=J.+Smithauthor=S.+Sohnauthor=V.+Tsuiauthor=M.+Ultschauthor=K.+Williamsauthor=L.+C.+Wuauthor=W.+Yangauthor=B.+Zhangauthor=S.+Magnuson&title=Identification+of+an+imidazopyridine+scaffold+to+generate+potent+and+selective+TYK2+inhibitors+that+demonstrate+activity+in+an+in+vivo+psoriasis+model&doi=10.1016%2Fj.bmcl.2017.08.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of an imidazopyridine scaffold to generate potent and selective TYK2 inhibitors that demonstrate activity in an in vivo psoriasis model</span></div><div class="casAuthors">Liang, Jun; Van Abbema, Anne; Balazs, Mercedesz; Barrett, Kathy; Berezhkovsky, Leo; Blair, Wade S.; Chang, Christine; Delarosa, Donnie; De Voss, Jason; Driscoll, Jim; Eigenbrot, Charles; Goodacre, Simon; Ghilardi, Nico; MacLeod, Calum; Johnson, Adam; Bir Kohli, Pawan; Lai, Yingjie; Lin, Zhonghua; Mantik, Priscilla; Menghrajani, Kapil; Nguyen, Hieu; Peng, Ivan; Sambrone, Amy; Shia, Steven; Smith, Jan; Sohn, Sue; Tsui, Vickie; Ultsch, Mark; Williams, Karen; Wu, Lawren C.; Yang, Wenqian; Zhang, Birong; Magnuson, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4370-4376</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Herein we report identification of an imidazopyridine class of potent and selective TYK2 inhibitors, exemplified by prototype 6, through constraint of the rotatable amide bond connecting the pyridine and aryl rings of compd. 1.  Further optimization led to generation of compd. 30 that potently inhibits the TYK2 enzyme and the IL-23 pathway in cells, exhibits selectivity against cellular JAK2 activity, and has good pharmacokinetic properties.  In mice, compd. 30 demonstrated dose-dependent redn. of IL-17 prodn. in a PK/PD model as well as in an imiquimod-induced psoriasis model.  In this efficacy model, the IL-17 decrease was accompanied by a redn. of ear thickness indicating the potential of TYK2 inhibition as a therapeutic approach for psoriasis patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoe2FqArjLnebVg90H21EOLACvtfcHk0lhTMhVIeGgkKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlOku7bJ&md5=d132566f504626660c52c680399c9a09</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.08.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.08.022%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DJ.%26aulast%3DVan%2BAbbema%26aufirst%3DA.%26aulast%3DBalazs%26aufirst%3DM.%26aulast%3DBarrett%26aufirst%3DK.%26aulast%3DBerezhkovsky%26aufirst%3DL.%26aulast%3DBlair%26aufirst%3DW.%2BS.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DDelarosa%26aufirst%3DD.%26aulast%3DDeVoss%26aufirst%3DJ.%26aulast%3DDriscoll%26aufirst%3DJ.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DGoodacre%26aufirst%3DS.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DMacLeod%26aufirst%3DC.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DBir%2BKohli%26aufirst%3DP.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DLin%26aufirst%3DZ.%26aulast%3DMantik%26aufirst%3DP.%26aulast%3DMenghrajani%26aufirst%3DK.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DPeng%26aufirst%3DI.%26aulast%3DSambrone%26aufirst%3DA.%26aulast%3DShia%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DJ.%26aulast%3DSohn%26aufirst%3DS.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DUltsch%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DK.%26aulast%3DWu%26aufirst%3DL.%2BC.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DMagnuson%26aufirst%3DS.%26atitle%3DIdentification%2520of%2520an%2520imidazopyridine%2520scaffold%2520to%2520generate%2520potent%2520and%2520selective%2520TYK2%2520inhibitors%2520that%2520demonstrate%2520activity%2520in%2520an%2520in%2520vivo%2520psoriasis%2520model%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26spage%3D4370%26epage%3D4376%26doi%3D10.1016%2Fj.bmcl.2017.08.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williams, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bamert, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walden, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilks, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fantino, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossjohn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucet, I. S.</span></span> <span> </span><span class="NLM_article-title">Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>387</i></span>,  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">232</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2009.01.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1016%2Fj.jmb.2009.01.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=19361440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivVegtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=387&publication_year=2009&pages=219-232&author=N.+K.+Williamsauthor=R.+S.+Bamertauthor=O.+Patelauthor=C.+Wangauthor=P.+M.+Waldenauthor=A.+F.+Wilksauthor=E.+Fantinoauthor=J.+Rossjohnauthor=I.+S.+Lucet&title=Dissecting+specificity+in+the+Janus+kinases%3A+the+structures+of+JAK-specific+inhibitors+complexed+to+the+JAK1+and+JAK2+protein+tyrosine+kinase+domains&doi=10.1016%2Fj.jmb.2009.01.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Dissecting Specificity in the Janus Kinases: The Structures of JAK-Specific Inhibitors Complexed to the JAK1 and JAK2 Protein Tyrosine Kinase Domains</span></div><div class="casAuthors">Williams, Neal K.; Bamert, Rebecca S.; Patel, Onisha; Wang, Christina; Walden, Patricia M.; Wilks, Andrew F.; Fantino, Emmanuelle; Rossjohn, Jamie; Lucet, Isabelle S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">387</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">219-232</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The Janus kinases (JAKs) are a pivotal family of protein tyrosine kinases (PTKs) that play prominent roles in numerous cytokine signaling pathways, with aberrant JAK activity assocd. with a variety of hematopoietic malignancies, cardiovascular diseases and immune-related disorders.  Whereas the structures of the JAK2 and JAK3 PTK domains have been detd., the structure of the JAK1 PTK domain is unknown.  Here, we report the high-resoln. crystal structures of the "active form" of the JAK1 PTK domain in complex with two JAK inhibitors, a tetracyclic pyridone 2-t-butyl-9-fluoro-3,6-dihydro-7H-benz[h]-imidaz[4,5-f]isoquinoline-7-one (CMP6) and (3R,4R)-3-[4-methyl-3-[N-methyl-N-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropionitrile (CP-690,550), and compare them with the corresponding JAK2 PTK inhibitor complexes.  Both inhibitors bound in a similar manner to JAK1, namely buried deep within a constricted ATP-binding site, thereby providing a basis for the potent inhibition of JAK1.  As expected, the mode of inhibitor binding in JAK1 was very similar to that obsd. in JAK2, highlighting the challenges in developing JAK-specific inhibitors that target the ATP-binding site.  Nevertheless, differences surrounding the JAK1 and JAK2 ATP-binding sites were apparent, thereby providing a platform for the rational design of JAK2- and JAK1-specific inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQDLkMkCgiLbVg90H21EOLACvtfcHk0lgLoOA1b6-QNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivVegtbo%253D&md5=79957755d04323057b5acf7e9d2c56ca</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2009.01.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2009.01.041%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DN.%2BK.%26aulast%3DBamert%26aufirst%3DR.%2BS.%26aulast%3DPatel%26aufirst%3DO.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DWalden%26aufirst%3DP.%2BM.%26aulast%3DWilks%26aufirst%3DA.%2BF.%26aulast%3DFantino%26aufirst%3DE.%26aulast%3DRossjohn%26aufirst%3DJ.%26aulast%3DLucet%26aufirst%3DI.%2BS.%26atitle%3DDissecting%2520specificity%2520in%2520the%2520Janus%2520kinases%253A%2520the%2520structures%2520of%2520JAK-specific%2520inhibitors%2520complexed%2520to%2520the%2520JAK1%2520and%2520JAK2%2520protein%2520tyrosine%2520kinase%2520domains%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2009%26volume%3D387%26spage%3D219%26epage%3D232%26doi%3D10.1016%2Fj.jmb.2009.01.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, K.-s.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chong, Y.</span></span> <span> </span><span class="NLM_article-title">Benzimidazole derivatives as potent JAK1-selective inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">7596</span>– <span class="NLM_lpage">7602</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01263</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01263" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=7596-7602&author=M.+K.+Kimauthor=H.+Shinauthor=K.-s.+Parkauthor=H.+Kimauthor=J.+Parkauthor=K.+Kimauthor=J.+Namauthor=H.+Chooauthor=Y.+Chong&title=Benzimidazole+derivatives+as+potent+JAK1-selective+inhibitors&doi=10.1021%2Facs.jmedchem.5b01263"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01263%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DM.%2BK.%26aulast%3DShin%26aufirst%3DH.%26aulast%3DPark%26aufirst%3DK.-s.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DK.%26aulast%3DNam%26aufirst%3DJ.%26aulast%3DChoo%26aufirst%3DH.%26aulast%3DChong%26aufirst%3DY.%26atitle%3DBenzimidazole%2520derivatives%2520as%2520potent%2520JAK1-selective%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D7596%26epage%3D7602%26doi%3D10.1021%2Facs.jmedchem.5b01263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Renert-Yuval, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guttman-Yassky, E.</span></span> <span> </span><span class="NLM_article-title">The changing landscape of alopecia areata: the therapeutic paradigm</span>. <i>Adv. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">1594</span>– <span class="NLM_lpage">1609</span>, <span class="refDoi"> DOI: 10.1007/s12325-017-0542-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1007%2Fs12325-017-0542-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2017&pages=1594-1609&author=Y.+Renert-Yuvalauthor=E.+Guttman-Yassky&title=The+changing+landscape+of+alopecia+areata%3A+the+therapeutic+paradigm&doi=10.1007%2Fs12325-017-0542-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1007%2Fs12325-017-0542-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12325-017-0542-7%26sid%3Dliteratum%253Aachs%26aulast%3DRenert-Yuval%26aufirst%3DY.%26aulast%3DGuttman-Yassky%26aufirst%3DE.%26atitle%3DThe%2520changing%2520landscape%2520of%2520alopecia%2520areata%253A%2520the%2520therapeutic%2520paradigm%26jtitle%3DAdv.%2520Ther.%26date%3D2017%26volume%3D34%26spage%3D1594%26epage%3D1609%26doi%3D10.1007%2Fs12325-017-0542-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Genovese, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kremer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamani, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludivico, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krogulec, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beattie, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardillo, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rooney, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macias, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Bono, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlichting, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smolen, J. S.</span></span> <span> </span><span class="NLM_article-title">Baricitinib in patients with refractory rheumatoid arthritis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>374</i></span>,  <span class="NLM_fpage">1243</span>– <span class="NLM_lpage">1252</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1507247</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1056%2FNEJMoa1507247" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=27028914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Kisr3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=2016&pages=1243-1252&author=M.+C.+Genoveseauthor=J.+Kremerauthor=O.+Zamaniauthor=C.+Ludivicoauthor=M.+Krogulecauthor=L.+Xieauthor=S.+D.+Beattieauthor=A.+E.+Kochauthor=T.+E.+Cardilloauthor=T.+P.+Rooneyauthor=W.+L.+Maciasauthor=S.+de+Bonoauthor=D.+E.+Schlichtingauthor=J.+S.+Smolen&title=Baricitinib+in+patients+with+refractory+rheumatoid+arthritis&doi=10.1056%2FNEJMoa1507247"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Baricitinib in patients with refractory rheumatoid arthritis</span></div><div class="casAuthors">Genovese, Mark C.; Kremer, Joel; Zamani, Omid; Ludivico, Charles; Krogulec, Marek; Xie, Li; Beattie, Scott D.; Koch, Alisa E.; Cardillo, Tracy E.; Rooney, Terence P.; Macias, William L.; de Bono, Stephanie; Schlichting, Douglas E.; Smolen, Josef S.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">374</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1243-1252</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND In phase 2 studies, baricitinib, an oral Janus kinase 1 and 2 inhibitor, reduced disease activity in patients with rheumatoid arthritis who had not previously received treatment with biol. disease-modifying antirheumatic drugs (DMARDs).  METHODS In this phase 3 study involving 527 patients with an inadequate response to or unacceptable side effects assocd. with one or more tumor necrosis factor inhibitors, other biol. DMARDs, or both, we randomly assigned the patients in a 1:1:1 ratio to baricitinib at a dose of 2 or 4 mg daily or placebo for 24 wk.  End points, tested hierarchically at week 12 to control type 1 error, were the American College of Rheumatol. 20% (ACR20) response (primary end point), the Health Assessment Questionnaire-Disability Index (HAQ-DI) score, the 28-joint Disease Activity Score based on C-reactive protein level (DAS28-CRP), and a Simplified Disease Activity Index (SDAI) score of 3.3 or less (on a scale of 0.1 to 86.0, with a score of 3.3 or less indicating remission).  Comparisons with placebo were made first with the 4-mg dose of baricitinib and then with the 2-mg dose.  RESULTS Significantly more patients receiving baricitinib at the 4-mg dose than those receiving placebo had an ACR20 response at week 12 (55% vs. 27%, P<0.001).  Differences between the higher-dose baricitinib group and the placebo group were also significant for the HAQ-DI score and the DAS28-CRP but not for an SDAI score of 3.3 or less.  Adverse-event rates through 24 wk were higher for patients receiving the 2-mg dose of baricitinib and those receiving the 4-mg dose than for patients receiving placebo (71% and 77%, resp., vs. 64%), including infections (44% and 40%, vs. 31%).  The rates of serious adverse events were 4%, 10%, and 7% in the three groups, resp.  Two nonmelanoma skin cancers and two major adverse cardiovascular events, including a fatal stroke, occurred in the higher-dose group.  Baricitinib was assocd. with a small redn. in neutrophil levels and increases in serum creatinine and low-d. lipoprotein cholesterol levels.  CONCLUSIONS In patients with rheumatoid arthritis and an inadequate response to biol. DMARDs, baricitinib at a daily dose of 4 mg was assocd. with clin. improvement at 12 wk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqj72FQTLOsQLVg90H21EOLACvtfcHk0lgLoOA1b6-QNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Kisr3E&md5=d7d317ee88fae38379b3b07c420349f6</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1507247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1507247%26sid%3Dliteratum%253Aachs%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26aulast%3DKremer%26aufirst%3DJ.%26aulast%3DZamani%26aufirst%3DO.%26aulast%3DLudivico%26aufirst%3DC.%26aulast%3DKrogulec%26aufirst%3DM.%26aulast%3DXie%26aufirst%3DL.%26aulast%3DBeattie%26aufirst%3DS.%2BD.%26aulast%3DKoch%26aufirst%3DA.%2BE.%26aulast%3DCardillo%26aufirst%3DT.%2BE.%26aulast%3DRooney%26aufirst%3DT.%2BP.%26aulast%3DMacias%26aufirst%3DW.%2BL.%26aulast%3Dde%2BBono%26aufirst%3DS.%26aulast%3DSchlichting%26aufirst%3DD.%2BE.%26aulast%3DSmolen%26aufirst%3DJ.%2BS.%26atitle%3DBaricitinib%2520in%2520patients%2520with%2520refractory%2520rheumatoid%2520arthritis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D374%26spage%3D1243%26epage%3D1252%26doi%3D10.1056%2FNEJMoa1507247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vannucchi, A. M.</span></span> <span> </span><span class="NLM_article-title">Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians</span>. <i>Ther. Adv. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">341</span>– <span class="NLM_lpage">354</span>, <span class="refDoi"> DOI: 10.1177/2040620712459746</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1177%2F2040620712459746" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=23606937" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnslWntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=341-354&author=C.+Harrisonauthor=A.+M.+Vannucchi&title=Ruxolitinib%3A+a+potent+and+selective+Janus+kinase+1+and+2+inhibitor+in+patients+with+myelofibrosis.+An+update+for+clinicians&doi=10.1177%2F2040620712459746"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians</span></div><div class="casAuthors">Harrison, Claire; Vannucchi, Alessandro N.</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutic Advances in Hematology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">341-354</span>CODEN:
                <span class="NLM_cas:coden">TAHHAT</span>;
        ISSN:<span class="NLM_cas:issn">2040-6207</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Ruxolitinib became the first US Food and Drug Administration approved therapy for myelofibrosis in 2011 and EU approval is anticipated in summer 2012.  Two large phase III trials (known as the COMFORT studies) were the basis for this approval and were published recently.  In this review article we discuss the challenges in managing myelofibrosis, the information to date about ruxolitinib and speculate as to the future direction with this and similar agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-1M-lwEgpCrVg90H21EOLACvtfcHk0lhXDFHkqhFCsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnslWntA%253D%253D&md5=6c88ade9fb3df126e6b0188b69a68d3c</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1177%2F2040620712459746&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F2040620712459746%26sid%3Dliteratum%253Aachs%26aulast%3DHarrison%26aufirst%3DC.%26aulast%3DVannucchi%26aufirst%3DA.%2BM.%26atitle%3DRuxolitinib%253A%2520a%2520potent%2520and%2520selective%2520Janus%2520kinase%25201%2520and%25202%2520inhibitor%2520in%2520patients%2520with%2520myelofibrosis.%2520An%2520update%2520for%2520clinicians%26jtitle%3DTher.%2520Adv.%2520Hematol.%26date%3D2012%26volume%3D3%26spage%3D341%26epage%3D354%26doi%3D10.1177%2F2040620712459746" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pardanani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tefferi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamieson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabrail, N. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebedinsky, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talpaz, M.</span></span> <span> </span><span class="NLM_article-title">A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis</span>. <i>Blood Cancer J.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">e335</span>, <span class="refDoi"> DOI: 10.1038/bcj.2015.63</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1038%2Fbcj.2015.63" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=26252788" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=e335&author=A.+Pardananiauthor=A.+Tefferiauthor=C.+Jamiesonauthor=N.+Y.+Gabrailauthor=C.+Lebedinskyauthor=G.+Gaoauthor=F.+Liuauthor=C.+Xuauthor=H.+Caoauthor=M.+Talpaz&title=A+phase+2+randomized+dose-ranging+study+of+the+JAK2-selective+inhibitor+fedratinib+%28SAR302503%29+in+patients+with+myelofibrosis&doi=10.1038%2Fbcj.2015.63"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fbcj.2015.63&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbcj.2015.63%26sid%3Dliteratum%253Aachs%26aulast%3DPardanani%26aufirst%3DA.%26aulast%3DTefferi%26aufirst%3DA.%26aulast%3DJamieson%26aufirst%3DC.%26aulast%3DGabrail%26aufirst%3DN.%2BY.%26aulast%3DLebedinsky%26aufirst%3DC.%26aulast%3DGao%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DXu%26aufirst%3DC.%26aulast%3DCao%26aufirst%3DH.%26aulast%3DTalpaz%26aufirst%3DM.%26atitle%3DA%2520phase%25202%2520randomized%2520dose-ranging%2520study%2520of%2520the%2520JAK2-selective%2520inhibitor%2520fedratinib%2520%2528SAR302503%2529%2520in%2520patients%2520with%2520myelofibrosis%26jtitle%3DBlood%2520Cancer%2520J.%26date%3D2015%26volume%3D5%26spage%3De335%26doi%3D10.1038%2Fbcj.2015.63" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, A. W.</span></span> <span> </span><span class="NLM_article-title">JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis</span>. <i>J. Immunol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>2014</i></span>,  <span class="NLM_fpage">283617</span>, <span class="refDoi"> DOI: 10.1155/2014/283617</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1155%2F2014%2F283617" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=24883332" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A280%3ADC%252BC2cfot1ehtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2014&publication_year=2014&pages=283617&author=L.+Hsuauthor=A.+W.+Armstrong&title=JAK+inhibitors%3A+treatment+efficacy+and+safety+profile+in+patients+with+psoriasis&doi=10.1155%2F2014%2F283617"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis</span></div><div class="casAuthors">Hsu Leeyen; Armstrong April W</div><div class="citationInfo"><span class="NLM_cas:title">Journal of immunology research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">2014</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">283617</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Janus kinase (JAK) pathways are key mediators in the immunopathogenesis of psoriasis.  Psoriasis treatment has evolved with the advent of targeted therapies, which inhibit specific components of the psoriasis proinflammatory cascade.  JAK inhibitors have been studied in early phase trials for psoriasis patients, and the data are promising for these agents as potential treatment options.  Tofacitinib, an oral or topically administered JAK1 and JAK3 inhibitor, and ruxolitinib, a topical JAK1 and JAK2 inhibitor, have been most extensively studied in psoriasis, and both improved clinical symptoms of psoriasis.  Additional JAK1 or JAK3 inhibitors are being studied in clinical trials.  In phase III trials for rheumatoid arthritis, tofacitinib was efficacious in patients with inadequate responses to tumor necrosis factor inhibitors, methotrexate monotherapy, or disease-modifying antirheumatic drugs.  The results of phase III trials are pending for these therapies in psoriasis, and these agents may represent important alternatives for patients with inadequate responses to currently available agents.  Further investigations with long-term clinical trials are necessary to verify their utility in psoriasis treatment and assess their safety in this patient population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS8NFwIZodl1tTiMd2aNQVUfW6udTcc2eaPOFcFMARVi7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cfot1ehtw%253D%253D&md5=241b16e23f36ea06d03b49fa4c53104f</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1155%2F2014%2F283617&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2014%252F283617%26sid%3Dliteratum%253Aachs%26aulast%3DHsu%26aufirst%3DL.%26aulast%3DArmstrong%26aufirst%3DA.%2BW.%26atitle%3DJAK%2520inhibitors%253A%2520treatment%2520efficacy%2520and%2520safety%2520profile%2520in%2520patients%2520with%2520psoriasis%26jtitle%3DJ.%2520Immunol.%2520Res.%26date%3D2014%26volume%3D2014%26spage%3D283617%26doi%3D10.1155%2F2014%2F283617" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moslin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santella, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duncia, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokarski, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strnad, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedicord, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blat, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zupa-Fernandez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sack, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muckelbauer, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tredup, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aranibar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, D. S.</span></span> <span> </span><span class="NLM_article-title">Identification of imidazo[1,2-b]pyridazine TYK2 pseudokinase ligands as potent and selective allosteric inhibitors of TYK2 signalling</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">700</span>– <span class="NLM_lpage">712</span>, <span class="refDoi"> DOI: 10.1039/C6MD00560H</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1039%2FC6MD00560H" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=30108788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVyru7jN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=700-712&author=R.+Moslinauthor=D.+Gardnerauthor=J.+Santellaauthor=Y.+Zhangauthor=J.+V.+Dunciaauthor=C.+Liuauthor=J.+Linauthor=J.+S.+Tokarskiauthor=J.+Strnadauthor=D.+Pedicordauthor=J.+Chenauthor=Y.+Blatauthor=A.+Zupa-Fernandezauthor=L.+Chengauthor=H.+Sunauthor=C.+Chaudhryauthor=C.+Huangauthor=C.+D%E2%80%99Arienzoauthor=J.+S.+Sackauthor=J.+K.+Muckelbauerauthor=C.+Changauthor=J.+Tredupauthor=D.+Xieauthor=N.+Aranibarauthor=J.+R.+Burkeauthor=P.+H.+Carterauthor=D.+S.+Weinstein&title=Identification+of+imidazo%5B1%2C2-b%5Dpyridazine+TYK2+pseudokinase+ligands+as+potent+and+selective+allosteric+inhibitors+of+TYK2+signalling&doi=10.1039%2FC6MD00560H"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of imidazo[1,2-b]pyridazine TYK2 pseudokinase ligands as potent and selective allosteric inhibitors of TYK2 signalling</span></div><div class="casAuthors">Moslin, R.; Gardner, D.; Santella, J.; Zhang, Y.; Duncia, J. V.; Liu, C.; Lin, J.; Tokarski, J. S.; Strnad, J.; Pedicord, D.; Chen, J.; Blat, Y.; Zupa-Fernandez, A.; Cheng, L.; Sun, H.; Chaudhry, C.; Huang, C.; D'Arienzo, C.; Sack, J. S.; Muckelbauer, J. K.; Chang, C.; Tredup, J.; Xie, D.; Aranibar, N.; Burke, J. R.; Carter, P. H.; Weinstein, D. S.</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">700-712</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">As a member of the Janus (JAK) family of non-receptor tyrosine kinases, TYK2 mediates the signaling of pro-inflammatory cytokines including IL-12, IL-23 and type 1 interferon (IFN), and therefore represents an attractive potential target for treating the various immuno-inflammatory diseases in which these cytokines have been shown to play a role.  Following up on our previous report that ligands to the pseudokinase domain (JH2) of TYK2 suppress cytokine-mediated receptor activation of the catalytic (JH1) domain, the imidazo[1,2-b]pyridazine (IZP) 7 was identified as a promising hit compd.  Through iterative modification of each of the substituents of the IZP scaffold, the cellular potency was improved while maintaining selectivity over the JH1 domain.  These studies led to the discovery of the JH2-selective TYK2 inhibitor 29, which provided encouraging systemic exposures after oral dosing in mice.  Phosphodiesterase 4 (PDE4) was identified as an off-target and potential liability of the IZP ligands, and selectivity for TYK2 JH2 over this enzyme was obtained by elaborating along selectivity vectors detd. from analyses of X-ray co-crystal structures of representative ligands of the IZP class bound to both proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobX5_XfvLHsLVg90H21EOLACvtfcHk0lh1gx7CXoQ4fA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVyru7jN&md5=67b06413866ee6096810903f62edd901</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1039%2FC6MD00560H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6MD00560H%26sid%3Dliteratum%253Aachs%26aulast%3DMoslin%26aufirst%3DR.%26aulast%3DGardner%26aufirst%3DD.%26aulast%3DSantella%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DDuncia%26aufirst%3DJ.%2BV.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DStrnad%26aufirst%3DJ.%26aulast%3DPedicord%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DBlat%26aufirst%3DY.%26aulast%3DZupa-Fernandez%26aufirst%3DA.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DChaudhry%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DC.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DMuckelbauer%26aufirst%3DJ.%2BK.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DTredup%26aufirst%3DJ.%26aulast%3DXie%26aufirst%3DD.%26aulast%3DAranibar%26aufirst%3DN.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DWeinstein%26aufirst%3DD.%2BS.%26atitle%3DIdentification%2520of%2520imidazo%255B1%252C2-b%255Dpyridazine%2520TYK2%2520pseudokinase%2520ligands%2520as%2520potent%2520and%2520selective%2520allosteric%2520inhibitors%2520of%2520TYK2%2520signalling%26jtitle%3DMedChemComm%26date%3D2017%26volume%3D8%26spage%3D700%26epage%3D712%26doi%3D10.1039%2FC6MD00560H" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sohn, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Abbema, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohli, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macleod, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurley, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulagowski, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewin-Koh, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dengler, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghilardi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blair, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnuson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L. C.</span></span> <span> </span><span class="NLM_article-title">A restricted role for TYK2 catalytic activity in human cytokine responses revealed by novel TYK2-selective inhibitors</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>191</i></span>,  <span class="NLM_fpage">2205</span>– <span class="NLM_lpage">2216</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1202859</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.4049%2Fjimmunol.1202859" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=23894201" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlSgtL%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2013&pages=2205-2216&author=S.+J.+Sohnauthor=K.+Barrettauthor=A.+Van+Abbemaauthor=C.+Changauthor=P.+B.+Kohliauthor=H.+Kandaauthor=J.+Smithauthor=Y.+Laiauthor=A.+Zhouauthor=B.+Zhangauthor=W.+Yangauthor=K.+Williamsauthor=C.+Macleodauthor=C.+A.+Hurleyauthor=J.+J.+Kulagowskiauthor=N.+Lewin-Kohauthor=H.+S.+Denglerauthor=A.+R.+Johnsonauthor=N.+Ghilardiauthor=M.+Zakauthor=J.+Liangauthor=W.+S.+Blairauthor=S.+Magnusonauthor=L.+C.+Wu&title=A+restricted+role+for+TYK2+catalytic+activity+in+human+cytokine+responses+revealed+by+novel+TYK2-selective+inhibitors&doi=10.4049%2Fjimmunol.1202859"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">A Restricted Role for TYK2 Catalytic Activity in Human Cytokine Responses Revealed by Novel TYK2-Selective Inhibitors</span></div><div class="casAuthors">Sohn, Sue J.; Barrett, Kathy; Van Abbema, Anne; Chang, Christine; Kohli, Pawan Bir; Kanda, Hidenobu; Smith, Janice; Lai, Yingjie; Zhou, Aihe; Zhang, Birong; Yang, Wenqian; Williams, Karen; MacLeod, Calum; Hurley, Christopher A.; Kulagowski, Janusz J.; Lewin-Koh, Nicholas; Dengler, Hart S.; Johnson, Adam R.; Ghilardi, Nico; Zak, Mark; Liang, Jun; Blair, Wade S.; Magnuson, Steven; Wu, Lawren C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">191</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2205-2216</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">TYK2 is a JAK family protein tyrosine kinase activated in response to multiple cytokines, including type I IFNs, IL-6, IL-10, IL-12, and IL-23.  Extensive studies of mice that lack TYK2 expression indicate that the IFN-α, IL-12, and IL-23 pathways, but not the IL-6 or IL-10 pathways, are compromised.  In contrast, there have been few studies of the role of TYK2 in primary human cells.  A genetic mutation at the tyk2 locus that results in a lack of TYK2 protein in a single human patient has been linked to defects in the IFN-α, IL-6, IL-10, IL-12, and IL-23 pathways, suggesting a broad role for TYK2 protein in human cytokine responses.  In this article, we have used a panel of novel potent TYK2 small-mol. inhibitors with varying degrees of selectivity against other JAK kinases to address the requirement for TYK2 catalytic activity in cytokine pathways in primary human cells.  Our results indicate that the biol. processes that require TYK2 catalytic function in humans are restricted to the IL-12 and IL-23 pathways, and suggest that inhibition of TYK2 catalytic activity may be an efficacious approach for the treatment of select autoimmune diseases without broad immunosuppression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgACYZYW8b07Vg90H21EOLACvtfcHk0lh1gx7CXoQ4fA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlSgtL%252FP&md5=527289e055e91fe2dfb15d3de7faa894</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1202859&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1202859%26sid%3Dliteratum%253Aachs%26aulast%3DSohn%26aufirst%3DS.%2BJ.%26aulast%3DBarrett%26aufirst%3DK.%26aulast%3DVan%2BAbbema%26aufirst%3DA.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DKohli%26aufirst%3DP.%2BB.%26aulast%3DKanda%26aufirst%3DH.%26aulast%3DSmith%26aufirst%3DJ.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DWilliams%26aufirst%3DK.%26aulast%3DMacleod%26aufirst%3DC.%26aulast%3DHurley%26aufirst%3DC.%2BA.%26aulast%3DKulagowski%26aufirst%3DJ.%2BJ.%26aulast%3DLewin-Koh%26aufirst%3DN.%26aulast%3DDengler%26aufirst%3DH.%2BS.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DZak%26aufirst%3DM.%26aulast%3DLiang%26aufirst%3DJ.%26aulast%3DBlair%26aufirst%3DW.%2BS.%26aulast%3DMagnuson%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DL.%2BC.%26atitle%3DA%2520restricted%2520role%2520for%2520TYK2%2520catalytic%2520activity%2520in%2520human%2520cytokine%2520responses%2520revealed%2520by%2520novel%2520TYK2-selective%2520inhibitors%26jtitle%3DJ.%2520Immunol.%26date%3D2013%26volume%3D191%26spage%3D2205%26epage%3D2216%26doi%3D10.4049%2Fjimmunol.1202859" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Menet, C. J.</span></span> <span> </span><span class="NLM_article-title">Toward selective TYK2 inhibitors as therapeutic agents for the treatment of inflammatory diseases</span>. <i>Pharm. Pat. Anal.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">449</span>– <span class="NLM_lpage">466</span>, <span class="refDoi"> DOI: 10.4155/ppa.14.23</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.4155%2Fppa.14.23" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=25291316" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslSkurjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2014&pages=449-466&author=C.+J.+Menet&title=Toward+selective+TYK2+inhibitors+as+therapeutic+agents+for+the+treatment+of+inflammatory+diseases&doi=10.4155%2Fppa.14.23"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Toward selective TYK2 inhibitors as therapeutic agents for the treatment of inflammatory diseases</span></div><div class="casAuthors">Menet, Christel J.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Patent Analyst</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">449-466</span>CODEN:
                <span class="NLM_cas:coden">PPAHCN</span>;
        ISSN:<span class="NLM_cas:issn">2046-8954</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">The family of JAK comprises four members and has received significant attention in recent years from the pharmaceutical industry as a therapeutic target.  The role of JAK is central to cytokine signaling pathways.  It is believed that selective modulation of one specific JAK can lead to the inhibition of a restricted set of cytokines, which should avoid undesired side effects and get closer to the profile of biol. therapies.  Consequently, selective JAK inhibition has become a major focus area of drug discovery research.  A review of the TYK2 patents indicates that industry attention has recently turned toward the development of specific inhibitors.  Importantly, despite the increasing no. of published patents, none of these drugs have yet made it to the clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcmMgH3Z8Ff7Vg90H21EOLACvtfcHk0lh1gx7CXoQ4fA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslSkurjF&md5=0a79df697117246c840c559260d8e7ba</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.4155%2Fppa.14.23&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Fppa.14.23%26sid%3Dliteratum%253Aachs%26aulast%3DMenet%26aufirst%3DC.%2BJ.%26atitle%3DToward%2520selective%2520TYK2%2520inhibitors%2520as%2520therapeutic%2520agents%2520for%2520the%2520treatment%2520of%2520inflammatory%2520diseases%26jtitle%3DPharm.%2520Pat.%2520Anal.%26date%3D2014%26volume%3D3%26spage%3D449%26epage%3D466%26doi%3D10.4155%2Fppa.14.23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Welsch, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holstein, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurence, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghoreschi, K.</span></span> <span> </span><span class="NLM_article-title">Targeting JAK/STAT signalling in inflammatory skin diseases with small molecule inhibitors</span>. <i>Eur. J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">1096</span>– <span class="NLM_lpage">1107</span>, <span class="refDoi"> DOI: 10.1002/eji.201646680</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1002%2Feji.201646680" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2017&pages=1096-1107&author=K.+Welschauthor=J.+Holsteinauthor=A.+Laurenceauthor=K.+Ghoreschi&title=Targeting+JAK%2FSTAT+signalling+in+inflammatory+skin+diseases+with+small+molecule+inhibitors&doi=10.1002%2Feji.201646680"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1002%2Feji.201646680&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Feji.201646680%26sid%3Dliteratum%253Aachs%26aulast%3DWelsch%26aufirst%3DK.%26aulast%3DHolstein%26aufirst%3DJ.%26aulast%3DLaurence%26aufirst%3DA.%26aulast%3DGhoreschi%26aufirst%3DK.%26atitle%3DTargeting%2520JAK%252FSTAT%2520signalling%2520in%2520inflammatory%2520skin%2520diseases%2520with%2520small%2520molecule%2520inhibitors%26jtitle%3DEur.%2520J.%2520Immunol.%26date%3D2017%26volume%3D47%26spage%3D1096%26epage%3D1107%26doi%3D10.1002%2Feji.201646680" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Farmer, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ledeboer, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoock, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnost, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bethiel, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennani, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brummel, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakilam, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorsch, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cochran, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrington, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogan, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laitinen, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahajan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marone, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Botella, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messersmith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namchuk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penney, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raybuck, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rugg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salituro, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saxena, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shannon, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shlyakter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swenson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, S.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Town, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wannamaker, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winquist, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuccola, H. J.</span></span> <span> </span><span class="NLM_article-title">Discovery of VX-509 (decernotinib): a potent and selective Janus kinase 3 inhibitor for the treatment of autoimmune diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">7195</span>– <span class="NLM_lpage">7216</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00301</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00301" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1KmsbbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=7195-7216&author=L.+J.+Farmerauthor=M.+W.+Ledeboerauthor=T.+Hoockauthor=M.+J.+Arnostauthor=R.+S.+Bethielauthor=Y.+L.+Bennaniauthor=J.+J.+Blackauthor=C.+L.+Brummelauthor=A.+Chakilamauthor=W.+A.+Dorschauthor=B.+Fanauthor=J.+E.+Cochranauthor=S.+Halasauthor=E.+M.+Harringtonauthor=J.+K.+Hoganauthor=D.+Howeauthor=H.+Huangauthor=D.+H.+Jacobsauthor=L.+M.+Laitinenauthor=S.+Liaoauthor=S.+Mahajanauthor=V.+Maroneauthor=G.+Martinez-Botellaauthor=P.+McCarthyauthor=D.+Messersmithauthor=M.+Namchukauthor=L.+Ohauthor=M.+S.+Penneyauthor=A.+C.+Pierceauthor=S.+A.+Raybuckauthor=A.+Ruggauthor=F.+G.+Salituroauthor=K.+Saxenaauthor=D.+Shannonauthor=D.+Shlyakterauthor=L.+Swensonauthor=S.-K.+Tianauthor=C.+Townauthor=J.+Wangauthor=T.+Wangauthor=M.+W.+Wannamakerauthor=R.+J.+Winquistauthor=H.+J.+Zuccola&title=Discovery+of+VX-509+%28decernotinib%29%3A+a+potent+and+selective+Janus+kinase+3+inhibitor+for+the+treatment+of+autoimmune+diseases&doi=10.1021%2Facs.jmedchem.5b00301"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases</span></div><div class="casAuthors">Farmer, Luc J.; Ledeboer, Mark W.; Hoock, Thomas; Arnost, Michael J.; Bethiel, Randy S.; Bennani, Youssef L.; Black, James J.; Brummel, Christopher L.; Chakilam, Ananthsrinivas; Dorsch, Warren A.; Fan, Bin; Cochran, John E.; Halas, Summer; Harrington, Edmund M.; Hogan, James K.; Howe, David; Huang, Hui; Jacobs, Dylan H.; Laitinen, Leena M.; Liao, Shengkai; Mahajan, Sudipta; Marone, Valerie; Martinez-Botella, Gabriel; McCarthy, Pamela; Messersmith, David; Namchuk, Mark; Oh, Luke; Penney, Marina S.; Pierce, Albert C.; Raybuck, Scott A.; Rugg, Arthur; Salituro, Francesco G.; Saxena, Kumkum; Shannon, Dean; Shlyakter, Dina; Swenson, Lora; Tian, Shi-Kai; Town, Christopher; Wang, Jian; Wang, Tiansheng; Wannamaker, M. Woods; Winquist, Raymond J.; Zuccola, Harmon J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7195-7216</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">While several therapeutic options exist, the need for more effective, safe, and convenient treatment for a variety of autoimmune diseases persists.  Targeting the Janus tyrosine kinases (JAKs), which play essential roles in cell signaling responses and can contribute to aberrant immune function assocd. with disease, has emerged as a novel and attractive approach for the development of new autoimmune disease therapies.  We screened our compd. library against JAK3, a key signaling kinase in immune cells, and identified multiple scaffolds showing good inhibitory activity for this kinase.  A particular scaffold of interest, the 1H-pyrrolo[2,3-b]pyridine series (7-azaindoles), was selected for further optimization in part on the basis of binding affinity (Ki) as well as on the basis of cellular potency.  Optimization of this chem. series led to the identification of VX-509 (decernotinib), a novel, potent, and selective JAK3 inhibitor, which demonstrates good efficacy in vivo in the rat host vs. graft model (HvG).  On the basis of these findings, it appears that VX-509 offers potential for the treatment of a variety of autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-CrqEc481PLVg90H21EOLACvtfcHk0liG8J2jqLZR7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1KmsbbO&md5=8ba1e0beb7570baaf68fd5f20b54f9f9</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00301%26sid%3Dliteratum%253Aachs%26aulast%3DFarmer%26aufirst%3DL.%2BJ.%26aulast%3DLedeboer%26aufirst%3DM.%2BW.%26aulast%3DHoock%26aufirst%3DT.%26aulast%3DArnost%26aufirst%3DM.%2BJ.%26aulast%3DBethiel%26aufirst%3DR.%2BS.%26aulast%3DBennani%26aufirst%3DY.%2BL.%26aulast%3DBlack%26aufirst%3DJ.%2BJ.%26aulast%3DBrummel%26aufirst%3DC.%2BL.%26aulast%3DChakilam%26aufirst%3DA.%26aulast%3DDorsch%26aufirst%3DW.%2BA.%26aulast%3DFan%26aufirst%3DB.%26aulast%3DCochran%26aufirst%3DJ.%2BE.%26aulast%3DHalas%26aufirst%3DS.%26aulast%3DHarrington%26aufirst%3DE.%2BM.%26aulast%3DHogan%26aufirst%3DJ.%2BK.%26aulast%3DHowe%26aufirst%3DD.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DJacobs%26aufirst%3DD.%2BH.%26aulast%3DLaitinen%26aufirst%3DL.%2BM.%26aulast%3DLiao%26aufirst%3DS.%26aulast%3DMahajan%26aufirst%3DS.%26aulast%3DMarone%26aufirst%3DV.%26aulast%3DMartinez-Botella%26aufirst%3DG.%26aulast%3DMcCarthy%26aufirst%3DP.%26aulast%3DMessersmith%26aufirst%3DD.%26aulast%3DNamchuk%26aufirst%3DM.%26aulast%3DOh%26aufirst%3DL.%26aulast%3DPenney%26aufirst%3DM.%2BS.%26aulast%3DPierce%26aufirst%3DA.%2BC.%26aulast%3DRaybuck%26aufirst%3DS.%2BA.%26aulast%3DRugg%26aufirst%3DA.%26aulast%3DSalituro%26aufirst%3DF.%2BG.%26aulast%3DSaxena%26aufirst%3DK.%26aulast%3DShannon%26aufirst%3DD.%26aulast%3DShlyakter%26aufirst%3DD.%26aulast%3DSwenson%26aufirst%3DL.%26aulast%3DTian%26aufirst%3DS.-K.%26aulast%3DTown%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DWannamaker%26aufirst%3DM.%2BW.%26aulast%3DWinquist%26aufirst%3DR.%2BJ.%26aulast%3DZuccola%26aufirst%3DH.%2BJ.%26atitle%3DDiscovery%2520of%2520VX-509%2520%2528decernotinib%2529%253A%2520a%2520potent%2520and%2520selective%2520Janus%2520kinase%25203%2520inhibitor%2520for%2520the%2520treatment%2520of%2520autoimmune%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D7195%26epage%3D7216%26doi%3D10.1021%2Facs.jmedchem.5b00301" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thorarensen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banker, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fensome, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juba, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czerwinski, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casimiro-Garcia, A.</span></span> <span> </span><span class="NLM_article-title">ATP-mediated kinome selectivity: the missing link in understanding the contribution of individual JAK kinase isoforms to cellular signaling</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1552</span>– <span class="NLM_lpage">1558</span>, <span class="refDoi"> DOI: 10.1021/cb5002125</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb5002125" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnslart7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1552-1558&author=A.+Thorarensenauthor=M.+E.+Bankerauthor=A.+Fensomeauthor=J.-B.+Telliezauthor=B.+Jubaauthor=F.+Vincentauthor=R.+M.+Czerwinskiauthor=A.+Casimiro-Garcia&title=ATP-mediated+kinome+selectivity%3A+the+missing+link+in+understanding+the+contribution+of+individual+JAK+kinase+isoforms+to+cellular+signaling&doi=10.1021%2Fcb5002125"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">ATP-Mediated Kinome Selectivity: The Missing Link in Understanding the Contribution of Individual JAK Kinase Isoforms to Cellular Signaling</span></div><div class="casAuthors">Thorarensen, Atli; Banker, Mary Ellen; Fensome, Andrew; Telliez, Jean-Baptiste; Juba, Brian; Vincent, Fabien; Czerwinski, Robert M.; Casimiro-Garcia, Agustin</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1552-1558</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Kinases constitute an important class of therapeutic targets being explored both by academia and the pharmaceutical industry.  The major focus of this effort was directed toward the identification of ATP competitive inhibitors.  Although it has long been recognized that the intracellular concn. of ATP is very different from the concns. utilized in biochem. enzyme assays, little thought has been devoted to incorporating this discrepancy into our understanding of translation from enzyme inhibition to cellular function.  Significant work has been dedicated to the discovery of JAK kinase inhibitors; however, a disconnect between enzyme and cellular function is prominently displayed in the literature for this class of inhibitors.  Herein, we demonstrate utilizing the four JAK family members (JAK1, JAK2, JAK3, and TYK2) that the difference in the ATP Km of each individual kinase has a significant impact on the enzyme to cell inhibition translation.  We evaluated a large no. of JAK inhibitors in enzymic assays utilizing either 1 mM ATP or Km ATP for the four isoforms as well as in primary cell assays.  This data set provided the opportunity to examine individual kinase contributions to the heterodimeric kinase complexes mediating cellular signaling.  In contrast to a recent study, we demonstrate that for IL-15 cytokine signaling it is sufficient to inhibit either JAK1 or JAK3 to fully inhibit downstream STAT5 phosphorylation.  This addnl. data thus provides a crit. piece of information explaining why JAK1 has incorrectly been thought to have a dominant role over JAK3.  Beyond enabling a deeper understanding of JAK signaling, conducting similar analyses for other kinases by taking into account potency at high ATP rather than Km ATP may provide crucial insights into a compd.'s activity and selectivity in cellular contexts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYiMVl7OpPFLVg90H21EOLACvtfcHk0liG8J2jqLZR7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnslart7s%253D&md5=c87874cb1748e13eef2aa241ecef3e79</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fcb5002125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb5002125%26sid%3Dliteratum%253Aachs%26aulast%3DThorarensen%26aufirst%3DA.%26aulast%3DBanker%26aufirst%3DM.%2BE.%26aulast%3DFensome%26aufirst%3DA.%26aulast%3DTelliez%26aufirst%3DJ.-B.%26aulast%3DJuba%26aufirst%3DB.%26aulast%3DVincent%26aufirst%3DF.%26aulast%3DCzerwinski%26aufirst%3DR.%2BM.%26aulast%3DCasimiro-Garcia%26aufirst%3DA.%26atitle%3DATP-mediated%2520kinome%2520selectivity%253A%2520the%2520missing%2520link%2520in%2520understanding%2520the%2520contribution%2520of%2520individual%2520JAK%2520kinase%2520isoforms%2520to%2520cellular%2520signaling%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2014%26volume%3D9%26spage%3D1552%26epage%3D1558%26doi%3D10.1021%2Fcb5002125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Genovese, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Østergaard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinnman, N.</span></span> <span> </span><span class="NLM_article-title">Efficacy of VX-509 (decernotinib) in combination with a disease-modifying antirheumatic drug in patients with rheumatoid arthritis: clinical and MRI findings</span>. <i>Ann. Rheum. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">1979</span>– <span class="NLM_lpage">1983</span>, <span class="refDoi"> DOI: 10.1136/annrheumdis-2015-208901</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1136%2Fannrheumdis-2015-208901" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=27084959" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFahs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2016&pages=1979-1983&author=M.+C.+Genoveseauthor=F.+Yangauthor=M.+%C3%98stergaardauthor=N.+Kinnman&title=Efficacy+of+VX-509+%28decernotinib%29+in+combination+with+a+disease-modifying+antirheumatic+drug+in+patients+with+rheumatoid+arthritis%3A+clinical+and+MRI+findings&doi=10.1136%2Fannrheumdis-2015-208901"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of VX-509 (decernotinib) in combination with a disease-modifying antirheumatic drug in patients with rheumatoid arthritis: clinical and MRI findings</span></div><div class="casAuthors">Genovese, Mark C.; Yang, Fang; Oestergaard, Mikkel; Kinnman, Nils</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the Rheumatic Diseases</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1979-1983</span>CODEN:
                <span class="NLM_cas:coden">ARDIAO</span>;
        ISSN:<span class="NLM_cas:issn">0003-4967</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Objective: To assess early effects on joint structures of VX-509 in combination with stable disease-modifying antirheumatic drug (DMARD) therapy using MRI in adults with rheumatoid arthritis (RA).  Methods: This phase II, placebo-controlled, double blind, dose-ranging study randomised patients with RA and inadequate DMARD response to VX-509 100 mg (n=11), 200 mg (n=10) or 300 mg (n=10) or placebo (n=12) once daily for 12 wk.  Outcome measures included American College of Rheumatol. score (ACR20; improvement of ≥20% ) and disease activity score (DAS28) using C reactive protein (CRP), and the RA MRI scoring (RAMRIS) system.  Results: ACR20 response at week 12 was 63.6%, 60.0% and 60.0% in the VX-509 100-mg, 200-mg and 300-mg groups, resp., compared with 25.0% in the placebo group.  DAS28-CRP scores decreased in a dose-dependent manner with increasing VX-509 doses.  Decreases in RAMRIS synovitis scores were significantly different from placebo for all VX-509 doses ( p<0.01) and for RAMRIS osteitis scores ( p<0.01) for VX-509 300 mg.  Treatment was generally well tolerated.  Conclusions: VX-509 plus a DMARD reduced the signs and symptoms of RA in patients with an inadequate response to a DMARD alone.  MRI responses were detected at week 12.  Treatment was generally well tolerated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgpFXc2bfqZLVg90H21EOLACvtfcHk0lgaHjfFmJWcxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFahs7c%253D&md5=b88684b8a805901d4836d3c8d7cce219</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1136%2Fannrheumdis-2015-208901&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fannrheumdis-2015-208901%26sid%3Dliteratum%253Aachs%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26aulast%3DYang%26aufirst%3DF.%26aulast%3D%25C3%2598stergaard%26aufirst%3DM.%26aulast%3DKinnman%26aufirst%3DN.%26atitle%3DEfficacy%2520of%2520VX-509%2520%2528decernotinib%2529%2520in%2520combination%2520with%2520a%2520disease-modifying%2520antirheumatic%2520drug%2520in%2520patients%2520with%2520rheumatoid%2520arthritis%253A%2520clinical%2520and%2520MRI%2520findings%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2016%26volume%3D75%26spage%3D1979%26epage%3D1983%26doi%3D10.1136%2Fannrheumdis-2015-208901" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Menet, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Lommen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geney, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanc, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smits, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jouannigot, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deprez, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Aar, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clement-Lacroix, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lepescheux, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galien, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vayssiere, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelles, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christophe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brys, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uhring, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciesielski, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Rompaey, L.</span></span> <span> </span><span class="NLM_article-title">Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">9323</span>– <span class="NLM_lpage">9342</span>, <span class="refDoi"> DOI: 10.1021/jm501262q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501262q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVGls7nN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=9323-9342&author=C.+J.+Menetauthor=S.+R.+Fletcherauthor=G.+Van+Lommenauthor=R.+Geneyauthor=J.+Blancauthor=K.+Smitsauthor=N.+Jouannigotauthor=P.+Deprezauthor=E.+M.+van+der%0AAarauthor=P.+Clement-Lacroixauthor=L.+Lepescheuxauthor=R.+Galienauthor=B.+Vayssiereauthor=L.+Nellesauthor=T.+Christopheauthor=R.+Brysauthor=M.+Uhringauthor=F.+Ciesielskiauthor=L.+Van+Rompaey&title=Triazolopyridines+as+selective+JAK1+inhibitors%3A+from+hit+identification+to+GLPG0634&doi=10.1021%2Fjm501262q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Triazolopyridines as Selective JAK1 Inhibitors: From Hit Identification to GLPG0634</span></div><div class="casAuthors">Menet, Christel J.; Fletcher, Stephen R.; Van Lommen, Guy; Geney, Raphael; Blanc, Javier; Smits, Koen; Jouannigot, Nolwenn; Deprez, Pierre; van der Aar, Ellen M.; Clement-Lacroix, Philippe; Lepescheux, Lien; Galien, Rene; Vayssiere, Beatrice; Nelles, Luc; Christophe, Thierry; Brys, Reginald; Uhring, Muriel; Ciesielski, Fabrice; Van Rompaey, Luc</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9323-9342</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Janus kinases (JAK1, JAK2, JAK3, and TYK2) are involved in the signaling of multiple cytokines important in cellular function.  Blockade of the JAK-STAT pathway with a small mol. has been shown to provide therapeutic immunomodulation.  Having identified JAK1 as a possible new target for arthritis at Galapagos, the compd. library was screened against JAK1, resulting in the identification of a triazolopyridine-based series of inhibitors represented by I.  Optimization within this chem. series led to identification of II (GLPG0634, filgotinib), a selective JAK1 inhibitor currently in phase 2B development for RA and phase 2A development for Crohn's disease (CD).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBHELw4zQ5QLVg90H21EOLACvtfcHk0lgaHjfFmJWcxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVGls7nN&md5=756f687dc30e6fd34004deb672fe8b23</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fjm501262q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501262q%26sid%3Dliteratum%253Aachs%26aulast%3DMenet%26aufirst%3DC.%2BJ.%26aulast%3DFletcher%26aufirst%3DS.%2BR.%26aulast%3DVan%2BLommen%26aufirst%3DG.%26aulast%3DGeney%26aufirst%3DR.%26aulast%3DBlanc%26aufirst%3DJ.%26aulast%3DSmits%26aufirst%3DK.%26aulast%3DJouannigot%26aufirst%3DN.%26aulast%3DDeprez%26aufirst%3DP.%26aulast%3Dvan%2Bder%2BAar%26aufirst%3DE.%2BM.%26aulast%3DClement-Lacroix%26aufirst%3DP.%26aulast%3DLepescheux%26aufirst%3DL.%26aulast%3DGalien%26aufirst%3DR.%26aulast%3DVayssiere%26aufirst%3DB.%26aulast%3DNelles%26aufirst%3DL.%26aulast%3DChristophe%26aufirst%3DT.%26aulast%3DBrys%26aufirst%3DR.%26aulast%3DUhring%26aufirst%3DM.%26aulast%3DCiesielski%26aufirst%3DF.%26aulast%3DVan%2BRompaey%26aufirst%3DL.%26atitle%3DTriazolopyridines%2520as%2520selective%2520JAK1%2520inhibitors%253A%2520from%2520hit%2520identification%2520to%2520GLPG0634%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D9323%26epage%3D9342%26doi%3D10.1021%2Fjm501262q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu-Farseeva, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, L.</span></span> <span> </span><span class="NLM_article-title">Selective JAK inhibitors</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1439</span>– <span class="NLM_lpage">1471</span>, <span class="refDoi"> DOI: 10.4155/fmc.14.92</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.4155%2Ffmc.14.92" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=25329199" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslOhu7jI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=1439-1471&author=B.+W.+Dymockauthor=E.+G.+Yangauthor=Y.+Chu-Farseevaauthor=L.+Yao&title=Selective+JAK+inhibitors&doi=10.4155%2Ffmc.14.92"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Selective JAK inhibitors</span></div><div class="casAuthors">Dymock, Brian W.; Yang, Eugene Guorong; Chu-Farseeva, Yuyi; Yao, Lianbin</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1439-1471</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Consisting of four members, JAK1, JAK2, JAK3 and TYK2, the JAK kinases have emerged as important targets for proliferative and immune-inflammatory disorders.  Recent progress in the discovery of selective inhibitors has been significant, with selective compds. now reported for each isoform.  This article summarizes the current state-of-the-art with a discussion of the most recently described selective compds.  X-ray co-crystal structures reveal the mol. reasons for the obsd. biochem. selectivity.  A concluding anal. of JAK inhibitors in the clinic highlights increased clin. trial activity and diversity of indications.  Selective JAK inhibitors, as single agents or in combination regimens, have a very promising future in the treatment of oncol., immune and inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6G9eFT7Ww27Vg90H21EOLACvtfcHk0lgaHjfFmJWcxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslOhu7jI&md5=343aa75228918e6e4e063adb1fed96f1</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.4155%2Ffmc.14.92&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.14.92%26sid%3Dliteratum%253Aachs%26aulast%3DDymock%26aufirst%3DB.%2BW.%26aulast%3DYang%26aufirst%3DE.%2BG.%26aulast%3DChu-Farseeva%26aufirst%3DY.%26aulast%3DYao%26aufirst%3DL.%26atitle%3DSelective%2520JAK%2520inhibitors%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2014%26volume%3D6%26spage%3D1439%26epage%3D1471%26doi%3D10.4155%2Ffmc.14.92" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Namour, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diderichsen, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vayssière, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der Aa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tasset, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van’t Klooster, G.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics and pharmacokinetic/pharmacodynamic modeling of filgotinib (GLPG0634), a selective JAK1 inhibitor, in support of phase IIB dose selection</span>. <i>Clin. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">859</span>– <span class="NLM_lpage">874</span>, <span class="refDoi"> DOI: 10.1007/s40262-015-0240-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1007%2Fs40262-015-0240-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=25681059" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2MXivFWktro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2015&pages=859-874&author=F.+Namourauthor=P.+M.+Diderichsenauthor=E.+Coxauthor=B.+Vayssi%C3%A8reauthor=A.+Van+der+Aaauthor=C.+Tassetauthor=G.+Van%E2%80%99t+Klooster&title=Pharmacokinetics+and+pharmacokinetic%2Fpharmacodynamic+modeling+of+filgotinib+%28GLPG0634%29%2C+a+selective+JAK1+inhibitor%2C+in+support+of+phase+IIB+dose+selection&doi=10.1007%2Fs40262-015-0240-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection</span></div><div class="casAuthors">Namour, Florence; Diderichsen, Paul Matthias; Cox, Eugene; Vayssiere, Beatrice; Van der Aa, Annegret; Tasset, Chantal; Van't Klooster, Gerben</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">859-874</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Background and Objectives: Filgotinib (GLPG0634) is a selective inhibitor of Janus kinase 1 (JAK1) currently in development for the treatment of rheumatoid arthritis and Crohn's disease.  While less selective JAK inhibitors have shown long-term efficacy in treating inflammatory conditions, this was accompanied by dose-limiting side effects.  Here, we describe the pharmacokinetics of filgotinib and its active metabolite in healthy volunteers and the use of pharmacokinetic-pharmacodynamic modeling and simulation to support dose selection for phase IIB in patients with rheumatoid arthritis.  Methods: Two trials were conducted in healthy male volunteers.  In the first trial, filgotinib was administered as single doses from 10 mg up to multiple daily doses of 200 mg.  In the second trial, daily doses of 300 and 450 mg for 10 days were evaluated.  Non-compartmental anal. was used to det. individual pharmacokinetic parameters for filgotinib and its metabolite.  The overall pharmacodynamic activity for the two moieties was assessed in whole blood using interleukin-6-induced phosphorylation of signal-transducer and activator of transcription 1 as a biomarker for JAK1 activity.  These data were used to conduct non-linear mixed-effects modeling to investigate a pharmacokinetic/pharmacodynamic relationship.  Results: Modeling and simulation on the basis of early clin. data suggest that the pharmacokinetics of filgotinib are dose proportional up to 200 mg, in agreement with obsd. data, and support that both filgotinib and its metabolite contribute to its pharmacodynamic effects.  Simulation of biomarker response supports that the max. pharmacodynamic effect is reached at a daily dose of 200 mg filgotinib.  Conclusion: Based on these results, a daily dose range up to 200 mg has been selected for phase IIB dose-finding studies in patients with rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqa_k98wV2QwLVg90H21EOLACvtfcHk0lgTXNjAetjpqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXivFWktro%253D&md5=fe06dc0e772239f0493601364273857f</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1007%2Fs40262-015-0240-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40262-015-0240-z%26sid%3Dliteratum%253Aachs%26aulast%3DNamour%26aufirst%3DF.%26aulast%3DDiderichsen%26aufirst%3DP.%2BM.%26aulast%3DCox%26aufirst%3DE.%26aulast%3DVayssi%25C3%25A8re%26aufirst%3DB.%26aulast%3DVan%2Bder%2BAa%26aufirst%3DA.%26aulast%3DTasset%26aufirst%3DC.%26aulast%3DVan%25E2%2580%2599t%2BKlooster%26aufirst%3DG.%26atitle%3DPharmacokinetics%2520and%2520pharmacokinetic%252Fpharmacodynamic%2520modeling%2520of%2520filgotinib%2520%2528GLPG0634%2529%252C%2520a%2520selective%2520JAK1%2520inhibitor%252C%2520in%2520support%2520of%2520phase%2520IIB%2520dose%2520selection%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2015%26volume%3D54%26spage%3D859%26epage%3D874%26doi%3D10.1007%2Fs40262-015-0240-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vanhoutte, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazur, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voloshyn, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanislavchuk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der Aa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namour, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galien, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meuleners, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van’t Klooster, G.</span></span> <span> </span><span class="NLM_article-title">Efficacy, safety, pharmacokinetics, and pharmacodynamics of filgotinib, a selective Janus kinase 1 inhibitor, after short-term treatment of rheumatoid arthritis: Results of two randomized Phase IIA trials</span>. <i>Arthritis Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">1949</span>– <span class="NLM_lpage">1959</span>, <span class="refDoi"> DOI: 10.1002/art.40186</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1002%2Fart.40186" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=28622463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFyrurjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2017&pages=1949-1959&author=F.+Vanhoutteauthor=M.+Mazurauthor=O.+Voloshynauthor=M.+Stanislavchukauthor=A.+Van+der+Aaauthor=F.+Namourauthor=R.+Galienauthor=L.+Meulenersauthor=G.+van%E2%80%99t+Klooster&title=Efficacy%2C+safety%2C+pharmacokinetics%2C+and+pharmacodynamics+of+filgotinib%2C+a+selective+Janus+kinase+1+inhibitor%2C+after+short-term+treatment+of+rheumatoid+arthritis%3A+Results+of+two+randomized+Phase+IIA+trials&doi=10.1002%2Fart.40186"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK-1 Inhibitor, After Short-Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials</span></div><div class="casAuthors">Vanhoutte, Frederic; Mazur, Minodora; Voloshyn, Oleksandr; Stanislavchuk, Mykola; Van der Aa, Annegret; Namour, Florence; Galien, Rene; Meuleners, Luc; van 't Klooster, Gerben</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1949-1959</span>CODEN:
                <span class="NLM_cas:coden">ARRHBO</span>;
        ISSN:<span class="NLM_cas:issn">2326-5191</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective : JAK inhibitors have shown efficacy in rheumatoid arthritis (RA).  We undertook this study to test our hypothesis that selective inhibition of JAK-1 would combine good efficacy with a better safety profile compared with less selective JAK inhibitors.  Methods : In two 4-wk exploratory, double-blind, placebo-controlled phase IIa trials, 127 RA patients with an insufficient response to methotrexate (MTX) received filgotinib (GLPG0634, GS-6034) oral capsules (100 mg twice daily or 30, 75, 150, 200, or 300 mg once daily) or placebo, added onto a stable regimen of MTX, to evaluate safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of filgotinib.  The primary efficacy end point was the no. and percentage of patients in each treatment group meeting the American College of Rheumatol. 20% improvement criteria (achieving an ACR20 response) at week 4.  Results : Treatment with filgotinib at 75-300 mg met the primary end point and showed early onset of efficacy.  ACR20 response rates progressively increased to week 4, and the Disease Activity Score in 28 joints using the C-reactive protein (CRP) level decreased.  Marked and sustained improvements were obsd. in serum CRP level and other PD markers.  The PK of filgotinib and its major metabolite was dose proportional over the 30-300 mg range.  Early side effects seen with other less selective JAK inhibitors were not obsd. (e.g., there was no worsening of anemia [JAK-2 inhibition related], no effects on liver transaminases, and no increase in low-d. lipoprotein or total cholesterol).  A limited decrease in neutrophils without neutropenia was consistent with immunomodulatory effects through JAK-1 inhibition.  There were no infections.  Overall, filgotinib was well tolerated.  Events related to study drug were mild or moderate and transient during therapy, and the most common such event was nausea.  Conclusion : Selective inhibition of JAK-1 with filgotinib shows initial efficacy in RA with an encouraging safety profile in these exploratory studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7oTo2cM5so7Vg90H21EOLACvtfcHk0lgTXNjAetjpqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFyrurjP&md5=b704bd2b69231f1aa95815120b8cf922</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1002%2Fart.40186&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.40186%26sid%3Dliteratum%253Aachs%26aulast%3DVanhoutte%26aufirst%3DF.%26aulast%3DMazur%26aufirst%3DM.%26aulast%3DVoloshyn%26aufirst%3DO.%26aulast%3DStanislavchuk%26aufirst%3DM.%26aulast%3DVan%2Bder%2BAa%26aufirst%3DA.%26aulast%3DNamour%26aufirst%3DF.%26aulast%3DGalien%26aufirst%3DR.%26aulast%3DMeuleners%26aufirst%3DL.%26aulast%3Dvan%25E2%2580%2599t%2BKlooster%26aufirst%3DG.%26atitle%3DEfficacy%252C%2520safety%252C%2520pharmacokinetics%252C%2520and%2520pharmacodynamics%2520of%2520filgotinib%252C%2520a%2520selective%2520Janus%2520kinase%25201%2520inhibitor%252C%2520after%2520short-term%2520treatment%2520of%2520rheumatoid%2520arthritis%253A%2520Results%2520of%2520two%2520randomized%2520Phase%2520IIA%2520trials%26jtitle%3DArthritis%2520Rheumatol.%26date%3D2017%26volume%3D69%26spage%3D1949%26epage%3D1959%26doi%3D10.1002%2Fart.40186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mascarenhas, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talpaz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foltz, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savona, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paquette, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coughlin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winton, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burn, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Assad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verstovsek, S.</span></span> <span> </span><span class="NLM_article-title">Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis</span>. <i>Haematologica</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">327</span>– <span class="NLM_lpage">335</span>, <span class="refDoi"> DOI: 10.3324/haematol.2016.151126</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.3324%2Fhaematol.2016.151126" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2017&pages=327-335&author=J.+O.+Mascarenhasauthor=M.+Talpazauthor=V.+Guptaauthor=L.+M.+Foltzauthor=M.+R.+Savonaauthor=R.+Paquetteauthor=A.+R.+Turnerauthor=P.+Coughlinauthor=E.+Wintonauthor=T.+C.+Burnauthor=P.+O%E2%80%99Neillauthor=J.+Clarkauthor=D.+Hunterauthor=A.+Assadauthor=R.+Hoffmanauthor=S.+Verstovsek&title=Primary+analysis+of+a+phase+II+open-label+trial+of+INCB039110%2C+a+selective+JAK1+inhibitor%2C+in+patients+with+myelofibrosis&doi=10.3324%2Fhaematol.2016.151126"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.3324%2Fhaematol.2016.151126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3324%252Fhaematol.2016.151126%26sid%3Dliteratum%253Aachs%26aulast%3DMascarenhas%26aufirst%3DJ.%2BO.%26aulast%3DTalpaz%26aufirst%3DM.%26aulast%3DGupta%26aufirst%3DV.%26aulast%3DFoltz%26aufirst%3DL.%2BM.%26aulast%3DSavona%26aufirst%3DM.%2BR.%26aulast%3DPaquette%26aufirst%3DR.%26aulast%3DTurner%26aufirst%3DA.%2BR.%26aulast%3DCoughlin%26aufirst%3DP.%26aulast%3DWinton%26aufirst%3DE.%26aulast%3DBurn%26aufirst%3DT.%2BC.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DP.%26aulast%3DClark%26aufirst%3DJ.%26aulast%3DHunter%26aufirst%3DD.%26aulast%3DAssad%26aufirst%3DA.%26aulast%3DHoffman%26aufirst%3DR.%26aulast%3DVerstovsek%26aufirst%3DS.%26atitle%3DPrimary%2520analysis%2520of%2520a%2520phase%2520II%2520open-label%2520trial%2520of%2520INCB039110%252C%2520a%2520selective%2520JAK1%2520inhibitor%252C%2520in%2520patients%2520with%2520myelofibrosis%26jtitle%3DHaematologica%26date%3D2017%26volume%3D102%26spage%3D327%26epage%3D335%26doi%3D10.3324%2Fhaematol.2016.151126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmieder, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Draelos, Z. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pariser, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banfield, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kieras, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parsons-Rich, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salganik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peeva, E.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: phase II, randomized, double-blind, placebo-controlled study</span>. <i>Br. J. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>, <span class="refDoi"> DOI: 10.1111/bjd.16004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1111%2Fbjd.16004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=28949012" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=G.+J.+Schmiederauthor=Z.+D.+Draelosauthor=D.+M.+Pariserauthor=C.+Banfieldauthor=L.+Coxauthor=M.+Hodgeauthor=E.+Kierasauthor=D.+Parsons-Richauthor=S.+Menonauthor=M.+Salganikauthor=K.+Pageauthor=E.+Peeva&title=Efficacy+and+safety+of+the+Janus+kinase+1+inhibitor+PF-04965842+in+patients+with+moderate-to-severe+psoriasis%3A+phase+II%2C+randomized%2C+double-blind%2C+placebo-controlled+study&doi=10.1111%2Fbjd.16004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1111%2Fbjd.16004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjd.16004%26sid%3Dliteratum%253Aachs%26aulast%3DSchmieder%26aufirst%3DG.%2BJ.%26aulast%3DDraelos%26aufirst%3DZ.%2BD.%26aulast%3DPariser%26aufirst%3DD.%2BM.%26aulast%3DBanfield%26aufirst%3DC.%26aulast%3DCox%26aufirst%3DL.%26aulast%3DHodge%26aufirst%3DM.%26aulast%3DKieras%26aufirst%3DE.%26aulast%3DParsons-Rich%26aufirst%3DD.%26aulast%3DMenon%26aufirst%3DS.%26aulast%3DSalganik%26aufirst%3DM.%26aulast%3DPage%26aufirst%3DK.%26aulast%3DPeeva%26aufirst%3DE.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520the%2520Janus%2520kinase%25201%2520inhibitor%2520PF-04965842%2520in%2520patients%2520with%2520moderate-to-severe%2520psoriasis%253A%2520phase%2520II%252C%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520study%26jtitle%3DBr.%2520J.%2520Dermatol.%26date%3D2018%26doi%3D10.1111%2Fbjd.16004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kettle, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Åstrand, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimster, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woessner, R.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of JAK-family kinases: an update on the patent literature 2013–2015, Part 2</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">145</span>– <span class="NLM_lpage">161</span>, <span class="refDoi"> DOI: 10.1080/13543776.2017.1252754</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1080%2F13543776.2017.1252754" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=27774822" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhsl2htrnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=145-161&author=J.+G.+Kettleauthor=A.+%C3%85strandauthor=M.+Catleyauthor=N.+P.+Grimsterauthor=M.+Nilssonauthor=Q.+Suauthor=R.+Woessner&title=Inhibitors+of+JAK-family+kinases%3A+an+update+on+the+patent+literature+2013%E2%80%932015%2C+Part+2&doi=10.1080%2F13543776.2017.1252754"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2</span></div><div class="casAuthors">Kettle, Jason G.; Astrand, Annika; Catley, Matthew; Grimster, Neil P.; Nilsson, Magnus; Su, Qibin; Woessner, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">145-161</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Janus kinases (JAKs) are a family of four enzymes; JAK1, JAK2, JAK3 and tyrosine kinase 2 (TYK2) that are crit. in cytokine signalling and are strongly linked to both cancer and inflammatory diseases.  There are currently two launched JAK inhibitors for the treatment of human conditions: tofacitinib for Rheumatoid arthritis (RA) and ruxolitinib for myeloproliferative neoplasms including intermediate or high risk myelofibrosis and polycythemia vera.  This review covers patents claiming activity against one or more JAK family members in the period 2013-2015 inclusive, and covers 95 patents from 42 applicants, split over two parts.  The authors have ordered recent patents according to the primary applicant's name, with part 2 covering J through Z.  Inhibition of JAK-family kinases is an area of growing interest, catalyzed by the maturity of data on marketed inhibitors ruxolitinib and tofacitinib in late stage clin. trials.  Many applicants are pursuing traditional fast-follower strategies around these inhibitors, with a range of chem. strategies adopted.  The challenge will be to show sufficient differentiation to the originator compds., since dose limiting toxicities with such agents appear to be on target and mechanism-related and also considering that such agents may be available as generic compds. by the time follower agents reach market.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3xWVX0ADy67Vg90H21EOLACvtfcHk0li9-pWrhMSkXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhsl2htrnI&md5=c75e5d123fd35306665e0713f801320c</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1080%2F13543776.2017.1252754&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2017.1252754%26sid%3Dliteratum%253Aachs%26aulast%3DKettle%26aufirst%3DJ.%2BG.%26aulast%3D%25C3%2585strand%26aufirst%3DA.%26aulast%3DCatley%26aufirst%3DM.%26aulast%3DGrimster%26aufirst%3DN.%2BP.%26aulast%3DNilsson%26aufirst%3DM.%26aulast%3DSu%26aufirst%3DQ.%26aulast%3DWoessner%26aufirst%3DR.%26atitle%3DInhibitors%2520of%2520JAK-family%2520kinases%253A%2520an%2520update%2520on%2520the%2520patent%2520literature%25202013%25E2%2580%25932015%252C%2520Part%25202%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2017%26volume%3D27%26spage%3D145%26epage%3D161%26doi%3D10.1080%2F13543776.2017.1252754" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storer, R. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabnis, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakenhut, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitlock, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">England, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukaiyama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dehnhardt, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coe, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kortum, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chrencik, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeoh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilty, I.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of a pan-Janus kinase inhibitor clinical candidate (PF-06263276) suitable for inhaled and topical delivery for the treatment of inflammatory diseases of the lungs and skin</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">767</span>– <span class="NLM_lpage">786</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01634</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01634" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFSnsr3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=767-786&author=P.+Jonesauthor=R.+I.+Storerauthor=Y.+A.+Sabnisauthor=F.+M.+Wakenhutauthor=G.+A.+Whitlockauthor=K.+S.+Englandauthor=T.+Mukaiyamaauthor=C.+M.+Dehnhardtauthor=J.+W.+Coeauthor=S.+W.+Kortumauthor=J.+E.+Chrencikauthor=D.+G.+Brownauthor=R.+M.+Jonesauthor=J.+R.+Murphyauthor=T.+Yeohauthor=P.+Morganauthor=I.+Kilty&title=Design+and+synthesis+of+a+pan-Janus+kinase+inhibitor+clinical+candidate+%28PF-06263276%29+suitable+for+inhaled+and+topical+delivery+for+the+treatment+of+inflammatory+diseases+of+the+lungs+and+skin&doi=10.1021%2Facs.jmedchem.6b01634"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of a Pan-Janus Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin</span></div><div class="casAuthors">Jones, Peter; Storer, R. Ian; Sabnis, Yogesh A.; Wakenhut, Florian M.; Whitlock, Gavin A.; England, Katherine S.; Mukaiyama, Takasuke; Dehnhardt, Christoph M.; Coe, Jotham W.; Kortum, Steve W.; Chrencik, Jill E.; Brown, David G.; Jones, Rhys M.; Murphy, John R.; Yeoh, Thean; Morgan, Paul; Kilty, Iain</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">767-786</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Using a structure-based computational method for identification of structurally novel JAK inhibitors predicted to bind beyond the ATP binding site, a potent series of indazoles was identified as selective pan-JAK inhibitors with a type 1.5 binding mode.  Optimization of the series for potency and increased duration of action commensurate with inhaled or topical delivery resulted in PF-06263276 which was advanced into clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEt2oMBlGsBbVg90H21EOLACvtfcHk0li9-pWrhMSkXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFSnsr3J&md5=a69247c21ff53a3b7d9c63cf0af72101</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01634%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DP.%26aulast%3DStorer%26aufirst%3DR.%2BI.%26aulast%3DSabnis%26aufirst%3DY.%2BA.%26aulast%3DWakenhut%26aufirst%3DF.%2BM.%26aulast%3DWhitlock%26aufirst%3DG.%2BA.%26aulast%3DEngland%26aufirst%3DK.%2BS.%26aulast%3DMukaiyama%26aufirst%3DT.%26aulast%3DDehnhardt%26aufirst%3DC.%2BM.%26aulast%3DCoe%26aufirst%3DJ.%2BW.%26aulast%3DKortum%26aufirst%3DS.%2BW.%26aulast%3DChrencik%26aufirst%3DJ.%2BE.%26aulast%3DBrown%26aufirst%3DD.%2BG.%26aulast%3DJones%26aufirst%3DR.%2BM.%26aulast%3DMurphy%26aufirst%3DJ.%2BR.%26aulast%3DYeoh%26aufirst%3DT.%26aulast%3DMorgan%26aufirst%3DP.%26aulast%3DKilty%26aufirst%3DI.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520a%2520pan-Janus%2520kinase%2520inhibitor%2520clinical%2520candidate%2520%2528PF-06263276%2529%2520suitable%2520for%2520inhaled%2520and%2520topical%2520delivery%2520for%2520the%2520treatment%2520of%2520inflammatory%2520diseases%2520of%2520the%2520lungs%2520and%2520skin%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D767%26epage%3D786%26doi%3D10.1021%2Facs.jmedchem.6b01634" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Elwood, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witter, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piesvaux, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraybill, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bays, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alpert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldenblatt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivanovska, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, C.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshmukh, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zielstorff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byford, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakravarthy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorosh, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivkin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klappenbach, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, B.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kariv, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinsmore, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slipetz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dandliker, P. J.</span></span> <span> </span><span class="NLM_article-title">Evaluation of JAK3 biology in autoimmune disease using a highly selective, irreversible JAK3 inhibitor</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>361</i></span>,  <span class="NLM_fpage">229</span>– <span class="NLM_lpage">244</span>, <span class="refDoi"> DOI: 10.1124/jpet.116.239723</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1124%2Fjpet.116.239723" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=28193636" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtV2js7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2017&pages=229-244&author=F.+Elwoodauthor=D.+J.+Witterauthor=J.+Piesvauxauthor=B.+Kraybillauthor=N.+Baysauthor=C.+Alpertauthor=P.+Goldenblattauthor=Y.+Quauthor=I.+Ivanovskaauthor=H.-H.+Leeauthor=C.-S.+Chiuauthor=H.+Tangauthor=M.+E.+Scottauthor=S.+V.+Deshmukhauthor=M.+Zielstorffauthor=A.+Byfordauthor=K.+Chakravarthyauthor=L.+Doroshauthor=A.+Rivkinauthor=J.+Klappenbachauthor=B.-S.+Panauthor=I.+Karivauthor=C.+Dinsmoreauthor=D.+Slipetzauthor=P.+J.+Dandliker&title=Evaluation+of+JAK3+biology+in+autoimmune+disease+using+a+highly+selective%2C+irreversible+JAK3+inhibitor&doi=10.1124%2Fjpet.116.239723"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of JAK3 biology in autoimmune disease using a highly selective, irreversible JAK3 inhibitor</span></div><div class="casAuthors">Elwood, Fiona; Witter, David J.; Piesvaux, Jennifer; Kraybill, Brian; Bays, Nathan; Alpert, Carla; Goldenblatt, Peter; Qu, Yujie; Ivanovska, Irena; Lee, Hyun-Hee; Chiu, Chi-Sung; Tang, Hao; Scott, Mark E.; Deshmukh, Sujal V.; Zielstorff, Mark; Byford, Alan; Chakravarthy, Kalyan; Dorosh, Lauren; Rivkin, Alexey; Klappenbach, Joel; Pan, Bo-Sheng; Kariv, Ilona; Dinsmore, Christopher; Slipetz, Deborah; Dandliker, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">361</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">229-244</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Reversible janus assocd. kinase (JAK) inhibitors such as tofacitinib and decernotinib block cytokine signaling and are efficacious in treating autoimmune diseases.  However, therapeutic doses are limited due to inhibition of other JAK/signal transducer and activator of transcription pathways assocd. with hematopoiesis, lipid biogenesis, infection, and immune responses.  A selective JAK3 inhibitor may have a better therapeutic index; however, until recently, no compds. have been described that maintain JAK3 selectivity in cells, as well as against the kinome, with good physicochem. properties to test the JAK3 hypothesis in vivo.  To quantify the biochem. basis for JAK isoenzyme selectivity, we detd. that the apparent Km value for each JAK isoenzyme ranged from 31.8 to 2.9 μM for JAK1 and JAK3, resp.  To confirm compd. activity in cells, we developed a novel enzyme complementation assay that read activity of single JAK isoenzymes in a cellular context.  Reversible JAK3 inhibitors cannot achieve sufficient selectivity against other isoenzymes in the cellular context due to inherent differences in enzyme ATP Km values.  Therefore, we developed irreversible JAK3 compds. that are potent and highly selective in vitro in cells and against the kinome.  Compd. 2, a potent inhibitor of JAK3 (0.15 nM) was 4300-fold selective for JAK3 over JAK1 in enzyme assays, 67-fold [interleukin (IL)-2 vs. IL-6] or 140-fold [IL-2 vs. erythropoietin or granulocyte-macrophage colony-stimulating factor (GMCSF)] selective in cellular reporter assays and >35-fold selective in human peripheral blood mononuclear cell assays (IL-7 vs. IL-6 or GMCSF).  In vivo, selective JAK3 inhibition was sufficient to block the development of inflammation in a rat model of rheumatoid arthritis, while sparing hematopoiesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpp6-yK4H1dDbVg90H21EOLACvtfcHk0lh6RB7S1qtJwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtV2js7vL&md5=942ec024e9681b696dfbfeaf22f5acb2</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1124%2Fjpet.116.239723&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.116.239723%26sid%3Dliteratum%253Aachs%26aulast%3DElwood%26aufirst%3DF.%26aulast%3DWitter%26aufirst%3DD.%2BJ.%26aulast%3DPiesvaux%26aufirst%3DJ.%26aulast%3DKraybill%26aufirst%3DB.%26aulast%3DBays%26aufirst%3DN.%26aulast%3DAlpert%26aufirst%3DC.%26aulast%3DGoldenblatt%26aufirst%3DP.%26aulast%3DQu%26aufirst%3DY.%26aulast%3DIvanovska%26aufirst%3DI.%26aulast%3DLee%26aufirst%3DH.-H.%26aulast%3DChiu%26aufirst%3DC.-S.%26aulast%3DTang%26aufirst%3DH.%26aulast%3DScott%26aufirst%3DM.%2BE.%26aulast%3DDeshmukh%26aufirst%3DS.%2BV.%26aulast%3DZielstorff%26aufirst%3DM.%26aulast%3DByford%26aufirst%3DA.%26aulast%3DChakravarthy%26aufirst%3DK.%26aulast%3DDorosh%26aufirst%3DL.%26aulast%3DRivkin%26aufirst%3DA.%26aulast%3DKlappenbach%26aufirst%3DJ.%26aulast%3DPan%26aufirst%3DB.-S.%26aulast%3DKariv%26aufirst%3DI.%26aulast%3DDinsmore%26aufirst%3DC.%26aulast%3DSlipetz%26aufirst%3DD.%26aulast%3DDandliker%26aufirst%3DP.%2BJ.%26atitle%3DEvaluation%2520of%2520JAK3%2520biology%2520in%2520autoimmune%2520disease%2520using%2520a%2520highly%2520selective%252C%2520irreversible%2520JAK3%2520inhibitor%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2017%26volume%3D361%26spage%3D229%26epage%3D244%26doi%3D10.1124%2Fjpet.116.239723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jussif, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balbo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crouse, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickinson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symanowicz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banker, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unwalla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayward, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montgomery, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trujillo, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casimiro-Garcia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vajdos, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geoghegan, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xuan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hett, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorarensen, A.</span></span> <span> </span><span class="NLM_article-title">Discovery of a JAK3-selective inhibitor: functional differentiation of JAK3-selective inhibition over pan-JAK or JAK1-selective inhibition</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">3442</span>– <span class="NLM_lpage">3451</span>, <span class="refDoi"> DOI: 10.1021/acschembio.6b00677</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.6b00677" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslGku7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=3442-3451&author=J.-B.+Telliezauthor=M.+E.+Dowtyauthor=L.+Wangauthor=J.+Jussifauthor=T.+Linauthor=L.+Liauthor=E.+Moyauthor=P.+Balboauthor=W.+Liauthor=Y.+Zhaoauthor=K.+Crouseauthor=C.+Dickinsonauthor=P.+Symanowiczauthor=M.+Hegenauthor=M.+E.+Bankerauthor=F.+Vincentauthor=R.+Unwallaauthor=S.+Liangauthor=A.+M.+Gilbertauthor=M.+F.+Brownauthor=M.+Haywardauthor=J.+Montgomeryauthor=X.+Yangauthor=J.+Baumanauthor=J.+I.+Trujilloauthor=A.+Casimiro-Garciaauthor=F.+F.+Vajdosauthor=L.+Leungauthor=K.+F.+Geogheganauthor=A.+Quaziauthor=D.+Xuanauthor=L.+Jonesauthor=E.+Hettauthor=K.+Wrightauthor=J.+D.+Clarkauthor=A.+Thorarensen&title=Discovery+of+a+JAK3-selective+inhibitor%3A+functional+differentiation+of+JAK3-selective+inhibition+over+pan-JAK+or+JAK1-selective+inhibition&doi=10.1021%2Facschembio.6b00677"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition</span></div><div class="casAuthors">Telliez, Jean-Baptiste; Dowty, Martin E.; Wang, Lu; Jussif, Jason; Lin, Tsung; Li, Li; Moy, Erick; Balbo, Paul; Li, Wei; Zhao, Yajuan; Crouse, Kimberly; Dickinson, Caitlyn; Symanowicz, Peter; Hegen, Martin; Banker, Mary Ellen; Vincent, Fabien; Unwalla, Ray; Liang, Sidney; Gilbert, Adam M.; Brown, Matthew F.; Hayward, Matthew; Montgomery, Justin; Yang, Xin; Bauman, Jonathan; Trujillo, John I.; Casimiro-Garcia, Agustin; Vajdos, Felix F.; Leung, Louis; Geoghegan, Kieran F.; Quazi, Amira; Xuan, Dejun; Jones, Lyn; Hett, Erik; Wright, Katherine; Clark, James D.; Thorarensen, Atli</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3442-3451</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">PF-06651600, a newly discovered potent JAK3-selective inhibitor is highly efficacious at inhibiting γc cytokine signaling which is dependent on both JAK1 and JAK3.  PF-06651600 allowed the comparison of JAK3-selective inhibition to pan-JAK or JAK1-selective inhibition, in relevant immune cells to a level that couldn't be achieved previously without such potency and selectivity.  In vitro, PF-06651600 inhibits Th1 and Th17 cell differentiation and function, and in vivo it reduces disease pathol. in the rat adjuvant-induced arthritis as well as in the mouse exptl. autoimmune encephalomyelitis models.  Importantly, by sparing JAK1 function, PF-06651600 selectively targets γc cytokine pathways while preserving JAK1-dependent anti-inflammatory signaling such as the IL-10 suppressive functions following LPS treatment in macrophages and the suppression of TNFα and IL-1β prodn. in IL-27-primed macrophages.  Thus, JAK3-selective inhibition differentiates from pan-JAK or JAK1 inhibition in various immune cellular responses which could potentially translate to advantageous clin. outcomes in inflammatory and autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNLk0mtStNSrVg90H21EOLACvtfcHk0lh6RB7S1qtJwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslGku7nK&md5=dd83978cf9ac22947f4a3f07c5eed8ab</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Facschembio.6b00677&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.6b00677%26sid%3Dliteratum%253Aachs%26aulast%3DTelliez%26aufirst%3DJ.-B.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DJussif%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DMoy%26aufirst%3DE.%26aulast%3DBalbo%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DCrouse%26aufirst%3DK.%26aulast%3DDickinson%26aufirst%3DC.%26aulast%3DSymanowicz%26aufirst%3DP.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DBanker%26aufirst%3DM.%2BE.%26aulast%3DVincent%26aufirst%3DF.%26aulast%3DUnwalla%26aufirst%3DR.%26aulast%3DLiang%26aufirst%3DS.%26aulast%3DGilbert%26aufirst%3DA.%2BM.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DHayward%26aufirst%3DM.%26aulast%3DMontgomery%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DBauman%26aufirst%3DJ.%26aulast%3DTrujillo%26aufirst%3DJ.%2BI.%26aulast%3DCasimiro-Garcia%26aufirst%3DA.%26aulast%3DVajdos%26aufirst%3DF.%2BF.%26aulast%3DLeung%26aufirst%3DL.%26aulast%3DGeoghegan%26aufirst%3DK.%2BF.%26aulast%3DQuazi%26aufirst%3DA.%26aulast%3DXuan%26aufirst%3DD.%26aulast%3DJones%26aufirst%3DL.%26aulast%3DHett%26aufirst%3DE.%26aulast%3DWright%26aufirst%3DK.%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DThorarensen%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520a%2520JAK3-selective%2520inhibitor%253A%2520functional%2520differentiation%2520of%2520JAK3-selective%2520inhibition%2520over%2520pan-JAK%2520or%2520JAK1-selective%2520inhibition%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2016%26volume%3D11%26spage%3D3442%26epage%3D3451%26doi%3D10.1021%2Facschembio.6b00677" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roskoski, R.</span></span> <span> </span><span class="NLM_article-title">Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">784</span>– <span class="NLM_lpage">803</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2016.07.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1016%2Fj.phrs.2016.07.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=27473820" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht12jurzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2016&pages=784-803&author=R.+Roskoski&title=Janus+kinase+%28JAK%29+inhibitors+in+the+treatment+of+inflammatory+and+neoplastic+diseases&doi=10.1016%2Fj.phrs.2016.07.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases</span></div><div class="casAuthors">Roskoski, Robert, Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">784-803</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The Janus kinase (JAK) family of non-receptor protein-tyrosine kinases consists of JAK1, JAK2, JAK3, and TYK2 (tyrosine kinase-2).  Each of these proteins contains a JAK homol. pseudokinase (JH2) domain that regulates the adjacent protein kinase domain (JH1).  JAK1/2 and TYK2 are ubiquitously expressed whereas JAK3 is found predominantly in hematopoietic cells.  The Janus kinase family is regulated by numerous cytokines including interleukins, interferons, and hormones such as erythropoietin, thrombopoietin, and growth hormone.  Ligand binding to cytokine and hormone receptors leads to the activation of assocd. Janus kinases, which then mediate the phosphorylation of the receptors.  The SH2 domain of STATs (signal transducers and activators of transcription) binds to the receptor phosphotyrosines thereby promoting STAT phosphorylation by the Janus kinases and consequent activation.  STAT dimers are translocated to the nucleus where they participate in the regulation of the expression of thousands of proteins.  JAK-STAT dysregulation results in autoimmune disorders such as rheumatoid arthritis, ulcerative colitis, and Crohn disease.  JAK-STAT dysregulation also plays a role in the pathogenesis of myelofibrosis, polycythemia vera, and other myeloproliferative illnesses.  An activating JAK2 V617F mutation occurs in 95% of people with polycythemia vera and in a lower percentage of people with other neoplasms.  JAK1/3 signaling participates in the pathogenesis of inflammatory afflictions while JAK1/2 signaling participates in the development of several malignancies including leukemias and lymphomas as well as myeloproliferative neoplasms.  Tofacitinib is a pan-JAK inhibitor that is approved by the FDA for the treatment of rheumatoid arthritis and ruxolitinib is a JAK1/2 inhibitor that is approved for the treatment of polycythemia vera and myelofibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGov32m4UjOrv7Vg90H21EOLACvtfcHk0lh6RB7S1qtJwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht12jurzJ&md5=a45fba1bb110eff4d5c1b31b78c1b3ac</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2016.07.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2016.07.038%26sid%3Dliteratum%253Aachs%26aulast%3DRoskoski%26aufirst%3DR.%26atitle%3DJanus%2520kinase%2520%2528JAK%2529%2520inhibitors%2520in%2520the%2520treatment%2520of%2520inflammatory%2520and%2520neoplastic%2520diseases%26jtitle%3DPharmacol.%2520Res.%26date%3D2016%26volume%3D111%26spage%3D784%26epage%3D803%26doi%3D10.1016%2Fj.phrs.2016.07.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lupardus, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ultsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallweber, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bir Kohli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span> <span> </span><span class="NLM_article-title">Structure of the pseudokinase–kinase domains from protein kinase TYK2 reveals a mechanism for Janus Kinase (JAK) autoinhibition</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">8025</span>– <span class="NLM_lpage">8030</span>, <span class="refDoi"> DOI: 10.1073/pnas.1401180111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1073%2Fpnas.1401180111" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=8025-8030&author=P.+J.+Lupardusauthor=M.+Ultschauthor=H.+Wallweberauthor=P.+Bir+Kohliauthor=A.+R.+Johnsonauthor=C.+Eigenbrot&title=Structure+of+the+pseudokinase%E2%80%93kinase+domains+from+protein+kinase+TYK2+reveals+a+mechanism+for+Janus+Kinase+%28JAK%29+autoinhibition&doi=10.1073%2Fpnas.1401180111"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1401180111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1401180111%26sid%3Dliteratum%253Aachs%26aulast%3DLupardus%26aufirst%3DP.%2BJ.%26aulast%3DUltsch%26aufirst%3DM.%26aulast%3DWallweber%26aufirst%3DH.%26aulast%3DBir%2BKohli%26aufirst%3DP.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DEigenbrot%26aufirst%3DC.%26atitle%3DStructure%2520of%2520the%2520pseudokinase%25E2%2580%2593kinase%2520domains%2520from%2520protein%2520kinase%2520TYK2%2520reveals%2520a%2520mechanism%2520for%2520Janus%2520Kinase%2520%2528JAK%2529%2520autoinhibition%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2014%26volume%3D111%26spage%3D8025%26epage%3D8030%26doi%3D10.1073%2Fpnas.1401180111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Puleo, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kucera, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammarén, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ungureanu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newton, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvennoinen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorgensen, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, J.</span></span> <span> </span><span class="NLM_article-title">Identification and characterization of JAK2 pseudokinase domain small molecule binders</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">618</span>– <span class="NLM_lpage">621</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00153</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00153" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnvFClsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=618-621&author=D.+E.+Puleoauthor=K.+Kuceraauthor=H.+M.+Hammar%C3%A9nauthor=D.+Ungureanuauthor=A.+S.+Newtonauthor=O.+Silvennoinenauthor=W.+L.+Jorgensenauthor=J.+Schlessinger&title=Identification+and+characterization+of+JAK2+pseudokinase+domain+small+molecule+binders&doi=10.1021%2Facsmedchemlett.7b00153"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and Characterization of JAK2 Pseudokinase Domain Small Molecule Binders</span></div><div class="casAuthors">Puleo, David E.; Kucera, Kaury; Hammaren, Henrik M.; Ungureanu, Daniela; Newton, Ana S.; Silvennoinen, Olli; Jorgensen, William L.; Schlessinger, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">618-621</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Janus kinases (JAKs) regulate hematopoiesis via the cytokine-mediated JAK-STAT signaling pathway.  JAKs contain tandem C-terminal pseudokinase (JH2) and tyrosine kinase (JH1) domains.  The JAK2 pseudokinase domain adopts a protein kinase fold and, despite its pseudokinase designation, binds ATP with micromolar affinity.  Recent evidence shows that displacing ATP from the JAK2 JH2 domain alters the hyperactivation state of the oncogenic JAK2 V617F protein while sparing the wild type JAK2 protein.  In this study, small mol. binders of JAK2 JH2 were identified via an in vitro screen.  Top hits were characterized using biophys. and structural approaches.  Development of pseudokinase-selective compds. may offer novel pharmacol. opportunities for treating cancers driven by JAK2 V617F and other oncogenic JAK mutants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmtcoH5qmUWrVg90H21EOLACvtfcHk0lgacdDi8-NWvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnvFClsr4%253D&md5=a3f1f6e10a8a1d3b64bb5691d246f5d0</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00153%26sid%3Dliteratum%253Aachs%26aulast%3DPuleo%26aufirst%3DD.%2BE.%26aulast%3DKucera%26aufirst%3DK.%26aulast%3DHammar%25C3%25A9n%26aufirst%3DH.%2BM.%26aulast%3DUngureanu%26aufirst%3DD.%26aulast%3DNewton%26aufirst%3DA.%2BS.%26aulast%3DSilvennoinen%26aufirst%3DO.%26aulast%3DJorgensen%26aufirst%3DW.%2BL.%26aulast%3DSchlessinger%26aufirst%3DJ.%26atitle%3DIdentification%2520and%2520characterization%2520of%2520JAK2%2520pseudokinase%2520domain%2520small%2520molecule%2520binders%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D618%26epage%3D621%26doi%3D10.1021%2Facsmedchemlett.7b00153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leroy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Constantinescu, S. N.</span></span> <span> </span><span class="NLM_article-title">Rethinking JAK2 inhibition: towards novel strategies of more specific and versatile Janus kinase inhibition</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">1023</span>– <span class="NLM_lpage">1038</span>, <span class="refDoi"> DOI: 10.1038/leu.2017.43</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1038%2Fleu.2017.43" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=28119526" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2sXislyms7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=1023-1038&author=E.+Leroyauthor=S.+N.+Constantinescu&title=Rethinking+JAK2+inhibition%3A+towards+novel+strategies+of+more+specific+and+versatile+Janus+kinase+inhibition&doi=10.1038%2Fleu.2017.43"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Rethinking JAK2 inhibition: towards novel strategies of more specific and versatile janus kinase inhibition</span></div><div class="casAuthors">Leroy, E.; Constantinescu, S. N.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1023-1038</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Janus kinases (JAKs) are required for cytokine receptor signaling.  Since the discovery of the highly prevalent JAK2 V617F mutation in myeloproliferative neoplasms (MPNs), JAK2 became a prime target for inhibition.  Only one approved JAK2 inhibitor exists, with pos., but not curative effects in MPNs, and promising effects in autoimmune diseases and cancer.  On the basis of recent advances in the structural features regulating both normal and mutant JAKs, as well as in small-mol. targeting, we review the current state of JAK2 inhibitor development and present novel avenues of selecting JAK2 inhibitors, with broad and narrow specificities and extend these approaches to other JAKs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLVJS8PwHOlbVg90H21EOLACvtfcHk0lgacdDi8-NWvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXislyms7w%253D&md5=0dc333d94e27daad1d32110dee26e637</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1038%2Fleu.2017.43&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2017.43%26sid%3Dliteratum%253Aachs%26aulast%3DLeroy%26aufirst%3DE.%26aulast%3DConstantinescu%26aufirst%3DS.%2BN.%26atitle%3DRethinking%2520JAK2%2520inhibition%253A%2520towards%2520novel%2520strategies%2520of%2520more%2520specific%2520and%2520versatile%2520Janus%2520kinase%2520inhibition%26jtitle%3DLeukemia%26date%3D2017%26volume%3D31%26spage%3D1023%26epage%3D1038%26doi%3D10.1038%2Fleu.2017.43" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misner, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belmont, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castanedo, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coraggio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erickson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghilardi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katewa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohli, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubach, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenzie, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortwine, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schutt, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tay, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span> <span> </span><span class="NLM_article-title">Discovery of GDC-0853, a potent, selective, and non-covalent Bruton’s tyrosine kinase inhibitor in early clinical development</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">2227</span>– <span class="NLM_lpage">2245</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01712</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01712" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=2227-2245&author=J.+J.+Crawfordauthor=A.+R.+Johnsonauthor=D.+L.+Misnerauthor=L.+D.+Belmontauthor=G.+M.+Castanedoauthor=R.+Choyauthor=M.+Coraggioauthor=L.+Dongauthor=C.+Eigenbrotauthor=R.+Ericksonauthor=N.+Ghilardiauthor=J.+Hauauthor=A.+Katewaauthor=P.+B.+Kohliauthor=W.+Leeauthor=J.+W.+Lubachauthor=B.+S.+McKenzieauthor=D.+F.+Ortwineauthor=L.+Schuttauthor=S.+Tayauthor=B.+Weiauthor=K.+Reifauthor=L.+Liuauthor=H.+Wongauthor=W.+B.+Young&title=Discovery+of+GDC-0853%2C+a+potent%2C+selective%2C+and+non-covalent+Bruton%E2%80%99s+tyrosine+kinase+inhibitor+in+early+clinical+development&doi=10.1021%2Facs.jmedchem.7b01712"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01712%26sid%3Dliteratum%253Aachs%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DMisner%26aufirst%3DD.%2BL.%26aulast%3DBelmont%26aufirst%3DL.%2BD.%26aulast%3DCastanedo%26aufirst%3DG.%2BM.%26aulast%3DChoy%26aufirst%3DR.%26aulast%3DCoraggio%26aufirst%3DM.%26aulast%3DDong%26aufirst%3DL.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DErickson%26aufirst%3DR.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DHau%26aufirst%3DJ.%26aulast%3DKatewa%26aufirst%3DA.%26aulast%3DKohli%26aufirst%3DP.%2BB.%26aulast%3DLee%26aufirst%3DW.%26aulast%3DLubach%26aufirst%3DJ.%2BW.%26aulast%3DMcKenzie%26aufirst%3DB.%2BS.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DSchutt%26aufirst%3DL.%26aulast%3DTay%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26atitle%3DDiscovery%2520of%2520GDC-0853%252C%2520a%2520potent%252C%2520selective%252C%2520and%2520non-covalent%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitor%2520in%2520early%2520clinical%2520development%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D2227%26epage%3D2245%26doi%3D10.1021%2Facs.jmedchem.7b01712" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mócsai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruland, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tybulewicz, V. L.</span></span> <span> </span><span class="NLM_article-title">The SYK tyrosine kinase: a crucial player in diverse biological functions</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">387</span>– <span class="NLM_lpage">402</span>, <span class="refDoi"> DOI: 10.1038/nri2765</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1038%2Fnri2765" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=20467426" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlvFOkurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=387-402&author=A.+M%C3%B3csaiauthor=J.+Rulandauthor=V.+L.+Tybulewicz&title=The+SYK+tyrosine+kinase%3A+a+crucial+player+in+diverse+biological+functions&doi=10.1038%2Fnri2765"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">The SYK tyrosine kinase: a crucial player in diverse biological functions</span></div><div class="casAuthors">Mocsai, Attila; Ruland, Jurgen; Tybulewicz, Victor L. J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">387-402</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Spleen tyrosine kinase (SYK) is known to have a crucial role in adaptive immune receptor signalling.  However, recent reports indicate that SYK also mediates other, unexpectedly diverse biol. functions, including cellular adhesion, innate immune recognition, osteoclast maturation, platelet activation and vascular development.  SYK is activated by C-type lectins and integrins, and activates new targets, including the CARD9-BCL-10-MALT1 pathway and the NLRP3 inflammasome.  Studies using Drosophila melanogaster suggest that there is an evolutionarily ancient origin of SYK-mediated signalling.  Moreover, SYK has a crucial role in autoimmune diseases and haematol. malignancies.  This Review summarizes our current understanding of the diverse functions of SYK and how this is being translated for therapeutic purposes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3YO5BcMqrf7Vg90H21EOLACvtfcHk0livXXuslN719g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlvFOkurk%253D&md5=85857a2b9beb84e0fe74263a90fa8a53</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1038%2Fnri2765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri2765%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25B3csai%26aufirst%3DA.%26aulast%3DRuland%26aufirst%3DJ.%26aulast%3DTybulewicz%26aufirst%3DV.%2BL.%26atitle%3DThe%2520SYK%2520tyrosine%2520kinase%253A%2520a%2520crucial%2520player%2520in%2520diverse%2520biological%2520functions%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2010%26volume%3D10%26spage%3D387%26epage%3D402%26doi%3D10.1038%2Fnri2765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Geahlen, R. L.</span></span> <span> </span><span class="NLM_article-title">Getting Syk: spleen tyrosine kinase as a therapeutic target</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">414</span>– <span class="NLM_lpage">422</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2014.05.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1016%2Fj.tips.2014.05.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=24975478" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVKhtbvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2014&pages=414-422&author=R.+L.+Geahlen&title=Getting+Syk%3A+spleen+tyrosine+kinase+as+a+therapeutic+target&doi=10.1016%2Fj.tips.2014.05.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Getting Syk: spleen tyrosine kinase as a therapeutic target</span></div><div class="casAuthors">Geahlen, Robert L.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">414-422</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Spleen tyrosine kinase (Syk) is a cytoplasmic protein tyrosine kinase well known for its ability to couple immune cell receptors to intracellular signaling pathways that regulate cellular responses to extracellular antigens and antigen-Ig (Ig) complexes of particular importance to the initiation of inflammatory responses.  Thus, Syk is an attractive target for therapeutic kinase inhibitors designed to ameliorate the symptoms and consequences of acute and chronic inflammation.  Its more recently recognized role as a promoter of cell survival in numerous cancer cell types ranging from leukemia to retinoblastoma has attracted considerable interest as a target for a new generation of anticancer drugs.  This review discusses the biol. processes in which Syk participates that have made this kinase such a compelling drug target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoE5Tut36Cq0LVg90H21EOLACvtfcHk0livXXuslN719g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVKhtbvK&md5=8b161de626d96f82c754eff4c5ef078f</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2014.05.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2014.05.007%26sid%3Dliteratum%253Aachs%26aulast%3DGeahlen%26aufirst%3DR.%2BL.%26atitle%3DGetting%2520Syk%253A%2520spleen%2520tyrosine%2520kinase%2520as%2520a%2520therapeutic%2520target%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2014%26volume%3D35%26spage%3D414%26epage%3D422%26doi%3D10.1016%2Fj.tips.2014.05.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silakari, O.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of switch kinase ‘spleen tyrosine kinase’ in inflammation and immune-mediated disorders: a review</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">434</span>– <span class="NLM_lpage">446</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2013.04.070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1016%2Fj.ejmech.2013.04.070" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2013&pages=434-446&author=M.+Kaurauthor=M.+Singhauthor=O.+Silakari&title=Inhibitors+of+switch+kinase+%E2%80%98spleen+tyrosine+kinase%E2%80%99+in+inflammation+and+immune-mediated+disorders%3A+a+review&doi=10.1016%2Fj.ejmech.2013.04.070"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.04.070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.04.070%26sid%3Dliteratum%253Aachs%26aulast%3DKaur%26aufirst%3DM.%26aulast%3DSingh%26aufirst%3DM.%26aulast%3DSilakari%26aufirst%3DO.%26atitle%3DInhibitors%2520of%2520switch%2520kinase%2520%25E2%2580%2598spleen%2520tyrosine%2520kinase%25E2%2580%2599%2520in%2520inflammation%2520and%2520immune-mediated%2520disorders%253A%2520a%2520review%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D67%26spage%3D434%26epage%3D446%26doi%3D10.1016%2Fj.ejmech.2013.04.070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuda, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Payan, D. G.</span></span> <span> </span><span class="NLM_article-title">Discovery and development of spleen tyrosine kinase (SYK) inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">3614</span>– <span class="NLM_lpage">3643</span>, <span class="refDoi"> DOI: 10.1021/jm201271b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201271b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC38XpsVOntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=3614-3643&author=R.+Singhauthor=E.+S.+Masudaauthor=D.+G.+Payan&title=Discovery+and+development+of+spleen+tyrosine+kinase+%28SYK%29+inhibitors&doi=10.1021%2Fjm201271b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Development of Spleen Tyrosine Kinase (SYK) Inhibitors</span></div><div class="casAuthors">Singh, Rajinder; Masuda, Esteban S.; Payan, Donald G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3614-3643</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Spleen tyrosine kinase (SYK) is a member of the cytoplasmic protein tyrosine kinase (PTK) family and has been identified as an important target for the development of therapeutics for the treatment of allergic and autoimmune diseases.  Maladies resulting from chronic inflammation and autoimmune dysfunction include, asthma, rheumatoid arthritis (RA), Crohn's disease, systemic lupus erythematosus (SLE) and idiopathic thrombocytopenia purpura (ITP).  SYK has garnered substantial attention because of its importance as a key signal transduction regulator through antigen and Fc receptors in hematopoietic cells.  Recently SYK has entered the mainstream of potential pharmaceutical targets with a no. of inhibitor classes being reported in the literature.  The true potential as a validated target for inhibition by small mols. has been investigated in the last few years, with the emergence of advanced clin. trial data.  Structurally SYK possesses a tandem N-terminal Src homol. 2 domains (SH2), referred to as N-SH2 and C-SH2 domains, followed by a C-terminal kinase domain and most closely related to ZAP-70.  The multiple phosphorylation sites on SYK are fundamental structural prerequisites for its diverse functional activity.  Overall, these phosphorylation sites contribute to maintaining the kinase in an inactivated state.  In addn., they are implicated in events leading to primary activation of the kinase catalytic domain, amplification of this activity, and the orchestrated phosphorylation of multiple substrates.  Utilization of the numerous sites of phosphorylation on SYK leads to the activation of a multitude of signaling networks relevant to immune and autoimmune maladies.  SYK serves as a master regulator of inflammatory responses in a multitude of immune cells and as a result, inhibiting SYK activity dampens inflammation broadly and comprehensively.  The validation of SYK as an effective target for therapeutic intervention in autoimmune and inflammatory disorders has picked up pace over the last decade.  In particular, this has been attributable to the recognition of key biol. findings, coupled with successful small mol. inhibitors of SYK that have shown early indications of clin. efficacy in diverse autoimmune and inflammatory diseases.  SYK as a target has gained reinforcement with the successful completion of several Phase 2 clin. studies in RA, ITP and B-cell lymphoma.  Addnl. clin. studies are under way that may further emphasize the position of SYK as a therapeutically relevant target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp363qA4V4g-rVg90H21EOLACvtfcHk0livXXuslN719g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpsVOntw%253D%253D&md5=1b51e1b658842f2b562d533edb05e685</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1021%2Fjm201271b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201271b%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DMasuda%26aufirst%3DE.%2BS.%26aulast%3DPayan%26aufirst%3DD.%2BG.%26atitle%3DDiscovery%2520and%2520development%2520of%2520spleen%2520tyrosine%2520kinase%2520%2528SYK%2529%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D3614%26epage%3D3643%26doi%3D10.1021%2Fjm201271b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Turner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph Mee, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costello, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duddy, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furlong, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geahlen, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tybulewicz, V. L. J.</span></span> <span> </span><span class="NLM_article-title">Perinatal lethality and blocked B-cell development in mice lacking the tyrosine kinase Syk</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>378</i></span>,  <span class="NLM_fpage">298</span>– <span class="NLM_lpage">302</span>, <span class="refDoi"> DOI: 10.1038/378298a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1038%2F378298a0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=378&publication_year=1995&pages=298-302&author=M.+Turnerauthor=P.+Joseph+Meeauthor=P.+S.+Costelloauthor=O.+Williamsauthor=A.+A.+Priceauthor=L.+P.+Duddyauthor=M.+T.+Furlongauthor=R.+L.+Geahlenauthor=V.+L.+J.+Tybulewicz&title=Perinatal+lethality+and+blocked+B-cell+development+in+mice+lacking+the+tyrosine+kinase+Syk&doi=10.1038%2F378298a0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1038%2F378298a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F378298a0%26sid%3Dliteratum%253Aachs%26aulast%3DTurner%26aufirst%3DM.%26aulast%3DJoseph%2BMee%26aufirst%3DP.%26aulast%3DCostello%26aufirst%3DP.%2BS.%26aulast%3DWilliams%26aufirst%3DO.%26aulast%3DPrice%26aufirst%3DA.%2BA.%26aulast%3DDuddy%26aufirst%3DL.%2BP.%26aulast%3DFurlong%26aufirst%3DM.%2BT.%26aulast%3DGeahlen%26aufirst%3DR.%2BL.%26aulast%3DTybulewicz%26aufirst%3DV.%2BL.%2BJ.%26atitle%3DPerinatal%2520lethality%2520and%2520blocked%2520B-cell%2520development%2520in%2520mice%2520lacking%2520the%2520tyrosine%2520kinase%2520Syk%26jtitle%3DNature%26date%3D1995%26volume%3D378%26spage%3D298%26epage%3D302%26doi%3D10.1038%2F378298a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jakus, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balázs, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mócsai, A.</span></span> <span> </span><span class="NLM_article-title">Genetic deficiency of Syk protects mice from autoantibody-induced arthritis</span>. <i>Arthritis Rheum.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">1899</span>– <span class="NLM_lpage">1910</span>, <span class="refDoi"> DOI: 10.1002/art.27438</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1002%2Fart.27438" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=20201079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1aqsL%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2010&pages=1899-1910&author=Z.+Jakusauthor=E.+Simonauthor=B.+Bal%C3%A1zsauthor=A.+M%C3%B3csai&title=Genetic+deficiency+of+Syk+protects+mice+from+autoantibody-induced+arthritis&doi=10.1002%2Fart.27438"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic deficiency of Syk protects mice from autoantibody-induced arthritis</span></div><div class="casAuthors">Jakus, Zoltan; Simon, Edina; Balazs, Balint; Mocsai, Attila</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1899-1910</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective: The Syk tyrosine kinase plays an important role in diverse functions in hematopoietic lineage cells.  Although previous in vitro and pharmacol. analyses suggested Syk to be a possible player in the development of autoimmune arthritis, no in vivo genetic studies addressing that issue have yet been reported.  The aim of the present study was to test whether genetic deficiency of Syk affects autoantibody-induced exptl. arthritis in the K/BxN serumtransfer model.  Methods: Syk-/- bone marrow chimeras carrying a Syk-deficient hematopoietic system were generated by transplanting Syk-/- fetal liver cells into lethally irradiated wild-type recipients.  After complete repopulation of the hematopoietic compartment, autoantibody-mediated arthritis was induced by injection of arthritogenic K/BxN serum.  Arthritis development was monitored by macroscopic and microscopic observation of the ankle joints, micro-computed tomog. of bone morphol., as well as joint function assay.  Results: Genetic deficiency of Syk in the hematopoietic compartment completely blocked the development of all macroscopic and microscopic signs of arthritis.  The Syk-/- mutation also prevented the appearance of periarticular bone erosions.  Finally, Syk-/- bone marrow chimeras were completely protected from arthritis-induced loss of articular function.  Conclusion: Our results indicate that Syk is critically involved in the development of all clin. relevant aspects of autoantibody-mediated K/BxN serumtransfer arthritis in exptl. mice.  These results provide the first in vivo genetic evidence of the role of Syk in the development of autoimmune arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMg3hF7NyGgrVg90H21EOLACvtfcHk0ljqcTf6q9qJOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1aqsL%252FO&md5=0dfab55caa648c3c556fcc8a63ba9a4f</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1002%2Fart.27438&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.27438%26sid%3Dliteratum%253Aachs%26aulast%3DJakus%26aufirst%3DZ.%26aulast%3DSimon%26aufirst%3DE.%26aulast%3DBal%25C3%25A1zs%26aufirst%3DB.%26aulast%3DM%25C3%25B3csai%26aufirst%3DA.%26atitle%3DGenetic%2520deficiency%2520of%2520Syk%2520protects%2520mice%2520from%2520autoantibody-induced%2520arthritis%26jtitle%3DArthritis%2520Rheum.%26date%3D2010%26volume%3D62%26spage%3D1899%26epage%3D1910%26doi%3D10.1002%2Fart.27438" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yi, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Son, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sung, G.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, J. Y.</span></span> <span> </span><span class="NLM_article-title">Functional roles of Syk in macrophage-mediated inflammatory responses</span>. <i>Mediators Inflammation</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>2014</i></span>,  <span class="NLM_fpage">270302</span>, <span class="refDoi"> DOI: 10.1155/2014/270302</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1155%2F2014%2F270302" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=25045209" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A280%3ADC%252BC2cbpslylsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2014&publication_year=2014&pages=270302&author=Y.-S.+Yiauthor=Y.-J.+Sonauthor=C.+Ryouauthor=G.-H.+Sungauthor=J.-H.+Kimauthor=J.+Y.+Cho&title=Functional+roles+of+Syk+in+macrophage-mediated+inflammatory+responses&doi=10.1155%2F2014%2F270302"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Functional roles of Syk in macrophage-mediated inflammatory responses</span></div><div class="casAuthors">Yi Young-Su; Cho Jae Youl; Son Young-Jin; Ryou Chongsuk; Sung Gi-Ho; Kim Jong-Hoon</div><div class="citationInfo"><span class="NLM_cas:title">Mediators of inflammation</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">2014</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">270302</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Inflammation is a series of complex biological responses to protect the host from pathogen invasion.  Chronic inflammation is considered a major cause of diseases, such as various types of inflammatory/autoimmune diseases and cancers.  Spleen tyrosine kinase (Syk) was initially found to be highly expressed in hematopoietic cells and has been known to play crucial roles in adaptive immune responses.  However, recent studies have reported that Syk is also involved in other biological functions, especially in innate immune responses.  Although Syk has been extensively studied in adaptive immune responses, numerous studies have recently presented evidence that Syk has critical functions in macrophage-mediated inflammatory responses and is closely related to innate immune response.  This review describes the characteristics of Syk-mediated signaling pathways, summarizes the recent findings supporting the crucial roles of Syk in macrophage-mediated inflammatory responses and diseases, and discusses Syk-targeted drug development for the therapy of inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSfGd8CCEOs1GZyxfu64m4ffW6udTcc2eah7HGq0hOqZbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cbpslylsQ%253D%253D&md5=35476f2963c8eeb92d14e2a55a6375e1</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1155%2F2014%2F270302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2014%252F270302%26sid%3Dliteratum%253Aachs%26aulast%3DYi%26aufirst%3DY.-S.%26aulast%3DSon%26aufirst%3DY.-J.%26aulast%3DRyou%26aufirst%3DC.%26aulast%3DSung%26aufirst%3DG.-H.%26aulast%3DKim%26aufirst%3DJ.-H.%26aulast%3DCho%26aufirst%3DJ.%2BY.%26atitle%3DFunctional%2520roles%2520of%2520Syk%2520in%2520macrophage-mediated%2520inflammatory%2520responses%26jtitle%3DMediators%2520Inflammation%26date%3D2014%26volume%3D2014%26spage%3D270302%26doi%3D10.1155%2F2014%2F270302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Braselmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sylvain, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baluom, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herlaar, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argade, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jurcevic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pine, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grossbard, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Payan, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuda, E. S.</span></span> <span> </span><span class="NLM_article-title">R406, an orally available spleen tyrosine kinase inhibitor blocks Fc receptor signaling and reduces immune complex-mediated inflammation</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>319</i></span>,  <span class="NLM_fpage">998</span>– <span class="NLM_lpage">1008</span>, <span class="refDoi"> DOI: 10.1124/jpet.106.109058</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1124%2Fjpet.106.109058" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=16946104" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1yltL7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=319&publication_year=2006&pages=998-1008&author=S.+Braselmannauthor=V.+Taylorauthor=H.+Zhaoauthor=S.+Wangauthor=C.+Sylvainauthor=M.+Baluomauthor=K.+Quauthor=E.+Herlaarauthor=A.+Lauauthor=C.+Youngauthor=B.+R.+Wongauthor=S.+Lovellauthor=T.+Sunauthor=G.+Parkauthor=A.+Argadeauthor=S.+Jurcevicauthor=P.+Pineauthor=R.+Singhauthor=E.+B.+Grossbardauthor=D.+G.+Payanauthor=E.+S.+Masuda&title=R406%2C+an+orally+available+spleen+tyrosine+kinase+inhibitor+blocks+Fc+receptor+signaling+and+reduces+immune+complex-mediated+inflammation&doi=10.1124%2Fjpet.106.109058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">R406, an orally available spleen tyrosine kinase inhibitor blocks Fc receptor signaling and reduces immune complex-mediated inflammation</span></div><div class="casAuthors">Braselmann, Sylvia; Taylor, Vanessa; Zhao, Haoran; Wang, Su; Sylvain, Catherine; Baluom, Muhammad; Qu, Kunbin; Herlaar, Ellen; Lau, Angela; Young, Chi; Wong, Brian R.; Lovell, Scott; Sun, Thomas; Park, Gary; Argade, Ankush; Jurcevic, Stipo; Pine, Polly; Singh, Rajinder; Grossbard, Elliott B.; Payan, Donald G.; Masuda, Esteban S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">319</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">998-1008</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Recent compelling evidence has lead to renewed interest in the role of antibodies and immune complexes in the pathogenesis of several autoimmune disorders, such as rheumatoid arthritis.  These immune complexes, consisting of autoantibodies to self-antigens, can mediate inflammatory responses largely through binding and activating the Ig Fc receptors (FcRs).  Using cell-based structure activity relationships with cultured human mast cells, we have identified the small mol. R406 [N4-(2,2-dimethyl-3-oxo-4H-pyrid[1,4]oxazin-6-yl)-5-fluoro-N2- (3,4,5-trimethoxyphenyl)-2,4-pyrimidinediamine] as a potent inhibitor of IgE (IgE)- and IgG-mediated activation of Fc receptor signaling (EC50 for degranulation = 56-64 nM).  Here we show that the primary target for R406 is the spleen tyrosine kinase (Syk), which plays a key role in the signaling of activating Fc receptors and the B-cell receptor (BCR).  R406 inhibited phosphorylation of Syk substrate linker for activation of T cells in mast cells and B-cell linker protein/SLP65 in B cells.  R406 bound to the ATP binding pocket of Syk and inhibited its kinase activity as an ATP-competitive inhibitor (Ki = 30 nM).  Furthermore, R406 blocked Syk-dependent FcR-mediated activation of monocytes/macrophages and neutrophils and BCR-mediated activation of B lymphocytes.  R406 was selective as assessed using a large panel of Syk-independent cell-based assays representing both specific and general signaling pathways.  Consistent with Syk inhibition, oral administration of R406 to mice reduced immune complex-mediated inflammation in a reverse-passive Arthus reaction and two antibody-induced arthritis models.  Finally, we report a first-in-human study showing that R406 is orally bioavailable, achieving exposures capable of inhibiting Syk-dependent IgE-mediated basophil activation.  Collectively, the results show R406 potential for modulating Syk activity in human disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohoeT9BJQAyLVg90H21EOLACvtfcHk0ljqcTf6q9qJOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1yltL7P&md5=18fea516041ea075d2123158f321a186</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1124%2Fjpet.106.109058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.106.109058%26sid%3Dliteratum%253Aachs%26aulast%3DBraselmann%26aufirst%3DS.%26aulast%3DTaylor%26aufirst%3DV.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DSylvain%26aufirst%3DC.%26aulast%3DBaluom%26aufirst%3DM.%26aulast%3DQu%26aufirst%3DK.%26aulast%3DHerlaar%26aufirst%3DE.%26aulast%3DLau%26aufirst%3DA.%26aulast%3DYoung%26aufirst%3DC.%26aulast%3DWong%26aufirst%3DB.%2BR.%26aulast%3DLovell%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DT.%26aulast%3DPark%26aufirst%3DG.%26aulast%3DArgade%26aufirst%3DA.%26aulast%3DJurcevic%26aufirst%3DS.%26aulast%3DPine%26aufirst%3DP.%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DGrossbard%26aufirst%3DE.%2BB.%26aulast%3DPayan%26aufirst%3DD.%2BG.%26aulast%3DMasuda%26aufirst%3DE.%2BS.%26atitle%3DR406%252C%2520an%2520orally%2520available%2520spleen%2520tyrosine%2520kinase%2520inhibitor%2520blocks%2520Fc%2520receptor%2520signaling%2520and%2520reduces%2520immune%2520complex-mediated%2520inflammation%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2006%26volume%3D319%26spage%3D998%26epage%3D1008%26doi%3D10.1124%2Fjpet.106.109058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baluom, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grossbard, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mant, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, D. T. W.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics of fostamatinib, a spleen tyrosine kinase (SYK) inhibitor, in healthy human subjects following single and multiple oral dosing in three phase I studies</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">78</span>– <span class="NLM_lpage">88</span>, <span class="refDoi"> DOI: 10.1111/bcp.12048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1111%2Fbcp.12048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=23190017" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpvFeksLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2013&pages=78-88&author=M.+Baluomauthor=E.+B.+Grossbardauthor=T.+Mantauthor=D.+T.+W.+Lau&title=Pharmacokinetics+of+fostamatinib%2C+a+spleen+tyrosine+kinase+%28SYK%29+inhibitor%2C+in+healthy+human+subjects+following+single+and+multiple+oral+dosing+in+three+phase+I+studies&doi=10.1111%2Fbcp.12048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics of fostamatinib, a spleen tyrosine kinase (SYK) inhibitor, in healthy human subjects following single and multiple oral dosing in three phase I studies</span></div><div class="casAuthors">Baluom, Muhammad; Grossbard, Elliott B.; Mant, Tim; Lau, David T. W.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">78-88</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">1365-2125</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Aim : Fostamatinib (R788) is an orally dosed prodrug designed to deliver the active metabolite R940406 (R406), a spleen tyrosine kinase (SYK) inhibitor, for the treatment of rheumatoid arthritis.  The objectives were to evaluate the human pharmacokinetic properties of fostamatinib and R406.  Method : Three clin. studies were conducted in healthy subjects: (A) A single ascending dose study for R406 with doses ranging from 80-600mg, (B) a single- and multiple-dose study of fostamatinib in aq. suspension, with single doses ranging from 80-400mg and multiple doses at 160mg twice daily and (C) a study comparing suspension and tablet of fostamatinib, with the latter tested in both fed and fasted states.  Results : These studies demonstrated that when administered as a soln., R406 was rapidly absorbed.  Increases in exposure were obsd. with doses up to 400mg.  A terminal half-life of 12-21h was obsd.  Similar R406 exposure could be achieved with fostamatinib suspension and steady-state was achieved after 3-4 days following twice daily administration.  Fostamatinib tablet and suspension exhibited similar R406 exposure.  Upon co-administration with food, a delay in peak time and lower peak concns. of R406 were obsd. but at the same time the overall exposure did not change.  Conclusion : Fostamatinib demonstrates rapid and extensive conversion to R406, an inhibitor of SYK.  Solid dosage forms of fostamatinib overcome the challenge of low aq. soly. of R406.  The PK profile of R406 could potentially allow once daily or twice daily oral administration of fostamatinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpely6sKuO98LVg90H21EOLACvtfcHk0li9KkJw_WHtMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpvFeksLw%253D&md5=1096322f44f8dcdd3ea408f1e0619298</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1111%2Fbcp.12048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcp.12048%26sid%3Dliteratum%253Aachs%26aulast%3DBaluom%26aufirst%3DM.%26aulast%3DGrossbard%26aufirst%3DE.%2BB.%26aulast%3DMant%26aufirst%3DT.%26aulast%3DLau%26aufirst%3DD.%2BT.%2BW.%26atitle%3DPharmacokinetics%2520of%2520fostamatinib%252C%2520a%2520spleen%2520tyrosine%2520kinase%2520%2528SYK%2529%2520inhibitor%252C%2520in%2520healthy%2520human%2520subjects%2520following%2520single%2520and%2520multiple%2520oral%2520dosing%2520in%2520three%2520phase%2520I%2520studies%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2013%26volume%3D76%26spage%3D78%26epage%3D88%26doi%3D10.1111%2Fbcp.12048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weinblatt, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genovese, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosiak-Jedrychowicz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kavanaugh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millson, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Heijde, D.</span></span> <span> </span><span class="NLM_article-title">Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study</span>. <i>Arthritis Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">3255</span>– <span class="NLM_lpage">3264</span>, <span class="refDoi"> DOI: 10.1002/art.38851</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1002%2Fart.38851" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=25223724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2MXislWmtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2014&pages=3255-3264&author=M.+E.+Weinblattauthor=M.+C.+Genoveseauthor=M.+Hoauthor=S.+Hollisauthor=K.+Rosiak-Jedrychowiczauthor=A.+Kavanaughauthor=D.+S.+Millsonauthor=G.+Leonauthor=M.+Wangauthor=D.+van+der+Heijde&title=Effects+of+fostamatinib%2C+an+oral+spleen+tyrosine+kinase+inhibitor%2C+in+rheumatoid+arthritis+patients+with+an+inadequate+response+to+methotrexate%3A+results+from+a+phase+III%2C+multicenter%2C+randomized%2C+double-blind%2C+placebo-controlled%2C+parallel-group+study&doi=10.1002%2Fart.38851"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel group study</span></div><div class="casAuthors">Weinblatt, Michael E.; Genovese, Mark C.; Ho, Meilien; Hollis, Sally; Rosiak-Jedrychowicz, Krystyna; Kavanaugh, Arthur; Millson, David S.; Leon, Gustavo; Wang, Millie; van der Heijde, Desiree</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3255-3264</span>CODEN:
                <span class="NLM_cas:coden">ARRHBO</span>;
        ISSN:<span class="NLM_cas:issn">2326-5191</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective. This phase III, 52-wk study compared fostamatinib with placebo (for 24 wk) in patients with active rheumatoid arthritis (RA) and an inadequate response to methotrexate (MTX) therapy.  Methods. Patients taking MTX were randomized (1:1:1) to receive fostamatinib 100 mg twice daily for 52 wk (group A), fostamatinib 100 mg twice daily for 4 wk and then 150 mg once daily (group B), or placebo for 24 wk and then fostamatinib 100 mg twice daily (group C).  At week 24, the co-primary end points were change from baseline in the American College of Rheumatol. 20% (ACR20) improvement response rates and change in the modified total Sharp/van der Heijde score of radiog. damage (SHS).  Results. In this study, 918 patients were randomized and received ≥1 dose of study drug (fostamatinib or placebo); the demog. and baseline clin. characteristics were well balanced.  Following treatment with both fostamatinib regimens, a statistically significant difference in the ACR20 improvement response was achieved at week 24 as compared with that in patients receiving placebo (49.0% [group A] and 44.4%, [group B] vs. 34.2%; P < 0.001 and P = 0.006, resp.), but there was no statistically significant difference in the SHS between either fostamatinib group and placebo (P = 0.25 and P = 0.17, resp.).  The most common adverse events in patients in groups A, B, and C were hypertension (15.8%, 15.1%, and 3.9%, resp.) and diarrhea (13.9%, 15.1%, and 3.9%, resp.).  Elevated blood pressure (≥140/90 mm Hg) occurred at ≥1 visit in 44.2%, 41.6%, and 19.3% of patients in each resp. group.  Conclusion. With the use of either fostamatinib regimen in patients with RA, statistically significant, but not clin. significant, improvements in the ACR20 improvement response over placebo were achieved at 24 wk, whereas a significant difference in the SHS was not seen.  The overall level of response to treatment with fostamatinib was lower than had been obsd. in the phase II program, but similar adverse events were reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwksjH3b98S7Vg90H21EOLACvtfcHk0li9KkJw_WHtMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXislWmtw%253D%253D&md5=dd477eceb0e92b09422be73161307b2a</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1002%2Fart.38851&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.38851%26sid%3Dliteratum%253Aachs%26aulast%3DWeinblatt%26aufirst%3DM.%2BE.%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26aulast%3DHo%26aufirst%3DM.%26aulast%3DHollis%26aufirst%3DS.%26aulast%3DRosiak-Jedrychowicz%26aufirst%3DK.%26aulast%3DKavanaugh%26aufirst%3DA.%26aulast%3DMillson%26aufirst%3DD.%2BS.%26aulast%3DLeon%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DM.%26aulast%3Dvan%2Bder%2BHeijde%26aufirst%3DD.%26atitle%3DEffects%2520of%2520fostamatinib%252C%2520an%2520oral%2520spleen%2520tyrosine%2520kinase%2520inhibitor%252C%2520in%2520rheumatoid%2520arthritis%2520patients%2520with%2520an%2520inadequate%2520response%2520to%2520methotrexate%253A%2520results%2520from%2520a%2520phase%2520III%252C%2520multicenter%252C%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%252C%2520parallel-group%2520study%26jtitle%3DArthritis%2520Rheumatol.%26date%3D2014%26volume%3D66%26spage%3D3255%26epage%3D3264%26doi%3D10.1002%2Fart.38851" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genovese, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenwood, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nasonov, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oemar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoilov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vencovsky, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinblatt, M.</span></span> <span> </span><span class="NLM_article-title">OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy</span>. <i>Ann. Rheum. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">2123</span>– <span class="NLM_lpage">2129</span>, <span class="refDoi"> DOI: 10.1136/annrheumdis-2014-205361</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1136%2Fannrheumdis-2014-205361" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=25074688" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC28XntVWis7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2015&pages=2123-2129&author=P.+C.+Taylorauthor=M.+C.+Genoveseauthor=M.+Greenwoodauthor=M.+Hoauthor=E.+Nasonovauthor=B.+Oemarauthor=R.+Stoilovauthor=J.+Vencovskyauthor=M.+Weinblatt&title=OSKIRA-4%3A+a+phase+IIb+randomised%2C+placebo-controlled+study+of+the+efficacy+and+safety+of+fostamatinib+monotherapy&doi=10.1136%2Fannrheumdis-2014-205361"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy</span></div><div class="casAuthors">Taylor, Peter C.; Genovese, Mark C.; Greenwood, Mike; Ho, Meilien; Nasonov, Evgeny; Oemar, Barry; Stoilov, Rumen; Vencovsky, Jiri; Weinblatt, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the Rheumatic Diseases</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2123-2129</span>CODEN:
                <span class="NLM_cas:coden">ARDIAO</span>;
        ISSN:<span class="NLM_cas:issn">0003-4967</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Objectives OSKIRA-4 evaluated the efficacy of fostamatinib monotherapy vs. placebo on the signs and symptoms of rheumatoid arthritis over 6 wk by Disease Activity Score C reactive protein (DAS-28(CRP)) and assessed non-inferiority to adalimumab monotherapy at Week 24 by DAS-28(CRP).  Methods Overall, 279 patients not currently taking disease-modifying antirheumatic drugs were randomised to: (A) fostamatinib 100 mg twice daily for 24 wk plus placebo injection every 2 wk (PBOI); (B) fostamatinib 100 mg twice daily for 4 wk, then 150 mg once daily up to Week 24, plus PBOI; (C) fostamatinib 100 mg twice daily for 4 wk, then 100 mg once daily up to Week 24, plus PBOI; (D) adalimumab 40 mg every 2 wk for 24 wk, plus oral placebo twice daily; or (E) oral placebo twice daily for 6 wk, plus PBOI, then a switch to arm A or B.  Results Fostamatinib demonstrated a significant improvement in DAS-28(CRP) score from baseline vs. placebo at Week 6 for arms A and B, but not C.  Fostamatinib was significantly less effective than adalimumab at Week 24 based on DAS-28(CRP).  Adverse events obsd. with fostamatinib treatment were consistent with those reported in previous studies, including hypertension and diarrhoea.  Conclusions Fostamatinib demonstrated efficacy as monotherapy, showing superior DAS-28(CRP) score changes between baseline and 6 wk when compared with placebo in treatment arms A and B.  However, all fostamatinib regimens demonstrated inferior responses compared with adalimumab at Week 24.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUtupT8ZIrf7Vg90H21EOLACvtfcHk0li9KkJw_WHtMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntVWis7s%253D&md5=7cd74465eaed6bc5692c448f5f0fb1c4</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1136%2Fannrheumdis-2014-205361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fannrheumdis-2014-205361%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DP.%2BC.%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26aulast%3DGreenwood%26aufirst%3DM.%26aulast%3DHo%26aufirst%3DM.%26aulast%3DNasonov%26aufirst%3DE.%26aulast%3DOemar%26aufirst%3DB.%26aulast%3DStoilov%26aufirst%3DR.%26aulast%3DVencovsky%26aufirst%3DJ.%26aulast%3DWeinblatt%26aufirst%3DM.%26atitle%3DOSKIRA-4%253A%2520a%2520phase%2520IIb%2520randomised%252C%2520placebo-controlled%2520study%2520of%2520the%2520efficacy%2520and%2520safety%2520of%2520fostamatinib%2520monotherapy%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2015%26volume%3D74%26spage%3D2123%26epage%3D2129%26doi%3D10.1136%2Fannrheumdis-2014-205361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Genovese, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Heijde, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keystone, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spindler, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benhamou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kavanaugh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fudman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lampl, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffield, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poiley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinblatt, M. E.</span></span> <span> </span><span class="NLM_article-title">A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of 2 dosing regimens of fostamatinib in patients with rheumatoid arthritis with an inadequate response to a tumor necrosis factor-α antagonist</span>. <i>J. Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">2120</span>– <span class="NLM_lpage">2128</span>, <span class="refDoi"> DOI: 10.3899/jrheum.140238</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.3899%2Fjrheum.140238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=25225285" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVyltLfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2014&pages=2120-2128&author=M.+C.+Genoveseauthor=D.+M.+van+der+Heijdeauthor=E.+C.+Keystoneauthor=A.+J.+Spindlerauthor=C.+Benhamouauthor=A.+Kavanaughauthor=E.+Fudmanauthor=K.+Lamplauthor=C.+O%E2%80%99Brienauthor=E.+L.+Duffieldauthor=J.+Poileyauthor=M.+E.+Weinblatt&title=A+phase+III%2C+multicenter%2C+randomized%2C+double-blind%2C+placebo-controlled%2C+parallel-group+study+of+2+dosing+regimens+of+fostamatinib+in+patients+with+rheumatoid+arthritis+with+an+inadequate+response+to+a+tumor+necrosis+factor-%CE%B1+antagonist&doi=10.3899%2Fjrheum.140238"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of 2 dosing regimens of fostamatinib in patients with rheumatoid arthritis with an inadequate response to a tumor necrosis factor-α antagonist</span></div><div class="casAuthors">Genovese, Mark C.; van der Heijde, Desiree M.; Keystone, Edward C.; Spindler, Alberto J.; Benhamou, Claude; Kavanaugh, Arthur; Fudman, Edward; Lampl, Kathy; O'Brien, Chris; Duffield, Emma L.; Poiley, Jeffrey; Weinblatt, Michael E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Rheumatology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2120-2128</span>CODEN:
                <span class="NLM_cas:coden">JRHUA9</span>;
        ISSN:<span class="NLM_cas:issn">0315-162X</span>.
    
            (<span class="NLM_cas:orgname">Journal of Rheumatology Publishing Co. Ltd.</span>)
        </div><div class="casAbstract">Objective. Our 24-wk study (NCT01197755; OSKIRA-3) compared the efficacy and safety of fostamatinib vs. placebo in patients taking background methotrexate treatment with active rheumatoid arthritis (RA) and an inadequate response to a single tumor necrosis factor-α antagonist.  Methods. Adult patients were randomized (1:1:1) to fostamatinib [100 mg bid for 24 wk (n = 105; Group A)], or 100 mg bid for 4 wk, then 150 mg qd (n = 108; Group B), or to placebo (n = 110; Group C) for 24 wk.  Nonresponders at Week 12 could enter a longterm extension study.  The primary endpoint was the proportion of patients achieving an American College of Rheumatol. 20% (ACR20) response at Week 24.  Results. Baseline characteristics were well balanced.  Significantly more patients in fostamatinib Group A (36.2%; p = 0.004), but not B (27.8%; p = 0.168), achieved ACR20 at Week 24 vs. placebo (21.1%).  Frequently reported adverse events were diarrhea, hypertension, and headache.  Elevated blood pressure (≥ 140/90 mm Hg) at ≥ 1 visit was obsd. in 46.7%, 51.9%, and 26.6% of patients, resp.  There were 2 deaths in the study, 1 in Group B and 1 in the placebo group.  Conclusion. Fostamatinib 100 mg bid, but not fostamatinib 100 mg bid for 4 wk then 150 mg qd, achieved statistical improvements in ACR20 at 24 wk vs. placebo.  Because of efficacy and safety results from the phase III clin. program, the companies developing fostamatinib have decided not to study it further in RA at this time.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqU3UHjiwj-cbVg90H21EOLACvtfcHk0lj1FJvKxq5msA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVyltLfI&md5=6fbb8ff3ec66561f2fd5c8d066ce814b</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.3899%2Fjrheum.140238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3899%252Fjrheum.140238%26sid%3Dliteratum%253Aachs%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26aulast%3Dvan%2Bder%2BHeijde%26aufirst%3DD.%2BM.%26aulast%3DKeystone%26aufirst%3DE.%2BC.%26aulast%3DSpindler%26aufirst%3DA.%2BJ.%26aulast%3DBenhamou%26aufirst%3DC.%26aulast%3DKavanaugh%26aufirst%3DA.%26aulast%3DFudman%26aufirst%3DE.%26aulast%3DLampl%26aufirst%3DK.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DC.%26aulast%3DDuffield%26aufirst%3DE.%2BL.%26aulast%3DPoiley%26aufirst%3DJ.%26aulast%3DWeinblatt%26aufirst%3DM.%2BE.%26atitle%3DA%2520phase%2520III%252C%2520multicenter%252C%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%252C%2520parallel-group%2520study%2520of%25202%2520dosing%2520regimens%2520of%2520fostamatinib%2520in%2520patients%2520with%2520rheumatoid%2520arthritis%2520with%2520an%2520inadequate%2520response%2520to%2520a%2520tumor%2520necrosis%2520factor-%25CE%25B1%2520antagonist%26jtitle%3DJ.%2520Rheumatol.%26date%3D2014%26volume%3D41%26spage%3D2120%26epage%3D2128%26doi%3D10.3899%2Fjrheum.140238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Currie, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kropf, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blomgren, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallion, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitney, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maclin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lansdon, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maciejewski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macaluso, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbosa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Paolo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, S. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">3856</span>– <span class="NLM_lpage">3873</span>, <span class="refDoi"> DOI: 10.1021/jm500228a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500228a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2cXls1CrsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=3856-3873&author=K.+S.+Currieauthor=J.+E.+Kropfauthor=T.+Leeauthor=P.+Blomgrenauthor=J.+Xuauthor=Z.+Zhaoauthor=S.+Gallionauthor=J.+A.+Whitneyauthor=D.+Maclinauthor=E.+B.+Lansdonauthor=P.+Maciejewskiauthor=A.+M.+Rossiauthor=H.+Rongauthor=J.+Macalusoauthor=J.+Barbosaauthor=J.+A.+Di+Paoloauthor=S.+A.+Mitchell&title=Discovery+of+GS-9973%2C+a+selective+and+orally+efficacious+inhibitor+of+spleen+tyrosine+kinase&doi=10.1021%2Fjm500228a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of GS-9973, a Selective and Orally Efficacious Inhibitor of Spleen Tyrosine Kinase</span></div><div class="casAuthors">Currie, Kevin S.; Kropf, Jeffrey E.; Lee, Tony; Blomgren, Peter; Xu, Jianjun; Zhao, Zhongdong; Gallion, Steve; Whitney, J. Andrew; Maclin, Deborah; Lansdon, Eric B.; Maciejewski, Patricia; Rossi, Ann Marie; Rong, Hong; Macaluso, Jennifer; Barbosa, James; Di Paolo, Julie A.; Mitchell, Scott A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3856-3873</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Spleen tyrosine kinase (Syk) is an attractive drug target in autoimmune, inflammatory, and oncol. disease indications.  The most advanced Syk inhibitor, R406, (or its prodrug form fostamatinib), has shown efficacy in multiple therapeutic indications, but its clin. progress has been hampered by dose-limiting adverse effects that have been attributed, at least in part, to the off-target activities of R406.  It is expected that a more selective Syk inhibitor would provide a greater therapeutic window.  Herein the authors report the discovery and optimization of a novel series of imidazo[1,2-a]pyrazine Syk inhibitors.  This work culminated in the identification of GS-9973, a highly selective and orally efficacious Syk inhibitor which is currently undergoing clin. evaluation for autoimmune and oncol. indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRyEcx9jKxCbVg90H21EOLACvtfcHk0lj1FJvKxq5msA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXls1CrsL4%253D&md5=fc53448de1f5416f2c6600876f8c6385</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1021%2Fjm500228a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500228a%26sid%3Dliteratum%253Aachs%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26aulast%3DKropf%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DT.%26aulast%3DBlomgren%26aufirst%3DP.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DGallion%26aufirst%3DS.%26aulast%3DWhitney%26aufirst%3DJ.%2BA.%26aulast%3DMaclin%26aufirst%3DD.%26aulast%3DLansdon%26aufirst%3DE.%2BB.%26aulast%3DMaciejewski%26aufirst%3DP.%26aulast%3DRossi%26aufirst%3DA.%2BM.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DMacaluso%26aufirst%3DJ.%26aulast%3DBarbosa%26aufirst%3DJ.%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%2BA.%26aulast%3DMitchell%26aufirst%3DS.%2BA.%26atitle%3DDiscovery%2520of%2520GS-9973%252C%2520a%2520selective%2520and%2520orally%2520efficacious%2520inhibitor%2520of%2520spleen%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D3856%26epage%3D3873%26doi%3D10.1021%2Fjm500228a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tam, F. W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAdoo, S. P.</span></span> <span> </span><span class="NLM_article-title">Fostamatinib disodium</span>. <i>Drugs Future</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">273</span>, <span class="refDoi"> DOI: 10.1358/dof.2011.036.04.1588554</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1358%2Fdof.2011.036.04.1588554" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=23284223" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpt1ylurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2011&pages=273&author=F.+W.+K.+Tamauthor=S.+P.+McAdoo&title=Fostamatinib+disodium&doi=10.1358%2Fdof.2011.036.04.1588554"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Fostamatinib disodium: tyrosine-protein kinase SYK/FLT3 inhibitor treatment of rheumatoid arthritis oncolytic</span></div><div class="casAuthors">McAdoo, S. P.; Tam, F. W. K.; Pandian, R.; Bolos, J.; Castaner, R.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of the Future</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">273-280</span>CODEN:
                <span class="NLM_cas:coden">DRFUD4</span>;
        ISSN:<span class="NLM_cas:issn">0377-8282</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  The non-receptor tyrosine-protein kinase SYK (spleen tyrosine kinase) has a diverse range of biol. functions, including a crit. role in the intracellular signaling cascade for the surface Ig receptor on B lymphocytes and the Fc receptor expressed on numerous immune effector cells.  It is therefore seen as a potential therapeutic target in a variety of conditions, including autoimmune, allergic and malignant diseases.  Fostamatinib disodium is the orally bioavailable prodrug of R-406, a relatively selective small-mol. inhibitor of SYK, that has accordingly shown activity in numerous cell types in vitro, and efficacy in a remarkable range of animal models in vivo, including rodent models of asthma, inflammatory arthritis, lupus, glomerulonephritis, diabetes and lymphoma.  Success in these models has translated to phase II clin. trials in autoimmune thrombocytopenia, lymphoma and, most notably, rheumatoid arthritis, in which larger phase III trials are currently in progress.  While the diverse biol. functions of SYK coupled with the potential off-target effects of this kinase inhibitor are a source of possible toxicity, the available data thus far augur well for future clin. use of fostamatinib in a wide range of human diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1UBbKHhezKrVg90H21EOLACvtfcHk0lj1FJvKxq5msA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpt1ylurs%253D&md5=762da3b1321b7eadbe9ae531221b5593</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1358%2Fdof.2011.036.04.1588554&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdof.2011.036.04.1588554%26sid%3Dliteratum%253Aachs%26aulast%3DTam%26aufirst%3DF.%2BW.%2BK.%26aulast%3DMcAdoo%26aufirst%3DS.%2BP.%26atitle%3DFostamatinib%2520disodium%26jtitle%3DDrugs%2520Future%26date%3D2011%26volume%3D36%26spage%3D273%26doi%3D10.1358%2Fdof.2011.036.04.1588554" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vollenhoven, R. v.</span>; <span class="NLM_string-name">Cohen, S. B.</span>; <span class="NLM_string-name">Mease, P. J.</span>; <span class="NLM_string-name">Peterfy, C. G.</span>; <span class="NLM_string-name">Spieler, W.</span>; <span class="NLM_string-name">Boice, J.</span>; <span class="NLM_string-name">Curtis, S.</span>; <span class="NLM_string-name">Li, Q.</span>; <span class="NLM_string-name">Yao, R.</span>; <span class="NLM_string-name">Baumgartner, R.</span>; <span class="NLM_string-name">Weng, H.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety of MK-8457, a novel SYK inhibitor for the treatment of rheumatoid arthritis in two randomized, controlled, phase 2 studies</span>. Presented at the 2014 ACR/ARHP Annual Meeting, Boston MA, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=R.+v.+Vollenhoven&author=S.+B.+Cohen&author=P.+J.+Mease&author=C.+G.+Peterfy&author=W.+Spieler&author=J.+Boice&author=S.+Curtis&author=Q.+Li&author=R.+Yao&author=R.+Baumgartner&author=H.+Weng&title=Efficacy+and+safety+of+MK-8457%2C+a+novel+SYK+inhibitor+for+the+treatment+of+rheumatoid+arthritis+in+two+randomized%2C+controlled%2C+phase+2+studies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DVollenhoven%26aufirst%3DR.%2Bv.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520MK-8457%252C%2520a%2520novel%2520SYK%2520inhibitor%2520for%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%2520in%2520two%2520randomized%252C%2520controlled%252C%2520phase%25202%2520studies%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coffey, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pak, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haberstock-Debic, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollenbach, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gretler, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mant, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jurcevic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinha, U.</span></span> <span> </span><span class="NLM_article-title">PRT062607 achieves complete inhibition of the spleen tyrosine kinase at tolerated exposures following oral dosing in healthy volunteers</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">194</span>– <span class="NLM_lpage">210</span>, <span class="refDoi"> DOI: 10.1002/jcph.794</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1002%2Fjcph.794" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=27406873" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2sXotlSrtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2017&pages=194-210&author=G.+Coffeyauthor=A.+Raniauthor=A.+Betzauthor=Y.+Pakauthor=H.+Haberstock-Debicauthor=A.+Pandeyauthor=S.+Hollenbachauthor=D.+D.+Gretlerauthor=T.+Mantauthor=S.+Jurcevicauthor=U.+Sinha&title=PRT062607+achieves+complete+inhibition+of+the+spleen+tyrosine+kinase+at+tolerated+exposures+following+oral+dosing+in+healthy+volunteers&doi=10.1002%2Fjcph.794"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">PRT062607 Achieves Complete Inhibition of the Spleen Tyrosine Kinase at Tolerated Exposures Following Oral Dosing in Healthy Volunteers</span></div><div class="casAuthors">Coffey, Greg; Rani, Aradhana; Betz, Andreas; Pak, Yvonne; Haberstock-Debic, Helena; Pandey, Anjali; Hollenbach, Stanley; Gretler, Daniel D.; Mant, Tim; Jurcevic, Stipo; Sinha, Uma</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">194-210</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The spleen tyrosine kinase (SYK) regulates immune cell activation in response to engagement of a variety of receptors, making it an intriguing target for the treatment of inflammatory and autoimmune disorders as well as certain B-cell malignancies.  We have previously reported on the discovery and preclin. characterization of PRT062607, a potent and highly selective inhibitor of SYK that exhibits robust anti-inflammatory activity in a variety of animal models.  Here we present data from our first human studies aimed at characterizing the pharmacokinetics (PK), pharmacodynamics (PD), and safety of PRT062607 in healthy volunteers following single and multiple oral administrations.  PRT062607 demonstrated a favorable PK profile and the ability to completely inhibit SYK activity in multiple whole-blood assays.  The PD half-life in the more sensitive assays was approx. 24 h and returned to predose levels by 72 h.  Selectivity for SYK was obsd. at all dose levels tested.  Anal. of the PK/PD relationship indicated an IC50 of 324 nM for inhibition of B-cell antigen receptor-mediated B-cell activation and 205 nM for inhibition of FcεRI-mediated basophil degranulation.  PRT062607 was safe and well tolerated across the entire range of doses.  Clin. PK/PD was related to in vivo anti-inflammatory activity of PRT062607 in the rat collagen-induced arthritis model, which predicts that therapeutic concns. may be safely achieved in humans for the treatment of autoimmune disease.  PRT062607 has a desirable PK profile and is capable of safely, potently, and selectively suppressing SYK kinase function in humans following once-daily oral dosing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCmfMLrtasGbVg90H21EOLACvtfcHk0ljuxTYfCyqVQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXotlSrtw%253D%253D&md5=93d8c5128dbd3d21a51335941f06a8c1</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1002%2Fjcph.794&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcph.794%26sid%3Dliteratum%253Aachs%26aulast%3DCoffey%26aufirst%3DG.%26aulast%3DRani%26aufirst%3DA.%26aulast%3DBetz%26aufirst%3DA.%26aulast%3DPak%26aufirst%3DY.%26aulast%3DHaberstock-Debic%26aufirst%3DH.%26aulast%3DPandey%26aufirst%3DA.%26aulast%3DHollenbach%26aufirst%3DS.%26aulast%3DGretler%26aufirst%3DD.%2BD.%26aulast%3DMant%26aufirst%3DT.%26aulast%3DJurcevic%26aufirst%3DS.%26aulast%3DSinha%26aufirst%3DU.%26atitle%3DPRT062607%2520achieves%2520complete%2520inhibition%2520of%2520the%2520spleen%2520tyrosine%2520kinase%2520at%2520tolerated%2520exposures%2520following%2520oral%2520dosing%2520in%2520healthy%2520volunteers%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2017%26volume%3D57%26spage%3D194%26epage%3D210%26doi%3D10.1002%2Fjcph.794" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di Paolo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blomgren, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kropf, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suekawa-Pirrone, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wise, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, K.</span></span> <span> </span><span class="NLM_article-title">Preclinical characterization of GS-9876, a novel, oral SYK inhibitor that shows efficacy in multiple established rat models of collagen-induced arthritis</span>. <i>Ann. Rheum. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">443</span>– <span class="NLM_lpage">444</span>, <span class="refDoi"> DOI: 10.1136/annrheumdis-2016-eular.2209</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1136%2Fannrheumdis-2016-eular.2209" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2016&pages=443-444&author=J.+Di+Paoloauthor=P.+Blomgrenauthor=M.+Doltonauthor=R.+Jonesauthor=J.+Kropfauthor=T.+Leeauthor=S.+Mitchellauthor=B.+Murrayauthor=K.+Suekawa-Pirroneauthor=S.+Wiseauthor=J.+Xuauthor=Z.+Zhaoauthor=K.+Currie&title=Preclinical+characterization+of+GS-9876%2C+a+novel%2C+oral+SYK+inhibitor+that+shows+efficacy+in+multiple+established+rat+models+of+collagen-induced+arthritis&doi=10.1136%2Fannrheumdis-2016-eular.2209"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1136%2Fannrheumdis-2016-eular.2209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fannrheumdis-2016-eular.2209%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%26aulast%3DBlomgren%26aufirst%3DP.%26aulast%3DDolton%26aufirst%3DM.%26aulast%3DJones%26aufirst%3DR.%26aulast%3DKropf%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DT.%26aulast%3DMitchell%26aufirst%3DS.%26aulast%3DMurray%26aufirst%3DB.%26aulast%3DSuekawa-Pirrone%26aufirst%3DK.%26aulast%3DWise%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DCurrie%26aufirst%3DK.%26atitle%3DPreclinical%2520characterization%2520of%2520GS-9876%252C%2520a%2520novel%252C%2520oral%2520SYK%2520inhibitor%2520that%2520shows%2520efficacy%2520in%2520multiple%2520established%2520rat%2520models%2520of%2520collagen-induced%2520arthritis%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2016%26volume%3D75%26spage%3D443%26epage%3D444%26doi%3D10.1136%2Fannrheumdis-2016-eular.2209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zammit, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denis, L.</span></span> <span> </span><span class="NLM_article-title">A novel dual SYK/JAK inhibitor with strong antitumor activity in both hematological and solid tumor xenograft models</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">4204</span>– <span class="NLM_lpage">4204</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2017-4204</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1158%2F1538-7445.AM2017-4204" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=4204-4204&author=S.+P.+Reddyauthor=N.+Raoauthor=D.+Zammitauthor=S.+K.+Thompsonauthor=R.+A.+Smithauthor=L.+Denis&title=A+novel+dual+SYK%2FJAK+inhibitor+with+strong+antitumor+activity+in+both+hematological+and+solid+tumor+xenograft+models&doi=10.1158%2F1538-7445.AM2017-4204"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2017-4204&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2017-4204%26sid%3Dliteratum%253Aachs%26aulast%3DReddy%26aufirst%3DS.%2BP.%26aulast%3DRao%26aufirst%3DN.%26aulast%3DZammit%26aufirst%3DD.%26aulast%3DThompson%26aufirst%3DS.%2BK.%26aulast%3DSmith%26aufirst%3DR.%2BA.%26aulast%3DDenis%26aufirst%3DL.%26atitle%3DA%2520novel%2520dual%2520SYK%252FJAK%2520inhibitor%2520with%2520strong%2520antitumor%2520activity%2520in%2520both%2520hematological%2520and%2520solid%2520tumor%2520xenograft%2520models%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26spage%3D4204%26epage%3D4204%26doi%3D10.1158%2F1538-7445.AM2017-4204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Lucca, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langevine, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batt, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaudoin
Bertrand, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yip, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traeger, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattoli, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obermeier, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vickery, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Discenza, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimrich, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulicicchio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galella, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebben, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muckelbauer, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rampulla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-Cid, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrish, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tino, J. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of 6-fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): a reversible inhibitor of Bruton’s tyrosine kinase (BTK) conformationally constrained by two locked atropisomers</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">9173</span>– <span class="NLM_lpage">9200</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01088</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01088" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVKjsrfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=9173-9200&author=S.+H.+Wattersonauthor=G.+V.+De+Luccaauthor=Q.+Shiauthor=C.+M.+Langevineauthor=Q.+Liuauthor=D.+G.+Battauthor=M.+Beaudoin%0ABertrandauthor=H.+Gongauthor=J.+Daiauthor=S.+Yipauthor=P.+Liauthor=D.+Sunauthor=D.-R.+Wuauthor=C.+Wangauthor=Y.+Zhangauthor=S.+C.+Traegerauthor=M.+A.+Pattoliauthor=S.+Skalaauthor=L.+Chengauthor=M.+T.+Obermeierauthor=R.+Vickeryauthor=L.+N.+Discenzaauthor=C.+J.+D%E2%80%99Arienzoauthor=Y.+Zhangauthor=E.+Heimrichauthor=K.+M.+Gilloolyauthor=T.+L.+Taylorauthor=C.+Pulicicchioauthor=K.+W.+McIntyreauthor=M.+A.+Galellaauthor=A.+J.+Tebbenauthor=J.+K.+Muckelbauerauthor=C.+Changauthor=R.+Rampullaauthor=A.+Mathurauthor=L.+Salter-Cidauthor=J.+C.+Barrishauthor=P.+H.+Carterauthor=A.+Furaauthor=J.+R.+Burkeauthor=J.+A.+Tino&title=Discovery+of+6-fluoro-5-%28R%29-%283-%28S%29-%288-fluoro-1-methyl-2%2C4-dioxo-1%2C2-dihydroquinazolin-3%284H%29-yl%29-2-methylphenyl%29-2-%28S%29-%282-hydroxypropan-2-yl%29-2%2C3%2C4%2C9-tetrahydro-1H-carbazole-8-carboxamide+%28BMS-986142%29%3A+a+reversible+inhibitor+of+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29+conformationally+constrained+by+two+locked+atropisomers&doi=10.1021%2Facs.jmedchem.6b01088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton's Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers</span></div><div class="casAuthors">Watterson, Scott H.; De Lucca, George V.; Shi, Qing; Langevine, Charles M.; Liu, Qingjie; Batt, Douglas G.; Beaudoin Bertrand, Myra; Gong, Hua; Dai, Jun; Yip, Shiuhang; Li, Peng; Sun, Dawn; Wu, Dauh-Rurng; Wang, Chunlei; Zhang, Yingru; Traeger, Sarah C.; Pattoli, Mark A.; Skala, Stacey; Cheng, Lihong; Obermeier, Mary T.; Vickery, Rodney; Discenza, Lorell N.; D'Arienzo, Celia J.; Zhang, Yifan; Heimrich, Elizabeth; Gillooly, Kathleen M.; Taylor, Tracy L.; Pulicicchio, Claudine; McIntyre, Kim W.; Galella, Michael A.; Tebben, Andy J.; Muckelbauer, Jodi K.; Chang, ChiehYing; Rampulla, Richard; Mathur, Arvind; Salter-Cid, Luisa; Barrish, Joel C.; Carter, Percy H.; Fura, Aberra; Burke, James R.; Tino, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">9173-9200</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK), a nonreceptor tyrosine kinase, is a member of the Tec family of kinases.  BTK plays an essential role in B cell receptor (BCR)-mediated signaling as well as Fcγ receptor signaling in monocytes and Fcε receptor signaling in mast cells and basophils, all of which have been implicated in the pathophysiol. of autoimmune disease.  As a result, inhibition of BTK is anticipated to provide an effective strategy for the clin. treatment of autoimmune diseases such as lupus and rheumatoid arthritis.  This article details the structure-activity relationships (SAR) leading to a novel series of highly potent and selective carbazole and tetrahydrocarbazole based, reversible inhibitors of BTK.  Of particular interest is that two atropisomeric centers were rotationally locked to provide a single, stable atropisomer, resulting in enhanced potency and selectivity as well as a redn. in safety liabilities.  With significantly enhanced potency and selectivity, excellent in vivo properties and efficacy, and a very desirable tolerability and safety profile, 14f (BMS-986142) was advanced into clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmpBAygRAsYrVg90H21EOLACvtfcHk0liJJ1gJZkrO2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVKjsrfF&md5=91098abc802521b9ad91563d20ac5893</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01088%26sid%3Dliteratum%253Aachs%26aulast%3DWatterson%26aufirst%3DS.%2BH.%26aulast%3DDe%2BLucca%26aufirst%3DG.%2BV.%26aulast%3DShi%26aufirst%3DQ.%26aulast%3DLangevine%26aufirst%3DC.%2BM.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DBatt%26aufirst%3DD.%2BG.%26aulast%3DBeaudoin%2BBertrand%26aufirst%3DM.%26aulast%3DGong%26aufirst%3DH.%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DYip%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DD.-R.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DTraeger%26aufirst%3DS.%2BC.%26aulast%3DPattoli%26aufirst%3DM.%2BA.%26aulast%3DSkala%26aufirst%3DS.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DObermeier%26aufirst%3DM.%2BT.%26aulast%3DVickery%26aufirst%3DR.%26aulast%3DDiscenza%26aufirst%3DL.%2BN.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%2BJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHeimrich%26aufirst%3DE.%26aulast%3DGillooly%26aufirst%3DK.%2BM.%26aulast%3DTaylor%26aufirst%3DT.%2BL.%26aulast%3DPulicicchio%26aufirst%3DC.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DGalella%26aufirst%3DM.%2BA.%26aulast%3DTebben%26aufirst%3DA.%2BJ.%26aulast%3DMuckelbauer%26aufirst%3DJ.%2BK.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DRampulla%26aufirst%3DR.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DSalter-Cid%26aufirst%3DL.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DFura%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DTino%26aufirst%3DJ.%2BA.%26atitle%3DDiscovery%2520of%25206-fluoro-5-%2528R%2529-%25283-%2528S%2529-%25288-fluoro-1-methyl-2%252C4-dioxo-1%252C2-dihydroquinazolin-3%25284H%2529-yl%2529-2-methylphenyl%2529-2-%2528S%2529-%25282-hydroxypropan-2-yl%2529-2%252C3%252C4%252C9-tetrahydro-1H-carbazole-8-carboxamide%2520%2528BMS-986142%2529%253A%2520a%2520reversible%2520inhibitor%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%2520conformationally%2520constrained%2520by%2520two%2520locked%2520atropisomers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D9173%26epage%3D9200%26doi%3D10.1021%2Facs.jmedchem.6b01088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohli, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katewa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gogol, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belmont, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penuel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burton, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortwine, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franke, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estevez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergeron, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span> <span> </span><span class="NLM_article-title">Battling Btk mutants with noncovalent inhibitors that overcome Cys481 and Thr474 mutations</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">2897</span>– <span class="NLM_lpage">2907</span>, <span class="refDoi"> DOI: 10.1021/acschembio.6b00480</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.6b00480" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVWltr3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=2897-2907&author=A.+R.+Johnsonauthor=P.+B.+Kohliauthor=A.+Katewaauthor=E.+Gogolauthor=L.+D.+Belmontauthor=R.+Choyauthor=E.+Penuelauthor=L.+Burtonauthor=C.+Eigenbrotauthor=C.+Yuauthor=D.+F.+Ortwineauthor=K.+Bowmanauthor=Y.+Frankeauthor=C.+Tamauthor=A.+Estevezauthor=K.+Mortaraauthor=J.+Wuauthor=H.+Liauthor=M.+Linauthor=P.+Bergeronauthor=J.+J.+Crawfordauthor=W.+B.+Young&title=Battling+Btk+mutants+with+noncovalent+inhibitors+that+overcome+Cys481+and+Thr474+mutations&doi=10.1021%2Facschembio.6b00480"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations</span></div><div class="casAuthors">Johnson, Adam R.; Kohli, Pawan Bir; Katewa, Arna; Gogol, Emily; Belmont, Lisa D.; Choy, Regina; Penuel, Elicia; Burton, Luciana; Eigenbrot, Charles; Yu, Christine; Ortwine, Daniel F.; Bowman, Krista; Franke, Yvonne; Tam, Christine; Estevez, Alberto; Mortara, Kyle; Wu, Jiansheng; Li, Hong; Lin, May; Bergeron, Philippe; Crawford, James J.; Young, Wendy B.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2897-2907</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The Bruton's tyrosine kinase (Btk) inhibitor ibrutinib has shown impressive clin. efficacy in a range of B-cell malignancies, however acquired resistance has emerged and second generation therapies are now being sought.  Ibrutinib is a covalent, irreversible inhibitor that modifies Cys481 in the ATP binding site of Btk and renders the enzyme inactive, thereby blocking B-cell receptor signal transduction.  Not surprisingly, Cys481 is the most commonly mutated Btk residue in cases of acquired resistance to ibrutinib.  Mutations at other sites, including Thr474, a gatekeeper residue, have also been detected.  Herein the authors describe noncovalent Btk inhibitors that differ from covalent inhibitors like ibrutinib in that they do not interact with Cys481, they potently inhibit the ibrutinib-resistant Btk C481S mutant in vitro and in cells, and they are exquisitely selective for Btk.  Noncovalent inhibitors such as GNE-431 also show excellent potency against the C481R, T474I, and T474M mutants.  X-ray crystallog. anal. of Btk provides insight into the unique mode of binding of these inhibitors that explains their high selectivity for Btk and their retained activity against mutant forms of Btk.  This class of noncovalent Btk inhibitors may provide a treatment option to patients, esp. those who have acquired resistance to ibrutinib by mutation of Cys481 or Thr474.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkuzaMmxhJ67Vg90H21EOLACvtfcHk0liJJ1gJZkrO2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVWltr3E&md5=1e0458160f967ed01c259751cc2118e1</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1021%2Facschembio.6b00480&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.6b00480%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DKohli%26aufirst%3DP.%2BB.%26aulast%3DKatewa%26aufirst%3DA.%26aulast%3DGogol%26aufirst%3DE.%26aulast%3DBelmont%26aufirst%3DL.%2BD.%26aulast%3DChoy%26aufirst%3DR.%26aulast%3DPenuel%26aufirst%3DE.%26aulast%3DBurton%26aufirst%3DL.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DBowman%26aufirst%3DK.%26aulast%3DFranke%26aufirst%3DY.%26aulast%3DTam%26aufirst%3DC.%26aulast%3DEstevez%26aufirst%3DA.%26aulast%3DMortara%26aufirst%3DK.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DLin%26aufirst%3DM.%26aulast%3DBergeron%26aufirst%3DP.%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26atitle%3DBattling%2520Btk%2520mutants%2520with%2520noncovalent%2520inhibitors%2520that%2520overcome%2520Cys481%2520and%2520Thr474%2520mutations%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2016%26volume%3D11%26spage%3D2897%26epage%3D2907%26doi%3D10.1021%2Facschembio.6b00480" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dougan, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komandla, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanouni, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knight, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawson, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabat, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyrick, C.</span></span> <span> </span><span class="NLM_article-title">Fragment-based discovery of a small molecule inhibitor of Bruton’s tyrosine kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">5437</span>– <span class="NLM_lpage">5444</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00734</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00734" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVans7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=5437-5444&author=C.+R.+Smithauthor=D.+R.+Douganauthor=M.+Komandlaauthor=T.+Kanouniauthor=B.+Knightauthor=J.+D.+Lawsonauthor=M.+Sabatauthor=E.+R.+Taylorauthor=P.+Vuauthor=C.+Wyrick&title=Fragment-based+discovery+of+a+small+molecule+inhibitor+of+Bruton%E2%80%99s+tyrosine+kinase&doi=10.1021%2Facs.jmedchem.5b00734"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment-Based Discovery of a Small Molecule Inhibitor of Bruton's Tyrosine Kinase</span></div><div class="casAuthors">Smith, Christopher R.; Dougan, Douglas R.; Komandla, Mallareddy; Kanouni, Toufike; Knight, Beverly; Lawson, J. David; Sabat, Mark; Taylor, Ewan R.; Vu, Phong; Wyrick, Corey</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5437-5444</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery and optimization of a series of 4-aminocinnoline-3-carboxamide inhibitors of Bruton's tyrosine kinase are reported.  A fragment-based screening approach incorporating x-ray cocrystallog. was used to identify a cinnoline fragment and characterize its binding mode in the ATP binding site of Btk.  Optimization of the fragment hit resulted in the identification of a lead compd. I which reduced paw swelling in a dose- and exposure-dependent fashion in a rat model of collagen-induced arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozENTW7pHlFrVg90H21EOLACvtfcHk0liJJ1gJZkrO2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVans7rF&md5=d6626fabcc3e2aa6a9180dc702a5030c</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00734&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00734%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DC.%2BR.%26aulast%3DDougan%26aufirst%3DD.%2BR.%26aulast%3DKomandla%26aufirst%3DM.%26aulast%3DKanouni%26aufirst%3DT.%26aulast%3DKnight%26aufirst%3DB.%26aulast%3DLawson%26aufirst%3DJ.%2BD.%26aulast%3DSabat%26aufirst%3DM.%26aulast%3DTaylor%26aufirst%3DE.%2BR.%26aulast%3DVu%26aufirst%3DP.%26aulast%3DWyrick%26aufirst%3DC.%26atitle%3DFragment-based%2520discovery%2520of%2520a%2520small%2520molecule%2520inhibitor%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D5437%26epage%3D5444%26doi%3D10.1021%2Facs.jmedchem.5b00734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuglstatter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondru, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, D. M.</span></span> <span> </span><span class="NLM_article-title">Bruton’s tyrosine kinase inhibitors: approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and B cell malignancies</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">4539</span>– <span class="NLM_lpage">4550</span>, <span class="refDoi"> DOI: 10.1021/jm300035p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300035p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC38XjsVChsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=4539-4550&author=Y.+Louauthor=T.+D.+Owensauthor=A.+Kuglstatterauthor=R.+K.+Kondruauthor=D.+M.+Goldstein&title=Bruton%E2%80%99s+tyrosine+kinase+inhibitors%3A+approaches+to+potent+and+selective+inhibition%2C+preclinical+and+clinical+evaluation+for+inflammatory+diseases+and+B+cell+malignancies&doi=10.1021%2Fjm300035p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton's Tyrosine Kinase Inhibitors: Approaches to Potent and Selective Inhibition, Preclinical and Clinical Evaluation for Inflammatory Diseases and B Cell Malignancies</span></div><div class="casAuthors">Lou, Yan; Owens, Timothy D.; Kuglstatter, Andreas; Kondru, Rama K.; Goldstein, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4539-4550</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRzAwa4gtFprVg90H21EOLACvtfcHk0lhjcqwxa5HcmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjsVChsb8%253D&md5=b470ba4ec4867e4bfb8d1cfa92b1cc6d</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1021%2Fjm300035p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300035p%26sid%3Dliteratum%253Aachs%26aulast%3DLou%26aufirst%3DY.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26aulast%3DKuglstatter%26aufirst%3DA.%26aulast%3DKondru%26aufirst%3DR.%2BK.%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26atitle%3DBruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitors%253A%2520approaches%2520to%2520potent%2520and%2520selective%2520inhibition%252C%2520preclinical%2520and%2520clinical%2520evaluation%2520for%2520inflammatory%2520diseases%2520and%2520B%2520cell%2520malignancies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D4539%26epage%3D4550%26doi%3D10.1021%2Fjm300035p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Akinleye, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukhi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span> <span> </span><span class="NLM_article-title">Ibrutinib and novel BTK inhibitors in clinical development</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">59</span>– <span class="NLM_lpage">67</span>, <span class="refDoi"> DOI: 10.1186/1756-8722-6-59</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1186%2F1756-8722-6-59" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=23958373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVagtrjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2013&pages=59-67&author=A.+Akinleyeauthor=Y.+Chenauthor=N.+Mukhiauthor=Y.+Songauthor=D.+Liu&title=Ibrutinib+and+novel+BTK+inhibitors+in+clinical+development&doi=10.1186%2F1756-8722-6-59"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Ibrutinib and novel BTK inhibitors in clinical development</span></div><div class="casAuthors">Akinleye, Akintunde; Chen, Yamei; Mukhi, Nikhil; Song, Yongping; Liu, Delong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">59</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Small mol. inhibitors targeting dysregulated pathways (RAS/RAF/MEK, PI3K/AKT/mTOR, JAK/STAT) have significantly improved clin. outcomes in cancer patients.  Recently Bruton's tyrosine kinase (BTK), a crucial terminal kinase enzyme in the B-cell antigen receptor (BCR) signaling pathway, has emerged as an attractive target for therapeutic intervention in human malignancies and autoimmune disorders.  Ibrutinib, a novel first-in-human BTK inhibitor, has demonstrated clin. effectiveness and tolerability in early clin. trials and has progressed into phase III trials.  However, addnl. research is necessary to identify the optimal dosing schedule, as well as patients most likely to benefit from BTK inhibition.  This review summarizes preclin. and clin. development of ibrutinib and other novel BTK inhibitors (GDC-0834, CGI-560, CGI-1746, HM-71224, CC-292 and ONO-4059, CNX-774, LFM-A13) in the treatment of B-cell malignancies and autoimmune disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-fz7_rhCHvbVg90H21EOLACvtfcHk0lhjcqwxa5HcmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVagtrjI&md5=e5067b998c61818e2efbb62da935b490</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1186%2F1756-8722-6-59&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1756-8722-6-59%26sid%3Dliteratum%253Aachs%26aulast%3DAkinleye%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DMukhi%26aufirst%3DN.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DD.%26atitle%3DIbrutinib%2520and%2520novel%2520BTK%2520inhibitors%2520in%2520clinical%2520development%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2013%26volume%3D6%26spage%3D59%26epage%3D67%26doi%3D10.1186%2F1756-8722-6-59" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Musumeci, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanna, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greco, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giacchello, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fallacara, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amato, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schenone, S.</span></span> <span> </span><span class="NLM_article-title">Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1305</span>– <span class="NLM_lpage">1318</span>, <span class="refDoi"> DOI: 10.1080/13543776.2017.1355908</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1080%2F13543776.2017.1355908" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=28705083" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1Sgt7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=1305-1318&author=F.+Musumeciauthor=M.+Sannaauthor=C.+Grecoauthor=I.+Giacchelloauthor=A.+L.+Fallacaraauthor=R.+Amatoauthor=S.+Schenone&title=Pyrrolo%5B2%2C3-d%5Dpyrimidines+active+as+Btk+inhibitors&doi=10.1080%2F13543776.2017.1355908"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors</span></div><div class="casAuthors">Musumeci, Francesca; Sanna, Monica; Greco, Chiara; Giacchello, Ilaria; Fallacara, Anna Lucia; Amato, Rosario; Schenone, Silvia</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1305-1318</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Introduction: Btk is a tyrosine kinase dysregulated in several B-cell malignancies and autoimmune diseases, and this has given rise to a search for Btk inhibitors.  Nevertheless, only one Btk inhibitor, ibrutinib, has been approved to date, although other compds. are currently being evaluated in clin. trials or in preclinal stages.  Area covered: This review, after a brief introduction on Btk and its inhibitors already in clin. trials, focusses on pyrrolo[2,3-d]pyrimidine derivs. patented in the last five years as Btk inhibitors.  Indeed, the pyrrolo[2,3-d]pyrimidine scaffold, being a deaza-isostere of adenine, the nitrogenous base of ATP, is an actively pursued target for Btk inhibitors.  The patent literature since 2012 have been extensively investigated, pointing out the general features of the patented compds. and, when it is possible, their mechanism of action.  Expert opinion: The recently patented pyrrolo[2,3-d]pyrimidines, acting as reversible or irreversible inhibitors, showed a very interesting in vitro activity.  For this reason, the development of compds. endowed with this scaffold could afford a significant impact in the search for drug candidates for the treatment of immune diseases or B-cell malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPT0s7eVqXebVg90H21EOLACvtfcHk0lhjcqwxa5HcmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1Sgt7vK&md5=294c9b8bcafe6f7831187cb963f2f072</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1080%2F13543776.2017.1355908&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2017.1355908%26sid%3Dliteratum%253Aachs%26aulast%3DMusumeci%26aufirst%3DF.%26aulast%3DSanna%26aufirst%3DM.%26aulast%3DGreco%26aufirst%3DC.%26aulast%3DGiacchello%26aufirst%3DI.%26aulast%3DFallacara%26aufirst%3DA.%2BL.%26aulast%3DAmato%26aufirst%3DR.%26aulast%3DSchenone%26aufirst%3DS.%26atitle%3DPyrrolo%255B2%252C3-d%255Dpyrimidines%2520active%2520as%2520Btk%2520inhibitors%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2017%26volume%3D27%26spage%3D1305%26epage%3D1318%26doi%3D10.1080%2F13543776.2017.1355908" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lanning, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitby, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dix, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douhan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hett, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joslyn, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kath, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niessen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnute, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hulce, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whiteley, L. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayward, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span> <span> </span><span class="NLM_article-title">A roadmap to evaluate the proteome-wide selectivity of covalent kinase inhibitors</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">760</span>– <span class="NLM_lpage">767</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1582</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1038%2Fnchembio.1582" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=25038787" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFygs7nO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=760-767&author=B.+R.+Lanningauthor=L.+R.+Whitbyauthor=M.+M.+Dixauthor=J.+Douhanauthor=A.+M.+Gilbertauthor=E.+C.+Hettauthor=T.+O.+Johnsonauthor=C.+Joslynauthor=J.+C.+Kathauthor=S.+Niessenauthor=L.+R.+Robertsauthor=M.+E.+Schnuteauthor=C.+Wangauthor=J.+J.+Hulceauthor=B.+Weiauthor=L.+O.+Whiteleyauthor=M.+M.+Haywardauthor=B.+F.+Cravatt&title=A+roadmap+to+evaluate+the+proteome-wide+selectivity+of+covalent+kinase+inhibitors&doi=10.1038%2Fnchembio.1582"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors</span></div><div class="casAuthors">Lanning, Bryan R.; Whitby, Landon R.; Dix, Melissa M.; Douhan, John; Gilbert, Adam M.; Hett, Erik C.; Johnson, Theodore O.; Joslyn, Chris; Kath, John C.; Niessen, Sherry; Roberts, Lee R.; Schnute, Mark E.; Wang, Chu; Hulce, Jonathan J.; Wei, Baoxian; Whiteley, Laurence O.; Hayward, Matthew M.; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">760-767</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinases are principal components of signal transduction pathways and the focus of intense basic and drug discovery research.  Irreversible inhibitors that covalently modify non-catalytic cysteines in kinase active sites have emerged as valuable probes and approved drugs.  Many protein classes, however, have functional cysteines, and therefore understanding the proteome-wide selectivity of covalent kinase inhibitors is imperative.  Here, we accomplish this objective using activity-based protein profiling coupled with quant. MS to globally map the targets, both specific and nonspecific, of covalent kinase inhibitors in human cells.  Many of the specific off-targets represent nonkinase proteins that, notably, have conserved active site cysteines.  We define windows of selectivity for covalent kinase inhibitors and show that, when these windows are exceeded, rampant proteome-wide reactivity and kinase target-independent cell death conjointly occur.  Our findings, taken together, provide an exptl. road map to illuminate opportunities and surmount challenges for the development of covalent kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMAiUlEg9R5rVg90H21EOLACvtfcHk0lhqAbxW7VHUKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFygs7nO&md5=6f17b0d1b00e088f37c511eea577d290</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1582&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1582%26sid%3Dliteratum%253Aachs%26aulast%3DLanning%26aufirst%3DB.%2BR.%26aulast%3DWhitby%26aufirst%3DL.%2BR.%26aulast%3DDix%26aufirst%3DM.%2BM.%26aulast%3DDouhan%26aufirst%3DJ.%26aulast%3DGilbert%26aufirst%3DA.%2BM.%26aulast%3DHett%26aufirst%3DE.%2BC.%26aulast%3DJohnson%26aufirst%3DT.%2BO.%26aulast%3DJoslyn%26aufirst%3DC.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DNiessen%26aufirst%3DS.%26aulast%3DRoberts%26aufirst%3DL.%2BR.%26aulast%3DSchnute%26aufirst%3DM.%2BE.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DHulce%26aufirst%3DJ.%2BJ.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DWhiteley%26aufirst%3DL.%2BO.%26aulast%3DHayward%26aufirst%3DM.%2BM.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DA%2520roadmap%2520to%2520evaluate%2520the%2520proteome-wide%2520selectivity%2520of%2520covalent%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2014%26volume%3D10%26spage%3D760%26epage%3D767%26doi%3D10.1038%2Fnchembio.1582" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Owens, T. D.</span></span> <span> </span><span class="NLM_article-title">Discovery of PRN1008: A reversible covalent BTK inhibitor for treatment of autoimmune diseases</span>. Presented at the 255th American Chemical Society National Meeting & Exposition, New Orleans, LA, March 21, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Owens%2C+T.+D.+Discovery+of+PRN1008%3A+A+reversible+covalent+BTK+inhibitor+for+treatment+of+autoimmune+diseases.+Presented+at+the+255th+American+Chemical+Society+National+Meeting+%26+Exposition%2C+New+Orleans%2C+LA%2C+March+21%2C+2018."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DOwens%26aufirst%3DT.%2BD.%26atitle%3DDiscovery%2520of%2520PRN1008%253A%2520A%2520reversible%2520covalent%2520BTK%2520inhibitor%2520for%2520treatment%2520of%2520autoimmune%2520diseases%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byun, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Son, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suh, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. B.</span></span> <span> </span><span class="NLM_article-title">HM71224, a novel Bruton’s tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: a potential drug for rheumatoid arthritis</span>. <i>Arthritis Res. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">91</span>– <span class="NLM_lpage">99</span>, <span class="refDoi"> DOI: 10.1186/s13075-016-0988-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1186%2Fs13075-016-0988-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=27090981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2sXivV2msLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2016&pages=91-99&author=J.+K.+Parkauthor=J.-Y.+Byunauthor=J.+A.+Parkauthor=Y.-Y.+Kimauthor=Y.+J.+Leeauthor=J.+I.+Ohauthor=S.+Y.+Jangauthor=Y.+H.+Kimauthor=Y.+W.+Songauthor=J.+Sonauthor=K.+H.+Suhauthor=Y.-M.+Leeauthor=E.+B.+Lee&title=HM71224%2C+a+novel+Bruton%E2%80%99s+tyrosine+kinase+inhibitor%2C+suppresses+B+cell+and+monocyte+activation+and+ameliorates+arthritis+in+a+mouse+model%3A+a+potential+drug+for+rheumatoid+arthritis&doi=10.1186%2Fs13075-016-0988-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">HM71224, a novel Bruton's tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: a potential drug for rheumatoid arthritis</span></div><div class="casAuthors">Park, Jin Kyun; Byun, Joo-Yun; Park, Ji Ah; Kim, Yu-Yon; Lee, Ye Ji; Oh, Jeong In; Jang, Sun Young; Kim, Young Hoon; Song, Yeong Wook; Son, Jeewoong; Suh, Kwee Hyun; Lee, Young-Mi; Lee, Eun Bong</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis Research & Therapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">91/1-91/9</span>CODEN:
                <span class="NLM_cas:coden">ARTRCV</span>;
        ISSN:<span class="NLM_cas:issn">1478-6362</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Bruton's tyrosine kinase (Btk) is crit. for activation of B cells and myeloid cells.  This study aimed to characterize the effects of HM71224, a novel Btk inhibitor, both in vitro and in a mouse model of exptl. arthritis.  Methods: The kinase inhibition profile of HM71224 was analyzed.  The in vitro effects of HM71224 on B cells and monocytes were analyzed by examg. phosphorylation of Btk and its downstream signaling mols., along with cytokine prodn. and osteoclast formation.  The in vivo effects of HM71224 were investigated in a mouse model of collagen-induced arthritis (CIA).  Results: HM71224 irreversibly bound to and inhibited Btk (IC50 = 1.95 nM).  The compd. also inhibited the phosphorylation of Btk and its downstream mols. such as PLCγ2, in activated Ramos B lymphoma cells and primary human B cells in a dose-dependent manner.  Furthermore, HM71224 effectively inhibited the prodn. of tumor necrosis factor (TNF)-α, interleukin (IL)-6, and IL-1β by human monocytes, and osteoclast formation by human monocytes.  Finally, HM71224 improved exptl. arthritis and prevented joint destruction in a murine model of CIA.  Conclusions: HM71224 inhibits Btk in B cells and monocytes and ameliorates exptl. arthritis in a mouse model.  Thus, HM71224 is a potential novel therapeutic agent for rheumatoid arthritis in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIE3CGRUJef7Vg90H21EOLACvtfcHk0lhqAbxW7VHUKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXivV2msLY%253D&md5=80eab623ff968690ba8f92bcd26301b7</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1186%2Fs13075-016-0988-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13075-016-0988-z%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DJ.%2BK.%26aulast%3DByun%26aufirst%3DJ.-Y.%26aulast%3DPark%26aufirst%3DJ.%2BA.%26aulast%3DKim%26aufirst%3DY.-Y.%26aulast%3DLee%26aufirst%3DY.%2BJ.%26aulast%3DOh%26aufirst%3DJ.%2BI.%26aulast%3DJang%26aufirst%3DS.%2BY.%26aulast%3DKim%26aufirst%3DY.%2BH.%26aulast%3DSong%26aufirst%3DY.%2BW.%26aulast%3DSon%26aufirst%3DJ.%26aulast%3DSuh%26aufirst%3DK.%2BH.%26aulast%3DLee%26aufirst%3DY.-M.%26aulast%3DLee%26aufirst%3DE.%2BB.%26atitle%3DHM71224%252C%2520a%2520novel%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitor%252C%2520suppresses%2520B%2520cell%2520and%2520monocyte%2520activation%2520and%2520ameliorates%2520arthritis%2520in%2520a%2520mouse%2520model%253A%2520a%2520potential%2520drug%2520for%2520rheumatoid%2520arthritis%26jtitle%3DArthritis%2520Res.%2520Ther.%26date%3D2016%26volume%3D18%26spage%3D91%26epage%3D99%26doi%3D10.1186%2Fs13075-016-0988-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, S. H.</span></span> <span> </span><span class="NLM_article-title">Discovery of BMS-986195: A strategy for identifying a highly potent and selective covalent inhibitor providing rapid inactivation of Bruton’s tyrosine kinase (BTK)</span>. Presented at the 255th American Chemical Society National Meeting & Exposition, New Orleans, LA, March 21, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Watterson%2C+S.+H.+Discovery+of+BMS-986195%3A+A+strategy+for+identifying+a+highly+potent+and+selective+covalent+inhibitor+providing+rapid+inactivation+of+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29.+Presented+at+the+255th+American+Chemical+Society+National+Meeting+%26+Exposition%2C+New+Orleans%2C+LA%2C+March+21%2C+2018."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DWatterson%26aufirst%3DS.%2BH.%26atitle%3DDiscovery%2520of%2520BMS-986195%253A%2520A%2520strategy%2520for%2520identifying%2520a%2520highly%2520potent%2520and%2520selective%2520covalent%2520inhibitor%2520providing%2520rapid%2520inactivation%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barf, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covey, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izumi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Kar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulrajani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Lith, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Hoek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Zwart, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittag, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demont, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verkaik, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krantz, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulrich, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaptein, A.</span></span> <span> </span><span class="NLM_article-title">Acalabrutinib: a differentiated covalent BTK inhibitor</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>363</i></span>,  <span class="NLM_fpage">240</span>– <span class="NLM_lpage">252</span>, <span class="refDoi"> DOI: 10.1124/jpet.117.242909</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1124%2Fjpet.117.242909" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=28882879" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtleltrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2017&pages=240-252&author=T.+Barfauthor=T.+Coveyauthor=R.+Izumiauthor=B.+van+de+Karauthor=M.+Gulrajaniauthor=B.+van+Lithauthor=M.+van+Hoekauthor=E.+de+Zwartauthor=D.+Mittagauthor=D.+Demontauthor=S.+Verkaikauthor=F.+Krantzauthor=P.+G.+Pearsonauthor=R.+Ulrichauthor=A.+Kaptein&title=Acalabrutinib%3A+a+differentiated+covalent+BTK+inhibitor&doi=10.1124%2Fjpet.117.242909"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Acalabrutinib (ACP-196): a covalent Bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile</span></div><div class="casAuthors">Barf, Tjeerd; Covey, Todd; Izumi, Raquel; van de Kar, Bas; Gulrajani, Michael; van Lith, Bart; van Hoek, Maaike; de Zwart, Edwin; Mittag, Diana; Demont, Dennis; Verkaik, Saskia; Krantz, Fanny; Pearson, Paul G.; Ulrich, Roger; Kaptein, Allard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">240-252</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Several small-mol. Bruton tyrosine kinase (BTK) inhibitors are in development for B cell malignancies and autoimmune disorders, each characterized by distinct potency and selectivity patterns.  Herein we describe the pharmacol. characterization of BTK inhibitor acalabrutinib [compd. 1, ACP-196 (4-[8- amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin1-yl]-N-(2-pyridyl)benzamide)].  Acalabrutinib possesses a reactive butynamide group that binds covalently to Cys481 in BTK.  Relative to the other BTK inhibitors described here, the reduced intrinsic reactivity of acalabrutinib helps to limit inhibition of off-target kinases having cysteine-mediated covalent binding potential.  Acalabrutinib demonstrated higher biochem. and cellular selectivity than ibrutinib and spebrutinib (compds. 2 and 3, resp.).  Importantly, off-target kinases, such as epidermal growth factor receptor (EGFR) and interleukin 2-inducible T cell kinase (ITK), were not inhibited.  Detn. of the inhibitory potential of anti-IgM-induced CD69 expression in human peripheral blood mononuclear cells and whole blood demonstrated that acalabrutinib is a potent functional BTK inhibitor.  In vivo evaluation in mice revealed that acalabrutinib is more potent than ibrutinib and spebrutinib.  Preclin. and clin. studies showed that the level and duration of BTK occupancy correlates with in vivo efficacy.  Evaluation of the pharmacokinetic properties of acalabrutinib in healthy adult volunteers demonstrated rapid absorption and fast elimination.  In these healthy individuals, a single oral dose of 100 mg showed approx. 99% median target coverage at 3 and 12 h and around 90% at 24 h in peripheral B cells.  In conclusion, acalabrutinib is a BTK inhibitor with key pharmacol. differentiators vs. ibrutinib and spebrutinib and is currently being evaluated in clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGol9xhDmwvup7Vg90H21EOLACvtfcHk0lhqAbxW7VHUKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtleltrnO&md5=73cbd3a87396abbf8cb20e4361f96f64</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1124%2Fjpet.117.242909&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.117.242909%26sid%3Dliteratum%253Aachs%26aulast%3DBarf%26aufirst%3DT.%26aulast%3DCovey%26aufirst%3DT.%26aulast%3DIzumi%26aufirst%3DR.%26aulast%3Dvan%2Bde%2BKar%26aufirst%3DB.%26aulast%3DGulrajani%26aufirst%3DM.%26aulast%3Dvan%2BLith%26aufirst%3DB.%26aulast%3Dvan%2BHoek%26aufirst%3DM.%26aulast%3Dde%2BZwart%26aufirst%3DE.%26aulast%3DMittag%26aufirst%3DD.%26aulast%3DDemont%26aufirst%3DD.%26aulast%3DVerkaik%26aufirst%3DS.%26aulast%3DKrantz%26aufirst%3DF.%26aulast%3DPearson%26aufirst%3DP.%2BG.%26aulast%3DUlrich%26aufirst%3DR.%26aulast%3DKaptein%26aufirst%3DA.%26atitle%3DAcalabrutinib%253A%2520a%2520differentiated%2520covalent%2520BTK%2520inhibitor%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2017%26volume%3D363%26spage%3D240%26epage%3D252%26doi%3D10.1124%2Fjpet.117.242909" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheerens, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sprengeler, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrill, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendonca, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, K. C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grothaus, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffery, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spoerke, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honigberg, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalrymple, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, J. T.</span></span> <span> </span><span class="NLM_article-title">Discovery of selective irreversible inhibitors for Bruton’s tyrosine kinase</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">58</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1002/cmdc.200600221</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1002%2Fcmdc.200600221" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=17154430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsVWjsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=58-61&author=Z.+Panauthor=H.+Scheerensauthor=S.-J.+Liauthor=B.+E.+Schultzauthor=P.+A.+Sprengelerauthor=L.+C.+Burrillauthor=R.+V.+Mendoncaauthor=M.+D.+Sweeneyauthor=K.+C.+K.+Scottauthor=P.+G.+Grothausauthor=D.+A.+Jefferyauthor=J.+M.+Spoerkeauthor=L.+A.+Honigbergauthor=P.+R.+Youngauthor=S.+A.+Dalrympleauthor=J.+T.+Palmer&title=Discovery+of+selective+irreversible+inhibitors+for+Bruton%E2%80%99s+tyrosine+kinase&doi=10.1002%2Fcmdc.200600221"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of selective irreversible inhibitors for bruton's tyrosine kinase</span></div><div class="casAuthors">Pan, Zhengying; Scheerens, Heleen; Li, Shyr-Jiann; Schultz, Brian E.; Sprengeler, Paul A.; Burrill, L. Chuck; Mendonca, Rohan V.; Sweeney, Michael D.; Scott, Keana C. K.; Grothaus, Paul G.; Jeffery, Douglas A.; Spoerke, Jill M.; Honigberg, Lee A.; Young, Peter R.; Dalrymple, Stacie A.; Palmer, James T.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-61</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Synthesis and pharmacol. evaluation of a series of peptidomimetic quinoline derivs. was undertaken to evaluate their efficacy in acting as selective irreversible inhibitors of Bruton's tyrosine kinase (Btk).  With the relative scarcity of knowledge on the inhibition of Btk it is crucial to discover a potent and selective tool compd. for this kinase.  Herein is described the discovery of selective irreversible Btk inhibitors and their efficacy in a mouse RA model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovT3kBCYECdbVg90H21EOLACvtfcHk0lgoj-KVRYM2Lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsVWjsbg%253D&md5=023ba8bca9942ad0127d7cf32293e9d2</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200600221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200600221%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DZ.%26aulast%3DScheerens%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DS.-J.%26aulast%3DSchultz%26aufirst%3DB.%2BE.%26aulast%3DSprengeler%26aufirst%3DP.%2BA.%26aulast%3DBurrill%26aufirst%3DL.%2BC.%26aulast%3DMendonca%26aufirst%3DR.%2BV.%26aulast%3DSweeney%26aufirst%3DM.%2BD.%26aulast%3DScott%26aufirst%3DK.%2BC.%2BK.%26aulast%3DGrothaus%26aufirst%3DP.%2BG.%26aulast%3DJeffery%26aufirst%3DD.%2BA.%26aulast%3DSpoerke%26aufirst%3DJ.%2BM.%26aulast%3DHonigberg%26aufirst%3DL.%2BA.%26aulast%3DYoung%26aufirst%3DP.%2BR.%26aulast%3DDalrymple%26aufirst%3DS.%2BA.%26aulast%3DPalmer%26aufirst%3DJ.%2BT.%26atitle%3DDiscovery%2520of%2520selective%2520irreversible%2520inhibitors%2520for%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%26jtitle%3DChemMedChem%26date%3D2007%26volume%3D2%26spage%3D58%26epage%3D61%26doi%3D10.1002%2Fcmdc.200600221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnarajah, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunn, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karr, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masjedizadeh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funk, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gourlay, S. G.</span></span> <span> </span><span class="NLM_article-title">A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton’s tyrosine kinase, in healthy volunteers</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">2367</span>– <span class="NLM_lpage">2376</span>, <span class="refDoi"> DOI: 10.1111/bcp.13351</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1111%2Fbcp.13351" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=28636208" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslWrsLnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2017&pages=2367-2376&author=P.+F.+Smithauthor=J.+Krishnarajahauthor=P.+A.+Nunnauthor=R.+J.+Hillauthor=D.+Karrauthor=D.+Tamauthor=M.+Masjedizadehauthor=J.+O.+Funkauthor=S.+G.+Gourlay&title=A+phase+I+trial+of+PRN1008%2C+a+novel+reversible+covalent+inhibitor+of+Bruton%E2%80%99s+tyrosine+kinase%2C+in+healthy+volunteers&doi=10.1111%2Fbcp.13351"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers</span></div><div class="casAuthors">Smith, Patrick F.; Krishnarajah, Janakan; Nunn, Philip A.; Hill, Ron J.; Karr, Dane; Tam, D.; Masjedizadeh, Mohammad; Funk, Jens O.; Gourlay, Steve G.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2367-2376</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">1365-2125</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">To evaluate the safety, tolerability, and pharmacokinetics/pharmacodynamics of PRN1008, a novel Bruton's tyrosine kinase (BTK) inhibitor, in healthy volunteers, and thus det. the dose range for future clin. studies.  This was a two-part randomized, placebo controlled study in healthy volunteers using a liq. formulation.  Part I was a single ascending dose design with dose levels of 50-1200 mg (n = 6 active, two placebos per cohort); Part II was a multiple ascending dose design, with dose regimens ranging from 300 to 900 mg daily, either four times or twice daily for 10 days.  Plasma pharmacokinetics, adverse events, vital signs, electrocardiograms and lab. parameters were assessed.  BTK occupancy in peripheral blood mononuclear cells was evaluated as a marker of target engagement.  PRN1008 was rapidly absorbed following oral administration, and was safe and well tolerated in all dose regimens evaluated in both single and multiple doses.  PRN1008 demonstrated a large vol. of distribution, and a half-life of approx. 3-4 h.  BTK occupancy of >90% was obsd. within 4 h after dosing in both single and multiple dose regimens, and was closely linked to max. plasma concn.  BTK occupancy decay was slow (-1.6% h-1), and occupancy was sustained despite drug concns. being undetectable.  No severe or serious adverse events occurred, and the most common adverse events were gastrointestinal in nature.  PRN1008 was safe and well-tolerated following oral administration, and achieved high, sustained levels of BTK occupancy in peripheral blood mononuclear cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDCmAr26_VXLVg90H21EOLACvtfcHk0lgoj-KVRYM2Lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslWrsLnE&md5=8da03545b8beec4c50cdd95854bcad8f</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1111%2Fbcp.13351&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcp.13351%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DP.%2BF.%26aulast%3DKrishnarajah%26aufirst%3DJ.%26aulast%3DNunn%26aufirst%3DP.%2BA.%26aulast%3DHill%26aufirst%3DR.%2BJ.%26aulast%3DKarr%26aufirst%3DD.%26aulast%3DTam%26aufirst%3DD.%26aulast%3DMasjedizadeh%26aufirst%3DM.%26aulast%3DFunk%26aufirst%3DJ.%2BO.%26aulast%3DGourlay%26aufirst%3DS.%2BG.%26atitle%3DA%2520phase%2520I%2520trial%2520of%2520PRN1008%252C%2520a%2520novel%2520reversible%2520covalent%2520inhibitor%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%252C%2520in%2520healthy%2520volunteers%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2017%26volume%3D83%26spage%3D2367%26epage%3D2376%26doi%3D10.1111%2Fbcp.13351" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bradshaw, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McFarland, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paavilainen, V. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bisconte, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phan, V. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romanov, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finkle, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ton, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loughhead, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunn, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karr, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerritsen, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funk, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brameld, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taunton, J.</span></span> <span> </span><span class="NLM_article-title">Prolonged and tunable residence time using reversible covalent kinase inhibitors</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">525</span>– <span class="NLM_lpage">531</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1817</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1038%2Fnchembio.1817" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=26006010" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFeju7%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=525-531&author=J.+M.+Bradshawauthor=J.+M.+McFarlandauthor=V.+O.+Paavilainenauthor=A.+Bisconteauthor=D.+Tamauthor=V.+T.+Phanauthor=S.+Romanovauthor=D.+Finkleauthor=J.+Shuauthor=V.+Patelauthor=T.+Tonauthor=X.+Liauthor=D.+G.+Loughheadauthor=P.+A.+Nunnauthor=D.+E.+Karrauthor=M.+E.+Gerritsenauthor=J.+O.+Funkauthor=T.+D.+Owensauthor=E.+Vernerauthor=K.+A.+Brameldauthor=R.+J.+Hillauthor=D.+M.+Goldsteinauthor=J.+Taunton&title=Prolonged+and+tunable+residence+time+using+reversible+covalent+kinase+inhibitors&doi=10.1038%2Fnchembio.1817"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Prolonged and tunable residence time using reversible covalent kinase inhibitors</span></div><div class="casAuthors">Bradshaw, J. Michael; McFarland, Jesse M.; Paavilainen, Ville O.; Bisconte, Angelina; Tam, Danny; Phan, Vernon T.; Romanov, Sergei; Finkle, David; Shu, Jin; Patel, Vaishali; Ton, Tony; Li, Xiaoyan; Loughhead, David G.; Nunn, Philip A.; Karr, Dane E.; Gerritsen, Mary E.; Funk, Jens Oliver; Owens, Timothy D.; Verner, Erik; Brameld, Ken A.; Hill, Ronald J.; Goldstein, David M.; Taunton, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">525-531</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Drugs with prolonged on-target residence times often show superior efficacy, yet general strategies for optimizing drug-target residence time are lacking.  Here the authors made progress toward this elusive goal by targeting a noncatalytic cysteine in Bruton's tyrosine kinase (BTK) with reversible covalent inhibitors.  Using an inverted orientation of the cysteine-reactive cyanoacrylamide electrophile, the authors identified potent and selective BTK inhibitors that demonstrated biochem. residence times spanning from minutes to 7 d.  An inverted cyanoacrylamide with prolonged residence time in vivo remained bound to BTK for more than 18 h after clearance from the circulation.  The inverted cyanoacrylamide strategy was further used to discover fibroblast growth factor receptor (FGFR) kinase inhibitors with residence times of several days, demonstrating the generalizability of the approach.  Targeting of noncatalytic cysteines with inverted cyanoacrylamides may serve as a broadly applicable platform that facilitates 'residence time by design', the ability to modulate and improve the duration of target engagement in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXCpNprhn6kLVg90H21EOLACvtfcHk0lh4gBXfSo7aaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFeju7%252FE&md5=85a73d9ecd62695d03166f7009c68dd8</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1817&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1817%26sid%3Dliteratum%253Aachs%26aulast%3DBradshaw%26aufirst%3DJ.%2BM.%26aulast%3DMcFarland%26aufirst%3DJ.%2BM.%26aulast%3DPaavilainen%26aufirst%3DV.%2BO.%26aulast%3DBisconte%26aufirst%3DA.%26aulast%3DTam%26aufirst%3DD.%26aulast%3DPhan%26aufirst%3DV.%2BT.%26aulast%3DRomanov%26aufirst%3DS.%26aulast%3DFinkle%26aufirst%3DD.%26aulast%3DShu%26aufirst%3DJ.%26aulast%3DPatel%26aufirst%3DV.%26aulast%3DTon%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLoughhead%26aufirst%3DD.%2BG.%26aulast%3DNunn%26aufirst%3DP.%2BA.%26aulast%3DKarr%26aufirst%3DD.%2BE.%26aulast%3DGerritsen%26aufirst%3DM.%2BE.%26aulast%3DFunk%26aufirst%3DJ.%2BO.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26aulast%3DVerner%26aufirst%3DE.%26aulast%3DBrameld%26aufirst%3DK.%2BA.%26aulast%3DHill%26aufirst%3DR.%2BJ.%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26aulast%3DTaunton%26aufirst%3DJ.%26atitle%3DProlonged%2520and%2520tunable%2520residence%2520time%2520using%2520reversible%2520covalent%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2015%26volume%3D11%26spage%3D525%26epage%3D531%26doi%3D10.1038%2Fnchembio.1817" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petter, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitty, A.</span></span> <span> </span><span class="NLM_article-title">The resurgence of covalent drugs</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">307</span>, <span class="refDoi"> DOI: 10.1038/nrd3410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1038%2Fnrd3410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=21455239" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=307&author=J.+Singhauthor=R.+C.+Petterauthor=T.+A.+Baillieauthor=A.+Whitty&title=The+resurgence+of+covalent+drugs&doi=10.1038%2Fnrd3410"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">The resurgence of covalent drugs</span></div><div class="casAuthors">Singh, Juswinder; Petter, Russell C.; Baillie, Thomas A.; Whitty, Adrian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">307-317</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Covalent drugs haveproved to be successful therapies for various indications, but largely owing to safety concerns, they are rarely considered when initiating a target-directed drug discovery project.  There is a need to reassess this important class of drugs, and to reconcile the discordance between the historic success of covalent drugs and the reluctance of most drug discovery teams to include them in their armamentarium.  This Review surveys the prevalence and pharmacol. advantages of covalent drugs, discusses how potential risks and challenges may be addressed through innovative design, and presents the broad opportunities provided by targeted covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreDCEmORV_NbVg90H21EOLACvtfcHk0lh4gBXfSo7aaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D&md5=2190289081e151416c097be4a5b04460</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1038%2Fnrd3410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3410%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26aulast%3DWhitty%26aufirst%3DA.%26atitle%3DThe%2520resurgence%2520of%2520covalent%2520drugs%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D307%26doi%3D10.1038%2Fnrd3410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Lucca, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batt, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaudoin Bertrand, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rampulla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Discenza, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obermeier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vickery, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marathe, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebben, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muckelbauer, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattoli, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kukral, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-Cid, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrish, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tino, J. A.</span></span> <span> </span><span class="NLM_article-title">Small molecule reversible inhibitors of Bruton’s tyrosine kinase (BTK): Structure–activity relationships leading to the identification of 7-(2-hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide (BMS-935177)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">7915</span>– <span class="NLM_lpage">7935</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00722</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00722" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlCrsL3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7915-7935&author=G.+V.+De+Luccaauthor=Q.+Shiauthor=Q.+Liuauthor=D.+G.+Battauthor=M.+Beaudoin+Bertrandauthor=R.+Rampullaauthor=A.+Mathurauthor=L.+Discenzaauthor=C.+D%E2%80%99Arienzoauthor=J.+Daiauthor=M.+Obermeierauthor=R.+Vickeryauthor=Y.+Zhangauthor=Z.+Yangauthor=P.+Maratheauthor=A.+J.+Tebbenauthor=J.+K.+Muckelbauerauthor=C.+J.+Changauthor=H.+Zhangauthor=K.+Gilloolyauthor=T.+Taylorauthor=M.+A.+Pattoliauthor=S.+Skalaauthor=D.+W.+Kukralauthor=K.+W.+McIntyreauthor=L.+Salter-Cidauthor=A.+Furaauthor=J.+R.+Burkeauthor=J.+C.+Barrishauthor=P.+H.+Carterauthor=J.+A.+Tino&title=Small+molecule+reversible+inhibitors+of+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29%3A+Structure%E2%80%93activity+relationships+leading+to+the+identification+of+7-%282-hydroxypropan-2-yl%29-4-%5B2-methyl-3-%284-oxo-3%2C4-dihydroquinazolin-3-yl%29phenyl%5D-9H-carbazole-1-carboxamide+%28BMS-935177%29&doi=10.1021%2Facs.jmedchem.6b00722"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Reversible Inhibitors of Bruton's Tyrosine Kinase (BTK): Structure-Activity Relationships Leading to the Identification of 7-(2-Hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide (BMS-935177)</span></div><div class="casAuthors">De Lucca, George V.; Shi, Qing; Liu, Qingjie; Batt, Douglas G.; Beaudoin Bertrand, Myra; Rampulla, Rick; Mathur, Arvind; Discenza, Lorell; D'Arienzo, Celia; Dai, Jun; Obermeier, Mary; Vickery, Rodney; Zhang, Yingru; Yang, Zheng; Marathe, Punit; Tebben, Andrew J.; Muckelbauer, Jodi K.; Chang, ChiehYing J.; Zhang, Huiping; Gillooly, Kathleen; Taylor, Tracy; Pattoli, Mark A.; Skala, Stacey; Kukral, Daniel W.; McIntyre, Kim W.; Salter-Cid, Luisa; Fura, Aberra; Burke, James R.; Barrish, Joel C.; Carter, Percy H.; Tino, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7915-7935</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK) belongs to the TEC family of nonreceptor tyrosine kinases and plays a crit. role in multiple cell types responsible for numerous autoimmune diseases.  This article will detail the structure-activity relationships (SARs) leading to a novel second generation series of potent and selective reversible carbazole inhibitors of BTK.  With an excellent pharmacokinetic profile as well as demonstrated in vivo activity and an acceptable safety profile, 7-(2-hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide 6 (BMS-935177) was selected to advance into clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1HUwZaRn_w7Vg90H21EOLACvtfcHk0lh4gBXfSo7aaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlCrsL3M&md5=7c7ec1a52121c541753c045c1cbf758b</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00722%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BLucca%26aufirst%3DG.%2BV.%26aulast%3DShi%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DBatt%26aufirst%3DD.%2BG.%26aulast%3DBeaudoin%2BBertrand%26aufirst%3DM.%26aulast%3DRampulla%26aufirst%3DR.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DDiscenza%26aufirst%3DL.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DObermeier%26aufirst%3DM.%26aulast%3DVickery%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DTebben%26aufirst%3DA.%2BJ.%26aulast%3DMuckelbauer%26aufirst%3DJ.%2BK.%26aulast%3DChang%26aufirst%3DC.%2BJ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DGillooly%26aufirst%3DK.%26aulast%3DTaylor%26aufirst%3DT.%26aulast%3DPattoli%26aufirst%3DM.%2BA.%26aulast%3DSkala%26aufirst%3DS.%26aulast%3DKukral%26aufirst%3DD.%2BW.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DSalter-Cid%26aufirst%3DL.%26aulast%3DFura%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DTino%26aufirst%3DJ.%2BA.%26atitle%3DSmall%2520molecule%2520reversible%2520inhibitors%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%253A%2520Structure%25E2%2580%2593activity%2520relationships%2520leading%2520to%2520the%2520identification%2520of%25207-%25282-hydroxypropan-2-yl%2529-4-%255B2-methyl-3-%25284-oxo-3%252C4-dihydroquinazolin-3-yl%2529phenyl%255D-9H-carbazole-1-carboxamide%2520%2528BMS-935177%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D7915%26epage%3D7935%26doi%3D10.1021%2Facs.jmedchem.6b00722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahia, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silakari, O.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of interleukin-2 inducible T-cell kinase as potential therapeutic candidates for the treatment of various inflammatory disease conditions</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">574</span>– <span class="NLM_lpage">588</span>, <span class="refDoi"> DOI: 10.1016/j.ejps.2012.07.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1016%2Fj.ejps.2012.07.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=22820564" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhtl2kurrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2012&pages=574-588&author=M.+Kaurauthor=M.+S.+Bahiaauthor=O.+Silakari&title=Inhibitors+of+interleukin-2+inducible+T-cell+kinase+as+potential+therapeutic+candidates+for+the+treatment+of+various+inflammatory+disease+conditions&doi=10.1016%2Fj.ejps.2012.07.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of interleukin-2 inducible T-cell kinase as potential therapeutic candidates for the treatment of various inflammatory disease conditions</span></div><div class="casAuthors">Kaur, Maninder; Bahia, Malkeet Singh; Silakari, Om</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">574-588</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Interleukin-2 inducible T-cell kinase (ITK), a member of Tec family of non-receptor protein tyrosine kinases plays a domineering role in the T-cell development, differentiation and prodn. of pro-inflammatory cytokines such as IL-2, IL-4, IL-5, IL-10, IL-13 and IL-17.  This kinase is also an important contributor in Th 2 cells mediated autoimmune and allergic disease conditions, e.g. psoriasis, atopic dermatitis and allergic asthma.  ITK modulates T-cell signaling by activating PLCγ1 and regulating the extent of Ca2+ flux.  It contributes in prolific T-cell responses by maintaining cellular adhesion and cytoskeleton reorganization via actin polymn. and integrin binding.  This review article describes the structure of ITK and its role in T-cell signaling.  In addn. to this, data regarding small mol. inhibitors of ITK has also been reviewed from different papers and patents published.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZRRvOoVByI7Vg90H21EOLACvtfcHk0ljLuyn908DRkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhtl2kurrO&md5=5944bca7430769906289d96b3b067498</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2012.07.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2012.07.013%26sid%3Dliteratum%253Aachs%26aulast%3DKaur%26aufirst%3DM.%26aulast%3DBahia%26aufirst%3DM.%2BS.%26aulast%3DSilakari%26aufirst%3DO.%26atitle%3DInhibitors%2520of%2520interleukin-2%2520inducible%2520T-cell%2520kinase%2520as%2520potential%2520therapeutic%2520candidates%2520for%2520the%2520treatment%2520of%2520various%2520inflammatory%2520disease%2520conditions%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2012%26volume%3D47%26spage%3D574%26epage%3D588%26doi%3D10.1016%2Fj.ejps.2012.07.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lo, H. Y.</span></span> <span> </span><span class="NLM_article-title">Itk inhibitors: a patent review</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">459</span>– <span class="NLM_lpage">469</span>, <span class="refDoi"> DOI: 10.1517/13543771003674409</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1517%2F13543771003674409" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=20218931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjslamu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=459-469&author=H.+Y.+Lo&title=Itk+inhibitors%3A+a+patent+review&doi=10.1517%2F13543771003674409"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Itk inhibitors: a patent review</span></div><div class="casAuthors">Lo, Ho Yin</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">459-469</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Importance of field: IL-2 inducible T-cell kinase (Itk) is a non-receptor tyrosine kinase of the Tec family.  It plays an important role in T cell signaling and the prodn. of various pro-inflammatory cytokines such as IL-2, IL-4, IL-5, IL-10 and IL-13.  Inhibition of Itk has been a target for the treatment of diseases related to inflammation disorders such as psoriasis and allergic asthma.  Rich resources on the structural information for Itk made discovery of novel selective Itk inhibitors blossom in the past decade.  Areas covered in this review: In this report, distinct structural classes of specific Itk inhibitors are summarized and their in vitro/in vivo properties are discussed.  What the reader will gain: A summary of 21 patents including 16 different chem. structure classes of Itk inhibitors.  The in vivo efficacies of some of the inhibitors in animal models are also discussed.  Take home message: Although some of the inhibitors show efficacy in different animal models, which implies potential for therapeutic use in human, there is not yet a chem. entity reported in clin. trials.  The prospects for Itk inhibitors will rely on the quality of the compd. and the validity of the target in patients within the selected therapeutic area.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKrKjXoATESLVg90H21EOLACvtfcHk0ljLuyn908DRkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjslamu7g%253D&md5=48ab6a3192e5805860d9f97a7d97de94</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1517%2F13543771003674409&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543771003674409%26sid%3Dliteratum%253Aachs%26aulast%3DLo%26aufirst%3DH.%2BY.%26atitle%3DItk%2520inhibitors%253A%2520a%2520patent%2520review%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2010%26volume%3D20%26spage%3D459%26epage%3D469%26doi%3D10.1517%2F13543771003674409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Norman, P.</span></span> <span> </span><span class="NLM_article-title">Inducible tyrosine kinase inhibitors: a review of the patent literature (2010 – 2013)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">979</span>– <span class="NLM_lpage">991</span>, <span class="refDoi"> DOI: 10.1517/13543776.2014.936381</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1517%2F13543776.2014.936381" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=24990480" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlKjtb3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=979-991&author=P.+Norman&title=Inducible+tyrosine+kinase+inhibitors%3A+a+review+of+the+patent+literature+%282010+%E2%80%93+2013%29&doi=10.1517%2F13543776.2014.936381"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Inducible tyrosine kinase inhibitors: a review of the patent literature (2010 - 2013)</span></div><div class="casAuthors">Norman, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">979-991</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: The non-receptor tyrosine kinase, inducible tyrosine kinase (Itk), plays an important role in thymus(T)-cell signalling and the prodn. of pro-inflammatory cytokines.  Itk, and the other Tec family members, Rlk and Tec, are viewed as attractive drug targets for new agents for the treatment of autoimmune and inflammatory diseases.  Interest in Itk inhibitors is still modest compared to other kinases such as the Janus kinase (JAK) family or Syk.  Areas covered: This article reviews the patent filings published from Jan. 2010 to Apr. 2014 that claim Itk inhibitors.  It first considers those applications that claim selective, or apparently selective, Itk inhibitors.  It then considers those applications that claim less-selective Itk inhibitors.  The recent interest in irreversible Itk inhibitors is also discussed.  Expert opinion: There is a difference of opinion as to the preferred utility for Itk inhibitors.  Progress has been made in designing selective Itk inhibitors but little clin. progress.  Until clin. data are available, it remains difficult to assess how well Itk inhibitors compare with JAK inhibitors as potential treatments for rheumatoid arthritis.  However, animal data suggest that irreversible Itk inhibitors could be useful in treating asthma, whereas dual Itk inhibitors may have more utility in treating rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWRBj5BlBRoLVg90H21EOLACvtfcHk0ljLuyn908DRkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlKjtb3I&md5=b48c10504c7bb8958c5519b1397b496a</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1517%2F13543776.2014.936381&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2014.936381%26sid%3Dliteratum%253Aachs%26aulast%3DNorman%26aufirst%3DP.%26atitle%3DInducible%2520tyrosine%2520kinase%2520inhibitors%253A%2520a%2520review%2520of%2520the%2520patent%2520literature%2520%25282010%2520%25E2%2580%2593%25202013%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2014%26volume%3D24%26spage%3D979%26epage%3D991%26doi%3D10.1517%2F13543776.2014.936381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sahu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">August, A.</span></span> <span> </span><span class="NLM_article-title">ITK inhibitors in inflammation and immune-mediated disorders</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">690</span>– <span class="NLM_lpage">703</span>, <span class="refDoi"> DOI: 10.2174/156802609789044443</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.2174%2F156802609789044443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=19689375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFehsLnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=690-703&author=N.+Sahuauthor=A.+August&title=ITK+inhibitors+in+inflammation+and+immune-mediated+disorders&doi=10.2174%2F156802609789044443"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">ITK inhibitors in inflammation and immune-mediated disorders</span></div><div class="casAuthors">Sahu, Nisebita; August, Avery</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">690-703</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Interleukin-2-inducible T cell kinase (ITK) is a non-receptor tyrosine kinase expressed in T cells, NKT cells and mast cells which plays a crucial role in regulating the T cell receptor (TCR), CD28, CD2, chemokine receptor CXCR4, and FcεR-mediated signaling pathways.  In T cells, ITK is an important mediator for actin reorganization, activation of PLCγ, mobilization of calcium, and activation of the NFAT transcription factor.  ITK plays an important role in the secretion of IL-2, but more critically, also has a pivotal role in the secretion of Th2 cytokines, IL-4, IL-5 and IL-13.  As such, ITK has been shown to regulate the development of effective Th2 response during allergic asthma as well as infections by parasitic worms.  This ability of ITK to regulate Th2 responses, along with its pattern of expression, has led to the proposal that it would represent an excellent target for Th2-mediated inflammation.  We discuss here the possibilities and pitfalls of targeting ITK for inflammatory disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQ4v3nHF04CLVg90H21EOLACvtfcHk0liDKwq7pIKpNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFehsLnM&md5=75c4ecb794cfa96eda65b6ed8841571e</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.2174%2F156802609789044443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802609789044443%26sid%3Dliteratum%253Aachs%26aulast%3DSahu%26aufirst%3DN.%26aulast%3DAugust%26aufirst%3DA.%26atitle%3DITK%2520inhibitors%2520in%2520inflammation%2520and%2520immune-mediated%2520disorders%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2009%26volume%3D9%26spage%3D690%26epage%3D703%26doi%3D10.2174%2F156802609789044443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andreotti, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartzberg, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berg, L. J.</span></span> <span> </span><span class="NLM_article-title">T-cell signaling regulated by the Tec family kinase, Itk</span>. <i>Cold Spring Harbor Perspect. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">a002287</span>, <span class="refDoi"> DOI: 10.1101/cshperspect.a002287</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1101%2Fcshperspect.a002287" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2010&pages=a002287&author=A.+H.+Andreottiauthor=P.+L.+Schwartzbergauthor=R.+E.+Josephauthor=L.+J.+Berg&title=T-cell+signaling+regulated+by+the+Tec+family+kinase%2C+Itk&doi=10.1101%2Fcshperspect.a002287"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1101%2Fcshperspect.a002287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fcshperspect.a002287%26sid%3Dliteratum%253Aachs%26aulast%3DAndreotti%26aufirst%3DA.%2BH.%26aulast%3DSchwartzberg%26aufirst%3DP.%2BL.%26aulast%3DJoseph%26aufirst%3DR.%2BE.%26aulast%3DBerg%26aufirst%3DL.%2BJ.%26atitle%3DT-cell%2520signaling%2520regulated%2520by%2520the%2520Tec%2520family%2520kinase%252C%2520Itk%26jtitle%3DCold%2520Spring%2520Harbor%2520Perspect.%2520Biol.%26date%3D2010%26volume%3D2%26spage%3Da002287%26doi%3D10.1101%2Fcshperspect.a002287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senger, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collier, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burch, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eastham-Anderson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staton, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Havnar, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaochico, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riol-Blanco, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choy, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arron, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenzie, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghilardi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ismaili, M. H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVoss, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrin, A. A.</span></span> <span> </span><span class="NLM_article-title">Inhibition of the kinase ITK in a mouse model of asthma reduces cell death and fails to inhibit the inflammatory response</span>. <i>Sci. Signaling</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">ra122</span>– <span class="NLM_lpage">ra122</span>, <span class="refDoi"> DOI: 10.1126/scisignal.aab0949</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1126%2Fscisignal.aab0949" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=26628680" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2015&pages=ra122-ra122&author=Y.+Sunauthor=I.+Pengauthor=J.+D.+Websterauthor=E.+Sutoauthor=J.+Leschauthor=X.+Wuauthor=K.+Sengerauthor=G.+Francisauthor=K.+Barrettauthor=J.+L.+Collierauthor=J.+D.+Burchauthor=M.+Zhouauthor=Y.+Chenauthor=C.+Chanauthor=J.+Eastham-Andersonauthor=H.+Nguauthor=O.+Liauthor=T.+Statonauthor=C.+Havnarauthor=A.+Jaochicoauthor=J.+Jackmanauthor=S.+Jeetauthor=L.+Riol-Blancoauthor=L.+C.+Wuauthor=D.+F.+Choyauthor=J.+R.+Arronauthor=B.+S.+McKenzieauthor=N.+Ghilardiauthor=M.+H.+A.+Ismailiauthor=Z.+Peiauthor=J.+DeVossauthor=C.+D.+Austinauthor=W.+P.+Leeauthor=A.+A.+Zarrin&title=Inhibition+of+the+kinase+ITK+in+a+mouse+model+of+asthma+reduces+cell+death+and+fails+to+inhibit+the+inflammatory+response&doi=10.1126%2Fscisignal.aab0949"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1126%2Fscisignal.aab0949&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscisignal.aab0949%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DY.%26aulast%3DPeng%26aufirst%3DI.%26aulast%3DWebster%26aufirst%3DJ.%2BD.%26aulast%3DSuto%26aufirst%3DE.%26aulast%3DLesch%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DSenger%26aufirst%3DK.%26aulast%3DFrancis%26aufirst%3DG.%26aulast%3DBarrett%26aufirst%3DK.%26aulast%3DCollier%26aufirst%3DJ.%2BL.%26aulast%3DBurch%26aufirst%3DJ.%2BD.%26aulast%3DZhou%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DChan%26aufirst%3DC.%26aulast%3DEastham-Anderson%26aufirst%3DJ.%26aulast%3DNgu%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DO.%26aulast%3DStaton%26aufirst%3DT.%26aulast%3DHavnar%26aufirst%3DC.%26aulast%3DJaochico%26aufirst%3DA.%26aulast%3DJackman%26aufirst%3DJ.%26aulast%3DJeet%26aufirst%3DS.%26aulast%3DRiol-Blanco%26aufirst%3DL.%26aulast%3DWu%26aufirst%3DL.%2BC.%26aulast%3DChoy%26aufirst%3DD.%2BF.%26aulast%3DArron%26aufirst%3DJ.%2BR.%26aulast%3DMcKenzie%26aufirst%3DB.%2BS.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DIsmaili%26aufirst%3DM.%2BH.%2BA.%26aulast%3DPei%26aufirst%3DZ.%26aulast%3DDeVoss%26aufirst%3DJ.%26aulast%3DAustin%26aufirst%3DC.%2BD.%26aulast%3DLee%26aufirst%3DW.%2BP.%26aulast%3DZarrin%26aufirst%3DA.%2BA.%26atitle%3DInhibition%2520of%2520the%2520kinase%2520ITK%2520in%2520a%2520mouse%2520model%2520of%2520asthma%2520reduces%2520cell%2520death%2520and%2520fails%2520to%2520inhibit%2520the%2520inflammatory%2520response%26jtitle%3DSci.%2520Signaling%26date%3D2015%26volume%3D8%26spage%3Dra122%26epage%3Dra122%26doi%3D10.1126%2Fscisignal.aab0949" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferrara, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ben-Jebria, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">August, A.</span></span> <span> </span><span class="NLM_article-title">Reduced airway hyperresponsiveness and tracheal responses during allergic asthma in mice lacking tyrosine kinase inducible T-cell kinase</span>. <i>J. Allergy Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">780</span>– <span class="NLM_lpage">786</span>, <span class="refDoi"> DOI: 10.1016/j.jaci.2005.12.1330</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1016%2Fj.jaci.2005.12.1330" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=16630934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BD28Xjslels7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2006&pages=780-786&author=T.+J.+Ferraraauthor=C.+Muellerauthor=N.+Sahuauthor=A.+Ben-Jebriaauthor=A.+August&title=Reduced+airway+hyperresponsiveness+and+tracheal+responses+during+allergic+asthma+in+mice+lacking+tyrosine+kinase+inducible+T-cell+kinase&doi=10.1016%2Fj.jaci.2005.12.1330"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Reduced airway hyperresponsiveness and tracheal responses during allergic asthma in mice lacking tyrosine kinase inducible T-cell kinase</span></div><div class="casAuthors">Ferrara, Tanna J.; Mueller, Cynthia; Sahu, Nisebita; Ben-Jebria, Abdellaziz; August, Avery</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Allergy and Clinical Immunology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">780-786</span>CODEN:
                <span class="NLM_cas:coden">JACIBY</span>;
        ISSN:<span class="NLM_cas:issn">0091-6749</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Background: Patients with allergic asthma have symptoms of a predominant TH2 response, including airway eosinophilic inflammation and increased mucous prodn. in the lungs.  This accompanies increased airways responsiveness, which can be life threatening.  Because TH2 cells and cytokines have been implicated in contributing to these symptoms, pathways that control the development of these cells or that regulate their cytokine prodn. represent good targets for controlling this disease.  Objective: We have previously shown that mice lacking the tyrosine kinase inducible T-cell kinase (ITK) have drastically reduced airway inflammation in a model of allergic asthma.  However, it was not clear whether this translated into reduced airways hyperresponsiveness.  We have analyzed tracheal responsiveness and airways hyperresponsiveness of wild-type (WT) and ITK null mice during induction of exptl. allergic asthma.  Methods: Exptl. allergic asthma was induced in WT and ITK knockout mice.  Tracheal responses to carbachol, acetylcholine, and potassium chloride were analyzed.  Airways hyperresponsiveness to methacholine challenge was also analyzed in allergen-challenged mice, along with lung and bronchoalveolar lavage fluid TH2 cytokine message and protein.  Results: ITK null mice have reduced tracheal responses to cholinergic challenge in vitro before as well as after allergen challenge.  These mice also have reduced airways hyperresponsiveness in response to allergen challenge, which could be rescued by transferring WT splenocytes or purified WT CD4+ T cells.  This reduced airways response was preferentially accompanied by reduced expression of TH2 cytokines in the lungs.  Conclusion: Our results indicate that the tyrosine kinase ITK and its function in T cells represent an attractive target for antiasthmatic drugs.  Clin. implications: Modulating the expression or activity of ITK may be a novel strategy to block allergic airway inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq64IqAG_bfV7Vg90H21EOLACvtfcHk0liDKwq7pIKpNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xjslels7k%253D&md5=2f1f14c05770b2c0eee0ffcd8fd1610b</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1016%2Fj.jaci.2005.12.1330&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaci.2005.12.1330%26sid%3Dliteratum%253Aachs%26aulast%3DFerrara%26aufirst%3DT.%2BJ.%26aulast%3DMueller%26aufirst%3DC.%26aulast%3DSahu%26aufirst%3DN.%26aulast%3DBen-Jebria%26aufirst%3DA.%26aulast%3DAugust%26aufirst%3DA.%26atitle%3DReduced%2520airway%2520hyperresponsiveness%2520and%2520tracheal%2520responses%2520during%2520allergic%2520asthma%2520in%2520mice%2520lacking%2520tyrosine%2520kinase%2520inducible%2520T-cell%2520kinase%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%26date%3D2006%26volume%3D117%26spage%3D780%26epage%3D786%26doi%3D10.1016%2Fj.jaci.2005.12.1330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oshida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obayashi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsui, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagata, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obayashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashiwabara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunji, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsujimoto, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katsunuma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akasawa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, H.</span></span> <span> </span><span class="NLM_article-title">Identification of highly expressed genes in peripheral blood T cells from patients with atopic dermatitis</span>. <i>Int. Arch. Allergy Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">327</span>– <span class="NLM_lpage">340</span>, <span class="refDoi"> DOI: 10.1159/000067589</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1159%2F000067589" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=12483038" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BD38XpsFKrsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2002&pages=327-340&author=Y.+Matsumotoauthor=T.+Oshidaauthor=I.+Obayashiauthor=Y.+Imaiauthor=K.+Matsuiauthor=N.+L.+Yoshidaauthor=N.+Nagataauthor=K.+Ogawaauthor=M.+Obayashiauthor=T.+Kashiwabaraauthor=S.+Gunjiauthor=T.+Nagasuauthor=Y.+Sugitaauthor=T.+Tanakaauthor=G.+Tsujimotoauthor=T.+Katsunumaauthor=A.+Akasawaauthor=H.+Saito&title=Identification+of+highly+expressed+genes+in+peripheral+blood+T+cells+from+patients+with+atopic+dermatitis&doi=10.1159%2F000067589"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Highly Expressed Genes in Peripheral Blood T cells from Patients with Atopic Dermatitis</span></div><div class="casAuthors">Matsumoto, Yoshiko; Oshida, Tadahilo; Obayashi, Izumi; Imai, Yukiho; Matsui, Keiko; Yoshida, Ning Lu; Nagata, Naoko; Ogawa, Kaoru; Obayashi, Masaya; Kashiwabara, Tomoko; Gunji, Shigemichi; Nagasu, Takeshi; Sugita, Yuji; Tanaka, Toshio; Tsujimoto, Gozoh; Katsunuma, Toshio; Akasawa, Akira; Saito, Hirohisa</div><div class="citationInfo"><span class="NLM_cas:title">International Archives of Allergy and Immunology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">327-340</span>CODEN:
                <span class="NLM_cas:coden">IAAIEG</span>;
        ISSN:<span class="NLM_cas:issn">1018-2438</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">Background: Anal. of genes that are differentially expressed in patients with atopic dermatitis (AD) and normal individuals will provide important information on the underlying mol. pathogenetic mechanisms of AD.  Methods: Transcript of freshly isolated peripheral blood T cells from 59 individuals were analyzed with a fluorescent differential display (FDD) method.  Ninety-two differentially expressed genes were identified in this manner.  Addnl., real-time quant. RT-PCR was employed to investigate the expression of the FDD-selected genes and also genes related to T cell function.  Results: A no. of genes, including CC chemokine receptor 4, T cell-specific tyrosine kinase (Emt/Itk), integrin β1, integrin α6, IQGAP1 and MAR/SAR DNA-binding protein (SATB1), were shown to be more highly expressed in patients with moderate and/or severe AD than in controls or patients with mild AD.  Because the products of these upregulated genes influence chemotaxis, adhesion, migration and Th2 polarization, it is suggested that in more severe AD, circulating T cells may function differently in this regard.  Several other genes, the role of which in T cell function is currently unknown, were also found to be differentially expressed in AD.  These included the heat shock protein 40 and vasopressin-activated calcium-mobilizing receptor 1.  Conclusion: The upregulated genes identified in this work may serve as useful markers for moderate to severe AD as opposed to normal or mild AD and also as markers indicating progression to more severe AD.  Further functional characterization will provide a better understanding of the pathophysiol. of circulating T cells in AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcEc0xdnxw7bVg90H21EOLACvtfcHk0lj48jawxre25w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XpsFKrsbY%253D&md5=3a8769c4279651610c56109905809c7d</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1159%2F000067589&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000067589%26sid%3Dliteratum%253Aachs%26aulast%3DMatsumoto%26aufirst%3DY.%26aulast%3DOshida%26aufirst%3DT.%26aulast%3DObayashi%26aufirst%3DI.%26aulast%3DImai%26aufirst%3DY.%26aulast%3DMatsui%26aufirst%3DK.%26aulast%3DYoshida%26aufirst%3DN.%2BL.%26aulast%3DNagata%26aufirst%3DN.%26aulast%3DOgawa%26aufirst%3DK.%26aulast%3DObayashi%26aufirst%3DM.%26aulast%3DKashiwabara%26aufirst%3DT.%26aulast%3DGunji%26aufirst%3DS.%26aulast%3DNagasu%26aufirst%3DT.%26aulast%3DSugita%26aufirst%3DY.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DTsujimoto%26aufirst%3DG.%26aulast%3DKatsunuma%26aufirst%3DT.%26aulast%3DAkasawa%26aufirst%3DA.%26aulast%3DSaito%26aufirst%3DH.%26atitle%3DIdentification%2520of%2520highly%2520expressed%2520genes%2520in%2520peripheral%2520blood%2520T%2520cells%2520from%2520patients%2520with%2520atopic%2520dermatitis%26jtitle%3DInt.%2520Arch.%2520Allergy%2520Immunol.%26date%3D2002%26volume%3D129%26spage%3D327%26epage%3D340%26doi%3D10.1159%2F000067589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Charrier, J.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knegtel, R. M. A.</span></span> <span> </span><span class="NLM_article-title">Advances in the design of ITK inhibitors</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">369</span>– <span class="NLM_lpage">381</span>, <span class="refDoi"> DOI: 10.1517/17460441.2013.769520</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1517%2F17460441.2013.769520" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=369-381&author=J.-D.+Charrierauthor=R.+M.+A.+Knegtel&title=Advances+in+the+design+of+ITK+inhibitors&doi=10.1517%2F17460441.2013.769520"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1517%2F17460441.2013.769520&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2013.769520%26sid%3Dliteratum%253Aachs%26aulast%3DCharrier%26aufirst%3DJ.-D.%26aulast%3DKnegtel%26aufirst%3DR.%2BM.%2BA.%26atitle%3DAdvances%2520in%2520the%2520design%2520of%2520ITK%2520inhibitors%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2013%26volume%3D8%26spage%3D369%26epage%3D381%26doi%3D10.1517%2F17460441.2013.769520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Das, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moquin, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spergel, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuster, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Day, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penhallow, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doweyko, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamath, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marathe, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanner, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodd, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrish, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wityak, J.</span></span> <span> </span><span class="NLM_article-title">Discovery and SAR of 2-amino-5-(thioaryl)thiazoles as potent and selective Itk inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">3706</span>– <span class="NLM_lpage">3712</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2006.04.060</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1016%2Fj.bmcl.2006.04.060" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=3706-3712&author=J.+Dasauthor=J.+A.+Furchauthor=C.+Liuauthor=R.+V.+Moquinauthor=J.+Linauthor=S.+H.+Spergelauthor=K.+W.+McIntyreauthor=D.+J.+Shusterauthor=K.+D.+O%E2%80%99Dayauthor=B.+Penhallowauthor=C.-Y.+Hungauthor=A.+M.+Doweykoauthor=A.+Kamathauthor=H.+Zhangauthor=P.+Maratheauthor=S.+B.+Kannerauthor=T.-A.+Linauthor=J.+H.+Doddauthor=J.+C.+Barrishauthor=J.+Wityak&title=Discovery+and+SAR+of+2-amino-5-%28thioaryl%29thiazoles+as+potent+and+selective+Itk+inhibitors&doi=10.1016%2Fj.bmcl.2006.04.060"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.04.060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.04.060%26sid%3Dliteratum%253Aachs%26aulast%3DDas%26aufirst%3DJ.%26aulast%3DFurch%26aufirst%3DJ.%2BA.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DMoquin%26aufirst%3DR.%2BV.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DSpergel%26aufirst%3DS.%2BH.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DShuster%26aufirst%3DD.%2BJ.%26aulast%3DO%25E2%2580%2599Day%26aufirst%3DK.%2BD.%26aulast%3DPenhallow%26aufirst%3DB.%26aulast%3DHung%26aufirst%3DC.-Y.%26aulast%3DDoweyko%26aufirst%3DA.%2BM.%26aulast%3DKamath%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DKanner%26aufirst%3DS.%2BB.%26aulast%3DLin%26aufirst%3DT.-A.%26aulast%3DDodd%26aufirst%3DJ.%2BH.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DWityak%26aufirst%3DJ.%26atitle%3DDiscovery%2520and%2520SAR%2520of%25202-amino-5-%2528thioaryl%2529thiazoles%2520as%2520potent%2520and%2520selective%2520Itk%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D3706%26epage%3D3712%26doi%3D10.1016%2Fj.bmcl.2006.04.060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burch, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVoss, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldsmith, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ismaili, M. H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortwine, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrin, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEwan, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barker, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellebrandt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kordt, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuen, P.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, Z.</span></span> <span> </span><span class="NLM_article-title">Tetrahydroindazoles as interleukin-2 inducible T-Cell kinase inhibitors. part II. Second-generation analogues with enhanced potency, selectivity, and pharmacodynamic modulation in vivo</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">3806</span>– <span class="NLM_lpage">3816</span>, <span class="refDoi"> DOI: 10.1021/jm501998m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501998m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlvVaktbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=3806-3816&author=J.+D.+Burchauthor=K.+Barrettauthor=Y.+Chenauthor=J.+DeVossauthor=C.+Eigenbrotauthor=R.+Goldsmithauthor=M.+H.+A.+Ismailiauthor=K.+Lauauthor=Z.+Linauthor=D.+F.+Ortwineauthor=A.+A.+Zarrinauthor=P.+A.+McEwanauthor=J.+J.+Barkerauthor=C.+Ellebrandtauthor=D.+Kordtauthor=D.+B.+Steinauthor=X.+Wangauthor=Y.+Chenauthor=B.+Huauthor=X.+Xuauthor=P.-W.+Yuenauthor=Y.+Zhangauthor=Z.+Pei&title=Tetrahydroindazoles+as+interleukin-2+inducible+T-Cell+kinase+inhibitors.+part+II.+Second-generation+analogues+with+enhanced+potency%2C+selectivity%2C+and+pharmacodynamic+modulation+in+vivo&doi=10.1021%2Fjm501998m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Tetrahydroindazoles as Interleukin-2 Inducible T-Cell Kinase Inhibitors. Part II. Second-Generation Analogues with Enhanced Potency, Selectivity, and Pharmacodynamic Modulation in Vivo</span></div><div class="casAuthors">Burch, Jason D.; Barrett, Kathy; Chen, Yuan; DeVoss, Jason; Eigenbrot, Charles; Goldsmith, Richard; Ismaili, M. Hicham A.; Lau, Kevin; Lin, Zhonghua; Ortwine, Daniel F.; Zarrin, Ali A.; McEwan, Paul A.; Barker, John J.; Ellebrandt, Claire; Kordt, Daniel; Stein, Daniel B.; Wang, Xiaolu; Chen, Yong; Hu, Baihua; Xu, Xiaofeng; Yuen, Po-Wai; Zhang, Yamin; Pei, Zhonghua</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3806-3816</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The medicinal chem. community has directed considerable efforts toward the discovery of selective inhibitors of interleukin-2 inducible T-cell kinase (ITK), given its role in T-cell signaling downstream of the T-cell receptor (TCR) and the implications of this target for inflammatory disorders such as asthma.  The authors have previously disclosed a structure- and property-guided lead optimization effort which resulted in the discovery of a new series of tetrahydroindazole-contg. selective ITK inhibitors.  Herein the authors disclose further optimization of this series that resulted in further potency improvements, reduced off-target receptor binding liabilities, and reduced cytotoxicity.  Specifically, the authors have identified a correlation between the basicity of solubilizing elements in the ITK inhibitors and off-target antiproliferative effects, which was exploited to reduce cytotoxicity while maintaining kinase selectivity.  Optimized analogs, e.g. I, were shown to reduce IL-2 and IL-13 prodn. in vivo following oral or i.p. dosing in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9z-34VWYnsbVg90H21EOLACvtfcHk0lh6pkwoxhdcwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlvVaktbo%253D&md5=59a2cd1c2c9d368f9b49344af9b75545</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1021%2Fjm501998m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501998m%26sid%3Dliteratum%253Aachs%26aulast%3DBurch%26aufirst%3DJ.%2BD.%26aulast%3DBarrett%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DDeVoss%26aufirst%3DJ.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DGoldsmith%26aufirst%3DR.%26aulast%3DIsmaili%26aufirst%3DM.%2BH.%2BA.%26aulast%3DLau%26aufirst%3DK.%26aulast%3DLin%26aufirst%3DZ.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DZarrin%26aufirst%3DA.%2BA.%26aulast%3DMcEwan%26aufirst%3DP.%2BA.%26aulast%3DBarker%26aufirst%3DJ.%2BJ.%26aulast%3DEllebrandt%26aufirst%3DC.%26aulast%3DKordt%26aufirst%3DD.%26aulast%3DStein%26aufirst%3DD.%2BB.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DB.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DYuen%26aufirst%3DP.-W.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DPei%26aufirst%3DZ.%26atitle%3DTetrahydroindazoles%2520as%2520interleukin-2%2520inducible%2520T-Cell%2520kinase%2520inhibitors.%2520part%2520II.%2520Second-generation%2520analogues%2520with%2520enhanced%2520potency%252C%2520selectivity%252C%2520and%2520pharmacodynamic%2520modulation%2520in%2520vivo%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D3806%26epage%3D3816%26doi%3D10.1021%2Fjm501998m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McLean, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaidi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dharanipragada, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jurcak, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillespy, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musick, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrague, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peppard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smicker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duguid, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parkar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fordham, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kominos, D.</span></span> <span> </span><span class="NLM_article-title">X-ray crystallographic structure-based design of selective thienopyrazole inhibitors for interleukin-2-inducible tyrosine kinase</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">3296</span>– <span class="NLM_lpage">3300</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.03.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1016%2Fj.bmcl.2012.03.016" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=3296-3300&author=L.+R.+McLeanauthor=Y.+Zhangauthor=N.+Zaidiauthor=X.+Biauthor=R.+Wangauthor=R.+Dharanipragadaauthor=J.+G.+Jurcakauthor=T.+A.+Gillespyauthor=Z.+Zhaoauthor=K.+Y.+Musickauthor=Y.-M.+Choiauthor=M.+Barragueauthor=J.+Peppardauthor=M.+Smickerauthor=M.+Duguidauthor=A.+Parkarauthor=J.+Fordhamauthor=D.+Kominos&title=X-ray+crystallographic+structure-based+design+of+selective+thienopyrazole+inhibitors+for+interleukin-2-inducible+tyrosine+kinase&doi=10.1016%2Fj.bmcl.2012.03.016"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.03.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.03.016%26sid%3Dliteratum%253Aachs%26aulast%3DMcLean%26aufirst%3DL.%2BR.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZaidi%26aufirst%3DN.%26aulast%3DBi%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DDharanipragada%26aufirst%3DR.%26aulast%3DJurcak%26aufirst%3DJ.%2BG.%26aulast%3DGillespy%26aufirst%3DT.%2BA.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DMusick%26aufirst%3DK.%2BY.%26aulast%3DChoi%26aufirst%3DY.-M.%26aulast%3DBarrague%26aufirst%3DM.%26aulast%3DPeppard%26aufirst%3DJ.%26aulast%3DSmicker%26aufirst%3DM.%26aulast%3DDuguid%26aufirst%3DM.%26aulast%3DParkar%26aufirst%3DA.%26aulast%3DFordham%26aufirst%3DJ.%26aulast%3DKominos%26aufirst%3DD.%26atitle%3DX-ray%2520crystallographic%2520structure-based%2520design%2520of%2520selective%2520thienopyrazole%2520inhibitors%2520for%2520interleukin-2-inducible%2520tyrosine%2520kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D3296%26epage%3D3300%26doi%3D10.1016%2Fj.bmcl.2012.03.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kutach, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villaseñor, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belunis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lok, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, L.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deval, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novak, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnett, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuglstatter, A.</span></span> <span> </span><span class="NLM_article-title">Crystal Structures of IL-2-inducible T cell Kinase Complexed with Inhibitors: Insights into Rational Drug Design and Activity Regulation</span>. <i>Chem. Biol. Drug Des.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">154</span>– <span class="NLM_lpage">163</span>, <span class="refDoi"> DOI: 10.1111/j.1747-0285.2010.00993.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1111%2Fj.1747-0285.2010.00993.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=20545945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptleqs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2010&pages=154-163&author=A.+K.+Kutachauthor=A.+G.+Villase%C3%B1orauthor=D.+Lamauthor=C.+Belunisauthor=C.+Jansonauthor=S.+Lokauthor=L.-N.+Hongauthor=C.-M.+Liuauthor=J.+Devalauthor=T.+J.+Novakauthor=J.+W.+Barnettauthor=W.+Chuauthor=D.+Shawauthor=A.+Kuglstatter&title=Crystal+Structures+of+IL-2-inducible+T+cell+Kinase+Complexed+with+Inhibitors%3A+Insights+into+Rational+Drug+Design+and+Activity+Regulation&doi=10.1111%2Fj.1747-0285.2010.00993.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structures of IL-2-inducible T cell kinase complexed with inhibitors: insights into rational drug design and activity regulation</span></div><div class="casAuthors">Kutach, Alan K.; Villasenor, Armando G.; Lam, Diana; Belunis, Charles; Janson, Cheryl; Lok, Stephen; Hong, Li-Na; Liu, Chao-Min; Deval, Jerome; Novak, Thomas J.; Barnett, Jim W.; Chu, Wei; Shaw, David; Kuglstatter, Andreas</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">154-163</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">IL-2-inducible T cell kinase plays an essential role in T cell receptor signaling and is considered a drug target for the treatment of Th2-mediated inflammatory diseases.  By applying high-throughput protein engineering and crystn., we have detd. the x-ray crystal structures of IL-2-inducible T cell kinase in complex with its selective inhibitor BMS-509744 and the broad-spectrum kinase inhibitors sunitinib and RO5191614.  Sunitinib uniquely stabilizes IL-2-inducible T cell kinase in the helix C-in conformation by inducing side chain conformational changes in the ATP-binding site.  This preference of sunitinib to bind to an active kinase conformation is reflective of its broad-spectrum kinase activity.  BMS-509744 uniquely stabilizes the activation loop in a substrate-blocking inactive conformation, indicating that structural changes described for Src family kinases are also involved in the regulation of IL-2-inducible T cell kinase activity.  The obsd. BMS-509744 binding mode allows rationalization of structure-activity relationships reported for this inhibitor class and facilitates further structure-based drug design.  Sequence-based anal. of this binding mode provides guidance for the rational design of inhibitor selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXxFkkRUV7B7Vg90H21EOLACvtfcHk0lh6pkwoxhdcwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptleqs7Y%253D&md5=24b9225c52eff5cca4e295dad1c554c3</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1111%2Fj.1747-0285.2010.00993.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1747-0285.2010.00993.x%26sid%3Dliteratum%253Aachs%26aulast%3DKutach%26aufirst%3DA.%2BK.%26aulast%3DVillase%25C3%25B1or%26aufirst%3DA.%2BG.%26aulast%3DLam%26aufirst%3DD.%26aulast%3DBelunis%26aufirst%3DC.%26aulast%3DJanson%26aufirst%3DC.%26aulast%3DLok%26aufirst%3DS.%26aulast%3DHong%26aufirst%3DL.-N.%26aulast%3DLiu%26aufirst%3DC.-M.%26aulast%3DDeval%26aufirst%3DJ.%26aulast%3DNovak%26aufirst%3DT.%2BJ.%26aulast%3DBarnett%26aufirst%3DJ.%2BW.%26aulast%3DChu%26aufirst%3DW.%26aulast%3DShaw%26aufirst%3DD.%26aulast%3DKuglstatter%26aufirst%3DA.%26atitle%3DCrystal%2520Structures%2520of%2520IL-2-inducible%2520T%2520cell%2520Kinase%2520Complexed%2520with%2520Inhibitors%253A%2520Insights%2520into%2520Rational%2520Drug%2520Design%2520and%2520Activity%2520Regulation%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2010%26volume%3D76%26spage%3D154%26epage%3D163%26doi%3D10.1111%2Fj.1747-0285.2010.00993.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heifetz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aldeghi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacKinnon, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEwan, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brookfield, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chudyk, E. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bodkin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burch, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortwine, D. F.</span></span> <span> </span><span class="NLM_article-title">Fragment molecular orbital method applied to lead optimization of novel interleukin-2 inducible T-cell kinase (ITK) inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">4352</span>– <span class="NLM_lpage">4363</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00045</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00045" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjs12jt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=4352-4363&author=A.+Heifetzauthor=G.+Traniauthor=M.+Aldeghiauthor=C.+H.+MacKinnonauthor=P.+A.+McEwanauthor=F.+A.+Brookfieldauthor=E.+I.+Chudykauthor=M.+Bodkinauthor=Z.+Peiauthor=J.+D.+Burchauthor=D.+F.+Ortwine&title=Fragment+molecular+orbital+method+applied+to+lead+optimization+of+novel+interleukin-2+inducible+T-cell+kinase+%28ITK%29+inhibitors&doi=10.1021%2Facs.jmedchem.6b00045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment Molecular Orbital Method Applied to Lead Optimization of Novel Interleukin-2 Inducible T-Cell Kinase (ITK) Inhibitors</span></div><div class="casAuthors">Heifetz, Alexander; Trani, Giancarlo; Aldeghi, Matteo; MacKinnon, Colin H.; McEwan, Paul A.; Brookfield, Frederick A.; Chudyk, Ewa I.; Bodkin, Mike; Pei, Zhonghua; Burch, Jason D.; Ortwine, Daniel F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4352-4363</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of inducible T-cell kinase (ITK), a nonreceptor tyrosine kinase, may represent a novel treatment for allergic asthma.  In our previous reports, we described the discovery of sulfonylpyridine (SAP), benzothiazole (BZT), indazole (IND), and tetrahydroindazole (THI) series as novel ITK inhibitors and how computational tools such as dihedral scans and docking were used to support this process.  X-ray crystallog. and modeling were applied to provide essential insight into ITK-ligand interactions.  However, "visual inspection" traditionally used for the rationalization of protein-ligand affinity cannot always explain the full complexity of the mol. interactions.  The fragment MO (FMO) quantum-mech. (QM) method provides a complete list of the interactions formed between the ligand and protein that are often omitted from traditional structure-based descriptions.  FMO methodol. was successfully used as part of a rational structure-based drug design effort to improve the ITK potency of high-throughput screening hits, ultimately delivering ligands with potency in the subnanomolar range.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTGF0Bo-GJM7Vg90H21EOLACvtfcHk0lhH_FMvVR2SAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjs12jt70%253D&md5=b0958d9c29f7d61aadcc730ac00e8f90</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00045%26sid%3Dliteratum%253Aachs%26aulast%3DHeifetz%26aufirst%3DA.%26aulast%3DTrani%26aufirst%3DG.%26aulast%3DAldeghi%26aufirst%3DM.%26aulast%3DMacKinnon%26aufirst%3DC.%2BH.%26aulast%3DMcEwan%26aufirst%3DP.%2BA.%26aulast%3DBrookfield%26aufirst%3DF.%2BA.%26aulast%3DChudyk%26aufirst%3DE.%2BI.%26aulast%3DBodkin%26aufirst%3DM.%26aulast%3DPei%26aufirst%3DZ.%26aulast%3DBurch%26aufirst%3DJ.%2BD.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26atitle%3DFragment%2520molecular%2520orbital%2520method%2520applied%2520to%2520lead%2520optimization%2520of%2520novel%2520interleukin-2%2520inducible%2520T-cell%2520kinase%2520%2528ITK%2529%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D4352%26epage%3D4363%26doi%3D10.1021%2Facs.jmedchem.6b00045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alder, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Champigny, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deakin, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harling, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longstaff, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maxwell, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mooney, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scullion, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, O. M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, I. E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somers, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tame, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wayne, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woolven, J. M.</span></span> <span> </span><span class="NLM_article-title">Identification of a novel and selective series of Itk inhibitors via a template-hopping strategy</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">948</span>– <span class="NLM_lpage">952</span>, <span class="refDoi"> DOI: 10.1021/ml400206q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml400206q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=948-952&author=C.+M.+Alderauthor=M.+Amblerauthor=A.+J.+Campbellauthor=A.+C.+Champignyauthor=A.+M.+Deakinauthor=J.+D.+Harlingauthor=C.+A.+Harrisauthor=T.+Longstaffauthor=S.+Lynnauthor=A.+C.+Maxwellauthor=C.+J.+Mooneyauthor=C.+Scullionauthor=O.+M.+P.+Singhauthor=I.+E.+D.+Smithauthor=D.+O.+Somersauthor=C.+J.+Tameauthor=G.+Wayneauthor=C.+Wilsonauthor=J.+M.+Woolven&title=Identification+of+a+novel+and+selective+series+of+Itk+inhibitors+via+a+template-hopping+strategy&doi=10.1021%2Fml400206q"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1021%2Fml400206q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml400206q%26sid%3Dliteratum%253Aachs%26aulast%3DAlder%26aufirst%3DC.%2BM.%26aulast%3DAmbler%26aufirst%3DM.%26aulast%3DCampbell%26aufirst%3DA.%2BJ.%26aulast%3DChampigny%26aufirst%3DA.%2BC.%26aulast%3DDeakin%26aufirst%3DA.%2BM.%26aulast%3DHarling%26aufirst%3DJ.%2BD.%26aulast%3DHarris%26aufirst%3DC.%2BA.%26aulast%3DLongstaff%26aufirst%3DT.%26aulast%3DLynn%26aufirst%3DS.%26aulast%3DMaxwell%26aufirst%3DA.%2BC.%26aulast%3DMooney%26aufirst%3DC.%2BJ.%26aulast%3DScullion%26aufirst%3DC.%26aulast%3DSingh%26aufirst%3DO.%2BM.%2BP.%26aulast%3DSmith%26aufirst%3DI.%2BE.%2BD.%26aulast%3DSomers%26aufirst%3DD.%2BO.%26aulast%3DTame%26aufirst%3DC.%2BJ.%26aulast%3DWayne%26aufirst%3DG.%26aulast%3DWilson%26aufirst%3DC.%26aulast%3DWoolven%26aufirst%3DJ.%2BM.%26atitle%3DIdentification%2520of%2520a%2520novel%2520and%2520selective%2520series%2520of%2520Itk%2520inhibitors%2520via%2520a%2520template-hopping%2520strategy%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D948%26epage%3D952%26doi%3D10.1021%2Fml400206q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strattan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butchar, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thornton, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porcu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradshaw, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bisconte, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brameld, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funk, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubovsky, J. A.</span></span> <span> </span><span class="NLM_article-title">Targeting interleukin-2-inducible T-cell kinase (ITK) and resting lymphocyte kinase (RLK) using a novel covalent inhibitor PRN694</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>290</i></span>,  <span class="NLM_fpage">5960</span>– <span class="NLM_lpage">5978</span>, <span class="refDoi"> DOI: 10.1074/jbc.M114.614891</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1074%2Fjbc.M114.614891" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=290&publication_year=2015&pages=5960-5978&author=Y.+Zhongauthor=S.+Dongauthor=E.+Strattanauthor=L.+Renauthor=J.+P.+Butcharauthor=K.+Thorntonauthor=A.+Mishraauthor=P.+Porcuauthor=J.+M.+Bradshawauthor=A.+Bisconteauthor=T.+D.+Owensauthor=E.+Vernerauthor=K.+A.+Brameldauthor=J.+O.+Funkauthor=R.+J.+Hillauthor=A.+J.+Johnsonauthor=J.+A.+Dubovsky&title=Targeting+interleukin-2-inducible+T-cell+kinase+%28ITK%29+and+resting+lymphocyte+kinase+%28RLK%29+using+a+novel+covalent+inhibitor+PRN694&doi=10.1074%2Fjbc.M114.614891"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M114.614891&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M114.614891%26sid%3Dliteratum%253Aachs%26aulast%3DZhong%26aufirst%3DY.%26aulast%3DDong%26aufirst%3DS.%26aulast%3DStrattan%26aufirst%3DE.%26aulast%3DRen%26aufirst%3DL.%26aulast%3DButchar%26aufirst%3DJ.%2BP.%26aulast%3DThornton%26aufirst%3DK.%26aulast%3DMishra%26aufirst%3DA.%26aulast%3DPorcu%26aufirst%3DP.%26aulast%3DBradshaw%26aufirst%3DJ.%2BM.%26aulast%3DBisconte%26aufirst%3DA.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26aulast%3DVerner%26aufirst%3DE.%26aulast%3DBrameld%26aufirst%3DK.%2BA.%26aulast%3DFunk%26aufirst%3DJ.%2BO.%26aulast%3DHill%26aufirst%3DR.%2BJ.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DDubovsky%26aufirst%3DJ.%2BA.%26atitle%3DTargeting%2520interleukin-2-inducible%2520T-cell%2520kinase%2520%2528ITK%2529%2520and%2520resting%2520lymphocyte%2520kinase%2520%2528RLK%2529%2520using%2520a%2520novel%2520covalent%2520inhibitor%2520PRN694%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2015%26volume%3D290%26spage%3D5960%26epage%3D5978%26doi%3D10.1074%2Fjbc.M114.614891" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harling, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deakin, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimley, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudry, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nye, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polyakova, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bessant, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barton, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somers, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graves, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanns, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerr, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solari, R.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel irreversible inhibitors of interleukin (IL)-2-inducible tyrosine kinase (Itk) by targeting cysteine 442 in the ATP pocket</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>288</i></span>,  <span class="NLM_fpage">28195</span>– <span class="NLM_lpage">28206</span>, <span class="refDoi"> DOI: 10.1074/jbc.M113.474114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1074%2Fjbc.M113.474114" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2013&pages=28195-28206&author=J.+D.+Harlingauthor=A.+M.+Deakinauthor=S.+Camposauthor=R.+Grimleyauthor=L.+Chaudryauthor=C.+Nyeauthor=O.+Polyakovaauthor=C.+M.+Bessantauthor=N.+Bartonauthor=D.+Somersauthor=J.+Barrettauthor=R.+H.+Gravesauthor=L.+Hannsauthor=W.+J.+Kerrauthor=R.+Solari&title=Discovery+of+novel+irreversible+inhibitors+of+interleukin+%28IL%29-2-inducible+tyrosine+kinase+%28Itk%29+by+targeting+cysteine+442+in+the+ATP+pocket&doi=10.1074%2Fjbc.M113.474114"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M113.474114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M113.474114%26sid%3Dliteratum%253Aachs%26aulast%3DHarling%26aufirst%3DJ.%2BD.%26aulast%3DDeakin%26aufirst%3DA.%2BM.%26aulast%3DCampos%26aufirst%3DS.%26aulast%3DGrimley%26aufirst%3DR.%26aulast%3DChaudry%26aufirst%3DL.%26aulast%3DNye%26aufirst%3DC.%26aulast%3DPolyakova%26aufirst%3DO.%26aulast%3DBessant%26aufirst%3DC.%2BM.%26aulast%3DBarton%26aufirst%3DN.%26aulast%3DSomers%26aufirst%3DD.%26aulast%3DBarrett%26aufirst%3DJ.%26aulast%3DGraves%26aufirst%3DR.%2BH.%26aulast%3DHanns%26aufirst%3DL.%26aulast%3DKerr%26aufirst%3DW.%2BJ.%26aulast%3DSolari%26aufirst%3DR.%26atitle%3DDiscovery%2520of%2520novel%2520irreversible%2520inhibitors%2520of%2520interleukin%2520%2528IL%2529-2-inducible%2520tyrosine%2520kinase%2520%2528Itk%2529%2520by%2520targeting%2520cysteine%2520442%2520in%2520the%2520ATP%2520pocket%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2013%26volume%3D288%26spage%3D28195%26epage%3D28206%26doi%3D10.1074%2Fjbc.M113.474114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zapf, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerstenberger, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Limburg, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caspers, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aulabaugh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurumbail, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spaulding, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czerwinski, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seth, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medley, Q. G.</span></span> <span> </span><span class="NLM_article-title">Covalent inhibitors of interleukin-2 inducible T cell kinase (Itk) with nanomolar potency in a whole-blood assay</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">10047</span>– <span class="NLM_lpage">10063</span>, <span class="refDoi"> DOI: 10.1021/jm301190s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301190s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFOlsbnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=10047-10063&author=C.+W.+Zapfauthor=B.+S.+Gerstenbergerauthor=L.+Xingauthor=D.+C.+Limburgauthor=D.+R.+Andersonauthor=N.+Caspersauthor=S.+Hanauthor=A.+Aulabaughauthor=R.+Kurumbailauthor=S.+Shakyaauthor=X.+Liauthor=V.+Spauldingauthor=R.+M.+Czerwinskiauthor=N.+Sethauthor=Q.+G.+Medley&title=Covalent+inhibitors+of+interleukin-2+inducible+T+cell+kinase+%28Itk%29+with+nanomolar+potency+in+a+whole-blood+assay&doi=10.1021%2Fjm301190s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent Inhibitors of Interleukin-2 Inducible T Cell Kinase (Itk) with Nanomolar Potency in a Whole-Blood Assay</span></div><div class="casAuthors">Zapf, Christoph W.; Gerstenberger, Brian S.; Xing, Li; Limburg, David C.; Anderson, David R.; Caspers, Nicole; Han, Seungil; Aulabaugh, Ann; Kurumbail, Ravi; Shakya, Subarna; Li, Xin; Spaulding, Vikki; Czerwinski, Robert M.; Seth, Nilufer; Medley, Quintus G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10047-10063</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We wish to report a strategy that targets interleukin-2 inducible T cell kinase (Itk) with covalent inhibitors.  Thus far, covalent inhibition of Itk has not been disclosed in the literature.  Structure-based drug design was utilized to achieve low nanomolar potency of the disclosed series even at high ATP concns.  Kinetic measurements confirmed an irreversible binding mode with off-rate half-lives exceeding 24 h and moderate on-rates.  The analogs are highly potent in a cellular IP1 assay as well as in a human whole-blood (hWB) assay.  Despite a half-life of approx. 2 h in resting primary T cells, the covalent inhibition of Itk resulted in functional silencing of the TCR pathway for more than 24 h.  This prolonged effect indicates that covalent inhibition is a viable strategy to target the inactivation of Itk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnh9j28SM8jbVg90H21EOLACvtfcHk0lhH_FMvVR2SAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFOlsbnP&md5=7e39a17151dc9493d13439bc48fa83a3</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1021%2Fjm301190s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301190s%26sid%3Dliteratum%253Aachs%26aulast%3DZapf%26aufirst%3DC.%2BW.%26aulast%3DGerstenberger%26aufirst%3DB.%2BS.%26aulast%3DXing%26aufirst%3DL.%26aulast%3DLimburg%26aufirst%3DD.%2BC.%26aulast%3DAnderson%26aufirst%3DD.%2BR.%26aulast%3DCaspers%26aufirst%3DN.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DAulabaugh%26aufirst%3DA.%26aulast%3DKurumbail%26aufirst%3DR.%26aulast%3DShakya%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DSpaulding%26aufirst%3DV.%26aulast%3DCzerwinski%26aufirst%3DR.%2BM.%26aulast%3DSeth%26aufirst%3DN.%26aulast%3DMedley%26aufirst%3DQ.%2BG.%26atitle%3DCovalent%2520inhibitors%2520of%2520interleukin-2%2520inducible%2520T%2520cell%2520kinase%2520%2528Itk%2529%2520with%2520nanomolar%2520potency%2520in%2520a%2520whole-blood%2520assay%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D10047%26epage%3D10063%26doi%3D10.1021%2Fjm301190s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schaeffer, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debnath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yap, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McVicar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, X. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Littman, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varmus, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenardo, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartzberg, P. L.</span></span> <span> </span><span class="NLM_article-title">Requirement for Tec kinases Rlk and Itk in T cell receptor signaling and immunity</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>284</i></span>,  <span class="NLM_fpage">638</span>– <span class="NLM_lpage">641</span>, <span class="refDoi"> DOI: 10.1126/science.284.5414.638</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1126%2Fscience.284.5414.638" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=284&publication_year=1999&pages=638-641&author=E.+M.+Schaefferauthor=J.+Debnathauthor=G.+Yapauthor=D.+McVicarauthor=X.+C.+Liaoauthor=D.+R.+Littmanauthor=A.+Sherauthor=H.+E.+Varmusauthor=M.+J.+Lenardoauthor=P.+L.+Schwartzberg&title=Requirement+for+Tec+kinases+Rlk+and+Itk+in+T+cell+receptor+signaling+and+immunity&doi=10.1126%2Fscience.284.5414.638"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1126%2Fscience.284.5414.638&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.284.5414.638%26sid%3Dliteratum%253Aachs%26aulast%3DSchaeffer%26aufirst%3DE.%2BM.%26aulast%3DDebnath%26aufirst%3DJ.%26aulast%3DYap%26aufirst%3DG.%26aulast%3DMcVicar%26aufirst%3DD.%26aulast%3DLiao%26aufirst%3DX.%2BC.%26aulast%3DLittman%26aufirst%3DD.%2BR.%26aulast%3DSher%26aufirst%3DA.%26aulast%3DVarmus%26aufirst%3DH.%2BE.%26aulast%3DLenardo%26aufirst%3DM.%2BJ.%26aulast%3DSchwartzberg%26aufirst%3DP.%2BL.%26atitle%3DRequirement%2520for%2520Tec%2520kinases%2520Rlk%2520and%2520Itk%2520in%2520T%2520cell%2520receptor%2520signaling%2520and%2520immunity%26jtitle%3DScience%26date%3D1999%26volume%3D284%26spage%3D638%26epage%3D641%26doi%3D10.1126%2Fscience.284.5414.638" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deakin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duddy, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latcham, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fulleylove, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fung, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedrick, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKevitt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felton, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quint, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fattah, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gough, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solari, R.</span></span> <span> </span><span class="NLM_article-title">Characterisation of a K390R ITK kinase dead transgenic mouse – implications for ITK as a therapeutic target</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">e107490</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0107490</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1371%2Fjournal.pone.0107490" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=e107490&author=A.+Deakinauthor=G.+Duddyauthor=S.+Wilsonauthor=S.+Harrisonauthor=J.+Latchamauthor=M.+Fulleyloveauthor=S.+Fungauthor=J.+Smithauthor=M.+Pedrickauthor=T.+McKevittauthor=L.+Feltonauthor=J.+Morleyauthor=D.+Quintauthor=D.+Fattahauthor=B.+Hayesauthor=J.+Goughauthor=R.+Solari&title=Characterisation+of+a+K390R+ITK+kinase+dead+transgenic+mouse+%E2%80%93+implications+for+ITK+as+a+therapeutic+target&doi=10.1371%2Fjournal.pone.0107490"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0107490&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0107490%26sid%3Dliteratum%253Aachs%26aulast%3DDeakin%26aufirst%3DA.%26aulast%3DDuddy%26aufirst%3DG.%26aulast%3DWilson%26aufirst%3DS.%26aulast%3DHarrison%26aufirst%3DS.%26aulast%3DLatcham%26aufirst%3DJ.%26aulast%3DFulleylove%26aufirst%3DM.%26aulast%3DFung%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DJ.%26aulast%3DPedrick%26aufirst%3DM.%26aulast%3DMcKevitt%26aufirst%3DT.%26aulast%3DFelton%26aufirst%3DL.%26aulast%3DMorley%26aufirst%3DJ.%26aulast%3DQuint%26aufirst%3DD.%26aulast%3DFattah%26aufirst%3DD.%26aulast%3DHayes%26aufirst%3DB.%26aulast%3DGough%26aufirst%3DJ.%26aulast%3DSolari%26aufirst%3DR.%26atitle%3DCharacterisation%2520of%2520a%2520K390R%2520ITK%2520kinase%2520dead%2520transgenic%2520mouse%2520%25E2%2580%2593%2520implications%2520for%2520ITK%2520as%2520a%2520therapeutic%2520target%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26spage%3De107490%26doi%3D10.1371%2Fjournal.pone.0107490" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cho, H.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haberstock-Debic, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funk, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradshaw, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berg, L. J.</span></span> <span> </span><span class="NLM_article-title">A small molecule inhibitor of ITK and RLK impairs Th1 differentiation and prevents colitis disease progression</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>195</i></span>,  <span class="NLM_fpage">4822</span>– <span class="NLM_lpage">4831</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1501828</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.4049%2Fjimmunol.1501828" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=195&publication_year=2015&pages=4822-4831&author=H.-S.+Choauthor=H.+M.+Shinauthor=H.+Haberstock-Debicauthor=Y.+Xingauthor=T.+D.+Owensauthor=J.+O.+Funkauthor=R.+J.+Hillauthor=J.+M.+Bradshawauthor=L.+J.+Berg&title=A+small+molecule+inhibitor+of+ITK+and+RLK+impairs+Th1+differentiation+and+prevents+colitis+disease+progression&doi=10.4049%2Fjimmunol.1501828"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1501828&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1501828%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DH.-S.%26aulast%3DShin%26aufirst%3DH.%2BM.%26aulast%3DHaberstock-Debic%26aufirst%3DH.%26aulast%3DXing%26aufirst%3DY.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26aulast%3DFunk%26aufirst%3DJ.%2BO.%26aulast%3DHill%26aufirst%3DR.%2BJ.%26aulast%3DBradshaw%26aufirst%3DJ.%2BM.%26aulast%3DBerg%26aufirst%3DL.%2BJ.%26atitle%3DA%2520small%2520molecule%2520inhibitor%2520of%2520ITK%2520and%2520RLK%2520impairs%2520Th1%2520differentiation%2520and%2520prevents%2520colitis%2520disease%2520progression%26jtitle%3DJ.%2520Immunol.%26date%3D2015%26volume%3D195%26spage%3D4822%26epage%3D4831%26doi%3D10.4049%2Fjimmunol.1501828" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coico, R.</span>; <span class="NLM_string-name">Sunshine, G.</span></span> <i>Immunology: A Short Course</i>, <span class="NLM_edition">6</span>th ed.; <span class="NLM_publisher-name">John Wiley & Sons</span>, <span class="NLM_year">2009</span>; p  <span class="NLM_fpage">391</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&pages=391&author=R.+Coico&author=G.+Sunshine&title=Immunology%3A+A+Short+Course"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DCoico%26aufirst%3DR.%26btitle%3DImmunology%253A%2520A%2520Short%2520Course%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%26date%3D2009%26spage%3D391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, K.</span></span> <i>Janeway’s Immunobiology</i>, <span class="NLM_edition">8</span>th ed.; <span class="NLM_publisher-name">Garland Science, Taylor & Francis Group, LLC</span>: <span class="NLM_publisher-loc">New York, NY</span>, <span class="NLM_year">2012</span>; p  <span class="NLM_fpage">888</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=888&author=K.+Murphy&title=Janeway%E2%80%99s+Immunobiology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DMurphy%26aufirst%3DK.%26btitle%3DJaneway%25E2%2580%2599s%2520Immunobiology%26pub%3DGarland%2520Science%252C%2520Taylor%2520%2526%2520Francis%2520Group%252C%2520LLC%26date%3D2012%26spage%3D888" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rokosz, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beasley, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appell, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, M. L.</span></span> <span> </span><span class="NLM_article-title">Kinase inhibitors as drugs for chronic inflammatory and immunological diseases: progress and challenges</span>. <i>Expert Opin. Ther. Targets</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">883</span>– <span class="NLM_lpage">903</span>, <span class="refDoi"> DOI: 10.1517/14728222.12.7.883</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1517%2F14728222.12.7.883" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=18554156" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BD1cXntFylsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2008&pages=883-903&author=L.+L.+Rokoszauthor=J.+R.+Beasleyauthor=C.+D.+Carrollauthor=T.+Linauthor=J.+Zhaoauthor=K.+C.+Appellauthor=M.+L.+Webb&title=Kinase+inhibitors+as+drugs+for+chronic+inflammatory+and+immunological+diseases%3A+progress+and+challenges&doi=10.1517%2F14728222.12.7.883"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase inhibitors as drugs for chronic inflammatory and immunological diseases: progress and challenges</span></div><div class="casAuthors">Rokosz, Laura L.; Beasley, James R.; Carroll, Carolyn DiIanni; Lin, Tsung; Zhao, Jiuqiao; Appell, Kenneth C.; Webb, Maria L.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">883-903</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  At the time of writing, there are seven marketed kinase inhibitor drugs.  The first kinase inhibitor, imatinib mesilate (Gleevec, Novartis), came to market in 2001, an inhibitor of the breakpoint cluster region (BCR)/Abelson murine leukemia oncogene homolog (ABL) fusion, platelet-derived growth factor (PDGF) receptor, and c-kit kinases.  The most recent kinase inhibitor to come to market, disatinib (Sprycel, Bristol-Myers Squibb), acts on c-SRC, ABL and Bruton's tyrosine kinase.  To date, kinase inhibitor drugs are approved for oncol. and demonstrate that it is possible to develop compds. with relative selectivity for the target kinase against the broader kinome.  However, the use of kinase inhibitors in chronic inflammatory and immunol. diseases may require greater selectivity for the target kinase.  This review addresses the opportunities and challenges of kinase inhibition as a therapeutic approach in chronic immune and inflammatory disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq458NGQKTbcbVg90H21EOLACvtfcHk0lgRIWjM2TyqIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXntFylsLY%253D&md5=6db3fdcc34b3ec97394c9dc6cdca8b99</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1517%2F14728222.12.7.883&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728222.12.7.883%26sid%3Dliteratum%253Aachs%26aulast%3DRokosz%26aufirst%3DL.%2BL.%26aulast%3DBeasley%26aufirst%3DJ.%2BR.%26aulast%3DCarroll%26aufirst%3DC.%2BD.%26aulast%3DLin%26aufirst%3DT.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DAppell%26aufirst%3DK.%2BC.%26aulast%3DWebb%26aufirst%3DM.%2BL.%26atitle%3DKinase%2520inhibitors%2520as%2520drugs%2520for%2520chronic%2520inflammatory%2520and%2520immunological%2520diseases%253A%2520progress%2520and%2520challenges%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2008%26volume%3D12%26spage%3D883%26epage%3D903%26doi%3D10.1517%2F14728222.12.7.883" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wesche, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, W.-C.</span></span> <span> </span><span class="NLM_article-title">IRAK-4 inhibitors for inflammation</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">724</span>– <span class="NLM_lpage">737</span>, <span class="refDoi"> DOI: 10.2174/156802609789044407</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.2174%2F156802609789044407" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=19689377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFehsLnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=724-737&author=Z.+Wangauthor=H.+Wescheauthor=T.+Stevensauthor=N.+Walkerauthor=W.-C.+Yeh&title=IRAK-4+inhibitors+for+inflammation&doi=10.2174%2F156802609789044407"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">IRAK-4 inhibitors for inflammation</span></div><div class="casAuthors">Wang, Zhulun; Wesche, Holger; Stevens, Tracey; Walker, Nigel; Yeh, Wen-Chen</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">724-737</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Interleukin-1 receptor-assocd. kinases (IRAKs) are key components in the signal transduction pathways utilized by interleukin-1 receptor (IL-1R), interleukin-18 receptor (IL-18R), and Toll-like receptors (TLRs).  Out of four members in the mammalian IRAK family, IRAK-4 is considered to be the "master IRAK", the only family member indispensable for IL-1R/TLR signaling.  In humans, mutations resulting in IRAK-4 deficiency have been linked to susceptibility to bacterial infections, esp. recurrent pyogenic bacterial infections.  Furthermore, knock-in expts. by several groups have clearly demonstrated that IRAK-4 requires its kinase activity for its function.  Given the crit. role of IRAK-4 in inflammatory processes, modulation of IRAK-4 kinase activity presents an attractive therapeutic approach for the treatment of immune and inflammatory diseases.  The recent success in the detn. of the 3-dimensional structure of the IRAK-4 kinase domain in complex with inhibitors has facilitated the understanding of the mechanistic role of IRAK-4 in immunity and inflammation as well as the development of specific IRAK-4 kinase inhibitors.  In this article, we review the biol. function of IRAK-4, the structural characteristics of the kinase domain, and the development of small mol. inhibitors targeting the kinase activity.  We also review the key pharmacophores required for several classes of inhibitors as well as important features for optimal protein/inhibitor interactions.  Lastly, we summarize how these insights can be translated into strategies to develop potent IRAK-4 inhibitors with desired properties as new anti-inflammatory therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRhyk3FnIbSrVg90H21EOLACvtfcHk0ljeP1NfbkaoFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFehsLnO&md5=c6a1278c9b9647aa8ce21edac373ddaa</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.2174%2F156802609789044407&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802609789044407%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DWesche%26aufirst%3DH.%26aulast%3DStevens%26aufirst%3DT.%26aulast%3DWalker%26aufirst%3DN.%26aulast%3DYeh%26aufirst%3DW.-C.%26atitle%3DIRAK-4%2520inhibitors%2520for%2520inflammation%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2009%26volume%3D9%26spage%3D724%26epage%3D737%26doi%3D10.2174%2F156802609789044407" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dudhgaonkar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranade, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasad, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karunanithi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatesh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selvam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnamurthy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mariappan, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saxena, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stetsko, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holloway, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruepp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santella, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duncia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hynes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carman, J. A.</span></span> <span> </span><span class="NLM_article-title">Selective IRAK4 inhibition attenuates disease in murine lupus models and demonstrates steroid sparing activity</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>198</i></span>,  <span class="NLM_fpage">1308</span>– <span class="NLM_lpage">1319</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1600583</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.4049%2Fjimmunol.1600583" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=28003376" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlaitb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=198&publication_year=2017&pages=1308-1319&author=S.+Dudhgaonkarauthor=S.+Ranadeauthor=J.+Nagarauthor=S.+Subramaniauthor=D.+S.+Prasadauthor=P.+Karunanithiauthor=R.+Srivastavaauthor=K.+Venkateshauthor=S.+Selvamauthor=P.+Krishnamurthyauthor=T.+T.+Mariappanauthor=A.+Saxenaauthor=L.+Fanauthor=D.+K.+Stetskoauthor=D.+A.+Hollowayauthor=X.+Liauthor=J.+Zhuauthor=W.-P.+Yangauthor=S.+Rueppauthor=S.+Nairauthor=J.+Santellaauthor=J.+Dunciaauthor=J.+Hynesauthor=K.+W.+McIntyreauthor=J.+A.+Carman&title=Selective+IRAK4+inhibition+attenuates+disease+in+murine+lupus+models+and+demonstrates+steroid+sparing+activity&doi=10.4049%2Fjimmunol.1600583"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Selective IRAK4 Inhibition Attenuates Disease in Murine Lupus Models and Demonstrates Steroid Sparing Activity</span></div><div class="casAuthors">Dudhgaonkar, Shailesh; Ranade, Sourabh; Nagar, Jignesh; Subramani, Siva; Prasad, Durga Shiv; Karunanithi, Preethi; Srivastava, Ratika; Venkatesh, Kamala; Selvam, Sabariya; Krishnamurthy, Prasad; Mariappan, T. Thanga; Saxena, Ajay; Fan, Li; Stetsko, Dawn K.; Holloway, Deborah A.; Li, Xin; Zhu, Jun; Yang, Wen-Pin; Ruepp, Stefan; Nair, Satheesh; Santella, Joseph; Duncia, John; Hynes, John; McIntyre, Kim W.; Carman, Julie A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">198</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1308-1319</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">The serine/threonine kinase IL-1R-assocd. kinase (IRAK)4 is a crit. regulator of innate immunity.  We have identified BMS-986126, a potent, highly selective inhibitor of IRAK4 kinase activity that demonstrates equipotent activity against multiple MyD88-dependent responses both in vitro and in vivo.  BMS-986126 failed to inhibit assays downstream of MyD88-independent receptors, including the TNF receptor and TLR3.  Very little activity was seen downstream of TLR4, which can also activate an MyD88-independent pathway.  In mice, the compd. inhibited cytokine prodn. induced by injection of several different TLR agonists, including those for TLR2, TLR7, and TLR9.  The compd. also significantly suppressed skin inflammation induced by topical administration of the TLR7 agonist imiquimod.  BMS-986126 demonstrated robust activity in the MRL/lpr and NZB/NZW models of lupus, inhibiting multiple pathogenic responses.  In the MRL/lpr model, robust activity was obsd. with the combination of suboptimal doses of BMS-986126 and prednisolone, suggesting the potential for steroid sparing activity.  BMS-986126 also demonstrated synergy with prednisolone in assays of TLR7- and TLR9-induced IFN target gene expression using human PBMCs.  Lastly, BMS-986126 inhibited TLR7- and TLR9-dependent responses using cells derived from lupus patients, suggesting that inhibition of IRAK4 has the potential for therapeutic benefit in treating lupus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrs4ZWIchaO6rVg90H21EOLACvtfcHk0ljeP1NfbkaoFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlaitb8%253D&md5=340ba834510cd04eb0e984e212731e17</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1600583&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1600583%26sid%3Dliteratum%253Aachs%26aulast%3DDudhgaonkar%26aufirst%3DS.%26aulast%3DRanade%26aufirst%3DS.%26aulast%3DNagar%26aufirst%3DJ.%26aulast%3DSubramani%26aufirst%3DS.%26aulast%3DPrasad%26aufirst%3DD.%2BS.%26aulast%3DKarunanithi%26aufirst%3DP.%26aulast%3DSrivastava%26aufirst%3DR.%26aulast%3DVenkatesh%26aufirst%3DK.%26aulast%3DSelvam%26aufirst%3DS.%26aulast%3DKrishnamurthy%26aufirst%3DP.%26aulast%3DMariappan%26aufirst%3DT.%2BT.%26aulast%3DSaxena%26aufirst%3DA.%26aulast%3DFan%26aufirst%3DL.%26aulast%3DStetsko%26aufirst%3DD.%2BK.%26aulast%3DHolloway%26aufirst%3DD.%2BA.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DW.-P.%26aulast%3DRuepp%26aufirst%3DS.%26aulast%3DNair%26aufirst%3DS.%26aulast%3DSantella%26aufirst%3DJ.%26aulast%3DDuncia%26aufirst%3DJ.%26aulast%3DHynes%26aufirst%3DJ.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DCarman%26aufirst%3DJ.%2BA.%26atitle%3DSelective%2520IRAK4%2520inhibition%2520attenuates%2520disease%2520in%2520murine%2520lupus%2520models%2520and%2520demonstrates%2520steroid%2520sparing%2520activity%26jtitle%3DJ.%2520Immunol.%26date%3D2017%26volume%3D198%26spage%3D1308%26epage%3D1319%26doi%3D10.4049%2Fjimmunol.1600583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Joosten, L. A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdollahi-Roodsaz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinarello, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Netea, M. G.</span></span> <span> </span><span class="NLM_article-title">Toll-like receptors and chronic inflammation in rheumatic diseases: new developments</span>. <i>Nat. Rev. Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">344</span>– <span class="NLM_lpage">357</span>, <span class="refDoi"> DOI: 10.1038/nrrheum.2016.61</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1038%2Fnrrheum.2016.61" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=27170508" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC28XnvV2ntb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=344-357&author=L.+A.+B.+Joostenauthor=S.+Abdollahi-Roodsazauthor=C.+A.+Dinarelloauthor=L.+O%E2%80%99Neillauthor=M.+G.+Netea&title=Toll-like+receptors+and+chronic+inflammation+in+rheumatic+diseases%3A+new+developments&doi=10.1038%2Fnrrheum.2016.61"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Toll-like receptors and chronic inflammation in rheumatic diseases: new developments</span></div><div class="casAuthors">Joosten, Leo A. B.; Abdollahi-Roodsaz, Shahla; Dinarello, Charles A.; O'Neill, Luke; Netea, Mihai G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Rheumatology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">344-357</span>CODEN:
                <span class="NLM_cas:coden">NRRACB</span>;
        ISSN:<span class="NLM_cas:issn">1759-4790</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In the past few years, new developments have been reported on the role of Toll-like receptors (TLRs) in chronic inflammation in rheumatic diseases.  The inhibitory function of TLR10 has been demonstrated.  Receptors that enhance the function of TLRs, and several TLR inhibitors, have been identified.  In addn., the role of the microbiome and TLRs in the onset of rheumatic diseases has been reported.  We review novel insights on the role of TLRs in several inflammatory joint diseases, including rheumatoid arthritis, systemic lupus erythematosus, gout and Lyme arthritis, with a focus on the signalling mechanisms mediated by the Toll-IL-1 receptor (TIR) domain, the exogenous and endogenous ligands of TLRs, and the current and future therapeutic strategies to target TLR signalling in rheumatic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBPDFqhEIq1rVg90H21EOLACvtfcHk0ljeP1NfbkaoFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnvV2ntb8%253D&md5=a561bbe778204e8e57d599efdbec093a</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1038%2Fnrrheum.2016.61&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrrheum.2016.61%26sid%3Dliteratum%253Aachs%26aulast%3DJoosten%26aufirst%3DL.%2BA.%2BB.%26aulast%3DAbdollahi-Roodsaz%26aufirst%3DS.%26aulast%3DDinarello%26aufirst%3DC.%2BA.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DL.%26aulast%3DNetea%26aufirst%3DM.%2BG.%26atitle%3DToll-like%2520receptors%2520and%2520chronic%2520inflammation%2520in%2520rheumatic%2520diseases%253A%2520new%2520developments%26jtitle%3DNat.%2520Rev.%2520Rheumatol.%26date%3D2016%26volume%3D12%26spage%3D344%26epage%3D357%26doi%3D10.1038%2Fnrrheum.2016.61" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhary, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, D. L.</span></span> <span> </span><span class="NLM_article-title">Recent advances in the discovery of small molecule inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4) as a therapeutic target for inflammation and oncology disorders</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">96</span>– <span class="NLM_lpage">110</span>, <span class="refDoi"> DOI: 10.1021/jm5016044</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5016044" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVCjsLzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=96-110&author=D.+Chaudharyauthor=S.+Robinsonauthor=D.+L.+Romero&title=Recent+advances+in+the+discovery+of+small+molecule+inhibitors+of+interleukin-1+receptor-associated+kinase+4+%28IRAK4%29+as+a+therapeutic+target+for+inflammation+and+oncology+disorders&doi=10.1021%2Fjm5016044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Advances in the Discovery of Small Molecule Inhibitors of Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) as a Therapeutic Target for Inflammation and Oncology Disorders</span></div><div class="casAuthors">Chaudhary, Divya; Robinson, Shaughnessy; Romero, Donna L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">96-110</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  IRAK4, a serine/threonine kinase, plays a key role in both inflammation and oncol. diseases.  Herein, we summarize the compelling biol. surrounding the IRAK4 signaling node in disease, review key structural features of IRAK4 including selectivity challenges, and describe efforts to discover clin. viable IRAK4 inhibitors.  Finally, a view of knowledge gained and remaining challenges is provided.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1K6ExwztfCLVg90H21EOLACvtfcHk0lju7A2H7pfAqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVCjsLzL&md5=795797f7f3f07597ecd0b5899498804b</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1021%2Fjm5016044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5016044%26sid%3Dliteratum%253Aachs%26aulast%3DChaudhary%26aufirst%3DD.%26aulast%3DRobinson%26aufirst%3DS.%26aulast%3DRomero%26aufirst%3DD.%2BL.%26atitle%3DRecent%2520advances%2520in%2520the%2520discovery%2520of%2520small%2520molecule%2520inhibitors%2520of%2520interleukin-1%2520receptor-associated%2520kinase%25204%2520%2528IRAK4%2529%2520as%2520a%2520therapeutic%2520target%2520for%2520inflammation%2520and%2520oncology%2520disorders%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D96%26epage%3D110%26doi%3D10.1021%2Fjm5016044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grogan, J. L.</span></span> <span> </span><span class="NLM_article-title">Immune complex-mediated cell activation from systemic lupus erythematosus and rheumatoid arthritis patients elaborate different requirements for IRAK1/4 kinase activity across human cell types</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>186</i></span>,  <span class="NLM_fpage">1279</span>– <span class="NLM_lpage">1288</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1002821</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.4049%2Fjimmunol.1002821" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=186&publication_year=2011&pages=1279-1288&author=E.+Y.+Chiangauthor=X.+Yuauthor=J.+L.+Grogan&title=Immune+complex-mediated+cell+activation+from+systemic+lupus+erythematosus+and+rheumatoid+arthritis+patients+elaborate+different+requirements+for+IRAK1%2F4+kinase+activity+across+human+cell+types&doi=10.4049%2Fjimmunol.1002821"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1002821&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1002821%26sid%3Dliteratum%253Aachs%26aulast%3DChiang%26aufirst%3DE.%2BY.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DGrogan%26aufirst%3DJ.%2BL.%26atitle%3DImmune%2520complex-mediated%2520cell%2520activation%2520from%2520systemic%2520lupus%2520erythematosus%2520and%2520rheumatoid%2520arthritis%2520patients%2520elaborate%2520different%2520requirements%2520for%2520IRAK1%252F4%2520kinase%2520activity%2520across%2520human%2520cell%2520types%26jtitle%3DJ.%2520Immunol.%26date%3D2011%26volume%3D186%26spage%3D1279%26epage%3D1288%26doi%3D10.4049%2Fjimmunol.1002821" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bothe, U.</span>; <span class="NLM_string-name">Wengner, A. M.</span>; <span class="NLM_string-name">Siebeneicher, H.</span>; <span class="NLM_string-name">Schmidt, N.</span>; <span class="NLM_string-name">Nubbemeyer, R.</span>; <span class="NLM_string-name">Bomer, U.</span>; <span class="NLM_string-name">Gunther, J.</span>; <span class="NLM_string-name">Steuber, H.</span>; <span class="NLM_string-name">Lange, M.</span>; <span class="NLM_string-name">Stegmann, C.</span>; <span class="NLM_string-name">Sutter, A.</span>; <span class="NLM_string-name">Neuhaus, R.</span></span> <span> </span><span class="NLM_article-title">Combinations of Inhibitors of IRAK4 with Inhibitors of BTK</span>. <span class="NLM_patent">WO2016/174183 A1</span>, Nov 3, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=U.+Bothe&author=A.+M.+Wengner&author=H.+Siebeneicher&author=N.+Schmidt&author=R.+Nubbemeyer&author=U.+Bomer&author=J.+Gunther&author=H.+Steuber&author=M.+Lange&author=C.+Stegmann&author=A.+Sutter&author=R.+Neuhaus&title=Combinations+of+Inhibitors+of+IRAK4+with+Inhibitors+of+BTK"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBothe%26aufirst%3DU.%26atitle%3DCombinations%2520of%2520Inhibitors%2520of%2520IRAK4%2520with%2520Inhibitors%2520of%2520BTK%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambler, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boscoe, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bree, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodfuehrer, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curran, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dehnhardt, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dower, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drozda, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frisbie, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavrin, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hepworth, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hope, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamtekar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilty, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, L.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovering, F. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathias, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papaioannou, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patny, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saiah, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samardjiev, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samas, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, M. W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soutter, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strohbach, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symanowicz, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomason, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trzupek, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vargas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zapf, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, S. W.</span></span> <span> </span><span class="NLM_article-title">Discovery of clinical candidate 1-{[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a potent, selective inhibitor of interleukin-1 receptor associated kinase 4 (IRAK4), by fragment-based drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">5521</span>– <span class="NLM_lpage">5542</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00231</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00231" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnslGqu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5521-5542&author=K.+L.+Leeauthor=C.+M.+Amblerauthor=D.+R.+Andersonauthor=B.+P.+Boscoeauthor=A.+G.+Breeauthor=J.+I.+Brodfuehrerauthor=J.+S.+Changauthor=C.+Choiauthor=S.+Chungauthor=K.+J.+Curranauthor=J.+E.+Dayauthor=C.+M.+Dehnhardtauthor=K.+Dowerauthor=S.+E.+Drozdaauthor=R.+K.+Frisbieauthor=L.+K.+Gavrinauthor=J.+A.+Goldbergauthor=S.+Hanauthor=M.+Hegenauthor=D.+Hepworthauthor=H.+R.+Hopeauthor=S.+Kamtekarauthor=I.+C.+Kiltyauthor=A.+Leeauthor=L.-L.+Linauthor=F.+E.+Loveringauthor=M.+D.+Loweauthor=J.+P.+Mathiasauthor=H.+M.+Morganauthor=E.+A.+Murphyauthor=N.+Papaioannouauthor=A.+Patnyauthor=B.+S.+Pierceauthor=V.+R.+Raoauthor=E.+Saiahauthor=I.+J.+Samardjievauthor=B.+M.+Samasauthor=M.+W.+H.+Shenauthor=J.+H.+Shinauthor=H.+H.+Soutterauthor=J.+W.+Strohbachauthor=P.+T.+Symanowiczauthor=J.+R.+Thomasonauthor=J.+D.+Trzupekauthor=R.+Vargasauthor=F.+Vincentauthor=J.+Yanauthor=C.+W.+Zapfauthor=S.+W.+Wright&title=Discovery+of+clinical+candidate+1-%7B%5B%282S%2C3S%2C4S%29-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl%5Dmethoxy%7D-7-methoxyisoquinoline-6-carboxamide+%28PF-06650833%29%2C+a+potent%2C+selective+inhibitor+of+interleukin-1+receptor+associated+kinase+4+%28IRAK4%29%2C+by+fragment-based+drug+design&doi=10.1021%2Facs.jmedchem.7b00231"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Clinical Candidate 1-{[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design</span></div><div class="casAuthors">Lee, Katherine L.; Ambler, Catherine M.; Anderson, David R.; Boscoe, Brian P.; Bree, Andrea G.; Brodfuehrer, Joanne I.; Chang, Jeanne S.; Choi, Chulho; Chung, Seungwon; Curran, Kevin J.; Day, Jacqueline E.; Dehnhardt, Christoph M.; Dower, Ken; Drozda, Susan E.; Frisbie, Richard K.; Gavrin, Lori K.; Goldberg, Joel A.; Han, Seungil; Hegen, Martin; Hepworth, David; Hope, Heidi R.; Kamtekar, Satwik; Kilty, Iain C.; Lee, Arthur; Lin, Lih-Ling; Lovering, Frank E.; Lowe, Michael D.; Mathias, John P.; Morgan, Heidi M.; Murphy, Elizabeth A.; Papaioannou, Nikolaos; Patny, Akshay; Pierce, Betsy S.; Rao, Vikram R.; Saiah, Eddine; Samardjiev, Ivan J.; Samas, Brian M.; Shen, Marina W. H.; Shin, Julia H.; Soutter, Holly H.; Strohbach, Joseph W.; Symanowicz, Peter T.; Thomason, Jennifer R.; Trzupek, John D.; Vargas, Richard; Vincent, Fabien; Yan, Jiangli; Zapf, Christoph W.; Wright, Stephen W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5521-5542</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Through fragment-based drug design focused on engaging the active site of IRAK4 and leveraging three-dimensional topol. in a ligand-efficient manner, a micromolar hit identified from a screen of a Pfizer fragment library was optimized to afford IRAK4 inhibitors with nanomolar potency in cellular assays.  The medicinal chem. effort featured the judicious placement of lipophilicity, informed by cocrystal structures with IRAK4 and optimization of ADME properties to deliver clin. candidate I.  This compd. benefitted from a 5-unit increase in lipophilic efficiency from the fragment hit, excellent kinase selectivity, and pharmacokinetic properties suitable for oral administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYrCep64bhMbVg90H21EOLACvtfcHk0lju7A2H7pfAqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnslGqu7c%253D&md5=9771ad2d33089f6ef3dba3556536ff1a</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00231&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00231%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DK.%2BL.%26aulast%3DAmbler%26aufirst%3DC.%2BM.%26aulast%3DAnderson%26aufirst%3DD.%2BR.%26aulast%3DBoscoe%26aufirst%3DB.%2BP.%26aulast%3DBree%26aufirst%3DA.%2BG.%26aulast%3DBrodfuehrer%26aufirst%3DJ.%2BI.%26aulast%3DChang%26aufirst%3DJ.%2BS.%26aulast%3DChoi%26aufirst%3DC.%26aulast%3DChung%26aufirst%3DS.%26aulast%3DCurran%26aufirst%3DK.%2BJ.%26aulast%3DDay%26aufirst%3DJ.%2BE.%26aulast%3DDehnhardt%26aufirst%3DC.%2BM.%26aulast%3DDower%26aufirst%3DK.%26aulast%3DDrozda%26aufirst%3DS.%2BE.%26aulast%3DFrisbie%26aufirst%3DR.%2BK.%26aulast%3DGavrin%26aufirst%3DL.%2BK.%26aulast%3DGoldberg%26aufirst%3DJ.%2BA.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DHepworth%26aufirst%3DD.%26aulast%3DHope%26aufirst%3DH.%2BR.%26aulast%3DKamtekar%26aufirst%3DS.%26aulast%3DKilty%26aufirst%3DI.%2BC.%26aulast%3DLee%26aufirst%3DA.%26aulast%3DLin%26aufirst%3DL.-L.%26aulast%3DLovering%26aufirst%3DF.%2BE.%26aulast%3DLowe%26aufirst%3DM.%2BD.%26aulast%3DMathias%26aufirst%3DJ.%2BP.%26aulast%3DMorgan%26aufirst%3DH.%2BM.%26aulast%3DMurphy%26aufirst%3DE.%2BA.%26aulast%3DPapaioannou%26aufirst%3DN.%26aulast%3DPatny%26aufirst%3DA.%26aulast%3DPierce%26aufirst%3DB.%2BS.%26aulast%3DRao%26aufirst%3DV.%2BR.%26aulast%3DSaiah%26aufirst%3DE.%26aulast%3DSamardjiev%26aufirst%3DI.%2BJ.%26aulast%3DSamas%26aufirst%3DB.%2BM.%26aulast%3DShen%26aufirst%3DM.%2BW.%2BH.%26aulast%3DShin%26aufirst%3DJ.%2BH.%26aulast%3DSoutter%26aufirst%3DH.%2BH.%26aulast%3DStrohbach%26aufirst%3DJ.%2BW.%26aulast%3DSymanowicz%26aufirst%3DP.%2BT.%26aulast%3DThomason%26aufirst%3DJ.%2BR.%26aulast%3DTrzupek%26aufirst%3DJ.%2BD.%26aulast%3DVargas%26aufirst%3DR.%26aulast%3DVincent%26aufirst%3DF.%26aulast%3DYan%26aufirst%3DJ.%26aulast%3DZapf%26aufirst%3DC.%2BW.%26aulast%3DWright%26aufirst%3DS.%2BW.%26atitle%3DDiscovery%2520of%2520clinical%2520candidate%25201-%257B%255B%25282S%252C3S%252C4S%2529-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl%255Dmethoxy%257D-7-methoxyisoquinoline-6-carboxamide%2520%2528PF-06650833%2529%252C%2520a%2520potent%252C%2520selective%2520inhibitor%2520of%2520interleukin-1%2520receptor%2520associated%2520kinase%25204%2520%2528IRAK4%2529%252C%2520by%2520fragment-based%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D5521%26epage%3D5542%26doi%3D10.1021%2Facs.jmedchem.7b00231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knight, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span> <span> </span><span class="NLM_article-title">Features of selective kinase inhibitors</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">621</span>– <span class="NLM_lpage">637</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2005.04.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1016%2Fj.chembiol.2005.04.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=15975507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlsFGhtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2005&pages=621-637&author=Z.+A.+Knightauthor=K.+M.+Shokat&title=Features+of+selective+kinase+inhibitors&doi=10.1016%2Fj.chembiol.2005.04.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Features of Selective Kinase Inhibitors</span></div><div class="casAuthors">Knight, Zachary A.; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">621-637</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Summary: Small-mol. inhibitors of protein and lipid kinases have emerged as indispensable tools for studying signal transduction.  Despite the widespread use of these reagents, there is little consensus about the biochem. criteria that define their potency and selectivity in cells.  We discuss some of the features that det. the cellular activity of kinase inhibitors and propose a framework for interpreting inhibitor selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAJWhVxtSrCLVg90H21EOLACvtfcHk0liikbeWwEblig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlsFGhtrc%253D&md5=ce5b3505a0326b04479172ec05573152</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2005.04.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2005.04.011%26sid%3Dliteratum%253Aachs%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DFeatures%2520of%2520selective%2520kinase%2520inhibitors%26jtitle%3DChem.%2520Biol.%26date%3D2005%26volume%3D12%26spage%3D621%26epage%3D637%26doi%3D10.1016%2Fj.chembiol.2005.04.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Picard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Bernuth, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghandil, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chrabieh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arkwright, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geha, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krause, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creech, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ku, C.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maŕodi, Ĺ.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Muhsen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Hajjar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Ghonaium, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day-Good, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holland, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speert, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Gallego, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colino, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garty, B.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roifman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshikawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonoyama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domachowske, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Issekutz, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smart, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zitnik, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoarau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumararatne, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thrasher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bethune, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirvent, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Ricaud, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camcioglu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasconcelos, J. u.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guedes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitor, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almazán, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ḿendez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aŕostegui, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alsina, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortuny, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichenbach, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verbsky, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bossuyt, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doffinger, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casanova, J.-L.</span></span> <span> </span><span class="NLM_article-title">Clinical features and outcome of patients with IRAK-4 and MyD88 deficiency</span>. <i>Medicine</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">403</span>– <span class="NLM_lpage">425</span>, <span class="refDoi"> DOI: 10.1097/MD.0b013e3181fd8ec3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1097%2FMD.0b013e3181fd8ec3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=21057262" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtl2lt7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2010&pages=403-425&author=C.+Picardauthor=H.+von+Bernuthauthor=P.+Ghandilauthor=M.+Chrabiehauthor=O.+Levyauthor=P.+D.+Arkwrightauthor=D.+McDonaldauthor=R.+S.+Gehaauthor=H.+Takadaauthor=J.+C.+Krauseauthor=C.+B.+Creechauthor=C.-L.+Kuauthor=S.+Ehlauthor=%C4%B9.+Ma%C5%95odiauthor=S.+Al-Muhsenauthor=S.+Al-Hajjarauthor=A.+Al-Ghonaiumauthor=N.+K.+Day-Goodauthor=S.+M.+Hollandauthor=J.+Gallinauthor=H.+Chapelauthor=D.+P.+Speertauthor=C.+Rodriguez-Gallegoauthor=E.+Colinoauthor=B.-Z.+Gartyauthor=C.+Roifmanauthor=T.+Haraauthor=H.+Yoshikawaauthor=S.+Nonoyamaauthor=J.+Domachowskeauthor=A.+C.+Issekutzauthor=M.+Tangauthor=J.+Smartauthor=S.+E.+Zitnikauthor=C.+Hoarauauthor=D.+Kumararatneauthor=A.+Thrasherauthor=E.+G.+Daviesauthor=C.+Bethuneauthor=N.+Sirventauthor=D.+de+Ricaudauthor=Y.+Camciogluauthor=J.+u.+Vasconcelosauthor=M.+Guedesauthor=A.+B.+Vitorauthor=C.+Rodrigoauthor=F.+Almaz%C3%A1nauthor=M.+%E1%B8%BEendezauthor=J.+I.+A%C5%95osteguiauthor=L.+Alsinaauthor=C.+Fortunyauthor=J.+Reichenbachauthor=J.+W.+Verbskyauthor=X.+Bossuytauthor=R.+Doffingerauthor=L.+Abelauthor=A.+Puelauthor=J.-L.+Casanova&title=Clinical+features+and+outcome+of+patients+with+IRAK-4+and+MyD88+deficiency&doi=10.1097%2FMD.0b013e3181fd8ec3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical features and outcome of patients with IRAK-4 and MyD88 deficiency</span></div><div class="casAuthors">Picard, Capucine; von Bernuth, Horst; Ghandil, Pegah; Chrabieh, Maya; Levy, Ofer; Arkwright, Peter D.; McDonald, Douglas; Geha, Raif S.; Takada, Hidetoshi; Krause, Jens C.; Creech, C. Buddy; Ku, Cheng-Lung; Ehl, Stephan; Marodi, Laszlo; Al-Muhsen, Saleh; Al-Hajjar, Sami; Al-Ghonaium, Abdulaziz; Day-Good, Noorbibi K.; Holland, Steven M.; Gallin, John I.; Chapel, Helen; Speert, David P.; Rodriguez-Gallego, Carlos; Colino, Elena; Garty, Ben-Zion; Roifman, Chaim; Hara, Toshiro; Yoshikawa, Hideto; Nonoyama, Shigeaki; Domachowske, Joseph; Issekutz, Andrew C.; Tang, Mimi; Smart, Joanne; Zitnik, Simona Eva; Hoarau, Cyrille; Kumararatne, Dinakantha S.; Thrasher, Adrian J.; Davies, E. Graham; Bethune, Claire; Sirvent, Nicolas; de Ricaud, Dominique; Camcioglu, Yildiz; Vasconcelos, Julia; Guedes, Margarida; Vitor, Artur Bonito; Rodrigo, Carlos; Almazan, Francisco; Mendez, Maria; Arostegui, Juan Ignacio; Alsina, Laia; Fortuny, Claudia; Reichenbach, Janine; Verbsky, James W.; Bossuyt, Xavier; Doffinger, Rainer; Abel, Laurent; Puel, Anne; Casanova, Jean-Laurent</div><div class="citationInfo"><span class="NLM_cas:title">Medicine (Hagerstown, MD, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">403-425</span>CODEN:
                <span class="NLM_cas:coden">MEDIAV</span>;
        ISSN:<span class="NLM_cas:issn">0025-7974</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Autosomal recessive interleukin-1 receptor-assocd. kinase (IRAK)-4 and myeloid differentiation factor (MyD)88 deficiencies impair Toll-like receptor (TLR)- and interleukin-1 receptor-mediated immunity.  We documented the clin. features and outcome of 48 patients with IRAK-4 deficiency and 12 patients with MyD88 deficiency, from 37 kindreds in 15 countries.The clin. features of IRAK-4 and MyD88 deficiency were indistinguishable.  There were no severe viral, parasitic, and fungal diseases, and the range of bacterial infections was narrow.  Noninvasive bacterial infections occurred in 52 patients, with a high incidence of infections of the upper respiratory tract and the skin, mostly caused by Pseudomonas aeruginosa and Staphylococcus aureus, resp.  The leading threat was invasive pneumococcal disease, documented in 41 patients (68%) and causing 72 documented invasive infections (52.2%).  P. aeruginosa and Staph. aureus documented invasive infections also occurred (16.7% and 16%, resp., in 13 and 13 patients, resp.).  Systemic signs of inflammation were usually weak or delayed.  The first invasive infection occurred before the age of 2 years in 53 (88.3%) and in the neonatal period in 19 (32.7%) patients.  Multiple or recurrent invasive infections were obsd. in most survivors (n = 36/50, 72%).Clin. outcome was poor, with 24 deaths, in 10 cases during the first invasive episode and in 16 cases of invasive pneumococcal disease.  However, no death and invasive infectious disease were reported in patients after the age of 8 years and 14 years, resp.  Antibiotic prophylaxis (n = 34), antipneumococcal vaccination (n = 31), and/or IgG infusion (n = 19), when instituted, had a beneficial impact on patients until the teenage years, with no seemingly detectable impact thereafter.IRAK-4 and MyD88 deficiencies predispose patients to recurrent life-threatening bacterial diseases, such as invasive pneumococcal disease in particular, in infancy and early childhood, with weak signs of inflammation.  Patients and families should be informed of the risk of developing life-threatening infections; empiric antibacterial treatment and immediate medical consultation are strongly recommended in cases of suspected infection or moderate fever.  Prophylactic measures in childhood are beneficial, until spontaneous improvement occurs in adolescence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGaZKIOSMgkLVg90H21EOLACvtfcHk0liikbeWwEblig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtl2lt7vI&md5=ed6d1e73355d1c7720c255073c999d9b</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1097%2FMD.0b013e3181fd8ec3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FMD.0b013e3181fd8ec3%26sid%3Dliteratum%253Aachs%26aulast%3DPicard%26aufirst%3DC.%26aulast%3Dvon%2BBernuth%26aufirst%3DH.%26aulast%3DGhandil%26aufirst%3DP.%26aulast%3DChrabieh%26aufirst%3DM.%26aulast%3DLevy%26aufirst%3DO.%26aulast%3DArkwright%26aufirst%3DP.%2BD.%26aulast%3DMcDonald%26aufirst%3DD.%26aulast%3DGeha%26aufirst%3DR.%2BS.%26aulast%3DTakada%26aufirst%3DH.%26aulast%3DKrause%26aufirst%3DJ.%2BC.%26aulast%3DCreech%26aufirst%3DC.%2BB.%26aulast%3DKu%26aufirst%3DC.-L.%26aulast%3DEhl%26aufirst%3DS.%26aulast%3DMa%25C5%2595odi%26aufirst%3D%25C4%25B9.%26aulast%3DAl-Muhsen%26aufirst%3DS.%26aulast%3DAl-Hajjar%26aufirst%3DS.%26aulast%3DAl-Ghonaium%26aufirst%3DA.%26aulast%3DDay-Good%26aufirst%3DN.%2BK.%26aulast%3DHolland%26aufirst%3DS.%2BM.%26aulast%3DGallin%26aufirst%3DJ.%26aulast%3DChapel%26aufirst%3DH.%26aulast%3DSpeert%26aufirst%3DD.%2BP.%26aulast%3DRodriguez-Gallego%26aufirst%3DC.%26aulast%3DColino%26aufirst%3DE.%26aulast%3DGarty%26aufirst%3DB.-Z.%26aulast%3DRoifman%26aufirst%3DC.%26aulast%3DHara%26aufirst%3DT.%26aulast%3DYoshikawa%26aufirst%3DH.%26aulast%3DNonoyama%26aufirst%3DS.%26aulast%3DDomachowske%26aufirst%3DJ.%26aulast%3DIssekutz%26aufirst%3DA.%2BC.%26aulast%3DTang%26aufirst%3DM.%26aulast%3DSmart%26aufirst%3DJ.%26aulast%3DZitnik%26aufirst%3DS.%2BE.%26aulast%3DHoarau%26aufirst%3DC.%26aulast%3DKumararatne%26aufirst%3DD.%26aulast%3DThrasher%26aufirst%3DA.%26aulast%3DDavies%26aufirst%3DE.%2BG.%26aulast%3DBethune%26aufirst%3DC.%26aulast%3DSirvent%26aufirst%3DN.%26aulast%3Dde%2BRicaud%26aufirst%3DD.%26aulast%3DCamcioglu%26aufirst%3DY.%26aulast%3DVasconcelos%26aufirst%3DJ.%2Bu.%26aulast%3DGuedes%26aufirst%3DM.%26aulast%3DVitor%26aufirst%3DA.%2BB.%26aulast%3DRodrigo%26aufirst%3DC.%26aulast%3DAlmaz%25C3%25A1n%26aufirst%3DF.%26aulast%3D%25E1%25B8%25BEendez%26aufirst%3DM.%26aulast%3DA%25C5%2595ostegui%26aufirst%3DJ.%2BI.%26aulast%3DAlsina%26aufirst%3DL.%26aulast%3DFortuny%26aufirst%3DC.%26aulast%3DReichenbach%26aufirst%3DJ.%26aulast%3DVerbsky%26aufirst%3DJ.%2BW.%26aulast%3DBossuyt%26aufirst%3DX.%26aulast%3DDoffinger%26aufirst%3DR.%26aulast%3DAbel%26aufirst%3DL.%26aulast%3DPuel%26aufirst%3DA.%26aulast%3DCasanova%26aufirst%3DJ.-L.%26atitle%3DClinical%2520features%2520and%2520outcome%2520of%2520patients%2520with%2520IRAK-4%2520and%2520MyD88%2520deficiency%26jtitle%3DMedicine%26date%3D2010%26volume%3D89%26spage%3D403%26epage%3D425%26doi%3D10.1097%2FMD.0b013e3181fd8ec3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Razani, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichardt, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, G.</span></span> <span> </span><span class="NLM_article-title">Non-canonical NF-κB signaling activation and regulation: principles and perspectives</span>. <i>Immunol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>244</i></span>,  <span class="NLM_fpage">44</span>– <span class="NLM_lpage">54</span>, <span class="refDoi"> DOI: 10.1111/j.1600-065X.2011.01059.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1111%2Fj.1600-065X.2011.01059.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=22017430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFagsL%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=244&publication_year=2011&pages=44-54&author=B.+Razaniauthor=A.+D.+Reichardtauthor=G.+Cheng&title=Non-canonical+NF-%CE%BAB+signaling+activation+and+regulation%3A+principles+and+perspectives&doi=10.1111%2Fj.1600-065X.2011.01059.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Non-canonical NF-κB signaling activation and regulation: principles and perspectives</span></div><div class="casAuthors">Razani, Bahram; Reichardt, Anna Devi; Cheng, Genhong</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">244</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">44-54</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">1600-065X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Nuclear-factor κB (NF-κB) transcription factors are activated by a wide variety of stimuli in diverse cell types and control key aspects of immune function and development.  Receptor-mediated activation of NF-κB appears to occur through two distinct signaling pathways termed as the canonical and non-canonical NF-κB pathways.  Although much work has demonstrated the physiol. importance of non-canonical NF-κB signaling to immunity and its involvement in diverse pathologies, such as cancers and autoimmune disease, the architecture and regulation of the pathway is only beginning to be understood.  The non-canonical pathway appears to be activated by a select set of receptors within the tumor necrosis factor superfamily, and we discuss the mol. mechanisms that connect ligation of these receptors to pathway activation.  It has become increasingly clear that the key regulatory step of the pathway involves modulation of the post-translational degrdn. of NF-κB-inducing kinase (NIK), the central activating kinase of non-canonical NF-κB signaling.  How NIK post-translational stability is controlled before and after receptor ligation is an important aspect of understanding non-canonical NF-κB signaling.  Furthermore, how release of NF-κB dimers downstream of the pathway's activation is actually connected to its identified physiol. and pathol. roles is a key remaining question in the field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxjtZ3BYUJjrVg90H21EOLACvtfcHk0liX6ib-0rI3Nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFagsL%252FK&md5=b4b7e40a5437602ea0a61aaa5577e1f3</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-065X.2011.01059.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-065X.2011.01059.x%26sid%3Dliteratum%253Aachs%26aulast%3DRazani%26aufirst%3DB.%26aulast%3DReichardt%26aufirst%3DA.%2BD.%26aulast%3DCheng%26aufirst%3DG.%26atitle%3DNon-canonical%2520NF-%25CE%25BAB%2520signaling%2520activation%2520and%2520regulation%253A%2520principles%2520and%2520perspectives%26jtitle%3DImmunol.%2520Rev.%26date%3D2011%26volume%3D244%26spage%3D44%26epage%3D54%26doi%3D10.1111%2Fj.1600-065X.2011.01059.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brightbill, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaquiere, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramamoorthi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sujatha-Bhaskar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gogol, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castanedo, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bents, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohli, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linge, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christian, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaochico, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berezhkovskiy, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modrusan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veliz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Townsend, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVoss, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godemann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenzie, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hackney, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staben, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alaoui Ismaili, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghilardi, N.</span></span> <span> </span><span class="NLM_article-title">NF-κB inducing kinase is a therapeutic target for systemic lupus erythematosus</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">179</span>– <span class="NLM_lpage">192</span>, <span class="refDoi"> DOI: 10.1038/s41467-017-02672-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1038%2Fs41467-017-02672-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=29330524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A280%3ADC%252BC1Mvgtlylug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=179-192&author=H.+D.+Brightbillauthor=E.+Sutoauthor=N.+Blaquiereauthor=N.+Ramamoorthiauthor=S.+Sujatha-Bhaskarauthor=E.+B.+Gogolauthor=G.+M.+Castanedoauthor=B.+T.+Jacksonauthor=Y.+C.+Kwonauthor=S.+Hallerauthor=J.+Leschauthor=K.+Bentsauthor=C.+Everettauthor=P.+B.+Kohliauthor=S.+Lingeauthor=L.+Christianauthor=K.+Barrettauthor=A.+Jaochicoauthor=L.+M.+Berezhkovskiyauthor=P.+W.+Fanauthor=Z.+Modrusanauthor=K.+Velizauthor=M.+J.+Townsendauthor=J.+DeVossauthor=A.+R.+Johnsonauthor=R.+Godemannauthor=W.+P.+Leeauthor=C.+D.+Austinauthor=B.+S.+McKenzieauthor=J.+A.+Hackneyauthor=J.+J.+Crawfordauthor=S.+T.+Stabenauthor=M.+H.+Alaoui+Ismailiauthor=L.+C.+Wuauthor=N.+Ghilardi&title=NF-%CE%BAB+inducing+kinase+is+a+therapeutic+target+for+systemic+lupus+erythematosus&doi=10.1038%2Fs41467-017-02672-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">NF-κB inducing kinase is a therapeutic target for systemic lupus erythematosus</span></div><div class="casAuthors">Brightbill Hans D; Sujatha-Bhaskar Swathi; Gogol Emily B; Jackson Benjamin T; Christian Laura; Wu Lawren C; Ghilardi Nico; Suto Eric; Kwon Youngsu C; Lesch Justin; DeVoss Jason; Lee Wyne P; McKenzie Brent S; Blaquiere Nicole; Castanedo Georgette M; Crawford James J; Staben Steven T; Ramamoorthi Nandhini; Townsend Michael J; Haller Susan; Austin Cary D; Bents Karin; Linge Sandra; Godemann Robert; Everett Christine; Kohli Pawan Bir; Barrett Kathy; Johnson Adam R; Alaoui Ismaili Moulay H; Jaochico Allan; Berezhkovskiy Leonid M; Fan Peter W; Modrusan Zora; Veliz Kelli; Hackney Jason A</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">179</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">NF-κB-inducing kinase (NIK) mediates non-canonical NF-κB signaling downstream of multiple TNF family members, including BAFF, TWEAK, CD40, and OX40, which are implicated in the pathogenesis of systemic lupus erythematosus (SLE).  Here, we show that experimental lupus in NZB/W F1 mice can be treated with a highly selective and potent NIK small molecule inhibitor.  Both in vitro as well as in vivo, NIK inhibition recapitulates the pharmacological effects of BAFF blockade, which is clinically efficacious in SLE.  Furthermore, NIK inhibition also affects T cell parameters in the spleen and proinflammatory gene expression in the kidney, which may be attributable to inhibition of OX40 and TWEAK signaling, respectively.  As a consequence, NIK inhibition results in improved survival, reduced renal pathology, and lower proteinuria scores.  Collectively, our data suggest that NIK inhibition is a potential therapeutic approach for SLE.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRSowPmlnIWxaqcneEtCi92fW6udTcc2eYQrRjpPwd4SLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mvgtlylug%253D%253D&md5=41a91514e1f4e8b2b44912ba6d6a4788</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1038%2Fs41467-017-02672-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-017-02672-0%26sid%3Dliteratum%253Aachs%26aulast%3DBrightbill%26aufirst%3DH.%2BD.%26aulast%3DSuto%26aufirst%3DE.%26aulast%3DBlaquiere%26aufirst%3DN.%26aulast%3DRamamoorthi%26aufirst%3DN.%26aulast%3DSujatha-Bhaskar%26aufirst%3DS.%26aulast%3DGogol%26aufirst%3DE.%2BB.%26aulast%3DCastanedo%26aufirst%3DG.%2BM.%26aulast%3DJackson%26aufirst%3DB.%2BT.%26aulast%3DKwon%26aufirst%3DY.%2BC.%26aulast%3DHaller%26aufirst%3DS.%26aulast%3DLesch%26aufirst%3DJ.%26aulast%3DBents%26aufirst%3DK.%26aulast%3DEverett%26aufirst%3DC.%26aulast%3DKohli%26aufirst%3DP.%2BB.%26aulast%3DLinge%26aufirst%3DS.%26aulast%3DChristian%26aufirst%3DL.%26aulast%3DBarrett%26aufirst%3DK.%26aulast%3DJaochico%26aufirst%3DA.%26aulast%3DBerezhkovskiy%26aufirst%3DL.%2BM.%26aulast%3DFan%26aufirst%3DP.%2BW.%26aulast%3DModrusan%26aufirst%3DZ.%26aulast%3DVeliz%26aufirst%3DK.%26aulast%3DTownsend%26aufirst%3DM.%2BJ.%26aulast%3DDeVoss%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DGodemann%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DW.%2BP.%26aulast%3DAustin%26aufirst%3DC.%2BD.%26aulast%3DMcKenzie%26aufirst%3DB.%2BS.%26aulast%3DHackney%26aufirst%3DJ.%2BA.%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26aulast%3DStaben%26aufirst%3DS.%2BT.%26aulast%3DAlaoui%2BIsmaili%26aufirst%3DM.%2BH.%26aulast%3DWu%26aufirst%3DL.%2BC.%26aulast%3DGhilardi%26aufirst%3DN.%26atitle%3DNF-%25CE%25BAB%2520inducing%2520kinase%2520is%2520a%2520therapeutic%2520target%2520for%2520systemic%2520lupus%2520erythematosus%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26spage%3D179%26epage%3D192%26doi%3D10.1038%2Fs41467-017-02672-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vallabhapurapu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karin, M.</span></span> <span> </span><span class="NLM_article-title">Regulation and function of NF-κB transcription factors in the immune system</span>. <i>Annu. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">693</span>– <span class="NLM_lpage">733</span>, <span class="refDoi"> DOI: 10.1146/annurev.immunol.021908.132641</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1146%2Fannurev.immunol.021908.132641" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=19302050" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsFSlt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=693-733&author=S.+Vallabhapurapuauthor=M.+Karin&title=Regulation+and+function+of+NF-%CE%BAB+transcription+factors+in+the+immune+system&doi=10.1146%2Fannurev.immunol.021908.132641"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation and function of NF-κB transcription factors in the immune system</span></div><div class="casAuthors">Vallabhapurapu, Sivakumar; Karin, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Immunology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">693-733</span>CODEN:
                <span class="NLM_cas:coden">ARIMDU</span>;
        ISSN:<span class="NLM_cas:issn">0732-0582</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  The mammalian Rel/NF-κB family of transcription factors, including RelA, c-Rel, RelB, NF-κB1 (p50 and its precursor p105), and NF-κB2 (p52 and its precursor p100), plays a central role in the immune system by regulating several processes ranging from the development and survival of lymphocytes and lymphoid organs to the control of immune responses and malignant transformation.  The 5 members of the NF-κB family are normally kept inactive in the cytoplasm by interaction with inhibitors called IκBs or the unprocessed forms of NF-κB1 and NF-κB2.  A wide variety of signals emanating from antigen receptors, pattern-recognition receptors, receptors for the members of TNF and IL-1 cytokine families, and others induce differential activation of NF-κB heterodimers.  Although work over the past two decades has shed significant light on the regulation of NF-κB transcription factors and their functions, much progress has been made in the past two years revealing new insights into the regulation and functions of NF-κB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAbeMOsSfPT7Vg90H21EOLACvtfcHk0liX6ib-0rI3Nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsFSlt7o%253D&md5=9353fabd1673c6191220ef4acaf95c32</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1146%2Fannurev.immunol.021908.132641&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.immunol.021908.132641%26sid%3Dliteratum%253Aachs%26aulast%3DVallabhapurapu%26aufirst%3DS.%26aulast%3DKarin%26aufirst%3DM.%26atitle%3DRegulation%2520and%2520function%2520of%2520NF-%25CE%25BAB%2520transcription%2520factors%2520in%2520the%2520immune%2520system%26jtitle%3DAnnu.%2520Rev.%2520Immunol.%26date%3D2009%26volume%3D27%26spage%3D693%26epage%3D733%26doi%3D10.1146%2Fannurev.immunol.021908.132641" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, S.-C.</span></span> <span> </span><span class="NLM_article-title">The non-canonical NF-κB pathway in immunity and inflammation</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">545</span>– <span class="NLM_lpage">558</span>, <span class="refDoi"> DOI: 10.1038/nri.2017.52</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1038%2Fnri.2017.52" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=28580957" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpt1OgsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=545-558&author=S.-C.+Sun&title=The+non-canonical+NF-%CE%BAB+pathway+in+immunity+and+inflammation&doi=10.1038%2Fnri.2017.52"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">The non-canonical NF-κB pathway in immunity and inflammation</span></div><div class="casAuthors">Sun, Shao-Cong</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">545-558</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The nuclear factor-κB (NF-κB) family of transcription factors is activated by canonical and non-canonical signalling pathways, which differ in both signalling components and biol. functions.  Recent studies have revealed important roles for the non-canonical NF-κB pathway in regulating different aspects of immune functions.  Defects in non-canonical NF-κB signalling are assocd. with severe immune deficiencies, whereas dysregulated activation of this pathway contributes to the pathogenesis of various autoimmune and inflammatory diseases.  Here we review the signalling mechanisms and the biol. function of the non-canonical NF-κB pathway.  We also discuss recent progress in elucidating the mol. mechanisms regulating non-canonical NF-κB pathway activation, which may provide new opportunities for therapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpz7QEbrIECD7Vg90H21EOLACvtfcHk0liFE_kvNwmMNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpt1OgsLw%253D&md5=b28dd6a87e76f3b61b5e108a24cf62f9</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1038%2Fnri.2017.52&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri.2017.52%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DS.-C.%26atitle%3DThe%2520non-canonical%2520NF-%25CE%25BAB%2520pathway%2520in%2520immunity%2520and%2520inflammation%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2017%26volume%3D17%26spage%3D545%26epage%3D558%26doi%3D10.1038%2Fnri.2017.52" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Madonna, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullman, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gentilcore, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmieri, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ascierto, P. A.</span></span> <span> </span><span class="NLM_article-title">NF-κB as potential target in the treatment of melanoma</span>. <i>J. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">53</span>– <span class="NLM_lpage">60</span>, <span class="refDoi"> DOI: 10.1186/1479-5876-10-53</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1186%2F1479-5876-10-53" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=22433222" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC38XosVelsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2012&pages=53-60&author=G.+Madonnaauthor=C.+D.+Ullmanauthor=G.+Gentilcoreauthor=G.+Palmieriauthor=P.+A.+Ascierto&title=NF-%CE%BAB+as+potential+target+in+the+treatment+of+melanoma&doi=10.1186%2F1479-5876-10-53"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">NF-κB as potential target in the treatment of melanoma</span></div><div class="casAuthors">Madonna, Gabriele; Dansky Ullman, Claudio; Gentilcore, Giusy; Palmieri, Giuseppe; Ascierto, Paolo Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Translational Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">53</span>CODEN:
                <span class="NLM_cas:coden">JTMOBV</span>;
        ISSN:<span class="NLM_cas:issn">1479-5876</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  The RAS/MAP kinase pathway has attracted attention because activating mutations of the BRAF serine/threonine kinase was described in over 50% of melanomas.  Very recently, selective and potent BRAF inhibitors have been developed.  Several other signal transduction pathways have been found to be constitutively active or mutated in other subsets of melanoma tumors that are potentially targetable with new agents.  Among these, NF-κB is another pathway that melanoma tumors use to achieve survival, proliferation and resistance to apoptosis.  Inhibition of NF-κB activation appears to be a very promising option for anti-cancer therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMWyr3R9S7XLVg90H21EOLACvtfcHk0liFE_kvNwmMNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XosVelsLc%253D&md5=0b57ca0a874ebb02384f0e23e0a3474d</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1186%2F1479-5876-10-53&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1479-5876-10-53%26sid%3Dliteratum%253Aachs%26aulast%3DMadonna%26aufirst%3DG.%26aulast%3DUllman%26aufirst%3DC.%2BD.%26aulast%3DGentilcore%26aufirst%3DG.%26aulast%3DPalmieri%26aufirst%3DG.%26aulast%3DAscierto%26aufirst%3DP.%2BA.%26atitle%3DNF-%25CE%25BAB%2520as%2520potential%2520target%2520in%2520the%2520treatment%2520of%2520melanoma%26jtitle%3DJ.%2520Transl.%2520Med.%26date%3D2012%26volume%3D10%26spage%3D53%26epage%3D60%26doi%3D10.1186%2F1479-5876-10-53" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thu, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, A.</span></span> <span> </span><span class="NLM_article-title">NF-κB inducing kinase: a key regulator in the immune system and in cancer</span>. <i>Cytokine Growth Factor Rev.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">213</span>– <span class="NLM_lpage">226</span>, <span class="refDoi"> DOI: 10.1016/j.cytogfr.2010.06.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1016%2Fj.cytogfr.2010.06.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=20685151" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFGjsbbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2010&pages=213-226&author=Y.+M.+Thuauthor=A.+Richmond&title=NF-%CE%BAB+inducing+kinase%3A+a+key+regulator+in+the+immune+system+and+in+cancer&doi=10.1016%2Fj.cytogfr.2010.06.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">NF-κB inducing kinase: A key regulator in the immune system and in cancer</span></div><div class="casAuthors">Thu, Yee Mon; Richmond, Ann</div><div class="citationInfo"><span class="NLM_cas:title">Cytokine & Growth Factor Reviews</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">213-226</span>CODEN:
                <span class="NLM_cas:coden">CGFRFB</span>;
        ISSN:<span class="NLM_cas:issn">1359-6101</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  NF-κB inducing kinase (NIK) is a kinase that activates the canonical and non-canonical NF-κB pathways to control transcriptional expression of certain proteins such as cytokines, chemokines and NF-κB signaling mols.  Many advances have been made in understanding the mol. mechanisms by which the stability of NIK is regulated to affect downstream signaling.  Genetic mouse models suggest that NIK plays an essential role in the regulation of the immune system as well as in the bone microenvironment.  Increasing evidence links NIK to the tumorigenesis of hematol. cancers, such as multiple myeloma, and solid tumors, such as pancreatic carcinoma and melanoma.  Understanding the mechanism by which NIK is de-regulated will potentially provide therapeutic options for certain diseases such as autoimmunity and cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMtga85N1_7LVg90H21EOLACvtfcHk0lju4ZAamI7E4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFGjsbbL&md5=5a8cebc7e8423336295544bcc4aab2d8</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1016%2Fj.cytogfr.2010.06.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cytogfr.2010.06.002%26sid%3Dliteratum%253Aachs%26aulast%3DThu%26aufirst%3DY.%2BM.%26aulast%3DRichmond%26aufirst%3DA.%26atitle%3DNF-%25CE%25BAB%2520inducing%2520kinase%253A%2520a%2520key%2520regulator%2520in%2520the%2520immune%2520system%2520and%2520in%2520cancer%26jtitle%3DCytokine%2520Growth%2520Factor%2520Rev.%26date%3D2010%26volume%3D21%26spage%3D213%26epage%3D226%26doi%3D10.1016%2Fj.cytogfr.2010.06.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kayagaki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seshasayee, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">French, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grewal, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cochran, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Starovasnik, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixit, V. M.</span></span> <span> </span><span class="NLM_article-title">BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-κB2</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">515</span>– <span class="NLM_lpage">524</span>, <span class="refDoi"> DOI: 10.1016/S1074-7613(02)00425-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1016%2FS1074-7613%2802%2900425-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2002&pages=515-524&author=N.+Kayagakiauthor=M.+Yanauthor=D.+Seshasayeeauthor=H.+Wangauthor=W.+Leeauthor=D.+M.+Frenchauthor=I.+S.+Grewalauthor=A.+G.+Cochranauthor=N.+C.+Gordonauthor=J.+Yinauthor=M.+A.+Starovasnikauthor=V.+M.+Dixit&title=BAFF%2FBLyS+receptor+3+binds+the+B+cell+survival+factor+BAFF+ligand+through+a+discrete+surface+loop+and+promotes+processing+of+NF-%CE%BAB2&doi=10.1016%2FS1074-7613%2802%2900425-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1016%2FS1074-7613%2802%2900425-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1074-7613%252802%252900425-9%26sid%3Dliteratum%253Aachs%26aulast%3DKayagaki%26aufirst%3DN.%26aulast%3DYan%26aufirst%3DM.%26aulast%3DSeshasayee%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DW.%26aulast%3DFrench%26aufirst%3DD.%2BM.%26aulast%3DGrewal%26aufirst%3DI.%2BS.%26aulast%3DCochran%26aufirst%3DA.%2BG.%26aulast%3DGordon%26aufirst%3DN.%2BC.%26aulast%3DYin%26aufirst%3DJ.%26aulast%3DStarovasnik%26aufirst%3DM.%2BA.%26aulast%3DDixit%26aufirst%3DV.%2BM.%26atitle%3DBAFF%252FBLyS%2520receptor%25203%2520binds%2520the%2520B%2520cell%2520survival%2520factor%2520BAFF%2520ligand%2520through%2520a%2520discrete%2520surface%2520loop%2520and%2520promotes%2520processing%2520of%2520NF-%25CE%25BAB2%26jtitle%3DImmunity%26date%3D2002%26volume%3D17%26spage%3D515%26epage%3D524%26doi%3D10.1016%2FS1074-7613%2802%2900425-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orrù, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Idda, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitzalis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pala, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zara, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sidore, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faà, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floris, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deiana, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asunis, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porcu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piras, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lobina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marongiu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serra, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marongiu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sole, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busonero, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maschio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cusano, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuccuru, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deidda, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poddie, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farina, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Virdis, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satta, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delitala, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cocco, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coghe, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorefice, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrigno, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ban, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barizzone, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerini, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piga, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firinu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kockum, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lima Bomfim, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfredsson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suarez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carreira, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castillo-Palma, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcus, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Congia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angius, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alarcón Riquelme, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">da Silva, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danieli, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Giacco, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathieu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montgomery, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosati, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawcer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Alfonso, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Todd, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novembre, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abecasis, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whalen, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marrosu, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meloni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanna, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorospe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiorillo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoledziewska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cucca, F.</span></span> <span> </span><span class="NLM_article-title">Overexpression of the cytokine BAFF and autoimmunity risk</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>376</i></span>,  <span class="NLM_fpage">1615</span>– <span class="NLM_lpage">1626</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1610528</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1056%2FNEJMoa1610528" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=28445677" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlOnsL%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=376&publication_year=2017&pages=1615-1626&author=M.+Steriauthor=V.+Orr%C3%B9author=M.+L.+Iddaauthor=M.+Pitzalisauthor=M.+Palaauthor=I.+Zaraauthor=C.+Sidoreauthor=V.+Fa%C3%A0author=M.+Florisauthor=M.+Deianaauthor=I.+Asunisauthor=E.+Porcuauthor=A.+Mulasauthor=M.+G.+Pirasauthor=M.+Lobinaauthor=S.+Laiauthor=M.+Marongiuauthor=V.+Serraauthor=M.+Marongiuauthor=G.+Soleauthor=F.+Busoneroauthor=A.+Maschioauthor=R.+Cusanoauthor=G.+Cuccuruauthor=F.+Deiddaauthor=F.+Poddieauthor=G.+Farinaauthor=M.+Deiauthor=F.+Virdisauthor=S.+Ollaauthor=M.+A.+Sattaauthor=M.+Paniauthor=A.+Delitalaauthor=E.+Coccoauthor=J.+Frauauthor=G.+Cogheauthor=L.+Loreficeauthor=G.+Fenuauthor=P.+Ferrignoauthor=M.+Banauthor=N.+Barizzoneauthor=M.+Leoneauthor=F.+R.+Gueriniauthor=M.+Pigaauthor=D.+Firinuauthor=I.+Kockumauthor=I.+Lima+Bomfimauthor=T.+Olssonauthor=L.+Alfredssonauthor=A.+Suarezauthor=P.+E.+Carreiraauthor=M.+J.+Castillo-Palmaauthor=J.+H.+Marcusauthor=M.+Congiaauthor=A.+Angiusauthor=M.+Melisauthor=A.+Gonzalezauthor=M.+E.+Alarc%C3%B3n+Riquelmeauthor=B.+M.+da+Silvaauthor=M.+Marchiniauthor=M.+G.+Danieliauthor=S.+Del+Giaccoauthor=A.+Mathieuauthor=A.+Paniauthor=S.+B.+Montgomeryauthor=G.+Rosatiauthor=J.+Hillertauthor=S.+Sawcerauthor=S.+D%E2%80%99Alfonsoauthor=J.+A.+Toddauthor=J.+Novembreauthor=G.+R.+Abecasisauthor=M.+B.+Whalenauthor=M.+G.+Marrosuauthor=A.+Meloniauthor=S.+Sannaauthor=M.+Gorospeauthor=D.+Schlessingerauthor=E.+Fiorilloauthor=M.+Zoledziewskaauthor=F.+Cucca&title=Overexpression+of+the+cytokine+BAFF+and+autoimmunity+risk&doi=10.1056%2FNEJMoa1610528"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Overexpression of the cytokine BAFF and autoimmunity risk</span></div><div class="casAuthors">Steri, M.; Orru, V.; Idda, M. L.; Pitzalis, M.; Pala, M.; Zara, I.; Sidore, C.; Faa, V.; Floris, M.; Deiana, M.; Asunis, I.; Porcu, E.; Mulas, A.; Piras, M. G.; Lobina, M.; Lai, S.; Marongiu, M.; Serra, V.; Sole, G.; Busonero, F.; Maschio, A.; Cusano, R.; Cuccuru, G.; Deidda, F.; Poddie, F.; Farina, G.; Dei, M.; Virdis, F.; Olla, S.; Satta, M. A.; Pani, M.; Delitala, A.; Cocco, E.; Frau, J.; Coghe, G.; Lorefice, L.; Fenu, G.; Ferrigno, P.; Ban, M.; Barizzone, N.; Leone, M.; Guerini, F. R.; Piga, M.; Firinu, D.; Kockum, I.; Lima Bomfim, I.; Olsson, T.; Alfredsson, L.; Suarez, A.; Carreira, P. E.; Castillo-Palma, M. J.; Marcus, J. H.; Congia, M.; Angius, A.; Melis, M.; Gonzalez, A.; Riquelme, M. E. A.; da Silva, B. M.; Marchini, M.; Danieli, M. G.; Del Giacco, S.; Mathieu, A.; Pani, A.; Montgomery, S. B.; Rosati, G.; Hillert, J.; Sawcer, S.; D'Alfonso, S.; Todd, J. A.; Novembre, J.; Abecasis, G. R.; Whalen, M. B.; Marrosu, M. G.; Meloni, A.; Sanna, S.; Gorospe, M.; Schlessinger, D.; Fiorillo, E.; Zoledziewska, M.; Cucca, F.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">376</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1615-1626</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Genomewide assocn. studies of autoimmune diseases have mapped hundreds of susceptibility regions in the genome.  However, only for a few assocn. signals has the causal gene been identified, and for even fewer have the causal variant and underlying mechanism been defined.  Coincident assocns. of DNA variants affecting both the risk of autoimmune disease and quant. immune variables provide an informative route to explore disease mechanisms and drug-targetable pathways.  METHODS Using case-control samples from Sardinia, Italy, we performed a genomewide assocn. study in multiple sclerosis followed by TNFSF13B locus-specific assocn. testing in systemic lupus erythematosus (SLE).  Extensive phenotyping of quant. immune variables, sequence-based fine mapping, cross-population and cross-phenotype analyses, and gene-expression studies were used to identify the causal variant and elucidate its mechanism of action.  Signatures of pos. selection were also investigated.  RESULTS A variant in TNFSF13B, encoding the cytokine and drug target B-cell activating factor (BAFF), was assocd. with multiple sclerosis as well as SLE.  The disease-risk allele was also assocd. with up-regulated humoral immunity through increased levels of sol. BAFF, B lymphocytes, and Igs.  The causal variant was identified: an insertion-deletion variant, GCTGT→A (in which A is the risk allele), yielded a shorter transcript that escaped microRNA inhibition and increased prodn. of sol. BAFF, which in turn up-regulated humoral immunity.  Population genetic signatures indicated that this autoimmunity variant has been evolutionarily advantageous, most likely by augmenting resistance to malaria.  CONCLUSIONS A TNFSF13B variant was assocd. with multiple sclerosis and SLE, and its effects were clarified at the population, cellular, and mol. levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqo_9hexYorUbVg90H21EOLACvtfcHk0lju4ZAamI7E4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlOnsL%252FK&md5=acf28962ecdf6bdf4fbe65cfe88f9fb2</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1610528&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1610528%26sid%3Dliteratum%253Aachs%26aulast%3DSteri%26aufirst%3DM.%26aulast%3DOrr%25C3%25B9%26aufirst%3DV.%26aulast%3DIdda%26aufirst%3DM.%2BL.%26aulast%3DPitzalis%26aufirst%3DM.%26aulast%3DPala%26aufirst%3DM.%26aulast%3DZara%26aufirst%3DI.%26aulast%3DSidore%26aufirst%3DC.%26aulast%3DFa%25C3%25A0%26aufirst%3DV.%26aulast%3DFloris%26aufirst%3DM.%26aulast%3DDeiana%26aufirst%3DM.%26aulast%3DAsunis%26aufirst%3DI.%26aulast%3DPorcu%26aufirst%3DE.%26aulast%3DMulas%26aufirst%3DA.%26aulast%3DPiras%26aufirst%3DM.%2BG.%26aulast%3DLobina%26aufirst%3DM.%26aulast%3DLai%26aufirst%3DS.%26aulast%3DMarongiu%26aufirst%3DM.%26aulast%3DSerra%26aufirst%3DV.%26aulast%3DMarongiu%26aufirst%3DM.%26aulast%3DSole%26aufirst%3DG.%26aulast%3DBusonero%26aufirst%3DF.%26aulast%3DMaschio%26aufirst%3DA.%26aulast%3DCusano%26aufirst%3DR.%26aulast%3DCuccuru%26aufirst%3DG.%26aulast%3DDeidda%26aufirst%3DF.%26aulast%3DPoddie%26aufirst%3DF.%26aulast%3DFarina%26aufirst%3DG.%26aulast%3DDei%26aufirst%3DM.%26aulast%3DVirdis%26aufirst%3DF.%26aulast%3DOlla%26aufirst%3DS.%26aulast%3DSatta%26aufirst%3DM.%2BA.%26aulast%3DPani%26aufirst%3DM.%26aulast%3DDelitala%26aufirst%3DA.%26aulast%3DCocco%26aufirst%3DE.%26aulast%3DFrau%26aufirst%3DJ.%26aulast%3DCoghe%26aufirst%3DG.%26aulast%3DLorefice%26aufirst%3DL.%26aulast%3DFenu%26aufirst%3DG.%26aulast%3DFerrigno%26aufirst%3DP.%26aulast%3DBan%26aufirst%3DM.%26aulast%3DBarizzone%26aufirst%3DN.%26aulast%3DLeone%26aufirst%3DM.%26aulast%3DGuerini%26aufirst%3DF.%2BR.%26aulast%3DPiga%26aufirst%3DM.%26aulast%3DFirinu%26aufirst%3DD.%26aulast%3DKockum%26aufirst%3DI.%26aulast%3DLima%2BBomfim%26aufirst%3DI.%26aulast%3DOlsson%26aufirst%3DT.%26aulast%3DAlfredsson%26aufirst%3DL.%26aulast%3DSuarez%26aufirst%3DA.%26aulast%3DCarreira%26aufirst%3DP.%2BE.%26aulast%3DCastillo-Palma%26aufirst%3DM.%2BJ.%26aulast%3DMarcus%26aufirst%3DJ.%2BH.%26aulast%3DCongia%26aufirst%3DM.%26aulast%3DAngius%26aufirst%3DA.%26aulast%3DMelis%26aufirst%3DM.%26aulast%3DGonzalez%26aufirst%3DA.%26aulast%3DAlarc%25C3%25B3n%2BRiquelme%26aufirst%3DM.%2BE.%26aulast%3Dda%2BSilva%26aufirst%3DB.%2BM.%26aulast%3DMarchini%26aufirst%3DM.%26aulast%3DDanieli%26aufirst%3DM.%2BG.%26aulast%3DDel%2BGiacco%26aufirst%3DS.%26aulast%3DMathieu%26aufirst%3DA.%26aulast%3DPani%26aufirst%3DA.%26aulast%3DMontgomery%26aufirst%3DS.%2BB.%26aulast%3DRosati%26aufirst%3DG.%26aulast%3DHillert%26aufirst%3DJ.%26aulast%3DSawcer%26aufirst%3DS.%26aulast%3DD%25E2%2580%2599Alfonso%26aufirst%3DS.%26aulast%3DTodd%26aufirst%3DJ.%2BA.%26aulast%3DNovembre%26aufirst%3DJ.%26aulast%3DAbecasis%26aufirst%3DG.%2BR.%26aulast%3DWhalen%26aufirst%3DM.%2BB.%26aulast%3DMarrosu%26aufirst%3DM.%2BG.%26aulast%3DMeloni%26aufirst%3DA.%26aulast%3DSanna%26aufirst%3DS.%26aulast%3DGorospe%26aufirst%3DM.%26aulast%3DSchlessinger%26aufirst%3DD.%26aulast%3DFiorillo%26aufirst%3DE.%26aulast%3DZoledziewska%26aufirst%3DM.%26aulast%3DCucca%26aufirst%3DF.%26atitle%3DOverexpression%2520of%2520the%2520cytokine%2520BAFF%2520and%2520autoimmunity%2520risk%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2017%26volume%3D376%26spage%3D1615%26epage%3D1626%26doi%3D10.1056%2FNEJMoa1610528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Noort, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Zoest, K. P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weijers, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koolwijk, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maracle, C. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novack, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siemerink, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlingemann, R. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tak, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tas, S. W.</span></span> <span> </span><span class="NLM_article-title">NF-κB-inducing kinase is a key regulator of inflammation-induced and tumour-associated angiogenesis</span>. <i>J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>234</i></span>,  <span class="NLM_fpage">375</span>– <span class="NLM_lpage">385</span>, <span class="refDoi"> DOI: 10.1002/path.4403</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1002%2Fpath.4403" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=25043127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslCqtrnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=234&publication_year=2014&pages=375-385&author=A.+R.+Noortauthor=K.+P.+M.+van+Zoestauthor=E.+M.+Weijersauthor=P.+Koolwijkauthor=C.+X.+Maracleauthor=D.+V.+Novackauthor=M.+J.+Siemerinkauthor=R.+O.+Schlingemannauthor=P.+P.+Takauthor=S.+W.+Tas&title=NF-%CE%BAB-inducing+kinase+is+a+key+regulator+of+inflammation-induced+and+tumour-associated+angiogenesis&doi=10.1002%2Fpath.4403"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">NF-κB-inducing kinase is a key regulator of inflammation-induced and tumour-associated angiogenesis</span></div><div class="casAuthors">Noort, Ae R.; van Zoest, Katinka PM; Weijers, Ester M.; Koolwijk, Pieter; Maracle, Chrissta X.; Novack, Deborah V.; Siemerink, Martin J.; Schlingemann, Reinier O.; Tak, Paul P.; Tas, Sander W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pathology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">234</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">375-385</span>CODEN:
                <span class="NLM_cas:coden">JPTLAS</span>;
        ISSN:<span class="NLM_cas:issn">1096-9896</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Angiogenesis is essential during development and in pathol. conditions such as chronic inflammation and cancer progression.  Inhibition of angiogenesis by targeting vascular endothelial growth factor (VEGF) blocks disease progression, but most patients eventually develop resistance which may result from compensatory signalling pathways.  In endothelial cells (ECs), expression of the pro-angiogenic chemokine CXCL12 is regulated by non-canonical nuclear factor (NF)-κB signalling.  Here, we report that NF-κB-inducing kinase (NIK) and subsequent non-canonical NF-κB signalling regulate both inflammation-induced and tumor-assocd. angiogenesis.  NIK is highly expressed in endothelial cells (ECs) in tumor tissues and inflamed rheumatoid arthritis synovial tissue.  Furthermore, non-canonical NF-κB signalling in human microvascular ECs significantly enhanced vascular tube formation, which was completely blocked by siRNA targeting NIK.  Interestingly, Nik-/- mice exhibited normal angiogenesis during development and unaltered TNFα- or VEGF-induced angiogenic responses, whereas angiogenesis induced by non-canonical NF-κB stimuli was significantly reduced.  In addn., angiogenesis in exptl. arthritis and a murine tumor model was severely impaired in these mice.  These studies provide evidence for a role of non-canonical NF-κB signalling in pathol. angiogenesis, and identify NIK as a potential therapeutic target in chronic inflammatory diseases and tumor neoangiogenesis. © 2014 The Authors.  The Journal of Pathol. published by John Wiley & Sons Ltd on behalf of Pathol. Society of Great Britain and Ireland.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGmctnhHR1SrVg90H21EOLACvtfcHk0lgtZ6xvr95IdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslCqtrnE&md5=94bdaa642c3246981d16f79958dbc5d9</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1002%2Fpath.4403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpath.4403%26sid%3Dliteratum%253Aachs%26aulast%3DNoort%26aufirst%3DA.%2BR.%26aulast%3Dvan%2BZoest%26aufirst%3DK.%2BP.%2BM.%26aulast%3DWeijers%26aufirst%3DE.%2BM.%26aulast%3DKoolwijk%26aufirst%3DP.%26aulast%3DMaracle%26aufirst%3DC.%2BX.%26aulast%3DNovack%26aufirst%3DD.%2BV.%26aulast%3DSiemerink%26aufirst%3DM.%2BJ.%26aulast%3DSchlingemann%26aufirst%3DR.%2BO.%26aulast%3DTak%26aufirst%3DP.%2BP.%26aulast%3DTas%26aufirst%3DS.%2BW.%26atitle%3DNF-%25CE%25BAB-inducing%2520kinase%2520is%2520a%2520key%2520regulator%2520of%2520inflammation-induced%2520and%2520tumour-associated%2520angiogenesis%26jtitle%3DJ.%2520Pathol.%26date%3D2014%26volume%3D234%26spage%3D375%26epage%3D385%26doi%3D10.1002%2Fpath.4403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aya, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alhawagri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagen-Stapleton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitaura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanagawa, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veis Novack, D.</span></span> <span> </span><span class="NLM_article-title">NF-κB-inducing kinase controls lymphocyte and osteoclast activities in inflammatory arthritis</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">1848</span>– <span class="NLM_lpage">1854</span>, <span class="refDoi"> DOI: 10.1172/JCI23763</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1172%2FJCI23763" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2005&pages=1848-1854&author=K.+Ayaauthor=M.+Alhawagriauthor=A.+Hagen-Stapletonauthor=H.+Kitauraauthor=O.+Kanagawaauthor=D.+Veis+Novack&title=NF-%CE%BAB-inducing+kinase+controls+lymphocyte+and+osteoclast+activities+in+inflammatory+arthritis&doi=10.1172%2FJCI23763"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1172%2FJCI23763&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI23763%26sid%3Dliteratum%253Aachs%26aulast%3DAya%26aufirst%3DK.%26aulast%3DAlhawagri%26aufirst%3DM.%26aulast%3DHagen-Stapleton%26aufirst%3DA.%26aulast%3DKitaura%26aufirst%3DH.%26aulast%3DKanagawa%26aufirst%3DO.%26aulast%3DVeis%2BNovack%26aufirst%3DD.%26atitle%3DNF-%25CE%25BAB-inducing%2520kinase%2520controls%2520lymphocyte%2520and%2520osteoclast%2520activities%2520in%2520inflammatory%2520arthritis%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2005%26volume%3D115%26spage%3D1848%26epage%3D1854%26doi%3D10.1172%2FJCI23763" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Storz, P.</span></span> <span> </span><span class="NLM_article-title">Targeting the alternative NF-κB pathway in pancreatic cancer: a new direction for therapy?</span>. <i>Expert Rev. Anticancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">501</span>– <span class="NLM_lpage">504</span>, <span class="refDoi"> DOI: 10.1586/era.13.28</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1586%2Fera.13.28" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=23617340" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmsFWlsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=501-504&author=P.+Storz&title=Targeting+the+alternative+NF-%CE%BAB+pathway+in+pancreatic+cancer%3A+a+new+direction+for+therapy%3F&doi=10.1586%2Fera.13.28"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the alternative NF-κB pathway in pancreatic cancer: a new direction for therapy?</span></div><div class="casAuthors">Storz, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anticancer Therapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">501-504</span>CODEN:
                <span class="NLM_cas:coden">ERATBJ</span>;
        ISSN:<span class="NLM_cas:issn">1473-7140</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  Pancreatic cancer, due to its late diagnosis,is difficult to treat.  In addn., current therapy options are insufficient and new approaches for combination treatment are required.  Recent demonstration of the importance of constitutive signaling of NF-κB-inducing kinase (NIK,also named MAP3K14) in maintaining the high basal activity of the alternative NF-κB pathway in pancreatic cancer suggests novel possibilities for therapeutic intervention.  Strategies to target the alternative NF-κB pathway include not only the use of small mol. inhibitors for NIK and IκB kinase a (IKKa), but also broad spectrum approaches such as using proteasome inhibitors or combinatorial approaches targeting both alternative and canonical pathways.  These may also act synergistically with currently used drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkO5O_6UCQkrVg90H21EOLACvtfcHk0liLiQurDFxzKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmsFWlsL4%253D&md5=a4945c62cf71cb211141608f6790b853</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1586%2Fera.13.28&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252Fera.13.28%26sid%3Dliteratum%253Aachs%26aulast%3DStorz%26aufirst%3DP.%26atitle%3DTargeting%2520the%2520alternative%2520NF-%25CE%25BAB%2520pathway%2520in%2520pancreatic%2520cancer%253A%2520a%2520new%2520direction%2520for%2520therapy%253F%26jtitle%3DExpert%2520Rev.%2520Anticancer%2520Ther.%26date%3D2013%26volume%3D13%26spage%3D501%26epage%3D504%26doi%3D10.1586%2Fera.13.28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Castanedo, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaquiere, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beresini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bravo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brightbill, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, H.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godemann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gogol, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hymowitz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kayagaki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohli, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knüppel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraemer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krüger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loke, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEwan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montalbetti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinbacher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sujatha-Bhaskar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staben, S. T.</span></span> <span> </span><span class="NLM_article-title">Structure-based design of tricyclic NF-κB inducing kinase (NIK) inhibitors that have high selectivity over phosphoinositide-3-kinase (PI3K)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">627</span>– <span class="NLM_lpage">640</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01363</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01363" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFCgs7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=627-640&author=G.+M.+Castanedoauthor=N.+Blaquiereauthor=M.+Beresiniauthor=B.+Bravoauthor=H.+Brightbillauthor=J.+Chenauthor=H.-F.+Cuiauthor=C.+Eigenbrotauthor=C.+Everettauthor=J.+Fengauthor=R.+Godemannauthor=E.+Gogolauthor=S.+Hymowitzauthor=A.+Johnsonauthor=N.+Kayagakiauthor=P.+B.+Kohliauthor=K.+Kn%C3%BCppelauthor=J.+Kraemerauthor=S.+Kr%C3%BCgerauthor=P.+Lokeauthor=P.+McEwanauthor=C.+Montalbettiauthor=D.+A.+Robertsauthor=M.+Smithauthor=S.+Steinbacherauthor=S.+Sujatha-Bhaskarauthor=R.+Takahashiauthor=X.+Wangauthor=L.+C.+Wuauthor=Y.+Zhangauthor=S.+T.+Staben&title=Structure-based+design+of+tricyclic+NF-%CE%BAB+inducing+kinase+%28NIK%29+inhibitors+that+have+high+selectivity+over+phosphoinositide-3-kinase+%28PI3K%29&doi=10.1021%2Facs.jmedchem.6b01363"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design of Tricyclic NF-κB Inducing Kinase (NIK) Inhibitors That Have High Selectivity over Phosphoinositide-3-kinase (PI3K)</span></div><div class="casAuthors">Castanedo, Georgette M.; Blaquiere, Nicole; Beresini, Maureen; Bravo, Brandon; Brightbill, Hans; Chen, Jacob; Cui, Hai-Feng; Eigenbrot, Charles; Everett, Christine; Feng, Jianwen; Godemann, Robert; Gogol, Emily; Hymowitz, Sarah; Johnson, Adam; Kayagaki, Nobuhiko; Kohli, Pawan Bir; Knuppel, Kathleen; Kraemer, Joachim; Kruger, Susan; Loke, Pui; McEwan, Paul; Montalbetti, Christian; Roberts, David A.; Smith, Myron; Steinbacher, Stefan; Sujatha-Bhaskar, Swathi; Takahashi, Ryan; Wang, Xiaolu; Wu, Lawren C.; Zhang, Yamin; Staben, Steven T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">627-640</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors report a structure-guided optimization of a novel series of NF-κB inducing kinase (NIK) inhibitors.  Starting from a modestly potent, low mol. wt. lead, activity was improved by designing a type I1/2 binding mode that accessed a back pocket past the methionine-471 gatekeeper.  Divergent binding modes in NIK and PI3K were used to dampen PI3K-inhibition while maintaining NIK inhibition within these series.  Potent compds. were discovered that selectively inhibit the nuclear translocation of NF-kB2 (p52/REL-B) but not canonical NF-kB1 (REL-A/p50).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrws-sPXJiSfLVg90H21EOLACvtfcHk0liLiQurDFxzKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFCgs7bK&md5=316b70f51a5b800ba810082d0b3862da</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01363%26sid%3Dliteratum%253Aachs%26aulast%3DCastanedo%26aufirst%3DG.%2BM.%26aulast%3DBlaquiere%26aufirst%3DN.%26aulast%3DBeresini%26aufirst%3DM.%26aulast%3DBravo%26aufirst%3DB.%26aulast%3DBrightbill%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DCui%26aufirst%3DH.-F.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DEverett%26aufirst%3DC.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DGodemann%26aufirst%3DR.%26aulast%3DGogol%26aufirst%3DE.%26aulast%3DHymowitz%26aufirst%3DS.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DKayagaki%26aufirst%3DN.%26aulast%3DKohli%26aufirst%3DP.%2BB.%26aulast%3DKn%25C3%25BCppel%26aufirst%3DK.%26aulast%3DKraemer%26aufirst%3DJ.%26aulast%3DKr%25C3%25BCger%26aufirst%3DS.%26aulast%3DLoke%26aufirst%3DP.%26aulast%3DMcEwan%26aufirst%3DP.%26aulast%3DMontalbetti%26aufirst%3DC.%26aulast%3DRoberts%26aufirst%3DD.%2BA.%26aulast%3DSmith%26aufirst%3DM.%26aulast%3DSteinbacher%26aufirst%3DS.%26aulast%3DSujatha-Bhaskar%26aufirst%3DS.%26aulast%3DTakahashi%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DL.%2BC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DStaben%26aufirst%3DS.%2BT.%26atitle%3DStructure-based%2520design%2520of%2520tricyclic%2520NF-%25CE%25BAB%2520inducing%2520kinase%2520%2528NIK%2529%2520inhibitors%2520that%2520have%2520high%2520selectivity%2520over%2520phosphoinositide-3-kinase%2520%2528PI3K%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D627%26epage%3D640%26doi%3D10.1021%2Facs.jmedchem.6b01363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de Leon-Boenig, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franke, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staben, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Starovasnik, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallweber, H. J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hymowitz, S. G.</span></span> <span> </span><span class="NLM_article-title">The Crystal Structure of the Catalytic Domain of the NF-κB Inducing Kinase Reveals a Narrow but Flexible Active Site</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1704</span>– <span class="NLM_lpage">1714</span>, <span class="refDoi"> DOI: 10.1016/j.str.2012.07.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1016%2Fj.str.2012.07.013" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=1704-1714&author=G.+de+Leon-Boenigauthor=K.+K.+Bowmanauthor=J.+A.+Fengauthor=T.+Crawfordauthor=C.+Everettauthor=Y.+Frankeauthor=A.+Ohauthor=M.+Stanleyauthor=S.+T.+Stabenauthor=M.+A.+Starovasnikauthor=H.+J.+A.+Wallweberauthor=J.+Wuauthor=L.+C.+Wuauthor=A.+R.+Johnsonauthor=S.+G.+Hymowitz&title=The+Crystal+Structure+of+the+Catalytic+Domain+of+the+NF-%CE%BAB+Inducing+Kinase+Reveals+a+Narrow+but+Flexible+Active+Site&doi=10.1016%2Fj.str.2012.07.013"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2012.07.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2012.07.013%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BLeon-Boenig%26aufirst%3DG.%26aulast%3DBowman%26aufirst%3DK.%2BK.%26aulast%3DFeng%26aufirst%3DJ.%2BA.%26aulast%3DCrawford%26aufirst%3DT.%26aulast%3DEverett%26aufirst%3DC.%26aulast%3DFranke%26aufirst%3DY.%26aulast%3DOh%26aufirst%3DA.%26aulast%3DStanley%26aufirst%3DM.%26aulast%3DStaben%26aufirst%3DS.%2BT.%26aulast%3DStarovasnik%26aufirst%3DM.%2BA.%26aulast%3DWallweber%26aufirst%3DH.%2BJ.%2BA.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DL.%2BC.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DHymowitz%26aufirst%3DS.%2BG.%26atitle%3DThe%2520Crystal%2520Structure%2520of%2520the%2520Catalytic%2520Domain%2520of%2520the%2520NF-%25CE%25BAB%2520Inducing%2520Kinase%2520Reveals%2520a%2520Narrow%2520but%2520Flexible%2520Active%2520Site%26jtitle%3DStructure%26date%3D2012%26volume%3D20%26spage%3D1704%26epage%3D1714%26doi%3D10.1016%2Fj.str.2012.07.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGee, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sudom, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubenstein, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anwer, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cushing, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayres, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eksterowicz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faulder, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waszkowycz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plotnikova, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrelly, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span> <span> </span><span class="NLM_article-title">Inhibiting NF-κB-inducing kinase (NIK): Discovery, structure-based design, synthesis, structure–activity relationship, and co-crystal structures</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1238</span>– <span class="NLM_lpage">1244</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.01.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1016%2Fj.bmcl.2013.01.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=23374866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVGmt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=1238-1244&author=K.+Liauthor=L.+R.+McGeeauthor=B.+Fisherauthor=A.+Sudomauthor=J.+Liuauthor=S.+M.+Rubensteinauthor=M.+K.+Anwerauthor=T.+D.+Cushingauthor=Y.+Shinauthor=M.+Ayresauthor=F.+Leeauthor=J.+Eksterowiczauthor=P.+Faulderauthor=B.+Waszkowyczauthor=O.+Plotnikovaauthor=E.+Farrellyauthor=S.-H.+Xiaoauthor=G.+Chenauthor=Z.+Wang&title=Inhibiting+NF-%CE%BAB-inducing+kinase+%28NIK%29%3A+Discovery%2C+structure-based+design%2C+synthesis%2C+structure%E2%80%93activity+relationship%2C+and+co-crystal+structures&doi=10.1016%2Fj.bmcl.2013.01.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibiting NF-κB-inducing kinase (NIK): Discovery, structure-based design, synthesis, structure-activity relationship, and co-crystal structures</span></div><div class="casAuthors">Li, Kexue; McGee, Lawrence R.; Fisher, Ben; Sudom, Athena; Liu, Jinsong; Rubenstein, Steven M.; Anwer, Mohmed K.; Cushing, Timothy D.; Shin, Youngsook; Ayres, Merrill; Lee, Fei; Eksterowicz, John; Faulder, Paul; Waszkowycz, Bohdan; Plotnikova, Olga; Farrelly, Ellyn; Xiao, Shou-Hua; Chen, Guoqing; Wang, Zhulun</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1238-1244</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The discovery, structure-based design, synthesis, and optimization of NIK inhibitors are described.  Our work began with an HTS hit, imidazopyridinyl pyrimidinamine I.  We utilized homol. modeling and conformational anal. to optimize the indole scaffold leading to the discovery of novel and potent conformationally constrained inhibitors such as compds. II [R1 = Br, C≡CCMe2OH].  Compds. II [R1 = Br] and III were co-crystd. with NIK kinase domain to provide structural insights.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpm5WqvTIrBqrVg90H21EOLACvtfcHk0li8kvP4Wlk8xA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVGmt7s%253D&md5=a382078cf3bf84a41749783be33a5988</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.01.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.01.012%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DK.%26aulast%3DMcGee%26aufirst%3DL.%2BR.%26aulast%3DFisher%26aufirst%3DB.%26aulast%3DSudom%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DRubenstein%26aufirst%3DS.%2BM.%26aulast%3DAnwer%26aufirst%3DM.%2BK.%26aulast%3DCushing%26aufirst%3DT.%2BD.%26aulast%3DShin%26aufirst%3DY.%26aulast%3DAyres%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DF.%26aulast%3DEksterowicz%26aufirst%3DJ.%26aulast%3DFaulder%26aufirst%3DP.%26aulast%3DWaszkowycz%26aufirst%3DB.%26aulast%3DPlotnikova%26aufirst%3DO.%26aulast%3DFarrelly%26aufirst%3DE.%26aulast%3DXiao%26aufirst%3DS.-H.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DZ.%26atitle%3DInhibiting%2520NF-%25CE%25BAB-inducing%2520kinase%2520%2528NIK%2529%253A%2520Discovery%252C%2520structure-based%2520design%252C%2520synthesis%252C%2520structure%25E2%2580%2593activity%2520relationship%252C%2520and%2520co-crystal%2520structures%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D1238%26epage%3D1244%26doi%3D10.1016%2Fj.bmcl.2013.01.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mortier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masereel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Remouchamps, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganeff, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piette, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">frederick, R.</span></span> <span> </span><span class="NLM_article-title">NF-κB inducing kinase (NIK) inhibitors: Identification of new scaffolds using virtual screening</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">4515</span>– <span class="NLM_lpage">4520</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.06.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1016%2Fj.bmcl.2010.06.027" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=4515-4520&author=J.+Mortierauthor=B.+Masereelauthor=C.+Remouchampsauthor=C.+Ganeffauthor=J.+Pietteauthor=R.+frederick&title=NF-%CE%BAB+inducing+kinase+%28NIK%29+inhibitors%3A+Identification+of+new+scaffolds+using+virtual+screening&doi=10.1016%2Fj.bmcl.2010.06.027"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.06.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.06.027%26sid%3Dliteratum%253Aachs%26aulast%3DMortier%26aufirst%3DJ.%26aulast%3DMasereel%26aufirst%3DB.%26aulast%3DRemouchamps%26aufirst%3DC.%26aulast%3DGaneff%26aufirst%3DC.%26aulast%3DPiette%26aufirst%3DJ.%26aulast%3Dfrederick%26aufirst%3DR.%26atitle%3DNF-%25CE%25BAB%2520inducing%2520kinase%2520%2528NIK%2529%2520inhibitors%253A%2520Identification%2520of%2520new%2520scaffolds%2520using%2520virtual%2520screening%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D4515%26epage%3D4520%26doi%3D10.1016%2Fj.bmcl.2010.06.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rui, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span> <span> </span><span class="NLM_article-title">A small-molecule inhibitor of NF-κB-inducing kinase (NIK) protects liver from toxin-induced inflammation, oxidative stress, and injury</span>. <i>FASEB J.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">711</span>– <span class="NLM_lpage">718</span>, <span class="refDoi"> DOI: 10.1096/fj.201600840R</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1096%2Ffj.201600840R" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=27871061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpsleit78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=711-718&author=X.+Renauthor=X.+Liauthor=L.+Jiaauthor=D.+Chenauthor=H.+Houauthor=L.+Ruiauthor=Y.+Zhaoauthor=Z.+Chen&title=A+small-molecule+inhibitor+of+NF-%CE%BAB-inducing+kinase+%28NIK%29+protects+liver+from+toxin-induced+inflammation%2C+oxidative+stress%2C+and+injury&doi=10.1096%2Ffj.201600840R"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">A small-molecule inhibitor of NF-κB-inducing kinase (NIK) protects liver from toxin-induced inflammation, oxidative stress, and injury</span></div><div class="casAuthors">Ren, Xiaomeng; Li, Xinzhi; Jia, Linna; Chen, Deheng; Hou, Hai; Rui, Liangyou; Zhao, Yujun; Chen, Zheng</div><div class="citationInfo"><span class="NLM_cas:title">FASEB Journal</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">711-718</span>CODEN:
                <span class="NLM_cas:coden">FAJOEC</span>;
        ISSN:<span class="NLM_cas:issn">0892-6638</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">Potent and selective chem. probes are valuable tools for discovery of novel treatments for human diseases.  NF-κB-inducing kinase (NIK) is a key trigger in the development of liver injury and fibrosis.  Whether inhibition of NIK activity by chem. probes ameliorates liver inflammation and injury is largely unknown.  In this study, a small-mol. inhibitor of NIK, B022, was found to be a potent and selective chem. probe for liver inflammation and injury.  B022 inhibited the NIK signaling pathway, including NIK-induced p100-to-p52 processing and inflammatory gene expression, both in vitro and in vivo.  Furthermore, in vivo administration of B022 protected against not only NIK but also CCl4-induced liver inflammation and injury.  Our data suggest that inhibition of NIK is a novel strategy for treatment of liver inflammation, oxidative stress, and injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAtVxDU8yQibVg90H21EOLACvtfcHk0li8kvP4Wlk8xA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpsleit78%253D&md5=84f05fa8fdf2fcfe79d167827ceea738</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1096%2Ffj.201600840R&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.201600840R%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DJia%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DHou%26aufirst%3DH.%26aulast%3DRui%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DZ.%26atitle%3DA%2520small-molecule%2520inhibitor%2520of%2520NF-%25CE%25BAB-inducing%2520kinase%2520%2528NIK%2529%2520protects%2520liver%2520from%2520toxin-induced%2520inflammation%252C%2520oxidative%2520stress%252C%2520and%2520injury%26jtitle%3DFASEB%2520J.%26date%3D2017%26volume%3D31%26spage%3D711%26epage%3D718%26doi%3D10.1096%2Ffj.201600840R" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sudom, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Min, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayres, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plotnikova, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span> <span> </span><span class="NLM_article-title">Structure of the nuclear factor κB-inducing kinase (NIK) kinase domain reveals a constitutively active conformation</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>287</i></span>,  <span class="NLM_fpage">27326</span>– <span class="NLM_lpage">27334</span>, <span class="refDoi"> DOI: 10.1074/jbc.M112.366658</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1074%2Fjbc.M112.366658" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=287&publication_year=2012&pages=27326-27334&author=J.+Liuauthor=A.+Sudomauthor=X.+Minauthor=Z.+Caoauthor=X.+Gaoauthor=M.+Ayresauthor=F.+Leeauthor=P.+Caoauthor=S.+Johnstoneauthor=O.+Plotnikovaauthor=N.+Walkerauthor=G.+Chenauthor=Z.+Wang&title=Structure+of+the+nuclear+factor+%CE%BAB-inducing+kinase+%28NIK%29+kinase+domain+reveals+a+constitutively+active+conformation&doi=10.1074%2Fjbc.M112.366658"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M112.366658&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M112.366658%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DSudom%26aufirst%3DA.%26aulast%3DMin%26aufirst%3DX.%26aulast%3DCao%26aufirst%3DZ.%26aulast%3DGao%26aufirst%3DX.%26aulast%3DAyres%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DF.%26aulast%3DCao%26aufirst%3DP.%26aulast%3DJohnstone%26aufirst%3DS.%26aulast%3DPlotnikova%26aufirst%3DO.%26aulast%3DWalker%26aufirst%3DN.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DZ.%26atitle%3DStructure%2520of%2520the%2520nuclear%2520factor%2520%25CE%25BAB-inducing%2520kinase%2520%2528NIK%2529%2520kinase%2520domain%2520reveals%2520a%2520constitutively%2520active%2520conformation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2012%26volume%3D287%26spage%3D27326%26epage%3D27334%26doi%3D10.1074%2Fjbc.M112.366658" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maracle, C. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kucharzewska, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helder, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Horst, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correa de Sampaio, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noort, A.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Zoest, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffioen, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tas, S. W.</span></span> <span> </span><span class="NLM_article-title">Targeting non-canonical nuclear factor-κB signalling attenuates neovascularization in a novel 3D model of rheumatoid arthritis synovial angiogenesis</span>. <i>Rheumatology</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">294</span>– <span class="NLM_lpage">302</span>, <span class="refDoi"> DOI: 10.1093/rheumatology/kew393</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1093%2Frheumatology%2Fkew393" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=294-302&author=C.+X.+Maracleauthor=P.+Kucharzewskaauthor=B.+Helderauthor=C.+van+der%0AHorstauthor=P.+Correa+de+Sampaioauthor=A.-R.+Noortauthor=K.+van+Zoestauthor=A.+W.+Griffioenauthor=H.+Olssonauthor=S.+W.+Tas&title=Targeting+non-canonical+nuclear+factor-%CE%BAB+signalling+attenuates+neovascularization+in+a+novel+3D+model+of+rheumatoid+arthritis+synovial+angiogenesis&doi=10.1093%2Frheumatology%2Fkew393"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1093%2Frheumatology%2Fkew393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Frheumatology%252Fkew393%26sid%3Dliteratum%253Aachs%26aulast%3DMaracle%26aufirst%3DC.%2BX.%26aulast%3DKucharzewska%26aufirst%3DP.%26aulast%3DHelder%26aufirst%3DB.%26aulast%3Dvan%2Bder%2BHorst%26aufirst%3DC.%26aulast%3DCorrea%2Bde%2BSampaio%26aufirst%3DP.%26aulast%3DNoort%26aufirst%3DA.-R.%26aulast%3Dvan%2BZoest%26aufirst%3DK.%26aulast%3DGriffioen%26aufirst%3DA.%2BW.%26aulast%3DOlsson%26aufirst%3DH.%26aulast%3DTas%26aufirst%3DS.%2BW.%26atitle%3DTargeting%2520non-canonical%2520nuclear%2520factor-%25CE%25BAB%2520signalling%2520attenuates%2520neovascularization%2520in%2520a%2520novel%25203D%2520model%2520of%2520rheumatoid%2520arthritis%2520synovial%2520angiogenesis%26jtitle%3DRheumatology%26date%3D2017%26volume%3D56%26spage%3D294%26epage%3D302%26doi%3D10.1093%2Frheumatology%2Fkew393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Humphries, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moynagh, P. N.</span></span> <span> </span><span class="NLM_article-title">RIP kinases: key decision makers in cell death and innate immunity</span>. <i>Cell Death Differ.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">225</span>– <span class="NLM_lpage">236</span>, <span class="refDoi"> DOI: 10.1038/cdd.2014.126</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1038%2Fcdd.2014.126" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=25146926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVCrsLnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=225-236&author=F.+Humphriesauthor=S.+Yangauthor=B.+Wangauthor=P.+N.+Moynagh&title=RIP+kinases%3A+key+decision+makers+in+cell+death+and+innate+immunity&doi=10.1038%2Fcdd.2014.126"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">RIP kinases: key decision makers in cell death and innate immunity</span></div><div class="casAuthors">Humphries, F.; Yang, S.; Wang, B.; Moynagh, P. N.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Differentiation</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">225-236</span>CODEN:
                <span class="NLM_cas:coden">CDDIEK</span>;
        ISSN:<span class="NLM_cas:issn">1350-9047</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Innate immunity represents the first line of defense against invading pathogens.  It consists of an initial inflammatory response that recruits white blood cells to the site of infection in an effort to destroy and eliminate the pathogen.  Some pathogens replicate within host cells, and cell death by apoptosis is an important effector mechanism to remove the replication niche for such microbes.  However, some microbes have evolved evasive strategies to block apoptosis, and in these cases host cells may employ further countermeasures, including an inflammatory form of cell death know as necroptosis.  This review aims to highlight the importance of the RIP kinase family in controlling these various defense strategies.  RIP1 is initially discussed as a key component of death receptor signalling and in the context of dictating whether a cell triggers a pathway of pro-inflammatory gene expression or cell death by apoptosis.  The mol. and functional interplay of RIP1 and RIP3 is described, esp. with respect to mediating necroptosis and as key mediators of inflammation.  The function of RIP2, with particular emphasis on its role in NOD signalling, is also explored.  Special attention is given to emphasizing the physiol. and pathophysiol. contexts for these various functions of RIP kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPApofbdnkLLVg90H21EOLACvtfcHk0livcD3_hKOd3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVCrsLnP&md5=f25195c56cf9a7553367a4eed0f1b34a</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1038%2Fcdd.2014.126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcdd.2014.126%26sid%3Dliteratum%253Aachs%26aulast%3DHumphries%26aufirst%3DF.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DMoynagh%26aufirst%3DP.%2BN.%26atitle%3DRIP%2520kinases%253A%2520key%2520decision%2520makers%2520in%2520cell%2520death%2520and%2520innate%2520immunity%26jtitle%3DCell%2520Death%2520Differ.%26date%3D2015%26volume%3D22%26spage%3D225%26epage%3D236%26doi%3D10.1038%2Fcdd.2014.126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, J.</span></span> <span> </span><span class="NLM_article-title">Receptor-interacting protein (RIP) kinase family</span>. <i>Cell. Mol. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">243</span>– <span class="NLM_lpage">249</span>, <span class="refDoi"> DOI: 10.1038/cmi.2010.10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1038%2Fcmi.2010.10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=20383176" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC3cXotlSms7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2010&pages=243-249&author=D.+Zhangauthor=J.+Linauthor=J.+Han&title=Receptor-interacting+protein+%28RIP%29+kinase+family&doi=10.1038%2Fcmi.2010.10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Receptor-interacting protein (RIP) kinase family</span></div><div class="casAuthors">Zhang, Duanwu; Lin, Juan; Han, Jiahuai</div><div class="citationInfo"><span class="NLM_cas:title">Cellular & Molecular Immunology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">243-249</span>CODEN:
                <span class="NLM_cas:coden">CMIEAO</span>;
        ISSN:<span class="NLM_cas:issn">1672-7681</span>.
    
            (<span class="NLM_cas:orgname">NPG Nature Asia-Pacific</span>)
        </div><div class="casAbstract">A review.  Receptor-interacting protein (RIP) kinases are a group of threonine/serine protein kinases with a relatively conserved kinase domain but distinct non-kinase regions.  A no. of different domain structures, such as death and caspase activation and recruitment domain (CARD) domains, were found in different RIP family members, and these domains should be keys in detg. the specific function of each RIP kinase.  It is known that RIP kinases participate in different biol. processes, including those in innate immunity, but their downstream substrates are largely unknown.  This review will give an overview of the structures and functions of RIP family members, and an update of recent progress in RIP kinase research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpICS9EnND6QLVg90H21EOLACvtfcHk0livcD3_hKOd3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXotlSms7w%253D&md5=e110b4cbd223b7ddef4855830c7d4156</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1038%2Fcmi.2010.10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcmi.2010.10%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DHan%26aufirst%3DJ.%26atitle%3DReceptor-interacting%2520protein%2520%2528RIP%2529%2520kinase%2520family%26jtitle%3DCell.%2520Mol.%2520Immunol.%26date%3D2010%26volume%3D7%26spage%3D243%26epage%3D249%26doi%3D10.1038%2Fcmi.2010.10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chirieleison, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kertesy, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbott, D. W.</span></span> <span> </span><span class="NLM_article-title">Synthetic biology reveals the uniqueness of the RIP kinase domain</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>196</i></span>,  <span class="NLM_fpage">4291</span>– <span class="NLM_lpage">4297</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1502631</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.4049%2Fjimmunol.1502631" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=27045108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC28XntlCntLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=196&publication_year=2016&pages=4291-4297&author=S.+M.+Chirieleisonauthor=S.+B.+Kertesyauthor=D.+W.+Abbott&title=Synthetic+biology+reveals+the+uniqueness+of+the+RIP+kinase+domain&doi=10.4049%2Fjimmunol.1502631"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic Biology Reveals the Uniqueness of the RIP Kinase Domain</span></div><div class="casAuthors">Chirieleison, Steven M.; Kertesy, Sylvia B.; Abbott, Derek W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">196</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4291-4297</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">The RIP kinases (RIPKs) play an essential role in inflammatory signaling and inflammatory cell death.  However, the function of their kinase activity has been enigmatic, and only recently has kinase domain activity been shown to be crucial for their signal transduction capacity.  Despite this uncertainty, the RIPKs have been the subject of intense pharmaceutical development with a no. of compds. currently in preclin. testing.  In this work, we seek to det. the functional redundancy between the kinase domains of the four major RIPK family members.  We find that although RIPK1, RIPK2, and RIPK4 are similar in that they can all activate NF-κB and induce NF-κB essential modulator ubiquitination, only RIPK2 is a dual-specificity kinase.  Domain swapping expts. showed that the RIPK4 kinase domain could be converted to a dual-specificity kinase and is essentially indistinct from RIPK2 in biochem. and mol. activity.  Surprisingly, however, replacement of RIPK2's kinase domain with RIPK4's did not complement a nucleotide-binding oligomerization domain 2 signaling or gene expression induction defect in RIPK2-/- macrophages.  These findings suggest that RIPK2's kinase domain is functionally unique compared with other RIPK family members and that pharmacol. targeting of RIPK2 can be sepd. from the other RIPKs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI0BtYagqNBrVg90H21EOLACvtfcHk0li4AytTKB-h9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntlCntLg%253D&md5=b5482ea6e9e0c17c8d097686d208430f</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1502631&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1502631%26sid%3Dliteratum%253Aachs%26aulast%3DChirieleison%26aufirst%3DS.%2BM.%26aulast%3DKertesy%26aufirst%3DS.%2BB.%26aulast%3DAbbott%26aufirst%3DD.%2BW.%26atitle%3DSynthetic%2520biology%2520reveals%2520the%2520uniqueness%2520of%2520the%2520RIP%2520kinase%2520domain%26jtitle%3DJ.%2520Immunol.%26date%3D2016%26volume%3D196%26spage%3D4291%26epage%3D4297%26doi%3D10.4049%2Fjimmunol.1502631" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Najjar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saleh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zelic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nogusa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finger, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polykratis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gough, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whalen, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasparakis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balachandran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelliher, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poltorak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degterev, A.</span></span> <span> </span><span class="NLM_article-title">RIPK1 and RIPK3 kinases promote cell-death-independent inflammation by toll-like receptor 4</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">46</span>– <span class="NLM_lpage">59</span>, <span class="refDoi"> DOI: 10.1016/j.immuni.2016.06.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1016%2Fj.immuni.2016.06.007" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2016&pages=46-59&author=M.+Najjarauthor=D.+Salehauthor=M.+Zelicauthor=S.+Nogusaauthor=S.+Shahauthor=A.+Taiauthor=J.+N.+Fingerauthor=A.+Polykratisauthor=P.+J.+Goughauthor=J.+Bertinauthor=M.+J.+Whalenauthor=M.+Pasparakisauthor=S.+Balachandranauthor=M.+Kelliherauthor=A.+Poltorakauthor=A.+Degterev&title=RIPK1+and+RIPK3+kinases+promote+cell-death-independent+inflammation+by+toll-like+receptor+4&doi=10.1016%2Fj.immuni.2016.06.007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1016%2Fj.immuni.2016.06.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.immuni.2016.06.007%26sid%3Dliteratum%253Aachs%26aulast%3DNajjar%26aufirst%3DM.%26aulast%3DSaleh%26aufirst%3DD.%26aulast%3DZelic%26aufirst%3DM.%26aulast%3DNogusa%26aufirst%3DS.%26aulast%3DShah%26aufirst%3DS.%26aulast%3DTai%26aufirst%3DA.%26aulast%3DFinger%26aufirst%3DJ.%2BN.%26aulast%3DPolykratis%26aufirst%3DA.%26aulast%3DGough%26aufirst%3DP.%2BJ.%26aulast%3DBertin%26aufirst%3DJ.%26aulast%3DWhalen%26aufirst%3DM.%2BJ.%26aulast%3DPasparakis%26aufirst%3DM.%26aulast%3DBalachandran%26aufirst%3DS.%26aulast%3DKelliher%26aufirst%3DM.%26aulast%3DPoltorak%26aufirst%3DA.%26aulast%3DDegterev%26aufirst%3DA.%26atitle%3DRIPK1%2520and%2520RIPK3%2520kinases%2520promote%2520cell-death-independent%2520inflammation%2520by%2520toll-like%2520receptor%25204%26jtitle%3DImmunity%26date%3D2016%26volume%3D45%26spage%3D46%26epage%3D59%26doi%3D10.1016%2Fj.immuni.2016.06.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Silke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rickard, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerlic, M.</span></span> <span> </span><span class="NLM_article-title">The diverse role of RIP kinases in necroptosis and inflammation</span>. <i>Nat. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">689</span>– <span class="NLM_lpage">697</span>, <span class="refDoi"> DOI: 10.1038/ni.3206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1038%2Fni.3206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=26086143" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1OmtL3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=689-697&author=J.+Silkeauthor=J.+A.+Rickardauthor=M.+Gerlic&title=The+diverse+role+of+RIP+kinases+in+necroptosis+and+inflammation&doi=10.1038%2Fni.3206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">The diverse role of RIP kinases in necroptosis and inflammation</span></div><div class="casAuthors">Silke, John; Rickard, James A.; Gerlic, Motti</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">689-697</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Inflammation is a healthy response to infection or danger and should be rapid, specific and terminated once the threat has passed.  Inflammatory diseases, where this regulation fails, cause considerable human suffering.  Treatments have successfully targeted pro-inflammatory cytokines, such as tumor-necrosis factor (TNF), that directly induce genes encoding inflammatory products.  Inflammatory signals, including TNF, may also directly induce caspase-independent cell death (necroptosis), which can also elicit inflammation.  Necroptosis was originally defined as being dependent on the kinase RIPK1 but is now known to be dependent on RIPK3 and the pseudo-kinase MLKL.  Therefore, RIPK1, RIPK3 and MLKL are potential therapeutic targets.  RIPK1 and RIPK3 also directly regulate inflammatory signaling, which complicates interpretation of their function but might alter their therapeutic utility.  This Review examines the role of cell death, particularly necroptosis, in inflammation, in the context of recent insights into the roles of the key necroptosis effector mols. RIPK1, RIPK3 and MLKL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQwQIKren3X7Vg90H21EOLACvtfcHk0li4AytTKB-h9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1OmtL3E&md5=124026d3c7caa25e1d416c6cb2bd8d87</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1038%2Fni.3206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni.3206%26sid%3Dliteratum%253Aachs%26aulast%3DSilke%26aufirst%3DJ.%26aulast%3DRickard%26aufirst%3DJ.%2BA.%26aulast%3DGerlic%26aufirst%3DM.%26atitle%3DThe%2520diverse%2520role%2520of%2520RIP%2520kinases%2520in%2520necroptosis%2520and%2520inflammation%26jtitle%3DNat.%2520Immunol.%26date%3D2015%26volume%3D16%26spage%3D689%26epage%3D697%26doi%3D10.1038%2Fni.3206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hildebrand, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, J. M.</span></span> <span> </span><span class="NLM_article-title">The highway to hell: a RIP kinase-directed shortcut to inflammatory cytokine production</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">3</span>, <span class="refDoi"> DOI: 10.1016/j.immuni.2016.06.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1016%2Fj.immuni.2016.06.029" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2016&pages=1-3&author=J.+M.+Hildebrandauthor=J.+M.+Murphy&title=The+highway+to+hell%3A+a+RIP+kinase-directed+shortcut+to+inflammatory+cytokine+production&doi=10.1016%2Fj.immuni.2016.06.029"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1016%2Fj.immuni.2016.06.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.immuni.2016.06.029%26sid%3Dliteratum%253Aachs%26aulast%3DHildebrand%26aufirst%3DJ.%2BM.%26aulast%3DMurphy%26aufirst%3DJ.%2BM.%26atitle%3DThe%2520highway%2520to%2520hell%253A%2520a%2520RIP%2520kinase-directed%2520shortcut%2520to%2520inflammatory%2520cytokine%2520production%26jtitle%3DImmunity%26date%3D2016%26volume%3D45%26spage%3D1%26epage%3D3%26doi%3D10.1016%2Fj.immuni.2016.06.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harris, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, J. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagilla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandyopadhyay, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campobasso, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capriotti, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dare, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eidam, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finger, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasparcova, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehr, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leister, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lich, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacDonald, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouellette, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reilly, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rendina, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaeffer, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sehon, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singhaus, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swift, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Totoritis, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vossenkämper, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wisnoski, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marquis, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gough, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertin, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of a first-in-class receptor interacting protein 1 (RIP1) kinase specific clinical candidate (GSK2982772) for the treatment of inflammatory diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1247</span>– <span class="NLM_lpage">1261</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01751</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01751" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVeksLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=1247-1261&author=P.+A.+Harrisauthor=S.+B.+Bergerauthor=J.+U.+Jeongauthor=R.+Nagillaauthor=D.+Bandyopadhyayauthor=N.+Campobassoauthor=C.+A.+Capriottiauthor=J.+A.+Coxauthor=L.+Dareauthor=X.+Dongauthor=P.+M.+Eidamauthor=J.+N.+Fingerauthor=S.+J.+Hoffmanauthor=J.+Kangauthor=V.+Kasparcovaauthor=B.+W.+Kingauthor=R.+Lehrauthor=Y.+Lanauthor=L.+K.+Leisterauthor=J.+D.+Lichauthor=T.+T.+MacDonaldauthor=N.+A.+Millerauthor=M.+T.+Ouelletteauthor=C.+S.+Paoauthor=A.+Rahmanauthor=M.+A.+Reillyauthor=A.+R.+Rendinaauthor=E.+J.+Riveraauthor=M.+C.+Schaefferauthor=C.+A.+Sehonauthor=R.+R.+Singhausauthor=H.+H.+Sunauthor=B.+A.+Swiftauthor=R.+D.+Totoritisauthor=A.+Vossenk%C3%A4mperauthor=P.+Wardauthor=D.+D.+Wisnoskiauthor=D.+Zhangauthor=R.+W.+Marquisauthor=P.+J.+Goughauthor=J.+Bertin&title=Discovery+of+a+first-in-class+receptor+interacting+protein+1+%28RIP1%29+kinase+specific+clinical+candidate+%28GSK2982772%29+for+the+treatment+of+inflammatory+diseases&doi=10.1021%2Facs.jmedchem.6b01751"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases</span></div><div class="casAuthors">Harris, Philip A.; Berger, Scott B.; Jeong, Jae U.; Nagilla, Rakesh; Bandyopadhyay, Deepak; Campobasso, Nino; Capriotti, Carol A.; Cox, Julie A.; Dare, Lauren; Dong, Xiaoyang; Eidam, Patrick M.; Finger, Joshua N.; Hoffman, Sandra J.; Kang, James; Kasparcova, Viera; King, Bryan W.; Lehr, Ruth; Lan, Yunfeng; Leister, Lara K.; Lich, John D.; MacDonald, Thomas T.; Miller, Nathan A.; Ouellette, Michael T.; Pao, Christina S.; Rahman, Attiq; Reilly, Michael A.; Rendina, Alan R.; Rivera, Elizabeth J.; Schaeffer, Michelle C.; Sehon, Clark A.; Singhaus, Robert R.; Sun, Helen H.; Swift, Barbara A.; Totoritis, Rachel D.; Vossenkamper, Anna; Ward, Paris; Wisnoski, David D.; Zhang, Daohua; Marquis, Robert W.; Gough, Peter J.; Bertin, John</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1247-1261</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">RIP1 regulates necroptosis and inflammation and may play an important role in contributing to a variety of human pathologies, including immune-mediated inflammatory diseases.  Small-mol. inhibitors of RIP1 kinase that are suitable for advancement into the clinic have yet to be described.  Herein, the authors report the lead optimization of a benzoxazepinone hit from a DNA-encoded library and the discovery and profile of clin. candidate GSK2982772 (compd. I), currently in phase 2a clin. studies for psoriasis, rheumatoid arthritis, and ulcerative colitis.  Compd. I potently binds to RIP1 with exquisite kinase specificity and has excellent activity in blocking many TNF-dependent cellular responses.  Highlighting its potential as a novel anti-inflammatory agent, the inhibitor was also able to reduce spontaneous prodn. of cytokines from human ulcerative colitis explants.  The highly favorable physicochem. and ADMET properties of I, combined with high potency, led to a predicted low oral dose in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZGRDTQv-vs7Vg90H21EOLACvtfcHk0li4AytTKB-h9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVeksLk%253D&md5=ee0c3c60bb1351dff696490ac9edb1cc</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01751&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01751%26sid%3Dliteratum%253Aachs%26aulast%3DHarris%26aufirst%3DP.%2BA.%26aulast%3DBerger%26aufirst%3DS.%2BB.%26aulast%3DJeong%26aufirst%3DJ.%2BU.%26aulast%3DNagilla%26aufirst%3DR.%26aulast%3DBandyopadhyay%26aufirst%3DD.%26aulast%3DCampobasso%26aufirst%3DN.%26aulast%3DCapriotti%26aufirst%3DC.%2BA.%26aulast%3DCox%26aufirst%3DJ.%2BA.%26aulast%3DDare%26aufirst%3DL.%26aulast%3DDong%26aufirst%3DX.%26aulast%3DEidam%26aufirst%3DP.%2BM.%26aulast%3DFinger%26aufirst%3DJ.%2BN.%26aulast%3DHoffman%26aufirst%3DS.%2BJ.%26aulast%3DKang%26aufirst%3DJ.%26aulast%3DKasparcova%26aufirst%3DV.%26aulast%3DKing%26aufirst%3DB.%2BW.%26aulast%3DLehr%26aufirst%3DR.%26aulast%3DLan%26aufirst%3DY.%26aulast%3DLeister%26aufirst%3DL.%2BK.%26aulast%3DLich%26aufirst%3DJ.%2BD.%26aulast%3DMacDonald%26aufirst%3DT.%2BT.%26aulast%3DMiller%26aufirst%3DN.%2BA.%26aulast%3DOuellette%26aufirst%3DM.%2BT.%26aulast%3DPao%26aufirst%3DC.%2BS.%26aulast%3DRahman%26aufirst%3DA.%26aulast%3DReilly%26aufirst%3DM.%2BA.%26aulast%3DRendina%26aufirst%3DA.%2BR.%26aulast%3DRivera%26aufirst%3DE.%2BJ.%26aulast%3DSchaeffer%26aufirst%3DM.%2BC.%26aulast%3DSehon%26aufirst%3DC.%2BA.%26aulast%3DSinghaus%26aufirst%3DR.%2BR.%26aulast%3DSun%26aufirst%3DH.%2BH.%26aulast%3DSwift%26aufirst%3DB.%2BA.%26aulast%3DTotoritis%26aufirst%3DR.%2BD.%26aulast%3DVossenk%25C3%25A4mper%26aufirst%3DA.%26aulast%3DWard%26aufirst%3DP.%26aulast%3DWisnoski%26aufirst%3DD.%2BD.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DMarquis%26aufirst%3DR.%2BW.%26aulast%3DGough%26aufirst%3DP.%2BJ.%26aulast%3DBertin%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520a%2520first-in-class%2520receptor%2520interacting%2520protein%25201%2520%2528RIP1%2529%2520kinase%2520specific%2520clinical%2520candidate%2520%2528GSK2982772%2529%2520for%2520the%2520treatment%2520of%2520inflammatory%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D1247%26epage%3D1261%26doi%3D10.1021%2Facs.jmedchem.6b01751" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harris, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandyopadhyay, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campobasso, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capriotti, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dare, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finger, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grady, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, J. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasparcova, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakdawala, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehr, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNulty, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagilla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouellette, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rendina, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaeffer, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Summerfield, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swift, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Totoritis, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marquis, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gough, P. J.</span></span> <span> </span><span class="NLM_article-title">DNA-encoded library screening identifies benzo[b][1,4]oxazepin-4-ones as highly potent and monoselective receptor interacting protein 1 kinase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">2163</span>– <span class="NLM_lpage">2178</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01898</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01898" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC28Xit1Kqsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=2163-2178&author=P.+A.+Harrisauthor=B.+W.+Kingauthor=D.+Bandyopadhyayauthor=S.+B.+Bergerauthor=N.+Campobassoauthor=C.+A.+Capriottiauthor=J.+A.+Coxauthor=L.+Dareauthor=X.+Dongauthor=J.+N.+Fingerauthor=L.+C.+Gradyauthor=S.+J.+Hoffmanauthor=J.+U.+Jeongauthor=J.+Kangauthor=V.+Kasparcovaauthor=A.+S.+Lakdawalaauthor=R.+Lehrauthor=D.+E.+McNultyauthor=R.+Nagillaauthor=M.+T.+Ouelletteauthor=C.+S.+Paoauthor=A.+R.+Rendinaauthor=M.+C.+Schaefferauthor=J.+D.+Summerfieldauthor=B.+A.+Swiftauthor=R.+D.+Totoritisauthor=P.+Wardauthor=A.+Zhangauthor=D.+Zhangauthor=R.+W.+Marquisauthor=J.+Bertinauthor=P.+J.+Gough&title=DNA-encoded+library+screening+identifies+benzo%5Bb%5D%5B1%2C4%5Doxazepin-4-ones+as+highly+potent+and+monoselective+receptor+interacting+protein+1+kinase+inhibitors&doi=10.1021%2Facs.jmedchem.5b01898"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">DNA-Encoded Library Screening Identifies Benzo[b][1,4]oxazepin-4-ones as Highly Potent and Monoselective Receptor Interacting Protein 1 Kinase Inhibitors</span></div><div class="casAuthors">Harris, Philip A.; King, Bryan W.; Bandyopadhyay, Deepak; Berger, Scott B.; Campobasso, Nino; Capriotti, Carol A.; Cox, Julie A.; Dare, Lauren; Dong, Xiaoyang; Finger, Joshua N.; Grady, LaShadric C.; Hoffman, Sandra J.; Jeong, Jae U.; Kang, James; Kasparcova, Viera; Lakdawala, Ami S.; Lehr, Ruth; McNulty, Dean E.; Nagilla, Rakesh; Ouellette, Michael T.; Pao, Christina S.; Rendina, Alan R.; Schaeffer, Michelle C.; Summerfield, Jennifer D.; Swift, Barbara A.; Totoritis, Rachel D.; Ward, Paris; Zhang, Aming; Zhang, Daohua; Marquis, Robert W.; Bertin, John; Gough, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2163-2178</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The recent discovery of the role of receptor interacting protein 1 (RIP1) kinase in tumor necrosis factor (TNF)-mediated inflammation has led to its emergence as a highly promising target for the treatment of multiple inflammatory diseases.  The authors screened RIP1 against GSK's DNA-encoded small-mol. libraries and identified a novel highly potent benzoxazepinone inhibitor series.  The authors demonstrate that this template possesses complete monokinase selectivity for RIP1 plus unique species selectivity for primate vs. nonprimate RIP1.  The authors elucidate the conformation of RIP1 bound to this benzoxazepinone inhibitor driving its high kinase selectivity and design specific mutations in murine RIP1 to restore potency to levels similar to primate RIP1.  This series differentiates itself from known RIP1 inhibitors in combining high potency and kinase selectivity with good pharmacokinetic profiles in rodents.  The favorable developability profile of this benzoxazepinone template, as exemplified by compd. 14 (GSK'481), makes it an excellent starting point for further optimization into a RIP1 clin. candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4XvpziWGWg7Vg90H21EOLACvtfcHk0ljrDfupjRBr1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xit1Kqsr8%253D&md5=d6325dcaed97b7c339d1830ca041298c</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01898&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01898%26sid%3Dliteratum%253Aachs%26aulast%3DHarris%26aufirst%3DP.%2BA.%26aulast%3DKing%26aufirst%3DB.%2BW.%26aulast%3DBandyopadhyay%26aufirst%3DD.%26aulast%3DBerger%26aufirst%3DS.%2BB.%26aulast%3DCampobasso%26aufirst%3DN.%26aulast%3DCapriotti%26aufirst%3DC.%2BA.%26aulast%3DCox%26aufirst%3DJ.%2BA.%26aulast%3DDare%26aufirst%3DL.%26aulast%3DDong%26aufirst%3DX.%26aulast%3DFinger%26aufirst%3DJ.%2BN.%26aulast%3DGrady%26aufirst%3DL.%2BC.%26aulast%3DHoffman%26aufirst%3DS.%2BJ.%26aulast%3DJeong%26aufirst%3DJ.%2BU.%26aulast%3DKang%26aufirst%3DJ.%26aulast%3DKasparcova%26aufirst%3DV.%26aulast%3DLakdawala%26aufirst%3DA.%2BS.%26aulast%3DLehr%26aufirst%3DR.%26aulast%3DMcNulty%26aufirst%3DD.%2BE.%26aulast%3DNagilla%26aufirst%3DR.%26aulast%3DOuellette%26aufirst%3DM.%2BT.%26aulast%3DPao%26aufirst%3DC.%2BS.%26aulast%3DRendina%26aufirst%3DA.%2BR.%26aulast%3DSchaeffer%26aufirst%3DM.%2BC.%26aulast%3DSummerfield%26aufirst%3DJ.%2BD.%26aulast%3DSwift%26aufirst%3DB.%2BA.%26aulast%3DTotoritis%26aufirst%3DR.%2BD.%26aulast%3DWard%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DMarquis%26aufirst%3DR.%2BW.%26aulast%3DBertin%26aufirst%3DJ.%26aulast%3DGough%26aufirst%3DP.%2BJ.%26atitle%3DDNA-encoded%2520library%2520screening%2520identifies%2520benzo%255Bb%255D%255B1%252C4%255Doxazepin-4-ones%2520as%2520highly%2520potent%2520and%2520monoselective%2520receptor%2520interacting%2520protein%25201%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D2163%26epage%3D2178%26doi%3D10.1021%2Facs.jmedchem.5b01898" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span> <span> </span><span class="NLM_article-title">Discovery of a highly potent, selective, and metabolically stable inhibitor of receptor-interacting protein 1 (RIP1) for the treatment of systemic inflammatory response syndrome</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">972</span>– <span class="NLM_lpage">986</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01196</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01196" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFaitbfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=972-986&author=Y.+Renauthor=Y.+Suauthor=L.+Sunauthor=S.+Heauthor=L.+Mengauthor=D.+Liaoauthor=X.+Liuauthor=Y.+Maauthor=C.+Liuauthor=S.+Liauthor=H.+Ruanauthor=X.+Leiauthor=X.+Wangauthor=Z.+Zhang&title=Discovery+of+a+highly+potent%2C+selective%2C+and+metabolically+stable+inhibitor+of+receptor-interacting+protein+1+%28RIP1%29+for+the+treatment+of+systemic+inflammatory+response+syndrome&doi=10.1021%2Facs.jmedchem.6b01196"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Highly Potent, Selective, and Metabolically Stable Inhibitor of Receptor-Interacting Protein 1 (RIP1) for the Treatment of Systemic Inflammatory Response Syndrome</span></div><div class="casAuthors">Ren, Yan; Su, Yaning; Sun, Liming; He, Sudan; Meng, Lingjun; Liao, Daohong; Liu, Xiao; Ma, Yongfen; Liu, Chunyan; Li, Sisi; Ruan, Hanying; Lei, Xiaoguang; Wang, Xiaodong; Zhang, Zhiyuan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">972-986</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Based on its essential role in driving inflammation and disease pathol., cell necrosis has gradually been verified as a promising therapeutic target for treating atherosclerosis, systemic inflammatory response syndrome (SIRS), and ischemia injury, among other diseases.  Most necrosis inhibitors targeting receptor-interacting protein 1 (RIP1) still require further optimization because of weak potency or poor metabolic stability.  The authors conducted a phenotypic screen and identified a micromolar hit with novel amide structure.  Medicinal chem. efforts yielded a highly-potent, selective, and metabolically stable drug candidate - compd. 56 (RIPA-56, N-benzyl-N-hydroxy-2,2-dimethylbutanamide).  Biochem. studies and mol. docking revealed that RIP1 is the direct target of this new series of type III kinase inhibitors.  In the SIRS mice disease model, 56 efficiently reduced tumor necrosis factor alpha (TNFα)-induced mortality and multi-organ damage.  Compared to known RIP1 inhibitors, 56 is potent in both human and murine cells, is much more stable in vivo, and is efficacious in animal model studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqos-N-fJJ4vbVg90H21EOLACvtfcHk0ljrDfupjRBr1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFaitbfO&md5=6e7045a9646be5f9dc9559d90efe8aed</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01196&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01196%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DY.%26aulast%3DSu%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DHe%26aufirst%3DS.%26aulast%3DMeng%26aufirst%3DL.%26aulast%3DLiao%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DRuan%26aufirst%3DH.%26aulast%3DLei%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DZ.%26atitle%3DDiscovery%2520of%2520a%2520highly%2520potent%252C%2520selective%252C%2520and%2520metabolically%2520stable%2520inhibitor%2520of%2520receptor-interacting%2520protein%25201%2520%2528RIP1%2529%2520for%2520the%2520treatment%2520of%2520systemic%2520inflammatory%2520response%2520syndrome%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D972%26epage%3D986%26doi%3D10.1021%2Facs.jmedchem.6b01196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Canning, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwerd, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hrdinka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maki, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saleh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suebsuwong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennan, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuny, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uhlig, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gyrd-Hansen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degterev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, A. N.</span></span> <span> </span><span class="NLM_article-title">Inflammatory signaling by NOD-RIPK2 is inhibited by clinically relevant type II kinase inhibitors</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1174</span>– <span class="NLM_lpage">1184</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2015.07.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1016%2Fj.chembiol.2015.07.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=26320862" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVajs7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=1174-1184&author=P.+Canningauthor=Q.+Ruanauthor=T.+Schwerdauthor=M.+Hrdinkaauthor=J.+L.+Makiauthor=D.+Salehauthor=C.+Suebsuwongauthor=S.+Rayauthor=P.+E.+Brennanauthor=G.+D.+Cunyauthor=H.+H.+Uhligauthor=M.+Gyrd-Hansenauthor=A.+Degterevauthor=A.+N.+Bullock&title=Inflammatory+signaling+by+NOD-RIPK2+is+inhibited+by+clinically+relevant+type+II+kinase+inhibitors&doi=10.1016%2Fj.chembiol.2015.07.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Inflammatory Signaling by NOD-RIPK2 Is Inhibited by Clinically Relevant Type II Kinase Inhibitors</span></div><div class="casAuthors">Canning, Peter; Ruan, Qui; Schwerd, Tobias; Hrdinka, Matous; Maki, Jenny L.; Saleh, Danish; Suebsuwong, Chalada; Ray, Soumya; Brennan, Paul E.; Cuny, Gregory D.; Uhlig, Holm H.; Gyrd-Hansen, Mads; Degterev, Alexei; Bullock, Alex N.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1174-1184</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">RIPK2 mediates pro-inflammatory signaling from the bacterial sensors NOD1 and NOD2, and is an emerging therapeutic target in autoimmune and inflammatory diseases.  We obsd. that cellular RIPK2 can be potently inhibited by type II inhibitors that displace the kinase activation segment, whereas ATP-competitive type I inhibition was only poorly effective.  The most potent RIPK2 inhibitors were the US Food and Drug Administration-approved drugs ponatinib and regorafenib.  Their mechanism of action was independent of NOD2 interaction and involved loss of downstream kinase activation as evidenced by lack of RIPK2 autophosphorylation.  Notably, these mols. also blocked RIPK2 ubiquitination and, consequently, inflammatory nuclear factor κB signaling.  In monocytes, the inhibitors selectively blocked NOD-dependent tumor necrosis factor prodn. without affecting lipopolysaccharide-dependent pathways.  We also detd. the first crystal structure of RIPK2 bound to ponatinib, and identified an allosteric site for inhibitor development.  These results highlight the potential for type II inhibitors to treat indications of RIPK2 activation as well as inflammation-assocd. cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6MemkG2eHFLVg90H21EOLACvtfcHk0liuu0ZgdLY76g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVajs7zP&md5=548df9cb0a629c1acdd831c9c716022c</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2015.07.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2015.07.017%26sid%3Dliteratum%253Aachs%26aulast%3DCanning%26aufirst%3DP.%26aulast%3DRuan%26aufirst%3DQ.%26aulast%3DSchwerd%26aufirst%3DT.%26aulast%3DHrdinka%26aufirst%3DM.%26aulast%3DMaki%26aufirst%3DJ.%2BL.%26aulast%3DSaleh%26aufirst%3DD.%26aulast%3DSuebsuwong%26aufirst%3DC.%26aulast%3DRay%26aufirst%3DS.%26aulast%3DBrennan%26aufirst%3DP.%2BE.%26aulast%3DCuny%26aufirst%3DG.%2BD.%26aulast%3DUhlig%26aufirst%3DH.%2BH.%26aulast%3DGyrd-Hansen%26aufirst%3DM.%26aulast%3DDegterev%26aufirst%3DA.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26atitle%3DInflammatory%2520signaling%2520by%2520NOD-RIPK2%2520is%2520inhibited%2520by%2520clinically%2520relevant%2520type%2520II%2520kinase%2520inhibitors%26jtitle%3DChem.%2520Biol.%26date%3D2015%26volume%3D22%26spage%3D1174%26epage%3D1184%26doi%3D10.1016%2Fj.chembiol.2015.07.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xie, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degterev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span> <span> </span><span class="NLM_article-title">Structural basis of RIP1 inhibition by necrostatins</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">493</span>– <span class="NLM_lpage">499</span>, <span class="refDoi"> DOI: 10.1016/j.str.2013.01.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1016%2Fj.str.2013.01.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=23473668" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktVOqsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=493-499&author=T.+Xieauthor=W.+Pengauthor=Y.+Liuauthor=C.+Yanauthor=J.+Makiauthor=A.+Degterevauthor=J.+Yuanauthor=Y.+Shi&title=Structural+basis+of+RIP1+inhibition+by+necrostatins&doi=10.1016%2Fj.str.2013.01.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis of RIP1 Inhibition by Necrostatins</span></div><div class="casAuthors">Xie, Tian; Peng, Wei; Liu, Yexing; Yan, Chuangye; Maki, Jenny; Degterev, Alexei; Yuan, Junying; Shi, Yigong</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">493-499</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Necroptosis is a cellular mechanism that mediates necrotic cell death.  The receptor-interacting serine/threonine protein kinase 1 (RIP1) is an essential upstream signaling mol. in tumor-necrosis-factor-α-induced necroptosis.  Necrostatins, a series of small-mol. inhibitors, suppress necroptosis by specifically inhibiting RIP1 kinase activity.  Both RIP1 structure and the mechanisms by which necrostatins inhibit RIP1 remain unknown.  Here, we report the crystal structures of the RIP1 kinase domain individually bound to necrostatin-1 analog, necrostatin-3 analog, and necrostatin-4.  Necrostatin, caged in a hydrophobic pocket between the N- and C-lobes of the kinase domain, stabilizes RIP1 in an inactive conformation through interactions with highly conserved amino acids in the activation loop and the surrounding structural elements.  Structural comparison of RIP1 with the inhibitor-bound oncogenic kinase B-RAF reveals partially overlapping binding sites for necrostatin and for the anticancer compd. PLX4032.  Our study provides a structural basis for RIP1 inhibition by necrostatins and offers insights into potential structure-based drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtw_1OVLFe4rVg90H21EOLACvtfcHk0liuu0ZgdLY76g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktVOqsLk%253D&md5=42a3f8951b390358b9068bb1b885445e</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2013.01.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2013.01.016%26sid%3Dliteratum%253Aachs%26aulast%3DXie%26aufirst%3DT.%26aulast%3DPeng%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DYan%26aufirst%3DC.%26aulast%3DMaki%26aufirst%3DJ.%26aulast%3DDegterev%26aufirst%3DA.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DY.%26atitle%3DStructural%2520basis%2520of%2520RIP1%2520inhibition%2520by%2520necrostatins%26jtitle%3DStructure%26date%3D2013%26volume%3D21%26spage%3D493%26epage%3D499%26doi%3D10.1016%2Fj.str.2013.01.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haile, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Votta, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marquis, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bury, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehlmann, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singhaus, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charnley, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakdawala, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Convery, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipshutz, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swift, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capriotti, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahajan, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reilly, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagilla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beal, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finger, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouellette, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Totoritis, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierdomenico, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negroni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stronati, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cucchiara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziółkowski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vossenkämper, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacDonald, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gough, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casillas, L. N.</span></span> <span> </span><span class="NLM_article-title">The identification and pharmacological characterization of 6-(tert-butylsulfonyl)-N-(5-fluoro-1H-indazol-3-yl)quinolin-4-amine (GSK583), a highly potent and selective inhibitor of RIP2 kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">4867</span>– <span class="NLM_lpage">4880</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00211</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00211" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC28Xms1GqsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=4867-4880&author=P.+A.+Haileauthor=B.+J.+Vottaauthor=R.+W.+Marquisauthor=M.+J.+Buryauthor=J.+F.+Mehlmannauthor=R.+Singhausauthor=A.+K.+Charnleyauthor=A.+S.+Lakdawalaauthor=M.+A.+Converyauthor=D.+B.+Lipshutzauthor=B.+M.+Desaiauthor=B.+Swiftauthor=C.+A.+Capriottiauthor=S.+B.+Bergerauthor=M.+K.+Mahajanauthor=M.+A.+Reillyauthor=E.+J.+Riveraauthor=H.+H.+Sunauthor=R.+Nagillaauthor=A.+M.+Bealauthor=J.+N.+Fingerauthor=M.+N.+Cookauthor=B.+W.+Kingauthor=M.+T.+Ouelletteauthor=R.+D.+Totoritisauthor=M.+Pierdomenicoauthor=A.+Negroniauthor=L.+Stronatiauthor=S.+Cucchiaraauthor=B.+Zi%C3%B3%C5%82kowskiauthor=A.+Vossenk%C3%A4mperauthor=T.+T.+MacDonaldauthor=P.+J.+Goughauthor=J.+Bertinauthor=L.+N.+Casillas&title=The+identification+and+pharmacological+characterization+of+6-%28tert-butylsulfonyl%29-N-%285-fluoro-1H-indazol-3-yl%29quinolin-4-amine+%28GSK583%29%2C+a+highly+potent+and+selective+inhibitor+of+RIP2+kinase&doi=10.1021%2Facs.jmedchem.6b00211"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">The Identification and Pharmacological Characterization of 6-(tert-Butylsulfonyl)-N-(5-fluoro-1H-indazol-3-yl)quinolin-4-amine (GSK583), a Highly Potent and Selective Inhibitor of RIP2 Kinase</span></div><div class="casAuthors">Haile, Pamela A.; Votta, Bartholomew J.; Marquis, Robert W.; Bury, Michael J.; Mehlmann, John F.; Singhaus, Robert; Charnley, Adam K.; Lakdawala, Ami S.; Convery, Maire A.; Lipshutz, David B.; Desai, Biva M.; Swift, Barbara; Capriotti, Carol A.; Berger, Scott B.; Majahan, Mukesh K.; Reilly, Michael A.; Rivera, Elizabeth J.; Sun, Helen H.; Nagilla, Rakesh; Beal, Allison M.; Finger, Joshua N.; Cook, Michael N.; King, Bryan W.; Ouellette, Michael T.; Totoritis, Rachel D.; Pierdomenico, Maria; Negroni, Anna; Stronati, Laura; Cucchiara, Salvatore; Ziolkowski, Bartlomiej; Vossenkamper, Anna; MacDonald, Thomas T.; Gough, Peter J.; Bertin, John; Casillas, Linda N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4867-4880</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">RIP2 kinase is a central component of the innate immune system and enables downstream signaling following activation of the pattern recognition receptors NOD1 and NOD2, leading to the prodn. of inflammatory cytokines.  Recently, several inhibitors of RIP2 kinase have been disclosed that have contributed to the fundamental understanding of the role of RIP2 in this pathway.  However, because they lack either broad kinase selectivity or strong affinity for RIP2, these tools have only limited utility to assess the role of RIP2 in complex environments.  We present, herein, the discovery and pharmacol. characterization of GSK583 (I), a next-generation RIP2 inhibitor possessing exquisite selectivity and potency.  Having demonstrated the pharmacol. precision of this tool compd., we report its use in elucidating the role of RIP2 kinase in a variety of in vitro, in vivo, and ex vivo expts., further clarifying our understanding of the role of RIP2 in NOD1 and NOD2 mediated disease pathogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4OmfRRg6RHrVg90H21EOLACvtfcHk0liuu0ZgdLY76g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xms1GqsLs%253D&md5=74a178c9f055232de8a729bd254fce3e</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00211%26sid%3Dliteratum%253Aachs%26aulast%3DHaile%26aufirst%3DP.%2BA.%26aulast%3DVotta%26aufirst%3DB.%2BJ.%26aulast%3DMarquis%26aufirst%3DR.%2BW.%26aulast%3DBury%26aufirst%3DM.%2BJ.%26aulast%3DMehlmann%26aufirst%3DJ.%2BF.%26aulast%3DSinghaus%26aufirst%3DR.%26aulast%3DCharnley%26aufirst%3DA.%2BK.%26aulast%3DLakdawala%26aufirst%3DA.%2BS.%26aulast%3DConvery%26aufirst%3DM.%2BA.%26aulast%3DLipshutz%26aufirst%3DD.%2BB.%26aulast%3DDesai%26aufirst%3DB.%2BM.%26aulast%3DSwift%26aufirst%3DB.%26aulast%3DCapriotti%26aufirst%3DC.%2BA.%26aulast%3DBerger%26aufirst%3DS.%2BB.%26aulast%3DMahajan%26aufirst%3DM.%2BK.%26aulast%3DReilly%26aufirst%3DM.%2BA.%26aulast%3DRivera%26aufirst%3DE.%2BJ.%26aulast%3DSun%26aufirst%3DH.%2BH.%26aulast%3DNagilla%26aufirst%3DR.%26aulast%3DBeal%26aufirst%3DA.%2BM.%26aulast%3DFinger%26aufirst%3DJ.%2BN.%26aulast%3DCook%26aufirst%3DM.%2BN.%26aulast%3DKing%26aufirst%3DB.%2BW.%26aulast%3DOuellette%26aufirst%3DM.%2BT.%26aulast%3DTotoritis%26aufirst%3DR.%2BD.%26aulast%3DPierdomenico%26aufirst%3DM.%26aulast%3DNegroni%26aufirst%3DA.%26aulast%3DStronati%26aufirst%3DL.%26aulast%3DCucchiara%26aufirst%3DS.%26aulast%3DZi%25C3%25B3%25C5%2582kowski%26aufirst%3DB.%26aulast%3DVossenk%25C3%25A4mper%26aufirst%3DA.%26aulast%3DMacDonald%26aufirst%3DT.%2BT.%26aulast%3DGough%26aufirst%3DP.%2BJ.%26aulast%3DBertin%26aufirst%3DJ.%26aulast%3DCasillas%26aufirst%3DL.%2BN.%26atitle%3DThe%2520identification%2520and%2520pharmacological%2520characterization%2520of%25206-%2528tert-butylsulfonyl%2529-N-%25285-fluoro-1H-indazol-3-yl%2529quinolin-4-amine%2520%2528GSK583%2529%252C%2520a%2520highly%2520potent%2520and%2520selective%2520inhibitor%2520of%2520RIP2%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D4867%26epage%3D4880%26doi%3D10.1021%2Facs.jmedchem.6b00211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Da Ros, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okram, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michellys, P.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iskandar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espinola, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursulaya, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreusch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spraggon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baaten, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clemmer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meeusen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen-Tran, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fathman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuntland, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollenbeck, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bordone, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span> <span> </span><span class="NLM_article-title">Identification of potent and selective RIPK2 inhibitors for the treatment of inflammatory diseases</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1048</span>– <span class="NLM_lpage">1053</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00258</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00258" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFOjtLjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1048-1053&author=X.+Heauthor=S.+Da+Rosauthor=J.+Nelsonauthor=X.+Zhuauthor=T.+Jiangauthor=B.+Okramauthor=S.+Jiangauthor=P.-Y.+Michellysauthor=M.+Iskandarauthor=S.+Espinolaauthor=Y.+Jiaauthor=B.+Bursulayaauthor=A.+Kreuschauthor=M.-Y.+Gaoauthor=G.+Spraggonauthor=J.+Baatenauthor=L.+Clemmerauthor=S.+Meeusenauthor=D.+Huangauthor=R.+Hillauthor=V.+Nguyen-Tranauthor=J.+Fathmanauthor=B.+Liuauthor=T.+Tuntlandauthor=P.+Gordonauthor=T.+Hollenbeckauthor=K.+Ngauthor=J.+Shiauthor=L.+Bordoneauthor=H.+Liu&title=Identification+of+potent+and+selective+RIPK2+inhibitors+for+the+treatment+of+inflammatory+diseases&doi=10.1021%2Facsmedchemlett.7b00258"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Potent and Selective RIPK2 Inhibitors for the Treatment of Inflammatory Diseases</span></div><div class="casAuthors">He, Xiaohui; Da Ros, Sara; Nelson, John; Zhu, Xuefeng; Jiang, Tao; Okram, Barun; Jiang, Songchun; Michellys, Pierre-Yves; Iskandar, Maya; Espinola, Sheryll; Jia, Yong; Bursulaya, Badry; Kreusch, Andreas; Gao, Mu-Yun; Spraggon, Glen; Baaten, Janine; Clemmer, Leah; Meeusen, Shelly; Huang, David; Hill, Robert; Nguyen-Tran, Van; Fathman, John; Liu, Bo; Tuntland, Tove; Gordon, Perry; Hollenbeck, Thomas; Ng, Kenneth; Shi, Jian; Bordone, Laura; Liu, Hong</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1048-1053</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">NOD2 (nucleotide-binding oligomerization domain-contg. protein 2) is an internal pattern recognition receptor that recognizes bacterial peptidoglycan and stimulates host immune responses.  Dysfunction of NOD2 pathway has been assocd. with a no. of autoinflammatory disorders.  To date, direct inhibitors of NOD2 have not been described due to tech. challenges of targeting the oligomeric protein complex.  Receptor interacting protein kinase 2 (RIPK2) is an intracellular serine/threonine/tyrosine kinase, a key signaling partner, and an obligate kinase for NOD2.  As such, RIPK2 represents an attractive target to probe the pathol. roles of NOD2 pathway.  To search for selective RIPK2 inhibitors, the authors employed virtual library screening (VLS) and structure based design that eventually led to a potent and selective RIPK2 inhibitor 8 (4-(7-ethoxy-6-(isopropylsulfonyl)imidazo[1,2-a]pyridin-3-yl)-6-fluoropyridin-2-amine) with excellent oral bioavailability, which was used to evaluate the effects of inhibition of RIPK2 in various in vitro assays and ex vivo and in vivo pharmacodynamic models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVdc_tBhQU-7Vg90H21EOLACvtfcHk0limgH7G0MjuuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFOjtLjJ&md5=87e32df13c63a9cd16b20652ae96b36a</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00258%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DX.%26aulast%3DDa%2BRos%26aufirst%3DS.%26aulast%3DNelson%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DT.%26aulast%3DOkram%26aufirst%3DB.%26aulast%3DJiang%26aufirst%3DS.%26aulast%3DMichellys%26aufirst%3DP.-Y.%26aulast%3DIskandar%26aufirst%3DM.%26aulast%3DEspinola%26aufirst%3DS.%26aulast%3DJia%26aufirst%3DY.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DKreusch%26aufirst%3DA.%26aulast%3DGao%26aufirst%3DM.-Y.%26aulast%3DSpraggon%26aufirst%3DG.%26aulast%3DBaaten%26aufirst%3DJ.%26aulast%3DClemmer%26aufirst%3DL.%26aulast%3DMeeusen%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DD.%26aulast%3DHill%26aufirst%3DR.%26aulast%3DNguyen-Tran%26aufirst%3DV.%26aulast%3DFathman%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DGordon%26aufirst%3DP.%26aulast%3DHollenbeck%26aufirst%3DT.%26aulast%3DNg%26aufirst%3DK.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DBordone%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DH.%26atitle%3DIdentification%2520of%2520potent%2520and%2520selective%2520RIPK2%2520inhibitors%2520for%2520the%2520treatment%2520of%2520inflammatory%2520diseases%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D1048%26epage%3D1053%26doi%3D10.1021%2Facsmedchemlett.7b00258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nachbur, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stafford, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bankovacki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindqvist, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiil, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khakham, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandow, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falk, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holien, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chau, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hildebrand, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vince, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharp, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackman, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mühlen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowes, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gyrd-Hansen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartland, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lew, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, D. C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lessene, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silke, J.</span></span> <span> </span><span class="NLM_article-title">A RIPK2 inhibitor delays NOD signalling events yet prevents inflammatory cytokine production</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">6442</span>– <span class="NLM_lpage">6455</span>, <span class="refDoi"> DOI: 10.1038/ncomms7442</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1038%2Fncomms7442" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=25778803" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2MXosFeltr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=6442-6455&author=U.+Nachburauthor=C.+A.+Staffordauthor=A.+Bankovackiauthor=Y.+Zhanauthor=L.+M.+Lindqvistauthor=B.+K.+Fiilauthor=Y.+Khakhamauthor=H.-J.+Koauthor=J.+J.+Sandowauthor=H.+Falkauthor=J.+K.+Holienauthor=D.+Chauauthor=J.+Hildebrandauthor=J.+E.+Vinceauthor=P.+P.+Sharpauthor=A.+I.+Webbauthor=K.+A.+Jackmanauthor=S.+M%C3%BChlenauthor=C.+L.+Kennedyauthor=K.+N.+Lowesauthor=J.+M.+Murphyauthor=M.+Gyrd-Hansenauthor=M.+W.+Parkerauthor=E.+L.+Hartlandauthor=A.+M.+Lewauthor=D.+C.+S.+Huangauthor=G.+Lesseneauthor=J.+Silke&title=A+RIPK2+inhibitor+delays+NOD+signalling+events+yet+prevents+inflammatory+cytokine+production&doi=10.1038%2Fncomms7442"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">A RIPK2 inhibitor delays NOD signalling events yet prevents inflammatory cytokine production</span></div><div class="casAuthors">Nachbur, Ueli; Stafford, Che A.; Bankovacki, Aleksandra; Zhan, Yifan; Lindqvist, Lisa M.; Fiil, Berthe K.; Khakham, Yelena; Ko, Hyun-Ja; Sandow, Jarrod J.; Falk, Hendrik; Holien, Jessica K.; Chau, Diep; Hildebrand, Joanne; Vince, James E.; Sharp, Phillip P.; Webb, Andrew I.; Jackman, Katherine A.; Muhlen, Sabrina; Kennedy, Catherine L.; Lowes, Kym N.; Murphy, James M.; Gyrd-Hansen, Mads; Parker, Michael W.; Hartland, Elizabeth L.; Lew, Andrew M.; Huang, David C. S.; Lessene, Guillaume; Silke, John</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">6442</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Intracellular nucleotide binding and oligomerization domain (NOD) receptors recognize antigens including bacterial peptidoglycans and initiate immune responses by triggering the prodn. of pro-inflammatory cytokines through activating NF-κB and MAP kinases.  Receptor interacting protein kinase 2 (RIPK2) is crit. for NOD-mediated NF-κB activation and cytokine prodn.  Here we develop and characterize a selective RIPK2 kinase inhibitor, WEHI-345, which delays RIPK2 ubiquitylation and NF-κB activation downstream of NOD engagement.  Despite only delaying NF-κB activation on NOD stimulation, WEHI-345 prevents cytokine prodn. in vitro and in vivo and ameliorates exptl. autoimmune encephalomyelitis in mice.  Our study highlights the importance of the kinase activity of RIPK2 for proper immune responses and demonstrates the therapeutic potential of inhibiting RIPK2 in NOD-driven inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUTcBfWapFu7Vg90H21EOLACvtfcHk0limgH7G0MjuuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXosFeltr4%253D&md5=d3e10fa28b4c5187e75085abc9d4a01b</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1038%2Fncomms7442&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms7442%26sid%3Dliteratum%253Aachs%26aulast%3DNachbur%26aufirst%3DU.%26aulast%3DStafford%26aufirst%3DC.%2BA.%26aulast%3DBankovacki%26aufirst%3DA.%26aulast%3DZhan%26aufirst%3DY.%26aulast%3DLindqvist%26aufirst%3DL.%2BM.%26aulast%3DFiil%26aufirst%3DB.%2BK.%26aulast%3DKhakham%26aufirst%3DY.%26aulast%3DKo%26aufirst%3DH.-J.%26aulast%3DSandow%26aufirst%3DJ.%2BJ.%26aulast%3DFalk%26aufirst%3DH.%26aulast%3DHolien%26aufirst%3DJ.%2BK.%26aulast%3DChau%26aufirst%3DD.%26aulast%3DHildebrand%26aufirst%3DJ.%26aulast%3DVince%26aufirst%3DJ.%2BE.%26aulast%3DSharp%26aufirst%3DP.%2BP.%26aulast%3DWebb%26aufirst%3DA.%2BI.%26aulast%3DJackman%26aufirst%3DK.%2BA.%26aulast%3DM%25C3%25BChlen%26aufirst%3DS.%26aulast%3DKennedy%26aufirst%3DC.%2BL.%26aulast%3DLowes%26aufirst%3DK.%2BN.%26aulast%3DMurphy%26aufirst%3DJ.%2BM.%26aulast%3DGyrd-Hansen%26aufirst%3DM.%26aulast%3DParker%26aufirst%3DM.%2BW.%26aulast%3DHartland%26aufirst%3DE.%2BL.%26aulast%3DLew%26aufirst%3DA.%2BM.%26aulast%3DHuang%26aufirst%3DD.%2BC.%2BS.%26aulast%3DLessene%26aufirst%3DG.%26aulast%3DSilke%26aufirst%3DJ.%26atitle%3DA%2520RIPK2%2520inhibitor%2520delays%2520NOD%2520signalling%2520events%2520yet%2520prevents%2520inflammatory%2520cytokine%2520production%26jtitle%3DNat.%2520Commun.%26date%3D2015%26volume%3D6%26spage%3D6442%26epage%3D6455%26doi%3D10.1038%2Fncomms7442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Estrada, A. A.</span>; <span class="NLM_string-name">Feng, J. A.</span>; <span class="NLM_string-name">Fox, B.</span>; <span class="NLM_string-name">Leslie, C. P.</span>; <span class="NLM_string-name">Lyssikatos, J. P.</span>; <span class="NLM_string-name">Pozzan, A.</span>; <span class="NLM_string-name">Sweeney, Z. K.</span>; <span class="NLM_string-name">Fidalgo, J. D. V.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of Receptor-Interacting Protein Kinase 1</span>. <span class="NLM_patent">WO2017136727</span>, Feb 3, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=A.+A.+Estrada&author=J.+A.+Feng&author=B.+Fox&author=C.+P.+Leslie&author=J.+P.+Lyssikatos&author=A.+Pozzan&author=Z.+K.+Sweeney&author=J.+D.+V.+Fidalgo&title=Inhibitors+of+Receptor-Interacting+Protein+Kinase+1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DEstrada%26aufirst%3DA.%2BA.%26atitle%3DInhibitors%2520of%2520Receptor-Interacting%2520Protein%2520Kinase%25201%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hart, A. C.</span>; <span class="NLM_string-name">Pitts, W. J.</span>; <span class="NLM_string-name">Mastalerz, H.</span>; <span class="NLM_string-name">Guo, J.</span>; <span class="NLM_string-name">Brown, G. D.</span></span> <span> </span><span class="NLM_article-title">Substituted Dihydro-1H-pyrrolo[3,2-c]pyridin-4(5H)-ones as RIPK3 Inhibitors</span>. <span class="NLM_patent">WO2016100166</span>, Dec 14, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=A.+C.+Hart&author=W.+J.+Pitts&author=H.+Mastalerz&author=J.+Guo&author=G.+D.+Brown&title=Substituted+Dihydro-1H-pyrrolo%5B3%2C2-c%5Dpyridin-4%285H%29-ones+as+RIPK3+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHart%26aufirst%3DA.%2BC.%26atitle%3DSubstituted%2520Dihydro-1H-pyrrolo%255B3%252C2-c%255Dpyridin-4%25285H%2529-ones%2520as%2520RIPK3%2520Inhibitors%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bonanomi, G.</span>; <span class="NLM_string-name">Estrada, A. A.</span>; <span class="NLM_string-name">Feng, J. A.</span>; <span class="NLM_string-name">Fox, B.</span>; <span class="NLM_string-name">Leslie, C. P.</span>; <span class="NLM_string-name">Lyssikatos, J. P.</span>; <span class="NLM_string-name">Napolitano, C.</span>; <span class="NLM_string-name">Pozzan, A.</span>; <span class="NLM_string-name">Sudhakar, A.</span>; <span class="NLM_string-name">Sweeney, Z. K.</span>; <span class="NLM_string-name">Tonelli, F.</span>; <span class="NLM_string-name">Fidalgo, J. D. V.</span></span> <span> </span><span class="NLM_article-title">Isoxazolidine Derived Inhibitors of Receptor Interacting Protein Kinase 1 (RIPK 1)</span>. <span class="NLM_patent">WO2017096301</span>, Dec 2, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=G.+Bonanomi&author=A.+A.+Estrada&author=J.+A.+Feng&author=B.+Fox&author=C.+P.+Leslie&author=J.+P.+Lyssikatos&author=C.+Napolitano&author=A.+Pozzan&author=A.+Sudhakar&author=Z.+K.+Sweeney&author=F.+Tonelli&author=J.+D.+V.+Fidalgo&title=Isoxazolidine+Derived+Inhibitors+of+Receptor+Interacting+Protein+Kinase+1+%28RIPK+1%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBonanomi%26aufirst%3DG.%26atitle%3DIsoxazolidine%2520Derived%2520Inhibitors%2520of%2520Receptor%2520Interacting%2520Protein%2520Kinase%25201%2520%2528RIPK%25201%2529%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moriwaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, F. K.-M.</span></span> <span> </span><span class="NLM_article-title">Necroptosis-independent signaling by the RIP kinases in inflammation</span>. <i>Cell. Mol. Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">2325</span>– <span class="NLM_lpage">2334</span>, <span class="refDoi"> DOI: 10.1007/s00018-016-2203-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1007%2Fs00018-016-2203-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=27048814" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC28XlsValurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2016&pages=2325-2334&author=K.+Moriwakiauthor=F.+K.-M.+Chan&title=Necroptosis-independent+signaling+by+the+RIP+kinases+in+inflammation&doi=10.1007%2Fs00018-016-2203-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Necroptosis-independent signaling by the RIP kinases in inflammation</span></div><div class="casAuthors">Moriwaki, Kenta; Chan, Francis Ka-Ming</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">11-12</span>),
    <span class="NLM_cas:pages">2325-2334</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Basel</span>)
        </div><div class="casAbstract">Recent advances have identified a signaling cascade involving receptor interacting protein kinase 1 (RIPK1), RIPK3 and the pseudokinase mixed lineage kinase domain-like (MLKL) that is crucial for induction of necroptosis, a non-apoptotic form of cell death.  RIPK1-RIPK3-MLKL-mediated necroptosis has been attributed to cause many inflammatory diseases through the release of cellular damage-assocd. mol. patterns (DAMPs).  In addn. to necroptosis, emerging evidence suggests that these necroptosis signal adaptors can also facilitate inflammation independent of cell death.  In particular, the RIP kinases can drive NF-κB and inflammasome activation independent of cell death.  In this review, we will discuss recent discoveries that led to this realization and present arguments why cell death-independent signaling by the RIP kinases may have a more important role in inflammation than necroptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6wW0-uJ6xhbVg90H21EOLACvtfcHk0lgVCLTZa_nt5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlsValurs%253D&md5=8ba1cc7565ca54604626eb5d030dce48</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1007%2Fs00018-016-2203-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-016-2203-4%26sid%3Dliteratum%253Aachs%26aulast%3DMoriwaki%26aufirst%3DK.%26aulast%3DChan%26aufirst%3DF.%2BK.-M.%26atitle%3DNecroptosis-independent%2520signaling%2520by%2520the%2520RIP%2520kinases%2520in%2520inflammation%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2016%26volume%3D73%26spage%3D2325%26epage%3D2334%26doi%3D10.1007%2Fs00018-016-2203-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mandal, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pillay, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriwaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lich, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasparcova, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Votta, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouellette, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wisnoski, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakdawala, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMartino, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casillas, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haile, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sehon, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marquis, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Upton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daley-Bauer, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roback, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramia, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dovey, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carette, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gough, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mocarski, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaiser, W. J.</span></span> <span> </span><span class="NLM_article-title">RIP3 induces apoptosis independent of pro-necrotic kinase activity</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">481</span>– <span class="NLM_lpage">495</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2014.10.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1016%2Fj.molcel.2014.10.021" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2014&pages=481-495&author=P.+Mandalauthor=S.+B.+Bergerauthor=S.+Pillayauthor=K.+Moriwakiauthor=C.+Huangauthor=H.+Guoauthor=J.+D.+Lichauthor=J.+Fingerauthor=V.+Kasparcovaauthor=B.+Vottaauthor=M.+Ouelletteauthor=B.+W.+Kingauthor=D.+Wisnoskiauthor=A.+S.+Lakdawalaauthor=M.+P.+DeMartinoauthor=L.+N.+Casillasauthor=P.+A.+Haileauthor=C.+A.+Sehonauthor=R.+W.+Marquisauthor=J.+Uptonauthor=L.+P.+Daley-Bauerauthor=L.+Robackauthor=N.+Ramiaauthor=C.+M.+Doveyauthor=J.+E.+Caretteauthor=F.+Chanauthor=J.+Bertinauthor=P.+J.+Goughauthor=E.+S.+Mocarskiauthor=W.+J.+Kaiser&title=RIP3+induces+apoptosis+independent+of+pro-necrotic+kinase+activity&doi=10.1016%2Fj.molcel.2014.10.021"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2014.10.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2014.10.021%26sid%3Dliteratum%253Aachs%26aulast%3DMandal%26aufirst%3DP.%26aulast%3DBerger%26aufirst%3DS.%2BB.%26aulast%3DPillay%26aufirst%3DS.%26aulast%3DMoriwaki%26aufirst%3DK.%26aulast%3DHuang%26aufirst%3DC.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DLich%26aufirst%3DJ.%2BD.%26aulast%3DFinger%26aufirst%3DJ.%26aulast%3DKasparcova%26aufirst%3DV.%26aulast%3DVotta%26aufirst%3DB.%26aulast%3DOuellette%26aufirst%3DM.%26aulast%3DKing%26aufirst%3DB.%2BW.%26aulast%3DWisnoski%26aufirst%3DD.%26aulast%3DLakdawala%26aufirst%3DA.%2BS.%26aulast%3DDeMartino%26aufirst%3DM.%2BP.%26aulast%3DCasillas%26aufirst%3DL.%2BN.%26aulast%3DHaile%26aufirst%3DP.%2BA.%26aulast%3DSehon%26aufirst%3DC.%2BA.%26aulast%3DMarquis%26aufirst%3DR.%2BW.%26aulast%3DUpton%26aufirst%3DJ.%26aulast%3DDaley-Bauer%26aufirst%3DL.%2BP.%26aulast%3DRoback%26aufirst%3DL.%26aulast%3DRamia%26aufirst%3DN.%26aulast%3DDovey%26aufirst%3DC.%2BM.%26aulast%3DCarette%26aufirst%3DJ.%2BE.%26aulast%3DChan%26aufirst%3DF.%26aulast%3DBertin%26aufirst%3DJ.%26aulast%3DGough%26aufirst%3DP.%2BJ.%26aulast%3DMocarski%26aufirst%3DE.%2BS.%26aulast%3DKaiser%26aufirst%3DW.%2BJ.%26atitle%3DRIP3%2520induces%2520apoptosis%2520independent%2520of%2520pro-necrotic%2520kinase%2520activity%26jtitle%3DMol.%2520Cell%26date%3D2014%26volume%3D56%26spage%3D481%26epage%3D495%26doi%3D10.1016%2Fj.molcel.2014.10.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mendoza, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Er, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blenis, J.</span></span> <span> </span><span class="NLM_article-title">The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation</span>. <i>Trends Biochem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">320</span>– <span class="NLM_lpage">328</span>, <span class="refDoi"> DOI: 10.1016/j.tibs.2011.03.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1016%2Fj.tibs.2011.03.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=21531565" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnsVOqs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2011&pages=320-328&author=M.+C.+Mendozaauthor=E.+E.+Erauthor=J.+Blenis&title=The+Ras-ERK+and+PI3K-mTOR+pathways%3A+cross-talk+and+compensation&doi=10.1016%2Fj.tibs.2011.03.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation</span></div><div class="casAuthors">Mendoza, Michelle C.; Er, E. Emrah; Blenis, John</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Biochemical Sciences</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">320-328</span>CODEN:
                <span class="NLM_cas:coden">TBSCDB</span>;
        ISSN:<span class="NLM_cas:issn">0968-0004</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The Ras-extracellular signal-regulated kinase (Ras-ERK) and phosphatidylinositol 3-kinase-mammalian target of rapamycin (PI3K-mTOR) signaling pathways are the chief mechanisms for controlling cell survival, differentiation, proliferation, metab., and motility in response to extracellular cues.  Components of these pathways were among the first to be discovered when scientists began cloning proto-oncogenes and purifying cellular kinase activities in the 1980s.  Ras-ERK and PI3K-mTOR were originally modeled as linear signaling conduits activated by different stimuli, yet even early expts. hinted that they might intersect to regulate each other and co-regulate downstream functions.  The extent of this cross-talk and its significance in cancer therapeutics are now becoming clear.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-3LOfCYc7_bVg90H21EOLACvtfcHk0lgVCLTZa_nt5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnsVOqs7k%253D&md5=d7d9938e5311b23932d23ef5379d6b12</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1016%2Fj.tibs.2011.03.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tibs.2011.03.006%26sid%3Dliteratum%253Aachs%26aulast%3DMendoza%26aufirst%3DM.%2BC.%26aulast%3DEr%26aufirst%3DE.%2BE.%26aulast%3DBlenis%26aufirst%3DJ.%26atitle%3DThe%2520Ras-ERK%2520and%2520PI3K-mTOR%2520pathways%253A%2520cross-talk%2520and%2520compensation%26jtitle%3DTrends%2520Biochem.%2520Sci.%26date%3D2011%26volume%3D36%26spage%3D320%26epage%3D328%26doi%3D10.1016%2Fj.tibs.2011.03.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sutherlin, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bisconte, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaney, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chantry, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castanedo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DePledge, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldsmith, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hancox, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knowles, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondru, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesnick, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadin, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonomiya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pegg, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safina, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salphati, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staben, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seward, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuttleworth, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sohal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, Z. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ultsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waszkowycz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B.</span></span> <span> </span><span class="NLM_article-title">Potent and selective inhibitors of PI3Kδ: Obtaining isoform selectivity from the affinity pocket and tryptophan shelf</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">4296</span>– <span class="NLM_lpage">4302</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.05.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1016%2Fj.bmcl.2012.05.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=22672799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC38XotVegur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=4296-4302&author=D.+P.+Sutherlinauthor=S.+Bakerauthor=A.+Bisconteauthor=P.+M.+Blaneyauthor=A.+Brownauthor=B.+K.+Chanauthor=D.+Chantryauthor=G.+Castanedoauthor=P.+DePledgeauthor=P.+Goldsmithauthor=D.+M.+Goldsteinauthor=T.+Hancoxauthor=J.+Kaurauthor=D.+Knowlesauthor=R.+Kondruauthor=J.+Lesnickauthor=M.+C.+Lucasauthor=C.+Lewisauthor=J.+Murrayauthor=A.+J.+Nadinauthor=J.+Nonomiyaauthor=J.+Pangauthor=N.+Peggauthor=S.+Priceauthor=K.+Reifauthor=B.+S.+Safinaauthor=L.+Salphatiauthor=S.+Stabenauthor=E.+M.+Sewardauthor=S.+Shuttleworthauthor=S.+Sohalauthor=Z.+K.+Sweeneyauthor=M.+Ultschauthor=B.+Waszkowyczauthor=B.+Wei&title=Potent+and+selective+inhibitors+of+PI3K%CE%B4%3A+Obtaining+isoform+selectivity+from+the+affinity+pocket+and+tryptophan+shelf&doi=10.1016%2Fj.bmcl.2012.05.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and selective inhibitors of PI3Kδ: Obtaining isoform selectivity from the affinity pocket and tryptophan shelf</span></div><div class="casAuthors">Sutherlin, Daniel P.; Baker, Stewart; Bisconte, Angelina; Blaney, Paul M.; Brown, Anthony; Chan, Bryan K.; Chantry, David; Castanedo, Georgette; DePledge, Paul; Goldsmith, Paul; Goldstein, David M.; Hancox, Timothy; Kaur, Jasmit; Knowles, David; Kondru, Rama; Lesnick, John; Lucas, Matthew C.; Lewis, Cristina; Murray, Jeremy; Nadin, Alan J.; Nonomiya, Jim; Pang, Jodie; Pegg, Neil; Price, Steve; Reif, Karin; Safina, Brian S.; Salphati, Laurent; Staben, Steven; Seward, Eileen M.; Shuttleworth, Stephen; Sohal, Sukhjit; Sweeney, Zachary K.; Ultsch, Mark; Waszkowycz, Bohdan; Wei, Binqing</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4296-4302</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A potent inhibitor of PI3Kδ that is ≥200 fold selective for the remaining three Class I PI3K isoforms and addnl. kinases is described.  The hypothesis for selectivity is illustrated through structure activity relationships and crystal structures of compds. bound to a K802T mutant of PI3Kγ.  Pharmacokinetic data in rats and mice support the use of 3 as a useful tool compd. to use for in vivo studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaSfg4K5zqbLVg90H21EOLACvtfcHk0lhQ14rbzLHSiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XotVegur0%253D&md5=d15c7cd8ce626cc5e9a13ac355557ce8</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.05.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.05.027%26sid%3Dliteratum%253Aachs%26aulast%3DSutherlin%26aufirst%3DD.%2BP.%26aulast%3DBaker%26aufirst%3DS.%26aulast%3DBisconte%26aufirst%3DA.%26aulast%3DBlaney%26aufirst%3DP.%2BM.%26aulast%3DBrown%26aufirst%3DA.%26aulast%3DChan%26aufirst%3DB.%2BK.%26aulast%3DChantry%26aufirst%3DD.%26aulast%3DCastanedo%26aufirst%3DG.%26aulast%3DDePledge%26aufirst%3DP.%26aulast%3DGoldsmith%26aufirst%3DP.%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26aulast%3DHancox%26aufirst%3DT.%26aulast%3DKaur%26aufirst%3DJ.%26aulast%3DKnowles%26aufirst%3DD.%26aulast%3DKondru%26aufirst%3DR.%26aulast%3DLesnick%26aufirst%3DJ.%26aulast%3DLucas%26aufirst%3DM.%2BC.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DNadin%26aufirst%3DA.%2BJ.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPegg%26aufirst%3DN.%26aulast%3DPrice%26aufirst%3DS.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DSafina%26aufirst%3DB.%2BS.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DStaben%26aufirst%3DS.%26aulast%3DSeward%26aufirst%3DE.%2BM.%26aulast%3DShuttleworth%26aufirst%3DS.%26aulast%3DSohal%26aufirst%3DS.%26aulast%3DSweeney%26aufirst%3DZ.%2BK.%26aulast%3DUltsch%26aufirst%3DM.%26aulast%3DWaszkowycz%26aufirst%3DB.%26aulast%3DWei%26aufirst%3DB.%26atitle%3DPotent%2520and%2520selective%2520inhibitors%2520of%2520PI3K%25CE%25B4%253A%2520Obtaining%2520isoform%2520selectivity%2520from%2520the%2520affinity%2520pocket%2520and%2520tryptophan%2520shelf%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D4296%26epage%3D4302%26doi%3D10.1016%2Fj.bmcl.2012.05.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rommel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camps, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, H.</span></span> <span> </span><span class="NLM_article-title">PI3Kδ and PI3Kγ: partners in crime in inflammation in rheumatoid arthritis and beyond?</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">191</span>, <span class="refDoi"> DOI: 10.1038/nri2036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1038%2Fnri2036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=17290298" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitVGrtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=191&author=C.+Rommelauthor=M.+Campsauthor=H.+Ji&title=PI3K%CE%B4+and+PI3K%CE%B3%3A+partners+in+crime+in+inflammation+in+rheumatoid+arthritis+and+beyond%3F&doi=10.1038%2Fnri2036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">PI3Kδ and PI3Kγ: partners in crime in inflammation in rheumatoid arthritis and beyond?</span></div><div class="casAuthors">Rommel, Christian; Camps, Montserrat; Ji, Hong</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">191-201</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Dysregulated signal transduction in innate and adaptive immune cells is known to be assocd. with the development of various autoimmune and inflammatory diseases.  Consequently, targeting intracellular signaling of the pro-inflammatory cytokine network heralds hope for the next generation of anti-inflammatory drugs.  Phosphoinositide 3-kinases (PI3Ks) generate lipid-based second messengers that control an array of intracellular signaling pathways that are known to have important roles in leukocytes.  In light of the recent progress in the development of selective PI3K inhibitors, and the beneficial effects of these inhibitors in models of acute and chronic inflammatory disorders, the authors discuss the therapeutic potential of blocking PI3K isoforms for the treatment of rheumatoid arthritis and other immune-mediated diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKSAduhwUrPrVg90H21EOLACvtfcHk0lhQ14rbzLHSiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitVGrtbk%253D&md5=2fdb3507d06ddf7d5485185f4573790f</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1038%2Fnri2036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri2036%26sid%3Dliteratum%253Aachs%26aulast%3DRommel%26aufirst%3DC.%26aulast%3DCamps%26aufirst%3DM.%26aulast%3DJi%26aufirst%3DH.%26atitle%3DPI3K%25CE%25B4%2520and%2520PI3K%25CE%25B3%253A%2520partners%2520in%2520crime%2520in%2520inflammation%2520in%2520rheumatoid%2520arthritis%2520and%2520beyond%253F%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2007%26volume%3D7%26spage%3D191%26doi%3D10.1038%2Fnri2036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dienstmann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serra, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabernero, J.</span></span> <span> </span><span class="NLM_article-title">Picking the point of inhibition: A comparative review of PI3K/AKT/mTOR pathway inhibitors</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1021</span>– <span class="NLM_lpage">1031</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0639</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1158%2F1535-7163.MCT-13-0639" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=24748656" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnsFWjs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=1021-1031&author=R.+Dienstmannauthor=J.+Rodonauthor=V.+Serraauthor=J.+Tabernero&title=Picking+the+point+of+inhibition%3A+A+comparative+review+of+PI3K%2FAKT%2FmTOR+pathway+inhibitors&doi=10.1158%2F1535-7163.MCT-13-0639"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors</span></div><div class="casAuthors">Dienstmann, Rodrigo; Rodon, Jordi; Serra, Violeta; Tabernero, Josep</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1021-1031</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The frequent activation of the PI3K/AKT/mTOR pathway in cancer, and its crucial role in cell growth and survival, has made it a much desired target for pharmacol. intervention.  Following the regulatory approval of the rapamycin analogs everolimus and temsirolimus, recent years have seen an explosion in the no. of phosphoinositide 3-kinase (PI3K) pathway inhibitors under clin. investigation.  These include: ATP-competitive, dual inhibitors of class I PI3K and mTORC1/2; "pan-PI3K" inhibitors, which inhibit all four isoforms of class I PI3K (α, β, δ, γ); isoform-specific inhibitors of the various PI3K isoforms; allosteric and catalytic inhibitors of AKT; and ATP-competitive inhibitors of mTOR only (and thus mTORC1 and mTORC2).  With so many agents in development, clinicians are currently faced with a wide array of clin. trials investigating a multitude of inhibitors with different mechanisms of action, being used both as single agents and in combination with other therapies.  Here, we provide a review of the literature, with the aim of differentiating the genomic contexts in which these various types of inhibitors may potentially have superior activity.  Mol Cancer Ther; 13(5); 1021-31. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3McPbkS5dm7Vg90H21EOLACvtfcHk0lhQ14rbzLHSiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnsFWjs78%253D&md5=7b5ef12e83be522233ad403ce3040719</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0639&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0639%26sid%3Dliteratum%253Aachs%26aulast%3DDienstmann%26aufirst%3DR.%26aulast%3DRodon%26aufirst%3DJ.%26aulast%3DSerra%26aufirst%3DV.%26aulast%3DTabernero%26aufirst%3DJ.%26atitle%3DPicking%2520the%2520point%2520of%2520inhibition%253A%2520A%2520comparative%2520review%2520of%2520PI3K%252FAKT%252FmTOR%2520pathway%2520inhibitors%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D1021%26epage%3D1031%26doi%3D10.1158%2F1535-7163.MCT-13-0639" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref170"><div class="reference"><strong class="refLabel"><a href="#ref170" class="rightTabRefNumLink">170</a></strong><div class="NLM_citation" id="rightTab-cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arthur, J. S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ley, S. C.</span></span> <span> </span><span class="NLM_article-title">Mitogen-activated protein kinases in innate immunity</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">679</span>– <span class="NLM_lpage">692</span>, <span class="refDoi"> DOI: 10.1038/nri3495</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1038%2Fnri3495" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=23954936" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1yltrjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=679-692&author=J.+S.+C.+Arthurauthor=S.+C.+Ley&title=Mitogen-activated+protein+kinases+in+innate+immunity&doi=10.1038%2Fnri3495"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Mitogen-activated protein kinases in innate immunity</span></div><div class="casAuthors">Arthur, J. Simon C.; Ley, Steven C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">679-692</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Following pathogen infection or tissue damage, the stimulation of pattern recognition receptors on the cell surface and in the cytoplasm of innate immune cells activates members of each of the major mitogen-activated protein kinase (MAPK) subfamilies - the extracellular signal-regulated kinase (ERK), p38 and Jun N-terminal kinase (JNK) subfamilies.  In conjunction with the activation of nuclear factor-κB and interferon-regulatory factor transcription factors, MAPK activation induces the expression of multiple genes that together regulate the inflammatory response.  In this Review, we discuss our current knowledge about the regulation and the function of MAPKs in innate immunity, as well as the importance of neg. feedback loops in limiting MAPK activity to prevent host tissue damage.  We also examine how pathogens have evolved complex mechanisms to manipulate MAPK activation to increase their virulence.  Finally, we consider the potential of the pharmacol. targeting of MAPK pathways to treat autoimmune and inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokaFaArJ0-rLVg90H21EOLACvtfcHk0lhE3R2O2jXhEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1yltrjI&md5=385a2fc463805b41ec03296345fb5d86</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1038%2Fnri3495&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri3495%26sid%3Dliteratum%253Aachs%26aulast%3DArthur%26aufirst%3DJ.%2BS.%2BC.%26aulast%3DLey%26aufirst%3DS.%2BC.%26atitle%3DMitogen-activated%2520protein%2520kinases%2520in%2520innate%2520immunity%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2013%26volume%3D13%26spage%3D679%26epage%3D692%26doi%3D10.1038%2Fnri3495" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref171"><div class="reference"><strong class="refLabel"><a href="#ref171" class="rightTabRefNumLink">171</a></strong><div class="NLM_citation" id="rightTab-cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xing, L.</span></span> <span> </span><span class="NLM_article-title">Clinical candidates of small molecule p38 MAPK inhibitors for inflammatory diseases</span>. <i>MAP Kinase</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">24</span>– <span class="NLM_lpage">30</span>, <span class="refDoi"> DOI: 10.4081/mk.2015.5508</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.4081%2Fmk.2015.5508" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2015&pages=24-30&author=L.+Xing&title=Clinical+candidates+of+small+molecule+p38+MAPK+inhibitors+for+inflammatory+diseases&doi=10.4081%2Fmk.2015.5508"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.4081%2Fmk.2015.5508&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4081%252Fmk.2015.5508%26sid%3Dliteratum%253Aachs%26aulast%3DXing%26aufirst%3DL.%26atitle%3DClinical%2520candidates%2520of%2520small%2520molecule%2520p38%2520MAPK%2520inhibitors%2520for%2520inflammatory%2520diseases%26jtitle%3DMAP%2520Kinase%26date%3D2015%26volume%3D4%26spage%3D24%26epage%3D30%26doi%3D10.4081%2Fmk.2015.5508" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref172"><div class="reference"><strong class="refLabel"><a href="#ref172" class="rightTabRefNumLink">172</a></strong><div class="NLM_citation" id="rightTab-cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hope, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burnette, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Compton, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devraj, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsch, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keith, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mbalaviele, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messing, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saabye, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schindler, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selness, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stillwell, L. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monahan, J. B.</span></span> <span> </span><span class="NLM_article-title">Anti-inflammatory properties of a novel N-phenyl pyridinone inhibitor of p38 mitogen-activated protein kinase: preclinical-to-clinical translation</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>331</i></span>,  <span class="NLM_fpage">882</span>– <span class="NLM_lpage">895</span>, <span class="refDoi"> DOI: 10.1124/jpet.109.158329</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1124%2Fjpet.109.158329" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=19720877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFaqsL3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=331&publication_year=2009&pages=882-895&author=H.+R.+Hopeauthor=G.+D.+Andersonauthor=B.+L.+Burnetteauthor=R.+P.+Comptonauthor=R.+V.+Devrajauthor=J.+L.+Hirschauthor=R.+H.+Keithauthor=X.+Liauthor=G.+Mbalavieleauthor=D.+M.+Messingauthor=M.+J.+Saabyeauthor=J.+F.+Schindlerauthor=S.+R.+Selnessauthor=L.+I.+Stillwellauthor=E.+G.+Webbauthor=J.+Zhangauthor=J.+B.+Monahan&title=Anti-inflammatory+properties+of+a+novel+N-phenyl+pyridinone+inhibitor+of+p38+mitogen-activated+protein+kinase%3A+preclinical-to-clinical+translation&doi=10.1124%2Fjpet.109.158329"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-inflammatory properties of a novel N-phenylpyridinone inhibitor of p38 mitogen-activated protein kinase: preclinical-to-clinical translation</span></div><div class="casAuthors">Hope, Heidi R.; Anderson, Gary D.; Burnette, Barry L.; Compton, Robert P.; Devraj, Rajesh V.; Hirsch, Jeffrey L.; Keith, Robert H.; Li, Xiong; Mbalaviele, Gabriel; Messing, Dean M.; Saabye, Matthew J.; Schindler, John F.; Selness, Shaun R.; Stillwell, Loreen I.; Webb, Elizabeth G.; Zhang, Jian; Monahan, Joseph B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">331</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">882-895</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Signal transduction through the p38 mitogen-activated protein (MAP) kinase pathway is central to the transcriptional and translational control of cytokine and inflammatory mediator prodn.  P38 MAP kinase inhibition hence constitutes a promising therapeutic strategy for treatment of chronic inflammatory diseases, based upon its potential to inhibit key pathways driving the inflammatory and destructive processes in these debilitating diseases.  The present study describes the pharmacol. properties of the N-phenylpyridinone p38 MAP kinase inhibitor benzamide [3-[3-bromo-4-[(2,4-difluorophenyl)methoxy]-6-methyl-2-oxo-1(2H)-pyridinyl]-N,4-dimethyl-, (-)-(9CI); PH-797804].  PH-797804 is an ATP-competitive, readily reversible inhibitor of the α isoform of human p38 MAP kinase, exhibiting a Ki = 5.8 nM.  In human monocyte and synovial fibroblast cell systems, PH-797804 blocks inflammation-induced prodn. of cytokines and proinflammatory mediators, such as prostaglandin E2, at concns. that parallel inhibition of cell-assocd. p38 MAP kinase.  After oral dosing, PH-797804 effectively inhibits acute inflammatory responses induced by systemically administered endotoxin in both rat and cynomolgus monkeys.  Furthermore, PH-797804 demonstrates robust anti-inflammatory activity in chronic disease models, significantly reducing both joint inflammation and assocd. bone loss in streptococcal cell wall-induced arthritis in rats and mouse collagen-induced arthritis.  Finally, PH-797804 reduced tumor necrosis factor-α and interleukin-6 prodn. in clin. studies after endotoxin administration in a dose-dependent manner, paralleling inhibition of the target enzyme.  Low-nanomolar biochem. enzyme inhibition potency correlated with p38 MAP kinase inhibition in human cells and in vivo studies.  In addn., a direct correspondence between p38 MAP kinase inhibition and anti-inflammatory activity was obsd. with PH-797804, thus providing confidence in dose projections for further human studies in chronic inflammatory disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr29aqHR77fj7Vg90H21EOLACvtfcHk0lhE3R2O2jXhEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFaqsL3K&md5=6b5455e9080767dd56b27d8a880f71c1</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1124%2Fjpet.109.158329&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.109.158329%26sid%3Dliteratum%253Aachs%26aulast%3DHope%26aufirst%3DH.%2BR.%26aulast%3DAnderson%26aufirst%3DG.%2BD.%26aulast%3DBurnette%26aufirst%3DB.%2BL.%26aulast%3DCompton%26aufirst%3DR.%2BP.%26aulast%3DDevraj%26aufirst%3DR.%2BV.%26aulast%3DHirsch%26aufirst%3DJ.%2BL.%26aulast%3DKeith%26aufirst%3DR.%2BH.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DMbalaviele%26aufirst%3DG.%26aulast%3DMessing%26aufirst%3DD.%2BM.%26aulast%3DSaabye%26aufirst%3DM.%2BJ.%26aulast%3DSchindler%26aufirst%3DJ.%2BF.%26aulast%3DSelness%26aufirst%3DS.%2BR.%26aulast%3DStillwell%26aufirst%3DL.%2BI.%26aulast%3DWebb%26aufirst%3DE.%2BG.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DMonahan%26aufirst%3DJ.%2BB.%26atitle%3DAnti-inflammatory%2520properties%2520of%2520a%2520novel%2520N-phenyl%2520pyridinone%2520inhibitor%2520of%2520p38%2520mitogen-activated%2520protein%2520kinase%253A%2520preclinical-to-clinical%2520translation%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2009%26volume%3D331%26spage%3D882%26epage%3D895%26doi%3D10.1124%2Fjpet.109.158329" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref173"><div class="reference"><strong class="refLabel"><a href="#ref173" class="rightTabRefNumLink">173</a></strong><div class="NLM_citation" id="rightTab-cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunoosamy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegelund-Myrback, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pehrson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taib, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenaway, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siew, L.</span></span> <span> </span><span class="NLM_article-title">AZD7624, an inhaled p38 inhibitor for COPD, attenuates lung and systemic inflammation after LPS challenge in humans</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">OA483</span>, <span class="refDoi"> DOI: 10.1183/13993003.congress-2015.OA483</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1183%2F13993003.congress-2015.OA483" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2015&pages=OA483&author=N.+Patelauthor=D.+Cunoosamyauthor=T.+Hegelund-Myrbackauthor=R.+Pehrsonauthor=Z.+Taibauthor=P.+Janssonauthor=S.+Lundinauthor=S.+Greenawayauthor=G.+Clarkeauthor=L.+Siew&title=AZD7624%2C+an+inhaled+p38+inhibitor+for+COPD%2C+attenuates+lung+and+systemic+inflammation+after+LPS+challenge+in+humans&doi=10.1183%2F13993003.congress-2015.OA483"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1183%2F13993003.congress-2015.OA483&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F13993003.congress-2015.OA483%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DN.%26aulast%3DCunoosamy%26aufirst%3DD.%26aulast%3DHegelund-Myrback%26aufirst%3DT.%26aulast%3DPehrson%26aufirst%3DR.%26aulast%3DTaib%26aufirst%3DZ.%26aulast%3DJansson%26aufirst%3DP.%26aulast%3DLundin%26aufirst%3DS.%26aulast%3DGreenaway%26aufirst%3DS.%26aulast%3DClarke%26aufirst%3DG.%26aulast%3DSiew%26aufirst%3DL.%26atitle%3DAZD7624%252C%2520an%2520inhaled%2520p38%2520inhibitor%2520for%2520COPD%252C%2520attenuates%2520lung%2520and%2520systemic%2520inflammation%2520after%2520LPS%2520challenge%2520in%2520humans%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2015%26volume%3D46%26spage%3DOA483%26doi%3D10.1183%2F13993003.congress-2015.OA483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref174"><div class="reference"><strong class="refLabel"><a href="#ref174" class="rightTabRefNumLink">174</a></strong><div class="NLM_citation" id="rightTab-cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walter, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wentsch, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bührmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Döring, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer-Wrangowski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sievers-Engler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willemsen-Seegers, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaman, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buijsman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lämmerhofer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S. A.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of novel type I1/2 p38α MAP kinase inhibitors with excellent selectivity, high potency, and prolonged target residence time by interfering with the R-spine</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">8027</span>– <span class="NLM_lpage">8054</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00745</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00745" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlOksb3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=8027-8054&author=N.+M.+Walterauthor=H.+K.+Wentschauthor=M.+B%C3%BChrmannauthor=S.+M.+Bauerauthor=E.+D%C3%B6ringauthor=S.+Mayer-Wrangowskiauthor=A.+Sievers-Englerauthor=N.+Willemsen-Seegersauthor=G.+Zamanauthor=R.+Buijsmanauthor=M.+L%C3%A4mmerhoferauthor=D.+Rauhauthor=S.+A.+Laufer&title=Design%2C+synthesis%2C+and+biological+evaluation+of+novel+type+I1%2F2+p38%CE%B1+MAP+kinase+inhibitors+with+excellent+selectivity%2C+high+potency%2C+and+prolonged+target+residence+time+by+interfering+with+the+R-spine&doi=10.1021%2Facs.jmedchem.7b00745"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Evaluation of Novel Type I1/2 p38α MAP Kinase Inhibitors with Excellent Selectivity, High Potency, and Prolonged Target Residence Time by Interfering with the R-Spine</span></div><div class="casAuthors">Walter, Niklas M.; Wentsch, Heike K.; Buehrmann, Mike; Bauer, Silke M.; Doering, Eva; Mayer-Wrangowski, Svenja; Sievers-Engler, Adrian; Willemsen-Seegers, Nicole; Zaman, Guido; Buijsman, Rogier; Laemmerhofer, Michael; Rauh, Daniel; Laufer, Stefan A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8027-8054</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We recently reported 1a (skepinone-L) as a type I p38α MAP kinase inhibitor with high potency and excellent selectivity in vitro and in vivo.  However, as a type I inhibitor, it is entirely ATP-competitive and shows just a moderate residence time.  Thus, the scope was to develop a new class of advanced compds. maintaining the structural binding features of skepinone-L scaffold like inducing a glycine flip at the hinge region and occupying both hydrophobic regions I and II.  Extending this scaffold with suitable residues resulted in an interference with the kinase's R-Spine.  By synthesizing 69 compds., we could significantly prolong the target residence time with one example to 3663 s, along with an excellent selectivity score of 0.006 and an outstanding potency of 1.0 nM.  This new binding mode was validated by cocrystn., showing all binding interactions typifying type I1/2 binding.  Moreover, microsomal studies showed convenient metabolic stability of the most potent, herein reported representatives.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAGz7uVuEJALVg90H21EOLACvtfcHk0limlYoL4tBS4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlOksb3M&md5=99afecb58a5cf1fff6d9a905eb9f3aca</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00745%26sid%3Dliteratum%253Aachs%26aulast%3DWalter%26aufirst%3DN.%2BM.%26aulast%3DWentsch%26aufirst%3DH.%2BK.%26aulast%3DB%25C3%25BChrmann%26aufirst%3DM.%26aulast%3DBauer%26aufirst%3DS.%2BM.%26aulast%3DD%25C3%25B6ring%26aufirst%3DE.%26aulast%3DMayer-Wrangowski%26aufirst%3DS.%26aulast%3DSievers-Engler%26aufirst%3DA.%26aulast%3DWillemsen-Seegers%26aufirst%3DN.%26aulast%3DZaman%26aufirst%3DG.%26aulast%3DBuijsman%26aufirst%3DR.%26aulast%3DL%25C3%25A4mmerhofer%26aufirst%3DM.%26aulast%3DRauh%26aufirst%3DD.%26aulast%3DLaufer%26aufirst%3DS.%2BA.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520novel%2520type%2520I1%252F2%2520p38%25CE%25B1%2520MAP%2520kinase%2520inhibitors%2520with%2520excellent%2520selectivity%252C%2520high%2520potency%252C%2520and%2520prolonged%2520target%2520residence%2520time%2520by%2520interfering%2520with%2520the%2520R-spine%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D8027%26epage%3D8054%26doi%3D10.1021%2Facs.jmedchem.7b00745" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref175"><div class="reference"><strong class="refLabel"><a href="#ref175" class="rightTabRefNumLink">175</a></strong><div class="NLM_citation" id="rightTab-cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Millan, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunnage, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butcher, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodd, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairman, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilty, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemaitre, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewthwaite, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahnke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathias, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philip, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefaniak, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeadon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, C.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of inhaled p38 inhibitors for the treatment of chronic obstructive pulmonary disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">7797</span>– <span class="NLM_lpage">7814</span>, <span class="refDoi"> DOI: 10.1021/jm200677b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200677b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlOqu73E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7797-7814&author=D.+S.+Millanauthor=M.+E.+Bunnageauthor=J.+L.+Burrowsauthor=K.+J.+Butcherauthor=P.+G.+Doddauthor=T.+J.+Evansauthor=D.+A.+Fairmanauthor=S.+J.+Hughesauthor=I.+C.+Kiltyauthor=A.+Lemaitreauthor=R.+A.+Lewthwaiteauthor=A.+Mahnkeauthor=J.+P.+Mathiasauthor=J.+Philipauthor=R.+T.+Smithauthor=M.+H.+Stefaniakauthor=M.+Yeadonauthor=C.+Phillips&title=Design+and+synthesis+of+inhaled+p38+inhibitors+for+the+treatment+of+chronic+obstructive+pulmonary+disease&doi=10.1021%2Fjm200677b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Inhaled p38 Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease</span></div><div class="casAuthors">Millan, David S.; Bunnage, Mark E.; Burrows, Jane L.; Butcher, Kenneth J.; Dodd, Peter G.; Evans, Timothy J.; Fairman, David A.; Hughes, Samantha J.; Kilty, Iain C.; Lemaitre, Arnaud; Lewthwaite, Russell A.; Mahnke, Axel; Mathias, John P.; Philip, James; Smith, Robert T.; Stefaniak, Mark H.; Yeadon, Michael; Phillips, Christopher</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7797-7814</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This paper describes the identification and optimization of a novel series of DFG-out binding p38 inhibitors as inhaled agents for the treatment of chronic obstructive pulmonary disease.  Structure based drug design and "inhalation by design" principles have been applied to the optimization of the lead series exemplified by compd. I.  Analogs have been designed to be potent and selective for p38, with an emphasis on slow enzyme dissocn. kinetics to deliver prolonged lung p38 inhibition.  Pharmacokinetic properties were tuned with high intrinsic clearance and low oral bioavailability in mind, to minimize systemic exposure and reduce systemically driven adverse events.  High CYP mediated clearance and glucuronidation were targeted to achieve high intrinsic clearance coupled with multiple routes of clearance to minimize drug-drug interactions.  Furthermore, pharmaceutical properties such as stability, crystallinity, and soly. were considered to ensure compatibility with a dry powder inhaler.  P38 Inhibitor II (PF-03715455) was subsequently identified as a clin. candidate from this series with efficacy and safety profiles confirming its potential as an inhaled agent for the treatment of COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzy5ivwDBL6rVg90H21EOLACvtfcHk0limlYoL4tBS4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlOqu73E&md5=9bc6cccf04a78831f50fb402bf7cb4b1</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1021%2Fjm200677b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200677b%26sid%3Dliteratum%253Aachs%26aulast%3DMillan%26aufirst%3DD.%2BS.%26aulast%3DBunnage%26aufirst%3DM.%2BE.%26aulast%3DBurrows%26aufirst%3DJ.%2BL.%26aulast%3DButcher%26aufirst%3DK.%2BJ.%26aulast%3DDodd%26aufirst%3DP.%2BG.%26aulast%3DEvans%26aufirst%3DT.%2BJ.%26aulast%3DFairman%26aufirst%3DD.%2BA.%26aulast%3DHughes%26aufirst%3DS.%2BJ.%26aulast%3DKilty%26aufirst%3DI.%2BC.%26aulast%3DLemaitre%26aufirst%3DA.%26aulast%3DLewthwaite%26aufirst%3DR.%2BA.%26aulast%3DMahnke%26aufirst%3DA.%26aulast%3DMathias%26aufirst%3DJ.%2BP.%26aulast%3DPhilip%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DR.%2BT.%26aulast%3DStefaniak%26aufirst%3DM.%2BH.%26aulast%3DYeadon%26aufirst%3DM.%26aulast%3DPhillips%26aufirst%3DC.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520inhaled%2520p38%2520inhibitors%2520for%2520the%2520treatment%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7797%26epage%3D7814%26doi%3D10.1021%2Fjm200677b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref176"><div class="reference"><strong class="refLabel"><a href="#ref176" class="rightTabRefNumLink">176</a></strong><div class="NLM_citation" id="rightTab-cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nejentsev, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Condliffe, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okkenhaug, K.</span></span> <span> </span><span class="NLM_article-title">PI3Kδ and primary immunodeficiencies</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">702</span>– <span class="NLM_lpage">714</span>, <span class="refDoi"> DOI: 10.1038/nri.2016.93</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1038%2Fnri.2016.93" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=27616589" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsV2isL3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=702-714&author=C.+L.+Lucasauthor=A.+Chandraauthor=S.+Nejentsevauthor=A.+M.+Condliffeauthor=K.+Okkenhaug&title=PI3K%CE%B4+and+primary+immunodeficiencies&doi=10.1038%2Fnri.2016.93"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">PI3Kδ and primary immunodeficiencies</span></div><div class="casAuthors">Lucas, Carrie L.; Chandra, Anita; Nejentsev, Sergey; Condliffe, Alison M.; Okkenhaug, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">702-714</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Primary immunodeficiencies are inherited disorders of the immune system, often caused by the mutation of genes required for lymphocyte development and activation.  Recently, several studies have identified gain-of-function mutations in the phosphoinositide 3-kinase (PI3K) genes PIK3CD (which encodes p110δ) and PIK3R1 (which encodes p85α) that cause a combined immunodeficiency syndrome, referred to as activated PI3Kδ syndrome (APDS; also known as p110δ-activating mutation causing senescent T cells, lymphadenopathy and immunodeficiency (PASLI)).  Paradoxically, both loss-of-function and gain-of-function mutations that affect these genes lead to immunosuppression, albeit via different mechanisms.  Here, we review the roles of PI3Kδ in adaptive immunity, describe the clin. manifestations and mechanisms of disease in APDS and highlight new insights into PI3Kδ gleaned from these patients, as well as implications of these findings for clin. therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqS1HjXfbEWt7Vg90H21EOLACvtfcHk0liU8Yr31Ajwqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsV2isL3O&md5=c10ce8e59ae67e476bccbefab52213b4</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1038%2Fnri.2016.93&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri.2016.93%26sid%3Dliteratum%253Aachs%26aulast%3DLucas%26aufirst%3DC.%2BL.%26aulast%3DChandra%26aufirst%3DA.%26aulast%3DNejentsev%26aufirst%3DS.%26aulast%3DCondliffe%26aufirst%3DA.%2BM.%26aulast%3DOkkenhaug%26aufirst%3DK.%26atitle%3DPI3K%25CE%25B4%2520and%2520primary%2520immunodeficiencies%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2016%26volume%3D16%26spage%3D702%26epage%3D714%26doi%3D10.1038%2Fnri.2016.93" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref177"><div class="reference"><strong class="refLabel"><a href="#ref177" class="rightTabRefNumLink">177</a></strong><div class="NLM_citation" id="rightTab-cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gross, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, P. J.</span></span> <span> </span><span class="NLM_article-title">New therapies for asthma and chronic obstructive pulmonary disease</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>195</i></span>,  <span class="NLM_fpage">159</span>– <span class="NLM_lpage">166</span>, <span class="refDoi"> DOI: 10.1164/rccm.201610-2074PP</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1164%2Frccm.201610-2074PP" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=27922751" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjt1SltLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=195&publication_year=2017&pages=159-166&author=N.+J.+Grossauthor=P.+J.+Barnes&title=New+therapies+for+asthma+and+chronic+obstructive+pulmonary+disease&doi=10.1164%2Frccm.201610-2074PP"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">New therapies for asthma and chronic obstructive pulmonary disease</span></div><div class="casAuthors">Gross, Nicholas J.; Barnes, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">195</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">159-166</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">In this paper we discuss new therapies for asthma and chronic obstructive pulmonary disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXeDlu2KlgQrVg90H21EOLACvtfcHk0liU8Yr31Ajwqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjt1SltLg%253D&md5=33192f02c8270268dd65b09e09f42568</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1164%2Frccm.201610-2074PP&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.201610-2074PP%26sid%3Dliteratum%253Aachs%26aulast%3DGross%26aufirst%3DN.%2BJ.%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26atitle%3DNew%2520therapies%2520for%2520asthma%2520and%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2017%26volume%3D195%26spage%3D159%26epage%3D166%26doi%3D10.1164%2Frccm.201610-2074PP" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref178"><div class="reference"><strong class="refLabel"><a href="#ref178" class="rightTabRefNumLink">178</a></strong><div class="NLM_citation" id="rightTab-cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Somoza, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koditek, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villaseñor, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novikov, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liclican, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lagpacan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papalia, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samuel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lad, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGrath, M. E.</span></span> <span> </span><span class="NLM_article-title">Structural, biochemical, and biophysical characterization of idelalisib binding to phosphoinositide 3-kinase δ</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>290</i></span>,  <span class="NLM_fpage">8439</span>– <span class="NLM_lpage">8446</span>, <span class="refDoi"> DOI: 10.1074/jbc.M114.634683</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1074%2Fjbc.M114.634683" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=25631052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlsVSqtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=290&publication_year=2015&pages=8439-8446&author=J.+R.+Somozaauthor=D.+Koditekauthor=A.+G.+Villase%C3%B1orauthor=N.+Novikovauthor=M.+H.+Wongauthor=A.+Liclicanauthor=W.+Xingauthor=L.+Lagpacanauthor=R.+Wangauthor=B.+E.+Schultzauthor=G.+A.+Papaliaauthor=D.+Samuelauthor=L.+Ladauthor=M.+E.+McGrath&title=Structural%2C+biochemical%2C+and+biophysical+characterization+of+idelalisib+binding+to+phosphoinositide+3-kinase+%CE%B4&doi=10.1074%2Fjbc.M114.634683"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Structural, Biochemical, and Biophysical Characterization of Idelalisib Binding to Phosphoinositide 3-Kinase δ</span></div><div class="casAuthors">Somoza, John R.; Koditek, David; Villasenor, Armando G.; Novikov, Nikolai; Wong, Melanie H.; Liclican, Albert; Xing, Weimei; Lagpacan, Leanna; Wang, Ruth; Schultz, Brian E.; Papalia, Giuseppe A.; Samuel, Dharmaraj; Lad, Latesh; McGrath, Mary E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">290</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">8439-8446</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Idelalisib (also known as GS-1101, CAL-101, IC489666, and Zydelig) is a PI3Kδ inhibitor that has recently been approved for the treatment of several hematol. malignancies.  Given its use in human diseases, we needed a clear picture of how idelalisib binds to and inhibits PI3Kδ.  Our data show that idelalisib is a potent and selective inhibitor of the kinase activity of PI3Kδ.  A kinetic characterization clearly demonstrated ATP-competitive inhibition, and several addnl. biochem. and biophys. assays showed that the compd. binds reversibly and noncovalently to the kinase.  A crystal structure of idelalisib bound to the p110δ subunit of PI3Kδ furthers our understanding of the binding interactions that confer the potency and selectivity of idelalisib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnXZo8_qK79rVg90H21EOLACvtfcHk0liU8Yr31Ajwqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlsVSqtrs%253D&md5=2969b7407f4edc367249215bbbf22a0e</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M114.634683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M114.634683%26sid%3Dliteratum%253Aachs%26aulast%3DSomoza%26aufirst%3DJ.%2BR.%26aulast%3DKoditek%26aufirst%3DD.%26aulast%3DVillase%25C3%25B1or%26aufirst%3DA.%2BG.%26aulast%3DNovikov%26aufirst%3DN.%26aulast%3DWong%26aufirst%3DM.%2BH.%26aulast%3DLiclican%26aufirst%3DA.%26aulast%3DXing%26aufirst%3DW.%26aulast%3DLagpacan%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DSchultz%26aufirst%3DB.%2BE.%26aulast%3DPapalia%26aufirst%3DG.%2BA.%26aulast%3DSamuel%26aufirst%3DD.%26aulast%3DLad%26aufirst%3DL.%26aulast%3DMcGrath%26aufirst%3DM.%2BE.%26atitle%3DStructural%252C%2520biochemical%252C%2520and%2520biophysical%2520characterization%2520of%2520idelalisib%2520binding%2520to%2520phosphoinositide%25203-kinase%2520%25CE%25B4%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2015%26volume%3D290%26spage%3D8439%26epage%3D8446%26doi%3D10.1074%2Fjbc.M114.634683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref179"><div class="reference"><strong class="refLabel"><a href="#ref179" class="rightTabRefNumLink">179</a></strong><div class="NLM_citation" id="rightTab-cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Down, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amour, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldwin, I. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, A. W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deakin, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felton, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guntrip, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keeling, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Livia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lunniss, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parr, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowland, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitulli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Washio, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamblin, J. N.</span></span> <span> </span><span class="NLM_article-title">Optimization of novel indazoles as highly potent and selective inhibitors of phosphoinositide 3-kinase δ for the treatment of respiratory disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">7381</span>– <span class="NLM_lpage">7399</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00767</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00767" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlyjsrvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=7381-7399&author=K.+Downauthor=A.+Amourauthor=I.+R.+Baldwinauthor=A.+W.+J.+Cooperauthor=A.+M.+Deakinauthor=L.+M.+Feltonauthor=S.+B.+Guntripauthor=C.+Hardyauthor=Z.+A.+Harrisonauthor=K.+L.+Jonesauthor=P.+Jonesauthor=S.+E.+Keelingauthor=J.+Leauthor=S.+Liviaauthor=F.+Lucasauthor=C.+J.+Lunnissauthor=N.+J.+Parrauthor=E.+Robinsonauthor=P.+Rowlandauthor=S.+Smithauthor=D.+A.+Thomasauthor=G.+Vitulliauthor=Y.+Washioauthor=J.+N.+Hamblin&title=Optimization+of+novel+indazoles+as+highly+potent+and+selective+inhibitors+of+phosphoinositide+3-kinase+%CE%B4+for+the+treatment+of+respiratory+disease&doi=10.1021%2Facs.jmedchem.5b00767"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of Novel Indazoles as Highly Potent and Selective Inhibitors of Phosphoinositide 3-Kinase δ for the Treatment of Respiratory Disease</span></div><div class="casAuthors">Down, Kenneth; Amour, Augustin; Baldwin, Ian R.; Cooper, Anthony W. J.; Deakin, Angela M.; Felton, Leigh M.; Guntrip, Stephen B.; Hardy, Charlotte; Harrison, Zoe A.; Jones, Katherine L.; Jones, Paul; Keeling, Suzanne E.; Le, Joelle; Livia, Stefano; Lucas, Fiona; Lunniss, Christopher J.; Parr, Nigel J.; Robinson, Ed; Rowland, Paul; Smith, Sarah; Thomas, Daniel A.; Vitulli, Giovanni; Washio, Yoshiaki; Hamblin, J. Nicole</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7381-7399</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Optimization of lead compd., through extensive use of structure-based design and a focus on PI3Kδ potency, isoform selectivity, and inhaled PK properties, led to the discovery of clin. candidates I (GSK2269557) and II (GSK2292767) for the treatment of respiratory indications via inhalation.  Compds. I and II are both highly selective for PI3Kδ over the closely related isoforms and are active in a disease relevant brown Norway rat acute OVA model of Th2-driven lung inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUYzpPxn_ArbVg90H21EOLACvtfcHk0lj_k_iRBMch4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlyjsrvJ&md5=2fe8e51a64e6f7c798bdcb63781d02ad</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00767&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00767%26sid%3Dliteratum%253Aachs%26aulast%3DDown%26aufirst%3DK.%26aulast%3DAmour%26aufirst%3DA.%26aulast%3DBaldwin%26aufirst%3DI.%2BR.%26aulast%3DCooper%26aufirst%3DA.%2BW.%2BJ.%26aulast%3DDeakin%26aufirst%3DA.%2BM.%26aulast%3DFelton%26aufirst%3DL.%2BM.%26aulast%3DGuntrip%26aufirst%3DS.%2BB.%26aulast%3DHardy%26aufirst%3DC.%26aulast%3DHarrison%26aufirst%3DZ.%2BA.%26aulast%3DJones%26aufirst%3DK.%2BL.%26aulast%3DJones%26aufirst%3DP.%26aulast%3DKeeling%26aufirst%3DS.%2BE.%26aulast%3DLe%26aufirst%3DJ.%26aulast%3DLivia%26aufirst%3DS.%26aulast%3DLucas%26aufirst%3DF.%26aulast%3DLunniss%26aufirst%3DC.%2BJ.%26aulast%3DParr%26aufirst%3DN.%2BJ.%26aulast%3DRobinson%26aufirst%3DE.%26aulast%3DRowland%26aufirst%3DP.%26aulast%3DSmith%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DD.%2BA.%26aulast%3DVitulli%26aufirst%3DG.%26aulast%3DWashio%26aufirst%3DY.%26aulast%3DHamblin%26aufirst%3DJ.%2BN.%26atitle%3DOptimization%2520of%2520novel%2520indazoles%2520as%2520highly%2520potent%2520and%2520selective%2520inhibitors%2520of%2520phosphoinositide%25203-kinase%2520%25CE%25B4%2520for%2520the%2520treatment%2520of%2520respiratory%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D7381%26epage%3D7399%26doi%3D10.1021%2Facs.jmedchem.5b00767" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref180"><div class="reference"><strong class="refLabel"><a href="#ref180" class="rightTabRefNumLink">180</a></strong><div class="NLM_citation" id="rightTab-cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Allen, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brookings, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delgado, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuttleworth, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merriman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fahy, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tewari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silva, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Healy, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, G. C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Twomey, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cutler, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crosby, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCluskey, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watt, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Payne, A.</span></span> <span> </span><span class="NLM_article-title">Seletalisib: characterization of a novel, potent, and selective inhibitor of PI3Kδ</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>361</i></span>,  <span class="NLM_fpage">429</span>– <span class="NLM_lpage">440</span>, <span class="refDoi"> DOI: 10.1124/jpet.116.237347</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1124%2Fjpet.116.237347" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=28442583" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFOqsLbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2017&pages=429-440&author=R.+A.+Allenauthor=D.+C.+Brookingsauthor=M.+J.+Powellauthor=J.+Delgadoauthor=L.+K.+Shuttleworthauthor=M.+Merrimanauthor=I.+J.+Fahyauthor=R.+Tewariauthor=J.+P.+Silvaauthor=L.+J.+Healyauthor=G.+C.+G.+Daviesauthor=B.+Twomeyauthor=R.+M.+Cutlerauthor=A.+Kotianauthor=A.+Crosbyauthor=G.+McCluskeyauthor=G.+F.+Wattauthor=A.+Payne&title=Seletalisib%3A+characterization+of+a+novel%2C+potent%2C+and+selective+inhibitor+of+PI3K%CE%B4&doi=10.1124%2Fjpet.116.237347"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Seletalisib: characterization of a novel, potent, and selective inhibitor of PI3Kδ</span></div><div class="casAuthors">Allen, Rodger A.; Brookings, Daniel C.; Powell, Mark J.; Delgado, Jean; Shuttleworth, Lindsay K.; Merriman, Mark; Fahy, Ian J.; Tewari, Roohi; Silva, John P.; Healy, Louise J.; Davies, Gareth C. G.; Twomey, Breda; Cutler, Rona M.; Kotian, Apoorva; Crosby, Andrea; McCluskey, Gillian; Watt, Gillian F.; Payne, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">361</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">429-440</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Phosphoinositide 3-kinases (PI3K) are key signaling enzymes regulating cellular survival, development, and function.  Expression of the PI3Kδ isoform is largely restricted to leukocytes and it plays a key role in immune cell development and function.  Seletalisib is a novel small-mol. inhibitor of PI3Kδ that was evaluated in biochem. assays, cellular assays of adaptive and innate immunity, and an in vivo rat model of inflammation.  Our findings show that seletalisib is a potent, ATP-competitive, and selective PI3Kδ inhibitor able to block protein kinase B (AKT) phosphorylation following activation of the B-cell receptor in a B-cell line.  Moreover, seletalisib inhibited N-formyl peptide-stimulated but not phorbol myristate acetate-stimulated superoxide release from human neutrophils, consistent with a PI3Kδ-specific activity.  No indications of cytotoxicity were obsd. in peripheral blood mononuclear cells (PBMCs) or other cell types treated with seletalisib.  Findings from cellular assays of adaptive immunity demonstrated that seletalisib blocks human T-cell prodn. of several cytokines from activated T-cells.  Addnl., seletalisib inhibited B-cell proliferation and cytokine release.  In human whole blood assays, seletalisib inhibited CD69 expression upon B-cell activation and anti-IgE-mediated basophil degranulation.  Seletalisib showed dose-dependent inhibition in an in vivo rat model of anti-CD3-antibody-induced interleukin 2 release.  Collectively, these data characterize seletalisib as a selective PI3Kδ inhibitor and potential therapeutic candidate for the treatment of B-cell malignancies and autoimmune diseases driven by dysregulated proinflammatory cytokine secretion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyxgOubZ1Ic7Vg90H21EOLACvtfcHk0lj_k_iRBMch4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFOqsLbI&md5=270c4866fe19b97aada323e9945715ab</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1124%2Fjpet.116.237347&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.116.237347%26sid%3Dliteratum%253Aachs%26aulast%3DAllen%26aufirst%3DR.%2BA.%26aulast%3DBrookings%26aufirst%3DD.%2BC.%26aulast%3DPowell%26aufirst%3DM.%2BJ.%26aulast%3DDelgado%26aufirst%3DJ.%26aulast%3DShuttleworth%26aufirst%3DL.%2BK.%26aulast%3DMerriman%26aufirst%3DM.%26aulast%3DFahy%26aufirst%3DI.%2BJ.%26aulast%3DTewari%26aufirst%3DR.%26aulast%3DSilva%26aufirst%3DJ.%2BP.%26aulast%3DHealy%26aufirst%3DL.%2BJ.%26aulast%3DDavies%26aufirst%3DG.%2BC.%2BG.%26aulast%3DTwomey%26aufirst%3DB.%26aulast%3DCutler%26aufirst%3DR.%2BM.%26aulast%3DKotian%26aufirst%3DA.%26aulast%3DCrosby%26aufirst%3DA.%26aulast%3DMcCluskey%26aufirst%3DG.%26aulast%3DWatt%26aufirst%3DG.%2BF.%26aulast%3DPayne%26aufirst%3DA.%26atitle%3DSeletalisib%253A%2520characterization%2520of%2520a%2520novel%252C%2520potent%252C%2520and%2520selective%2520inhibitor%2520of%2520PI3K%25CE%25B4%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2017%26volume%3D361%26spage%3D429%26epage%3D440%26doi%3D10.1124%2Fjpet.116.237347" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref181"><div class="reference"><strong class="refLabel"><a href="#ref181" class="rightTabRefNumLink">181</a></strong><div class="NLM_citation" id="rightTab-cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcoux, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batt, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornelius, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, L.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neels, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaudoin-Bertrand, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherney, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weigelt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obermeier, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sleczka, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefanski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fancher, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padmanabhan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rp, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kundu, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajareddy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hennan, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levesque, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedicord, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yarde, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstine, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rampulla, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arunachalam, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sack, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muckelbauer, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cvijic, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-Cid, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhide, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poss, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hynes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macor, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruepp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schieven, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tino, J. A.</span></span> <span> </span><span class="NLM_article-title">Identification of a potent, selective, and efficacious phosphatidylinositol 3-kinase δ (PI3Kδ) inhibitor for the treatment of immunological disorders</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">5193</span>– <span class="NLM_lpage">5208</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00618</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00618" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2sXos1Sgtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5193-5208&author=Q.+Liuauthor=Q.+Shiauthor=D.+Marcouxauthor=D.+G.+Battauthor=L.+Corneliusauthor=L.-Y.+Qinauthor=Z.+Ruanauthor=J.+Neelsauthor=M.+Beaudoin-Bertrandauthor=A.+S.+Srivastavaauthor=L.+Liauthor=R.+J.+Cherneyauthor=H.+Gongauthor=S.+H.+Wattersonauthor=C.+Weigeltauthor=K.+M.+Gilloolyauthor=K.+W.+McIntyreauthor=J.+H.+Xieauthor=M.+T.+Obermeierauthor=A.+Furaauthor=B.+Sleczkaauthor=K.+Stefanskiauthor=R.+M.+Fancherauthor=S.+Padmanabhanauthor=T.+Rpauthor=I.+Kunduauthor=K.+Rajareddyauthor=R.+Smithauthor=J.+K.+Hennanauthor=D.+Xingauthor=J.+Fanauthor=P.+C.+Levesqueauthor=Q.+Ruanauthor=S.+Pittauthor=R.+Zhangauthor=D.+Pedicordauthor=J.+Panauthor=M.+Yardeauthor=H.+Luauthor=J.+Lippyauthor=C.+Goldstineauthor=S.+Skalaauthor=R.+A.+Rampullaauthor=A.+Mathurauthor=A.+Guptaauthor=P.+N.+Arunachalamauthor=J.+S.+Sackauthor=J.+K.+Muckelbauerauthor=M.+E.+Cvijicauthor=L.+M.+Salter-Cidauthor=R.+S.+Bhideauthor=M.+A.+Possauthor=J.+Hynesauthor=P.+H.+Carterauthor=J.+E.+Macorauthor=S.+Rueppauthor=G.+L.+Schievenauthor=J.+A.+Tino&title=Identification+of+a+potent%2C+selective%2C+and+efficacious+phosphatidylinositol+3-kinase+%CE%B4+%28PI3K%CE%B4%29+inhibitor+for+the+treatment+of+immunological+disorders&doi=10.1021%2Facs.jmedchem.7b00618"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a Potent, Selective, and Efficacious Phosphatidylinositol 3-Kinase δ (PI3Kδ) Inhibitor for the Treatment of Immunological Disorders</span></div><div class="casAuthors">Liu, Qingjie; Shi, Qing; Marcoux, David; Batt, Douglas G.; Cornelius, Lyndon; Qin, Lan-Ying; Ruan, Zheming; Neels, James; Beaudoin-Bertrand, Myra; Srivastava, Anurag S.; Li, Ling; Cherney, Robert J.; Gong, Hua; Watterson, Scott H.; Weigelt, Carolyn; Gillooly, Kathleen M.; McIntyre, Kim W.; Xie, Jenny H.; Obermeier, Mary T.; Fura, Aberra; Sleczka, Bogdan; Stefanski, Kevin; Fancher, R. M.; Padmanabhan, Shweta; Thatipamula, R. P.; Kundu, Ipsit; Rajareddy, Kallem; Smith, Rodney; Hennan, James K.; Xing, Dezhi; Fan, Jingsong; Levesque, Paul C.; Ruan, Qian; Pitt, Sidney; Zhang, Rosemary; Pedicord, Donna; Pan, Jie; Yarde, Melissa; Lu, Hao; Lippy, Jonathan; Goldstine, Christine; Skala, Stacey; Rampulla, Richard A.; Mathur, Arvind; Gupta, Anuradha; Arunachalam, Pirama Nayagam; Sack, John S.; Muckelbauer, Jodi K.; Cvijic, Mary Ellen; Salter-Cid, Luisa M.; Bhide, Rajeev S.; Poss, Michael A.; Hynes, John; Carter, Percy H.; Macor, John E.; Ruepp, Stefan; Schieven, Gary L.; Tino, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5193-5208</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">PI3Kδ plays an important role controlling immune cell function and has therefore been identified as a potential target for the treatment of immunol. disorders.  This article highlights the work toward the identification of a potent, selective, and efficacious PI3Kδ inhibitor.  Through careful SAR, the successful replacement of a polar pyrazole group by a simple chloro or trifluoromethyl group led to improved Caco-2 permeability, reduced Caco-2 efflux, reduced hERG PC activity, and increased selectivity profile while maintaining potency in the CD69 hWB assay.  The optimization of the aryl substitution then identified a 4'-CN group that improved the human/rodent correlation in microsomal metabolic stability.  The lead mol. is very potent in PK/PD assays and highly efficacious in a mouse collagen-induced arthritis model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCnrlN1J_ib7Vg90H21EOLACvtfcHk0lhW5hm0gsmHRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXos1Sgtbc%253D&md5=4bcbe85e7b82c19e47065be4fbeccdc8</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00618%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DShi%26aufirst%3DQ.%26aulast%3DMarcoux%26aufirst%3DD.%26aulast%3DBatt%26aufirst%3DD.%2BG.%26aulast%3DCornelius%26aufirst%3DL.%26aulast%3DQin%26aufirst%3DL.-Y.%26aulast%3DRuan%26aufirst%3DZ.%26aulast%3DNeels%26aufirst%3DJ.%26aulast%3DBeaudoin-Bertrand%26aufirst%3DM.%26aulast%3DSrivastava%26aufirst%3DA.%2BS.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DCherney%26aufirst%3DR.%2BJ.%26aulast%3DGong%26aufirst%3DH.%26aulast%3DWatterson%26aufirst%3DS.%2BH.%26aulast%3DWeigelt%26aufirst%3DC.%26aulast%3DGillooly%26aufirst%3DK.%2BM.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DXie%26aufirst%3DJ.%2BH.%26aulast%3DObermeier%26aufirst%3DM.%2BT.%26aulast%3DFura%26aufirst%3DA.%26aulast%3DSleczka%26aufirst%3DB.%26aulast%3DStefanski%26aufirst%3DK.%26aulast%3DFancher%26aufirst%3DR.%2BM.%26aulast%3DPadmanabhan%26aufirst%3DS.%26aulast%3DRp%26aufirst%3DT.%26aulast%3DKundu%26aufirst%3DI.%26aulast%3DRajareddy%26aufirst%3DK.%26aulast%3DSmith%26aufirst%3DR.%26aulast%3DHennan%26aufirst%3DJ.%2BK.%26aulast%3DXing%26aufirst%3DD.%26aulast%3DFan%26aufirst%3DJ.%26aulast%3DLevesque%26aufirst%3DP.%2BC.%26aulast%3DRuan%26aufirst%3DQ.%26aulast%3DPitt%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DPedicord%26aufirst%3DD.%26aulast%3DPan%26aufirst%3DJ.%26aulast%3DYarde%26aufirst%3DM.%26aulast%3DLu%26aufirst%3DH.%26aulast%3DLippy%26aufirst%3DJ.%26aulast%3DGoldstine%26aufirst%3DC.%26aulast%3DSkala%26aufirst%3DS.%26aulast%3DRampulla%26aufirst%3DR.%2BA.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DArunachalam%26aufirst%3DP.%2BN.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DMuckelbauer%26aufirst%3DJ.%2BK.%26aulast%3DCvijic%26aufirst%3DM.%2BE.%26aulast%3DSalter-Cid%26aufirst%3DL.%2BM.%26aulast%3DBhide%26aufirst%3DR.%2BS.%26aulast%3DPoss%26aufirst%3DM.%2BA.%26aulast%3DHynes%26aufirst%3DJ.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DMacor%26aufirst%3DJ.%2BE.%26aulast%3DRuepp%26aufirst%3DS.%26aulast%3DSchieven%26aufirst%3DG.%2BL.%26aulast%3DTino%26aufirst%3DJ.%2BA.%26atitle%3DIdentification%2520of%2520a%2520potent%252C%2520selective%252C%2520and%2520efficacious%2520phosphatidylinositol%25203-kinase%2520%25CE%25B4%2520%2528PI3K%25CE%25B4%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520immunological%2520disorders%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D5193%26epage%3D5208%26doi%3D10.1021%2Facs.jmedchem.7b00618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref182"><div class="reference"><strong class="refLabel"><a href="#ref182" class="rightTabRefNumLink">182</a></strong><div class="NLM_citation" id="rightTab-cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yap, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjerke, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, P.</span></span> <span> </span><span class="NLM_article-title">Drugging PI3K in cancer: refining targets and therapeutic strategies</span>. <i>Curr. Opin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">98</span>– <span class="NLM_lpage">107</span>, <span class="refDoi"> DOI: 10.1016/j.coph.2015.05.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1016%2Fj.coph.2015.05.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=26117819" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVWrt7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=98-107&author=T.+A.+Yapauthor=L.+Bjerkeauthor=P.+A.+Clarkeauthor=P.+Workman&title=Drugging+PI3K+in+cancer%3A+refining+targets+and+therapeutic+strategies&doi=10.1016%2Fj.coph.2015.05.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">Drugging PI3K in cancer: refining targets and therapeutic strategies</span></div><div class="casAuthors">Yap, Timothy A.; Bjerke, Lynn; Clarke, Paul A.; Workman, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">98-107</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The phosphatidylinositol-3 kinase (PI3K) pathway is one of the most frequently activated pathogenic signalling routes in human cancers, making it a rational and important target for innovative anticancer drug development and precision medicine.  The three main classes of PI3K inhibitors currently in clin. testing comprise dual pan-Class I PI3K/mTOR inhibitors, pan-Class I PI3K inhibitors lacking significant mTOR activity and isoform-selective PI3K inhibitors.  A major step forward in recent years is the progression of over 30 small mol. PI3K inhibitors into clin. trials and the first regulatory approval of the PI3Kδ inhibitor idelalisib for multiple B-cell malignancies.  This review article focuses on the progress made in the discovery and development of novel PI3K inhibitors, with an emphasis on antitumor activity and tolerability profiles for agents that have entered clin. trials.  We also discuss the key issues of drug resistance, patient selection approaches and rational targeted combinations.  Finally, we envision the future development and use of PI3K inhibitors for the treatment of patients with a range of malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDxyCAEREi_7Vg90H21EOLACvtfcHk0lhW5hm0gsmHRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVWrt7bJ&md5=9a0238f97d8ecdc54e0c5b9b6ce4fc76</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2015.05.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2015.05.016%26sid%3Dliteratum%253Aachs%26aulast%3DYap%26aufirst%3DT.%2BA.%26aulast%3DBjerke%26aufirst%3DL.%26aulast%3DClarke%26aufirst%3DP.%2BA.%26aulast%3DWorkman%26aufirst%3DP.%26atitle%3DDrugging%2520PI3K%2520in%2520cancer%253A%2520refining%2520targets%2520and%2520therapeutic%2520strategies%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2015%26volume%3D23%26spage%3D98%26epage%3D107%26doi%3D10.1016%2Fj.coph.2015.05.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref183"><div class="reference"><strong class="refLabel"><a href="#ref183" class="rightTabRefNumLink">183</a></strong><div class="NLM_citation" id="rightTab-cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Greenwell, I. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ip, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, J. B.</span></span> <span> </span><span class="NLM_article-title">PI3K inhibitors: understanding toxicity mechanisms and management</span>. <i>Oncology (Williston Park)</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">821</span>– <span class="NLM_lpage">828</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=29179250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A280%3ADC%252BC1M3ltlGntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=821-828&author=I.+B.+Greenwellauthor=A.+Ipauthor=J.+B.+Cohen&title=PI3K+inhibitors%3A+understanding+toxicity+mechanisms+and+management"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">PI3K Inhibitors: Understanding Toxicity Mechanisms and Management</span></div><div class="casAuthors">Greenwell I Brian; Ip Andrew; Cohen Jonathon B</div><div class="citationInfo"><span class="NLM_cas:title">Oncology (Williston Park, N.Y.)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">821-8</span>
        ISSN:<span class="NLM_cas:issn">0890-9091</span>.
    </div><div class="casAbstract">The phosphatidylinositol 3-kinase (PI3K) pathway has attracted immense interest as a therapeutic target for cancer treatment.  Idelalisib was the first PI3K inhibitor approved by the US Food and Drug Administration and is utilized in the treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and follicular lymphoma.  Copanlisib has subsequently been approved for relapsed follicular lymphoma in patients who have received at least two prior systemic therapies.  There are multiple other PI3K agents currently in development; these target various combinations of PI3K isoforms.  Despite the therapeutic benefit, there have been concerns about the severe and sometimes fatal adverse effects of this class of drug.  Several side effects are unusual and have poorly understood mechanisms; these include autoimmune dysfunction, opportunistic infections, skin toxicity, hypertension, and hyperglycemia.  An understanding of these unusual toxicities, as well as a good grasp of management principles, will be important as more PI3K inhibitors are approved and become incorporated into routine practice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR5yvT6h5ErjpQHPYJuLg8TfW6udTcc2eZhIKp_aLYCHLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M3ltlGntA%253D%253D&md5=6c477dd4ae70ee2393283cd0b43ec885</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGreenwell%26aufirst%3DI.%2BB.%26aulast%3DIp%26aufirst%3DA.%26aulast%3DCohen%26aufirst%3DJ.%2BB.%26atitle%3DPI3K%2520inhibitors%253A%2520understanding%2520toxicity%2520mechanisms%2520and%2520management%26jtitle%3DOncology%2520%2528Williston%2520Park%2529%26date%3D2017%26volume%3D31%26spage%3D821%26epage%3D828" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref184"><div class="reference"><strong class="refLabel"><a href="#ref184" class="rightTabRefNumLink">184</a></strong><div class="NLM_citation" id="rightTab-cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Craige, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kant, S.</span></span> <span> </span><span class="NLM_article-title">Mixed-lineage protein kinases (MLKs) in inflammation, metabolism, and other disease states</span>. <i>Biochim. Biophys. Acta, Mol. Basis Dis.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>1862</i></span>,  <span class="NLM_fpage">1581</span>– <span class="NLM_lpage">1586</span>, <span class="refDoi"> DOI: 10.1016/j.bbadis.2016.05.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=10.1016%2Fj.bbadis.2016.05.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=27259981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;key=1%3ACAS%3A528%3ADC%252BC28XptVWkt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1862&publication_year=2016&pages=1581-1586&author=S.+M.+Craigeauthor=M.+M.+Reifauthor=S.+Kant&title=Mixed-lineage+protein+kinases+%28MLKs%29+in+inflammation%2C+metabolism%2C+and+other+disease+states&doi=10.1016%2Fj.bbadis.2016.05.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">Mixed-lineage protein kinases (MLKs) in inflammation, metabolism, and other disease states</span></div><div class="casAuthors">Craige, Siobhan M.; Reif, Michaella M.; Kant, Shashi</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular Basis of Disease</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">1862</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1581-1586</span>CODEN:
                <span class="NLM_cas:coden">BBADEX</span>;
        ISSN:<span class="NLM_cas:issn">0925-4439</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">A review.  Mixed lineage kinases, or MLKs, are members of the MAP kinase kinase kinase (MAP3K) family, which were originally identified among the activators of the major stress-dependent mitogen activated protein kinases (MAPKs), JNK and p38.  During stress, the activation of JNK and p38 kinases targets several essential downstream substrates that react in a specific manner to the unique stressor and thus det. the fate of the cell in response to a particular challenge.  Recently, the MLK family was identified as a specific modulator of JNK and p38 signaling in metabolic syndrome.  Moreover, the MLK family of kinases appears to be involved in a very wide spectrum of disorders.  This review discusses the newly identified functions of MLKs in multiple diseases including metabolic disorders, inflammation, cancer, and neurol. diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvCjWSVZ3aH7Vg90H21EOLACvtfcHk0lgKMH7Bxac00A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XptVWkt7k%253D&md5=35fe462e637637958849af5dbbe6f542</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1016%2Fj.bbadis.2016.05.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbadis.2016.05.022%26sid%3Dliteratum%253Aachs%26aulast%3DCraige%26aufirst%3DS.%2BM.%26aulast%3DReif%26aufirst%3DM.%2BM.%26aulast%3DKant%26aufirst%3DS.%26atitle%3DMixed-lineage%2520protein%2520kinases%2520%2528MLKs%2529%2520in%2520inflammation%252C%2520metabolism%252C%2520and%2520other%2520disease%2520states%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Basis%2520Dis.%26date%3D2016%26volume%3D1862%26spage%3D1581%26epage%3D1586%26doi%3D10.1016%2Fj.bbadis.2016.05.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2018.61.issue-20%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.8b00667%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.8b00667" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                8MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-b425991822a79ada59b3.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-fb88834b824b41b135ad.js"></script>

<script type="text/javascript" src="/wro/ke1q~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"66797cbff9f83291","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
